
<html lang="en"     class="pb-page"  data-request-id="d9438fd2-f415-493d-905e-676ad4fdd669"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00917;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Designing around Structural Alerts in Drug Discovery" /></meta><meta name="dc.Creator" content="Amit S.  Kalgutkar" /></meta><meta name="dc.Description" content="Cumulative research over several decades has implicated the involvement of reactive metabolites in many idiosyncratic adverse drug reactions (IADRs). Consequently, “avoidance” strategies have been ..." /></meta><meta name="Description" content="Cumulative research over several decades has implicated the involvement of reactive metabolites in many idiosyncratic adverse drug reactions (IADRs). Consequently, “avoidance” strategies have been ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 9, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00917" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00917" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00917" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00917" /></link>
        
    
    

<title>Designing around Structural Alerts in Drug Discovery | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00917" /></meta><meta property="og:title" content="Designing around Structural Alerts in Drug Discovery" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0027.jpeg" /></meta><meta property="og:description" content="Cumulative research over several decades has implicated the involvement of reactive metabolites in many idiosyncratic adverse drug reactions (IADRs). Consequently, “avoidance” strategies have been inserted into drug discovery paradigms, which include the exclusion of structural alerts and possible termination of reactive metabolite-positive compounds. Several noteworthy examples where reactive metabolite-related liabilities have been resolved through structure–metabolism studies are presented herein. Considerable progress has also been made in addressing the limitations of the avoidance strategy and further refining the process of managing reactive metabolite issues in drug development. These efforts primarily stemmed from the observation that numerous drugs, which contain structural alerts and/or form reactive metabolites, are devoid of ADRs. The Perspective also dwells into an analysis of the structural alert/reactive metabolite concept with a discussion of risk mitigation tactics to support the progression of reactive metabolite-positive drug candidates." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00917"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00917">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00917&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00917&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00917&amp;href=/doi/10.1021/acs.jmedchem.9b00917" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 6276-6302</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01625" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00026" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Designing around Structural Alerts in Drug Discovery</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Amit S. Kalgutkar</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amit S. Kalgutkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Worldwide Research, Development and Medical, 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (617) 551-3336. E-mail: <a href="/cdn-cgi/l/email-protection#d3b2bebaa7fdb8b2bfb4a6a7b8b2a193a3b5baa9b6a1fdb0bcbe"><span class="__cf_email__" data-cfemail="99f8f4f0edb7f2f8f5feecedf2f8ebd9e9fff0e3fcebb7faf6f4">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amit+S.++Kalgutkar">Amit S. Kalgutkar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9701-756X" title="Orcid link">http://orcid.org/0000-0001-9701-756X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00917&amp;href=/doi/10.1021%2Facs.jmedchem.9b00917" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 6276–6302</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 9, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 June 2019</li><li><span class="item_label"><b>Published</b> online</span>9 September 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00917" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00917</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6276%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAmit%2BS.%2BKalgutkar%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D12%26contentID%3Dacs.jmedchem.9b00917%26title%3DDesigning%2Baround%2BStructural%2BAlerts%2Bin%2BDrug%2BDiscovery%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6302%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00917"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">14065</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00917" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Designing around Structural Alerts in Drug Discovery&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Amit&quot;,&quot;last_name&quot;:&quot;S. Kalgutkar&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6276-6302&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00917&quot;},&quot;abstract&quot;:&quot;Cumulative research over several decades has implicated the involvement of reactive metabolites in many idiosyncratic adverse drug reactions (IADRs). Consequently, “avoidance” strategies have been inserted into drug discovery paradigms, which include the exclusion of structural alerts and possible termination of reactive metabolite-positive compounds. Several noteworthy examples where reactive metabolite-related liabilities have been resolved through structure–metabolism studies are presented herein. Considerable progress has also been made in addressing the limitations of the avoidance strategy and further refining the process of managing reactive metabolite issues in drug development. These efforts primarily stemmed from the observation that numerous drugs, which contain structural alerts and/or form reactive metabolites, are devoid of ADRs. The Perspective also dwells into an analysis of the structural alert/reactive metabolite concept with a discussion of risk mitigation tactics to support the progression&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00917&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00917" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00917&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00917" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00917&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00917" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00917&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00917&amp;href=/doi/10.1021/acs.jmedchem.9b00917" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00917" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00917" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00917%26sid%3Dliteratum%253Aachs%26pmid%3D31497963%26genre%3Darticle%26aulast%3DKalgutkar%26date%3D2020%26atitle%3DDesigning%2Baround%2BStructural%2BAlerts%2Bin%2BDrug%2BDiscovery%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D12%26spage%3D6276%26epage%3D6302%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292547" title="Adducts">Adducts</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=292082" title="Bioactivation">Bioactivation</a>,</li><li><a href="/action/doSearch?ConceptID=291645" title="Acyls">Acyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/jmcmar.2020.63.issue-12/20200625/jmcmar.2020.63.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cumulative research over several decades has implicated the involvement of reactive metabolites in many idiosyncratic adverse drug reactions (IADRs). Consequently, “avoidance” strategies have been inserted into drug discovery paradigms, which include the exclusion of structural alerts and possible termination of reactive metabolite-positive compounds. Several noteworthy examples where reactive metabolite-related liabilities have been resolved through structure–metabolism studies are presented herein. Considerable progress has also been made in addressing the limitations of the avoidance strategy and further refining the process of managing reactive metabolite issues in drug development. These efforts primarily stemmed from the observation that numerous drugs, which contain structural alerts and/or form reactive metabolites, are devoid of ADRs. The Perspective also dwells into an analysis of the structural alert/reactive metabolite concept with a discussion of risk mitigation tactics to support the progression of reactive metabolite-positive drug candidates.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/12"><issue-title>Drug Metabolism and Toxicology</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Reliably predicting the likelihood that an investigational drug candidate will cause idiosyncratic adverse drug reactions (IADRs) is difficult, since these reactions usually surface in large scale clinical trials (e.g., phase 3) or once a marketed drug is used to treat vast numbers of patients. IADRs can manifest as rare (1 in 10 000 or more) and occasionally severe reactions (e.g., liver injury, agranulocytosis, cutaneous reactions, etc.), which are unrelated to the pharmacologic action of the drug. For example, acetaminophen is used to treat inflammation but can trigger idiosyncratic drug-induced liver injury (iDILI). IADRs are characteristically not observed in standard regulatory animal toxicology studies, since the idiosyncratic nature of the adverse events in humans is unpredictable in animals.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Among all IADRs, iDILI is most common and the principal reason leading to drug recalls (e.g., bromfenac, troglitazone, trovafloxacin, nefazodone, sitaxentan, etc.) and/or black box warning (BBW) restrictions (e.g., pazopanib, sunitinib, flupertine, etc.) on marketed drugs.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> DILI can be further subdivided into intrinsic and idiosyncratic types of reactions. Intrinsic DILI is predictable, is reproducible in animals, and has a clear dose-dependency. The anti-inflammatory drug acetaminophen (<b>1</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) is the best-known example of a marketed drug associated with intrinsic DILI, where consumption of doses of >7.5 g can lead to acute liver toxicity. Moreover, intake of <b>1</b> at the licensed dose of 4 g/day over a period of 2 weeks results in increases of alanine aminotransferase (ALT) above 3× the upper limit of normal (ULN) in a third of treated patients.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> To date, the toxicity of <b>1</b> presents a major liability and is the one of the largest source of acute liver failure cases in the U.S. and U.K.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In contrast with intrinsic DILI, the onset of iDILI, which is very rare but nonetheless responsible for ∼10–15% of acute liver failures in the USA, is almost impossible to predict.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. CYP-Catalyzed Bioactivation of Acetaminophen (<b>1</b>) to a an Electrophilic Quinone Imine Intermediate <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Precise mechanisms of IADRs including intrinsic and idiosyncratic DILI remain unclear. While it is apparent that molecular mechanisms of drug-induced toxicity are numerous, it is now generally accepted that many IADRs (including iDILI) result from the metabolism (also referred to as metabolic activation and/or bioactivation) of small molecule xenobiotics (including drugs) into electrophilic reactive metabolites. Covalent modification of host proteins in the target tissue (e.g., liver in the case of iDILI) by reactive species is thought to result in direct toxicity by negatively impacting critical protein function or an immune response via presentation of drug–protein adducts as neoantigens.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Evidence for reactive metabolite involvement in iDILI is derived from observations such as adaptive immune responses (e.g., drug-specific T-cell responses, serum autoantibodies to cytochrome P450 (CYP) enzymes, and antibodies to drug–liver protein adducts) in patients that exhibit iDILI with drugs (e.g., halothane, isoniazid, etc.) but not in drug-treated patients who do not experience iDILI.<a onclick="showRef(event, 'ref8 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref10 ref11">(8,10,11)</a> It is not surprising that the liver serves as the recurrent target for IADRs given the organ’s role in metabolizing drugs (and xenobiotics) including the generation of reactive metabolites. It is also noteworthy to point out that the same drug can be associated with different IADRs in patients. For example, the antiviral agent nevirapine causes serious cutaneous reactions in some patients and iDILI in others, via distinct bioactivation pathways.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Examples of toxicity arising from bioactivation are also available in the works of Elizabeth and James Miller. For example, the Millers established that the hepatocarcinogenicity arising from exposure to aminoazo dyes (e.g., 4-dimethylaminoazobenzene) resulted from the bioactivation of the aniline functional group to reactive metabolites.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The Millers also proposed the key concept that the carcinogenicity and mutagenicity of many chemicals are likely derived from their bioactivation to reactive intermediates, which covalently modify DNA.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Approximately 50% of the chemicals categorized as “known” (e.g., aflatoxin B1 and benzene) or “probable” (e.g., furan and thiourea) carcinogens are thought to require bioactivation to elicit carcinogenicity. Because of the robust scientific rationale and the central importance of ensuring that investigational drug candidates will not pose the risk of causing cancer, risk evaluation approaches have been issued by the regulatory agencies and are widely agreed upon.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p last">Evidence for reactive metabolite involvement in DILI was first demonstrated in studies on marketed drugs such as halothane, furosemide, and <b>1</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In the case of <b>1</b>, metabolic clearance routes involving glucuronidation and sulfation are saturated after a toxic overdose, and instead, <b>1</b> is bioactivated by CYP enzymes to an electrophilic quinone-imine species, NAPQI (<b>2</b>), which covalently adducts with the antioxidant glutathione (GSH) (compound <b>3</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), resulting in the depletion of the endogenous GSH pool.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21">(17−21)</a><i>N</i>-Acetylcysteine, which replenishes the depleted antioxidant pool, has been used as an antidote to treat suspected cases of acetaminophen poisoning. However, this treatment option is helpful if administered within the first 20 h following acetaminophen overdose.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The reduction of hepatic GSH concentration is a prerequisite step, followed by secondary events involving covalent modification of hepatic proteins by <b>2</b>, which leads to inhibition of cellular protein function and cell death.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">The Structural Alert Concept</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Structural alerts (also referred to as toxicophores) are functional groups or substructures, which are frequently found in drugs (or investigational drug substances) that are associated with ADRs. Some 37 years ago, a comprehensive description of oxidative bioactivation pathways of structural alerts to electrophilic reactive metabolites was published in the <i>Journal of Medicinal Chemistry</i>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The paper, which discussed several structural alerts (e.g., anilines, acetanilides, hydrazines, benzenoid and nitroaromatics, five-membered heteroaromatics, alkenes, alkynes, thiols, etc.), has served as the backdrop for further expansion of the structural alert list based on the emergence of new reactive metabolite formation pathways for drugs associated with IADRs.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26−29)</a> Examples include the metabolism of the carboxylic acid group to acyl glucuronide metabolites and/or acyl-coenzyme A thioesters<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34">(30−34)</a> and the oxidative bioactivation of 2-aminothiazoles and thiazolidinediones to electrophilic thiourea and <i>S</i>-oxide/isocyanate metabolites, respectively.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> Existing disease states (e.g., inflammation) and genetic and/or environmental factors are also thought to increase the risk of IADRs arising from protein covalent modification by reactive metabolites.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Since it is practically impossible to pinpoint individual risk factors during drug development, prediction of the toxicological potential of an investigational drug candidate remains limited at best. Consequently, efforts to avoid, or at least minimize exposure to, reactive metabolites represent a viable approach toward mitigating toxicity risks with drug candidates. Since the mechanism(s) by which reactive metabolites ultimately cause IADRs is poorly understood, one strategy frequently accepted in drug discovery is that of circumvention, which refers to a theoretical argument wherein structural alerts must be omitted in drug design, irrespective of their benefits (e.g., improvements in pharmacologic potency and pharmacokinetic attributes such as oral absorption and clearance). Such a perception is further supported by a recent survey of withdrawn or BBW-labeled drugs wherein structural alerts were found in 55 out of 68 drugs (80.8%) and the propensity to form reactive metabolites (inferred from the formation of GSH adducts and/or protein covalent binding) was demonstrated with 36 out of the 55 drugs (65%).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">A persuasive argument for structural alert-specific IADRs is also evident in metabolism studies, wherein absence of a reactive metabolite liability is also associated with improvements in safety. For instance, the iDILI incidences reported with the antidepressant nefazodone (<b>4</b>) are rarely encountered with the anxiolytic agent buspirone (<b>11</b>), despite decades of clinical use. Circumstantial evidence has been presented that links liver injury associated with <b>4</b> to its oxidative bioactivation (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). A principal metabolite of <b>4</b> in circulation in humans is <i>para</i>-hydroxynefazodone (<b>5</b>),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> a hydroxyaniline derivative, which is bioactivated by CYP3A4 to electrophilic quinone-imine (<b>6</b>) and 1,4-benzoquinone (<b>8</b>) intermediates, which are trapped as GSH adducts <b>7</b> and <b>9</b>, respectively, in human liver microsomal incubations fortified with NADPH and GSH (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> The detection of the N-dearylated metabolite <b>10</b> as a stable metabolite provides further evidence for the liberation of <b>8</b> following the oxidative metabolism of <b>4</b>. Significant covalent binding to proteins has also been observed upon incubating <b>4</b> with human hepatic tissue (e.g., NADPH-supplemented liver microsomes, liver S9 and/or human hepatocytes), which is consistent with the formation of reactive metabolites that irreversibly modify proteins.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> The metabolism of <b>11</b> in humans parallels the one noted for <b>4</b> in that <i>para</i>-hydroxybuspirone (<b>12</b>), a hydroxypyrimidine derivative, also represents a major metabolite in circulation in human plasma.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> However, absence of GSH adducts in human liver microsomal incubations of <b>11</b> implies that quinone-imine species (e.g., <b>13</b>) are not formed during the CYP-mediated oxidation of <b>12</b>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Consistent with the experimental observations, quantum mechanical calculations suggest that the greater acidity and poor resonance stabilization of the oxidation products of <b>12</b> disfavor the oxidation of <b>12</b> to <b>13</b>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Bioactivation Potential of the Hepatotoxin Nefazodone (<b>4</b>) and Non-Hepatotoxin Buspirone (<b>11</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another illustration of structural alert peculiarity is evident with the antipsychotics clozapine (<b>14</b>), quetiapine (<b>17</b>), and loxapine (<b>18</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). While the use of <b>14</b> is restricted by a high frequency of agranulocytosis (∼1.3%) leading to a BBW, <b>17</b> and <b>18</b> are rarely associated with this adverse event. In vitro studies have demonstrated that the covalent binding of <b>14</b> to human neutrophils occurs through a myeloperoxidase (MPO)-catalyzed oxidation of the dibenzodiazepine motif to a electrophilic quinone-diimine <b>15</b>, which reacts irreversibly with GSH (to yield adduct <b>16</b>) and neutrophils.<a onclick="showRef(event, 'ref44 ref45 ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46 ref47 ref48 ref49">(44−49)</a> Covalently modified neutrophils have been detected in <b>14</b>-treated patients, which provides relevance to the in vitro experimental data.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Compounds <b>17</b> and <b>18</b> cannot form the quinone-diimine species because the nitrogen atom is substituted with a sulfur and oxygen atom, respectively.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Structure–Metabolism Relationships for Clozapine (<b>14</b>) versus Quetiapine (<b>17</b>) and Loxapine (<b>18</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A rather dramatic difference in toxicity arising from a subtle structural change is apparent with the DILI-causing nonsteroidal anti-inflammatory drug (NSAID) ibufenac (<b>19</b>) and its structural analog ibuprofen (<b>20</b>), which is one of the safest anti-inflammatory drugs sold in the market (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Although never approved in the U.S., <b>19</b> was recalled from the UK market within 2 years of its approval in 1968.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Circumstantial evidence for IADRs, noted with several carboxylic acid-based NSAIDs, has been linked with their metabolism by uridine glucuronosyl transferases (UGTs) to the corresponding acyl glucuronide conjugates, on the basis of their ability to covalently adduct to plasma proteins (e.g., albumin).<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Covalent modification of plasma proteins by acyl glucuronides (compound <b>21</b> in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) is thought to occur via pathways involving either transacylation or an acyl migration within the β-<i>O</i>-glucuronide unit to an electrophilic α-hydroxyaldehyde intermediate <b>23</b> (obtained from rearrangement of <b>22</b>).<a onclick="showRef(event, 'ref30 ref31 ref32 ref51 ref52 ref53 ref54 ref55 ref56 ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref51 ref52 ref53 ref54 ref55 ref56 ref57 ref58 ref59">(30−32,51−59)</a> Condensation of <b>23</b> with protein amino acid residues (e.g., N terminus lysines) generates the glycated iminium derivative <b>24</b>. The pathway leading to <b>24</b> is reversible; however, an Amadori rearrangement of the imino sugar in <b>24</b> can yield a 1-amino-2-keto derivative <b>25</b> as a stable end-product of the reaction.<a onclick="showRef(event, 'ref31 ref53'); return false;" href="javascript:void(0);" class="ref ref31 ref53">(31,53)</a> Evidence for the formation of <b>23</b> and its subsequent reaction with proteins to yield <b>24</b> was obtained in albumin covalent binding studies with the tolmetin acyl glucuronide conjugate, specifically through the characterization of the stable protein adduct <b>25</b> after chemical (sodium cyanoborohydride) reduction of <b>24</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> More recently, in vitro studies, which addressed the covalent binding of acyl glucuronide metabolites of several NSAIDs to human serum albumin, have demonstrated the existence of stable adducts generated from both the transacylation and glycosylation pathways via detection of intact modified proteins by mass spectrometry.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Corresponding incubations of serum albumin with unconjugated glucuronic acid did not result in protein labeling.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Mechanisms for Plasma Protein Covalent Binding by Acyl Glucuronide Metabolites of Carboxylic Acid-Containing Drugs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From a structure–toxicity relationship perspective, carboxylic acid derivatives with α-carbon substituents (e.g., <b>19</b> versus <b>20</b> and gemfibrozil, which contains a geminal-dimethyl group) or certain benzoic acid derivatives (e.g., NSAIDs from the fenamate class such as mefenamic- and meclofenamic acid) demonstrate significantly reduced rates of acyl migration, which further translates into a reduction in protein covalent binding.<a onclick="showRef(event, 'ref52 ref56 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref52 ref56 ref57 ref58 ref59 ref60">(52,56−60)</a> While acyl glucuronidation is the primary route of clearance of <b>19</b> and <b>20</b> in animals and humans, the presence of the additional α-methyl substituent in <b>20</b> attenuates acyl glucuronide migration (and protein covalent binding) relative to <b>19</b>, which has been used as an explanation for the toxicological differences. In addition to steric hindrance, electronic effects also play a significant role in governing acyl migration rates as evident with the benzoic acid derivatives probenecid (acyl glucuronide <i>t</i><sub>1/2</sub> = 0.27 h) and mefenamic/meclofenemic acid derivatives (acyl glucuronide <i>t</i><sub>1/2</sub> = 16.5–28.1 h), wherein electron-donating groups appear to attenuate the rate of acyl rearrangement (see <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). In an analysis of 21 carboxylic acid-containing drugs spanning a gamut of DILI risk, the cutoff value of acyl glucuronide half-life (<i>t</i><sub>1/2</sub>), which separated safe drugs from those recalled from the market, was estimated to be 3.6 h.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Because acyl glucuronide degradation rates (<i>t</i><sub>1/2</sub> measurements) empirically correlate with toxicity, acyl glucuronide rearrangement studies have been deemed as important for derisking toxicity of carboxylic acid containing drug candidates.</div><div class="NLM_p">However, the potential utility of acyl glucuronide rearrangement rates as a surrogate of protein reactivity and toxicity has been questioned based upon structure-metabolism analysis and clinical covalent binding studies with safe NSAIDs such as <b>20</b> and naproxen.<a onclick="showRef(event, 'ref32 ref61'); return false;" href="javascript:void(0);" class="ref ref32 ref61">(32,61)</a> For example, the acyl glucuronide metabolite of probenecid is considerably unstable in buffer with a half-life lower than the one measured for <b>19</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). However, unlike <b>19</b>, probenecid is not associated with iDILI, despite administration at a high total daily dose of 1000 mg. Likewise, protein adducts derived from covalent reaction with the acyl glucuronide metabolite of <b>20</b> have been detected in human plasma, and moreover, a robust association between the degree of protein covalent binding and the circulating concentrations of the acyl glucuronide metabolite of <b>20</b> has been established.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Furthermore, patients who were resistant to drug-related hypersensitivity caused by the NSAID diclofenac also revealed the presence of plasma albumin adducts involving N-acylations or acyl glucuronide glycations, suggesting that albumin–acyl glucuronide adduct formation is not necessarily a causative factor leading to hypersensitivity with this NSAID.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Additional examples of NSAIDs (e.g., zomepirac and benoxaprofen), wherein the IADRs are likely to be mediated by mechanisms other than the generation of protein-reactive acyl glucuronides, have also been recently discussed.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> For example, the incidences of anaphylaxis and renal toxicity associated with the use of zomepirac have been attributed to the reactivity of its acyl glucuronide metabolite, which is unstable in buffer (<i>t</i><sub>1/2</sub> = 0.5 h) and covalently modifies rat dipeptidyl peptidase IV and bovine brain microtubular protein in vitro.<a onclick="showRef(event, 'ref53 ref60 ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref53 ref60 ref63 ref64 ref65">(53,60,63−65)</a> Evidence implying a mechanism distinct from protein covalent modification was recently demonstrated in rodent studies, wherein treatment of BALB/c mice with zomepirac and tri-<i>o</i>-tolyl phosphate (a nonspecific inhibitor of esterases including glucuronidases) led to considerable elevations in blood urea nitrogen and creatinine levels, which are endogenous biomarkers of renal injury.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> No changes in renal biomarkers (and function) were observed in mice treated with zomepirac alone, implying a potential role for the acyl glucuronide metabolite in renal injury. Consistent with this hypothesis, mice coadministered with zomepirac and the esterase inhibitor also led to considerable increases in the concentration of the acyl glucuronide metabolite in blood, liver, and kidney tissue, which correlated with the increases in blood urea nitrogen and creatinine. Importantly, attenuation of zomepirac-induced renal injury by the antioxidant tempol suggested the involvement of oxidative stress rather than covalent protein modification. Consistent with the oxidative stress hypothesis, elevated levels in the mRNA of several immune-, inflammatory-, and oxidative stress-related genes were also observed kidney tissue from the treated animals. More recently, Iwamura et al.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> also demonstrated that only acyl glucuronide metabolites of toxic NSAIDs induced immune modulators such as interleukin-8 in a human peripheral blood mononuclear cell assay. As a matter of fact, the authors were able to distinguish safe versus toxic drugs by utilizing a relative integrated score of mRNA expression of five immune modulating genes. Collectively, what these observations suggest is that acyl glucuronide rearrangement may be a common feature for several NSAIDs, regardless of safety profile, but it is possible that toxicity arising from acyl glucuronide metabolites can result because of mechanisms other than protein covalent binding, each of which will require detailed investigations as outlined in the work with zomepirac.</div><div class="NLM_p">Adding to the controversy are observations that many carboxylic acid-containing drugs (e.g., diclofenac, bromfenac, pirprofen, etc.) also undergo oxidative bioactivation to reactive metabolites in a CYP-dependent fashion, and in some instances (e.g., diclofenac), the principal clearance mechanism in humans involves oxidative metabolism rather than the conjugation pathway leading to acyl glucuronide metabolites.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> So it is difficult to ascertain which bioactivation pathway(s) can ultimately result in toxicity. Finally, it is important to note that an analogous reaction to protein glycosylation by acyl glucuronides is also evident with glucose.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> In fact, nonenzymatic glycosylation of proteins including albumin is a frequent occurrence and has been claimed to be relevant in the development of certain complications in type 2 diabetes mellitus (T2DM).<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">Although evidence for in vivo toxicity derived from an acyl glucuronide metabolite is scant, a recent guidance document by the United States Food and Drug Administration (see <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm" class="ext-link">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm</a>) denotes acyl glucuronides as toxic metabolites in what appears to be a generalized conclusion for these conjugates. While <i>O</i>-sulfates and <i>O</i>-glucuronides derived from conjugation of aliphatic and aromatic alcohols as well as quaternary <i>N</i><sup>+</sup>-glucuronides are viewed as benign from a human safety standpoint, systemic coverage of acyl glucuronide metabolites (including additional diligence around acyl glucuronide stability/rearrangement) is likely to be warranted under the Metabolites in Safety Testing guidance because of concerns on their reactivity.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Toward this end, a pragmatic approach, which compares circulating concentrations of acyl glucuronide metabolites in human and animals, based on total body burden estimates, has been recently published.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Besides bioactivation via the acyl glucuronide route, carboxylic acid-containing drugs can also undergo metabolism to electrophilic acyl-coenzyme A thioesters (acyl-CoAs) (e.g., compound <b>26</b>), which possess higher reactivity (∼40–70 times greater) than acyl glucuronides toward covalent interactions with hepatic proteins, and can also react with GSH to yield thiol adducts such as <b>27</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).<a onclick="showRef(event, 'ref33 ref34 ref70 ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref70 ref71 ref72 ref73">(33,34,70−73)</a> In recent work, Darnell et al.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> demonstrated that the reactivities of the CoA conjugates of seven radiolabeled NSAIDs including <b>19</b> and <b>20</b> were much higher compared with those of their corresponding acyl glucuronide and oxidative metabolites, as estimated from the degree of covalent binding to human liver microsomal protein. Interestingly, all seven NSAIDs formed acyl glucuronide metabolites in abundant quantities in uridine 5′-diphosphoglucuronic acid (UDPGA)-supplemented human liver microsomes, but none of them demonstrated covalent binding to liver microsomes containing UDPGA. On the basis of these observations, the authors speculated that the previously reported covalent binding data for the seven NSAIDs in human hepatocytes are likely to involve the formation of the electrophilic acyl-CoA thioester metabolites (as opposed to acyl glucuronide conjugates). However, the possibility that the acyl glucuronide metabolites of the seven drugs could covalently adduct specifically to proteins present in hepatocytes but not in liver microsomes remains to be studied. It is noteworthy to point out that the high levels of human liver microsomal covalent binding (∼1000–8600 pmol drug equivalent/mg protein) by hepatotoxic <b>19</b> and nonhepatotoxic <b>20</b> challenge the putative role of these conjugates in toxicity (e.g., DILI), especially when considering that both NSAIDs are high total daily dose drugs (>500 mg).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Electrophilicity of Acyl CoA Thioester (<b>26</b>) Metabolites of Carboxylic Acid Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As such, the metabolic conversion of carboxylic acids to their respective acyl-CoA thioester derivatives is well precedented for in fatty acid catabolism, where conversion of fatty acids to the corresponding acyl-CoA derivatives by acyl-CoA ligases occurs prior to their entry into the mitochondria.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Moreover, acyl-CoA metabolites of several carboxylic acid-containing drugs (including NSAIDs) have been observed in in vitro and in vivo studies, and in many instances, these acyl-CoA derivatives also act as intermediates in conjugation reactions with amino acids.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> In addition to their acylating properties, acyl CoA conjugates can impersonate fatty acid CoA derivatives and potentially interfere with mitochondrial lipid metabolism, resulting in the reduction of mitochondrial ATP production and, in some scenarios, organ failure.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p">A recent case where retrospective mechanistic studies have been used in rationalizing iDILI outcome in chronic animal toxicology studies and in the clinic is illustrated with fasiglifam (TAK-875, <b>28</b>, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>), a selective agonist of the G-protein-coupled receptor 40, which was withdrawn from phase 3 clinical trials for the treatment of T2DM. On the basis of the liver injury findings in rats and dogs after chronic repeat dosing with <b>28</b>, a detailed liver safety monitoring program was inserted in the phase 3 clinical trials.<a onclick="showRef(event, 'ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77">(75−77)</a> Analysis of the safety data in 15 double-blind controlled studies in T2DM patients revealed significant elevations in serum ALT levels (>3× ULN) for 2.7% of <b>28</b>-treated patients compared with 0.5% and 0.8% for placebo and active comparators. Furthermore, the pattern of iDILI with <b>28</b> was hepatocellular, and in most cases, ALT elevations resolved promptly upon discontinuation of treatment. The parent compound <b>28</b>, which is an acetic acid derivative, is primarily metabolized by UGTs to the acyl glucuronide conjugate <b>29</b> in animals and humans (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Consistent with the behavior of acyl glucuronide conjugates of acetic acid analogs, Otieno et al.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> observed that <b>29</b> was subject to rapid acyl migration (<i>t</i><sub>1/2</sub> ∼ 0.5 h) in buffer. Moreover, <b>28</b> was also metabolized to an electrophilic acyl CoA intermediate <b>30</b> in human hepatocytes,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> which reacted with GSH in GSH-supplemented human liver microsomal incubations to yield the thioester conjugate <b>31</b>.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Protein covalent binding observed upon incubating <sup>14</sup>C-<b>28</b> with human hepatocytes lends further credence to the potential involvement of <b>29</b> and/or <b>30</b> in the iDILI observed with <b>28</b>.</div><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Metabolic Bioactivation of the G-Protein-Coupled Receptor 40 agonist Fasiglifam (<b>28</b>), Which Was Withdrawn from Phase 3 Clinical Trials for iDILI</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">While anecdotal and/or controversial to some degree, such retrospective structure–toxicity relationship studies suggest that avoiding structural alerts in drug candidates is a pragmatic starting point toward mitigating IADR risks, which can occur due to the formation of reactive metabolites.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Elimination of Reactive Metabolite Liability in Preclinical Drug Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Reactive Metabolite Trapping Assays</h3><div class="NLM_p last">In the early 2000s, the widespread opinion that reactive metabolites (instead of the parent precursors) are accountable for some of the iDILI associated with withdrawn drugs led to the implementation of screening strategies to inspect the formation of reactive intermediates from new chemical entities, through appropriate in vitro incubations supplemented with nucleophile “trapping agents”. Electrophilic reactive metabolites generated from the process of metabolism cannot be detected due to their instability, and therefore, they need to be captured as stable adducts with nucleophiles that are supplemented in the incubation. The underlying assumption of the “trapping” method was that reactive metabolites trapped with nucleophiles serve as surrogates of protein covalent binding. Liquid chromatography–tandem mass spectrometry-based approaches remain the most important tool for assessing reactive metabolite liabilities (detection of reactive metabolite–nucleophile adducts) in a drug discovery setting. Qualitative (and/or semiquantitative) assessment of oxidative bioactivation by CYP enzymes generally involves incubations of the experimental compounds in human liver microsomes supplemented with NADPH and relevant soft and/or hard nucleophiles such as GSH, semicarbazide, methoxylamine, and potassium cyanide.<a onclick="showRef(event, 'ref81 ref82 ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref81 ref82 ref83 ref84 ref85">(81−85)</a> Liver microsomes can be replaced with other drug-metabolizing systems such as human hepatocytes, human liver cytosol/S-9 fractions, and neutrophils to evaluate bioactivation by non-CYP enzymes such UGTs, monoamine oxidases (MAOs) and MPO. Unlike reactive metabolites generated by oxidative enzymes, acyl glucuronide and/or acyl CoA thioester conjugates are usually detected as stable metabolites. A measure of acyl glucuronide stability (<i>t</i><sub>1/2</sub>) and their ability to undergo acyl migration to yield isomeric conjugates can be used to estimate the reactivity of acyl glucuronide metabolites with proteins. A typical experiment entails the preparation of an authentic standard of the acyl glucuronide and determination of its <i>t</i><sub>1/2</sub> in protein-free aqueous buffer.<a onclick="showRef(event, 'ref55 ref56 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57 ref58 ref59 ref60">(55−60)</a> Acyl glucuronide metabolites generated biochemically in vitro or in vivo have also been used in cases where preparation of the pure synthetic standard is complex. Acyl CoA thioester adduct formation can be studied in primary hepatocytes or in liver microsomes fortified with CoASH, Mg<sup>2+</sup>, and ATP as cofactors.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> While the mass spectrometric detection of CoA adducts (molecular weight of the parent carboxylic acid precursor +749 Da) can be straightforward due to their large molecular weight and prototypic mass spectral fragmentation, CoA conjugates tend to be unstable on occasions and require extra precautionary steps during sample processing.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Protein Covalent Binding Assays</h3><div class="NLM_p last">Availability of radiolabeled (<sup>3</sup>H or <sup>14</sup>C) compounds can also facilitate a quantitative evaluation of the extent of covalent binding either in vitro (e.g., nonextractable radioactivity determination in liver microsomes or hepatocytes) or in tissue or blood/plasma obtained from in vivo animal studies.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Protein covalent binding data (usually denoted in terms of pmol equivalent/mg protein) are indicative of the propensity of an experimental compound to form reactive metabolites under both in vitro and in vivo conditions. Covalent binding data obtained in hepatocytes and in vivo (e.g., toxicology animal species) are more meaningful since the biochemical matrices represent a complete biological system with all relevant metabolic pathways including endogenous detoxication pathways (e.g., the metabolic step involving GSH conjugation to a reactive metabolite). Moreover, studies in human hepatocytes, in principle, provide data in a system that is most relevant to the clinical situation. Direct measurement of covalent binding potential of reactive metabolites to proteins also allows an insight into the fraction of the overall metabolic intrinsic clearance that leads to reactive metabolites as demonstrated previously in our laboratories.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Value of Reactive Metabolite Trapping and/or Protein Covalent Binding Studies in Drug Discovery</h3><div class="NLM_p">When structural alerts are present in a lead chemical series, it is critical to experimentally demonstrate whether they are metabolized to reactive species. In the case of reactive metabolite-positive compounds, structural insights into the reactive species (usually inferred from the mass spectroscopic or NMR characterization of the stable conjugate of the reactive metabolite with appropriate nucleophiles) can be used to chemically modify the structure of reactive metabolite-positive molecules as illustrated with the antiepileptic drug felbamate (<b>32</b>). Within its first year of release, <b>32</b> was associated with several cases of fatal aplastic anemia and DILI.<a onclick="showRef(event, 'ref86 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref86 ref87 ref88">(86−88)</a> Compelling evidence linking the toxicity of <b>32</b> with its metabolism to a reactive metabolite has been presented.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> The bioactivation pathway (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>) involves an initial hydrolysis of one of the pendant carbamoyl groups in <b>32</b> to afford the monocarbamate <b>33</b>, which is oxidized to the corresponding propionic acid derivative (<b>35</b>), the major metabolite of <b>32</b> in humans.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The intermediate carbamoyl-aldehyde species <b>34</b> is very unstable (<i>t</i><sub>1/2</sub> < 30 s, pH 7.4) and freely decomposes to the α,β-unsaturated aldehyde <b>36</b>, which reacts readily with GSH in a nonenzymatic (e.g., pH 7.4 buffer) and enzymatic (glutathione transferases (GSTs)) fashion to yield <b>37</b>.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Unambiguous proof for the manifestation of the bioactivation pathway in vivo has been obtained via the characterization of downstream mercapturic acid metabolites <b>38</b> and <b>39</b> in felbamate-treated patients.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The mechanistic information pertaining to the bioactivation of <b>32</b> to <b>36</b> was utilized in the design of fluorofelbamate (<b>40</b>). Insertion of the fluorine atom on the benzylic position in <b>40</b> prevents the formation of <b>36</b>, and instead, the predominant route of metabolism in human involves oxidative metabolism to the corresponding primary alcohol <b>41</b> and carboxylic acid metabolites <b>42</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Whether the lack of bioactivation would have resulted in a favorable safety profile will remain unknown, as the clinical trials<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> with <b>40</b> appeared to have been terminated (inferred from the lack of published information since 2007).</div><figure id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Mitigating the Bioactivation Liability of the Antiepileptic Agent Felbamate (<b>32</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In practice, if a structural alert (especially the one that is metabolized to a reactive metabolite) can be readily exchanged with an alternative functional motif without a significant sacrifice in the pharmacology and drug disposition characteristics, then it is prudent to do so and thereby abolish the requirement for additional risk mitigation strategies beyond the conventional drug safety studies used to support regulatory filing.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Resolution of Reactive Metabolite Liabilities of Electron-Rich Aromatic Rings</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of published accounts, there appear to be approximately four major groups of reactive species derived from enzymatic bioactivation, which include (a) Michael acceptors such as quinones, quinone-imines, quinone-diimines, quinone-methides, and imine-methides obtained from the two-electron oxidation of electron-rich aromatics such as catechols, hydroxyanilines, dianilines, alkylphenols, and alkylanilines, respectively, (b) epoxides derived from CYP-mediated oxidation of aryl (e.g., phenyl) and heteroaromatic rings, (c) Michael acceptors generated from S-oxidation of sulfur-containing heteroaromatic rings (e.g., thiazole), and (d) cyclic amine ring scission to electrophilic iminium and/or aldehyde intermediates. Case studies demonstrating successful resolution of reactive metabolite issues, which primarily involve removal of the structural alert, modulation of electronic character (e.g., reduction in electron-richness of aromatic/heteroaromatic rings), strategic placement of functional groups to block bioactivation, and introduction of alternate metabolic soft spots, are abundant in the medicinal chemistry literature. Noteworthy examples are highlighted below. With reference to acyl glucuronide and/or acyl CoA thioesters arising from the metabolism of carboxylic acid derivatives, most of the work has been done in a retrospective fashion (to account for unanticipated clinical toxicity). There are no published accounts where necessary diligence was conducted to study reactivity of acyl glucuronide or acyl CoA thioester metabolites in a drug discovery setting, and the issue was addressed via appropriate modifications (e.g., replacement of the carboxylic acid substituent with a bioisostere such as tetrazole).</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Example 1</h3><div class="NLM_p">The immune-mediated toxicity (DILI and agranulocytosis) associated with the clinical use of the antimalarial agent amodiaquine (<b>43</b>) (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>) has been speculated to occur due to the metabolism of <b>43</b> to a quinone-imine species <b>44</b>, as inferred from reactive metabolite trapping studies with GSH and extensive covalent binding to cellular proteins.<a onclick="showRef(event, 'ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97">(95−97)</a> Replacement of the C′-4-phenol substituent in <b>43</b> with a fluorine atom results in <b>45</b> that does not yield an electrophilic quinone-imine.<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> Alternatively, isomerization of the 3′ and 4’ substituents in <b>43</b> generates <b>46</b> and <b>47</b>, which do not form reactive metabolites (judged from the lack of formation of GSH conjugates).<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> It is interesting to note that CYP-mediated oxidative defluorination of <b>45</b> (and <b>46</b>) can generate a 4-hydroxyaniline metabolite (amodiaquine (<b>43</b>) in the case of <b>45</b>), which is primed for metabolic activation to <b>44</b> (see <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> However, this metabolic fate does not appear to occur with <b>45</b> and <b>46</b>. On the basis of its potent antimalarial activity, good oral bioavailability, and an satisfactory safety profile in animals, compound <b>46</b> has been advanced as a candidate for clinical testing.<a onclick="showRef(event, 'ref100 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref100 ref102 ref103">(100,102,103)</a></div><figure id="sch8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0012.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Mitigating the Formation of Electrophilic Quinone-imine with the Antimalarial Drug Amodiaquine (<b>43</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Example 2</h3><div class="NLM_p">In another account, a series of electron-rich 5-aminooxindole-based inhibitors (exemplified by <b>48</b>) of the proline-rich tyrosine kinase 2 (PYK2) underwent CYP-catalyzed oxidation on the 5-aminooxindole motif to a quinone-diimine species <b>49</b>, which was trapped with as GSH adduct <b>50</b> in human liver microsomes (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Reactive metabolite formation with the 5-aminooxindoles was also associated with potent time-dependent inactivation of CYP3A4 enzyme activity in human liver microsomes.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Introduction of electron-deficient aniline ring substituents as five-membered lactam ring replacements led to compounds exemplified by <b>51</b>–<b>54</b> that were devoid of reactive metabolite and CYP3A4 inactivation liabilities while exhibiting selective PYK2 inhibition and metabolic stability, which was similar or greater than the corresponding 5-aminooxindole derivatives.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><figure id="sch9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0013.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Mitigating the Formation of Electrophilic Quinone-diimines with 5-Aminooxindole-Containing PYK2 Inhibitor <b>48</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Example 3</h3><div class="NLM_p">The pyrazinone-based corticotrophin-releasing factor-1 (CRF<sub>1</sub>) receptor antagonist <b>55</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>) was shown to undergo extensive CYP metabolism in a bile duct-cannulated rat pharmacokinetics study, which also resulted in the formation of GSH adducts.<a onclick="showRef(event, 'ref105 ref106 ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref105 ref106 ref107 ref108">(105−108)</a> Approximately, 40% of the drug-related material recovered in rat bile comprised of GSH adducts, which implied that <b>55</b> was bioactivated to reactive metabolites in vivo.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Studies on the bioactivation mechanism in human liver microsomes revealed two distinct pathways involving the oxidation of the chloropyrazinone ring to yield an electrophilic epoxide <b>56</b>, which was trapped as GSH adduct <b>57</b>, and O-dealkylation of the difluoromethylphenoxy group to the phenol <b>58</b>, which was oxidized to the quinone-imine species <b>59</b> (trapped as the GSH conjugate <b>60)</b>. Replacement of the aniline structural alert with a pyridine motif as well as the chlorine atom in the chloropyrazinone ring in <b>55</b> with the more electron-deficient cyano group led to <b>61</b>, which demonstrated a considerable reduction in the formation of reactive metabolites in liver microsomes from rat and human while retaining the pharmacokinetic and pharmacologic (CRF<sub>1</sub> antagonism) benefits of the lead molecule <b>55</b>.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106,107)</a> Moreover, following in vivo administration of <b>61</b> to rats, <5% of total drug-related material recovered in rat bile comprised GSH conjugates.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106,107)</a></div><figure id="sch10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0014.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Structure–Metabolism Studies to Mitigate the Formation of Reactive Metabolites with the Pyrazinone-Based CRF<sub>1</sub> Receptor Antagonist <b>55</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Example 4</h3><div class="NLM_p">During discovery efforts directed toward the identification of potent and selective antagonists of the cannabinoid-1 receptor, it was noted that the lead compound <b>62</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) revealed considerable covalent binding to human liver microsomal protein in a NADPH-dependent manner. A bioactivation pathway involving CYP-mediated epoxidation on the phenoxy ring in <b>62</b> to a reactive arene oxide species was proposed, since compound <b>63</b>, which possessed an electron-deficient trifluoromethylpyridyl ring instead of the phenoxy substituent, was devoid of covalent binding to microsomal proteins.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Compound <b>63</b> (taranabant) has also been studied in phase 3 clinical trials for the treatment of obesity.</div><figure id="fig1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0001.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolism-guided discovery of the cannabinoid-1 receptor inhibitor taranabant (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Resolution of Reactive Metabolite Liabilities of Five-Membered Heteroaromatic Rings</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51306" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51306" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Example 1</h3><div class="NLM_p">Incubation of a acetamidothiazolyl-containing nonpeptidyl thrombopoietin receptor agonist (compound <b>64</b>) in human liver microsomes containing NADPH and GSH furnished a thiol adduct <b>68</b>, obtained through the conjugation of GSH to a 2-aminothiazole (<b>65</b>) metabolite of <b>64</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Mass spectral fragmentation and <sup>1</sup>H NMR analysis on the isolated GSH adduct <b>68</b> indicated that GSH was attached to the thiazole ring on the C-5 position. A likely bioactivation mechanism, which accounts for the formation of <b>68</b> (from <b>65</b>) involves initial N-oxidation of <b>65</b> to a hydroxylamine metabolite <b>66</b>, which upon dehydration would afford an electrophilic species <b>67</b>. The thiazole ring in <b>64</b> and <b>65</b> was latent toward epoxidation by CYP enzymes, which is likely due to the steric hindrance caused by the C-4 aryl substituent. Introduction of a fluorine atom at the thiazole C-5 position or exchanging the thiazole ring with a 1,2,4-thiadiazole substituent led to <b>69</b> or <b>70</b>, respectively, which did led to GSH conjugates in human liver microsomes.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Consistent with the bioactivation differences, in vivo rat safety studies demonstrated considerable elevations in liver enzymes with rats dosed with <b>64</b> but not with <b>69</b>.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Compound <b>69</b> was considered for further preclinical profiling as a potential clinical candidate.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0015.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Mitigating Reactive Metabolite Liability and Preclinical Safety Concerns with Acetamidothiazolyl Nonpeptidyl Thrombopoietin Receptor Agonist <b>64</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Example 2</h3><div class="NLM_p">In contrast with the case study involving <b>64</b>, CYP-catalyzed bioactivation of the 2-aminothiazole-based protein kinase B (AKT) inhibitor (compound <b>71</b>) in human liver microsomes led to multiple GSH adducts obtained from an initial reaction of the sulfur nucleophile to an electrophilic epoxide intermediate <b>72</b> (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Nucleophilic addition of GSH to <b>72</b> affords <b>73</b>, which is converted to <b>74</b> following dehydration. A potential mechanism (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>) for the generation of the rearranged GSH adducts <b>78</b> and <b>79</b> involves an initial ring opening in <b>73</b> to afford the thiourea intermediate <b>75</b>, which undergoes an intramolecular cyclization (with the concomitant loss of H<sub>2</sub>S) to the 2-imidazoline derivative <b>76</b>. An intramolecular nucleophilic addition of the secondary amine nitrogens in <b>77</b> (the tautomer of <b>76</b>) across the carbonyl group, followed by a loss of a water molecule, would yield the final GSH conjugates <b>78</b> and <b>79</b>, respectively. Human liver microsomes that were co-incubated with NADPH, GSH, and <sup>14</sup>C-<b>71</b> led to a dramatic reduction in protein covalent binding, which correlated with the trapping of the electrophilic epoxide metabolite <b>72</b> by GSH, since <b>72</b> represents the rate-limiting step in the bioactivation of <b>71</b> by CYP enzymes. Epoxidation was abolished when the thiazole ring in <b>71</b> was replaced with a 1,2,4-thiadiazole ring (e.g., compounds <b>80</b> and <b>81</b> in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Lack of GSH adduct formation was also observed with compounds such as <b>82</b> and <b>83</b> (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>) where introduction of electron-deficient aromatics in lieu of the oxindole ring led to a reduction in the electron-richness of the aminothiazole-biaryl system.<a onclick="showRef(event, 'ref112 ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref112 ref113 ref114">(112−114)</a> 2-Amino-thiadiazole <b>81</b> and -thiazole <b>83</b> were also found to be active as AKT inhibitors in vitro and in in vivo animal models of cancer.<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113,114)</a></div><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0016.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Eliminating the Formation of Reactive Metabolites Obtained by Thiazole Ring Epoxidation with the AKT Inhibitor <b>69</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Example 3</h3><div class="NLM_p">Phase I clinical trials with the prototype glucokinase activator RO0281675 (<b>84</b>, <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>) were terminated because of a narrow therapeutic index in animal toxicology studies.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Chronic treatment of <b>84</b> in animals led to fatty liver disease, which was attributed to the metabolic ring scission of the 2-aminothiazole substituent to a thiourea metabolite <b>85</b>. The proposal was further validated based on two observations: (a) thiourea <b>85</b> was a major metabolite of <b>84</b> in liver microsomes from animals and human, and (b) the fatty liver syndrome was also observed in a 5-day repeat dose rat toxicology study with the synthetic standard of <b>85</b>. The formation of <b>85</b> was avoided with the pyrazine-based analog <b>86</b> (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>). In vitro metabolism studies on <b>86</b> in liver microsomes also led to the several cyclopentyl ring oxidation products, which were synthesized and found to retain glucokinase activation comparable to <b>86</b>. The cyclopentanone metabolite of <b>86</b> (compound <b>87</b>) was selected as a clinical candidate, since chronic safety studies in rats and dogs did not reveal the hepatic lipidosis findings observed with <b>84</b>. Compound <b>87</b> (piragliatin) is the first glucokinase activator, which has shown efficacy in phase 2 clinical trials in a T2DM patient population.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0017.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Metabolism-Guided Identification of the Glucokinase Activator and Clinical Candidate Piragliatin (<b>87</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Example 4</h3><div class="NLM_p">Recently, Norman et al.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> also reported on the CYP-catalyzed bioactivation of representative members (LY3031207 (<b>88</b>) and LY3023703 (<b>95</b>), <a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>) of the 2-aminoimidazole class of microsomal prostaglandin E synthase-1 enzyme inhibitors for the potential treatment of osteoarthritis pain. Both compounds were suspended from phase I clinical testing due to dose-dependent increases in ALT (5–45× ULN) and DILI-like signals.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Three GSH conjugates were detected in human liver microsomal incubations of <b>88</b> conducted in the presence of NADPH and GSH, which provided indirect information for the participation of reactive metabolites in the clinical DILI.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The bioactivation of <b>88</b> involved CYP-mediated oxidation on the C4–C5 imidazole ring to yield epoxide <b>89</b>, in a manner similar to that noted with 2-aminothiazoles. The formation of a stable acylguanidine metabolite <b>91</b> was consistent with a biotransformation sequence involving hydrolysis of <b>89</b> to the corresponding diol <b>90</b> followed by imidazole ring scission. The detection of GSH conjugates <b>92</b>–<b>94</b> was consistent with the addition of the thiol nucleophile to the epoxide <b>89</b>. Metabolites derived from imidazole ring modification such as <b>91</b> and <b>93</b> were also observed in clinical samples as circulating and/or urinary metabolites, which demonstrated the bioactivation of <b>88</b> in vivo. In the case of <b>95</b>, the detection of the stable acylguanidine metabolite <b>98</b> in microsomal incubations and as a urinary metabolite in clinical samples was also suggestive of CYP-mediated imidazole ring scission via the corresponding epoxide (<b>96</b>) and diol (<b>97</b>) intermediates. A GSH conjugate <b>101</b>, obtained via the direct addition of GSH to <b>95</b>, was also observed in human liver microsomes. A proposed mechanism, which accounted for the formation of <b>101</b>, involves an initial monohydroxylation on the 4-methyl group on the imidazole ring to the primary alcohol <b>99</b>, which loses water to afford the electrophilic imine-methide <b>100</b>, amenable to trapping by GSH. During structure–metabolism relationship studies, it was noted that attachment of electron-withdrawing substituents to the imidazole ring (e.g., compounds <b>102</b> and <b>103</b>) mitigated heterocyclic ring scission and/or GSH conjugate formation.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><figure id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0018.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Mitigating Bioactivation on the 2-Aminoimidazole Ring Present in Inhibitors (<b>88</b> and <b>95</b>) of Microsomal Prostaglandin E Synthase-1</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Resolution of Reactive Metabolite Liabilities of Cyclic Amines</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Example 1</h3><div class="NLM_p">The first example highlights the mutagenicity of a pyrazinyl-piperazine derivative and 5-hydroxytryptamine 2C agonist <b>104</b> (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>) in the bacterial <i>Salmonella</i> Ames assay.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> In the Ames test, <b>104</b> led to significant increases in mutations in strains TA1537 and TA100, which are particularly sensitive to frame-shift and base-pair mutagens. The in vitro mutagenicity of <b>104</b> was only observed when the Ames assay included a metabolic activation arm (Aroclor 1254-induced rat liver S-9 fraction and the CYP cofactor NADPH), which suggested that a metabolite(s) of <b>104</b> was responsible for the mutagenic response. In vitro incubations of calf-thymus DNA with [<sup>14</sup>C]-<b>104</b> revealed dose-dependent covalent binding to DNA, which also required the presence of liver S-9 fraction/NADPH. Collectively, these findings suggested that <b>104</b> was most likely metabolized to a reactive metabolite(s), which covalently modified DNA and caused a mutagenic response in the Ames test. Consistent with this proposal, rat liver S-9/NADPH incubations containing <b>104</b> and nucleophilic trapping agents methoxylamine, GSH, and/or cyanide led to the detection of amine (<b>107</b>), GSH (<b>110</b>), and cyano (<b>113</b>) conjugates of oxidized metabolites of <b>104</b>. The mass spectral fragmentation data of the conjugates were used to decipher the structure of the adducts, which also allowed mechanistic insights into the bioactivation pathways of <b>104</b>. Thus, conjugate <b>107</b> was shown to be a Schiff base, which was generated from the reaction of methoxylamine with an aminoaldehyde metabolite <b>106</b> that represents the tautomer of the initial piperazine ring hydroxylation product <b>105</b>. The formation of the GSH conjugate <b>110</b> was consistent with aromatic ring hydroxylation (on the 3-chlorobenzyl scaffold) to yield <b>108</b> as the initial metabolite. β-Elimination in <b>108</b> resulted in a quinone-methide species <b>109</b> that was trapped as the GSH adduct <b>110</b>. The generation of the cyano adduct <b>113</b> requires an initial oxidation of the terminal piperazine nitrogen to the hydroxylamine metabolite <b>111</b>, which is oxidized further to an electrophilic nitrone <b>112</b> that can be trapped by cyanide anion. Incidentally, both methoxylamine and GSH reduced the mutagenic response of <b>104</b> in the Ames test, which suggested that the nucleophiles effectively scavenged reactive species (<b>106</b> and <b>109</b>) that irreversibly adducted to DNA. On the basis of the information gleaned from these mechanistic studies, medicinal chemistry efforts were initiated toward the design of nongenotoxic 5-HT<sub>2C</sub> agonists such as compound <b>114</b> (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Compound <b>114</b> cannot form a reactive quinone-methide analogous to <b>109</b>, and moreover, <b>114</b> demonstrated a dramatic reduction in piperazine ring opening, presumably due to the presence of the metabolically labile methyl group.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><figure id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0019.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Bioactivation of the 5-Hydroxytryptamine 2C agonist <b>104</b> to Reactive Metabolites, Which Covalently Modify DNA and Cause a Mutagenic Response in the <i>Salmonella</i> Ames Test</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Example 2</h3><div class="NLM_p">Representative members of the arylindenopyrimidine class of selective dual A<sub>2A</sub>/A<sub>1</sub> adenosine receptor antagonists (exemplified by compound <b>115</b>, <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>) also demonstrated a mutagenic response in <i>Salmonella</i> Ames and mouse lymphoma L5178Y assays.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Covalent binding of <b>115</b> to calf-thymus DNA also required the presence of the rat liver S9 fraction and NADPH cofactor. Reduction in covalent binding to DNA in the presence of cyanide and methoxylamine nucleophiles suggested that the mutagenicity occurred via covalent interactions of DNA with a reactive metabolite(s). In rat liver S9 fractions supplemented with NADPH, <b>115</b> was metabolized to multiple reactive species including an iminium ion <b>116</b> (trapped as the cyano conjugate <b>117</b>) and an amino aldehyde <b>118</b> (trapped as the methoxylamine adduct <b>119</b>). Analogs of <b>115</b> (e.g., compounds <b>120</b> and <b>121</b>) were not genotoxic, which reaffirmed the notion that bioactivation was responsible for the mutagenic effects in in vitro assays. It was proposed that <b>115</b> was also likely to be mutagenic in humans since <b>116</b> was also observed as a metabolite in corresponding incubations of <b>115</b> with human liver S9 fractions.</div><figure id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0020.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Metabolic Activation of a Pyrrolidine Substituted Arylindenopyrimidine Derivative <b>115</b> to Reactive Species, Which Covalently Modify DNA in the Ames Test</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Example 3</h3><div class="NLM_p">Doss et al.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> reported a unique metabolic activation mechanism on the 1,3-disubstituted piperazine ring present in the melanocortin receptor agonist MB243 (<b>122</b>), which demonstrated extensive covalent binding (>2000 pmol equivalent/mg of microsomal protein) to rat and human liver microsomes in CYP-dependent fashion. Inclusion of GSH in the microsomal incubations also led to the detection of two sulfur-containing conjugates <b>127</b> and <b>128</b>. These conjugates were also detected as metabolites in bile-duct cannulated rats dosed with <b>122</b>. Characterization of the GSH adduct structures led to a proposed bioactivation pathway involving a six-electron oxidation of the piperazine ring in <b>122</b> to the electrophilic imine-methide <b>123</b>, which can be trapped as GSH adduct <b>124</b> (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>). Hydrolysis of the glutamic acid portion in <b>124</b> results in <b>125</b>, which is converted to the thiazolidine intermediate <b>126</b> via an intramolecular nucleophilic attack of the free amino group on the cysteinyl portion on the thioaminal piperazine ring carbon atom in <b>125</b>. Dehydration in <b>126</b> leads to the cyclized conjugate <b>127</b>, which undergoes hydrolysis on the glycine residue to afford GSH adduct <b>128</b>. On the basis of this mechanistic information, various piperazine analogs with pendant alkyl groups (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>) were prepared and tested for protein covalent binding with radiolabeled versions of the parent compounds.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Several alkylpiperazines <b>129</b>–<b>132</b> retained melanocortin receptor agonist activity and demonstrated ∼10-fold reduction in covalent binding (relative to <b>122</b>).<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> In particular, a bridged isoquinuclidine derivative <b>133</b>, which exhibited considerably less covalent binding (∼26 pmol equivalent/mg of microsomal protein) to rat and human microsomal protein when compared with <b>122</b>, was also orally active as a melanocortin receptor agonist.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><figure id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0021.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Mitigating Bioactivation of a 1,3-Disubstitutedpiperazine Ring in the Melanocortin Receptor Agonist <b>122</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The bioactivation-dependent mutagenic effects of <b>104</b> and <b>115</b> in the <i>Salmonella</i> Ames test appear to be unique, as there are no other published accounts on the formation of DNA-reactive iminium and/or aldehyde intermediates arising from the oxidative bioactivation of cyclic basic amine-containing drugs (or drug candidates). The DNA specificity of the reactive species arising from the bioactivation of <b>104</b> and <b>115</b> may be due to the “flatness” of the chemical structures of the parent precursors, considering that such a trend is observed with several procarcinogenic compounds such as aflatoxin B<sub>1</sub> and polycyclic aromatic hydrocarbons. There are numerous marketed drugs that contain cyclic basic amine motifs in their chemical architectures that are devoid of mutagenicity in the Ames test (and related assays) in the presence of metabolic activation. Likewise, many marketed drugs (particularly kinase inhibitors for the treatment of oncology) that possess cyclic amine substituents are associated with IADRs (e.g., DILI), but there is no evidence to suggest that liver injury arises specifically via α-carbon oxidation of the amine functional groups to reactive metabolites.</div><div class="NLM_p last">From a structure–activity relationship perspective, an overall conclusion from these examples is that introduction of pendant alkyl groups in five- or six-membered cyclic amines likely represents a potential strategy to prevent the formation of reactive metabolites originating from the oxidative bioactivation of the α-carbon nitrogen bond in the cyclic amine motif. While detailed metabolism studies have not been performed in these case studies, it is very likely that alkyl functionalities serve as alternative metabolic soft spots (e.g., methyl group hydroxylation favored over piperazine ring scission).</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Shortcomings of the Structural Alert Concept</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many safe drugs possess structural alerts that do not form reactive intermediates upon metabolism. This is because the formation of reactive species is dependent on the binding mode of the parent precursor in the catalytic active site of the metabolizing enzyme (e.g., CYP) and on the subsequent alignment of the structural alert toward the catalytic center for conversion to a reactive metabolite. There will be several instances where the metabolic transformation will occur at a site that is distinct from the structural alert and will furnish nonreactive products as metabolites. For instance, the 2-aminothiazole alert is a common structural feature in the enolcarboxamide-based NSAIDs exemplified by hepatotoxic sudoxicam (<b>134</b>) and nonhepatotoxic meloxicam (<b>138</b>). Protein covalent binding studies on [<sup>14</sup>C]-<b>134</b> and [<sup>14</sup>C]-<b>138</b> indicate that both NSAIDs covalently adduct to human liver microsomes in a NADPH-dependent fashion.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The bioactivation mechanism for the two NSAIDs is identical and involves CYP-mediated oxidative scission of the thiazole ring to yield a acylthiourea metabolite <b>137</b>. The mechanism of toxicity with substituted thioureas is well studied and thought to involve an S-oxidation step, which results in the formation of sulfenic or sulfinic acid derivatives capable of oxidizing or covalently modifying proteins as well as GSH.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Because the two NSAIDs undergo very slow metabolism in human liver microsomes and human hepatocytes, the intrinsic clearance is very low, and therefore, the extent of protein covalent binding is much lower than that reported for prototypic hepatotoxins (typically >50 pmol bound/mg of protein) that are associated with much higher rates of metabolism. Despite the low metabolic turnover, <b>138</b> (3.6 pmol bound/mg protein) demonstrated ∼2-fold higher covalent binding than <b>134</b> (1.4 pmol bound/mg protein). While co-incubation with GSH led to a decrease in protein covalent binding and a decrease in the formation of <b>137</b> for both NSAIDs, the reduction in covalent binding and metabolic conversion to <b>137</b> was more pronounced for <b>138</b>.</div><div class="NLM_p">Comparison of protein covalent binding data obtained with the two NSAIDs would suggest that <b>138</b> is likely to be more toxic than <b>134</b>. However, several factors are expected to counterbalance these observations. First, in the case of <b>134</b>, the bioactivation pathway leading to <b>137</b> (via the epoxide <b>135</b> and diol <b>136</b> intermediates) also represents its principal metabolic fate in animals and humans (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In contrast, with the exclusive thiazole ring opening in <b>134</b>, the metabolism of <b>138</b> is split between CYP-mediated thiazole ring scission (compound <b>137</b>) and oxidation on the C-5 methyl group (on the thiazole ring) yielding the corresponding alcohol <b>139</b> and carboxylic acid <b>140</b> derivatives as nonreactive metabolites (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>).<a onclick="showRef(event, 'ref35 ref125'); return false;" href="javascript:void(0);" class="ref ref35 ref125">(35,125)</a> As such, the latter biotransformation sequence also constitutes the major metabolic clearance pathway of <b>138</b> in humans, which means that the thiazole ring opening pathway is a minor route of metabolism.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> The existence of parallel detoxication pathways (e.g., methyl group hydroxylation and potential scavenging of reactive species by GSH) and a 3-fold lower total daily dose of <b>138</b> relative to <b>134</b> suggests that the total body burden to the reactive thiourea metabolite is considerably less for <b>138</b> compared with <b>134</b> and is unlikely to surpass the threshold needed for eliciting a toxicological response. Finally, it is interesting to note that the C-5 methyl substituent in <b>138</b> was not strategically introduced to block the bioactivation pathway observed with <b>134</b>. Instead, it was included because the resulting substitution offered superior selectivity toward inhibition of cyclooxygenase-2 (relative to cyclooxygenase-1) by <b>138</b>.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><figure id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0022.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Structure–Metabolism Differences between Hepatotoxic (Sudoxicam (<b>134</b>) and Alpidem (<b>141</b>)) and Nonhepatotoxic (Meloxicam (<b>138</b>) and Zolpidem (<b>145</b>)) in Humans</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A second example is evident with the anxiolytic agents and imidazopyridine analogs alpidem (<b>141</b>) and zolpidem (<b>145</b>) (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>). Compound <b>141</b> was recalled from the market due to severe DILI incidences,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> whereas <b>145</b> does not share the hepatotoxic liabilities of <b>141</b>. Evidence for reactive metabolite involvement has been presented for <b>141</b> in the way of a CYP-mediated oxidation on the chloroimidazopyridine ring to afford an electrophilic arene oxide <b>142</b> that covalently modifies human liver microsomal protein and is also trapped by GSH to yield adducts <b>143</b> and <b>144</b>.<a onclick="showRef(event, 'ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref128 ref129">(128,129)</a> The characterization of mercapturic acid metabolites (related to <b>144</b>) in human excreta serves as confirmation for the operation of the bioactivation pathway in vivo.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> A key structural difference between <b>141</b> and <b>145</b> is the substitution of the two chlorine atoms in <b>141</b> with the metabolically labile methyl substituents in <b>145</b>. Consequently, <b>145</b> is metabolized in humans via oxidative metabolism on the pendant methyl groups to afford the corresponding alcohol and carboxylic acid metabolites. Unlike <b>141</b>, <b>145</b> is not subject to oxidation on the imidazopyridine ring to yield arene oxide <b>146</b>.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The formation of GSH adducts with <b>141</b> is consistent with its ability to deplete GSH in human hepatocyte cultures.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> In contrast, no depletion of GSH pool is observed in human hepatocytes with <b>145</b>, even when incubated at very high concentrations.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">The presence of structural alerts is also evident in the chemical structures of several drugs, which have recently been approved (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). For example, canagliflozin (<b>147</b>) is a sodium glucose co-transporter 2 inhibitor and antidiabetic agent, which contains the thiophene structural alert. In humans, <b>147</b> is principally cleared through metabolism (on the sugar moiety) by UGT enzymes.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Failure to detect thiophene ring metabolites and/or GSH adducts in human liver microsomal incubations with <b>147</b> suggests that the thiophene ring is latent to oxidation by CYP enzymes (unpublished observations). Likewise, rivaroxaban (<b>148</b>), a selective direct factor Xa inhibitor, contains two structural alerts: chlorothiophene and dianilide. Metabolite identification work in human liver microsomes and human hepatocytes as well as human mass balance studies using [<sup>14</sup>C]-<b>148</b> revealed that neither structural alert in <b>148</b> is subject to metabolic activation.<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a> The main route of metabolism involves oxidative modifications on the morpholinone ring system in <b>148</b>.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> It is important to note that the pendant chlorothiophene ring in <b>148</b> is required for pharmacology and cannot be changed.</div><figure id="fig2" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0002.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of safe marketed drugs, which contain structural alerts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Most structural alerts that undergo bioactivation to reactive metabolites are aromatic compounds, including ones that contain a phenyl ring. Bioactivation of the phenyl substituent, which generates hydroquinone, catechol, and the corresponding electrophilic quinone species, is also responsible for the carcinogenicity associated with the organic solvent benzene.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a> It is practically impossible to remove unsubstituted phenyl rings from the collection of available functional groups. If medicinal chemists abstained from the synthesis of phenyl ring-containing compounds because the phenyl ring is considered as a structural alert, humanity would be deprived of countless life-saving drugs. Rather than exclusively focusing on the structural alert itself, Claesson and Minidis have recently provided a more systematic SMARTS approach for a color (red, yellow, or green) classification of clinical/safety data for drugs and indirectly to structural alerts present within these drugs, with detailed searchable information on their bioactivation pathways.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> While reactive metabolites obtained via two-electron oxidations of electron-rich aromatic compounds are generally predictable, certain bioactivation pathways (e.g., bioactivation of <b>32</b>, which lacks a classic structural alert) leading to reactive metabolites are only observed in rare instances and are difficult to generalize. Moreover, as de novo substructures are pursued in drug design, it is likely that unexpected bioactivation pathways will materialize, as was demonstrated with the 2-aminoimidazole (compounds <b>88</b> and <b>95</b> in <a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>) and piperazine (compound <b>122</b> in <a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>) derivatives, which are not typical structural alerts.</div><div class="NLM_p">The categorization of structural alerts is information-based and has led to the deployment of knowledge-derived software (e.g., Derek for Windows), which is utilized to a priori predict the toxicity of a chemical based on its structure.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Predictions from knowledge-based systems, however, can be incorrect sometimes. For example, the 2-aminopyridine and 2-aminopyrimidine functional groups, which are often exploited as aniline replacements in medicinal chemistry, are not forecasted as structural alerts in the Derek program. Consistent with the Derek prediction, the 2-aminopyrimidine scaffold in <b>11</b> is not metabolized to a reactive metabolite, unlike the aniline-containing and reactive metabolite-positive hepatotoxin <b>4</b>. However, there are exceptions to the rule as evident from the two-electron oxidation of the aminopyridine motif (present within an electron-rich structural environment) in the analgesic flupirtine (<b>149</b>) to an electrophilic quinone-diimine intermediate <b>150</b> in human liver microsomes, which is trapped as the GSH adduct <b>151</b> (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>).<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The clinical use of <b>149</b>, which is marketed in Europe as an alternative to NSAIDs and opioids, can lead to transient elevation of ALTs, exacerbation of preexisting liver disease, and in isolated cases, fatal liver failure.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> While the exact cause(s) of iDILI observed with <b>149</b> remains unclear, a recent metabolism study in humans revealed that approximately 8–12% of orally bioavailable dose (100–400 mg) of <b>149</b> was eliminated as mercapturic acid conjugates <b>152</b> and <b>153</b> in urine.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></div><figure id="sch19" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0023.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. In Vivo Bioactivation of the Analgesic and Idiosyncratic Hepatotoxin Flupirtine (<b>149</b>) in Humans</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additionally, the simplistic concept that the lack of a structural alert and/or reactive metabolite formation in an investigational drug candidate will mitigate IADR risks is also not necessarily true. For instance, the first oral thrombin inhibitor ximelagatran (<b>154</b>) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which has been withdrawn from the market due to iDILI, does not possess a known structural alert and is not metabolized to reactive species.<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a></div><figure id="fig3" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0003.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structure of ximelagatran (<b>154</b>), which was withdrawn due to iDILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several marketed drugs (with blockbuster status) contain structural alerts and are bioactivated to reactive metabolites, and yet these drugs are rarely associated with IADRs. A survey of 108 most prescribed drugs in 2009 revealed that 58 (53%) possessed structural alerts with bioactivation data (reactive metabolite formation) available for 24 out of the 58 (41%) cases.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Likewise, out of 15 small molecule drugs, which topped the 2009 list on the basis of sales, 13 contained structural alerts, and in vitro data showcasing bioactivation on the structural alerts to reactive species were presented for 10 out of the 13 drugs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In fact, the percentage of structural alert-containing (e.g., aniline/anilide, thiophene, olefin, and quinone precursors) and/or reactive metabolite-positive compounds in the most prescribed or total sales drug category is generally similar to the one noted for drugs recalled or associated with a BBW. Noteworthy examples are depicted in <a class="ref internalNav" href="#sch20" aria-label="Schemes 20">Schemes 20</a> and <a class="ref internalNav" href="#sch21" aria-label="21">21</a> and even include atorvastatin (<b>155</b>), which was ranked number one in terms of total sales and dispensed prescriptions for 2009. The biotransformation of <b>155</b> in humans, which is principally mediated by CYP3A4, occurs on the acetanilide alert to the pharmacologically active <i>ortho</i>- and <i>para</i>-hydroxyacetanilide metabolites <b>156</b> and <b>157</b>, respectively.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> NADPH-dependent covalent binding of <b>155</b> to human liver microsomes would suggest that the metabolites <b>156</b> and <b>157</b> are metabolized to reactive quinone-imine intermediates by CYP3A4.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The major ADRs noted with <b>155</b> are elevated liver enzymes and rhabdomyolysis, which are related to the primary pharmacology and not due to the formation of reactive intermediates.</div><figure id="sch20" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Marketed Drugs That Are Bioactivated to Reactive Metabolites</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch21" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Illustrative Examples of the Most Prescribed Drugs from 2009, Which Form Reactive Metabolites</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antidepressant duloxetine (<b>158</b>) possesses the thiophene structural alert, which can be metabolized to reactive species via S-oxidation and/or oxidative ring scission of the thiophene ring. Consistent with this hypothesis, GSH conjugates of <b>158</b> have been detected in human liver microsomal incubations.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> However, elucidation of the structures of the GSH adducts (e.g., <b>160</b>) implies that the bioactivation of <b>158</b> exclusively proceeds via the epoxidation on the naphthalene ring to an electrophilic arene oxide intermediate <b>159</b>. Consistent with the in vitro observations, the predominant metabolites of <b>158</b> in humans are also obtained from mono- and dihydroxylations on the naphthyl ring, presumably via the arene oxide <b>159</b>.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p">The P2Y<sub>12</sub> purinoreceptor antagonist clopidogrel (<b>161</b>) also contains a thiophene structural alert, which is metabolized by multiple CYP enzymes to a pharmacologically active reactive sulfenic acid <b>164</b> via the thiolactone (<b>162</b>) and <i>S</i>-oxide (<b>163</b>) intermediates.<a onclick="showRef(event, 'ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref146 ref147">(146,147)</a> Covalent disulfide bond formation between <b>164</b> and a cysteine amino acid residue on the P2Y<sub>12</sub> receptor in platelets yields covalent adduct <b>165</b> and results in the irreversible inhibition of platelet aggregation.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><div class="NLM_p last">The rate-limiting step in the metabolism of the antidepressant paroxetine (<b>166</b>) in humans involves a CYP2D6-catalyzed ring opening of the 1,3-benzodioxole motif to a catechol intermediate <b>167</b>.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Protein covalent binding and the formation of multiple GSH conjugates (e.g., compound <b>169</b>) derived from addition of GSH to electrophilic quinone metabolites (e.g., compound <b>168</b>) (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>) have been demonstrated in incubations of [<sup>3</sup>H]-<b>166</b> in human liver microsomes and human liver S9 fractions.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Likewise, the selective estrogen receptor modulator raloxifene (<b>170</b>) is bioactivated by CYP3A4 on the electron-rich bis-phenol motif to yield reactive quinone species <b>171</b> that is trapped as the GSH conjugate <b>172</b> in human liver microsomes (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>).<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Collectively, these findings imply that the structural alert avoidance concept and/or reactive metabolite screening assays are too rigorous and could potentially terminate the progression of many small molecule therapeutics.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Factors That Mitigate Idiosyncratic Toxicity Risks Posed by Reactive Metabolite-Positive Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Bioactivation versus Detoxication</h3><div class="NLM_p">Reactive metabolite trapping studies, which are typically conducted in human liver microsomes containing NADPH and GSH, are only capable of inspecting oxidative bioactivation by CYP enzymes. In several instances, CYP-dependent metabolism to a reactive metabolite may be observed in human liver microsomes, but in vivo, the parent compound, the reactive metabolite precursor, or the reactive metabolite itself may be efficiently detoxicated through alternative metabolic routes yielding innocuous products. For example, in the case of paroxetine (<b>166</b>), which is rarely associated with IADRs, the catechol metabolite (and quinone reactive metabolite precursor) <b>167</b> is readily detoxicated via O-methylation in humans.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> In fact, the predominant metabolites of <b>166</b> in humans are the corresponding O-methylated catechol isomers, obtained via cytosolic catechol-<i>O</i>-methyl transferase (COMT)-catalyzed methylation of both the hydroxy groups in the catechol metabolite <b>167</b>.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Consistent with this in vivo observation, protein covalent binding observed upon incubation of [<sup>3</sup>H]-<b>166</b> in NADPH-supplemented human liver S-9 fraction is dramatically reduced when <i>S</i>-adenosylmethionine, the required cofactor for COMT, is included in the S-9 incubations.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Likewise, preincubation of [<sup>14</sup>C]-<b>170</b> with UDPGA-fortified human intestinal microsomes followed by addition of the intestinal microsomal incubation mixture to an NADPH-supplemented human liver microsomal incubation significantly reduces the amount of [<sup>14</sup>C]-<b>170</b>, which covalently modifies microsomal protein via the reactive quinone species.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> This finding is consistent with the efficient and extensive glucuronidation of both the phenolic OH groups in <b>170</b> by human intestine-specific UGT 1A10 and 1A8, which restricts the bioactivation of <b>170</b> in the liver.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> It is highly unlikely that <b>166</b> and <b>170</b> would be nominated as clinical candidates if information from in vitro reactive metabolite trapping assay and human liver microsomal covalent binding studies were to be used as standalone predictors of idiosyncratic toxicity risk.</div><div class="NLM_p">As noted earlier with <b>104</b> and <b>115</b>, cyclic tertiary amines can be bioactivated to reactive iminium and/or amino aldehyde intermediates in a CYP-dependent fashion in human liver microsomes. However, the iminium ions can also undergo efficient oxidation by aldehyde oxidase (AO) to the corresponding nonreactive lactam derivatives.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Because AO is a cytosolic enzyme, the detoxication mechanism (following the CYP-mediated bioactivation step to iminium) can only be studied in human hepatocytes and human liver S-9 fractions. Detoxication of iminium species to lactams by AO has been described with xenobiotics such as nicotine (<b>173</b>) and the nigrostratial neurotoxin and Parkinsonian-causing agent <i>N</i>-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<b>174</b>) (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>).<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> Compounds <b>173</b> and <b>174</b> are metabolized by CYP or MAO to stable iminium intermediates nicotine-Δ<sup>1′ (5′)</sup>-iminium (<b>175</b>) and <i>N</i>-methyl-4-phenyl-2,3-dihydropyridinium (<b>178</b>), which can be trapped with cyanide to yield <b>176</b> and <b>179</b>, respectively, in human liver microsomes, liver mitochondria, and/or recombinant MAO incubations.<a onclick="showRef(event, 'ref155 ref157'); return false;" href="javascript:void(0);" class="ref ref155 ref157">(155,157)</a> Iminiums <b>175</b> and <b>178</b> can be efficiently detoxicated in the liver (e.g., in the presence of liver S9 fractions or hepatocytes) to the lactams <b>177</b> and <b>181</b>, respectively. Incidentally, the principal clearance mechanism of <b>173</b> in humans involves oxidative metabolism to the lactam derivative <b>177</b> (cotinine). In the case of <b>174</b>, the intermediate iminium <b>178</b> can undergo further oxidation in the brain to yield the ultimate neurotoxin <i>N</i>-methyl-4-phenylpyridinium <b>180</b> species. Because of the lack of AO activity in the brain, the detoxication pathway involving the conversion of iminium <b>178</b> to lactam <b>181</b> is restricted to the liver.</div><figure id="sch22" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Detoxication of Iminium Ions by Cytosolic AO</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two recent examples, one involving a multikinase inhibitor KW-2449 (<b>182</b>) and the other involving momelotinib (<b>183</b>), a small molecule inhibitor of Janus kinase 1/2 and clinical candidate for the treatment of myeloproliferative neoplasms, also describe a similar phenomenon involving the detoxication of electrophilic iminium species (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>).<a onclick="showRef(event, 'ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref158 ref159">(158,159)</a> In human liver microsomal incubations, the piperazine ring in <b>182</b> is metabolized by MAO-B to an electrophilic iminium ion <b>184</b>, which is trapped as the cyanide adduct <b>185</b>. However, subsequent incubations of <b>182</b> in human liver S-9 or human hepatocytes revealed the almost exclusive conversion of <b>182</b> to the lactam <b>186</b>, the formation of which was dependent on cytosolic AO activity. Consistent with the in vitro finding, lactam <b>186</b> was the principal circulating metabolite of <b>182</b> in humans, with circulating metabolite concentrations ∼10 times higher than those of the parent compound. In the case of <b>183</b>, the morpholine ring is oxidatively metabolized by CYP enzymes in human liver microsomes to the iminium <b>187</b>, which is trapped with cyanide to yield <b>188</b>. An alternative detoxication pathway emerged in subsequent human hepatocyte incubations involving the AO-mediated conversion of <b>187</b> to the corresponding lactam metabolite <b>189</b>, which is pharmacologically active as a Janus kinase 1/2 inhibitor and is observed as a major circulating metabolite in a human mass balance study with [<sup>14</sup>C]-<b>183</b>.</div><div class="NLM_p last">These in vitro/in vivo observations point out to the importance of detailed follow-up studies to access bioactivation (to reactive metabolites) versus detoxication (to stable, innocuous metabolites) in physiologically relevant matrices (e.g., human hepatocytes) to minimize false positives generated in reactive metabolites screens run in human liver microsomes. Moreover, these results also raise the possibility of eliminating human liver microsomes-based reactive metabolite assays altogether and instead focusing on a holistic characterization of all metabolites (including conjugates derived from the covalent adduction of reactive metabolites to GSH) for representative members of a new lead chemical series in human hepatocytes, which contain the full suite of oxidative (bioactivating, CYPs, MAOs, etc.) and conjugating (detoxicating, UGTs, COMT, <i>N</i>-acetyltransferases, glutathione transferases, etc.) enzymes. Of course, to do so, appropriate assay validation (e.g., confirmation of GSH adduct formation for known hepatotoxins such as acetaminophen) will be required in the hepatocyte system. If GSH-based conjugates are detected in primary hepatocytes, then efforts to dial out reactive metabolite liability can be executed using isolated systems (e.g., human liver microsomes for CYP-mediated formation of a reactive metabolite) depending on the enzyme(s) involved in the bioactivation. As such, detailed insights on drug disposition pathways characterized in animal studies and the ones anticipated in humans, contextualized in relation to reactive metabolite data (usually obtained from in vitro assays), should ultimately lead to a pragmatic decision-making process with respect to the selection of a clinical candidate.</div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Total Daily Dose</h3><div class="NLM_p">IADRs were originally thought of as dose-independent, since adverse reactions are not observed in most patients at any dose and the therapeutic dose range is often narrow. Regardless of these nuances, a relationship between dose strength and the occurrence of both intrinsic and idiosyncratic ADRs is usually observed. For instance, the intrinsic DILI associated with acetaminophen has a clear dose-dependent component; the recommended dose for adults is 650–1000 mg every 4–6 h (not to exceed 4 g/day). Toxicity develops at 7.5–10 g a day.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Likewise, treatment of hypertension with the hydrazine-based antihypertensive agent hydralazine is associated with a rare lupus syndrome, the incidence of which is clearly dependent on the dose (e.g., lupus incidences of 5.4% and 10.4% at the total daily doses of 100 and 200 mg).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Circumstantial evidence for the bioactivation of the hydrazine motif in hydralazine to reactive metabolites has been described in a previous publication.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In the recent analysis by Stepan et al.,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> low daily dose drugs (<50 mg) were rarely associated with IADRs discerned with their high daily dose counterparts (>100 mg). Moreover, the majority of the drugs from the top 200 list (based on total prescription/sales), which possessed structural alerts and/or generated reactive metabolites, were low total daily dose drugs, suggesting that a low projected daily dose for an investigational drug candidate may be a key factor in reducing IADR risks, particularly for compounds that generate reactive metabolites.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> While most reactive metabolite-positive drugs appear to follow this simple empirical correlation, fasiglifam (TAK-875, <b>28</b>, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>) is an exception since iDILI was observed at doses of ≤50 mg.</div><div class="NLM_p">The impact of the daily dose on IADR occurrence is shown with three examples (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Olanzapine (<b>190</b>) generates a reactive quinone-diimine metabolite similar to that (quinone-diimine <b>15</b>) demonstrated with clozapine (<b>14</b>) (see <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>); however olanzapine is not associated with a high incidence rate of agranulocytosis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A key difference between the two drugs is their daily dose (<b>14</b> >300 mg/day and <b>190</b> ∼10 mg/day). Likewise, reactive arene oxide intermediates are formed with the tricyclic antidepressants amineptine (<b>191</b>) and tianeptine (<b>192</b>), but only <b>191</b> is associated with DILI, which can be attributed to its higher daily dose (<b>191</b> ∼200 mg and <b>192</b> ∼37.5 mg).<a onclick="showRef(event, 'ref27 ref162'); return false;" href="javascript:void(0);" class="ref ref27 ref162">(27,162)</a> A relationship between DILI and daily dose is also evident with the thiazolidinedione antidiabetic drugs troglitazone (<b>193</b>, withdrawn due to DILI, daily dose of ∼200 mg), pioglitazone (<b>194</b>, not associated with DILI, daily dose of ∼30–45 mg), and rosiglitazone (<b>195</b>, not associated with DILI, daily dose of ∼8 mg), which are bioactivated on their thiazolidinedione ring systems to reactive isocyanate and sulfenic acid species.<a onclick="showRef(event, 'ref27 ref37'); return false;" href="javascript:void(0);" class="ref ref27 ref37">(27,37)</a> Finally, in the case of clopidogrel (<b>161</b>), carboxylesterases are responsible for the hydrolysis of the majority (>70%) of its daily dose (75 mg) to a pharmacologically inactive carboxylic acid derivative, which constitutes 80–85% of circulating metabolites.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Consequently, only a small percentage of <b>161</b> (≤20 mg) is theoretically available for metabolic conversion to the pharmacologically active electrophilic sulfenic acid <b>164</b>. Consistent with this hypothesis, human mass balance studies with radiolabeled <b>161</b> demonstrate that covalent binding to platelets accounts for only 2% of the administered radiolabeled dose (Plavix package insert).</div><figure id="fig4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0004.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Association between total daily dose and IADRs for reactive metabolite-positive drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The association between iDILI and daily dose of oral drugs was also explored using pharmaceutical databases in the United States and Sweden.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> A statistically significant relationship between daily dose and clinical accounts of liver failure (<i>p</i> = 0.009), liver transplantation (<i>p</i> < 0.001), and fatalities caused by iDILI (<i>p</i> = 0.004) was described among U.S. prescription medicines categorized by ≤10 mg/day, 11–49 mg/day, and ≥50 mg/day dose strengths. Likewise, out of ∼600 Swedish DILI cases, the majority (∼77%) were caused by medications administered at doses of ≥50 mg/day, whereas the incidences of liver injury belonging to the ≤10 mg/day and 11–49 mg/day groups were considerably lower at 9% and 14.2%, respectively. An empirical correlation has also been established between iDILI and drugs which are extensively metabolized in the liver.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> For ∼207 most commonly prescribed oral drugs in the United States, 12 drugs with no reported hepatic metabolism had no reports of DILI. In contrast, drugs that underwent extensive metabolism in the liver (>50% hepatic metabolism, <i>n</i> = 149) had considerably higher rate of ALTs at >3× the ULN (35% versus 11%, <i>p</i> = 0.001), liver failure (28% versus 9%, <i>p</i> = 0.004), and fatal DILI (23% versus 4%, <i>p</i> = 0.001). When the relationship between DILI, metabolism and daily dose was studied further, drugs (<i>n</i> = 50) with substantial metabolic clearance in the liver and daily dose of >50 mg were more hepatotoxic than drugs belonging to other groups. Extension of this analysis<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> using orally administered drugs (<i>n</i> = 254) from the U.S. Food and Drug Administration Liver Toxicity Knowledge Base Benchmark Dataset (<a href="https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb" class="extLink">https://www.fda.gov/science-research/bioinformatics-tools/liver-toxicity-knowledge-base-ltkb</a>) revealed that high total daily dose drugs, which were also subject to CYP metabolism, possessed a greater possibility of causing DILI [odds ratio, 3.99; 95% confidence interval, 2.07–7.67; <i>p</i> < 0.0001]. A link between DILI, total daily dose, and lipophilicity was also established recently.<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a> For ∼164 oral drugs approved by the U.S. Food and Drug Administration, the risk of DILI increased significantly (odds ratio, 14.05, <i>p</i> < 0.001) for drugs dosed at ≥100 mg and octanol–water partition coefficient (log <i>P</i>) of ≥3, which has also led the authors to propose a “rule-of-two” (high log <i>P</i> and high total daily dose) as a predictor of DILI potential.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> These empirical correlates are not altogether surprising; drugs that are extensively metabolized in the liver (and in the gastrointestinal tract) are generally lipophilic and require high daily doses to maintain the desired therapeutic concentrations in humans.</div><div class="NLM_p last">As such, a drive toward simultaneous optimization of primary pharmacologic potency and pharmacokinetics properties (e.g., reduction of metabolic intrinsic clearance, which may lead to superior oral absorption and a long elimination half-life in vivo) as a means of decreasing the projected total daily dose is a standard modus operandi in most oral small molecule drug discovery programs. Over the past decade or so, the collective output linking DILI risks as a function of high metabolism and high daily dose suggests that the standard practice of striving toward a low total daily dose (≤50 mg) could potentially circumvent idiosyncratic risks by reducing “body burden” of parent drug molecule and all its metabolites (including reactive ones).</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several marketed drugs (e.g., aniline-based epidermal growth factor receptor tyrosine kinase inhibitors) intended to treat life-threatening ailments such as cancer cause IADRs and carry a BBW label for adverse reactions including iDILI; many such drugs are also bioactivated to reactive metabolites.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> For instance, DILI occurs in one-third of patients treated with a protein kinase inhibitor, with fatalities reported for pazopanib, sunitinib, and regorafenib.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Many such drugs remain prescribed because of a favorable risk–benefit considerations. Additionally, significant efforts in the recent years have been devoted toward the discovery of targeted therapeutic options for rare specialty diseases with a high unmet medical need (e.g., Duchenne’s muscular dystrophy, cystic fibrosis, etc.) as well as on discovering personalized treatments for smaller segments of the overall disease population. Given the average incidence of IADRs of 1 in 10 000 patients, such precision medicines may never be administered to a large enough population to pose a significant population hazard. Furthermore, since patients with rare diseases have no alternative treatment options, they are generally more motivated to accept higher risk in return for the potential for slowing or reversing disease progression. In such a scenario, it may be prudent to pursue development of rare disease drug candidates, which carry a small risk for IADR that cannot be predicted with any degree of certainty.</div><div class="NLM_p last">Over the past decade, considerable progress has been made in addressing the limitations of the structural alert avoidance strategy and further refinement of the process of managing bioactivation issues in drug discovery. As noted above, the ensuing work over the past 10 years has focused on integrating bioactivation risk with other attributes, such as total daily dose and fractional clearance attributed to reactive metabolite formation (bioactivation versus detoxication), which collectively determine the total body burden of reactive metabolites. While the emphasis of this review was on bioactivation as a possible causative factor in drug toxicity, it is worth commenting on the multifaceted nature of IADRs. For instance, iDILI associated with the antidepressant nefazodone (<b>4</b>), which is characterized by centrilobular necrosis, bile duct proliferation, and cholestatic jaundice, has been attributed to metabolism-mediated (generation of reactive quinone metabolites such as <b>6</b> and <b>8</b>) as well as parent-mediated (inhibitory effects on the ATP-dependent transporter bile salt export pump (BSEP) and (c) impairment of mitochondrial function) mechanisms.<a onclick="showRef(event, 'ref39 ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref39 ref170 ref171">(39,170,171)</a> Inhibition of BSEP, which is responsible for the secretion of bile acids into the bile, can lead to the buildup of cytotoxic bile acids in the liver and, subsequently, lead to cholestatic liver injury.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Evidence in support of this hypothesis is available from genetic studies, which have revealed that inherited mutant or polymorphic forms of BSEP are responsible for progressive familial intrahepatic cholestasis and severe liver disease.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Mitochondrial impairment by small molecule drugs (and xenobiotics) is thought to occur via several distinct pathways, including the uncoupling of the electron transport chain during the process of ATP synthesis and inhibition of β-oxidation catabolism of fatty acids.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Similar multifactorial DILI mechanisms have been demonstrated with several other drugs such as the recently withdrawn G protein receptor 40 coupled agonist and carboxylic acid derivative fasiglifam (TAK-875, <b>28</b>).<a onclick="showRef(event, 'ref70 ref174'); return false;" href="javascript:void(0);" class="ref ref70 ref174">(70,174)</a> It is also important to take into consideration the fact that most acidic compounds (and their acyl glucuronide metabolites) will be substrates for hepatic organic anion transporters and can accumulate in the liver to concentrations which align with their ability inhibit hepatobiliary transporters such as BSEP.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Consequently, both metabolism-dependent (e.g., bioactivation) and -independent (e.g., inhibitory effects on hepatobiliary transporters) mechanisms will collectively need to be taken into account (e.g., assignment of an integrated score for each liability as a function of predicted total daily dose) while attempting to mitigate idiosyncratic toxicity potential of new drug candidates as was described in recently published articles on this topic.<a onclick="showRef(event, 'ref175 ref176 ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref175 ref176 ref177 ref178">(175−178)</a></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00917" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amit S. Kalgutkar</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer Worldwide Research, Development and Medical, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9701-756X" title="Orcid link">http://orcid.org/0000-0001-9701-756X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#33525e5a471d58525f5446475852417343555a4956411d505c5e"><span class="__cf_email__" data-cfemail="61000c08154f0a000d0614150a0013211107081b04134f020e0c">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares the following competing financial interest(s): A.S.K. was employed by Pfizer Inc. at the time this manuscript was written.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Amit S. Kalgutkar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=BIO-d7e3190-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Amit S.Kalgutkar</b> is a Research Fellow in the Medicine Design group at Pfizer. He received his Ph.D. degree in Chemistry from Virginia Tech, VA, and carried out postdoctoral research at Vanderbilt University, TN. He has ∼20 years’ experience in drug discovery/development, spanning multiple therapeutic areas with over 15 investigational drug candidates nominated for clinical development. He has published over 160 peer-reviewed papers, reviews and book chapters, and holds several patents. He has served on the editorial board of <i>Chemical Research in Toxicology</i> and is presently an editorial board member for <i>Drug Metabolism and Disposition</i> and <i>Xenobiotica</i>. Besides his current position in Pfizer, he is also an Adjunct Professor at the Department of Biomedical and Pharmaceutical Sciences, School of Pharmacy, University of Rhode Island.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">acyl-CoA</td><td class="NLM_def"><p class="first last">acyl-coenzyme A thioester</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AO</td><td class="NLM_def"><p class="first last">aldehyde oxidase</p></td></tr><tr><td class="NLM_term">BBW</td><td class="NLM_def"><p class="first last">black box warning</p></td></tr><tr><td class="NLM_term">BSEP</td><td class="NLM_def"><p class="first last">bile salt export pump</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol-<i>O</i>-methyl transferase</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DILI</td><td class="NLM_def"><p class="first last">drug-induced liver injury</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">IADR</td><td class="NLM_def"><p class="first last">idiosyncratic adverse drug reaction</p></td></tr><tr><td class="NLM_term">iDILI</td><td class="NLM_def"><p class="first last">idiosyncratic drug-induced liver injury</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MPO</td><td class="NLM_def"><p class="first last">myeloperoxidase</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drug</p></td></tr><tr><td class="NLM_term">PYK2</td><td class="NLM_def"><p class="first last">proline-rich tyrosine kinase</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">T2DM</td><td class="NLM_def"><p class="first last">type 2 diabetes mellitus</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine 5′-diphosphoglucuronic acid</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">uridine glucuronosyl transferases</p></td></tr><tr><td class="NLM_term">ULN</td><td class="NLM_def"><p class="first last">upper limit of normal</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 178 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shenton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">Animal models of idiosyncratic drug reactions</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2004.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.cbi.2004.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15522261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=53-70&author=J.+M.+Shentonauthor=J.+Chenauthor=J.+P.+Uetrecht&title=Animal+models+of+idiosyncratic+drug+reactions&doi=10.1016%2Fj.cbi.2004.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of idiosyncratic drug reactions</span></div><div class="casAuthors">Shenton, Jacintha M.; Chen, Jie; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-70</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug reactions represent a major problem.  In most cases the mechanisms of these reactions are unknown, but circumstantial evidence points to the involvement of reactive metabolites and the characteristics of the reactions suggest involvement of the immune system.  If progress is to be made in dealing with these adverse reactions it is essential that the authors have a better understanding of their mechanisms, and it is hard to imagine testing mechanistic hypotheses without good animal models.  Unfortunately, idiosyncratic reactions are also idiosyncratic in animals so few good models exist.  The best models, in which a rodent develops a clin. syndrome similar to that which occurs in humans, appear to be penicillamine-induced autoimmunity in Brown Norway rats and nevirapine-induced skin rash in rats.  Sulfamethoxazole-induced hypersensitivity in dogs and propylthiouracil-induced autoimmunity in cats are also similar to adverse reactions that occur in people, but they have practical limitations.  Halothane-induced liver toxicity in guinea pigs and amodiaquine-induced bone marrow and liver toxicity in rats represent models in which there is an immune response and mild, reversible toxicity.  It is possible that the development of immune tolerance is what limits the toxicity in these models, and if this is true, interventions that prevent tolerance might lead to good models.  Although the history of developing animal models of idiosyncratic drug reactions is mostly one of failure, such models are essential.  A better understanding of immune tolerance may greatly facilitate the development of better models; transgenic technol. may also provide an important tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBKpDqQqY8_bVg90H21EOLACvtfcHk0liJcztFUEwbeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOntb0%253D&md5=001eb894c559412f2b21acb21f2dca71</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2004.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2004.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DShenton%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DAnimal%2520models%2520of%2520idiosyncratic%2520drug%2520reactions%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2004%26volume%3D150%26spage%3D53%26epage%3D70%26doi%3D10.1016%2Fj.cbi.2004.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwakar, J. A.</span></span>; <span class="NLM_contrib-group">DILIN Network.</span> <span> </span><span class="NLM_article-title">Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2014.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1053%2Fj.gastro.2014.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24681128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2014&pages=96-108&author=R.+J.+Fontanaauthor=P.+H.+Hayashiauthor=J.+Guauthor=K.+R.+Reddyauthor=H.+Barnhartauthor=P.+B.+Watkinsauthor=J.+Serranoauthor=W.+M.+Leeauthor=N.+Chalasaniauthor=A.+Stolzauthor=T.+Davernauthor=J.+A.+Talwakarauthor=DILIN+Network.&title=Idiosyncratic+drug-induced+liver+injury+is+associated+with+substantial+morbidity+and+mortality+within+6+months+from+onset&doi=10.1053%2Fj.gastro.2014.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset</span></div><div class="casAuthors">Fontana, Robert J.; Hayashi, Paul H.; Gu, Jiezhun; Reddy, K. Rajender; Barnhart, Huiman; Watkins, Paul B.; Serrano, Jose; Lee, William M.; Chalasani, Naga; Stolz, Andrew; Davern, Timothy; Talwakar, Jayant A.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-108.e4</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Little is known about the incidence of drug-induced liver injury (DILI) and risk factors for adverse outcomes.  We evaluated short-term outcomes of a large cohort of patients with DILI enrolled in an ongoing multicenter prospective study.  Data were collected from 660 adults with definite, highly likely, or probable DILI.  Regression methods were used to identify risk factors for early liver-related death or liver transplantation and chronic liver injury.Patients' median age was 51.4 years; 59.5% were female and 59.1% required hospitalization.  Within 6 mo of DILI onset, 30 patients received liver transplants (4.5%; 95% confidence interval [CI], 3.0%-6.1%) and 32 died (5%; 95% CI, 3.2%-6.5%); 53% of the deaths were liver related.  Asian race, absence of itching, lung disease, low serum albumin levels, low platelet counts, and high serum levels of alanine aminotransferase and total bilirubin at presentation were independent risk factors for reduced times to liver-related death or liver transplantation (C-statistic = 0.87).  At 6 mo after DILI onset, 18.9% of the 598 evaluable subjects had persistent liver damage.  African-American race, higher serum levels of alk. phosphatase, and prior heart disease or malignancy requiring treatment were independent risk factors for chronic DILI (C-statistic = 0.71).  Nearly 1 in 10 patients die or undergo liver transplantation within 6 mo of DILI onset and nearly 1 in 5 of the remaining patients have evidence of persistent liver injury at 6 mo.  The profile of liver injury at presentation, initial severity, patient's race, and medical comorbidities are important determinants of the likelihood of death/transplantation or persistent liver injury within 6 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoSmPoXLbnOLVg90H21EOLACvtfcHk0lizX4Thapx4KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemurzL&md5=f544165ea7a64be953c6e571db8c8e17</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DBarnhart%26aufirst%3DH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DDavern%26aufirst%3DT.%26aulast%3DTalwakar%26aufirst%3DJ.%2BA.%26aulast%3D%26atitle%3DIdiosyncratic%2520drug-induced%2520liver%2520injury%2520is%2520associated%2520with%2520substantial%2520morbidity%2520and%2520mortality%2520within%25206%2520months%2520from%2520onset%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D147%26spage%3D96%26epage%3D108%26doi%3D10.1053%2Fj.gastro.2014.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">End, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbes, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span> <span> </span><span class="NLM_article-title">Drug-induced liver injury: recent advances in diagnosis and risk assessment</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1164</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2016-313369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1136%2Fgutjnl-2016-313369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28341748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGrt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1154-1164&author=G.+A.+Kullak-Ublickauthor=R.+J.+Andradeauthor=M.+Merzauthor=P.+Endauthor=A.+Benesicauthor=A.+L.+Gerbesauthor=G.+P.+Aithal&title=Drug-induced+liver+injury%3A+recent+advances+in+diagnosis+and+risk+assessment&doi=10.1136%2Fgutjnl-2016-313369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: recent advances in diagnosis and risk assessment</span></div><div class="casAuthors">Kullak-Ublick, Gerd A.; Andrade, Raul J.; Merz, Michael; End, Peter; Benesic, Andreas; Gerbes, Alexander L.; Aithal, Guruprasad P.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1154-1165</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (IDILI) is a rare but potentially severe adverse drug reaction that should be considered in patients who develop lab. criteria for liver injury secondary to the administration of a potentially hepatotoxic drug.  Although currently used liver parameters are sensitive in detecting DILI, they are neither specific nor able to predict the patient's subsequent clin. course.  Genetic risk assessment is useful mainly due to its high neg. predictive value, with several human leukocyte antigen alleles being assocd. with DILI.  New emerging biomarkers which could be useful in assessing DILI include total keratin18 (K18) and caspase-cleaved keratin18 (ccK18), macrophage colony-stimulating factor receptor 1, high mobility group box 1 and microRNA-122.  From the numerous in vitro test systems that are available, monocyte-derived hepatocytes generated from patients with DILI show promise in identifying the DILI-causing agent from among a panel of coprescribed drugs.  Several computer-based algorithms are available that rely on cumulative scores of known risk factors such as the administered dose or potential liabilities such as mitochondrial toxicity, inhibition of the bile salt export pump or the formation of reactive metabolites.  A novel DILI cluster score is being developed which predicts DILI from multiple complimentary cluster and classification models using absorption-distribution-metab.-elimination-related as well as physicochem. properties, diverse substructural descriptors and known structural liabilities.  The provision of more advanced scientific and regulatory guidance for liver safety assessment will depend on validating the new diagnostic markers in the ongoing DILI registries, biobanks and public-private partnerships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg0rCsrcAOVrVg90H21EOLACvtfcHk0lizX4Thapx4KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGrt7nE&md5=6b89c8bd16584d2fefe6905a43bb9a5d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-313369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-313369%26sid%3Dliteratum%253Aachs%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DBenesic%26aufirst%3DA.%26aulast%3DGerbes%26aufirst%3DA.%2BL.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26atitle%3DDrug-induced%2520liver%2520injury%253A%2520recent%2520advances%2520in%2520diagnosis%2520and%2520risk%2520assessment%26jtitle%3DGut%26date%3D2017%26volume%3D66%26spage%3D1154%26epage%3D1164%26doi%3D10.1136%2Fgutjnl-2016-313369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wysowski, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, L.</span></span> <span> </span><span class="NLM_article-title">Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1001/archinte.165.12.1363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1001%2Farchinte.165.12.1363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15983284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2005&pages=1363-1369&author=D.+K.+Wysowskiauthor=L.+Swartz&title=Adverse+drug+event+surveillance+and+drug+withdrawals+in+the+United+States%2C+1969%E2%80%932002%3A+the+importance+of+reporting+suspected+reactions&doi=10.1001%2Farchinte.165.12.1363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions</span></div><div class="casAuthors">Wysowski Diane K; Swartz Lynette</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1363-9</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">BACKGROUND:  The Adverse Event Reporting System is the primary surveillance database used by the Food and Drug Administration for identifying postmarketing drug safety problems.  METHODS:  We analyzed all reports of suspected adverse drug reactions submitted to the Food and Drug Administration from the inception of the Adverse Event Reporting System database in 1969 through December 2002.  We documented drug withdrawals and restricted distribution programs based on safety concerns.  RESULTS:  During the 33-year period from 1969 when adverse drug event reporting was initiated through 2002, about 2.3 million case reports of adverse events for the cumulative number of approximately 6000 marketed drugs were entered in the database.  Most reports were for female patients.  During this period, numerous drug reactions have been identified and added to the product labeling as boxed warnings, warnings, precautions, contraindications, and adverse reactions.  More than 75 drugs/drug products have been removed from the market due to safety problems.  In addition, 11 drugs have special requirements for prescriptions or have restricted distribution programs.  Drugs withdrawn or restricted represent a small proportion (about 1%) of marketed drugs.  CONCLUSIONS:  The Food and Drug Administration's Adverse Event Reporting System is the primary surveillance database used for the identification of safety problems of marketed drugs.  Despite the limitations of underreporting, differential reporting, and uneven quality, submitted reports often allow the identification of serious adverse events that are added to the product labeling information.  In rare instances, additional regulations, up to and including market removal, have been required.  We encourage physicians, pharmacists, other health care professionals, and patients to continue to report serious suspected and known adverse drug reactions to manufacturers and the Food and Drug Administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZo2wh-0te33ELvajU9pjPfW6udTcc2eZaDABxUKEIvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtFCgtg%253D%253D&md5=2bc9a0da05fc6f4cfaee071d354ed04d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Farchinte.165.12.1363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.165.12.1363%26sid%3Dliteratum%253Aachs%26aulast%3DWysowski%26aufirst%3DD.%2BK.%26aulast%3DSwartz%26aufirst%3DL.%26atitle%3DAdverse%2520drug%2520event%2520surveillance%2520and%2520drug%2520withdrawals%2520in%2520the%2520United%2520States%252C%25201969%25E2%2580%25932002%253A%2520the%2520importance%2520of%2520reporting%2520suspected%2520reactions%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2005%26volume%3D165%26spage%3D1363%26epage%3D1369%26doi%3D10.1001%2Farchinte.165.12.1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slattery, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonese, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. C.</span></span> <span> </span><span class="NLM_article-title">Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1001/jama.296.1.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1001%2Fjama.296.1.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16820551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1KmsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2006&pages=87-93&author=P.+B.+Watkinsauthor=N.+Kaplowitzauthor=J.+T.+Slatteryauthor=C.+R.+Coloneseauthor=S.+V.+Colucciauthor=P.+W.+Stewartauthor=S.+C.+Harris&title=Aminotransferase+elevations+in+healthy+adults+receiving+4+grams+of+acetaminophen+daily%3A+a+randomized+controlled+trial&doi=10.1001%2Fjama.296.1.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. A randomized controlled trial</span></div><div class="casAuthors">Watkins, Paul B.; Kaplowitz, Neil; Slattery, John T.; Colonese, Connie R.; Colucci, Salvatore V.; Stewart, Paul W.; Harris, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: During a clin. trial of a novel hydrocodone/acetaminophen combination, a high incidence of serum alanine aminotransferase (ALT) elevations was obsd.  Objective: To characterize the incidence and magnitude of ALT elevations in healthy participants receiving 4 g of acetaminophen daily, either alone or in combination with selected opioids, as compared with participants treated with placebo.  Design, Setting, and Participants: A randomized, single-blind, placebo-controlled, 5-treatment, parallel-group, inpatient, diet-controlled (meals provided), longitudinal study of 145 healthy adults in 2 US inpatient clin. pharmacol. units.  Intervention: Each participant received either placebo (n = 39), 1 of 3 acetaminophen/opioid combinations (n = 80), or acetaminophen alone (n = 26).  Each active treatment included 4 g of acetaminophen daily, the max. recommended daily dosage.  The intended treatment duration was 14 days.  Main Outcomes: Serum liver chemistries and trough acetaminophen concns. measured daily through 8 days, and at 1- or 2-day intervals thereafter.  Results: None of the 39 participants assigned to placebo had a max. ALT of more than 3 times the upper limit of normal.  In contrast, the incidence of max. ALT of more than 3 times the upper limits of normal was 31% to 44% in the 4 treatment groups receiving acetaminophen, including those participants treated with acetaminophen alone.  Compared with placebo, treatment with acetaminophen was assocd. with a markedly higher median max. ALT (ratio of medians, 2.78; 95% confidence interval, 1.47-4.09; P <.001).  Trough acetaminophen concns. did not exceed therapeutic limits in any participant and, after active treatment was discontinued, often decreased to undetectable levels before ALT elevations resolved.  Conclusions: Initiation of recurrent daily intake of 4 g of acetaminophen in healthy adults is assocd. with ALT elevations and concomitant treatment with opioids does not seem to increase this effect.  History of acetaminophen ingestion should be considered in the differential diagnosis of serum aminotransferase elevations, even in the absence of measurable serum acetaminophen concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrek-7Eqb9QjrVg90H21EOLACvtfcHk0lio2J-GRvWqew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1KmsL0%253D&md5=3ced6c5b3b4d44c1072b0f1a6a2935bc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.296.1.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.296.1.87%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DSlattery%26aufirst%3DJ.%2BT.%26aulast%3DColonese%26aufirst%3DC.%2BR.%26aulast%3DColucci%26aufirst%3DS.%2BV.%26aulast%3DStewart%26aufirst%3DP.%2BW.%26aulast%3DHarris%26aufirst%3DS.%2BC.%26atitle%3DAminotransferase%2520elevations%2520in%2520healthy%2520adults%2520receiving%25204%2520grams%2520of%2520acetaminophen%2520daily%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJAMA%26date%3D2006%26volume%3D296%26spage%3D87%26epage%3D93%26doi%3D10.1001%2Fjama.296.1.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostapowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiødt, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCashland, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakil, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crippin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blei, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span> <span> </span><span class="NLM_article-title">U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-137-12-200212170-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.7326%2F0003-4819-137-12-200212170-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12484709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BD38jit1Ogsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2002&pages=947-954&author=G.+Ostapowiczauthor=R.+J.+Fontanaauthor=F.+V.+Schi%C3%B8dtauthor=A.+Larsonauthor=T.+J.+Davernauthor=S.+H.+Hanauthor=T.+M.+McCashlandauthor=A.+O.+Shakilauthor=J.+E.+Hayauthor=L.+Hynanauthor=J.+S.+Crippinauthor=A.+T.+Bleiauthor=G.+Samuelauthor=J.+Reischauthor=W.+M.+Lee&title=U.S.+Acute+Liver+Failure+Study+Group.+Results+of+a+prospective+study+of+acute+liver+failure+at+17+tertiary+care+centers+in+the+United+States&doi=10.7326%2F0003-4819-137-12-200212170-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States</span></div><div class="casAuthors">Ostapowicz George; Fontana Robert J; Schiodt Frank V; Larson Anne; Davern Timothy J; Han Steven H B; McCashland Timothy M; Shakil A Obaid; Hay J Eileen; Hynan Linda; Crippin Jeffrey S; Blei Andres T; Samuel Grace; Reisch Joan; Lee William M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">947-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Because acute liver failure is rare, related data have been sparse.  Studies have suggested that viral hepatitis is the most common underlying cause of this condition.  OBJECTIVE:  To describe the clinical features, presumed causes, and short-term outcomes of acute liver failure.  DESIGN:  Prospective cohort study.  SETTING:  17 tertiary care centers participating in the U.S.  Acute Liver Failure Study Group.  PATIENTS:  308 consecutive patients with acute liver failure, admitted over a 41-month period.  MEASUREMENTS:  Detailed clinical and laboratory data collected during hospitalization, including outcome 3 weeks after study admission.  RESULTS:  73% of patients were women; median age was 38 years.  Acetaminophen overdose was the most common apparent cause of acute liver failure, accounting for 39% of cases.  Idiosyncratic drug reactions were the presumptive cause in 13% of cases, viral hepatitis A and B combined were implicated in 12% of cases, and 17% of cases were of indeterminate cause.  Overall patient survival at 3 weeks was 67%.  Twenty-nine percent of patients had liver transplantation, and 43% survived without transplantation.  Short-term transplant-free survival varied greatly, from 68% for patients with acetaminophen-related liver failure to 25% and 17% for those with other drug reactions and liver failure of indeterminate cause, respectively.  Coma grade at admission appeared to be associated with outcome, but age and symptom duration did not.  CONCLUSIONS:  Acetaminophen overdose and idiosyncratic drug reactions have replaced viral hepatitis as the most frequent apparent causes of acute liver failure.  Apparent cause and coma grade at admission were associated with outcome.  Although transplantation may improve patient survival, it was unavailable or unnecessary for most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6T3w9o9NPtZSWdIdmEou5fW6udTcc2eZt0O2yjw4lYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jit1Ogsw%253D%253D&md5=a21fc41e5462193a5d5a520498182585</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-137-12-200212170-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-137-12-200212170-00007%26sid%3Dliteratum%253Aachs%26aulast%3DOstapowicz%26aufirst%3DG.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DSchi%25C3%25B8dt%26aufirst%3DF.%2BV.%26aulast%3DLarson%26aufirst%3DA.%26aulast%3DDavern%26aufirst%3DT.%2BJ.%26aulast%3DHan%26aufirst%3DS.%2BH.%26aulast%3DMcCashland%26aufirst%3DT.%2BM.%26aulast%3DShakil%26aufirst%3DA.%2BO.%26aulast%3DHay%26aufirst%3DJ.%2BE.%26aulast%3DHynan%26aufirst%3DL.%26aulast%3DCrippin%26aufirst%3DJ.%2BS.%26aulast%3DBlei%26aufirst%3DA.%2BT.%26aulast%3DSamuel%26aufirst%3DG.%26aulast%3DReisch%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26atitle%3DU.S.%2520Acute%2520Liver%2520Failure%2520Study%2520Group.%2520Results%2520of%2520a%2520prospective%2520study%2520of%2520acute%2520liver%2520failure%2520at%252017%2520tertiary%2520care%2520centers%2520in%2520the%2520United%2520States%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2002%26volume%3D137%26spage%3D947%26epage%3D954%26doi%3D10.7326%2F0003-4819-137-12-200212170-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span> <span> </span><span class="NLM_article-title">Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a multicenter, prospective study</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2065</span>– <span class="NLM_lpage">2076</span>, <span class="refDoi"> DOI: 10.1002/hep.23937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.23937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20949552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BC3cbosVylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=2065-2076&author=A.+Reubenauthor=D.+G.+Kochauthor=W.+M.+Lee&title=Acute+Liver+Failure+Study+Group.+Drug-induced+acute+liver+failure%3A+results+of+a+multicenter%2C+prospective+study&doi=10.1002%2Fhep.23937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced acute liver failure: results of a U.S. multicenter, prospective study</span></div><div class="casAuthors">Reuben Adrian; Koch David G; Lee William M</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2065-76</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Acute liver failure (ALF) due to drug-induced liver injury (DILI), though uncommon, is a concern for both clinicians and patients.  The Acute Liver Failure Study Group has prospectively collected cases of all forms of acute liver failure since 1998.  We describe here cases of idiosyncratic DILI ALF enrolled during a 10.5-year period.  Data were collected prospectively, using detailed case report forms, from 1198 subjects enrolled at 23 sites in the United States, all of which had transplant services.  A total of 133 (11.1%) ALF subjects were deemed by expert opinion to have DILI; 81.1% were considered highly likely, 15.0% probable, and 3.8% possible.  Subjects were mostly women (70.7%) and there was overrepresentation of minorities for unclear reasons.  Over 60 individual agents were implicated, the most common were antimicrobials (46%).  Transplant-free (3-week) survival was poor (27.1%), but with highly successful transplantation in 42.1%, overall survival was 66.2%.  Transplant-free survival in DILI ALF is determined by the degree of liver dysfunction, specifically baseline levels of bilirubin, prothrombin time/international normalized ratio, and Model for End-Stage Liver Disease scores.  CONCLUSION:  DILI is an uncommon cause of ALF that evolves slowly, affects a disproportionate number of women and minorities, and shows infrequent spontaneous recovery, but transplantation affords excellent survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHFYOHUFfJ7-kdrW1FkXG-fW6udTcc2ebGg42kl_3j87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbosVylsg%253D%253D&md5=56694fae7b7d926de9a472105bfe4a67</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fhep.23937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23937%26sid%3Dliteratum%253Aachs%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DD.%2BG.%26aulast%3DLee%26aufirst%3DW.%2BM.%26atitle%3DAcute%2520Liver%2520Failure%2520Study%2520Group.%2520Drug-induced%2520acute%2520liver%2520failure%253A%2520results%2520of%2520a%2520multicenter%252C%2520prospective%2520study%26jtitle%3DHepatology%26date%3D2010%26volume%3D52%26spage%3D2065%26epage%3D2076%26doi%3D10.1002%2Fhep.23937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Update on advances in research on idiosyncratic drug-induced liver injury</span>. <i>Allergy, Asthma Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.4168/aair.2016.8.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.4168%2Faair.2016.8.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=26540496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVSlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=3-11&author=S.+H.+Kimauthor=D.+J.+Naisbitt&title=Update+on+advances+in+research+on+idiosyncratic+drug-induced+liver+injury&doi=10.4168%2Faair.2016.8.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Update on advances in research on idiosyncratic drug induced liver injury</span></div><div class="casAuthors">Kim, Seung-Hyun; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Allergy, Asthma & Immunology Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-11</span>CODEN:
                <span class="NLM_cas:coden">AAIRBQ</span>;
        ISSN:<span class="NLM_cas:issn">2092-7355</span>.
    
            (<span class="NLM_cas:orgname">Korean Academy of Asthma, Allergy and Clinical Immunology</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings.  Thus, it is important to identify biomarkers for early prediction to increase our understanding of mechanisms underlying DILI that will ultimately aid in the exploration of novel therapeutic strategies to prevent or manage DILI.  DILI can be subdivided into 'intrinsic' and 'idiosyncratic' categories, although the validity of this classification remains controversial.  Idiosyncratic DILI occurs in a minority of susceptible individuals with a prolonged latency, while intrinsic DILI results from drug- induced direct hepatotoxicity over the course of a few days.  The rare occurrence of idiosyncratic DILI requires multicenter collaborative investigations and phenotype standardization.  Recent progress in research on idiosyncratic DILI is based on key developments in 3 areas: (1) newly developed high-throughput genotyping across the whole genome allowing for the identification of genetic susceptibility markers, (2) new mechanistic concepts on the pathogenesis of DILI revealing a key role of drug-responsive T lymphocytes in the immunol. response, and (3) broad multidisciplinary approaches using different platform "-omics" technologies that have identified novel biomarkers for the prediction of DILI.  An assocn. of a specific human leukocyte antigen (HLA) allele with DILI has been reported for several drugs.  HLA-restricted T-cell immune responses have also been investigated using lymphocytes and T-cell clones isolated from patients.  A microRNA, miR-122, has been discovered as a promising biomarker for the early prediction of DILI.  In this review, we summarize recent advances in research on idiosyncratic DILI with an understanding of the key role of adaptive immune systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosy7gsP5cRU7Vg90H21EOLACvtfcHk0lhO0UlWziOcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVSlu7o%253D&md5=28a6aed0fba78a442c96cdd48af244ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4168%2Faair.2016.8.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4168%252Faair.2016.8.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DUpdate%2520on%2520advances%2520in%2520research%2520on%2520idiosyncratic%2520drug-induced%2520liver%2520injury%26jtitle%3DAllergy%252C%2520Asthma%2520Immunol.%2520Res.%26date%3D2016%26volume%3D8%26spage%3D3%26epage%3D11%26doi%3D10.4168%2Faair.2016.8.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic reaction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=295-314&author=T.+Choauthor=J.+P.+Uetrecht&title=How+reactive+metabolites+induce+an+immune+response+that+sometimes+leads+to+an+idiosyncratic+reaction&doi=10.1021%2Facs.chemrestox.6b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction</span></div><div class="casAuthors">Cho, Tiffany; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-314</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Little is known with certainty about the mechanisms of idiosyncratic drug reactions (IDRs); however, there is substantive evidence that reactive metabolites are involved in most, but not all, IDRs.  In addn., evidence also suggests that most IDRs are immune mediated.  That raises the question of how reactive metabolites induce an immune response that can lead to an IDR.  The dominant hypotheses are the hapten and danger hypotheses.  These are complementary hypotheses: a reactive metabolite can act as a hapten to produce neoantigens, and it can also cause cell damage leading to the release of danger-assocd. mol. pattern mols. that activate antigen presenting cells.  Both are required for an immune response.  In addn., drugs may induce an immune response through inflammasome activation.  The authors have found examples in which the ability to activate inflammasomes differentiated drugs that cause IDRs from similar drugs that do not.  There are other hypotheses that do not involve an immune mechanism such as mitochondrial injury and bile salt export pump (BSEP) inhibition.  With some possible exception, these hypotheses are unlikely to be able to completely explain IDRs.  However, some types of mitochondrial injury or BSEP inhibition could produce danger signals.  The major mechanism that protects individuals from IDRs appears to be immune tolerance.  Consistent with this hypothesis, the authors used checkpoint inhibition to develop the first animal model of idiosyncratic drug-induced liver injury that has the same characteristics as the idiosyncratic injury in humans.  This was accomplished by treating Pd-1-/- mice with anti-CTLA-4 antibodies and amodiaquine.  The combination of the Pd-1-/- mouse and anti-CTLA-4 also unmasks the ability of other drugs such as isoniazid to cause delayed type liver injury.  This model should allow rigorous testing of mechanistic hypotheses that was impossible in the past.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhl49wBgcXLVg90H21EOLACvtfcHk0ljMFOkQVfbfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M&md5=04137ee96f32fea06c39a22eea4e4200</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00357%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DHow%2520reactive%2520metabolites%2520induce%2520an%2520immune%2520response%2520that%2520sometimes%2520leads%2520to%2520an%2520idiosyncratic%2520reaction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26spage%3D295%26epage%3D314%26doi%3D10.1021%2Facs.chemrestox.6b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metushi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span> <span> </span><span class="NLM_article-title">Mechanism of isoniazid-induced hepatotoxicity: then and now</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1030</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1111/bcp.12885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fbcp.12885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=26773235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BC28ngvVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=1030-1036&author=I.+Metushiauthor=J.+Uetrechtauthor=E.+Phillips&title=Mechanism+of+isoniazid-induced+hepatotoxicity%3A+then+and+now&doi=10.1111%2Fbcp.12885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of isoniazid-induced hepatotoxicity: then and now</span></div><div class="casAuthors">Metushi Imir; Uetrecht Jack; Phillips Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1030-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Isoniazid (INH) remains a mainstay for the treatment of tuberculosis despite the fact that it can cause liver failure.  Previous mechanistic hypotheses have classified this type of drug-induced liver injury (DILI) as 'metabolic idiosyncrasy' which was thought not to involve an immune response and was mainly due to the bioactivation of the acetylhydrazine metabolite.  However, more recent studies support an alternative hypothesis, specifically, that INH itself is directly bioactivated to a reactive metabolite, which in some patients leads to an immune response and liver injury.  Furthermore, there appear to be two phenotypes of INH-induced liver injury.  Most cases involve mild liver injury, which resolves with immune tolerance, while other cases appear to have a more severe phenotype that is associated with the production of anti-drug/anti-CYP P450 antibodies and can progress to liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxLs_2BQTg9LesJRIHUP1ofW6udTcc2eY3OsmT0MUH0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngvVyrtg%253D%253D&md5=a3ac61a3e529fb04b6d365fff5391506</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12885%26sid%3Dliteratum%253Aachs%26aulast%3DMetushi%26aufirst%3DI.%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DE.%26atitle%3DMechanism%2520of%2520isoniazid-induced%2520hepatotoxicity%253A%2520then%2520and%2520now%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D81%26spage%3D1030%26epage%3D1036%26doi%3D10.1111%2Fbcp.12885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hankins, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span> <span> </span><span class="NLM_article-title">Clinical isoflurane metabolism by cytochrome P 450 2E1</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1097/00000542-199903000-00019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1097%2F00000542-199903000-00019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10078678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFKhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1999&pages=766-771&author=E.+D.+Kharaschauthor=D.+C.+Hankinsauthor=K.+Cox&title=Clinical+isoflurane+metabolism+by+cytochrome+P+450+2E1&doi=10.1097%2F00000542-199903000-00019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical isoflurane metabolism by cytochrome P450 2E1</span></div><div class="casAuthors">Kharasch, Evan D.; Hankins, Douglas C.; Cox, Kathy</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">766-771</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Some evidence suggests that isoflurane metab. to trifluoroacetic acid and inorg. fluoride by human liver microsomes in vitro is catalyzed by cytochrome P 450 2E1 (CYP2E1).  This investigation tested the hypothesis that P 450 2E1 predominantly catalyzes human isoflurane metab. in vivo.  Disulfiram, which is converted in vivo to a selective inhibitor of P 450 2E1, was used as a metabolic probe for P 450 2E1.  Twenty-two elective surgery patients who provided institutionally-approved written informed consent were randomized to receive disulfiram (500 mg orally, N = 12) or nothing (controls, N = 10) the evening before surgery.  All patients received a std. isoflurane anesthetic (1.5% end-tidal in oxygen) for 8 h.  Urine and plasma trifluoroacetic acid and fluoride concns. were quantitated in samples obtained for 4 days postoperatively.  Patient groups were similar with respect to age, wt., gender, duration of surgery, blood loss, and delivered isoflurane dose, measured by cumulative end-tidal isoflurane concns. (9.7-10.2 MAC-hr).  Postoperative urine excretion of trifluoroacetic acid (days 1-4) and fluoride (days 1-3) was significantly (P < 0.05) diminished in disulfiram-treated patients.  Cumulative 0-96 h excretion of trifluoroacetic acid and fluoride in disulfiram-treated patients was 34 ± 72 and 270 ± 70 μmoles (mean ± SD), resp., compared to 440 ± 360 and 1500 ± 800 μmoles in controls (P < 0.05 for both).  Disulfiram also abolished the rise in plasma metabolite concns.  Disulfiram, a selective inhibitor of human hepatic P 450 2E1, prevented 80-90% of isoflurane metab.  These results suggest that P 450 2E1 is the predominant P 450 isoform responsible for human clin. isoflurane metab. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOiG5F2J-HV7Vg90H21EOLACvtfcHk0liRCcvLLcGJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFKhur4%253D&md5=4b4c448ff90ee438102a0aafdf520d67</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2F00000542-199903000-00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-199903000-00019%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DHankins%26aufirst%3DD.%2BC.%26aulast%3DCox%26aufirst%3DK.%26atitle%3DClinical%2520isoflurane%2520metabolism%2520by%2520cytochrome%2520P%2520450%25202E1%26jtitle%3DAnesthesiology%26date%3D1999%26volume%3D90%26spage%3D766%26epage%3D771%26doi%3D10.1097%2F00000542-199903000-00019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. A.</span></span> <span> </span><span class="NLM_article-title">The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazobenzene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1947</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaH1cXhsVWrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1947&pages=468-480&author=E.+C.+Millerauthor=J.+A.+Miller&title=The+presence+and+significance+of+bound+aminoazo+dyes+in+the+livers+of+rats+fed+p-dimethylaminoazobenzene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazobenzene</span></div><div class="casAuthors">Miller, Elizabeth C.; Miller, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1947</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">468-80</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">cf. C.A. 41, 198h.  The livers (but not liver tumors) of rats fed p-dimethylaminoazobenzene (I) contained aminoazo dyes bound tightly to a cellular constituent, probably protein.  The bound dye (II), and no free aminoazo dye, appeared in a crude liver powder consisting of at least 97% protein + nucleoprotein.  II liberated by alk. hydrolysis was fractionated into p-methylaminoazobenzene (III), p-aminoazobenzene (IV) and an unidentified polar dye.  No II was found in rat tissues in which I did not produce tumors, i.e., small intestine, kidney, spleen, lung, heart, skeletal muscle.  Small amts. of II were found in blood plasma proteins, none in crythrocytes.  The feeding of III (carcinogenic metabolite of I) led to the same II production as did the feeding of I.  Feeding of IV (noncarcinogenic) led to the production of only bound IV and very low levels of an apparently nonmethylated polar bound dye in the liver.  Mice, which develop liver tumors slowly, showed lower liver II levels than rats.  No II was found in the livers of guinea pigs, rabbits, cotton rats, or chickens, species which resist I carcinogenesis.  When I was fed to rats, the II level in the liver reached a max. in 4-6 weeks, and then slowly decreased.  Throughout a I-feeding period of 5 months, the liver II level was increased by a protective diet high in riboflavin.  The role of II in I carcinogenesis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrwHW-N3N6BbVg90H21EOLACvtfcHk0liRCcvLLcGJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaH1cXhsVWrsQ%253D%253D&md5=c81f018b96d098fa2c6a4d877f7e7362</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DE.%2BC.%26aulast%3DMiller%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520presence%2520and%2520significance%2520of%2520bound%2520aminoazo%2520dyes%2520in%2520the%2520livers%2520of%2520rats%2520fed%2520p-dimethylaminoazobenzene%26jtitle%3DCancer%2520Res.%26date%3D1947%26volume%3D7%26spage%3D468%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. A.</span></span> <span> </span><span class="NLM_article-title">The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis. A collaboration with Elizabeth Cavert Miller and our associates</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.3109/03602539808996326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602539808996326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9844805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXotVertrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1998&pages=645-674&author=J.+A.+Miller&title=The+metabolism+of+xenobiotics+to+reactive+electrophiles+in+chemical+carcinogenesis+and+mutagenesis.+A+collaboration+with+Elizabeth+Cavert+Miller+and+our+associates&doi=10.3109%2F03602539808996326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates</span></div><div class="casAuthors">Miller, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">645-674</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review and discussion with 111 refs.  Aminoazo dyes, discovery of the covalent binding of N,N-dimethyl-4-aminoazobenzene to protein and nucleic acids in vivo, discovery of the metab. of aminoazo dyes by hepatic microsomal enzymes, central role of electrophilic xenobiotics in carcinogenesis and mutagenesis, etc., are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8HgUOUGqbS7Vg90H21EOLACvtfcHk0liRCcvLLcGJsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVertrw%253D&md5=f930aaa9697c541a9a17214186f5c12c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3109%2F03602539808996326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602539808996326%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520metabolism%2520of%2520xenobiotics%2520to%2520reactive%2520electrophiles%2520in%2520chemical%2520carcinogenesis%2520and%2520mutagenesis.%2520A%2520collaboration%2520with%2520Elizabeth%2520Cavert%2520Miller%2520and%2520our%2520associates%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1998%26volume%3D30%26spage%3D645%26epage%3D674%26doi%3D10.3109%2F03602539808996326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benigni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossa, C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2536</span>, <span class="refDoi"> DOI: 10.1021/cr100222q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr100222q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=2507-2536&author=R.+Benigniauthor=C.+Bossa&title=Mechanisms+of+chemical+carcinogenicity+and+mutagenicity%3A+a+review+with+implications+for+predictive+toxicology&doi=10.1021%2Fcr100222q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Chemical Carcinogenicity and Mutagenicity: A Review with Implications for Predictive Toxicology</span></div><div class="casAuthors">Benigni, Romualdo; Bossa, Cecilia</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2507-2536</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A review discusses the mechanisms of action of carcinogens and the mutagenicity and carcinogenicity.  It also presents the theor. models on the relationship between chem. structure and the mol. mechanisms of toxic activity; however, this is limited only to those studies that contribute to a better mechanistic understanding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAGOG5oiD49LVg90H21EOLACvtfcHk0ljeTUGPbC_eIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7w%253D&md5=a7806197d387db12fd3f875a8511c3cb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fcr100222q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr100222q%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DBossa%26aufirst%3DC.%26atitle%3DMechanisms%2520of%2520chemical%2520carcinogenicity%2520and%2520mutagenicity%253A%2520a%2520review%2520with%2520implications%2520for%2520predictive%2520toxicology%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D2507%26epage%3D2536%26doi%3D10.1021%2Fcr100222q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>International
Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use. Guidance on Genotoxicity Testing
and Data Interpretation for Pharmaceuticals Intended for Human Use;
S2(R1). <a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf" class="extLink">https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf</a> (November, <span class="NLM_year">2011</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International%0AConference+on+Harmonisation+of+Technical+Requirements+for+Registration%0Aof+Pharmaceuticals+for+Human+Use.+Guidance+on+Genotoxicity+Testing%0Aand+Data+Interpretation+for+Pharmaceuticals+Intended+for+Human+Use%3B%0AS2%28R1%29.+https%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FSafety%2FS2_R1%2FStep4%2FS2R1_Step4.pdf+%28November%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Drug metabolism as a cause of drug toxicity</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4149413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2MXhtV2isw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1973&pages=418-423&author=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Drug+metabolism+as+a+cause+of+drug+toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Drug metabolism as a cause of drug toxicity</span></div><div class="casAuthors">Mitchell, Jerry R.; Jollow, D. J.; Gillette, James R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">418-23</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">A review with 29 refs. on the metab. of drugs in vivo to produce toxic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBJi3P8Ybo7Vg90H21EOLACvtfcHk0ljeTUGPbC_eIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhtV2isw%253D%253D&md5=5697ed4d6a8a15e2234181846dd15909</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DDrug%2520metabolism%2520as%2520a%2520cause%2520of%2520drug%2520toxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1973%26volume%3D1%26spage%3D418%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4746326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVCmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=185-194&author=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=W.+Z.+Potterauthor=D.+C.+Davisauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+I.+Role+of+drug+metabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  I.  Role of drug metabolism</span></div><div class="casAuthors">Mitchell, J. R.; Jollow, D. J.; Potter, W. Z.; Davis, D. C.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-94</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Massive overdoses of acetaminophen (I) [103-90-2] produce an hepatic necrosis in man and such necrosis may be mediated by a toxic metabolite of I.  I concns. in rat and mouse tissues were compared with the severity of liver damage after alteration of the rate of metab. of I.  Phenobarbital [50-06-6] pretreatment stimulated the disappearance of I from tissues but markedly potentiated the hepatic necrosis.  In contrast, piperonyl butoxide [51-03-6] pretreatment inhibited the metab. and disappearance of I from tissues yet dramatically protected against hepatic necrosis.  Cobaltous chloride [7646-79-9], which inhibits synthesis of cytochrome P 450, prevented the hepatic damage.  The data indicate that potent metabolites formed in small quantities are responsible for the I toxicity, and that the toxic metabolite arises from a cytochrome P 450-dependent pathway of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd85kEAGt9arVg90H21EOLACvtfcHk0lgAP3iQFOCEHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVCmsw%253D%253D&md5=45a5734dfc02dfc4b352f09025599d37</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%2520I.%2520Role%2520of%2520drug%2520metabolism%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D185%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4746327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVCmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=195-202&author=D.+J.+Jollowauthor=J.+R.+Mitchellauthor=W.+Z.+Potterauthor=D.+C.+Davisauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+II.+Role+of+covalent+binding+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  II.  Role of covalent binding in vivo</span></div><div class="casAuthors">Jollow, D. J.; Mitchell, J. R.; Potter, W. Z.; Davis, D. C.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-202</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Doses of tritiated acetaminophen (I) [103-90-2] (300-750 mg/kg) that cause necrosis in mice resulted in large amts. of radiolabeled material covalently bound to mouse liver protein in vivo.  Both covalent binding and hepatic necrosis were dose dependent, and the peak level of binding preceded the development of recognizable necrosis by at least 1-2 hr.  Pretreatment of mice with phenobarbital [50-06-6], piperonyl butoxide [51-03-6], or cobaltous chloride [7646-79-9], which changed the rate of metab. of 3H-I and altered the severity of hepatic necrosis, similarly affected the extent of hepatic binding of radiolabeled metabolite.  Furthermore, the degree of binding in individual mice was always directly proportional to the severity of hepatic necrosis regardless of the biol. variation among animals.  Apparently, I-induced hepatic necrosis is caused by the covalent binding of a chem. reactive metabolite to vital hepatic macromols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoSDW2K-BYj7Vg90H21EOLACvtfcHk0lgAP3iQFOCEHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVCmsA%253D%253D&md5=fbf3c4b0e660e7fdd41591e63c72b696</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%2520II.%2520Role%2520of%2520covalent%2520binding%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D195%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4147720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=203-210&author=W.+Z.+Potterauthor=D.+C.+Davisauthor=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+3.+Cytochrome+P-450-mediated+covalent+binding+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  III.  Cytochrome P 450-mediated covalent binding in vitro</span></div><div class="casAuthors">Potter, W. Z.; Davis, D. C.; Mitchell, J. R.; Jollow, D. J.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">203-10</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The covalent binding of acetaminophen (I) [103-90-2] to rat and mouse hepatic microsomal protein was linear with time and with protein concn.  NADPH and O were necessary for the binding while carbon monoxide or cobaltous chloride pretreatment inhibited it, demonstrating that a cytochrome P 450 [9035-51-2]-dependent, mixed function oxidase [9035-73-8] mediated the binding.  The extent of in vitro binding correlated with treatments that alter hepatic necrosis and in vivo binding, indicating that in vitro binding was a valid index of I-induced hepatotoxicity.  Analogous studies with 2-acetylaminofluorene [53-96-3] showed that its binding to microsomal protein also was dependent on cytochrome P 450.  Since the toxicity of 2-acetylaminofluorene results from its conversion to an N-hydroxy deriv., the hepatotoxic metabolite of I may be an N-hydroxy deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxRuUZA6b7FbVg90H21EOLACvtfcHk0lgTiNSB0-gNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVehsg%253D%253D&md5=0e7dab9c264d1b753e7afe2caefbedcd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%25203.%2520Cytochrome%2520P-450-mediated%2520covalent%2520binding%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D203%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4746329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXislQ%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=211-217&author=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=W.+Z.+Potterauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+IV.+Protective+role+of+glutathione"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  IV.  Protective role of glutathione</span></div><div class="casAuthors">Mitchell, J. R.; Jollow, D. J.; Potter, W. Z.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">211-17</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Pretreatment of mice with diethyl maleate, which depletes hepatic glutathione [70-18-8], potentiated acetaminophen (I) [103-90-2]-induced hepatic necrosis, whereas pretreatment with cysteine, a glutathione precursor, prevented hepatic damage.  Administration of I caused a dose-dependent depletion of hepatic glutathione.  Glutathione depletion by I was enhanced by treatments that potentiate the hepatic necrosis and covalent binding produced by the toxic metabolite of I.  Conversely, glutathione depletion was inhibited by treatments that protect against these toxic effects.  Moreover, covalent binding of this metabolite to hepatic macromols. did not occur until the availability of glutathione was exhausted through conjugation with the metabolite.  Similarly, alteration of glutathione availability by pretreatment with diethyl maleate or cysteine, resp., increased or decreased covalent binding of the toxic metabolite.  Apparently, glutathione protects tissues against electrophilic attack by drug metabolites and other alkylating agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5c4UbpA9FA7Vg90H21EOLACvtfcHk0lgTiNSB0-gNbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXislQ%253D&md5=a73871b7fd81aa793a35337576a2c43a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%2520IV.%2520Protective%2520role%2520of%2520glutathione%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D211%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span> <span> </span><span class="NLM_article-title">N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1073/pnas.81.5.1327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1073%2Fpnas.81.5.1327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6424115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL2cXhs1Olurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1984&pages=1327-1331&author=D.+C.+Dahlinauthor=G.+T.+Miwaauthor=A.+Y.+Luauthor=S.+D.+Nelson&title=N-acetyl-p-benzoquinone+imine%3A+a+cytochrome+P-450-mediated+oxidation+product+of+acetaminophen&doi=10.1073%2Fpnas.81.5.1327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">N-Acetyl-p-benzoquinone imine:  a cytochrome P-450-mediated oxidation product of acetaminophen</span></div><div class="casAuthors">Dahlin, David C.; Miwa, Gerald T.; Lu, Anthony Y. H.; Nelson, Sidney D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1327-31</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Direct detection of N-acetyl-p-benzoquinone imine (NAPQI)  [50700-49-7] formed as an oxidn. product of acetaminophen  [103-90-2] by cytochrome P-450  [9035-51-2] and cumene hydroperoxide is presented.  Indirect evidence for NAPQI formation from acetaminophen by cytochrome P-450, NADPH  [53-57-6], and NADPH-cytochrome P-450 reductase  [9039-06-9] is presented.  Evidence is provided for the rapid redn. of NAPQI back to acetaminophen by NADPH and NADPH-cytochrome P-450 reductase such that steady-state levels of NAPQI were below its detection limits of 6.7 × 10-8 M.  In mouse liver microsomal incubations, radiolabeled analogs of both NAPQI and acetaminophen bound covalently to microsomal protein with the loss of ∼20% of the acetyl group as acetamide  [60-35-5].  The binding in each case was decreased by glutathione  [70-18-8] with concomitant formation of 3-S-glutathionylacetaminophen  [64889-81-2].  The binding also was decreased by L-ascorbic acid, NADPH, and NADH  [58-68-4] with redn. of NAPQI to acetaminophen.  Results of partitioning expts. indicate that NAPQI is a major metabolite of acetaminophen, a considerable fraction of which is rapidly reduced back to acetaminophen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX3_U_K2KCf7Vg90H21EOLACvtfcHk0lhZWNJAFvRWlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhs1Olurg%253D&md5=73f702bec27640961cce65b3153b3e4f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.81.5.1327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.81.5.1327%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DD.%2BC.%26aulast%3DMiwa%26aufirst%3DG.%2BT.%26aulast%3DLu%26aufirst%3DA.%2BY.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DN-acetyl-p-benzoquinone%2520imine%253A%2520a%2520cytochrome%2520P-450-mediated%2520oxidation%2520product%2520of%2520acetaminophen%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1984%26volume%3D81%26spage%3D1327%26epage%3D1331%26doi%3D10.1073%2Fpnas.81.5.1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Schwartz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyon, S.</span></span> <span> </span><span class="NLM_article-title">Intravenous acetylcysteine for the treatment of acetaminophen overdose</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1517/14656566.2011.537261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1517%2F14656566.2011.537261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=21126198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFKqurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=119-130&author=W.+Klein-Schwartzauthor=S.+Doyon&title=Intravenous+acetylcysteine+for+the+treatment+of+acetaminophen+overdose&doi=10.1517%2F14656566.2011.537261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Intravenous acetylcysteine for the treatment of acetaminophen overdose</span></div><div class="casAuthors">Klein-Schwartz, Wendy; Doyon, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Acetaminophen is a leading cause of overdose-related hepatotoxicity.  Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen.  Areas covered in this review: The article evaluates evidence regarding i.v. acetylcysteine's effectiveness in patients with acute overdoses who receive treatment within 10 h or > 10 h, patients with chronic supratherapeutic ingestions, and those with acetaminophen-induced fulminant hepatic failure.  I.v. and oral acetylcysteine are compared.  What the reader will gain: A one-size-fits-all approach towards acetylcysteine therapy provides suboptimal care in some patients.  High-risk patients are identified.  Specific discontinuation criteria are presented.  Take home message: The std. i.v. regimen will effectively treat most early-presenting uncomplicated overdoses.  Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concns. may be persistently elevated at the end of the infusion or in late presenters.  More studies are needed to evaluate the optimal i.v. dosage regimen and the role of oral acetylcysteine in these high-risk patients.  Treatment decisions may be aided by consultation with a poison center and/or clin. toxicologist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtbb9lG-qQCLVg90H21EOLACvtfcHk0lhZWNJAFvRWlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFKqurjI&md5=588091f5bdf86d90ee296840c7aeeb2c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14656566.2011.537261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2011.537261%26sid%3Dliteratum%253Aachs%26aulast%3DKlein-Schwartz%26aufirst%3DW.%26aulast%3DDoyon%26aufirst%3DS.%26atitle%3DIntravenous%2520acetylcysteine%2520for%2520the%2520treatment%2520of%2520acetaminophen%2520overdose%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2011%26volume%3D12%26spage%3D119%26epage%3D130%26doi%3D10.1517%2F14656566.2011.537261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span> <span> </span><span class="NLM_article-title">Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2099</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(74)90092-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0024-3205%2874%2990092-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4847802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2MXhtVKgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1974&pages=2099-2109&author=D.+C.+Davisauthor=W.+Z.+Potterauthor=D.+J.+Jollowauthor=J.+R.+Mitchell&title=Species+differences+in+hepatic+glutathione+depletion%2C+covalent+binding+and+hepatic+necrosis+after+acetaminophen&doi=10.1016%2F0024-3205%2874%2990092-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Species differences in hepatic glutathione depletion, covalent binding, and hepatic necrosis after acetaminophen</span></div><div class="casAuthors">Davis, Donald C.; Potter, William Z.; Jollow, David J.; Mitchell, Jerry R.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2099-109</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">The severity of hepatic injury in 5 mammals after acetaminophen (I) [103-90-2] (150-1500 mg/kg, i.p.) administration correlated with the extent of covalent binding of I by liver microsomes and with the rate of hepatic glutathione [70-18-8] depletion in vivo.  I (300 mg/kg) depleted glutathione ∼80% in hamsters and mice, which were extremely susceptible to I-induced hepatotoxicity, and only 30% in guinea pigs and 10% in rats, which were less susceptible.  Hepatic microsomal enzymes may convert I to a toxic arylating agent which is detoxified by conjugation with glutathione until glutathione availability is exceeded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq41RvgdIp1ZbVg90H21EOLACvtfcHk0liGUNNzK8Udbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhtVKgsr4%253D&md5=4e650884f843517aab2386997e1d0547</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2874%2990092-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252874%252990092-7%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26atitle%3DSpecies%2520differences%2520in%2520hepatic%2520glutathione%2520depletion%252C%2520covalent%2520binding%2520and%2520hepatic%2520necrosis%2520after%2520acetaminophen%26jtitle%3DLife%2520Sci.%26date%3D1974%26volume%3D14%26spage%3D2099%26epage%3D2109%26doi%3D10.1016%2F0024-3205%2874%2990092-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of the hepatotoxicity caused by acetaminophen</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1040482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1055%2Fs-2008-1040482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=2281334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK3M7is1Ghuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=267-278&author=S.+D.+Nelson&title=Molecular+mechanisms+of+the+hepatotoxicity+caused+by+acetaminophen&doi=10.1055%2Fs-2008-1040482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of the hepatotoxicity caused by acetaminophen</span></div><div class="casAuthors">Nelson S D</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in liver disease</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-78</span>
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8S4fz-S7CaIIRAdBLKY41fW6udTcc2eaZ8hDC1yo_R7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7is1Ghuw%253D%253D&md5=9e4982d996288af3db4f1894acd7683c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1040482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1040482%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DMolecular%2520mechanisms%2520of%2520the%2520hepatotoxicity%2520caused%2520by%2520acetaminophen%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D1990%26volume%3D10%26spage%3D267%26epage%3D278%26doi%3D10.1055%2Fs-2008-1040482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation and drug toxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1021/jm00349a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00349a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL38XktVSjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1982&pages=753-765&author=S.+D.+Nelson&title=Metabolic+activation+and+drug+toxicity&doi=10.1021%2Fjm00349a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation and drug toxicity</span></div><div class="casAuthors">Nelson, Sidney D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">753-65</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A review with 128 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzUsG75cxLYLVg90H21EOLACvtfcHk0liGUNNzK8Udbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktVSjsL8%253D&md5=89c759fff948a83bb8edebef1c8cdbad</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00349a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00349a001%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DMetabolic%2520activation%2520and%2520drug%2520toxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1982%26volume%3D25%26spage%3D753%26epage%3D765%26doi%3D10.1021%2Fjm00349a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, S. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0lhwY-OUtJj7nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lhwY-OUtJj7nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span>; <span class="NLM_string-name">Dalvie, D.</span>; <span class="NLM_string-name">Obach, R. S.</span>; <span class="NLM_string-name">Smith, D. A.</span></span> <span> </span><span class="NLM_article-title">Pathways of Reactive Metabolite Formation with Toxicophores/Structural Alerts</span>. In  <i>Reactive Drug Metabolites</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannhold, R.</span>, <span class="NLM_string-name">Kubinyi, H.</span>, <span class="NLM_string-name">Folkers, G.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinhheim, Germany</span>, <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">55</span>; pp  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">130</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2F9783527655748.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=93-130&author=A.+S.+Kalgutkar&author=D.+Dalvie&author=R.+S.+Obach&author=D.+A.+Smithauthor=R.+Mannhold&author=H.+Kubinyi&author=G.+Folkers&title=Reactive+Drug+Metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F9783527655748.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527655748.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DPathways%2520of%2520Reactive%2520Metabolite%2520Formation%2520with%2520Toxicophores%252FStructural%2520Alerts%26btitle%3DReactive%2520Drug%2520Metabolites%26aulast%3DMannhold%26aufirst%3DR.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2012%26volume%3D55%26spage%3D93%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolleddula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worboys, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span> <span> </span><span class="NLM_article-title">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3109/03602532.2014.924962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602532.2014.924962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24909234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=379-419&author=J.+Bolleddulaauthor=K.+DeMentauthor=J.+P.+Driscollauthor=P.+Worboysauthor=P.+J.+Brassilauthor=D.+L.+Bourdet&title=Biotransformation+and+bioactivation+reactions+of+alicyclic+amines+in+drug+molecules&doi=10.3109%2F03602532.2014.924962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span></div><div class="casAuthors">Bolleddula, Jayaprakasam; DeMent, Kevin; Driscoll, James P.; Worboys, Philip; Brassil, Patrick J.; Bourdet, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-419</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aliph. nitrogen heterocycles such as piperazine, piperidine, pyrrolidine, morpholine, aziridine, azetidine, and azepane are well known building blocks in drug design and important core structures in approved drug therapies.  These core units have been targets for metabolic attack by P450s and other drug metabolizing enzymes such as aldehyde oxidase and monoamine oxidase (MAOs).  The electron rich nitrogen and/or α-carbons are often major sites of metab. of alicyclic amines.  The most common biotransformations include N-oxidn., N-conjugation, oxidative N-dealkylation, ring oxidn., and ring opening.  In some instances, the metabolic pathways generate electrophilic reactive intermediates and cause bioactivation.  However, potential bioactivation related adverse events can be attenuated by structural modifications.  Hence it is important to understand the biotransformation pathways to design stable drug candidates that are devoid of metabolic liabilities early in the discovery stage.  The current review provides a comprehensive summary of biotransformation and bioactivation pathways of aliph. nitrogen contg. heterocycles and strategies to mitigate metabolic liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgryPqDMy3f7Vg90H21EOLACvtfcHk0lh0ffvYK9TGIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO&md5=f20339b5306805f531cbd22f0640e8b6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3109%2F03602532.2014.924962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2014.924962%26sid%3Dliteratum%253Aachs%26aulast%3DBolleddula%26aufirst%3DJ.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DDriscoll%26aufirst%3DJ.%2BP.%26aulast%3DWorboys%26aufirst%3DP.%26aulast%3DBrassil%26aufirst%3DP.%2BJ.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26atitle%3DBiotransformation%2520and%2520bioactivation%2520reactions%2520of%2520alicyclic%2520amines%2520in%2520drug%2520molecules%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2014%26volume%3D46%26spage%3D379%26epage%3D419%26doi%3D10.3109%2F03602532.2014.924962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn-Langguth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutschler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E. T.</span></span> <span> </span><span class="NLM_article-title">Predictability of the covalent binding of acidic drugs in man</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(93)90279-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0024-3205%2893%2990279-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8390596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=141-146&author=L.+Z.+Benetauthor=H.+Spahn-Langguthauthor=S.+Iwakawaauthor=C.+Vollandauthor=T.+Mizumaauthor=S.+Mayerauthor=E.+Mutschlerauthor=E.+T.+Lin&title=Predictability+of+the+covalent+binding+of+acidic+drugs+in+man&doi=10.1016%2F0024-3205%2893%2990279-C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of the covalent binding of acidic drugs in man</span></div><div class="casAuthors">Benet, Leslie Z.; Spahn-Langguth, Hildegard; Iwakawa, Seigo; Volland, Christine; Mizuma, Takashi; Mayer, Sascha; Mutschler, Ernst; Lin, Emil T.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">PL141-PL146</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">Although metab. via glucuronide conjugation has generally been considered a detoxification route for carboxylic acids, the newly discovered chem. reactivity of these conjugates, leading to covalent binding with proteins, is consistent with the toxicity obsd. for drugs contg. the carboxylic acid moiety.  Here the authors report that degrdn. rates (intramol. rearrangement and hydrolysis) for 9 drug glucuronide metabolites show an excellent correlation (r2 = 0.995) with the extents of drug covalent binding to albumin in vitro.  Furthermore, this binding capacity is predictable based on chem. structure of the acid and depends on the degree of substitution at the carbon alpha to the carboxylic acid.  The in vivo covalent binding in humans for these drugs is also predictable (r2 = 0.873) when the extent of adduct formation is cor. for the measured plasma glucuronide concns.  These results suggest that the structure of a carboxylic acid drug may predict the degree to which the corresponding acyl glucuronides will form covalent adducts that probably/possibly lead to toxicity.  This information could be a useful adjunct in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroJx0DCGigdrVg90H21EOLACvtfcHk0lh0ffvYK9TGIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFWltb8%253D&md5=150fa0fdee47150d1a9a280ec40f63b0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2893%2990279-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252893%252990279-C%26sid%3Dliteratum%253Aachs%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DSpahn-Langguth%26aufirst%3DH.%26aulast%3DIwakawa%26aufirst%3DS.%26aulast%3DVolland%26aufirst%3DC.%26aulast%3DMizuma%26aufirst%3DT.%26aulast%3DMayer%26aufirst%3DS.%26aulast%3DMutschler%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DE.%2BT.%26atitle%3DPredictability%2520of%2520the%2520covalent%2520binding%2520of%2520acidic%2520drugs%2520in%2520man%26jtitle%3DLife%2520Sci.%26date%3D1993%26volume%3D53%26spage%3D141%26epage%3D146%26doi%3D10.1016%2F0024-3205%2893%2990279-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojingwa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonagh, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">3797</span>– <span class="NLM_lpage">3801</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.9.3797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1073%2Fpnas.90.9.3797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8483897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3sXktF2ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=3797-3801&author=A.+Dingauthor=J.+C.+Ojingwaauthor=A.+F.+McDonaghauthor=A.+L.+Burlingameauthor=L.+Z.+Benet&title=Evidence+for+covalent+binding+of+acyl+glucuronides+to+serum+albumin+via+an+imine+mechanism+as+revealed+by+tandem+mass+spectrometry&doi=10.1073%2Fpnas.90.9.3797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry</span></div><div class="casAuthors">Ding, Andreas; Ojingwa, Joseph C.; McDonagh, Antony F.; Burlingame, Alma L.; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3797-801</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Acyl glucuronide metabolites of bilirubin and many drugs can react with serum albumin in vivo to form covalent adducts.  Such adducts may be responsible for some toxic effects of carboxylic nonsteroidal antiinflammatory agents.  The mechanism of formation of the adducts and their chem. structures are unknown.  This paper describes the use of tandem mass spectrometry to locate binding sites and elucidate the binding mechanism involved in the formation of covalent adducts from tolmetin glucuronide and albumin in vitro.  Human serum albumin and excess tolmetin glucuronide were coincubated in the presence of sodium cyanoborohydride to trap imine intermediates.  The total protein product was reduced, carboxymethylated, and digested with trypsin.  Six tolmetin-contg. peptides (indicated by absorbance at 313 nm) were isolated by high-pressure liq. chromatog. and analyzed by liq. secondary-ion mass spectrometry and collision-induced dissocn., using a four-sector tandem mass spectrometer.  All six peptides contained tolmetin linked covalently via a glucuronic acid to protein lysine groups.  Major attachment sites on the protein were Lys-195, -199, and -525; minor sites were identified as Lys-137, -351, and -541.  These results show unambiguously that the glucuronic acid moiety of acyl glucuronides can be retained within the structure when these reactive metabolites bind covalently to proteins, and they suggest that acyl migration followed by Schiff base (imine) formation is a credible mechanism for the generation of covalent adducts in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr93nwF0tc3k7Vg90H21EOLACvtfcHk0liIXfK0WltL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktF2ru7c%253D&md5=00930c76bcd00535b590b8b4e14dfa27</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.9.3797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.9.3797%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DA.%26aulast%3DOjingwa%26aufirst%3DJ.%2BC.%26aulast%3DMcDonagh%26aufirst%3DA.%2BF.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvidence%2520for%2520covalent%2520binding%2520of%2520acyl%2520glucuronides%2520to%2520serum%2520albumin%2520via%2520an%2520imine%2520mechanism%2520as%2520revealed%2520by%2520tandem%2520mass%2520spectrometry%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D3797%26epage%3D3801%26doi%3D10.1073%2Fpnas.90.9.3797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Acyl glucuronides: The good, the bad and the ugly</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1002/bdd.720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fbdd.720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20830700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=367-395&author=S.+L.+Reganauthor=J.+L.+Maggsauthor=T.+G.+Hammondauthor=C.+Lambertauthor=D.+P.+Williamsauthor=B.+K.+Park&title=Acyl+glucuronides%3A+The+good%2C+the+bad+and+the+ugly&doi=10.1002%2Fbdd.720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl glucuronides: the good, the bad and the ugly</span></div><div class="casAuthors">Regan, Sophie L.; Maggs, James L.; Hammond, Thomas G.; Lambert, Craig; Williams, Dominic P.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">367-395</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid drugs in mammals.  The physiol. consequences of this biotransformation have been investigated incompletely but include effects on drug metab., protein binding, distribution and clearance that impact upon pharmacol. and toxicol. outcomes.  In marked contrast, the exceptional but widely disparate chem. reactivity of acyl glucuronides has attracted far greater attention.  Specifically, the complex transacylation and glycation reactions with proteins have provoked much inconclusive debate over the safety of drugs metabolised to acyl glucuronides.  It has been hypothesised that these covalent modifications could initiate idiosyncratic adverse drug reactions.  However, despite a large body of in vitro data on the reactions of acyl glucuronides with protein, evidence for adduct formation from acyl glucuronides in vivo is limited and potentially ambiguous.  The causal connection of protein adduction to adverse drug reactions remains uncertain.  This review has assessed the intrinsic reactivity, metabolic stability and pharmacokinetic properties of acyl glucuronides in the context of physiol., pharmacol. and toxicol. perspectives.  Although numerous expts. have characterised the reactions of acyl glucuronides with proteins, these might be attenuated substantially in vivo by rapid clearance of the conjugates.  Consequently, to delineate a relationship between acyl glucuronide formation and toxicol. phenomena, detailed pharmacokinetic anal. of systemic exposure to the acyl glucuronide should be undertaken adjacent to detg. protein adduct concns. in vivo.  Further investigation is required to ascertain whether acyl glucuronide clearance is sufficient to prevent covalent modification of endogenous proteins and consequentially a potential immunol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ1hIcbM_oZ7Vg90H21EOLACvtfcHk0liIXfK0WltL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L&md5=8c45d4dbb68c12bd128af1dba7a08c16</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fbdd.720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.720%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DAcyl%2520glucuronides%253A%2520The%2520good%252C%2520the%2520bad%2520and%2520the%2520ugly%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2010%26volume%3D31%26spage%3D367%26epage%3D395%26doi%3D10.1002%2Fbdd.720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidenius, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skonberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. H.</span></span> <span> </span><span class="NLM_article-title">In vitro reactivity of carboxylic acid-CoA thioesters with glutathione</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/tx034127o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034127o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFGkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=75-81&author=U.+Sideniusauthor=C.+Skonbergauthor=J.+Olsenauthor=S.+H.+Hansen&title=In+vitro+reactivity+of+carboxylic+acid-CoA+thioesters+with+glutathione&doi=10.1021%2Ftx034127o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Reactivity of Carboxylic Acid-CoA Thioesters with Glutathione</span></div><div class="casAuthors">Sidenius, Ulrik; Skonberg, Christian; Olsen, Jorgen; Hansen, Steen Honore</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The chem. reactivity of acyl-CoA thioesters toward nucleophiles has been demonstrated in several recent studies.  Thus, intracellularly formed acyl-CoAs of xenobiotic carboxylic acids may react covalently with endogenous proteins and potentially lead to adverse effects.  The purpose of this study was to investigate whether a correlation could be found between the structure of acyl-CoA thioesters and their reactivities toward the tripeptide, glutathione (γ-Glu-Cys-Gly).  The acyl-CoA thioesters of eight carboxylic acids (ibuprofen, clofibric acid, indomethacin, fenbufen, tolmetin, salicylic acid, 2-phenoxypropionic acid, and (4-chloro-2-methyl-phenoxy)acetic acid (MCPA)) were synthesized, and each acyl-CoA (0.5 mM) was incubated with glutathione (5.0 mM) in 0.1 M potassium phosphate (pH 7.4, 37°).  All of the acyl-CoAs reacted with glutathione to form the resp. acyl-S-glutathione products, with MCPA-CoA having the highest rate of conjugate formation (120 μM/min) and ibuprofen-CoA having the lowest (1.0 μM/min).  The relative reactivities of the acyl-CoAs were dependent on the substitution at the carbon atom α to the acyl carbon and on the presence of an oxygen atom in a position β to the acyl carbon and were as follows: phenoxyacetic acid > o-hydroxybenzoic acid ∼ phenoxypropionic acid > arylacetic acid derivs. > 2-methyl-2-phenoxypropionic acid ∼ 2-phenylpropionic acid.  For each acyl-CoA thioester, the overall hydrolysis rate was detd. as the time-dependent formation of parent compd.  A linear trend was obsd. when comparing the reactivities of the acyl-CoAs with glutathione with the corresponding overall hydrolysis rates.  Thus, the most reactive compd. (MCPA-CoA) was also the compd. with the highest rate of hydrolysis and the least reactive compds. (ibuprofen-CoA, clofibryl-CoA) were also the compds. least susceptible to hydrolysis.  The possibility of drug toxicity is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob0S3Ko-tAgLVg90H21EOLACvtfcHk0lhxidz4KmV0hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFGkt7c%253D&md5=87cc30ffb83882674fbf75a03850e31e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx034127o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034127o%26sid%3Dliteratum%253Aachs%26aulast%3DSidenius%26aufirst%3DU.%26aulast%3DSkonberg%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vitro%2520reactivity%2520of%2520carboxylic%2520acid-CoA%2520thioesters%2520with%2520glutathione%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D75%26epage%3D81%26doi%3D10.1021%2Ftx034127o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skonberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, M. P.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of carboxylic acids</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1517/17425255.4.4.425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1517%2F17425255.4.4.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18433345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=425-438&author=C.+Skonbergauthor=J.+Olsenauthor=K.+G.+Madsenauthor=S.+H.+Hansenauthor=M.+P.+Grillo&title=Metabolic+activation+of+carboxylic+acids&doi=10.1517%2F17425255.4.4.425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of carboxylic acids</span></div><div class="casAuthors">Skonberg, Christian; Olsen, Jorgen; Madsen, Kim Grimstrup; Hansen, Steen Honore; Grillo, Mark P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-438</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Carboxylic acids constitute a large and heterogeneous class of both endogenous and xenobiotic compds.  A no. of carboxylic acid drugs have been assocd. with adverse reactions, linked to the metabolic activation of the carboxylic acid moiety of the compds., i.e., formation of acyl-glucuronides and acyl-CoA thioesters.  Objective: The objective is to give an overview of the current knowledge on metabolic activation of carboxylic acids and how such metabolites may play a role in adverse reactions and toxicity.  Methods: Literature concerning the formation and disposition of acyl glucuronides and acyl-CoA thioesters was searched.  Also included were papers on the chem. reactivity of acyl glutathione-thioesters, and literature concerning possible links between metabolic activation of carboxylic acids and reported cellular and clin. effects.  Results/conclusion: This review demonstrates that metabolites of carboxylic acid drugs must be considered chem. reactive, and that the current knowledge about metabolic activation of this compd. class can be a good starting-point for further studies on the consequences of chem. reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdB7y_4L2TirVg90H21EOLACvtfcHk0lhxidz4KmV0hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D&md5=fec1dbee0f4e4bf93c95ba2441b48004</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1517%2F17425255.4.4.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.4.4.425%26sid%3Dliteratum%253Aachs%26aulast%3DSkonberg%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%2BG.%26aulast%3DHansen%26aufirst%3DS.%2BH.%26aulast%3DGrillo%26aufirst%3DM.%2BP.%26atitle%3DMetabolic%2520activation%2520of%2520carboxylic%2520acids%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2008%26volume%3D4%26spage%3D425%26epage%3D438%26doi%3D10.1517%2F17425255.4.4.425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1890</span>– <span class="NLM_lpage">1899</span>, <span class="refDoi"> DOI: 10.1021/tx800185b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800185b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1890-1899&author=R.+S.+Obachauthor=A.+S.+Kalgutkarauthor=T.+F.+Ryderauthor=G.+S.+Walker&title=In+vitro+metabolism+and+covalent+binding+of+enol-carboxamide+derivatives+and+anti-inflammatory+agents+sudoxicam+and+meloxicam%3A+insights+into+the+hepatotoxicity+of+sudoxicam&doi=10.1021%2Ftx800185b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Metabolism and Covalent Binding of Enol-Carboxamide Derivatives and Anti-Inflammatory Agents Sudoxicam and Meloxicam: Insights into the Hepatotoxicity of Sudoxicam</span></div><div class="casAuthors">Obach, R. Scott; Kalgutkar, Amit S.; Ryder, Tim F.; Walker, Gregory S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1890-1899</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sudoxicam and meloxicam are nonsteroidal anti-inflammatory drugs (NSAIDs) from the enol-carboxamide class.  While the only structural difference between the two NSAIDs is the presence of a Me group on the C5-position of the 2-carboxamidothiazole motif in meloxicam, a marked difference in their toxicol. profile in humans has been discerned.  In clin. trials, sudoxicam was assocd. with several cases of severe hepatotoxicity that led to its discontinuation, while meloxicam has been in the market for over a decade and is devoid of hepatotoxicity.  In an attempt to understand the biochem. basis for the differences in safety profile, an in vitro investigation of the metabolic pathways and covalent binding of the two NSAIDs was conducted in NADPH-supplemented human liver microsomes.  Both compds. demonstrated NADPH-dependent covalent binding to human liver microsomes; however, the extent of binding of [14C]-meloxicam was ∼2-fold greater than that of [14C]-sudoxicam.  While inclusion of glutathione (GSH) in microsomal incubations resulted in a decrease in covalent binding for both NSAIDs, the redn. in binding was more pronounced for meloxicam.  Metabolite identification studies on [14C]-sudoxicam in NADPH-supplemented human liver microsomes indicated that the primary route of metab. involved a P 450-mediated thiazole ring scission to the corresponding acylthiourea metabolite (S3), a well-established pro-toxin.  The mechanism of formation of S3 presumably proceeds via (a) epoxidn. of the C4-C5-thiazole ring double bond, (b) epoxide hydrolysis to the corresponding thiazole-4,5-dihydrodiol deriv., which was obsd. as a stable metabolite (S2), (c) ring opening of the thiazole-4,5-dihydrodiol to an 2-oxoethylidene thiourea intermediate, and (d) hydrolysis of the imine bond within this intermediate to yield S3.  In the case of meloxicam, the corresponding acylthiourea metabolite M3 was also obsd., but to a lesser extent; the main route of meloxicam metab. involved hydroxylation of the 5'-Me group, a finding that is consistent with the known metabolic fate of this NSAID.  Inclusion of GSH led to a decrease in the formation of M3 with the concomitant formation of an unusual two-electron redn. product (metabolite M7).  The formation of M7 is proposed to arise via redn. of the imine bond in 2-oxopropylidene thiourea, an intermediate in the thiazole ring scission pathway in meloxicam.  In conclusion, the results of our anal. suggest that if the covalent binding of the two NSAIDs is important to the overall hepatotoxicity risk, the differences in metab. (differential preponderance of formation of the acylthiourea relative to total metab.), differential effects of GSH on covalent binding, and finally differences in daily doses of the two NSAIDs may serve as a plausible explanation for the marked differences in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41ErheTuDvLVg90H21EOLACvtfcHk0lhZ0UoVSljkdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFSls7o%253D&md5=af142bb2df6107277dcbbb82b0907c21</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Ftx800185b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800185b%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DRyder%26aufirst%3DT.%2BF.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26atitle%3DIn%2520vitro%2520metabolism%2520and%2520covalent%2520binding%2520of%2520enol-carboxamide%2520derivatives%2520and%2520anti-inflammatory%2520agents%2520sudoxicam%2520and%2520meloxicam%253A%2520insights%2520into%2520the%2520hepatotoxicity%2520of%2520sudoxicam%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D1890%26epage%3D1899%26doi%3D10.1021%2Ftx800185b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassahun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1021/tx000180q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx000180q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=62-70&author=K.+Kassahunauthor=P.+G.+Pearsonauthor=W.+Tangauthor=I.+McIntoshauthor=K.+Leungauthor=C.+Elmoreauthor=D.+Deanauthor=R.+Wangauthor=G.+Dossauthor=T.+A.+Baillie&title=Studies+on+the+metabolism+of+troglitazone+to+reactive+intermediates+in+vitro+and+in+vivo.+Evidence+for+novel+biotransformation+pathways+involving+quinone+methide+formation+and+thiazolidinedione+ring+scission&doi=10.1021%2Ftx000180q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission</span></div><div class="casAuthors">Kassahun, Kelem; Pearson, Paul G.; Tang, Wei; McIntosh, Ian; Leung, Kwan; Elmore, Charles; Dean, Dennis; Wang, Regina; Doss, George; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-70</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been assocd. with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market.  While the mechanism of this toxicity remains unknown, it is possible that chem. reactive metabolites of the drug play a causative role.  In an effort to address this possibility, this study was undertaken to det. whether troglitazone undergoes metab. in human liver microsomal prepns. to electrophilic intermediates.  Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P 450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS anal.  In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic std. prepd. by synthesis.  The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidn. of the substituted chromane ring system to a reactive o-quinone methide deriv., while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic α-ketoisocyanate and sulfenic acid intermediates.  When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo.  The finding that metab. of the TZD ring of troglitazone was catalyzed selectively by P 450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes.  The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob7YBc5ZoVmbVg90H21EOLACvtfcHk0lhZ0UoVSljkdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosVKjtA%253D%253D&md5=cd7dd61cf7f367a40dc9c5f09757aad7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx000180q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx000180q%26sid%3Dliteratum%253Aachs%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DMcIntosh%26aufirst%3DI.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DElmore%26aufirst%3DC.%26aulast%3DDean%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DDoss%26aufirst%3DG.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DStudies%2520on%2520the%2520metabolism%2520of%2520troglitazone%2520to%2520reactive%2520intermediates%2520in%2520vitro%2520and%2520in%2520vivo.%2520Evidence%2520for%2520novel%2520biotransformation%2520pathways%2520involving%2520quinone%2520methide%2520formation%2520and%2520thiazolidinedione%2520ring%2520scission%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D62%26epage%3D70%26doi%3D10.1021%2Ftx000180q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montavon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahler, A.</span></span> <span> </span><span class="NLM_article-title">Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1106</span>– <span class="NLM_lpage">1116</span>, <span class="refDoi"> DOI: 10.1021/tx050353h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050353h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2ktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=1106-1116&author=R.+Alvarez-Sanchezauthor=F.+Montavonauthor=T.+Hartungauthor=A.+Pahler&title=Thiazolidinedione+bioactivation%3A+a+comparison+of+the+bioactivation+potentials+of+troglitazone%2C+rosiglitazone%2C+and+pioglitazone+using+stable+isotope-labeled+analogues+and+liquid+chromatography+tandem+mass+spectrometry&doi=10.1021%2Ftx050353h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazolidinedione Bioactivation: A Comparison of the Bioactivation Potentials of Troglitazone, Rosiglitazone, and Pioglitazone Using Stable Isotope-Labeled Analogues and Liquid Chromatography Tandem Mass Spectrometry</span></div><div class="casAuthors">Alvarez-Sanchez, Ruben; Montavon, Francois; Hartung, Thomas; Paehler, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1106-1116</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Troglitazone, a thiazolidinedione (TZD) type insulin sensitizer for the treatment of diabetes, was withdrawn from the U.S. Market after several fatal cases of hepatotoxicity.  Although the mechanism(s) of these idiosyncratic adverse reactions are not completely understood, circumstantial evidence suggests at least a partial contribution of reactive metabolite formation.  Despite isolated case reports of hepatotoxicity, the other TZD derivs. pioglitazone and rosiglitazone are comparatively safe.  Herein, the authors report on the bioactivation potential of these drugs and their TZD ring isotope-labeled 2-15N-3,4,5-13C3 analogs in rat and human liver microsomes supplemented with glutathione (GSH).  Screening for GSH adducts as surrogate markers for reactive intermediate formation was performed by liq. chromatog. tandem mass spectrometry.  Chem. characterization of the GSH conjugates was conducted by acquisition of their resp. product ion spectra and the comparison between unlabeled and stable isotope-labeled TZD derivs.  The data suggest that all drugs undergo bioactivation processes via a common metabolic activation on the TZD ring, yielding disulfide type GSH conjugates as evidenced by the loss of labeled positions in the TZD moiety.  Addnl. bioactivation processes leading to GSH adducts not involving TZD ring scission were evident for troglitazone.  In human liver microsomes at low substrate concns., only troglitazone yielded a predominant GSH adduct not involving TZD ring scission.  This property may contribute, together with other factors such as the relatively high dose administered as well as its potential to induce hepatic cholestasis and oxidative stress, to the hepatotoxicity of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpuWvWcmTx1rVg90H21EOLACvtfcHk0lhkGlcjtvH4AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2ktrY%253D&md5=f97dbc03b974a05f3c8d2da703ecc274</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Ftx050353h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050353h%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DMontavon%26aufirst%3DF.%26aulast%3DHartung%26aufirst%3DT.%26aulast%3DPahler%26aufirst%3DA.%26atitle%3DThiazolidinedione%2520bioactivation%253A%2520a%2520comparison%2520of%2520the%2520bioactivation%2520potentials%2520of%2520troglitazone%252C%2520rosiglitazone%252C%2520and%2520pioglitazone%2520using%2520stable%2520isotope-labeled%2520analogues%2520and%2520liquid%2520chromatography%2520tandem%2520mass%2520spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D1106%26epage%3D1116%26doi%3D10.1021%2Ftx050353h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayol, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8013286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2cXis1SnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=304-311&author=R.+F.+Mayolauthor=C.+A.+Coleauthor=G.+M.+Lukeauthor=K.+L.+Colsonauthor=E.+H.+Kerns&title=Characterization+of+the+metabolites+of+the+antidepressant+drug+nefazodone+in+human+urine+and+plasma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma</span></div><div class="casAuthors">Mayol, R. F.; Cole, C. A.; Luke, G. M.; Colson, K. L.; Kerns, E. H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-11</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">Metab. of the antidepressant drug nefazodone was studied in humans after single and multiple 50 and 200 mg oral doses of [14C] nefazodone as part of a single and multiple dose balance study.  Deuterium was included in the mol. to facilitate structural characterization of the metabolites my mass spectrometry.  Metabolites were isolated from a 0-24 h pooled urine from three subjects and purified to homogeneity by HPLC.  Chem. structures of the metabolites were proposed based on collisionally induced dissocn. (CID) and electron impact ionization MS.  The profile of radioactivity showed three main urinary metabolites, one of which was a conjugate, and several minor metabolites.  The three major metabolites were identified as the phenoxyethyl triazolone propionic acid resulting from N-dealkylation of both nefazodone and hydroxynefazodone (OH-Nef), as well as a corresponding phenoxyethyl triazolone propanol metabolite of N-dealkylated nefazodone, present exclusively as a conjugate.  The more polar minor components were not identified.  The excretion of total radioactivity in the 24-h sample was 49% of the dose, of which the identified metabolites comprised 38% of the dose.  There was no difference in the qual. or quant. urinary profile of the metabolites at 50 or 200 mg dose levels after single or multiple oral dosing.  These N-dealkylated metabolites were also present in pooled human plasma samples along with nefazodone, OH-Nef, and an unknown metabolite that was present in plasma in large amts. relative to nefazodone and OH-Nef.  This metabolite was isolated from plasma and from a human liver S9 incubation and identified by CID tandem MS and NMR as the triazoledione of nefazodone.  A scheme for the metab. of nefazodone is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLYj6lzOLJUrVg90H21EOLACvtfcHk0lhkGlcjtvH4AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1SnurY%253D&md5=6393ad7f1338c3d2d1d2e33df0d47729</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayol%26aufirst%3DR.%2BF.%26aulast%3DCole%26aufirst%3DC.%2BA.%26aulast%3DLuke%26aufirst%3DG.%2BM.%26aulast%3DColson%26aufirst%3DK.%2BL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DCharacterization%2520of%2520the%2520metabolites%2520of%2520the%2520antidepressant%2520drug%2520nefazodone%2520in%2520human%2520urine%2520and%2520plasma%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1994%26volume%3D22%26spage%3D304%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lame, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramov, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendsch, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1124/dmd.104.001735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.104.001735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15523046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Cjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=243-253&author=A.+S.+Kalgutkarauthor=A.+D.+Vazauthor=M.+E.+Lameauthor=K.+R.+Henneauthor=J.+Sogliaauthor=S.+X.+Zhaoauthor=Y.+A.+Abramovauthor=F.+Lombardoauthor=C.+Collinauthor=Z.+S.+Hendschauthor=C.+E.+Hop&title=Bioactivation+of+the+nontricyclic+antidepressant+nefazodone+to+a+reactive+quinone-imine+species+in+human+liver+microsomes+and+recombinant+cytochrome+P450+3A4&doi=10.1124%2Fdmd.104.001735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4</span></div><div class="casAuthors">Kalgutkar, Amit S.; Vaz, Alfin D. N.; Lame, Mary E.; Henne, Kirk R.; Soglia, John; Zhao, Sabrina X.; Abramov, Yuri A.; Lombardo, Franco; Collin, Claire; Hendsch, Zachary S.; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-253</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The therapeutic benefits of the antidepressant nefazodone have been hampered by several cases of acute hepatotoxicity/liver failure.  Although the mechanism of hepatotoxicity remains unknown, it is possible that reactive metabolites of nefazodone play a causative role.  Studies were initiated to det. whether nefazodone undergoes bioactivation in human liver microsomes to electrophilic intermediates.  Following incubation of nefazodone with microsomes or recombinant P 4503A4 in the presence of sulfhydryl nucleophiles, conjugates derived from the addn. of thiol to a monohydroxylated nefazodone metabolite were obsd.  Product ion spectra suggested that hydroxylation and sulfhydryl conjugation occurred on the 3-chlorophenylpiperazine-ring, consistent with a bioactivation pathway involving initial formation of p-hydroxynefazodone, followed by its two-electron oxidn. to the reactive quinone-imine intermediate.  The formation of novel N-dearylated nefazodone metabolites was also discernible in these incubations, and 2-chloro-1,4-benzoquinone, a byproduct of N-dearylation, was trapped with glutathione to afford the corresponding hydroquinone-sulfhydryl adduct.  Nefazodone also displayed NADPH-, time-, and concn.-dependent inactivation of P 450 3A4 activity, suggesting that reactive metabolites derived from nefazodone bioactivation are capable of covalently modifying P 4503A4.  A causative role for 2-chloro-1,4-benzoquinone and/or the quinone-imine intermediate(s) in nefazodone hepatotoxicity is speculated.  Although the antianxiety agent buspirone, which contains a pyrimidine ring in place of the 3-chlorophenyl-ring, also generated p-hydroxybuspirone in liver microsomes, no sulfhydryl conjugates of this metabolite were obsd.  This finding is consistent with the proposal that two-electron oxidn. of p-hydroxybuspirone to the corresponding quinone-imine is less favorable due to differences in the protonation state at physiol. pH and due to weaker resonance stabilization of the oxidn. products as predicted from ab initio measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm8ZzhHTzKarVg90H21EOLACvtfcHk0lite0YwEnvYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Cjsbc%253D&md5=7f6d27921d2236e202256ad0035fedce</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.001735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.001735%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DVaz%26aufirst%3DA.%2BD.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DSoglia%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DAbramov%26aufirst%3DY.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DCollin%26aufirst%3DC.%26aulast%3DHendsch%26aufirst%3DZ.%2BS.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DBioactivation%2520of%2520the%2520nontricyclic%2520antidepressant%2520nefazodone%2520to%2520a%2520reactive%2520quinone-imine%2520species%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520cytochrome%2520P450%25203A4%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D243%26epage%3D253%26doi%3D10.1124%2Fdmd.104.001735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.020545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18332080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1016-1029&author=J.+S.+Baumanauthor=K.+S.+Frederickauthor=A.+Sawantauthor=R.+L.+Walskyauthor=L.+M.+Coxauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=Comparison+of+the+bioactivation+potential+of+the+antidepressant+and+hepatotoxin+nefazodone+with+aripiprazole%2C+a+structural+analog+and+marketed+drug&doi=10.1124%2Fdmd.108.020545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span></div><div class="casAuthors">Bauman, Jonathan N.; Frederick, Kosea S.; Sawant, Aarti; Walsky, Robert L.; Cox, Loretta M.; Obach, Ronald S.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1016-1029</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In vitro metab./bioactivation of structurally related central nervous system agents nefazodone (hepatotoxin) and aripiprazole (nonhepatotoxin) were undertaken in human liver microsomes in an attempt to understand the differences in toxicol. profile.  NADPH-supplemented microsomal incubations of nefazodone and glutathione generated conjugates derived from addn. of thiol to quinonoid intermediates.  Inclusion of cyanide afforded cyano conjugates to iminium ions derived from α-carbon oxidn. of the piperazine ring in nefazodone and downstream metabolites.  Although the arylpiperazine motif in aripiprazole did not succumb to bioactivation, the dihydroquinolinone group was bioactivated via an intermediate monohydroxy metabolite to a reactive species, which was trapped by glutathione.  Studies with synthetic dehydroaripiprazole metabolite revealed an analogous glutathione conjugate with mol. wt. 2 Da lower.  Based on the proposed structure of the glutathione conjugate(s), a bioactivation sequence involving arom. ortho- or para-hydroxylation on the quinolinone followed by oxidn. to a quinone-imine was proposed.  P 4503A4 inactivation studies in microsomes indicated that, unlike nefazodone, aripiprazole was not a time- and concn.-dependent inactivator of the enzyme.  Overall, these studies reinforce the notion that not all drugs that are bioactivated in vitro elicit a toxicol. response in vivo.  A likely explanation for the markedly improved safety profile of aripiprazole (vs. nefazodone) despite the accompanying bioactivation liability is the vastly improved pharmacokinetics (enhanced oral bioavailability, longer elimination half-life) due to reduced P 4503A4-mediated metab./bioactivation, which result in a lower daily dose (5-20 mg/day) compared with nefazodone (200-400 mg/day).  This attribute probably reduces the total body burden to reactive metabolite exposure and may not exceed a threshold needed for toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpVGcV7pKb7Vg90H21EOLACvtfcHk0lite0YwEnvYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D&md5=fbc3413e2855e61631687d253971a08c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020545%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BS.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSawant%26aufirst%3DA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DCox%26aufirst%3DL.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DComparison%2520of%2520the%2520bioactivation%2520potential%2520of%2520the%2520antidepressant%2520and%2520hepatotoxin%2520nefazodone%2520with%2520aripiprazole%252C%2520a%2520structural%2520analog%2520and%2520marketed%2520drug%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1016%26epage%3D1029%26doi%3D10.1124%2Fdmd.108.020545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span> <span> </span><span class="NLM_article-title">Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1814</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1021/tx800161s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800161s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1814-1822&author=R.+S.+Obachauthor=A.+S.+Kalgutkarauthor=J.+R.+Sogliaauthor=S.+X.+Zhao&title=Can+in+vitro+metabolism-dependent+covalent+binding+data+in+liver+microsomes+distinguish+hepatotoxic+from+nonhepatotoxic+drugs%3F+An+analysis+of+18+drugs+with+consideration+of+intrinsic+clearance+and+daily+dose&doi=10.1021%2Ftx800161s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose</span></div><div class="casAuthors">Obach, R. Scott; Kalgutkar, Amit S.; Soglia, John R.; Zhao, Sabrina X.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1814-1822</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vitro covalent binding assessments of drugs have been useful in providing retrospective insights into the assocn. between drug metab. and a resulting toxicol. response.  On the basis of these studies, it has been advocated that in vitro covalent binding to liver microsomal proteins in the presence and the absence of NADPH be used routinely to screen drug candidates.  However, the utility of this approach in predicting toxicities of drug candidates accurately remains an unanswered question.  Importantly, the years of research that have been invested in understanding metabolic bioactivation and covalent binding and its potential role in toxicity have focused only on those compds. that demonstrate toxicity.  Investigations have not frequently queried whether in vitro covalent binding could be obsd. with drugs with good safety records.  Eighteen drugs (nine hepatotoxins and nine nonhepatotoxins in humans) were assessed for in vitro covalent binding in NADPH-supplemented human liver microsomes.  Of the two sets of nine drugs, seven in each set were shown to undergo some degree of covalent binding.  Among hepatotoxic drugs, acetaminophen, carbamazepine, diclofenac, indomethacin, nefazodone, sudoxicam, and tienilic acid demonstrated covalent binding, while benoxaprofen and felbamate did not.  Of the nonhepatotoxic drugs evaluated, buspirone, diphenhydramine, meloxicam, paroxetine, propranolol, raloxifene, and simvastatin demonstrated covalent binding, while ibuprofen and theophylline did not.  A quant. comparison of covalent binding in vitro intrinsic clearance did not sep. the two groups of compds., and in fact, paroxetine, a nonhepatotoxin, showed the greatest amt. of covalent binding in microsomes.  Including factors such as the fraction of total metab. comprised by covalent binding and the total daily dose of each drug improved the discrimination between hepatotoxic and nontoxic drugs based on in vitro covalent binding data; however, the approach still would falsely identify some agents as potentially hepatotoxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9_hVRAC3RD7Vg90H21EOLACvtfcHk0lite0YwEnvYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D&md5=67c82883825ef529c84d03f462b1f669</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx800161s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800161s%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26atitle%3DCan%2520in%2520vitro%2520metabolism-dependent%2520covalent%2520binding%2520data%2520in%2520liver%2520microsomes%2520distinguish%2520hepatotoxic%2520from%2520nonhepatotoxic%2520drugs%253F%2520An%2520analysis%2520of%252018%2520drugs%2520with%2520consideration%2520of%2520intrinsic%2520clearance%2520and%2520daily%2520dose%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D1814%26epage%3D1822%26doi%3D10.1021%2Ftx800161s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1021/tx800407w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800407w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlOnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=332-340&author=J.+N.+Baumanauthor=J.+M.+Kellyauthor=S.+Tripathyauthor=S.+X.+Zhaoauthor=W.+W.+Lamauthor=A.+S.+Kalgutkarauthor=R.+S.+Obach&title=Can+in+vitro+metabolism-dependent+covalent+binding+data+distinguish+hepatotoxic+from+nonhepatotoxic+drugs%3F+An+analysis+using+human+hepatocytes+and+liver+S-9+fraction&doi=10.1021%2Ftx800407w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction</span></div><div class="casAuthors">Bauman, Jonathon N.; Kelly, Joan M.; Tripathy, Sakambari; Zhao, Sabrina X.; Lam, Wing W.; Kalgutkar, Amit S.; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-340</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vitro covalent binding studies in which xenobiotics are shown to undergo metab.-dependent covalent binding to macromols. have been commonly used to shed light on the biochem. mechanisms of xenobiotic-induced toxicity.  In this paper hepatotoxins and nonhepatotoxins were tested for their proclivity to demonstrate metab.-dependent covalent binding to macromols. in human liver S-9 fraction (9000 g supernatant) or human hepatocytes, as an extension to previous work that used human liver microsomes published in this journal [Obachet al. (2008) Chem. Res. Toxicol.21, 1814-1822].  In the S-9 fraction, seven out of the nine drugs in each category demonstrated some level of metab.-dependent covalent binding.  Inclusion of reduced glutathione, cofactors needed by conjugating enzymes, and other parameters (total daily dose and fraction of total intrinsic clearance comprised by covalent binding) improved the ability of the system to sep. hepatotoxins from nonhepatotoxins to a limited extent.  Covalent binding in human hepatocytes showed that six out of the nine hepatotoxins and four out of eight nonhepatotoxins demonstrated covalent binding.  Taking into account ests. of total daily body burden of covalent binding from the hepatocyte data showed an improvement over other in vitro systems for distinguishing hepatotoxins from nonhepatotoxins; however, this metab. system still displayed some false positives.  Combined with the previous study using liver microsomes, these findings identify the limitations of in vitro covalent binding data for prospective prediction of hepatotoxicity for new drug candidates and highlight the need for a better understanding of the link between drug bioactivation, covalent adduct formation, and toxicity outcomes.  Directly relating covalent binding to hepatotoxicity is likely an oversimplification of the process whereby adduct formation ultimately leads to toxicity.  Understanding underlying complexities (e.g., which macromols. are important covalent binding targets, interindividual differences in susceptibility, etc.) will be essential to any understanding of the problem of metab.-dependent hepatotoxicity and predicting toxicity from in vitro expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTemi_XkByprVg90H21EOLACvtfcHk0lgip3mGA7EzrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlOnuw%253D%253D&md5=5904378a0deda8e27d73ab0218b03506</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Ftx800407w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800407w%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DTripathy%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DLam%26aufirst%3DW.%2BW.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DCan%2520in%2520vitro%2520metabolism-dependent%2520covalent%2520binding%2520data%2520distinguish%2520hepatotoxic%2520from%2520nonhepatotoxic%2520drugs%253F%2520An%2520analysis%2520using%2520human%2520hepatocytes%2520and%2520liver%2520S-9%2520fraction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D332%26epage%3D340%26doi%3D10.1021%2Ftx800407w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jajoo, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayol, R. F.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.3109/00498259009046892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F00498259009046892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=2219961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVCitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1990&pages=779-786&author=H.+K.+Jajooauthor=I.+A.+Blairauthor=L.+J.+Klunkauthor=R.+F.+Mayol&title=In+vitro+metabolism+of+the+antianxiety+drug+buspirone+as+a+predictor+of+its+metabolism+in+vivo&doi=10.3109%2F00498259009046892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo</span></div><div class="casAuthors">Jajoo, H. K.; Blair, I. A.; Klunk, L. J.; Mayol, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-86</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    </div><div class="casAbstract">Metab. of antianxiety drug buspirone was studied by in vitro incubations with rat liver microsomes and hepatocytes.  Metabolites were isolated and purified by HPLC.  The purified metabolites were identified by co-elution on HPLC with authentic stds. and by GLC-electron impact mass spectrometry of their trimethylsilyl (TMS) derivs.  Five metabolites of buspirone were identified in the microsomal incubate and seven in the hepatocyte incubate.  The major metabolites arose from arom. hydroxylation at C-5, N-dealkylation of the Bu chain, the hydroxylation at C-6' and C-3' on the azaspirodecanedione moiety.  Metab. of buspirone by rat liver microsomes was NADPH-dependent and was completely inhibited by cytochrome P 450 inhibitors SKF-525A and metyrapone.  Metabolites of buspirone formed in vitro were good predictors of the primary metabolites formed in vivo.  Hepatocytes and phenobarbital-induced rat liver microsomes were better predictors of in vivo metab. of buspirone than non-induced rat liver microsomes.  These in vitro systems should provide excellent models for studying the metab. of other azaspirodecanedione-contg. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-cZf5ni68K7Vg90H21EOLACvtfcHk0lgip3mGA7EzrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVCitLk%253D&md5=f2b54e912a5485f62d19f9e381f54a06</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3109%2F00498259009046892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498259009046892%26sid%3Dliteratum%253Aachs%26aulast%3DJajoo%26aufirst%3DH.%2BK.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26aulast%3DKlunk%26aufirst%3DL.%2BJ.%26aulast%3DMayol%26aufirst%3DR.%2BF.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520the%2520antianxiety%2520drug%2520buspirone%2520as%2520a%2520predictor%2520of%2520its%2520metabolism%2520in%2520vivo%26jtitle%3DXenobiotica%26date%3D1990%26volume%3D20%26spage%3D779%26epage%3D786%26doi%3D10.3109%2F00498259009046892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8531118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK28XhvV2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1995&pages=1476-1483&author=Z.+C.+Liuauthor=J.+P.+Uetrecht&title=Clozapine+is+oxidized+by+activated+human+neutrophils+to+a+reactive+nitrenium+ion+that+irreversibly+binds+to+the+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells</span></div><div class="casAuthors">Liu, Zhao Chao; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1476-83</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Clozapine was oxidized to a reactive intermediate by HOCl, which is the major oxidant produced by activated neutrophils.  A mass spectrum was obtained of this reactive intermediate by using a flow system in which the reactants were fed into a mixing chamber and the products flowed directly into a Sciex API III mass spectrometer.  The intermediate was obsd. at m/z 325, which is 2 mass units less than the protonated mol. ion of the parent drug.  This intermediate reacted with water to form several products with a m/z at 343.  The same products were produced by the oxidn. of clozapine by the combination of myeloperoxidase, hydrogen peroxide and chloride ion.  The reactive intermediate was trapped by glutathione (GSH) and several conjugates were formed.  NMR spectra of the two major conjugates indicated GSH bound to the 6 and 9 positions of the arom. ring.  These data provide further evidence for the formation of a formal nitrenium ion in which the pos. charge is highly delocalized.  Clozapine was also oxidized by activated neutrophils, and in the presence of GSH, the same GSH conjugates were formed.  When therapeutic concns. of radiolabeled clozapine were used, up to 7% of the drug became irreversibly bound to the neutrophils.  Covalent binding was inhibited by about 30% in the presence of 1 mM GSH but was almost abolished at 5 mM GSH.  The putative nitrenium ion formed by activated leukocytes could be responsible for clozapine-induced agranulocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdakyhGXFzVLVg90H21EOLACvtfcHk0lgip3mGA7EzrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvV2jsw%253D%253D&md5=042000d7c36bd6e330482ab383fc61d8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%2BC.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DClozapine%2520is%2520oxidized%2520by%2520activated%2520human%2520neutrophils%2520to%2520a%2520reactive%2520nitrenium%2520ion%2520that%2520irreversibly%2520binds%2520to%2520the%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D275%26spage%3D1476%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1463</span>– <span class="NLM_lpage">1475</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8531117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK287gvVKnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1995&pages=1463-1475&author=J.+L.+Maggsauthor=D.+Williamsauthor=M.+Pirmohamedauthor=B.+K.+Park&title=The+metabolic+formation+of+reactive+intermediates+from+clozapine%2C+a+drug+associated+with+agranulocytosis+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man</span></div><div class="casAuthors">Maggs J L; Williams D; Pirmohamed M; Park B K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1463-75</span>
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Clozapine, a dibenzodiazepine antipsychotic, is associated with a 0.8% incidence of agranulocytosis.  This clinically restrictive toxicity has been attributed to its chemically reactive metabolites.  The generation of such metabolites--assessed via covalent binding and formation of thioether adducts--was investigated using human, rat and mouse liver microsomes and human neutrophils and bone marrow cells.  In every instance, one major glutathione adduct of clozapine--C-6 glutathionyl clozapine--was formed in the presence of added glutathione.  Adduct formation by the neutrophils and myeloid cells was dependent on cell activation by phorbol myristate acetate.  Small fractions of drug underwent covalent binding to microsomes (1-6.8%) and to protein coincubated with neutrophils (0.47%) and myeloid cells (0.21%).  Clozapine did not deplete intracellular glutathione in activated neutrophils.  Clozapine was also metabolized in vivo to glutathione conjugates in rats and mice, the conjugates eliminated in bile over a 3-hr period representing 38% and 33% of the dose, respectively.  In addition to the principal clozapine adduct found in vitro, the C-8 glutathionyl derivative of deschloroclozapine was excreted by both species.  It is concluded that clozapine undergoes bioactivation in several tissues and considerable bioactivation in vivo.  The reactive metabolites generated by neutrophils and myeloid cells may play an important role in the metabolic causation of clozapine-induced agranuiocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ8NBvkV4aL-IHSmpohpd0fW6udTcc2eZ6PRi7B2q_4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287gvVKnsQ%253D%253D&md5=16f9d0cd50455f82ea3e9d6ba59d3e6a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520metabolic%2520formation%2520of%2520reactive%2520intermediates%2520from%2520clozapine%252C%2520a%2520drug%2520associated%2520with%2520agranulocytosis%2520in%2520man%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D275%26spage%3D1463%26epage%3D1475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Metabolism and bioactivation of clozapine by human liver in vitro</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">990</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7891353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2MXktl2ksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1995&pages=984-990&author=M.+Pirmohamedauthor=D.+Williamsauthor=S.+Maddenauthor=E.+Templetonauthor=B.+K.+Park&title=Metabolism+and+bioactivation+of+clozapine+by+human+liver+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and bioactivation of clozapine by human liver in vitro</span></div><div class="casAuthors">Pirmohamed, Munir; Williams, Dominic; Madden, Stephen; Templeton, Elizabeth; Park B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">984-90</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The metab. of clozapine by human liver has been investigated in vitro.  Irreversible protein-binding and conjugation with model nucleophiles have been used as markers for bioactivation of clozapine, while stable metabolite formation has been assessed using radiometric HPLC.  In all nine liver microsomal prepns. investigated, clozapine was extensively metabolized to the stable products desmethylclozapine (range 19%-27.2%), N-oxide (1.5-2.0%) and three polar metabolites (0-20.8%), and was bioactivated to a protein-reactive metabolite (0.6-2.1%).  The CYP2D6 genotype did not influence the capacity of the livers to form these metabolites.  All metabolic pathways were inhibited by ketoconazole, indicating the involvement of the cytochrome P 450 enzymes.  Isoenzyme-selective inhibitor studies demonstrated that whereas demethylation was performed by CYP1A2, N-oxidn. and chem. reactive metabolite formation were dependent upon multiple forms of P 450.  The N-oxide was readily reduced back to clozapine in the presence of NADPH, this conversion being inhibited by ascorbic acid.  Glutathione (1 mM) decreased covalent binding by 70%.  The amt. of putative adduct formed in the presence of glutathione (13.4 ± 0.9%) was much greater than the covalent binding (mean 1.1 ± 0.2%).  The bioactivation of clozapine was, like the N-oxidn. of clozapine, a reversible process.  In summary, our results indicate that clozapine undergoes extensive metab. by human liver to both stable and chem. reactive metabolites, the formation of which is catalyzed by the cytochrome P 450 enzymes.  The role of the reactive metabolite, which may be a free radical, in the pathogenesis of clozapine agranulocytosis and hepatotoxicity requires further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorxcmRuhShhbVg90H21EOLACvtfcHk0lj0k-isKF7E3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktl2ksr4%253D&md5=c1293610c13c2196790c180dab37dd7d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DMadden%26aufirst%3DS.%26aulast%3DTempleton%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DMetabolism%2520and%2520bioactivation%2520of%2520clozapine%2520by%2520human%2520liver%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D272%26spage%3D984%26epage%3D990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhit, S.</span></span> <span> </span><span class="NLM_article-title">Structural features associated with reactive metabolite formation in clozapine analogues</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(97)00017-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2897%2900017-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9212779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2sXkt12ksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1997&pages=117-129&author=J.+P.+Uetrechtauthor=N.+Zahidauthor=A.+Tehimauthor=J.+M.+Fuauthor=S.+Rakhit&title=Structural+features+associated+with+reactive+metabolite+formation+in+clozapine+analogues&doi=10.1016%2FS0009-2797%2897%2900017-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural features associated with reactive metabolite formation in clozapine analogs</span></div><div class="casAuthors">Uetrecht, Jack; Zahid, Nasir; Tehim, Ashik; Fu, J. Mim; Rakhit, Suman</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Clozapine is assocd. with a high incidence of agranulocytosis.  We had previously found that it is oxidized by granulocytes, or simply HOCl, to a reactive metabolite that irreversibly binds to the cells, and we proposed that this reactive metabolite is responsible for clozapine-induced agranulocytosis.  The reactive metabolite appeared to be a nitrenium ion formed by chlorination of the nitrogen bridge between the two arom. rings.  If this is correct, analogs that contain this structural feature should also be oxidized to a reactive intermediate while those not possessing this feature would, at least, not form the same type of reactive intermediate and, therefore, may not induce agranulocytosis.  We tested the first part of this hypothesis, with three clozapine analogs that do contain a nitrogen bridge and three that do not.  Consistent with the hypothesis, the three analogs that do contain the nitrogen bridge formed reactive intermediates that could be trapped with glutathione when oxidized by HOCl, myeloperoxidase or activated neutrophils.  In contrast, we found no evidence of a reactive intermediate on oxidn. of analogs that contained an oxygen or sulfur bridge rather than a nitrogen bridge.  If such reactive metabolites are responsible for drug-induced agranulocytosis, it should be possible to use such a simple screening method to test drugs at an early stage in their development for the potential to induce agranulocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3e71WkafCt7Vg90H21EOLACvtfcHk0lj0k-isKF7E3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt12ksrw%253D&md5=2e2dc1d697c3f9b8cd36a5e7b5965b9f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2897%2900017-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252897%252900017-3%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26aulast%3DZahid%26aufirst%3DN.%26aulast%3DTehim%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DJ.%2BM.%26aulast%3DRakhit%26aufirst%3DS.%26atitle%3DStructural%2520features%2520associated%2520with%2520reactive%2520metabolite%2520formation%2520in%2520clozapine%2520analogues%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1997%26volume%3D104%26spage%3D117%26epage%3D129%26doi%3D10.1016%2FS0009-2797%2897%2900017-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeder, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1008</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9614201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVOmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=999-1008&author=I.+Gardnerauthor=J.+S.+Leederauthor=T.+Chinauthor=N.+Zahidauthor=J.+P.+Uetrecht&title=A+comparison+of+the+covalent+binding+of+clozapine+and+olanzapine+to+human+neutrophils+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo</span></div><div class="casAuthors">Gardner, Iain; Leeder, J. Steven; Chin, Terrence; Zahid, Nasir; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1008</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Covalent binding of a reactive metabolite of clozapine to neutrophils or their precursors is thought to play a role in the development of clozapine-induced agranulocytosis.  Immunoblotting studies with an anti-clozapine antiserum detected covalent binding of clozapine to human neutrophils in vitro when HOCl was used to generate clozapine reactive metabolite (major clozapine adducts of 31, 49, 58, 78, 86, 126, 160, and 204 kDa).  In addn., incubating neutrophils with clozapine and H2O2 (major clozapine adducts of 49 and 58 kDa) or clozapine, H2O2, and human myeloperoxidase (major clozapine adducts of 31, 49, 58, and 126 kDa) also resulted in covalent binding of clozapine to the neutrophils.  The covalent binding of clozapine to neutrophils was inhibited by extracellular glutathione when HOCl, but not H2O2 was used to generate reactive metabolite.  We found that the antiserum against clozapine also recognized olanzapine, an antipsychotic drug that forms a similar reactive metabolite to clozapine but has not been assocd. with induction of agranulocytosis.  Repeating the in vitro expts. with olanzapine revealed that the major olanzapine-modified polypeptides had mol. masses of 96, 130-170, and 218 kDa.  Only relatively low levels of 31, 49, and 58 kDa adducts were obsd.  Clozapine-modified polypeptides also were detected in neutrophils from patients being treated with clozapine.  A major 58-kDa clozapine-modified polypeptide was detected in all patients tested.  In contrast, no drug-modified polypeptides were detected in neutrophils from patients taking olanzapine.  The differences in covalent binding exhibited by the two compds. and, in particular, the lack of olanzapine binding to human neutrophils in vivo may help to explain the difference in toxicity of these two drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsGnBgZHe9dbVg90H21EOLACvtfcHk0lj0k-isKF7E3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVOmtbw%253D&md5=9768c84986d3c1f1a9411e521eadaa24</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DLeeder%26aufirst%3DJ.%2BS.%26aulast%3DChin%26aufirst%3DT.%26aulast%3DZahid%26aufirst%3DN.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comparison%2520of%2520the%2520covalent%2520binding%2520of%2520clozapine%2520and%2520olanzapine%2520to%2520human%2520neutrophils%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26spage%3D999%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masubuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, N.</span></span> <span> </span><span class="NLM_article-title">Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1021/tx060234h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx060234h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVCjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=455-464&author=N.+Masubuchiauthor=C.+Makinoauthor=N.+Murayama&title=Prediction+of+in+vivo+potential+for+metabolic+activation+of+drugs+into+chemically+reactive+intermediate%3A+correlation+of+in+vitro+and+in+vivo+generation+of+reactive+intermediates+and+in+vitro+glutathione+conjugate+formation+in+rats+and+humans&doi=10.1021%2Ftx060234h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of in Vivo Potential for Metabolic Activation of Drugs into Chemically Reactive Intermediate: Correlation of in Vitro and in Vivo Generation of Reactive Intermediates and in Vitro Glutathione Conjugate Formation in Rats and Humans</span></div><div class="casAuthors">Masubuchi, Noriko; Makino, Chie; Murayama, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The covalent binding of reactive intermediates to macromols. might have potential involvement in severe adverse drug reactions.  Thus, quantification of reactive metabolites is necessary during the early stage of drug discovery to avoid serious toxicity.  In this study, the relation between covalent binding and glutathione (GSH) conjugate formation in rat and human liver microsomes were investigated using 10 representative radioactive compds. that have been reported as hepatotoxic or having other toxicity derived from their reactive intermediates: acetaminophen, amodiaquine, carbamazepine, clozapine, diclofenac, furosemide, imipramine, indomethacin, isoniazid, and tienilic acid, all at a concn. of 10 μM.  The GSH conjugate formation rate correlates well with the covalent binding of radioactivity (both rat and human, r2 = 0.93), which suggests that quantification of the GSH conjugate can be used to est. covalent binding.  To quantify the GSH-conjugation rate with non-radiolabeled compds. in vitro, the validation study for the detn. of GSH conjugate formation using 35S-GSH by radio-HPLC was useful to predict metabolic activation.  Following oral administration of 20 mg/kg of the radiolabeled compds. to rats, radioactivity that covalently bound to plasma and liver proteins was detd.  The in vivo max. covalent binding level in liver based on the free fraction of plasma area under the concn. curve (AUC) and in vitro covalent binding rate was found to correlate well (r2 = 0.79).  Therefore, this model for in vitro covalent binding studies in human and rat and in vivo rat studies might be useful in predicting human metabolic activation of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoslCBzhwS0HrVg90H21EOLACvtfcHk0lhAGpl3xNPp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVCjsb0%253D&md5=110aa3cd8bc1b027d61439cdc933ad80</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Ftx060234h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx060234h%26sid%3Dliteratum%253Aachs%26aulast%3DMasubuchi%26aufirst%3DN.%26aulast%3DMakino%26aufirst%3DC.%26aulast%3DMurayama%26aufirst%3DN.%26atitle%3DPrediction%2520of%2520in%2520vivo%2520potential%2520for%2520metabolic%2520activation%2520of%2520drugs%2520into%2520chemically%2520reactive%2520intermediate%253A%2520correlation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520generation%2520of%2520reactive%2520intermediates%2520and%2520in%2520vitro%2520glutathione%2520conjugate%2520formation%2520in%2520rats%2520and%2520humans%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D455%26epage%3D464%26doi%3D10.1021%2Ftx060234h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldkind, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, L.</span></span> <span> </span><span class="NLM_article-title">A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/pds.1207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fpds.1207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16456879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFGmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=213-220&author=L.+Goldkindauthor=L.+Laine&title=A+systematic+review+of+NSAIDs+withdrawn+from+the+market+due+to+hepatotoxicity%3A+lessons+learned+from+the+bromfenac+experience&doi=10.1002%2Fpds.1207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience</span></div><div class="casAuthors">Goldkind, Lawrence; Laine, Loren</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and Drug Safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">PDSAEA</span>;
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Drug-induced hepatotoxicity is the leading cause of acute liver failure (ALF) in the US and the most common adverse event causing drug non-approval and drug withdrawal by the U.S. Food and Drug Administration (FDA).  Three different nonsteroidal anti-inflammatory drugs (NSAIDs) have been withdrawn in the UK and/or the US due to hepatotoxicity (bromfenac, ibufenac, and benoxaprofen).  A systematic review of clin. trials data for these drugs was performed in an effort to identify possible early signals that could have predicted post-marketing serious hepatotoxicity.  There were very limited published data on benoxaprofen and none on ibufenac or bromfenac.  The publicly accessible archives of the FDA provided information on bromfenac.  Flu-like symptoms assocd. with hepatic enzyme elevation and a case of possible drug-related hepatocellular jaundice may in retrospect have been signals for serious hepatotoxicity in the database of 1195 subjects reviewed by the FDA.  Following approval, rates of acute liver failure for bromfenac were estd. to be in the range of 1:10 000.  In addn., the safety databases of several drugs also accessed through FDA archives have been reviewed (simvastatin, tacrine, troglitazone, and ximelagatran).  These data suggest that while ALT elevations alone do not reliably signal serious hepatotoxicity, elevated transaminases in assocn. with symptomatic hepatitis or jaundice may be predictors of an increased risk of ALF.  At present, however, pre-approval databases are generally not large enough to rule out low rates of serious hepatotoxicity.  Therefore, it remains crit. that clinicians report such cases to the FDA through the MED-WATCH system and that active post-marketing monitoring studies be used to identify potential rare cases of hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFSR7CRsJb7Vg90H21EOLACvtfcHk0lhAGpl3xNPp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFGmsrc%253D&md5=510690d4e5966ac6f0924507e7c27679</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fpds.1207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1207%26sid%3Dliteratum%253Aachs%26aulast%3DGoldkind%26aufirst%3DL.%26aulast%3DLaine%26aufirst%3DL.%26atitle%3DA%2520systematic%2520review%2520of%2520NSAIDs%2520withdrawn%2520from%2520the%2520market%2520due%2520to%2520hepatotoxicity%253A%2520lessons%2520learned%2520from%2520the%2520bromfenac%2520experience%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26spage%3D213%26epage%3D220%26doi%3D10.1002%2Fpds.1207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span> <span> </span><span class="NLM_article-title">Chemistry and reactivity of acyl glucuronides</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.2174/138920011795101822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2174%2F138920011795101822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20946098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVOnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=215-221&author=A.+V.+Stachulski&title=Chemistry+and+reactivity+of+acyl+glucuronides&doi=10.2174%2F138920011795101822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and reactivity of acyl glucuronides</span></div><div class="casAuthors">Stachulski, Andrew V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-221</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review presents a survey of acyl glucuronides (AGs) from the perspective of a synthetic medicinal chemist.  After a brief introduction to the biogenesis of AGs and current attitudes of the pharmaceutical industry towards them, the importance of the availability of pure synthetic AGs as probe mols. is stressed.  Current synthetic methods including the selective acylation method and enzymic procedures are discussed with actual drug examples.  The major reaction pathways of AGs, acyl migration and direct acyl transfer, are then examd. with consideration of both in vitro and in vivo situations.  Both the aglycon and the carbohydrate residue are shown to be important in detg. the reactivity of AGs, esp. the α-substitution in aryl acetates and propionates and aryl substitution in benzoates.  The significance of these effects for important drugs such as the NSAIDs diclofenac and ibuprofen is noted.  Appropriate models of the reactivity of AGs with proteins are presented, from short model peptides to body proteins, and examples where AGs clearly interact with protein in vivo (e. g. mycophenolic acid) are presented.  Recent results with AGs in plasma, where half-lives differ significantly from their values in aq. buffer, show the importance of considering the external medium esp. when other hydrolytic enzymes are present.  Finally, the importance of considering the reactivity of acyl thioesters-which may be formed directly or via AGs as intermediates- is also stressed.  This pathway may lead to different protein reactivity than shown for AGs themselves, including interference with the glutathione pathway as shown for NSAID-like carboxylic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAwIQ0A8tN7Vg90H21EOLACvtfcHk0lhAGpl3xNPp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVOnu78%253D&md5=f13fcde37949577e4b30ac0681e388e0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F138920011795101822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920011795101822%26sid%3Dliteratum%253Aachs%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26atitle%3DChemistry%2520and%2520reactivity%2520of%2520acyl%2520glucuronides%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2011%26volume%3D12%26spage%3D215%26epage%3D221%26doi%3D10.2174%2F138920011795101822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monrad, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iddon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrie, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. G.</span></span> <span> </span><span class="NLM_article-title">Dissecting the reaction of phase II metabolites of ibuprofen and other NSAIDs with human plasma protein</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3789</span>– <span class="NLM_lpage">3794</span>, <span class="refDoi"> DOI: 10.1039/C4SC01329H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1039%2FC4SC01329H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSltrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3789-3794&author=R.+N.+Monradauthor=J.+C.+Erreyauthor=C.+S.+Barryauthor=M.+Iqbalauthor=X.+Mengauthor=L.+Iddonauthor=J.+A.+Perrieauthor=J.+R.+Hardingauthor=I.+D.+Wilsonauthor=A.+V.+Stachulskiauthor=B.+G.+Davis&title=Dissecting+the+reaction+of+phase+II+metabolites+of+ibuprofen+and+other+NSAIDs+with+human+plasma+protein&doi=10.1039%2FC4SC01329H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting the reaction of Phase II metabolites of ibuprofen and other NSAIDS with human plasma protein</span></div><div class="casAuthors">Monrad, Rune Nygaard; Errey, James C.; Barry, Conor S.; Iqbal, Mazhar; Meng, Xiaoli; Iddon, Lisa; Perrie, Jennifer A.; Harding, John R.; Wilson, Ian D.; Stachulski, Andrew V.; Davis, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3789-3794</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs on the market.  While they are considered safe, several NSAIDs have been withdrawn from the market as a result of adverse drug reactions.  NSAIDs are extensively metabolised to their 1-β-O-acyl glucuronides (AGs), and the risk of NSAID AGs covalently modifying biomacromols. such as proteins or DNA, leading to immune responses and cellular dysfunction constitutes a major concern in drug discovery and development.  The assessment of the degree of protein modification and potential toxicity of individual NSAID AGs is therefore of importance in both drug monitoring and development.  Herein, we report the covalent reaction of 1-β-O-acyl glucuronides of ibuprofen and several NSAID analogs with human serum albumin (HSA) protein in vitro under concns. encountered in therapy.  Stable transacylation and glycosylation adducts are formed; the obsd. protein product ratios can be rationalised by the degree of α-substitution in the acyl group.  Structure-based protein reactivity correlations of AGs, such as these, may prove a useful tool in distinguishing between carboxylic acid-contg. drugs of similar structure that ultimately prove beneficial (e.g., ibuprofen) from those that prove toxic (e.g., ibufenac).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0KHabMaN60LVg90H21EOLACvtfcHk0lj9uxLwwy0WuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSltrrL&md5=3106c6381f0bac854d7c628406b3d552</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FC4SC01329H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4SC01329H%26sid%3Dliteratum%253Aachs%26aulast%3DMonrad%26aufirst%3DR.%2BN.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DBarry%26aufirst%3DC.%2BS.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DIddon%26aufirst%3DL.%26aulast%3DPerrie%26aufirst%3DJ.%2BA.%26aulast%3DHarding%26aufirst%3DJ.%2BR.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DDavis%26aufirst%3DB.%2BG.%26atitle%3DDissecting%2520the%2520reaction%2520of%2520phase%2520II%2520metabolites%2520of%2520ibuprofen%2520and%2520other%2520NSAIDs%2520with%2520human%2520plasma%2520protein%26jtitle%3DChem.%2520Sci.%26date%3D2014%26volume%3D5%26spage%3D3789%26epage%3D3794%26doi%3D10.1039%2FC4SC01329H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcdonagh, A. F.</span></span> <span> </span><span class="NLM_article-title">Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">644</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1981713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3MXhsVE%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1990&pages=639-644&author=P.+C.+Smithauthor=L.+Z.+Benetauthor=A.+F.+Mcdonagh&title=Covalent+binding+of+zomepirac+glucuronide+to+proteins%3A+evidence+for+a+Schiff+base+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent binding of zomepirac glucuronide to proteins:  evidence for a Schiff base mechanism</span></div><div class="casAuthors">Smith, Philip C.; Benet, Leslie Z.; McDonagh, Antony F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-44</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">Carboxylic acids can undergo irreversible binding to proteins via their acyl glucuronide metabolites.  Such binding occurs in humans and in vitro for bilirubin and the anti-inflammatory drugs zomepirac and tolmetin and may have toxicol. significance.  The mechanism of the binding is uncertain, but is thought to involve nucleophilic displacement of glucuronic acid by free cysteine thiols, tyrosine, or lysine residues of the protein.  Evidence is now presented, using zomepirac glucuronide, for an alternative mechanism where irreversible binding occurs by isomerization of the glucuronide and formation of an imine linkage between the glucuronic acid moiety of the conjugate and a lysine or terminal amino group of the protein.  Involvement of a protein thiol in the binding mechanism was ruled out by expts. with the thiol-blocking agent p-hydroxymercuribenzoate.  Moreover, significant irreversible binding occurred when the cysteine-free protein α1-casein was incubated in soln. with zomepirac glucuronide in vitro.  When zomepirac glucuronide was added to solns. with albumin in the presence of the imine-trapping reagent NaCN or the reducing agent NaCNBH3, irreversible binding of zomepirac increased 8.3- and 5.5-fold relative to controls, resp., after 6 h at 37°.  The product formed after treatment of solns. of zomepirac glucuronide and albumin after NaCNBH3 was stable in dil. acid, whereas similar acid treatment of zomepirac-albumin adduct from control incubations, obtained after NaCN exposure, released 30% of the total adduct.  Only isomeric conjugates of zomepirac glucuronide were released from zomepirac-albumin adduct by mild acid; no β1-isomer was detected.  These results support a mechanism of covalent binding of zomepirac glucuronide to proteins in which isomerization of the glucuronide by acyl migration is a prerequisite to imine formation between the 1 position of glucuronic acid and an NH2 group of the protein.  The incomplete hydrolysis of the zomepirac-albumin adduct by dil. acid suggests that further Amadori rearrangement of the imino sugar to a more stable 1-amino-2-ketose product may also be a significant process in the irreversible binding of acyl glucuronides to proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aI4rDgHKS7Vg90H21EOLACvtfcHk0lj9uxLwwy0WuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsVE%253D&md5=750bc15e9270db255df0893f6d6fa77d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BC.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DMcdonagh%26aufirst%3DA.%2BF.%26atitle%3DCovalent%2520binding%2520of%2520zomepirac%2520glucuronide%2520to%2520proteins%253A%2520evidence%2520for%2520a%2520Schiff%2520base%2520mechanism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1990%26volume%3D18%26spage%3D639%26epage%3D644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. C.</span></span> <span> </span><span class="NLM_article-title">Disposition and covalent binding of ibuprofen and it acyl glucuronide in the elderly</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/0009-9236(95)90226-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0009-9236%2895%2990226-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7781263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK2MzgtVChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1995&pages=636-644&author=M.+Castilloauthor=Y.+W.+F.+Lamauthor=M.+A.+Dooleyauthor=E.+Stahlauthor=P.+C.+Smith&title=Disposition+and+covalent+binding+of+ibuprofen+and+it+acyl+glucuronide+in+the+elderly&doi=10.1016%2F0009-9236%2895%2990226-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly</span></div><div class="casAuthors">Castillo M; Lam Y W; Dooley M A; Stahl E; Smith P C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-44</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">Ibuprofen is an over-the-counter nonsteroidal anti-inflammatory drug with a low incidence of severe adverse reactions.  It is metabolized by oxidation to carboxyibuprofen and hydroxyibuprofen and by conjugation to an acyl glucuronide.  In vitro studies have indicated that ibuprofen glucuronide is labile and reactive, forming covalent adducts with proteins.  To verify the formation of ibuprofen-protein adducts in vivo, the pharmacokinetics of ibuprofen glucuronide and its covalent binding to plasma proteins were studied in five elderly patients who received long-term administration of oral doses of ibuprofen.  Plasma levels of ibuprofen glucuronide were low relative to those of ibuprofen; the ratio of area under the plasma concentration versus time curve for the glucuronide relative to the parent drug was only 4%.  Covalent binding of ibuprofen to plasma protein was observed in all patients, correlating well with the area under the plasma concentration versus time curve of ibuprofen glucuronide (r = 0.966).  Compared with reports for other nonsteroidal anti-inflammatory drugs that form acyl glucuronides, plasma levels of ibuprofen-protein adduct are low during long-term administration.  The observed lower reactivity in vivo is probably attributable to the greater stability of ibuprofen glucuronide relative to other acyl glucuronides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT421jhw9HMF_6xYuD7tu2XfW6udTcc2eaZYNlqp0PE9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2MzgtVChtg%253D%253D&md5=a017d65c93d744a5526453709995eeeb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0009-9236%2895%2990226-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0009-9236%252895%252990226-0%26sid%3Dliteratum%253Aachs%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DY.%2BW.%2BF.%26aulast%3DDooley%26aufirst%3DM.%2BA.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%2BC.%26atitle%3DDisposition%2520and%2520covalent%2520binding%2520of%2520ibuprofen%2520and%2520it%2520acyl%2520glucuronide%2520in%2520the%2520elderly%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1995%26volume%3D57%26spage%3D636%26epage%3D644%26doi%3D10.1016%2F0009-9236%2895%2990226-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaat, R.</span></span> <span> </span><span class="NLM_article-title">A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1021/tx049900+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx049900%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt12qurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=1206-1216&author=J.+Wangauthor=M.+Davisauthor=F.+Liauthor=F.+Azamauthor=J.+Scatinaauthor=R.+Talaat&title=A+novel+approach+for+predicting+acyl+glucuronide+reactivity+via+Schiff+base+formation%3A+development+of+rapidly+formed+peptide+adducts+for+LC%2FMS%2FMS+measurements&doi=10.1021%2Ftx049900%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Approach for Predicting Acyl Glucuronide Reactivity via Schiff Base Formation: Development of Rapidly Formed Peptide Adducts for LC/MS/MS Measurements</span></div><div class="casAuthors">Wang, Jianyao; Davis, Margaret; Li, Fangbiao; Azam, Farooq; Scatina, JoAnn; Talaat, Rasmy</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1206-1216</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel technique to study the reactivity of acyl glucuronide metabolites to protein has been developed and is described herein.  Considered here are acyl glucuronide metabolites, which have undergone the rearrangement of the glucuronic acid moiety at physiol. temp. and pH.  The investigation of the reactivity of these electrophilic metabolites was carried out by measuring the rate of reaction of rearranged AG metabolites in forming the corresponding acyl glucuronide-peptide adduct in the presence of Lys-Phe.  This differs from the parallel technique used in forming AG adducts of proteins that have been previously reported.  In the study described here, the Schiff base adduct, diclofenac acyl glucuronide-Lys-Phe product, was generated and structurally elucidated by liq. chromatog. tandem mass spectrometry (LC/MS/MS) anal.  The product structure was proved to be a Schiff base adduct by chem. derivatization by nucleophilic addn. of HCN and chem. redn. with NaCNBH3, followed by LC/MS/MS anal.  It is proposed here that the degree of reactivity of acyl glucuronides as measured by covalent binding to protein is proportional to the amt. of its peptide adduct generated with the peptide technique described.  The application of this technique to the assessment of the degree of reactivity of acyl glucuronide metabolites was validated by developing a reactivity rank of seven carboxylic acid-contg. drugs.  Consistency was achieved between the ranking of reactivity in the peptide technique for these seven compds. and the rankings found in the literature.  In addn., a correlation (R2 = 0.95) was revealed between the formation of a peptide adduct and the rearrangement rate of the primary acyl glucuronide of seven tested compds.  A structure effect on the degree of reactivity has demonstrated the rate order: acetic acid > propionic acid > benzoic acid derivs.  A rational explanation of this order was proposed, based on the inherent electronic and steric properties of each specific aglycon.  In addn., adaptation of this technique to automation in order to more rapidly assess the ranking of reactivity of acyl glucuronide covalent binding to proteins by new chem. entities is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzH7J0RPEhrVg90H21EOLACvtfcHk0lj9uxLwwy0WuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt12qurg%253D&md5=1cee861849c7acb1ae3fe47d7c1b5d87</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Ftx049900%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx049900%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DAzam%26aufirst%3DF.%26aulast%3DScatina%26aufirst%3DJ.%26aulast%3DTalaat%26aufirst%3DR.%26atitle%3DA%2520novel%2520approach%2520for%2520predicting%2520acyl%2520glucuronide%2520reactivity%2520via%2520Schiff%2520base%2520formation%253A%2520development%2520of%2520rapidly%2520formed%2520peptide%2520adducts%2520for%2520LC%252FMS%252FMS%2520measurements%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D1206%26epage%3D1216%26doi%3D10.1021%2Ftx049900%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atherton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reily, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A.</span></span> <span> </span><span class="NLM_article-title">Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1021/tx600297u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx600297u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvVymtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=876-886&author=G.+S.+Walkerauthor=J.+Athertonauthor=J.+Baumanauthor=C.+Kohlauthor=W.+Lamauthor=M.+Reilyauthor=Z.+Louauthor=A.+Mutlib&title=Determination+of+degradation+pathways+and+kinetics+of+acyl+glucuronides+by+NMR+spectroscopy&doi=10.1021%2Ftx600297u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of Degradation Pathways and Kinetics of Acyl Glucuronides by NMR Spectroscopy</span></div><div class="casAuthors">Walker, Gregory S.; Atherton, James; Bauman, Jonathan; Kohl, Christopher; Lam, Wing; Reily, Michael; Lou, Zhen; Mutlib, Abdul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">876-886</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl glucuronides have been implicated in the toxicity of many xenobiotics and marketed drugs.  These toxicities are hypothesized to be a consequence of covalent binding of the reactive forms of the acyl glucuronide to proteins.  Reactive intermediates of the acyl glucuronide arise from the migration of the aglycon leading to other positional and stereoisomers under physiol. conditions.  In order to screen for the potential liabilities of these metabolites during the early phase of pharmaceutical development, an NMR method based on the disappearance of the anomeric resonance of the O-1-acyl glucuronide was used to monitor the degrdn. kinetics of 11 structurally diverse acyl glucuronides, including those produced from the known nonsteroidal anti-inflammatory drugs (NSAIDs).  The acyl glucuronides were either chem. synthesized or were isolated from biol. matrixes (bile, urine, and liver microsomal exts.).  The half-lives attained utilizing this method were found to be comparable to those reported in the literature.  NMR anal. also enabled the delineation of the two possible pathways of degrdn.: acyl migration and hydrolytic cleavage.  The previously characterized 1H resonances of acyl migrated products are quite distinguishable from those that arise from hydrolysis.  The NMR method described here could be used to rank order acyl glucuronide forming discovery compds. based on the potential reactivity of the conjugates and their routes of decompn. under physiol. conditions.  Furthermore, we have shown that in vitro systems such as liver microsomal prepns. can be used to generate sufficient quantities of acyl glucuronides from early discovery compds. for NMR characterization.  This is particularly important, as we often have limited supply of early discovery compds. to conduct in vivo studies to generate sufficient quantities of acyl glucuronides for further characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aeMkwVvVErVg90H21EOLACvtfcHk0ljr-LhGTTjvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvVymtrw%253D&md5=b0ffe295d85c8a7a6816f3e22eac5bec</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Ftx600297u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx600297u%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DLam%26aufirst%3DW.%26aulast%3DReily%26aufirst%3DM.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DMutlib%26aufirst%3DA.%26atitle%3DDetermination%2520of%2520degradation%2520pathways%2520and%2520kinetics%2520of%2520acyl%2520glucuronides%2520by%2520NMR%2520spectroscopy%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D876%26epage%3D886%26doi%3D10.1021%2Ftx600297u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships for the degradation reaction of 1-beta-O-acyl glucuronides. Part 3: Electronic and steric descriptors predicting the reactivity of aralkyl carboxylic acid 1-beta-O-acyl glucuronides</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.1021/tx9002963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9002963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1998-2008&author=A.+Babaauthor=T.+Yoshioka&title=Structure-activity+relationships+for+the+degradation+reaction+of+1-beta-O-acyl+glucuronides.+Part+3%3A+Electronic+and+steric+descriptors+predicting+the+reactivity+of+aralkyl+carboxylic+acid+1-beta-O-acyl+glucuronides&doi=10.1021%2Ftx9002963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships for the Degradation Reaction of 1-β-O-Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β-O-Acyl Glucuronides</span></div><div class="casAuthors">Baba, Akiko; Yoshioka, Tadao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1998-2008</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since 1-β-O-acyl glucuronides (βGAs) are thought to be chem. reactive metabolites capable of binding to tissue proteins, possibly leading to adverse drug reactions of the parent carboxylic acid drugs, we have initiated research efforts to derive structure-activity relationships (SARs) of βGAs, with a focus on finding appropriate descriptors that predict their intrinsic electrophilic reactivity or degrdn. rate consts. (k values).  Our previous SAR studies on the k values of βGAs derived from o-, m-, and p-substituted benzoic acids demonstrated that the diversity and complexity of the k values were controlled by the electronic and/or steric effects of the parent carboxylic acids.  In the present study, we performed further SAR studies on the k values of 13 βGAs derived from aralkyl carboxylic acids, focusing on the substituents and stereochem. at the α-position of the parent carboxylic acids.  In single regression analyses, the pKa and 1H NMR chem. shifts (δCOOH) of the parent carboxylic acids correlated well with the log k values of seven βGAs derived from five arylacetic and two (R)-2-arylpropionic acids, whereas the 13C NMR chem. shifts [δC=O and δ(C=O)OH] correlated with the log k values of another seven βGAs derived from the five arylacetic and two (S)-2-arylpropionic acids.  Excellent correlations were also obtained between the log k values of four βGAs with a common 4-phenylbenzyl moiety and the partial at. charges (natural type) of the corresponding carboxylic hydrogen atoms (Hpac), the molar volume (MV), and the molar refractivity (MR).  In multiple regression analyses, appropriate combinations of electronic (δCOOH or pKa) and steric [Taft's steric const. (Es) or δ(C=O)OH] descriptors could predict the log k values of βGAs; electron-withdrawing 1-β-O-acyl groups increased the k values, while increasing steric hindrance around the linkages decreased them.  The std. partial regression coeffs. indicated that the steric effects of the 1-β-O-acyl groups of βGAs affected the k values as strongly as the electronic effects.  External validation of the derived SAR models is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMRVLPvP_JALVg90H21EOLACvtfcHk0ljr-LhGTTjvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F&md5=5b25cd783fa5597dff4183ed56474dd3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Ftx9002963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9002963%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DA.%26aulast%3DYoshioka%26aufirst%3DT.%26atitle%3DStructure-activity%2520relationships%2520for%2520the%2520degradation%2520reaction%2520of%25201-beta-O-acyl%2520glucuronides.%2520Part%25203%253A%2520Electronic%2520and%2520steric%2520descriptors%2520predicting%2520the%2520reactivity%2520of%2520aralkyl%2520carboxylic%2520acid%25201-beta-O-acyl%2520glucuronides%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1998%26epage%3D2008%26doi%3D10.1021%2Ftx9002963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iddon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, J. C.</span></span> <span> </span><span class="NLM_article-title">Integrated HPLC-MS and <sup>1</sup>H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.3109/00498250903348720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F00498250903348720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19919325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGrsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=9-23&author=C.+H.+Johnsonauthor=E.+Karlssonauthor=S.+Sardaauthor=L.+Iddonauthor=M.+Iqbalauthor=X.+Mengauthor=J.+R.+Hardingauthor=A.+V.+Stachulskiauthor=J.+K.+Nicholsonauthor=I.+D.+Wilsonauthor=J.+C.+Lindon&title=Integrated+HPLC-MS+and+1H-NMR+spectroscopic+studies+on+acyl+migration+reaction+kinetics+of+model+drug+ester+glucuronides&doi=10.3109%2F00498250903348720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated HPLC-MS and 1H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides</span></div><div class="casAuthors">Johnson, C. H.; Karlsson, E.; Sarda, S.; Iddon, L.; Iqbal, M.; Meng, X.; Harding, J. R.; Stachulski, A. V.; Nicholson, J. K.; Wilson, I. D.; Lindon, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-23</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Acyl glucuronides (AGs) are common, chem. reactive metabolites of acidic xenobiotics.  Concerns about the potential of this class of conjugate to cause toxicity in man require efficient methods for the detn. of reactivity, and this is commonly done by measuring transacylation kinetics.  High-performance liq. chromatog.-mass spectrometry (HPLC-MS) and NMR spectroscopy were applied to the kinetic anal. of AG isomerization and hydrolysis for the 1-β-O-AGs of ibufenac, (R)- and (S)-ibuprofen, and an α,α-dimethylated ibuprofen analog.  Each AG was incubated in either aq. buffer at pH 7.4 or human plasma at 37°C.  Aliquots of these samples, taken throughout the reaction time course, were analyzed by HPLC-MS and 1H-NMR spectroscopy and the results compared.  For identification of the AGs incubated in pH 7.4 buffer and for anal. of kinetic rates, 1H-NMR spectroscopy generally gave the most complete set of data, but for human plasma the use of 1H-NMR spectroscopy was impractical and HPLC-MS was more suitable.  HPLC-MS was more sensitive than 1H-NMR spectroscopy, but the lack of suitable stable-isotope labeled internal stds., together with differences in response between glucuronides and aglycons, made quantification problematic.  Using HPLC-MS a specific 1-β-O-AG-related ion at m/z 193 (the glucuronate fragment) was noted enabling selective detn. of these isomers.  In buffer, transacylation reactions predominated, with relatively little hydrolysis to the free aglycon obsd.  In human plasma incubations the obsd. rates of reaction were much faster than for buffer, and hydrolysis to the free aglycon was the major route.  These results illustrate the strengths and weaknesses of each anal. approach for this class of analyte.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnMhHybe8wv7Vg90H21EOLACvtfcHk0ljr-LhGTTjvog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGrsLfK&md5=299e594ae1826566a644afd9e383f1c0</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.3109%2F00498250903348720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498250903348720%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BH.%26aulast%3DKarlsson%26aufirst%3DE.%26aulast%3DSarda%26aufirst%3DS.%26aulast%3DIddon%26aufirst%3DL.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DHarding%26aufirst%3DJ.%2BR.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DNicholson%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DLindon%26aufirst%3DJ.%2BC.%26atitle%3DIntegrated%2520HPLC-MS%2520and%25201H-NMR%2520spectroscopic%2520studies%2520on%2520acyl%2520migration%2520reaction%2520kinetics%2520of%2520model%2520drug%2520ester%2520glucuronides%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D40%26spage%3D9%26epage%3D23%26doi%3D10.3109%2F00498250903348720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogiso, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, M.</span></span> <span> </span><span class="NLM_article-title">Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.ejps.2017.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29174986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOiu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2018&pages=132-138&author=H.+Shimadaauthor=Y.+Kobayashiauthor=S.+Tanahashiauthor=A.+Kawaseauthor=T.+Ogisoauthor=M.+Iwaki&title=Correlation+between+glucuronidation+and+covalent+adducts+formation+with+proteins+of+nonsteroidal+anti-inflammatory+drugs&doi=10.1016%2Fj.ejps.2017.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs</span></div><div class="casAuthors">Shimada, Hiroaki; Kobayashi, Yuri; Tanahashi, Sakiko; Kawase, Atsushi; Ogiso, Taro; Iwaki, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-138</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause idiosyncratic liver injury.  Mechanisms involved in NSAID-induced liver injury are complex.  Previous studies have suggested that acyl glucuronide of NSAIDs (NSAIDs-Glu) plays an important role in the development of liver injury via covalently binds to proteins and the resultant adduct induces immunol. toxicity.  As only some NSAIDs-Glu are com. available, the evaluation of covalent protein adduct formation using ready-made NSAIDs-Glu is difficult and inconvenient.  Moreover, glucuronidation potency varies with the NSAID, including stereoisomers.  Therefore, in this study, we simultaneously examd. the glucuronidation and covalent adduct formation using enantiomers of parent NSAIDs (ibuprofen, naproxen, pranoprofen, ketoprofen, and flurbiprofen) in rat liver microsomes.  Glucuronides and covalent adducts were quantified by HPLC.  The amt. of covalent adduct increased with NSAIDs-Glu formation in the rat liver microsomes in a time-dependent manner.  A significant pos. correlation was obsd. between the AUC of NSAIDs-Glu and that of covalent adduct, except ketoprofen.  Although ketoprofen exhibited the highest glucuronidation rate among the NSAIDs investigated, the amt. of covalent adduct was similar to that for pranoprofen, which had the lowest glucuronidation rate.  Thus, it may be difficult for ketoprofen glucuronide to covalently bind with proteins in the rat liver microsomes.  Our results suggested that the amt. of glucuronide formed is a key factor in predicting covalent bond formation with protein in NSAIDs, in addn. to degradability and bindability with proteins of NSAIDs-Glu.  Further studies are required to confirm the relationship between the tendency of glucuronidation and the formation of covalent adducts of NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYDM98-jibbVg90H21EOLACvtfcHk0lin2yIsterF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOiu73I&md5=2712c60153ccab592202baecf361e266</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTanahashi%26aufirst%3DS.%26aulast%3DKawase%26aufirst%3DA.%26aulast%3DOgiso%26aufirst%3DT.%26aulast%3DIwaki%26aufirst%3DM.%26atitle%3DCorrelation%2520between%2520glucuronidation%2520and%2520covalent%2520adducts%2520formation%2520with%2520proteins%2520of%2520nonsteroidal%2520anti-inflammatory%2520drugs%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D112%26spage%3D132%26epage%3D138%26doi%3D10.1016%2Fj.ejps.2017.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okudaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.034173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.110.034173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20606003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1857-1864&author=R.+Sawamuraauthor=N.+Okudairaauthor=K.+Watanabeauthor=T.+Muraiauthor=Y.+Kobayashiauthor=M.+Tachibanaauthor=T.+Ohnukiauthor=K.+Masudaauthor=H.+Honmaauthor=A.+Kuriharaauthor=O.+Okazaki&title=Predictability+of+idiosyncratic+drug+toxicity+risk+for+carboxylic+acid-containing+drugs+based+on+the+chemical+stability+of+acyl+glucuronide&doi=10.1124%2Fdmd.110.034173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide</span></div><div class="casAuthors">Sawamura, Ryoko; Okudaira, Noriko; Watanabe, Kengo; Murai, Takahiro; Kobayashi, Yoshimasa; Tachibana, Masaya; Ohnuki, Takashi; Masuda, Kayoko; Honma, Hidehito; Kurihara, Atsushi; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acyl glucuronides (AGs) formed from carboxylic acid-contg. drugs have been considered to be a cause of idiosyncratic drug toxicity (IDT).  Chem. stability of AGs is supposed to relate to their reactivity.  In this study, the half-lives of 21 AGs of carboxylic drugs in potassium phosphate buffer (KPB), human serum albumin (HSA) soln., and human fresh plasma were analyzed in relation to the IDT risk derived from these drugs.  The carboxylic drugs were classified into three safety categories of "safe," "warning," and "withdrawn" in terms of their IDT risk.  As for the results, the half-lives of AGs in KPB correlated with the IDT risk better than those in HSA soln. or in human fresh plasma with regard to the sepn. of the safe drugs from the warning drugs or the withdrawn drugs.  In KPB, whereas the half-lives in the safe category were 7.2 h or longer, those in the withdrawn category were 1.7 h or shorter.  The classification value of the half-life in KPB, which sepd. the safe drugs from the withdrawn drugs was calcd. to be 3.6 h by regression anal.  In conclusion, this is the first report that clearly shows the relationship between the IDT risk and chem. stability of AGs in several in vitro systems.  The KPB system was considered to be the best for evaluating the stability of AGs, and the classification value of the half-life in KPB serves as a useful key predictor for the IDT risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxa_NqrJXKWLVg90H21EOLACvtfcHk0lin2yIsterF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP&md5=f11cee720da5c3b00314e5a5771d0250</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.034173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.034173%26sid%3Dliteratum%253Aachs%26aulast%3DSawamura%26aufirst%3DR.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DOhnuki%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DHonma%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DPredictability%2520of%2520idiosyncratic%2520drug%2520toxicity%2520risk%2520for%2520carboxylic%2520acid-containing%2520drugs%2520based%2520on%2520the%2520chemical%2520stability%2520of%2520acyl%2520glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1857%26epage%3D1864%26doi%3D10.1124%2Fdmd.110.034173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelazo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, S. N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnshaw, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.215079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fjpet.114.215079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wqsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=387-402&author=T.+G.+Hammondauthor=X.+Mengauthor=R.+E.+Jenkinsauthor=J.+L.+Maggsauthor=A.+S.+Castelazoauthor=S.+L.+Reganauthor=S.+N.+L.+Bennettauthor=C.+J.+Earnshawauthor=G.+P.+Aithalauthor=I.+Pandeauthor=J.+G.+Kennaauthor=A.+V.+Stachulskiauthor=B.+K.+Parkauthor=D.+P.+Williams&title=Mass+spectrometric+characterization+of+circulating+covalent+protein+adducts+derived+from+a+drug+acyl+glucuronide+metabolite%3A+multiple+albumin+adductions+in+diclofenac+patients&doi=10.1124%2Fjpet.114.215079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients</span></div><div class="casAuthors">Hammond, Thomas G.; Meng, Xiaoli; Jenkins, Rosalind E.; Maggs, James L.; Castelazo, Anahi Santoyo; Regan, Sophie L.; Bennett, Stuart N. L.; Earnshaw, Caroline J.; Aithal, Guruprasad P.; Pande, Ira; Kenna, J. Gerry; Stachulski, Andrew V.; Park, B. Kevin; Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-402, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Covalent protein modifications by electrophilic acyl glucuronide (AG) metabolites are hypothetical causes of hypersensitivity reactions assocd. with certain carboxylate drugs.  The complex rearrangements and reactivities of drug AG have been defined in great detail, and protein adducts of carboxylate drugs, such as diclofenac, have been found in liver and plasma of exptl. animals and humans.  However, in the absence of definitive mol. characterization, and specifically, identification of signature glycation conjugates retaining the glucuronyl and carboxyl residues, it cannot be assumed any of these adducts is derived uniquely or even fractionally from AG metabolites.  We have therefore undertaken targeted mass spectrometric analyses of human serum albumin (HSA) isolated from diclofenac patients to characterize drug-derived structures and, thereby, for the first time, have deconstructed conclusively the pathways of adduct formation from a drug AG and its isomeric rearrangement products in vivo.  These analyses were informed by a thorough understanding of the reactions of HSA with diclofenac AG in vitro.  HSA from six patients without drug-related hypersensitivities had either a single drug-derived adduct or one of five combinations of 2-8 adducts from among seven diclofenac N-acylations and three AG glycations on seven of the protein's 59 lysines.  Only acylations were found in every patient.  We present evidence that HSA modifications by diclofenac in vivo are complicated and variable, that at least a fraction of these modifications are derived from the drug's AG metabolite, and that albumin adduction is not inevitably a causation of hypersensitivity to carboxylate drugs or a coincidental assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJaMIu3mSolLVg90H21EOLACvtfcHk0lin2yIsterF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wqsb%252FK&md5=4ea9902f538c70aa671bdb1df8149375</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.215079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.215079%26sid%3Dliteratum%253Aachs%26aulast%3DHammond%26aufirst%3DT.%2BG.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DCastelazo%26aufirst%3DA.%2BS.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DBennett%26aufirst%3DS.%2BN.%2BL.%26aulast%3DEarnshaw%26aufirst%3DC.%2BJ.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DPande%26aufirst%3DI.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DMass%2520spectrometric%2520characterization%2520of%2520circulating%2520covalent%2520protein%2520adducts%2520derived%2520from%2520a%2520drug%2520acyl%2520glucuronide%2520metabolite%253A%2520multiple%2520albumin%2520adductions%2520in%2520diclofenac%2520patients%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D387%26epage%3D402%26doi%3D10.1124%2Fjpet.114.215079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Safety assessment of acyl glucuronides – A simplified paradigm</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.080515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.118.080515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29559442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=908-912&author=D.+A.+Smithauthor=T.+Hammondauthor=T.+A.+Baillie&title=Safety+assessment+of+acyl+glucuronides+%E2%80%93+A+simplified+paradigm&doi=10.1124%2Fdmd.118.080515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Safety assessment of acyl glucuronides-a simplified paradigm</span></div><div class="casAuthors">Smith, Dennis A.; Hammond, Timothy; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-912</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">While simple O-(ether-linked) and N-glucuronide drug conjugates generally are unreactive and considered benign from a safety perspective, the acyl glucuronides that derive from metab. of carboxylic acid-contg. xenobiotics can exhibit a degree of chem. reactivity that is dependent upon their mol. structure.  As a result, concerns have arisen over the safety of acyl glucuronides as a class, several members of which have been implicated in the toxicity of their resp. parent drugs.  However, direct evidence in support of these claims remains sparse, and due to frequently encountered species differences in the systemic exposure to acyl glucuronides (both of the parent drug and oxidized derivs. thereof), coupled with their instability in aq. media and potential to undergo chem. rearrangement (acyl migration), qualification of these conjugates by traditional safety assessment methods can be very challenging.  In this Commentary, we discuss alternative (non-acyl glucuronide)mechanisms by which carboxylic acids may cause serious adverse reactions, and propose a novel, practical approach to compare systemic exposure to acyl glucuronide metabolites in humans to that in animal species used in preclin. safety assessment based on relative ests. of the total body burden of these circulating conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEevJPQ6waKbVg90H21EOLACvtfcHk0ljEhRSAwgrD_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK&md5=bb4d99cdc5bf87751b6d796366ed7e46</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.080515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.080515%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DHammond%26aufirst%3DT.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DSafety%2520assessment%2520of%2520acyl%2520glucuronides%2520%25E2%2580%2593%2520A%2520simplified%2520paradigm%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D908%26epage%3D912%26doi%3D10.1124%2Fdmd.118.080515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, T.</span></span> <span> </span><span class="NLM_article-title">Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.tiv.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=26528891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2murvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=241-249&author=A.+Iwamuraauthor=M.+Itoauthor=H.+Mitsuiauthor=J.+Hasegawaauthor=K.+Kosakaauthor=I.+Kinoauthor=M.+Tsudaauthor=M.+Nakajimaauthor=T.+Yokoiauthor=T.+Kume&title=Toxicological+evaluation+of+acyl+glucuronides+utilizing+half-lives%2C+peptide+adducts%2C+and+immunostimulation+assays&doi=10.1016%2Fj.tiv.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays</span></div><div class="casAuthors">Iwamura, Atsushi; Ito, Masahito; Mitsui, Hideaki; Hasegawa, Jun; Kosaka, Keigo; Kino, Ichiro; Tsuda, Minoru; Nakajima, Miki; Yokoi, Tsuyoshi; Kume, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1_Part_B</span>),
    <span class="NLM_cas:pages">241-249</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chem. reactivity of acyl glucuronides (AGs) is believed to be involved in the toxicity of carboxylic acid-contg. drugs.  Both direct and immune-mediated toxicity have been suggested as possible mechanisms of toxicity; however, it remains unclear.  In the present study, we performed assays of half-lives, peptide adducts, and immunostimulation to evaluate the potential risk of AGs of 21 drugs and analyzed the relationship to the toxic category.  AGs of all withdrawn drugs tested in this study showed short half-lives and peptide adducts formation, but so did those of several safe drugs.  In contrast, only AGs of withdrawn and warning drugs induced interleukin-8 (IL-8) in human peripheral blood mononuclear cells (hPBMCs).  Using a DNA microarray assay, we found that zomepirac AG induced the mRNAs of 5 genes, including IL-8 in hPBMCs.  In addn., withdrawn and warning drugs were distinguished from safe drugs by an integrated score of relative mRNA expression levels of 5 genes.  The immunostimulation assay showed higher sensitivity, specificity, and accuracy compared with other methods.  In preclin. drug development, the evaluation of the reactivity of AGs using half-lives and peptide adducts assays followed by the evaluation of immunostimulation by highly reactive AGs using hPBMCs can contribute to improved drug safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDeT1JFabzj7Vg90H21EOLACvtfcHk0ljEhRSAwgrD_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2murvN&md5=7b5a574cc46c21a6d9151999b101c47c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DMitsui%26aufirst%3DH.%26aulast%3DHasegawa%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DK.%26aulast%3DKino%26aufirst%3DI.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DKume%26aufirst%3DT.%26atitle%3DToxicological%2520evaluation%2520of%2520acyl%2520glucuronides%2520utilizing%2520half-lives%252C%2520peptide%2520adducts%252C%2520and%2520immunostimulation%2520assays%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2015%26volume%3D30%26spage%3D241%26epage%3D249%26doi%3D10.1016%2Fj.tiv.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrell, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaughan, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, R. G.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(00)00981-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0024-3205%2800%2900981-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=11205870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2001&pages=785-797&author=M.+Wangauthor=M.+D.+Gorrellauthor=G.+W.+McCaughanauthor=R.+G.+Dickinson&title=Dipeptidyl+peptidase+IV+is+a+target+for+covalent+adduct+formation+with+the+acyl+glucuronide+metabolite+of+the+anti-inflammatory+drug+zomepirac&doi=10.1016%2FS0024-3205%2800%2900981-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac</span></div><div class="casAuthors">Wang, Min; Gorrell, Mark D.; McCaughan, Geoffrey W.; Dickinson, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">785-797</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The nonsteroidal anti-inflammatory drug zomepirac (ZP) is metabolised to a chem. reactive acyl glucuronide conjugate (ZAG) which can form covalent adducts with proteins.  In vivo, such adducts could initiate immune or toxic responses.  In rats given ZP, the major band detected in liver homogenates by immunoblotting with a polyclonal ZP antiserum was at 110 kDa.  This adduct was identified as ZP-modified dipeptidyl peptidase IV (DPP IV) by immunoblotting using the polyclonal ZP antiserum and monoclonal DPP IV antibodies OX-61 and 236.3.  In vitro, ZAG, but not ZP itself, covalently modified recombinant human and rat DPP IV.  Both monoclonal antibodies recognized DPP IV in livers from ZP- and vehicle-dosed rats.  Confirmation that the 110 kDa bands which were immunoreactive with the ZP and DPP IV antibodies represented the same mol. was obtained from a rat liver ext. reciprocally immunodepleted of antigens reactive with these two antibodies.  Furthermore, immunopptns. with OX-61 antibody followed by immunolotting with ZP antiserum, and the reciprocal expt., showed that both these antibodies recognized the same 110 kDa mol. in exts. of ZP-dosed rat liver.  The results verify that DPP IV is one of the protein targets for covalent modification during hepatic transport and biliary excretion of ZAG in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom8sQEIb9WerVg90H21EOLACvtfcHk0ljEhRSAwgrD_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVWhsQ%253D%253D&md5=fcd370f0d6b59f60080fbf2f1844ce51</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2800%2900981-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252800%252900981-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DGorrell%26aufirst%3DM.%2BD.%26aulast%3DMcCaughan%26aufirst%3DG.%2BW.%26aulast%3DDickinson%26aufirst%3DR.%2BG.%26atitle%3DDipeptidyl%2520peptidase%2520IV%2520is%2520a%2520target%2520for%2520covalent%2520adduct%2520formation%2520with%2520the%2520acyl%2520glucuronide%2520metabolite%2520of%2520the%2520anti-inflammatory%2520drug%2520zomepirac%26jtitle%3DLife%2520Sci.%26date%3D2001%26volume%3D68%26spage%3D785%26epage%3D797%26doi%3D10.1016%2FS0024-3205%2800%2900981-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worrall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jersey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, R. G.</span></span> <span> </span><span class="NLM_article-title">Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(98)00071-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2898%2900071-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9826947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXls1Oks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1998&pages=153-166&author=M.+J.+Baileyauthor=S.+Worrallauthor=J.+de+Jerseyauthor=R.+G.+Dickinson&title=Zomepirac+acyl+glucuronide+covalently+modifies+tubulin+in+vitro+and+in+vivo+and+inhibits+its+assembly+in+an+in+vitro+system&doi=10.1016%2FS0009-2797%2898%2900071-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system</span></div><div class="casAuthors">Bailey, Mark J.; Worrall, Simon; de Jersey, John; Dickinson, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Drugs possessing a carboxylate functional group usually form acyl glucuronides as major metabolites.  These electrophilic metabolites can undergo several spontaneous reactions, including covalent adduct formation with proteins.  The present study examd. whether covalent adducts were formed with microtubular protein (MTP, 85% α/β-tubulin) and whether this influenced its ability to assemble into microtubules.  Bovine brain microtubular protein (MTP) was purified by assembly-disassembly cycles and incubated with the non-steroidal anti-inflammatory drug (NSAID) zomepirac (ZP), its acyl glucuronide (ZAG) and rearrangement isomers (iso-ZAG) at various concns. for 2 h at room temp. and pH 7.5.  Assembly was monitored by change in turbidity (increase in absorbance at 340 nm).  Both ZAG and iso-ZAG caused dose-dependent inhibition of assembly (50% inhibition at about 1 mM), while ZP caused modest inhibition (<50% inhibition at 4 mM).  In a slightly different system, incubation of performed microtubules with 4 mM ZAG caused about 35% inhibition of reassembly ability, while modification of MTP under similar conditions resulted in about 85% redn. of assembly ability.  Immunoblotting with a ZP antiserum showed that ZAG and iso-ZAG covalently modified MTP in a dose-dependent manner, while ZP itself caused no modification.  Tubulin and many minor proteins comprising MTP were modified.  ZP-modified tubulin was shown to be present in the cytosol of livers from rats dosed twice daily for 3 days with ZP at 50 mg/kg, using a sandwich ELISA with ZP and tubulin antisera.  Whether any perturbation of microtubule assembly occurs in vivo as a result of this in vivo modification is currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVyk4zug18I7Vg90H21EOLACvtfcHk0lhdRt53Ib99Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1Oks7Y%253D&md5=ed332b8053c2c29a8d0f32c6a60a0523</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2898%2900071-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252898%252900071-4%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DM.%2BJ.%26aulast%3DWorrall%26aufirst%3DS.%26aulast%3Dde%2BJersey%26aufirst%3DJ.%26aulast%3DDickinson%26aufirst%3DR.%2BG.%26atitle%3DZomepirac%2520acyl%2520glucuronide%2520covalently%2520modifies%2520tubulin%2520in%2520vitro%2520and%2520in%2520vivo%2520and%2520inhibits%2520its%2520assembly%2520in%2520an%2520in%2520vitro%2520system%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1998%26volume%3D115%26spage%3D153%26epage%3D166%26doi%3D10.1016%2FS0009-2797%2898%2900071-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishinosono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuneyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Zomepirac acyl glucuronide is responsible for zomepirac-induced acute kidney injury in mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">888</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.069575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.116.069575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=27112166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWlt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=888-896&author=A.+Iwamuraauthor=K.+Watanabeauthor=S.+Akaiauthor=T.+Nishinosonoauthor=K.+Tsuneyamaauthor=S.+Odaauthor=T.+Kumeauthor=T.+Yokoi&title=Zomepirac+acyl+glucuronide+is+responsible+for+zomepirac-induced+acute+kidney+injury+in+mice&doi=10.1124%2Fdmd.116.069575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Zomepirac acyl glucuronide is responsible for zomepirac-induced acute kidney injury in mice</span></div><div class="casAuthors">Iwamura, Atsushi; Watanabe, Katsuhito; Akai, Sho; Nishinosono, Tsubasa; Tsuneyama, Koichi; Oda, Shingo; Kume, Toshiyuki; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">888-896</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Glucuronidation, an important phase II metabolic route, is generally considered to be a detoxification pathway.  However, acyl glucuronides (AGs) have been implicated in the toxicity of carboxylic acid drugs due to their electrophilic reactivity.  Zomepirac (ZP) was withdrawn from the market because of adverse effects such as renal toxicity.  Although ZP is mainly metabolized to acyl glucuronide (ZP-AG) by UDP-glucuronosyltransferase, the role of ZP-AG in renal toxicity is unknown.  In this study, we established a ZP-induced kidney injury mouse model by pretreatment with tri-o-tolyl phosphate (TOTP), a nonselective esterase inhibitor, and L-buthionine-(S,R)-sulfoximine (BSO), a glutathione synthesis inhibitor.  The role of ZP-AG in renal toxicity was investigated using this model.  The model showed significant increases in blood urea nitrogen (BUN) and creatinine (CRE), but not alanine aminotransferase.  The ZP-AG concns. were elevated by cotreatment with TOTP in the plasma and liver and esp. in the kidney.  The ZP-AG concns. in the kidney correlated with values for BUN and CRE.  Upon histopathol. examn., vacuoles and infiltration of mononuclear cells were obsd. in the model mouse.  In addn. to immune-related responses, oxidative stress markers, such as the glutathione/ disulfide glutathione ratio and malondialdehyde levels, were different in the mouse model.  The suppression of ZP-induced kidney injury by tempol, an antioxidant agent, suggested the involvement of oxidative stress in ZP-induced kidney injury.  This is the first study to demonstrate that AG accumulation in the kidney by TOTP and BSO treatment could explain renal toxicity and to show the in vivo toxicol. potential of AGs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLp4EJB433w7Vg90H21EOLACvtfcHk0lhdRt53Ib99Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWlt7rK&md5=dcfdac0221feea276b38d3743ded05d8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.069575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.069575%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAkai%26aufirst%3DS.%26aulast%3DNishinosono%26aufirst%3DT.%26aulast%3DTsuneyama%26aufirst%3DK.%26aulast%3DOda%26aufirst%3DS.%26aulast%3DKume%26aufirst%3DT.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DZomepirac%2520acyl%2520glucuronide%2520is%2520responsible%2520for%2520zomepirac-induced%2520acute%2520kidney%2520injury%2520in%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D888%26epage%3D896%26doi%3D10.1124%2Fdmd.116.069575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flückiger, R.</span></span> <span> </span><span class="NLM_article-title">Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">13542</span>– <span class="NLM_lpage">13545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3759977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL28XlvVKhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1986&pages=13542-13545&author=N.+Ibergauthor=R.+Fl%C3%BCckiger&title=Nonenzymatic+glycosylation+of+albumin+in+vivo.+Identification+of+multiple+glycosylated+sites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Nonenzymic glycosylation of albumin in vivo.  Identification of multiple glycosylated sites</span></div><div class="casAuthors">Iberg, Niggi; Flueckiger, Rudolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13542-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Nonenzymic glycosylation (glycation) of albumin in vivo occurred at multiple sites.  Glucose became attached to lysine-(Lys-) 199, Lys-281, Lys-439, and Lys-525 as well as to some other Lys residues.  The principal glycated site was Lys-525; ∼33% of the overall glycation occurred at this site.  This site specificity was remarkable and was postulated to be a consequence of local catalysis of the glycation reaction.  Apparently, pos. charged amino groups in the protein catalyzed an Amadori rearrangement at specific sites.  The principal glycated site, Lys-525, was in a Lys-Lys sequence; other glycated sites were in Lys-Lys, Lys-His, and Lys-His-Lys sequences or were near disulfide bridges which were likely to place amino groups of more remote parts of the protein closer to these sites.  The occurrence of glycation at most of the identified sites in albumin from diabetic patients was explained by the concept of local acid-base catalysis of the Amadori rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjV56t468B7Vg90H21EOLACvtfcHk0lhmxBqkHCmrcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XlvVKhsL0%253D&md5=d55f42b2425ec44234bdaed3104f3a48</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIberg%26aufirst%3DN.%26aulast%3DFl%25C3%25BCckiger%26aufirst%3DR.%26atitle%3DNonenzymatic%2520glycosylation%2520of%2520albumin%2520in%2520vivo.%2520Identification%2520of%2520multiple%2520glycosylated%2520sites%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1986%26volume%3D261%26spage%3D13542%26epage%3D13545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garlick, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazer, J. S.</span></span> <span> </span><span class="NLM_article-title">The principal site of nonenzymatic glycosylation of human serum albumin in vivo</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>258</i></span>,  <span class="NLM_fpage">6142</span>– <span class="NLM_lpage">6146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6853480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL3sXktlCksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1983&pages=6142-6146&author=R.+L.+Garlickauthor=J.+S.+Mazer&title=The+principal+site+of+nonenzymatic+glycosylation+of+human+serum+albumin+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The principal site of nonenzymic glycosylation of human serum albumin in vivo</span></div><div class="casAuthors">Garlick, Robert L.; Mazer, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6142-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The major site of nonenzymic glycosylation of human serum albumin was detd. in vivo.  This was accomplished by reacting freshly purified human serum albumin with Na[3H]BH4 followed by aminoethylation and tryptic digestion.  The tryptic peptides were sepd. into a sol. fraction which contained 88% of the total 3H radioactivity and an insol. fraction.  To isolate the 3H-labeled glycosylated peptides, the sol. tryptic peptide fraction was first subjected to boronic acid affinity chromatog.  Cation-exchange chromatog. then sepd. the sol. glycosylated peptides into a major peak which contained 48% of the total recovered 3H radioactivity and a no. of minor peptide fractions.  The amino acid compn. of the major peptide was: threonine, 2 glutamate, alanine, 2 valine, 2 leucine, lysine, and lysino-1-deoxysorbitol.  In accord with the primary structure of human serum albumin, this amino acid compn. corresponds precisely to residues 525-534.  Glucitol-lysine, the N-terminal residue of this peptide, is totally resistant to cleavage by trypsin.  Thus, lysine-525 is the predominant site of nonenzymic glycosylation of human serum albumin in vivo.  Chromatog. on GlycoGel B boronic acid affinity gel indicates that 10-12% of normal serum albumin is glycosylated.  The rate of nonenzymic glycosylation of this protein in vivo is ∼9-fdd that of human Hb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLDV_9QCWL7Vg90H21EOLACvtfcHk0lhmxBqkHCmrcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXktlCksrY%253D&md5=2c29884bd986679cbb8bd50293f23b4c</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarlick%26aufirst%3DR.%2BL.%26aulast%3DMazer%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520principal%2520site%2520of%2520nonenzymatic%2520glycosylation%2520of%2520human%2520serum%2520albumin%2520in%2520vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1983%26volume%3D258%26spage%3D6142%26epage%3D6146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baynes, J. W.</span></span> <span> </span><span class="NLM_article-title">Non-enzymatic glycosylation and the chronic complications of diabetes: an overview</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/BF00281113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2FBF00281113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6370764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaL2c7otleluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1984&pages=93-98&author=L.+Kennedyauthor=J.+W.+Baynes&title=Non-enzymatic+glycosylation+and+the+chronic+complications+of+diabetes%3A+an+overview&doi=10.1007%2FBF00281113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Non-enzymatic glycosylation and the chronic complications of diabetes: an overview</span></div><div class="casAuthors">Kennedy L; Baynes J W</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-8</span>
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoYEoXH1FwkPtos8R3JUhXfW6udTcc2eZws_e_pbrD0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7otleluw%253D%253D&md5=32a2347c51ce27998c02b53aadd634ea</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2FBF00281113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00281113%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DL.%26aulast%3DBaynes%26aufirst%3DJ.%2BW.%26atitle%3DNon-enzymatic%2520glycosylation%2520and%2520the%2520chronic%2520complications%2520of%2520diabetes%253A%2520an%2520overview%26jtitle%3DDiabetologia%26date%3D1984%26volume%3D26%26spage%3D93%26epage%3D98%26doi%3D10.1007%2FBF00281113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boelsterli, U. A.</span></span> <span> </span><span class="NLM_article-title">Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/1389200023337315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2174%2F1389200023337315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12093359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlCqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=439-450&author=U.+A.+Boelsterli&title=Xenobiotic+acyl+glucuronides+and+acyl+CoA+thioesters+as+protein-reactive+metabolites+with+the+potential+to+cause+idiosyncratic+drug+reactions&doi=10.2174%2F1389200023337315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions</span></div><div class="casAuthors">Boelsterli, Urs A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-450</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Some carboxylic acid-contg. drugs have been implicated in rare but serious adverse reactions.  These compds. can be bioactivated via two distinct pathways: by UDP-glucuronosyltransferase-catalyzed conjugation with glucuronic acid, resulting in the formation of acyl glucuronides, or by acyl-CoA synthetase-catalyzed formation of acyl-CoA thioesters.  This review compares the two types of potentially reactive metabolites with respect to their stability, protein-reactivity, target selectivity, and disposition in the liver, and summarizes the evidence which links acyl glucuronide and acyl-CoA thioester formation with downstream toxicol. effects.  While with increasing drug concn. the acyl glucuronide pathway may prevail, CoA intermediates may be more reactive.  Both metabolites are electrophilic species which can acylate target proteins if they escape inactivation by S-glutathione-thioester formation.  A crucial factor is the up-concn. of acyl glucuronides in hepatocytes and the biliary tree, due to vectorial transport by conjugate export pumps, where they may selectively acylate canalicular membrane proteins.  Furthermore, positional isomers, which are avidly formed by acyl migration, can glycate proteins in the liver and at more distal sites.  In contrast, acyl-CoA esters may be more rapidly hydrolyzed or further metabolized in hepatocytes, and their hepatobiliary transport has not been well explored.  While there is accumulating evidence that acyl glucuronides can alter cellular function by various mechanisms, including haptenation of peptides, crit. protein acylation or glycation, or direct stimulation of neutrophils and macrophages, the role of acyl-CoA intermediates is less clear.  More work is needed to provide a causal link between protein-reactive acyl glucuronides and acyl-CoA thioesters and the rare and unpredictable idiosyncratic drug reactions in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiV3rWJsqFyLVg90H21EOLACvtfcHk0lhmxBqkHCmrcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlCqtrc%253D&md5=0cf501c56ea4a4ce5ba884ebb14fdba0</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2174%2F1389200023337315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200023337315%26sid%3Dliteratum%253Aachs%26aulast%3DBoelsterli%26aufirst%3DU.%2BA.%26atitle%3DXenobiotic%2520acyl%2520glucuronides%2520and%2520acyl%2520CoA%2520thioesters%2520as%2520protein-reactive%2520metabolites%2520with%2520the%2520potential%2520to%2520cause%2520idiosyncratic%2520drug%2520reactions%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2002%26volume%3D3%26spage%3D439%26epage%3D450%26doi%3D10.2174%2F1389200023337315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didolkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.004341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.105.004341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16251255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=145-151&author=Q.+Chenauthor=G.+A.+Dossauthor=E.+C.+Tungauthor=W.+Liuauthor=Y.+S.+Tangauthor=M.+P.+Braunauthor=V.+Didolkarauthor=J.+R.+Straussauthor=R.+W.+Wangauthor=R.+A.+Stearnsauthor=D.+C.+Evansauthor=T.+A.+Baillieauthor=W.+Tang&title=Evidence+for+the+bioactivation+of+zomepirac+and+tolmetin+by+an+oxidative+pathway%3A+identification+of+glutathione+adducts+in+vitro+in+human+liver+microsomes+and+in+vivo+in+rats&doi=10.1124%2Fdmd.105.004341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: Identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats</span></div><div class="casAuthors">Chen, Qing; Doss, George A.; Tung, Elaine C.; Liu, Wensheng; Tang, Yui S.; Braun, Matthew P.; Didolkar, Varsha; Strauss, John R.; Wang, Regina W.; Stearns, Ralph A.; Evans, David C.; Baillie, Thomas A.; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although zomepirac (ZP) and tolmetin (TM) induce anaphylactic reactions and form reactive acyl glucuronides, a direct link between the two events remains obscure.  We report herein that, in addn. to acyl glucuronidation, both drugs are subject to oxidative bioactivation.  Following incubations of ZP with human liver microsomes fortified with NADPH and glutathione (GSH), a metabolite with an MH+ ion at m/z 597 was detected by LC/MS/MS.  On the basis of collision-induced dissocn. and NMR evidence, the structure of this metabolite was detd. to be 5-[4'-chlorobenzoyl]-1,4-dimethyl-3-glutathionylpyrrole-2-acetic acid (ZP-SG), suggesting that the pyrrole moiety of ZP had undergone oxidn. to an epoxide intermediate, followed by addn. of GSH and loss of the elements of H2O to yield the obsd. conjugate.  The oxidative bioactivation of ZP most likely is catalyzed by cytochrome P 450 3A4, since the formation of ZP-SG was reduced to ∼10% of control values following pretreatment of human liver microsomes with ketoconazole or with an inhibitory anti-P 450 3A4 IgG.  A similar GSH adduct, namely 5-[4'-methylbenzoyl]-1-methyl-3-glutathionylpyrrole-2-acetic acid (TM-SG), was identified when TM was incubated with human liver microsomal prepns.  The relevance of these in vitro findings to the in vivo situation was established through the detection of the same thiol adducts in rats treated with ZP and TM, resp.  Taken together, these data suggest that, in addn. to the formation of acyl glucuronides, oxidative metab. of ZP and TM affords reactive species that may haptenize proteins and thereby contribute to the drug-mediated anaphylactic reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3QasE3CrJIrVg90H21EOLACvtfcHk0lh7odlyiPEtRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslyisA%253D%253D&md5=b73ce8c9810c8a60131e488effd82b2c</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004341%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DTung%26aufirst%3DE.%2BC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DY.%2BS.%26aulast%3DBraun%26aufirst%3DM.%2BP.%26aulast%3DDidolkar%26aufirst%3DV.%26aulast%3DStrauss%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DEvidence%2520for%2520the%2520bioactivation%2520of%2520zomepirac%2520and%2520tolmetin%2520by%2520an%2520oxidative%2520pathway%253A%2520identification%2520of%2520glutathione%2520adducts%2520in%2520vitro%2520in%2520human%2520liver%2520microsomes%2520and%2520in%2520vivo%2520in%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D145%26epage%3D151%26doi%3D10.1124%2Fdmd.105.004341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osbild, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maunit, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaume, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapicque, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaglia, E.</span></span> <span> </span><span class="NLM_article-title">Interaction of the electrophilic ketoprofenyl-glucuronide and ketoprofenyl-coenzyme A conjugates with cytosolic glutathione S-transferases</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.016808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.107.016808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=17962374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=260-267&author=S.+Osbildauthor=J.+Bourauthor=B.+Maunitauthor=C.+Guillaumeauthor=C.+Asensioauthor=J.+F.+Mullerauthor=P.+Netterauthor=G.+Kirschauthor=D.+Bagrelauthor=F.+Lapicqueauthor=E.+Battaglia&title=Interaction+of+the+electrophilic+ketoprofenyl-glucuronide+and+ketoprofenyl-coenzyme+A+conjugates+with+cytosolic+glutathione+S-transferases&doi=10.1124%2Fdmd.107.016808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the electrophilic ketoprofenyl-glucuronide and ketoprofenyl-coenzyme A conjugates with cytosolic glutathione S-transferases</span></div><div class="casAuthors">Osbild, Sandra; Bour, Jerome; Maunit, Benoit; Guillaume, Cecile; Asensio, Carine; Muller, Jean-Francois; Netter, Patrick; Kirsch, Gilbert; Bagrel, Denyse; Lapicque, Francoise; Battaglia, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-267</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Carboxylic acid-contg. drugs are metabolized mainly through the formation of glucuronide and CoA esters.  These conjugates have been suspected to be responsible for the toxicity of several nonsteroidal anti-inflammatory drugs because of the reactivity of the electrophilic ester bond.  In the present study we investigated the reactivity of ketoprofenyl-acylglucuronide (KPF-OG) and ketoprofenyl-acyl-CoA (KPF-SCoA) toward cytosolic rat liver glutathione S-transferases (GST).  We obsd. that KPF-SCoA, but not KPF-OG inhibited the conjugation of 1-chloro-2,4-dinitrobenzene and 4-nitroquinoline N-oxide catalyzed by both purified cytosolic rat liver GST and GST from FAO and H5-6 rat hepatoma cell lines.  Photoaffinity labeling with KPF-SCoA suggested that the binding of this metabolite may overlap the binding site of 4-methylumbelliferone sulfate.  Furthermore, high-performance liq. chromatog. and mass spectrometry anal. showed that both hydrolysis and transacylation reactions were obsd. in the presence of GST and glutathione.  The formation of ketoprofenyl-S-acyl-glutathione could be kinetically characterized (apparent Km = 196.0 ± 70.6 μM).  It is concluded that KPF-SCoA is both a GST inhibitor and a substrate of a GST-dependent transacylation reaction.  The reactivity and inhibitory potency of thioester CoA derivs. toward GST may have potential implications on the reported in vivo toxicity of some carboxylic acid-contg. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp38LSCw5PvibVg90H21EOLACvtfcHk0lh7odlyiPEtRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yktbY%253D&md5=078ea39bd856f4f95e7d253f8cf56f87</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.016808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.016808%26sid%3Dliteratum%253Aachs%26aulast%3DOsbild%26aufirst%3DS.%26aulast%3DBour%26aufirst%3DJ.%26aulast%3DMaunit%26aufirst%3DB.%26aulast%3DGuillaume%26aufirst%3DC.%26aulast%3DAsensio%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DJ.%2BF.%26aulast%3DNetter%26aufirst%3DP.%26aulast%3DKirsch%26aufirst%3DG.%26aulast%3DBagrel%26aufirst%3DD.%26aulast%3DLapicque%26aufirst%3DF.%26aulast%3DBattaglia%26aufirst%3DE.%26atitle%3DInteraction%2520of%2520the%2520electrophilic%2520ketoprofenyl-glucuronide%2520and%2520ketoprofenyl-coenzyme%2520A%2520conjugates%2520with%2520cytosolic%2520glutathione%2520S-transferases%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D260%26epage%3D267%26doi%3D10.1124%2Fdmd.107.016808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitholtz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurva, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span> <span> </span><span class="NLM_article-title">Significantly different covalent binding of oxidative metabolites, acyl glucuronides, and S-acyl CoA conjugates formed from xenobiotic carboxylic acids in human liver microsomes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">886</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1021/tx500514z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500514z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2ht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=886-896&author=M.+Darnellauthor=K.+Breitholtzauthor=E.+M.+Isinauthor=U.+Jurvaauthor=L.+Weidolf&title=Significantly+different+covalent+binding+of+oxidative+metabolites%2C+acyl+glucuronides%2C+and+S-acyl+CoA+conjugates+formed+from+xenobiotic+carboxylic+acids+in+human+liver+microsomes&doi=10.1021%2Ftx500514z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes</span></div><div class="casAuthors">Darnell, Malin; Breitholtz, Katarina; Isin, Emre M.; Jurva, Ulrik; Weidolf, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">886-896</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Xenobiotic carboxylic acids may be metabolized to oxidative metabolites, acyl glucuronides, and/or S-acyl-CoA thioesters (CoA conjugates) in vitro, e.g., in hepatocytes, and in vivo.  These metabolites can potentially be reactive species and bind covalently to tissue proteins and are generally considered to mediate adverse drug reactions in humans.  Acyl glucuronide metabolites have been the focus of reactive metabolite research for decades, whereas drug-CoA conjugates, which have been shown to be up to 40-70 times more reactive, have been given much less attention.  In an attempt to dissect the contribution of different pathways to covalent binding, we utilized human liver microsomes supplemented with NADPH, uridine 5'-diphosphoglucuronic acid (UDPGA), or CoA to evaluate the reactivity of each metabolite sep.  Seven carboxylic acid drugs were included in this study.  While ibuprofen and tolmetin are still on the market, ibufenac, fenclozic acid, tienilic acid, suprofen, and zomepirac were stopped before their launch or withdrawn.  The reactivities of the CoA conjugates of ibuprofen, ibufenac, fenclozic acid, and tolmetin were higher compared to those of their corresponding oxidative metabolites and acyl glucuronides, as measured by the level of covalent binding to human liver microsomal proteins.  The highest covalent binding was obsd. for ibuprofenyl-CoA and ibufenacyl-CoA, to levels of 1000 and 8600 pmol drug eq/mg protein, resp.  In contrast and in agreement with the proposed P 450-mediated toxicity for these drug mols., the reactivities of oxidative metabolites of suprofen and tienilic acid were higher compared to the reactivities of their conjugated metabolites, with NADPH-dependent covalent binding of 250 pmol drug eq/mg protein for both drugs.  The seven drugs all formed UDPGA-dependent acyl glucuronides, but none of these resulted in covalent binding.  This study shows that, unlike studies with hepatocytes or in vivo, human liver microsomes provide an opportunity to investigate the reactivity of individual metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWKWURekmygLVg90H21EOLACvtfcHk0lh7odlyiPEtRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2ht7k%253D&md5=770a4825095e7651d8271b66c86568a1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Ftx500514z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500514z%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DM.%26aulast%3DBreitholtz%26aufirst%3DK.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DJurva%26aufirst%3DU.%26aulast%3DWeidolf%26aufirst%3DL.%26atitle%3DSignificantly%2520different%2520covalent%2520binding%2520of%2520oxidative%2520metabolites%252C%2520acyl%2520glucuronides%252C%2520and%2520S-acyl%2520CoA%2520conjugates%2520formed%2520from%2520xenobiotic%2520carboxylic%2520acids%2520in%2520human%2520liver%2520microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26spage%3D886%26epage%3D896%26doi%3D10.1021%2Ftx500514z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brass, E. P.</span></span> <span> </span><span class="NLM_article-title">Overview of coenzyme A metabolism and its role in cellular toxicity</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/0009-2797(94)90010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0009-2797%2894%2990010-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8168169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFOgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1994&pages=203-214&author=E.+P.+Brass&title=Overview+of+coenzyme+A+metabolism+and+its+role+in+cellular+toxicity&doi=10.1016%2F0009-2797%2894%2990010-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of coenzyme A metabolism and its role in cellular toxicity</span></div><div class="casAuthors">Brass, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-14</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    </div><div class="casAbstract">A review with 72 refs. on the role of CoA as a cofactor for a no. of oxidative and biosynthetic reactions in intermediary metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhg79FIJiH7Vg90H21EOLACvtfcHk0ljw8FFGWgrhPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFOgtbc%253D&md5=01957e5e80b8287f9a210505b9a68059</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0009-2797%2894%2990010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0009-2797%252894%252990010-8%26sid%3Dliteratum%253Aachs%26aulast%3DBrass%26aufirst%3DE.%2BP.%26atitle%3DOverview%2520of%2520coenzyme%2520A%2520metabolism%2520and%2520its%2520role%2520in%2520cellular%2520toxicity%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1994%26volume%3D90%26spage%3D203%26epage%3D214%26doi%3D10.1016%2F0009-2797%2894%2990010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A. Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csizmadia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakilynejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragan, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, P. J.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfx018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28108665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2017&pages=50-61&author=F.+S.+Wolenskiauthor=A.+Z.+X.+Zhuauthor=M.+Johnsonauthor=S.+Yuauthor=Y.+Moriyaauthor=T.+Ebiharaauthor=V.+Csizmadiaauthor=J.+Grievesauthor=M.+Patonauthor=M.+Liaoauthor=C.+Gemskiauthor=L.+Panauthor=M.+Vakilynejadauthor=Y.+P.+Draganauthor=S.+K.+Chowdhuryauthor=P.+J.+Kirby&title=Fasiglifam+%28TAK-875%29+alters+bile+acid+homeostasis+in+rats+and+dogs%3A+a+potential+cause+of+drug+induced+liver+injury&doi=10.1093%2Ftoxsci%2Fkfx018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury</span></div><div class="casAuthors">Wolenski, Francis S.; Zhu, Andy Z. X.; Johnson, Mike; Yu, Shaoxia; Moriya, Yuu; Ebihara, Takuya; Csizmadia, Vilmos; Grieves, Jessica; Paton, Martin; Liao, Mingxiang; Gemski, Christopher; Pan, Liping; Vakilynejad, Majid; Dragan, Yvonne P.; Chowdhury, Swapan K.; Kirby, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-61</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects.  A mechanistic investigation described in this manuscript focused on the inhibition of bile acid (BA) transporters as a driver of the liver findings.  TAK-875 was an in vitro inhibitor of multiple influx (NTCP and OATPs) and efflux (BSEP and MRPs) hepatobiliary BA transporters at micromolar concns.  Repeat dose studies detd. that TAK-875 caused a dose-dependent increase in serum total BA in rats and dogs.  Addnl., there were dose-dependent increases in both unconjugated and conjugated individual BAs in both species.  Rats had an increase in serum markers of liver injury without correlative microscopic signs of tissue damage.  Two of 6 dogs that received the highest dose of TAK-875 developed liver injury with clin. pathol. changes, and by microscopic anal. had portal granulomatous inflammation with neutrophils around a cryst. deposition.  The BA compn. of dog bile also significantly changed in a dose-dependent manner following TAK-875 administration.  At the highest dose, levels of taurocholic acid were 50% greater than in controls with a corresponding 50% decrease in taurochenodeoxycholic acid.  Transporter inhibition by TAK-875 may cause liver injury in dogs through altered bile BA compn. characteristics, as evidenced by cryst. deposition, likely composed of test article, in the bile duct.  In conclusion, a combination of in vitro and in vivo evidence suggests that BA transporter inhibition could contribute to TAK-875-mediated liver injury in dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVd38JAy40nrVg90H21EOLACvtfcHk0ljw8FFGWgrhPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsrg%253D&md5=028c43e6fe1d5a2b0f7f75d03926993a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx018%26sid%3Dliteratum%253Aachs%26aulast%3DWolenski%26aufirst%3DF.%2BS.%26aulast%3DZhu%26aufirst%3DA.%2BZ.%2BX.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DMoriya%26aufirst%3DY.%26aulast%3DEbihara%26aufirst%3DT.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DGrieves%26aufirst%3DJ.%26aulast%3DPaton%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DGemski%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DVakilynejad%26aufirst%3DM.%26aulast%3DDragan%26aufirst%3DY.%2BP.%26aulast%3DChowdhury%26aufirst%3DS.%2BK.%26aulast%3DKirby%26aufirst%3DP.%2BJ.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%2520alters%2520bile%2520acid%2520homeostasis%2520in%2520rats%2520and%2520dogs%253A%2520a%2520potential%2520cause%2520of%2520drug%2520induced%2520liver%2520injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D157%26spage%3D50%26epage%3D61%26doi%3D10.1093%2Ftoxsci%2Fkfx018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcinak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munsaka, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span> <span> </span><span class="NLM_article-title">Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1007/s40264-018-0642-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2Fs40264-018-0642-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29492878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=625-640&author=J.+Marcinakauthor=M.+S.+Munsakaauthor=P.+B.+Watkinsauthor=T.+Ohiraauthor=N.+Smith&title=Liver+safety+of+fasiglifam+%28TAK-875%29+in+patients+with+type+2+diabetes%3A+review+of+the+global+clinical+trial+experience&doi=10.1007%2Fs40264-018-0642-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience</span></div><div class="casAuthors">Marcinak, John F.; Munsaka, Melvin S.; Watkins, Paul B.; Ohira, Takashi; Smith, Neila</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">625-640</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: Fasiglifam (TAK-875) is a G protein-coupled receptor 40 agonist that was being investigated for treatment of type 2 diabetes mellitus (T2DM).  A development program was terminated late in phase III clin. trials due to liver safety concerns.  Methods: The liver safety of fasiglifam was assessed from data based on six phase II and nine phase III double-blind studies and two open-label studies with emphasis on pooled data from 15 double-blind studies from both global and Japanese development programs.  Taking into consideration different daily doses of fasiglifam administered in clin. studies, the primary comparisons were between all patients exposed to fasiglifam (any dose) vs. placebo, and, where applicable, vs. the two active comparators, sitagliptin or glimepiride.  A Liver Safety Evaluation Committee consisting of hepatologists blinded to treatment assignments evaluated hepatic adverse events (AEs) and serious AEs (SAEs) for causal relationship to study drug.  Results: The anal. included data from 9139 patients with T2DM in 15 double-blind controlled studies who received either fasiglifam (n = 5359, fasiglifam group), fasiglifam and sitagliptin (n = 123), or a comparator agent (n = 3657, non-exposed group consisting of placebo and other antidiabetic agents).  Exposure to treatment for more than 1 yr ranged from 249 patients in the placebo arm, to 370 patients in the glimepiride arm and 617 patients in the fasiglifam 50 mg arm.  The primary focus of the anal. was on the hepatic safety of fasiglifam.  The overall safety profile based on treatment-emergent AEs (TEAEs), SAEs, deaths, and withdrawal due to AEs was similar between fasiglifam and placebo (excluding liver test abnormalities).  However, there was an increased incidence rate of serum alanine aminotransferase (ALT) elevations > 3 × upper limit of normal (ULN), 5 × ULN, and 10 × ULN in fasiglifam-treated patients compared with those treated with placebo or active comparators.  ALT elevations > 3 × ULN for fasiglifam were 2.7% compared with 0.8 and 0.5% for the active comparators and placebo.  There did not appear to be a clear dose response in incidence of ALT elevations between patients receiving 25 or 50 mg daily.  The cumulative incidence of elevations in serum ALT > 3 × ULN was higher in the first 6 mo of treatment with fasiglifam compared with both placebo and the active comparators, but the rate of new ALT elevations appeared to be similar across all treatment groups thereafter.  No demog. or baseline patient characteristics were identified to predict elevations exceeding ALT > 3 × ULN in fasiglifam-treated patients.  The pattern of liver injury with fasiglifam was hepatocellular, and there were no reports of liver-related deaths, liver failure or life-threatening liver injury.  Most fasiglifam-assocd. ALT elevations were asymptomatic and resolved promptly upon discontinuing treatment, but in two patients the recovery was prolonged.  Importantly, three important serious liver injury cases were identified among fasiglifam-treated patients; one case was adjudicated to be a clear Hy's Law case and the two remaining cases were considered to closely approx. Hy's Law cases.  Conclusions: Although the incidence of overall AEs, SAEs, and deaths was similar between fasiglifam and placebo, a liver signal was identified based primarily on the difference in liver chem. values in the fasiglifam group compared with the placebo and active comparator groups.  Three serious liver injuries were attributed to fasiglifam treatment.  Clin. development of fasiglifam was halted due to these liver safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3GJELAHno-rVg90H21EOLACvtfcHk0ljw8FFGWgrhPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKnt7s%253D&md5=8b10e5b20ea33dda3dd7871d97569f0f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs40264-018-0642-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-018-0642-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DMunsaka%26aufirst%3DM.%2BS.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DOhira%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DN.%26atitle%3DLiver%2520safety%2520of%2520fasiglifam%2520%2528TAK-875%2529%2520in%2520patients%2520with%2520type%25202%2520diabetes%253A%2520review%2520of%2520the%2520global%2520clinical%2520trial%2520experience%26jtitle%3DDrug%2520Saf.%26date%3D2018%26volume%3D41%26spage%3D625%26epage%3D640%26doi%3D10.1007%2Fs40264-018-0642-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shavadia, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLeve, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Home, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, C. B.</span></span> <span> </span><span class="NLM_article-title">Determination of fasiglifam-induced liver toxicity: insights from the data monitoring committee of the fasiglifam clinical trials program</span>. <i>Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1177/1740774519836766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1177%2F1740774519836766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30880443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BB3cbltVemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=253-262&author=J.+S.+Shavadiaauthor=A.+Sharmaauthor=X.+Guauthor=J.+Neatonauthor=L.+DeLeveauthor=D.+Holmesauthor=P.+Homeauthor=R.+H.+Eckelauthor=P.+B.+Watkinsauthor=C.+B.+Granger&title=Determination+of+fasiglifam-induced+liver+toxicity%3A+insights+from+the+data+monitoring+committee+of+the+fasiglifam+clinical+trials+program&doi=10.1177%2F1740774519836766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program</span></div><div class="casAuthors">Shavadia Jay S; Sharma Abhinav; Gu Xiangqiong; Granger Christopher B; Shavadia Jay S; Neaton James; DeLeve Laurie; Holmes David; Home Phillip; Eckel Robert H; Watkins Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical trials (London, England)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-262</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Different approaches to safety event collection influence the determination of liver toxicity within drug development programs.  Herein, a description of how fasiglifam-induced liver injury was detected is provided.  METHODS:  This eight-trial drug development program was intended to evaluate fasiglifam (25 mg, 50 mg) against placebo or active comparators (glimepiride, sitagliptin) in approximately 11,000 suboptimally controlled patients with type 2 diabetes (terminated Dec 2013 due to liver toxicity).  Liver safety had been pre-identified as a concern, and within the phase 3 trials, was measured through (1) adverse event reporting, (2) central predefined liver monitoring schedule with various thresholds for potential drug-induced liver injury, and (3) blinded adjudication of serious liver toxicity by a panel of experts in drug-induced liver injury.  A single data monitoring committee provided safety oversight across all trials within the program.  FINDINGS:  Prior to program termination, 7595 of 7602 (99.9%) randomized participants across the eight trials received at least one dose of the study drug (fasiglifam, placebo, or active control).  No concerning trends were noted in adverse or serious adverse event frequency, suspected unexpected serious adverse reaction, alanine or aspartate transaminase elevations, or hepatobiliary or gastrointestinal adverse events as reported by local site investigators.  However, the predefined central liver safety measurements revealed a greater frequency of possible Hy's Law cases (5 vs 2) and a 3- to 7-fold greater relative risk in alanine or aspartate transaminase elevation (with respect to upper limit of normal) within fasiglifam recipients compared with placebo/active control: alanine or aspartate transaminase > 3×: relative risk 3.34 (95% confidence interval 2.29-4.90), alanine or aspartate transaminase > 5×: relative risk 6.60 (95% confidence interval 3.03-14.38), alanine or aspartate transaminase > 8×: relative risk 6.14 (95% confidence interval 2.18-17.27), and alanine or aspartate transaminase > 10×: relative risk 6.74 (95% confidence interval 2.05, 22.14).  All elevations resolved on study drug discontinuation.  Drug-induced liver injury was adjudicated as highly likely or probably related in 0.64% of fasiglifam-treated versus 0.06% placebo or active control-treated patients.  CONCLUSION:  In spite of clear liver toxicity detected with a systematic surveillance program, liver safety signals were not identified from investigator adverse event reporting alone.  By integrating key safety monitoring processes within the randomized design of adequately sized clinical trials, the rare but serious liver toxicity signal became clear, leading to timely program termination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLkSQnxSaNr75oR8RchjrrfW6udTcc2eYEMBvrcQlGQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbltVemsA%253D%253D&md5=0a04972e2057f6d04a94f8ace971a312</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1177%2F1740774519836766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1740774519836766%26sid%3Dliteratum%253Aachs%26aulast%3DShavadia%26aufirst%3DJ.%2BS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DNeaton%26aufirst%3DJ.%26aulast%3DDeLeve%26aufirst%3DL.%26aulast%3DHolmes%26aufirst%3DD.%26aulast%3DHome%26aufirst%3DP.%26aulast%3DEckel%26aufirst%3DR.%2BH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26atitle%3DDetermination%2520of%2520fasiglifam-induced%2520liver%2520toxicity%253A%2520insights%2520from%2520the%2520data%2520monitoring%2520committee%2520of%2520the%2520fasiglifam%2520clinical%2520trials%2520program%26jtitle%3DClin.%2520Trials%26date%3D2019%26volume%3D16%26spage%3D253%26epage%3D262%26doi%3D10.1177%2F1740774519836766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kogame, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, Y.</span></span> <span> </span><span class="NLM_article-title">Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1080/00498254.2018.1453100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F00498254.2018.1453100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29557709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntV2qsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=433-445&author=A.+Kogameauthor=R.+Leeauthor=L.+Panauthor=M.+Sudoauthor=M.+Nonakaauthor=Y.+Moriyaauthor=T.+Higuchiauthor=Y.+Tagawa&title=Disposition+and+metabolism+of+the+G+protein-coupled+receptor+40+agonist+TAK-875+%28fasiglifam%29+in+rats%2C+dogs%2C+and+humans&doi=10.1080%2F00498254.2018.1453100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans</span></div><div class="casAuthors">Kogame, Akifumi; Lee, Ronald; Pan, Liping; Sudo, Miyako; Nonaka, Masami; Moriya, Yuu; Higuchi, Tomoaki; Tagawa, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">433-445</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The absorption, distribution, metab., and excretion of fasiglifam were investigated in rats, dogs, and humans.  The abs. oral bioavailability of fasiglifam was high in all species (>76.0%).  After oral administration of [14C]fasiglifam, the administered radioactivity was quant. recovered and the major route of excretion of radioactivity was via feces in all species.  Fasiglifam was a major component in the plasma and feces in all species.  Its oxidative metabolite (M-I) was obsd. as a minor metabolite in rat and human plasma (<10% of plasma radioactivity).  In human plasma, hydroxylated fasiglifam (T-1676427), the glucuronide of fasiglifam (fasiglifam-G), and the glucuronide of M-I were detected as addnl. minor metabolites (<2% of plasma radioactivity).  None of these metabolites were specific to humans.  Fasiglifam-G was the major component in the rat and dog bile.  In vitro cytochrome P 450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) reaction phenotyping indicated that oxidn. (to form M-I and T-1676427) and glucuronidation of fasiglifam are mainly mediated by CYP3A4/5 and UGT1A3, resp.  Fasiglifam and fasiglifam-G are substrates of BCRP and Mrp2/MRP2, resp.  Glucuronidation of fasiglifam-G was found to be the predominant elimination pathway of fasiglifam in all species tested, including humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEs8-FNDQE47Vg90H21EOLACvtfcHk0ljkzKUU6AdFPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntV2qsb8%253D&md5=282fac60fc0726e63958f90a2d7e8fd3</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1080%2F00498254.2018.1453100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498254.2018.1453100%26sid%3Dliteratum%253Aachs%26aulast%3DKogame%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DSudo%26aufirst%3DM.%26aulast%3DNonaka%26aufirst%3DM.%26aulast%3DMoriya%26aufirst%3DY.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DTagawa%26aufirst%3DY.%26atitle%3DDisposition%2520and%2520metabolism%2520of%2520the%2520G%2520protein-coupled%2520receptor%252040%2520agonist%2520TAK-875%2520%2528fasiglifam%2529%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DXenobiotica%26date%3D2019%26volume%3D49%26spage%3D433%26epage%3D445%26doi%3D10.1080%2F00498254.2018.1453100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaggs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfx040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28206647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGltbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2018&pages=374-384&author=M.+A.+Otienoauthor=J.+Snoeysauthor=W.+Lamauthor=A.+Ghoshauthor=M.+R.+Playerauthor=A.+Pocaiauthor=R.+Salterauthor=D.+Simicauthor=H.+Skaggsauthor=B.+Singhauthor=H.+K.+Lim&title=Fasiglifam+%28TAK-875%29%3A+mechanistic+investigation+and+retrospective+identification+of+hazards+for+drug+induced+liver+injury&doi=10.1093%2Ftoxsci%2Fkfx040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury</span></div><div class="casAuthors">Otieno, Monicah A.; Snoeys, Jan; Lam, Wing; Ghosh, Avi; Player, Mark R.; Pocai, Alessandro; Salter, Rhys; Simic, Damir; Skaggs, Hollie; Singh, Bhanu; Lim, Heng-Keang</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-384</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">TAK-875, a GPR40 agonist, was withdrawn from Phase III clin. trials due to drug-induced liver injury (DILI).  Mechanistic studies were conducted to identify potential DILI hazards (covalent binding burden (CVB), hepatic transporter inhibition, mitochondrial toxicity, and liver toxicity in rats) assocd. with TAK-875.  Treatment of hepatocytes with radiolabeled TAK-875 resulted in a CVB of 2.0 mg/day, which is above the threshold of 1 mg/day considered to be a risk for DILI.  Covalent binding to hepatocytes was due to formation of a reactive acyl glucuronide (AG) and, possibly, an acyl-CoA thioester intermediate.  Formation of TAK-875AG in hepatocytes and/or in vivo was in the order of non-rodents > human (in vitro only) > rat.  These data suggest that non-rodents, and presumably humans, form TAK-875AG more efficiently than rats, and that AG-mediated toxicities in rats may only occur at high doses.  TAK-875 (1000 mg/kg/day) formed significant amts. of AG metabolite (≤32.7 μM) in rat liver that was assocd. with increases in ALT (× 4), bilirubin (× 9), and bile acids (× 3.4), and microscopic findings of hepatocellular hypertrophy and single cell necrosis.  TAK-875 and TAK-875AG had similar potencies (within 3-fold) for human multi-drug resistant assocd. protein 2/4 (MRP2/4) and bile salt export pump, but TAK-875AG was exceptionally potent against MRP3 (0.21 μM).  Inhibition of MRPs may contribute to liver accumulation of TAK-875AG.  TAK-875 also inhibited mitochondrial respiration in HepG2 cells, and mitochondrial Complex 1 and 2 activities in isolated rat mitochondria.  In summary, formation of TAK-875AG, and possibly TAK-875CoA in hepatocytes, coupled with inhibition of hepatic transporters and mitochondrial respiration may be key contributors to TAK-875-mediated DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZrkrYD3NSbVg90H21EOLACvtfcHk0ljkzKUU6AdFPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGltbbO&md5=17b0cf793843a6feb351f3da455fee15</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx040%26sid%3Dliteratum%253Aachs%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DLam%26aufirst%3DW.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DSalter%26aufirst%3DR.%26aulast%3DSimic%26aufirst%3DD.%26aulast%3DSkaggs%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DLim%26aufirst%3DH.%2BK.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%253A%2520mechanistic%2520investigation%2520and%2520retrospective%2520identification%2520of%2520hazards%2520for%2520drug%2520induced%2520liver%2520injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D163%26spage%3D374%26epage%3D384%26doi%3D10.1093%2Ftoxsci%2Fkfx040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, S. Y.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo metabolic profiles of fasiglifam using ultrahigh-performance liquid chromatography combined with Q-exactive orbitrap tandem mass spectrometry</span>. <i>Rapid Commun. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1387</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1002/rcm.8174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Frcm.8174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29790616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1387-1395&author=J.+Q.+Liauthor=J.+Liauthor=J.+F.+Wangauthor=S.+H.+Zhangauthor=D.+Heauthor=R.+S.+Yongauthor=S.+Y.+She&title=In+vitro+and+in+vivo+metabolic+profiles+of+fasiglifam+using+ultrahigh-performance+liquid+chromatography+combined+with+Q-exactive+orbitrap+tandem+mass+spectrometry&doi=10.1002%2Frcm.8174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo metabolic profiles of fasiglifam using ultrahigh-performance liquid chromatography combined with Q-Exactive Orbitrap tandem mass spectrometry</span></div><div class="casAuthors">Li, Jin-Qi; Li, Jie; Wang, Jia-Feng; Zhang, Shu-han; He, Dan; Yong, Rong-Sheng; She, Shu-Ya</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Rationale : Fasiglifam is an orally available and selective partial agonist of hGPR40 receptor, which was unexpectedly terminated at phase III clin. trials due to its severe hepatotoxicity.  To fully understand the mechanism of action of fasiglifam, it is necessary to investigate its in vitro and in vivo metabolic profiles.  Methods : For in vitro metab., fasiglifam was incubated with rat or human liver microsomes in the presence of β-NADP tetrasodium salt, glutathione (GSH) and uridine diphosphate glucuronic acid trisodium salt for 60 min.  For in vivo metab., fasiglifam was orally administered to rats at a single dose of 20 mg/kg and the bile was collected.  In vitro and in vivo samples were analyzed by the developed ultrahigh-performance liq. chromatog. combined with Q-Exactive Orbitrap tandem mass spectrometry.  The structures of metabolites were proposed according to their accurate masses and fragment ions.  Results : A total of eight metabolites, including an acyl-GSH adduct, were detected and identified.  M1 (acylglucuronide) and M5 (carboxylic acid deriv.) were the major metabolites of fasiglifam.  Metabolic pathways of fasiglifam involved oxygenation, oxidative dealkylation, dehydrogenation, glucuronidation and GSH conjugation.  Fasiglifam may undergo metabolic bioactivation via acylglucuronide.  Conclusions : Oxidative dealkylation and glucuronidation were the predominant metabolic pathways of fasiglifam in vitro and in vivo.  Metabolic bioactivation via acylglucuronide may be the perpetrator of its hepatotoxicity.  The authors findings would be helpful in understanding the disposition of fasiglifam as well as its hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFUjb_33ym1LVg90H21EOLACvtfcHk0limbITBplxIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjtLnF&md5=c705bf3d1d28d6f97737a25ec3c87adc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Frcm.8174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.8174%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DS.%2BH.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DYong%26aufirst%3DR.%2BS.%26aulast%3DShe%26aufirst%3DS.%2BY.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520metabolic%2520profiles%2520of%2520fasiglifam%2520using%2520ultrahigh-performance%2520liquid%2520chromatography%2520combined%2520with%2520Q-exactive%2520orbitrap%2520tandem%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2018%26volume%3D32%26spage%3D1387%26epage%3D1395%26doi%3D10.1002%2Frcm.8174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorrod, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aislaitner, G.</span></span> <span> </span><span class="NLM_article-title">The metabolism of alicyclic amines to reactive iminium ion intermediates</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1007/BF03188923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2FBF03188923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7867663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2MXitlSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1994&pages=209-217&author=J.+W.+Gorrodauthor=G.+Aislaitner&title=The+metabolism+of+alicyclic+amines+to+reactive+iminium+ion+intermediates&doi=10.1007%2FBF03188923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of alicyclic amines to reactive iminium ion intermediates</span></div><div class="casAuthors">Gorrod, J. W.; Aislaitner, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-17</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Medecine et Hygiene</span>)
        </div><div class="casAbstract">The evidence implicating the formation of iminium ions as reactive intermediates in the metab. of alicyclic amines has been reviewed with 44 refs.  The mechanism of formation of iminium ions and their conversion to α-carbonyl compds. or demethylated amines is discussed.  The use of a simple cyanide trapping technique for iminium ions has been demonstrated to monitor a large no. of alicyclic drugs for iminium ion formation.  The possible role of iminium ions in the pharmacol. and toxicol. of alicyclic amines is considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeB4VEvyLM2rVg90H21EOLACvtfcHk0limbITBplxIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitlSjtrc%253D&md5=d633c5ff744b9c66373cc8ec85546e90</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2FBF03188923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03188923%26sid%3Dliteratum%253Aachs%26aulast%3DGorrod%26aufirst%3DJ.%2BW.%26aulast%3DAislaitner%26aufirst%3DG.%26atitle%3DThe%2520metabolism%2520of%2520alicyclic%2520amines%2520to%2520reactive%2520iminium%2520ion%2520intermediates%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D1994%26volume%3D19%26spage%3D209%26epage%3D217%26doi%3D10.1007%2FBF03188923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contillo, L. G.</span></span> <span> </span><span class="NLM_article-title">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2004.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.jpba.2004.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15351054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=105-116&author=J.+R.+Sogliaauthor=S.+P.+Harrimanauthor=S.+Zhaoauthor=J.+Barberiaauthor=M.+J.+Coleauthor=J.+G.+Boydauthor=L.+G.+Contillo&title=The+development+of+a+higher+throughput+reactive+intermediate+screening+assay+incorporating+micro-bore+liquid+chromatography-micro-electrospray+ionization-tandem+mass+spectrometry+and+glutathione+ethyl+ester+as+an+in+vitro+conjugating+agent&doi=10.1016%2Fj.jpba.2004.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span></div><div class="casAuthors">Soglia, John R.; Harriman, Shawn P.; Zhao, Sabrina; Barberia, John; Cole, Mark J.; Boyd, James G.; Contillo, Leonard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-116</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An in vitro reactive intermediate screening assay, incorporating the use of the close analog of glutathione, glutathione Et ester (GSH-EE) as a conjugating agent, was developed to identify compds. that form reactive intermediates in an in vitro metabolite generating system.  The biol. assay consisted of substrate [s] = 10 μM, human liver microsomes, an NADPH generating system, and glutathione Et ester.  Conjugates were extd. from the biol. matrix using a combination of protein pptn. and a semi-automated 96-well plate solid phase extn. (SPE) procedure.  A micro-bore liq. chromatog.-micro-electrospray ionization-tandem mass spectrometry (μLC-μESI-MS/MS) method detected glutathione Et ester conjugates using selected reaction monitoring (SRM) to simultaneously monitor for multiple MH+ to [MH - 129]+ transitions, where the 129 mass unit (Da) represents the neutral loss of the pyroglutamate moiety from GSH-EE.  The multiple MH+ to [MH - 129]+ transitions (SRM mass table) were generated for potential reactive intermediates of each compd.  Glutathione (GSH) and GSH-EE conjugate stds. were used to evaluate MS detection sensitivity.  Based on direct comparison of std. curve data, an approx. 10-fold increase in sensitivity was obsd. for conjugates contg. GSH-EE moiety vs. GSH.  In vitro expts. were conducted using literature substrates acetaminophen, rosiglitazone, clozapine, diclofenac and either GSH-EE or GSH as a reactive intermediate conjugating agent.  An increase in detection sensitivity was obsd. for each GSH-EE conjugate and in the case of acetaminophen-GSH-EE the peak area increase was approx. 80-fold.  Twelve drug compds., each having known biotransformation mechanisms, were used to further test the detection capabilities of the assay and establish a concordance to literature data.  When GSH was used in the assay, conjugates were detected for 4 out of the 12 test compds. (33%).  When GSH-EE was used in the assay, conjugates were detected for 10 out of the 12 test compds. (83%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NwMX6-E_3LVg90H21EOLACvtfcHk0limbITBplxIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D&md5=23e4c3df8558019ad3770d748a1f9815</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2004.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2004.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBarberia%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DBoyd%26aufirst%3DJ.%2BG.%26aulast%3DContillo%26aufirst%3DL.%2BG.%26atitle%3DThe%2520development%2520of%2520a%2520higher%2520throughput%2520reactive%2520intermediate%2520screening%2520assay%2520incorporating%2520micro-bore%2520liquid%2520chromatography-micro-electrospray%2520ionization-tandem%2520mass%2520spectrometry%2520and%2520glutathione%2520ethyl%2520ester%2520as%2520an%2520in%2520vitro%2520conjugating%2520agent%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2004%26volume%3D36%26spage%3D105%26epage%3D116%26doi%3D10.1016%2Fj.jpba.2004.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/tx034170b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development&doi=10.1021%2Ftx034170b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0ljyJoG0KfRxcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16%26doi%3D10.1021%2Ftx034170b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argoti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conteh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bershas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vouros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E.</span></span> <span> </span><span class="NLM_article-title">Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1544</span>, <span class="refDoi"> DOI: 10.1021/tx0501637</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0501637" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1537-1544&author=D.+Argotiauthor=L.+Liangauthor=A.+Contehauthor=L.+Chenauthor=D.+Bershasauthor=C.+P.+Yuauthor=P.+Vourosauthor=E.+Yang&title=Cyanide+trapping+of+iminium+ion+reactive+intermediates+followed+by+detection+and+structure+identification+using+liquid+chromatography-tandem+mass+spectrometry&doi=10.1021%2Ftx0501637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Cyanide Trapping of Iminium Ion Reactive Intermediates Followed by Detection and Structure Identification Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)</span></div><div class="casAuthors">Argoti, Dayana; Liang, Li; Conteh, Abdul; Chen, Liangfu; Bershas, Dave; Yu, Chung-Ping; Vouros, Paul; Yang, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1537-1544</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Secondary and tertiary alicyclic amines are widely found in pharmaceuticals and environmental compds.  The formation of iminium ions as reactive intermediates in the metabolic activation of alicyclic amines has previously been investigated in radiometric assays where radiolabeled cyanide is typically employed.  In this paper, the authors report a relatively high throughput LC-MS/MS method for the detection of the nonradiolabeled cyanide adduct formed in rat or human liver microsomal incubations via const. neutral loss scan followed by structural characterization using product ion scan on a triple quadrupole mass spectrometer.  A total of 14 alicyclic amine compds. were investigated with the cyanide trapping LC-MS/MS screen and also with the glutathione (GSH) trapping screen, a well-established and commonly employed technique for reactive metabolite screening.  The authors' results are found to be in general agreement with the previous metab. reports for these compds., demonstrating the effectiveness, speed, and simplicity of the cyanide trapping LC-MS/MS method to study the iminium ion intermediates from alicyclic amines and its complementarities to GSH trapping method for reactive metabolite screenings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWbsW3G51jQbVg90H21EOLACvtfcHk0ljyJoG0KfRxcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrt7%252FI&md5=98c9128150ca5fc710e35a7d81555c69</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Ftx0501637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0501637%26sid%3Dliteratum%253Aachs%26aulast%3DArgoti%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DConteh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBershas%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.%2BP.%26aulast%3DVouros%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DE.%26atitle%3DCyanide%2520trapping%2520of%2520iminium%2520ion%2520reactive%2520intermediates%2520followed%2520by%2520detection%2520and%2520structure%2520identification%2520using%2520liquid%2520chromatography-tandem%2520mass%2520spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1537%26epage%3D1544%26doi%3D10.1021%2Ftx0501637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, K.</span></span> <span> </span><span class="NLM_article-title">Comparison of the reactivity of trapping reagents towards electrophiles: cysteine derivatives can be bifunctional trapping reagents</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00129</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=1546-1555&author=K.+Inoueauthor=K.+Fukudaauthor=T.+Yoshimuraauthor=K.+Kusano&title=Comparison+of+the+reactivity+of+trapping+reagents+towards+electrophiles%3A+cysteine+derivatives+can+be+bifunctional+trapping+reagents&doi=10.1021%2Facs.chemrestox.5b00129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the Reactivity of Trapping Reagents toward Electrophiles: Cysteine Derivatives Can Be Bifunctional Trapping Reagents</span></div><div class="casAuthors">Inoue, Kazuko; Fukuda, Katsuyuki; Yoshimura, Tsutomu; Kusano, Kazutomi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1546-1555</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trapping reagents are powerful tools to detect unstable reactive metabolites.  There are a variety of trapping reagents based on chem. reactivity to electrophiles, and we investigated the reactivity of thiol and amine trapping reagents to metabolically generated electrophiles and com. available electrophilic compds.  Glutathione (GSH) and N-acetylcysteine (Nac) trapped soft electrophiles, and amine derivs. such as semicarbazide (SC) and methoxyamine (MeA) reacted as hard nucleophiles to trap aldehydes as imine derivs.  Cysteine (Cys) and homocysteine (HCys) captured both soft electrophiles and hard electrophilic aldehydes.  There were no qual. differences in trapping soft electrophiles among Cys, HCys, GSH, and Nac, although quant. reactivity to trap soft electrophiles varied likely depending on the pKa values of their thiol group.  In the reactivity with aldehydes, Cys and HCys showed relatively lower reactivity as compared with SC and MeA.  Nonetheless, they can trap aldehydes, and the resulting conjugates were stable and detected easily because their amino group formed imines after reaction with aldehydes, which are successively attacked by the intramol. thiol group to form stable ring structures.  This report demonstrated that Cys and HCys are advantageous to evaluate the formations of both soft electrophiles and aldehyde-type derivs. from a lot of drug candidates at early drug discovery by their unique structural characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZLv0MyCEUrVg90H21EOLACvtfcHk0ljyJoG0KfRxcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt7vK&md5=3769df41f5878af170f9791113a0ce9c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00129%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DYoshimura%26aufirst%3DT.%26aulast%3DKusano%26aufirst%3DK.%26atitle%3DComparison%2520of%2520the%2520reactivity%2520of%2520trapping%2520reagents%2520towards%2520electrophiles%253A%2520cysteine%2520derivatives%2520can%2520be%2520bifunctional%2520trapping%2520reagents%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26spage%3D1546%26epage%3D1555%26doi%3D10.1021%2Facs.chemrestox.5b00129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of case reports of aplastic anemia among patients treated with felbamate</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1265</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1157.1997.tb00062.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fj.1528-1157.1997.tb00062.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9578520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXltFaj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=1265-1269&author=D.+W.+Kaufmanauthor=J.+P.+Kellyauthor=T.+Andersonauthor=D.+C.+Harmonauthor=S.+Shapiro&title=Evaluation+of+case+reports+of+aplastic+anemia+among+patients+treated+with+felbamate&doi=10.1111%2Fj.1528-1157.1997.tb00062.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of case reports of aplastic anemia among patients treated with felbamate</span></div><div class="casAuthors">Kaufman, D. W.; Kelly, J. P.; Anderson, T.; Harmon, D. C.; Shapiro, S.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1265-1269</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Felbamate (FBM) is a new antiepileptic drug (AED) that is often effective in seizure disorders refractory to other treatments; its use has been greatly restricted after cases of aplastic anemia were reported.  To elucidate the putative assocn. between FBM and aplastic anemia, we made a detailed evaluation of the first 31 reports.  Hematol. review according to the criteria of the International Agranulocytosis and Aplastic Anemia Study (IAAAS) confirmed 23 cases (74%) as aplastic anemia; FBM was judged to be the only plausible cause for three; confounding (mostly by other drugs) was considered possible, but FBM remained the most likely cause for 11; and there was at least one other plausible cause for 9.  Using a denominator from sales data of 110,000 persons exposed and a numerator of the cases for which FBM was considered the only plausible cause, we established a lower limit of incidence of 27 cases of aplastic anemia per million users as compared with the general population rate of 2.0 per million per yr.  With all confirmed cases used as the numerator, the upper limit of incidence was 209 per million.  The "most probable" incidence was estd. to be 127 per million.  Intensive, systematic investigation can maximize the utility of case reports for assessing risks of newly released drugs.  The present evaluation confirmed an assocn. between FBM and aplastic anemia; however, confounding was significant for most cases and there was a tenfold range in the "best case" and "worst case" incidence ests. among users.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXqFKKAYuTC7Vg90H21EOLACvtfcHk0lh-HqZv7FiZyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFaj&md5=1eae15e6f92d5308897a7fd7716918ce</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1157.1997.tb00062.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1157.1997.tb00062.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaufman%26aufirst%3DD.%2BW.%26aulast%3DKelly%26aufirst%3DJ.%2BP.%26aulast%3DAnderson%26aufirst%3DT.%26aulast%3DHarmon%26aufirst%3DD.%2BC.%26aulast%3DShapiro%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520case%2520reports%2520of%2520aplastic%2520anemia%2520among%2520patients%2520treated%2520with%2520felbamate%26jtitle%3DEpilepsia%26date%3D1997%26volume%3D38%26spage%3D1265%26epage%3D1269%26doi%3D10.1111%2Fj.1528-1157.1997.tb00062.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdun, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGown, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">Felbamate-associated fatal acute hepatic necrosis</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1212/WNL.46.5.1457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1212%2FWNL.46.5.1457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8628501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK283ht1Gqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1996&pages=1457-1459&author=M.+G.+O%E2%80%99Neilauthor=C.+S.+Perdunauthor=M.+B.+Wilsonauthor=S.+T.+McGownauthor=S.+Patel&title=Felbamate-associated+fatal+acute+hepatic+necrosis&doi=10.1212%2FWNL.46.5.1457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Felbamate-associated fatal acute hepatic necrosis</span></div><div class="casAuthors">O'Neil M G; Perdun C S; Wilson M B; McGown S T; Patel S</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1457-9</span>
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    </div><div class="casAbstract">Thirty-six cases of hepatic toxicity associated with felbamate therapy have been collected by the Food and Drug Administration.  Five patients died.  We describe a case of massive acute hepatic necrosis and death within 40 days of initiation of felbamate therapy for a generalized tonic-clonic seizure disorder.  We describe the clinical and histopathologic features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBxb8aur7NHedfST00W0BcfW6udTcc2eYfy6uGWdPsNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283ht1Gqtg%253D%253D&md5=3f2ef7c53040df5e31921b060845d0c8</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1212%2FWNL.46.5.1457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.46.5.1457%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DM.%2BG.%26aulast%3DPerdun%26aufirst%3DC.%2BS.%26aulast%3DWilson%26aufirst%3DM.%2BB.%26aulast%3DMcGown%26aufirst%3DS.%2BT.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DFelbamate-associated%2520fatal%2520acute%2520hepatic%2520necrosis%26jtitle%3DNeurology%26date%3D1996%26volume%3D46%26spage%3D1457%26epage%3D1459%26doi%3D10.1212%2FWNL.46.5.1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nightingale, S. L.</span></span> <span> </span><span class="NLM_article-title">Recommendation to immediately withdraw patients from treatment with felbamate</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">995</span>, <span class="refDoi"> DOI: 10.1001/jama.1994.03520130027011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1001%2Fjama.1994.03520130027012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8089899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK2czns1emsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1994&pages=995&author=S.+L.+Nightingale&title=Recommendation+to+immediately+withdraw+patients+from+treatment+with+felbamate&doi=10.1001%2Fjama.1994.03520130027011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">From the Food and Drug Administration</span></div><div class="casAuthors">Nightingale S L</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">995</span>
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7nqybF38QiYNpW7w2tapOfW6udTcc2eYfy6uGWdPsNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2czns1emsA%253D%253D&md5=d5ac9d768a4ce1e6c6def1b301a50d1e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1001%2Fjama.1994.03520130027012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1994.03520130027012%26sid%3Dliteratum%253Aachs%26aulast%3DNightingale%26aufirst%3DS.%2BL.%26atitle%3DRecommendation%2520to%2520immediately%2520withdraw%2520patients%2520from%2520treatment%2520with%2520felbamate%26jtitle%3DJAMA%26date%3D1994%26volume%3D272%26spage%3D995%26doi%3D10.1001%2Fjama.1994.03520130027011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapetanovic, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekawa, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieckhaus, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupferberg, H. J.</span></span> <span> </span><span class="NLM_article-title">Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(02)00058-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2802%2900058-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12399159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVKrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2002&pages=119-134&author=I.+M.+Kapetanovicauthor=C.+D.+Torchinauthor=J.+M.+Strongauthor=W.+D.+Yonekawaauthor=C.+Luauthor=A.+P.+Liauthor=C.+M.+Dieckhausauthor=W.+L.+Santosauthor=T.+L.+Macdonaldauthor=R.+D.+Sofiaauthor=H.+J.+Kupferberg&title=Reactivity+of+atropaldehyde%2C+a+felbamate+metabolite+in+human+liver+tissue+in+vitro&doi=10.1016%2FS0009-2797%2802%2900058-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro</span></div><div class="casAuthors">Kapetanovic, Izet M.; Torchin, Cynthia D.; Strong, John M.; Yonekawa, Wayne D.; Lu, Chuang; Li, Albert P.; Dieckhaus, Christine M.; Santos, Webster L.; MacDonald, Timothy L.; Sofia, R. Duane; Kupferberg, Harvey J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">119-134</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Antiepileptic therapy with a broad spectrum drug felbamate (FBM) has been limited due to reports of hepatotoxicity and aplastic anemia assocd. with its use.  It was proposed that a bioactivation of FBM leading to formation of α,β-unsatd. aldehyde, atropaldehyde (ATPAL) could be responsible for toxicities assocd. with the parent drug.  Other members of this class of compds., acrolein and 4-hydroxynonenal (HNE), are known for their reactivity and toxicity.  It has been proposed that the bioactivation of FBM to ATPAL proceeds though a more stable cyclized product, 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one (CCMF) whose formation has been shown recently.  Aldehyde dehydrogenase (ALDH) and glutathione transferase (GST) are detoxifying enzymes and targets for reactive aldehydes.  This study examd. effects of ATPAL and its precursor, CCMF on ALDH, GST and cell viability in liver, the target tissue for its metab. and toxicity.  A known toxin, HNE, which is also a substrate for ALDH and GST, was used for comparison.  Interspecies difference in metab. of FBM is well documented, therefore, human tissue was deemed most relevant and used for these studies.  ATPAL inhibited ALDH and GST activities and led to a loss of hepatocyte viability.  Several fold greater concns. of CCMF were necessary to demonstrate a similar degree of ALDH inhibition or cytotoxicity as obsd. with ATPAL.  This is consistent with CCMF requiring prior conversion to the more proximate toxin, ATPAL.  GSH was shown to protect against ALDH inhibition by ATPAL.  In this context, ALDH and GST are detoxifying pathways and their inhibition would lead to an accumulation of reactive species from FBM metab. and/or metab. of other endogenous or exogenous compds. and predisposing to or causing toxicity.  Therefore, mechanisms of reactive aldehydes toxicity could include direct interaction with crit. cellular macromols. or indirect interference with cellular detoxification mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowv3ix1_vDHrVg90H21EOLACvtfcHk0lh-HqZv7FiZyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVKrt7w%253D&md5=ca2ca0812084df77f02f42807c9a5372</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2802%2900058-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252802%252900058-3%26sid%3Dliteratum%253Aachs%26aulast%3DKapetanovic%26aufirst%3DI.%2BM.%26aulast%3DTorchin%26aufirst%3DC.%2BD.%26aulast%3DStrong%26aufirst%3DJ.%2BM.%26aulast%3DYonekawa%26aufirst%3DW.%2BD.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DA.%2BP.%26aulast%3DDieckhaus%26aufirst%3DC.%2BM.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DSofia%26aufirst%3DR.%2BD.%26aulast%3DKupferberg%26aufirst%3DH.%2BJ.%26atitle%3DReactivity%2520of%2520atropaldehyde%252C%2520a%2520felbamate%2520metabolite%2520in%2520human%2520liver%2520tissue%2520in%2520vitro%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2002%26volume%3D142%26spage%3D119%26epage%3D134%26doi%3D10.1016%2FS0009-2797%2802%2900058-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieckhaus, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of idiosyncratic drug reactions: the case of felbamate</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(02)00057-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2802%2900057-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12399158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVKrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2002&pages=99-117&author=C.+M.+Dieckhausauthor=C.+D.+Thompsonauthor=S.+G.+Rollerauthor=T.+L.+MacDonald&title=Mechanisms+of+idiosyncratic+drug+reactions%3A+the+case+of+felbamate&doi=10.1016%2FS0009-2797%2802%2900057-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of idiosyncratic drug reactions: the case of Felbamate</span></div><div class="casAuthors">Dieckhaus, Christine M.; Thompson, Charles D.; Roller, Shane G.; MacDonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">99-117</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug reactions (IDR) are a specific type of drug toxicity characterized by their delayed onset, low incidence, and reactive metabolite formation with little, if any, correlation between pharmacokinetics or pharmacodynamics and the toxicol. outcome.  As the name implies, IDR are unpredictable and often result in the post-marketing failure of otherwise useful therapies.  Examples of drugs, which have failed as a result of IDR in recent years, include Trovafloxacin, Zileuton, Troglitazone, Tolcapone, and Felbamate.  To date there exists no pre-clin. model to predict these adverse drug reactions and a mechanistic understanding of these toxicities remains limited.  In an attempt to better understand this class of drug toxicities and gain mechanistic insight, the authors have studied the IDR assocd. with a model compd., Felbamate.  The studies with Felbamate are consistent with the theory that compds. which cause IDR undergo bioactivation to a highly reactive electrophilic metabolite that is capable of forming covalent protein adducts in vivo.  In addn., the data suggest that under normal physiol. conditions glutathione plays a protective role in preventing IDR during Felbamate therapy, further emphasizing a correlation between reactive metabolite formation and a toxic outcome.  Clin. studies with Felbamate have been able to demonstrate an assocn. between reactive metabolite formation and a clin. relevant toxicity; however, addnl. research is required to more fully understand the link between reactive metabolite formation and the events which elicit toxicity.  Going forward, it seems reasonable that screening for reactive metabolite formation in early drug discovery may be an important tool in eliminating the post-marketing failure of otherwise useful therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL1vhL9PChYLVg90H21EOLACvtfcHk0lhr_P2VKZE_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVKrt78%253D&md5=ade528b1c851e1bf204984d1ae9cf957</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2802%2900057-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252802%252900057-1%26sid%3Dliteratum%253Aachs%26aulast%3DDieckhaus%26aufirst%3DC.%2BM.%26aulast%3DThompson%26aufirst%3DC.%2BD.%26aulast%3DRoller%26aufirst%3DS.%2BG.%26aulast%3DMacDonald%26aufirst%3DT.%2BL.%26atitle%3DMechanisms%2520of%2520idiosyncratic%2520drug%2520reactions%253A%2520the%2520case%2520of%2520felbamate%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2002%26volume%3D142%26spage%3D99%26epage%3D117%26doi%3D10.1016%2FS0009-2797%2802%2900057-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adusumalli, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanyshyn, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparadoski, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wichmann, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharczyk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R. D.</span></span> <span> </span><span class="NLM_article-title">Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">710</span>– <span class="NLM_lpage">716</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8104132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3sXmtFKksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1993&pages=710-716&author=V.+E.+Adusumalliauthor=Y.+M.+Choiauthor=L.+A.+Romanyshynauthor=R.+E.+Sparadoskiauthor=J.+K.+Wichmannauthor=K.+K.+Wongauthor=N.+Kucharczykauthor=R.+D.+Sofia&title=Isolation+and+identification+of+3-carbamoyloxy-2-phenylpropionic+acid+as+a+major+human+urinary+metabolite+of+felbamate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate</span></div><div class="casAuthors">Adusumalli, V. E.; Choi, Y. M.; Romanyshyn, L. A.; Sparadoski, R. E., Jr.; Wichmann, J. K.; Wong, K. K.; Kucharczyk, N.; Sofia, R. D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">710-16</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">A new metabolite of felbamate, isolated from the polar metabolite fraction of a human urine sample, was identified as 3-carbamoyloxy-2-phenylpropionic acid (CPPA) by electron impact and Cl/MS of the Me ester in the isolated fraction.  Its presence in the unconjugated free form in two different human urine samples was confirmed by HPLC comparison of retention times with authentic synthetic CPPA and by online neg. ion HPLC thermospray tandem mass spectrometric techniques.  The amt. of CPPA in 0-4 h postdose human urine was estd. to be ∼12% of the drug-derived substances present in the urine.  Some CPPA was also found to be present in dog urine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpydnoOlfZIBbVg90H21EOLACvtfcHk0lhr_P2VKZE_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmtFKksr4%253D&md5=0864c86c16f8b162a063e598589eb62c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdusumalli%26aufirst%3DV.%2BE.%26aulast%3DChoi%26aufirst%3DY.%2BM.%26aulast%3DRomanyshyn%26aufirst%3DL.%2BA.%26aulast%3DSparadoski%26aufirst%3DR.%2BE.%26aulast%3DWichmann%26aufirst%3DJ.%2BK.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DKucharczyk%26aufirst%3DN.%26aulast%3DSofia%26aufirst%3DR.%2BD.%26atitle%3DIsolation%2520and%2520identification%2520of%25203-carbamoyloxy-2-phenylpropionic%2520acid%2520as%2520a%2520major%2520human%2520urinary%2520metabolite%2520of%2520felbamate%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1993%26volume%3D21%26spage%3D710%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudspeth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perhach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Quantitation in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1157.1999.tb00777.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fj.1528-1157.1999.tb00777.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10368077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1SjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=769-776&author=C.+D.+Thompsonauthor=M.+T.+Barthenauthor=D.+W.+Hopperauthor=T.+A.+Millerauthor=M.+Quiggauthor=C.+Hudspethauthor=G.+Montourisauthor=L.+Marshauthor=J.+L.+Perhachauthor=R.+D.+Sofiaauthor=T.+L.+Macdonald&title=Quantitation+in+patient+urine+samples+of+felbamate+and+three+metabolites%3A+acid+carbamate+and+two+mercapturic+acids&doi=10.1111%2Fj.1528-1157.1999.tb00777.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids</span></div><div class="casAuthors">Thompson, Charles D.; Barthen, Mary T.; Hopper, Darrin W.; Miller, Thomas A.; Quigg, Mark; Hudspeth, Candice; Montouris, Georgia; Marsh, LaDonna; Perhach, James L.; Sofia, R. Duane; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">769-776</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: Previously we proposed and provided evidence for the metabolic pathway of felbamate (FBM), which leads to the reactive metabolite, 3-carbamoyl-2-phenylpropion-aldehyde.  This aldehyde carbamate was suggested to be the reactive intermediate in the oxidn. of 2-phenyl-1,3-propanediol monocarbamate to the major human metabolite 3-carbamoyl-2-phenylpropionic acid.  In addn., the aldehyde carbamate was found to undergo spontaneous elimination to 2-phenylpropenal, commonly known as atropaldehyde.  Moreover, atropaldehyde was proposed to play a role in the development of toxicity during FBM therapy.  Evidence for atropaldehyde formation in vivo was reported with the identification of modified N-acetyl-cysteine conjugates of atropaldehyde in both human and rat urine after FBM administration.  Identification of the atropaldehyde-derived mercapturic acids in urine after FBM administration is consistent with the hypothesis that atropaldehyde is formed in vivo and that it reacts with thiol nucleophiles.  Based on the hypothesis that the potential for toxicity will correlate to the amt. of atropaldehyde formed, we sought to develop an analytic method that would quantify the amt. of relevant metabolites excreted in patient urine.  Methods: We summarize the results of an LC/MS method used to quantify FBM, 3-carbamoyl-2-phenylpropionic acid and two atropaldehyde-derived mercapturic acids in the patient population.  Results: Anal. was performed on 31 patients undergoing FBM therapy.  The abs. quantities of FBM and three metabolites were measured.  Conclusions: This method demonstrated sufficient precision for the identification of patients exhibiting "abnormal" levels of atropaldehyde conjugates and may hold potential for patient monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjMxzH378jjbVg90H21EOLACvtfcHk0lhr_P2VKZE_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1SjtLc%253D&md5=a5cb91815151ed3a0a3b3ee843ecec25</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1157.1999.tb00777.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1157.1999.tb00777.x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DC.%2BD.%26aulast%3DBarthen%26aufirst%3DM.%2BT.%26aulast%3DHopper%26aufirst%3DD.%2BW.%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DQuigg%26aufirst%3DM.%26aulast%3DHudspeth%26aufirst%3DC.%26aulast%3DMontouris%26aufirst%3DG.%26aulast%3DMarsh%26aufirst%3DL.%26aulast%3DPerhach%26aufirst%3DJ.%2BL.%26aulast%3DSofia%26aufirst%3DR.%2BD.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DQuantitation%2520in%2520patient%2520urine%2520samples%2520of%2520felbamate%2520and%2520three%2520metabolites%253A%2520acid%2520carbamate%2520and%2520two%2520mercapturic%2520acids%26jtitle%3DEpilepsia%26date%3D1999%26volume%3D40%26spage%3D769%26epage%3D776%26doi%3D10.1111%2Fj.1528-1157.1999.tb00777.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roecklein, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupferberg, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, J. M.</span></span> <span> </span><span class="NLM_article-title">Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by postmitochondrial suspensions</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1842</span>– <span class="NLM_lpage">1848</span>, <span class="refDoi"> DOI: 10.1021/tx050130r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050130r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1eitrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1842-1848&author=R.+J.+Parkerauthor=N.+R.+Hartmanauthor=B.+A.+Roeckleinauthor=H.+Mortkoauthor=H.+J.+Kupferbergauthor=J.+Stablesauthor=J.+M.+Strong&title=Stability+and+comparative+metabolism+of+selected+felbamate+metabolites+and+postulated+fluorofelbamate+metabolites+by+postmitochondrial+suspensions&doi=10.1021%2Ftx050130r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Stability and Comparative Metabolism of Selected Felbamate Metabolites and Postulated Fluorofelbamate Metabolites by Postmitochondrial Suspensions</span></div><div class="casAuthors">Parker, Robert J.; Hartman, Neil R.; Roecklein, Bryan A.; Mortko, Henry; Kupferberg, Harvey J.; Stables, James; Strong, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1842-1848</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Evidence has been presented suggesting that a reactive metabolite, 2-phenylpropenal (ATPAL), may be responsible for the toxicities obsd. during therapy with the antiepileptic drug felbamate (FBM).  Formation of ATPAL from its unstable immediate precursor, 3-carbamoyl-2-phenylpropionaldedhyde (CBMA) requires the loss of the hydrogen atom at position 2 in the propane chain, and it has been postulated that substitution of this atom with fluorine would prevent the formation of ATPAL.  On the basis of this hypothesis, 2-fluoro-2-phenyl-1,3-propanediol dicarbamate (F-FBM) was synthesized and is presently undergoing drug development.  To test this hypothesis, the authors compared the metab. by human liver postmitochondrial suspensions (S9) in vitro of selected FBM and postulated F-FBM metabolites leading to formation of CBMA or 3-carbamoyl-2-fluoro-2-phenyl-propionaldehyde (F-CBMA).  All S9 incubations included GSH as a trapping agent for any reactive metabolites formed.  Our results indicated that, in phosphate buffer, pH 7.4, at 37°, the half-life for 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one (CCMF) was 2.8 and 3.6 h in the presence or absence of GSH, resp.; compared to 4-hydroxy-5-fluoro-5-phenyl-tetrahydro-1,3-oxazin-2-one (F-CCMF) which lost only 2.5% or 4.9% over 24 h under the same conditions.  When incubated with S9 in the presence of the cofactor, NAD+, 2-phenyl-1,3-propanediol monocarbamate (MCF) was oxidized to CCMF which was further oxidized to 3-carbamoyl-2-phenylpropionic acid (CPPA).  2-Fluoro-2-phenyl-1,3-propanediol monocarbamate (F-MCF) under similar conditions was stable, and no metabolites were obsd.  When CCMF was incubated with S9 in the presence of NAD+ cofactor, oxidn. to CPPA and redn. to MCF were obsd.  In addn., a new atropic acid GSH adduct (ATPA-GSH) was identified by mass spectrometry.  When F-CCMF was incubated under the same conditions as CCMF, both reduced and oxidized metabolites, F-MCF and 3-carbamoyl-2-fluoro-2-phenylpropionic acid (F-CPPA), resp., were formed but at significantly lower rates, and no GSH conjugates were identified.  Our results support the hypothesis that F-FBM and F-CCMF are not metabolized by S9 in vitro to the known reactive FBM metabolite, ATPAL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9aisWkyFRkLVg90H21EOLACvtfcHk0lj7HmZxsYHsGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1eitrnP&md5=fb13997626f64f4b726caa7894bb9fa2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Ftx050130r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050130r%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DR.%2BJ.%26aulast%3DHartman%26aufirst%3DN.%2BR.%26aulast%3DRoecklein%26aufirst%3DB.%2BA.%26aulast%3DMortko%26aufirst%3DH.%26aulast%3DKupferberg%26aufirst%3DH.%2BJ.%26aulast%3DStables%26aufirst%3DJ.%26aulast%3DStrong%26aufirst%3DJ.%2BM.%26atitle%3DStability%2520and%2520comparative%2520metabolism%2520of%2520selected%2520felbamate%2520metabolites%2520and%2520postulated%2520fluorofelbamate%2520metabolites%2520by%2520postmitochondrial%2520suspensions%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1842%26epage%3D1848%26doi%3D10.1021%2Ftx050130r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roecklein, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacks, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J.</span></span> <span> </span><span class="NLM_article-title">Fluorofelbamate</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2006.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.nurt.2006.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=17199021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFaksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=97-101&author=B.+A.+Roeckleinauthor=H.+J.+Sacksauthor=H.+Mortkoauthor=J.+Stables&title=Fluorofelbamate&doi=10.1016%2Fj.nurt.2006.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoro0felbamate</span></div><div class="casAuthors">Roecklein, Bryan A.; Sacks, Harry J.; Mortko, Henry; Stables, James</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-101</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The incidence of refractory seizures has remained at 30-40%, even with the approval of nine new anticonvulsants over the past 12 years.  In attempts to reduce seizure frequency and severity, physicians routinely resort to combining two or more anticonvulsants, ideally with different mechanisms of action.  These combinatorial therapies are difficult to administer for both patient and caregiver and often result in tolerability issues.  Hence, a broad spectrum anticonvulsant, with multiple mechanisms of action, that is well tolerated, would provide physicians with an important option in their armamentarium to control seizures.  Felbamate initially fit this profile and was demonstrated to effectively control both partial and generalized seizures in clin. studies supporting registration.  Unfortunately, unanticipated idiosyncratic toxicity was obsd. after approval and the drug is now relegated to second or third line therapy, depending on patient history and seizure type.  Epileptologists still prescribe this drug for refractory seizures, and a recent communication indicates that 35,000 to 46,000 new patients have tried Felbatol (MedPointe Pharmaceuticals, Somerset, NJ) since 1995.  The continued utilization of Felbatol, in light of its risk:benefit issues, highlights the need for new efficacious therapeutic options.  Fluorofelbamate (Med-Pointe Pharmaceuticals), a phase I drug candidate, was designed to retain the broad spectrum multimechanistic activity of felbamate, with a modified metab. that has demonstrated, in vitro, to avoid the prodn. of the reactive metabolite believed to cause the idiosyncratic toxicity.  This drug candidate is one of several carbamates either in development or currently on the market for treatment of seizures and other CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLY6kz-AVDFLVg90H21EOLACvtfcHk0lj7HmZxsYHsGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFaksLk%253D&md5=24365b8c44f2be9837ac64ede8dca327</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2006.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2006.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DRoecklein%26aufirst%3DB.%2BA.%26aulast%3DSacks%26aufirst%3DH.%2BJ.%26aulast%3DMortko%26aufirst%3DH.%26aulast%3DStables%26aufirst%3DJ.%26atitle%3DFluorofelbamate%26jtitle%3DNeurotherapeutics%26date%3D2007%26volume%3D4%26spage%3D97%26epage%3D101%26doi%3D10.1016%2Fj.nurt.2006.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tingle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Drug – protein conjugates. 14. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(88)90733-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-2952%2888%2990733-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3342086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL1cXitFGrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1988&pages=303-311&author=J.+L.+Maggsauthor=M.+D.+Tingleauthor=N.+R.+Kitteringhamauthor=B.+K.+Park&title=Drug+%E2%80%93+protein+conjugates.+14.+Mechanisms+of+formation+of+protein-arylating+intermediates+from+amodiaquine%2C+a+myelotoxin+and+hepatotoxin+in+man&doi=10.1016%2F0006-2952%2888%2990733-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-protein conjugates.  XIV.  Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man</span></div><div class="casAuthors">Maggs, J. L.; Tingle, M. D.; Kitteringham, N. R.; Park, B. K.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-11</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The enzymic and nonenzymic formation of protein-arylating intermediates from amodiaquine (I) was studied in vitro.  [14C]-I in phosphate buffer, pH 7.4, under air was autoxidized to a reactive deriv.(s) which possessed characteristics indicative of a semiquinone/quinone imine: redn. by NADPH and ascorbic acid, conjugation with thiols and irreversible binding to microsomal and sol. proteins.  Cysteinyl SH groups were major sites of arylation.  Radiolabeled material irreversibly bound to human serum albumin after 24 h and to human liver microsomes after 4 h represented 26.5 % and 31.4% of incubated [14C]-I (10 μM), resp.  The quinone imine (II) of I was synthesized, and displayed the same oxidative and electrophilic reactions as the product(s) of I autoxidn.  A water-sol. product formed in buffered solns. of I and N-acetylcysteine was identified as an I mercapturate by comparison with an adduct prepd. from synthetic II.  Irreversible binding of [14]C-I was inhibited by a radical scavenger; this indicated that the semiquinone imine contributed to the binding.  Although I was extensively deethylated by human liver microsomes, oxidn. by cytochrome P 450 did not appear to be principally responsible fo its activation and irreversible binding in microsomal incubations.  I was oxidized to protein-arylating intermediates by horseradish peroxidase.  It also formed reactive derivs., possibly N-chloro compds., in chlorine solns.  Thus, I can give rise to chem. reactive species by at least 3 distinct mechanisms, viz. autoxidn. in neutral soln. under air, peroxidase-catalyzed oxidn. and N-chlorination.  Formation of such species in liver and myeloid cells might be responsible for the adverse reactions assocd. with I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogGgzRVYPMorVg90H21EOLACvtfcHk0ljPj5HpFCT1Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXitFGrtrk%253D&md5=c0e11569fd4d2cb20b50795c2955eeee</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2888%2990733-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252888%252990733-2%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DTingle%26aufirst%3DM.%2BD.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DDrug%2520%25E2%2580%2593%2520protein%2520conjugates.%252014.%2520Mechanisms%2520of%2520formation%2520of%2520protein-arylating%2520intermediates%2520from%2520amodiaquine%252C%2520a%2520myelotoxin%2520and%2520hepatotoxin%2520in%2520man%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1988%26volume%3D37%26spage%3D303%26epage%3D311%26doi%3D10.1016%2F0006-2952%2888%2990733-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Irreversible binding of amodiaquine to human liver microsomes: chemical and metabolic factors</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">649</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1987&pages=649&author=J.+L.+Maggsauthor=J.+Colbertauthor=P.+A.+Winstanleyauthor=M.+L.+Ormeauthor=B.+K.+Park&title=Irreversible+binding+of+amodiaquine+to+human+liver+microsomes%3A+chemical+and+metabolic+factors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DColbert%26aufirst%3DJ.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DOrme%26aufirst%3DM.%2BL.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DIrreversible%2520binding%2520of%2520amodiaquine%2520to%2520human%2520liver%2520microsomes%253A%2520chemical%2520and%2520metabolic%2520factors%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1987%26volume%3D23%26spage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tingle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The bioactivation of amodiaquine by human polymorphonuclear leucocytes <i>in vitro</i>: Chemical mechanisms and the effects of fluorine substitution</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1113</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(95)00236-S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-2952%2895%2900236-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7575670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2MXovVSnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=1113-1119&author=M.+D.+Tingleauthor=H.+Jewellauthor=J.+L.+Maggsauthor=P.+M.+O%E2%80%99Neillauthor=B.+K.+Park&title=The+bioactivation+of+amodiaquine+by+human+polymorphonuclear+leucocytes+in+vitro%3A+Chemical+mechanisms+and+the+effects+of+fluorine+substitution&doi=10.1016%2F0006-2952%2895%2900236-S"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The bioactivation of amodiaquine by human polymorphonuclear leukocytes in vitro: chemical mechanisms and the effects of fluorine substitution</span></div><div class="casAuthors">Tingle, M. D.; Jewell, H.; Maggs, J. L.; O'Neill, P. M.; Park, B. K.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1113-19</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Amodiaquine, a 4-aminoquinoline antimalarial, has been assocd. with hepatitis and agranulocytosis in humans.  Drugs hypersensitivity reactions, esp. agranulocytosis have been attributed to reactive intermediates generated by the oxidants discharged from stimulated polymorphonuclear leukocytes (PMN).  The metab. of amodiaquine to both stable and chem. reactive metabolites by human PMN has been investigated in vitro.  Incubation of [14C]-amodiaquine with PMN resulted in irreversible binding of radiolabel to protein and depletion of intracellular reduced glutathione, which were enhanced by phorbol myristate acetate (PMA), a PMN activator.  Two metabolites were identified: the C-5' glutathione adduct of amodiaquine, derived from both endogenous and exogenous glutathione, and 4-amino-7-chloroquinoline, which was presumed to be formed by hydrolysis of amodiaquine quinoneimine.  Desethylamodiaquine, the major plasma metabolic of amodiaquine in humans, also underwent bioactivation to a chem. reactive species in the presence of PMA-stimulated PMN.  Substitution of the 4'-hydroxyl group in amodiaquine with fluorine significantly reduced irreversible binding to protein and abolished depletion of intracellular glutathione in the presence of PMA.  These findings indicate that the bioactivation of amodiaquine by PMN is assocd. with the formation of a quinone-imine intermediate.  Such a reactive metabolite, if produced in PMN or bone marrow in vivo, may be responsible for the drug myelotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyzWCNjsmQLVg90H21EOLACvtfcHk0ljPj5HpFCT1Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVSnuro%253D&md5=33bab1893484b86d195ab9f5e45f183b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2895%2900236-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252895%252900236-S%26sid%3Dliteratum%253Aachs%26aulast%3DTingle%26aufirst%3DM.%2BD.%26aulast%3DJewell%26aufirst%3DH.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520bioactivation%2520of%2520amodiaquine%2520by%2520human%2520polymorphonuclear%2520leucocytes%2520in%2520vitro%253A%2520Chemical%2520mechanisms%2520and%2520the%2520effects%2520of%2520fluorine%2520substitution%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D1113%26epage%3D1119%26doi%3D10.1016%2F0006-2952%2895%2900236-S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storr, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1021/jm00035a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00035a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1ehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1362-1370&author=P.+M.+O%E2%80%99Neillauthor=A.+C.+Harrisonauthor=R.+C.+Storrauthor=S.+R.+Hawleyauthor=S.+A.+Wardauthor=B.+K.+Park&title=The+effect+of+fluorine+substitution+on+the+metabolism+and+antimalarial+activity+of+amodiaquine&doi=10.1021%2Fjm00035a017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Fluorine Substitution on the Metabolism and Antimalarial Activity of Amodiaquine</span></div><div class="casAuthors">O'Neill, Paul M.; Harrison, Anthony C.; Storr, Richard C.; Hawley, Shaun R.; Ward, Stephen A.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1362-70</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Amodiaquine (I, R = OH, R1-R3 = H) is a 4-aminoquinoline antimalarial which causes adverse side effects such as agranulocytosis and liver damage.  The obsd. drug toxicity is believed to be related to the formation of an electrophilic metabolite, amodiaquinequinonimine, which can bind to cellular macromols. and initiate hypersensitivity reactions.  Fluoroamodiaquines I (R = OH; R1 = F, R2, R3 = H; R1 = R2 = F, R3 = H; R1 = H, R2 = R3 = F; R1-R3 = F) and I (R = F, R1-R3 = H) have been synthesized to assess the effect of fluorine substitution on the oxidn. potential, metab., and in vitro antimalarial activity of amodiaquine.  The oxidn. potentials were measured by cyclic voltammetry, and it was obsd. that I (R = OH, R1 = H, R2 = R3 = F; R = F, R1-R3 = H) had significantly higher oxidn. potentials than the parent drug.  These analogs were also more resistant to bioactivation.  Thus, I (R = OH, R1 = H, R2 = R3 = F; R = F, R1-R3 = H) produced thioether conjugates corresponding to 2.17% (SD: ±0.27%) and 0% of the dose compared with 11.87% (SD: ±1.31%) of the dose for amodiaquine.  In general the fluorinated analogs had similar in vitro antimalarial activity to amodiaquine against the chloroquine-resistant K1 strain and the chloroquine-sensitive T9-96 strain of Plasmodium falciparum with the notable exception of I (R = OH, R1-R3 = F).  The data presented indicate that I (R = OH, R1 = H, R2 = R3 F; R = F, R1-R3 = H) maintain antimalarial efficacy in vitro and are more resistant to oxidn. and hence less likely to form toxic quinonimine metabolites in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBGBtIXfHxTbVg90H21EOLACvtfcHk0lgqZU8s4j-nfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1ehsbY%253D&md5=9a79eac45b716fc242c4c57d8f73585b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm00035a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00035a017%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DHarrison%26aufirst%3DA.%2BC.%26aulast%3DStorr%26aufirst%3DR.%2BC.%26aulast%3DHawley%26aufirst%3DS.%2BR.%26aulast%3DWard%26aufirst%3DS.%2BA.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520effect%2520of%2520fluorine%2520substitution%2520on%2520the%2520metabolism%2520and%2520antimalarial%2520activity%2520of%2520amodiaquine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1362%26epage%3D1370%26doi%3D10.1021%2Fjm00035a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storr, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4933</span>– <span class="NLM_lpage">4945</span>, <span class="refDoi"> DOI: 10.1021/jm030796n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030796n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Wmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4933-4945&author=P.+M.+O%E2%80%99Neillauthor=A.+Mukhtarauthor=P.+A.+Stocksauthor=L.+E.+Randleauthor=S.+Hindleyauthor=S.+A.+Wardauthor=R.+C.+Storrauthor=J.+F.+Bickleyauthor=I.+A.+O%E2%80%99Neilauthor=J.+L.+Maggsauthor=R.+H.+Hughesauthor=P.+A.+Winstanleyauthor=P.+G.+Brayauthor=B.+K.+Park&title=Isoquine+and+related+amodiaquine+analogues%3A+a+new+generation+of+improved+4-aminoquinoline+antimalarials&doi=10.1021%2Fjm030796n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Isoquine and Related Amodiaquine Analogues: A New Generation of Improved 4-Aminoquinoline Antimalarials</span></div><div class="casAuthors">O'Neill, Paul M.; Mukhtar, Amira; Stocks, Paul A.; Randle, Laura E.; Hindley, Stephen; Ward, Stephen A.; Storr, Richard C.; Bickley, Jamie F.; O'Neil, Ian A.; Maggs, James L.; Hughes, Ruth H.; Winstanley, Peter A.; Bray, Patrick G.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4933-4945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amodiaquine (AQ) is a 4-aminoquinoline antimalarial that can cause adverse side effects including agranulocytosis and liver damage.  The obsd. drug toxicity is believed to involve the formation of an electrophilic metabolite, amodiaquine quinoneimine (AQQI), which can bind to cellular macromols. and initiate hypersensitivity reactions.  We proposed that interchange of the 3'-hydroxyl and the 4'-Mannich side-chain function of amodiaquine would provide a new series of analogs that cannot form toxic quinoneimine metabolites via cytochrome P 450-mediated metab.  By a simple two-step procedure, 10 isomeric amodiaquine analogs were prepd. and subsequently examd. against the chloroquine resistant K1 and sensitive HB3 strains of Plasmodium falciparum in vitro.  Several analogs displayed potent antimalarial activity against both strains.  On the basis of the results of in vitro testing, isoquine (ISQ1) (IC50 = 6.01 nM ± 8.0 vs. K1 strain), the direct isomer of amodiaquine, was selected for in vivo antimalarial assessment.  The potent in vitro antimalarial activity of isoquine was translated into excellent oral in vivo ED50 activity of 1.6 and 3.7 mg/kg against the P. yoelii NS strain compared to 7.9 and 7.4 mg/kg for amodiaquine.  Subsequent metab. studies in the rat model demonstrated that isoquine does not undergo in vivo bioactivation, as evidenced by the complete lack of glutathione metabolites in bile.  In sharp contrast to amodiaquine, isoquine (and Phase I metabolites) undergoes clearance by Phase II glucuronidation.  On the basis of these promising initial studies, isoquine (ISQ1) represents a new second generation lead worthy of further investigation as a cost-effective and potentially safer alternative to amodiaquine.  Crystal structures of two products were also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWnYDr5dXE7Vg90H21EOLACvtfcHk0lgqZU8s4j-nfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Wmurk%253D&md5=46f85a3035ce34c0bbe7dd3efb43df67</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm030796n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030796n%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DMukhtar%26aufirst%3DA.%26aulast%3DStocks%26aufirst%3DP.%2BA.%26aulast%3DRandle%26aufirst%3DL.%2BE.%26aulast%3DHindley%26aufirst%3DS.%26aulast%3DWard%26aufirst%3DS.%2BA.%26aulast%3DStorr%26aufirst%3DR.%2BC.%26aulast%3DBickley%26aufirst%3DJ.%2BF.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DI.%2BA.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DHughes%26aufirst%3DR.%2BH.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DIsoquine%2520and%2520related%2520amodiaquine%2520analogues%253A%2520a%2520new%2520generation%2520of%2520improved%25204-aminoquinoline%2520antimalarials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4933%26epage%3D4945%26doi%3D10.1021%2Fjm030796n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shone, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asadollahy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigandi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-de-Las-Heras, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parapini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taramelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4′-fluoro and 4′-chloro analogues of amodiaquine. Identification of a suitable “back-up” compound for N-tert-butyl isoquine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1828</span>– <span class="NLM_lpage">1844</span>, <span class="refDoi"> DOI: 10.1021/jm8012757</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8012757" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1828-1844&author=P.+M.+O%E2%80%99Neillauthor=A.+E.+Shoneauthor=D.+Stanfordauthor=G.+Nixonauthor=E.+Asadollahyauthor=B.+K.+Parkauthor=J.+L.+Maggsauthor=P.+Robertsauthor=P.+A.+Stocksauthor=G.+Biaginiauthor=P.+G.+Brayauthor=J.+Daviesauthor=N.+Berryauthor=C.+Hallauthor=K.+Rimmerauthor=P.+A.+Winstanleyauthor=S.+Hindleyauthor=R.+B.+Bambalauthor=C.+B.+Davisauthor=M.+Batesauthor=S.+L.+Greshamauthor=R.+A.+Brigandiauthor=F.+M.+Gomez-de-Las-Herasauthor=D.+V.+Gargalloauthor=S.+Parapiniauthor=L.+Vivasauthor=H.+Landerauthor=D.+Taramelliauthor=S.+A.+Ward&title=Synthesis%2C+antimalarial+activity%2C+and+preclinical+pharmacology+of+a+novel+series+of+4%E2%80%B2-fluoro+and+4%E2%80%B2-chloro+analogues+of+amodiaquine.+Identification+of+a+suitable+%E2%80%9Cback-up%E2%80%9D+compound+for+N-tert-butyl+isoquine&doi=10.1021%2Fjm8012757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4'-Fluoro and 4'-Chloro Analogues of Amodiaquine. Identification of a Suitable "Back-Up" Compound for N-tert-Butyl Isoquine</span></div><div class="casAuthors">O'Neill, Paul M.; Shone, Alison E.; Stanford, Deborah; Nixon, Gemma; Asadollahy, Eghbaleh; Park, B. Kevin; Maggs, James L.; Roberts, Phil; Stocks, Paul A.; Biagini, Giancarlo; Bray, Patrick G.; Davies, Jill; Berry, Neil; Hall, Charlotte; Rimmer, Karen; Winstanley, Peter A.; Hindley, Stephen; Bambal, Ramesh B.; Davis, Charles B.; Bates, Martin; Gresham, Stephanie L.; Brigandi, Richard A.; Gomez-de-las-Heras, Federico M.; Gargallo, Domingo V.; Parapini, Silvia; Vivas, Livia; Lander, Hollie; Taramelli, Donatella; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1828-1844</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of a mechanistic understanding of the toxicity of the 4-aminoquinoline amodiaquine, three series of amodiaquine analogs have been prepd. where the 4-aminophenol "metabolic alert" has been modified by replacement of the 4'-hydroxy group with a hydrogen, fluorine, or chlorine atom.  Following antimalarial assessment and studies on mechanism of action, two candidates were selected for detailed ADME studies and in vitro and in vivo toxicol. assessment.  4'-Fluoro-N-tert-butylamodiaquine was subsequently identified as a candidate for further development studies based on potent activity vs. chloroquine-sensitive and resistant parasites, moderate to excellent oral bioavailability, low toxicity in in vitro studies, and an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomw8jiAgxkRbVg90H21EOLACvtfcHk0liV51GOr3i1TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKitLo%253D&md5=02183e75ef6d150e2c0d37569cb8c756</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm8012757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012757%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DShone%26aufirst%3DA.%2BE.%26aulast%3DStanford%26aufirst%3DD.%26aulast%3DNixon%26aufirst%3DG.%26aulast%3DAsadollahy%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DStocks%26aufirst%3DP.%2BA.%26aulast%3DBiagini%26aufirst%3DG.%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DDavies%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DRimmer%26aufirst%3DK.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DHindley%26aufirst%3DS.%26aulast%3DBambal%26aufirst%3DR.%2BB.%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DBates%26aufirst%3DM.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DBrigandi%26aufirst%3DR.%2BA.%26aulast%3DGomez-de-Las-Heras%26aufirst%3DF.%2BM.%26aulast%3DGargallo%26aufirst%3DD.%2BV.%26aulast%3DParapini%26aufirst%3DS.%26aulast%3DVivas%26aufirst%3DL.%26aulast%3DLander%26aufirst%3DH.%26aulast%3DTaramelli%26aufirst%3DD.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%252C%2520antimalarial%2520activity%252C%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520novel%2520series%2520of%25204%25E2%2580%25B2-fluoro%2520and%25204%25E2%2580%25B2-chloro%2520analogues%2520of%2520amodiaquine.%2520Identification%2520of%2520a%2520suitable%2520%25E2%2580%259Cback-up%25E2%2580%259D%2520compound%2520for%2520N-tert-butyl%2520isoquine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1828%26epage%3D1844%26doi%3D10.1021%2Fjm8012757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span> <span> </span><span class="NLM_article-title">Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1021/tx0002583</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0002583" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=611-650&author=F.+P.+Guengerich&title=Common+and+uncommon+cytochrome+P450+reactions+related+to+metabolism+and+chemical+toxicity&doi=10.1021%2Ftx0002583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">611-650</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 417 refs.  Cytochrome P 450 enzymes catalyze a variety of reactions and convert chems. to potentially reactive products as well as make compds. less toxic.  Most of the P 450 reactions are oxidns.  The majority of these can be rationalized in the context of an FeO3+ intermediate and odd electron abstraction/rebound mechanisms; however, other iron-oxygen complexes are possible and alternate chemistries can be considered.  Another issue regarding P 450-catalyzed reactions is the delineation of rate-limiting steps in the catalytic cycle and the contribution to reaction selectivity.  In addn. to the rather classical oxidns., P 450s also catalyze less generally discussed reactions including redn., desatn., ester cleavage, ring expansion, ring formation, aldehyde scission, dehydration, ipso attack, one-electron oxidn., coupling reactions, rearrangement of fatty acid and prostaglandin hydroperoxides, and phospholipase activity.  Most of these reactions are rationalized in the context of high-valent iron-oxygen intermediates and Fe2+ redns., but others are not and may involve acid-base catalysis.  Some of these transformations are involved in the bioactivation and detoxication of xenobiotic chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznx-XkuM1OrVg90H21EOLACvtfcHk0liV51GOr3i1TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D&md5=9398501ce17beed3fc0bad4840187eea</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Ftx0002583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0002583%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DCommon%2520and%2520uncommon%2520cytochrome%2520P450%2520reactions%2520related%2520to%2520metabolism%2520and%2520chemical%2520toxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D611%26epage%3D650%26doi%3D10.1021%2Ftx0002583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shone, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1002/jps.21469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fjps.21469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18563832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1WitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2009&pages=362-377&author=C.+B.+Davisauthor=R.+Bambalauthor=G.+S.+Moorthyauthor=E.+Huggerauthor=H.+Xiangauthor=B.+K.+Parkauthor=A.+E.+Shoneauthor=P.+M.+O%E2%80%99Neillauthor=S.+A.+Ward&title=Comparative+preclinical+drug+metabolism+and+pharmacokinetic+evaluation+of+novel+4-aminoquinoline+anti-malarials&doi=10.1002%2Fjps.21469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials</span></div><div class="casAuthors">Davis, Charles B.; Bambal, Ramesh; Moorthy, Ganesh S.; Hugger, Erin; Xiang, Hong; Park, Brian Kevin; Shone, Allison E.; O'Neill, Paul M.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">362-377</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The disposition of three 4-aminoquinoline leads, namely isoquine (ISO), des-Et isoquine (DEI) and N-tert-Bu isoquine (NTBI), were studied in a range of in vivo and in vitro assays to assist in selecting an appropriate candidate for further development.  Analogous to amodiaquine (ADQ), ISO undergoes oxidative N-dealkylation to form DEI in vivo.  Blood clearance of DEI was as much as 10-fold lower than that of ISO in animals and after oral administration, metabolite exposure exceeded that of parent by as much as 14-fold.  Replacement of the N-Et with an N-tert-Bu substituent substantially reduced N-dealkylation as blood clearance of NTBI was ∼2 to 3-fold lower than DEI in mouse, rat, dog and monkey.  Mean NTBI oral bioavailability was generally higher than the other leads (≥68%).  Blood cell assocn. was substantial for NTBI, particularly in dog and monkey, where blood to plasma concn. ratios >4 were obsd.  Human plasma protein binding was similar for NTBI, DEI, and des-Et amodiaquine (DEA).  Allometric scaling predicted human blood clearance (CL) for NTBI to be low (∼12% liver blood flow).  All the 4-aminoquinolines inhibited recombinant human cytochrome P 450 2D6 with similar potency; DEI also inhibited 1A2.  On balance, NTBI appeared the most promising lead to progress towards full development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRauKF2IFKXrVg90H21EOLACvtfcHk0liV51GOr3i1TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1WitA%253D%253D&md5=2aa5b721095b74bae200438025393144</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fjps.21469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21469%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DBambal%26aufirst%3DR.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DXiang%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DShone%26aufirst%3DA.%2BE.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DComparative%2520preclinical%2520drug%2520metabolism%2520and%2520pharmacokinetic%2520evaluation%2520of%2520novel%25204-aminoquinoline%2520anti-malarials%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D98%26spage%3D362%26epage%3D377%26doi%3D10.1002%2Fjps.21469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shone, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonar-Law, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigandi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-delas-Heras, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1021/jm8012618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8012618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFShsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1408-1415&author=P.+M.+O%E2%80%99Neillauthor=B.+K.+Parkauthor=A.+E.+Shoneauthor=J.+L.+Maggsauthor=P.+Robertsauthor=P.+A.+Stocksauthor=G.+A.+Biaginiauthor=P.+G.+Brayauthor=P.+Gibbonsauthor=N.+Berryauthor=P.+A.+Winstanleyauthor=A.+Mukhtarauthor=R.+Bonar-Lawauthor=S.+Hindleyauthor=R.+B.+Bambalauthor=C.+B.+Davisauthor=M.+Batesauthor=T.+K.+Hartauthor=S.+L.+Greshamauthor=R.+M.+Lawrenceauthor=R.+A.+Brigandiauthor=F.+M.+Gomez-delas-Herasauthor=D.+V.+Gargalloauthor=S.+A.+Ward&title=Candidate+selection+and+preclinical+evaluation+of+N-tert-butyl+isoquine+%28GSK369796%29%2C+an+affordable+and+effective+4-aminoquinoline+antimalarial+for+the+21st+century&doi=10.1021%2Fjm8012618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate Selection and Preclinical Evaluation of N-tert-Butyl Isoquine (GSK369796), An Affordable and Effective 4-Aminoquinoline Antimalarial for the 21st Century</span></div><div class="casAuthors">O'Neill, Paul M.; Park, B. Kevin; Shone, Alison E.; Maggs, James L.; Roberts, Phillip; Stocks, Paul A.; Biagini, Giancarlo A.; Bray, Patrick G.; Gibbons, Peter; Berry, Neil; Winstanley, Peter A.; Mukhtar, Amira; Bonar-Law, Richard; Hindley, Stephen; Bambal, Ramesh B.; Davis, Charles B.; Bates, Martin; Hart, Timothy K.; Gresham, Stephanie L.; Lawrence, Ron M.; Brigandi, Richard A.; Gomez-delas-Heras, Federico M.; Gargallo, Domingo V.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1408-1415</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-tert-Bu isoquine (4) (GSK369796) is a 4-aminoquinoline drug candidate selected and developed as part of a public-private partnership between academics at Liverpool, MMV, and GSK pharmaceuticals.  This mol. was rationally designed based on chem., toxicol., pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo.  The optimized chem. delivered this novel synthetic quinoline in a two-step procedure from cheap and readily available starting materials.  The mol. has a full industry std. preclin. development program allowing first into humans to proceed.  Employing chloroquine (1) and amodiaquine (2) as comparator mols. in the preclin. plan, the first preclin. dossier of pharmacokinetic, toxicity, and safety pharmacol. has also been established for the 4-aminoquinoline antimalarial class.  These studies have revealed preclin. liabilities that have never translated into the human experience.  This has resulted in the availability of crit. information to other drug development teams interested in developing antimalarials within this class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD8p09GaCH5bVg90H21EOLACvtfcHk0ljn7e4yK2HV1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFShsbo%253D&md5=d08b37c74a7393eaefb5b86fd5a265dc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm8012618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012618%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DShone%26aufirst%3DA.%2BE.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DStocks%26aufirst%3DP.%2BA.%26aulast%3DBiagini%26aufirst%3DG.%2BA.%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DMukhtar%26aufirst%3DA.%26aulast%3DBonar-Law%26aufirst%3DR.%26aulast%3DHindley%26aufirst%3DS.%26aulast%3DBambal%26aufirst%3DR.%2BB.%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DBates%26aufirst%3DM.%26aulast%3DHart%26aufirst%3DT.%2BK.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DBrigandi%26aufirst%3DR.%2BA.%26aulast%3DGomez-delas-Heras%26aufirst%3DF.%2BM.%26aulast%3DGargallo%26aufirst%3DD.%2BV.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DCandidate%2520selection%2520and%2520preclinical%2520evaluation%2520of%2520N-tert-butyl%2520isoquine%2520%2528GSK369796%2529%252C%2520an%2520affordable%2520and%2520effective%25204-aminoquinoline%2520antimalarial%2520for%2520the%252021st%2520century%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1408%26epage%3D1415%26doi%3D10.1021%2Fjm8012618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspnes, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-McLeod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlynn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autry, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnette, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span> <span> </span><span class="NLM_article-title">Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6071</span>– <span class="NLM_lpage">6077</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2008.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18951788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6071-6077&author=D.+P.+Walkerauthor=F.+C.+Biauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=S.+X.+Zhaoauthor=J.+R.+Sogliaauthor=G.+E.+Aspnesauthor=D.+W.+Kungauthor=J.+Klug-McLeodauthor=M.+P.+Zawistoskiauthor=M.+A.+McGlynnauthor=R.+Oliverauthor=M.+Dunnauthor=J.+C.+Liauthor=D.+T.+Richterauthor=B.+A.+Cooperauthor=J.+C.+Kathauthor=C.+A.+Hulfordauthor=C.+L.+Autryauthor=M.+J.+Luzzioauthor=E.+J.+Ungauthor=W.+G.+Robertsauthor=P.+C.+Bonnetteauthor=L.+Buckbinderauthor=A.+Mistryauthor=M.+C.+Grifforauthor=S.+Hanauthor=A.+Guzman-Perez&title=Trifluoromethylpyrimidine-based+inhibitors+of+proline-rich+tyrosine+kinase+2+%28PYK2%29%3A+structure-activity+relationships+and+strategies+for+the+elimination+of+reactive+metabolite+formation&doi=10.1016%2Fj.bmcl.2008.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure-activity relationships and strategies for the elimination of reactive metabolite formation</span></div><div class="casAuthors">Walker, Daniel P.; Bi, F. Christopher; Kalgutkar, Amit S.; Bauman, Jonathan N.; Zhao, Sabrina X.; Soglia, John R.; Aspnes, Gary E.; Kung, Daniel W.; Klug-McLeod, Jacquelyn; Zawistoski, Michael P.; McGlynn, Molly A.; Oliver, Robert; Dunn, Matthew; Li, Jian-Cheng; Richter, Daniel T.; Cooper, Beth A.; Kath, John C.; Hulford, Catherine A.; Autry, Christopher L.; Luzzio, Michael J.; Ung, Ethan J.; Roberts, W. Gregory; Bonnette, Peter C.; Buckbinder, Leonard; Mistry, Anil; Griffor, Matthew C.; Han, Seungil; Guzman-Perez, Angel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6071-6077</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis and SAR for a series of diaminopyrimidines as PYK2 inhibitors are described.  Using a combination of library and traditional medicinal chem. techniques, a FAK-selective chem. series was transformed into compds. possessing good PYK2 potency and 10- to 20-fold selectivity against FAK.  Subsequent studies found that the majority of the compds. were pos. in a reactive metabolite assay, an indicator for potential toxicol. liabilities.  Based on the proposed mechanism for bioactivation, as well as a combination of structure-based drug design and traditional medicinal chem. techniques, a follow-up series of PYK2 inhibitors was identified that maintained PYK2 potency, FAK selectivity and HLM stability, yet were neg. in the RM assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobVdPk7MYsA7Vg90H21EOLACvtfcHk0ljn7e4yK2HV1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhsbbN&md5=614dba2d30b2f139562b7d3c6575d55e</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DMcGlynn%26aufirst%3DM.%2BA.%26aulast%3DOliver%26aufirst%3DR.%26aulast%3DDunn%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BC.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DAutry%26aufirst%3DC.%2BL.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DUng%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26atitle%3DTrifluoromethylpyrimidine-based%2520inhibitors%2520of%2520proline-rich%2520tyrosine%2520kinase%25202%2520%2528PYK2%2529%253A%2520structure-activity%2520relationships%2520and%2520strategies%2520for%2520the%2520elimination%2520of%2520reactive%2520metabolite%2520formation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6071%26epage%3D6077%26doi%3D10.1016%2Fj.bmcl.2008.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafalski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditta, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deskus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanitis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4161</span>– <span class="NLM_lpage">4172</span>, <span class="refDoi"> DOI: 10.1021/jm900302q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900302q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1Ogurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4161-4172&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=M.+Rafalskiauthor=W.+D.+Schmitzauthor=A.+B.+Brennerauthor=D.+J.+Denhartauthor=J.+L.+Dittaauthor=J.+A.+Deskusauthor=E.+W.+Yueauthor=A.+G.+Arvanitisauthor=S.+Lelasauthor=Y.+W.+Liauthor=T.+F.+Molskiauthor=H.+Wongauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=J.+Liauthor=N.+J.+Lodgeauthor=R.+Zaczekauthor=A.+P.+Combsauthor=R.+E.+Olsonauthor=R.+J.+Mattsonauthor=J.+J.+Bronsonauthor=J.+E.+Macor&title=In+vitro+intrinsic+clearance-based+optimization+of+N3-phenylpyrazinones+as+corticotropin-releasing+factor-1+%28CRF1%29+receptor+antagonists&doi=10.1021%2Fjm900302q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Intrinsic Clearance-Based Optimization of N3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Rafalski, Maria; Schmitz, William D.; Brenner, Allison B.; Denhart, Derek J.; Ditta, Jonathan L.; Deskus, Jeffrey A.; Yue, Eddy W.; Arvanitis, Argyrios G.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Wong, Harvey; Grace, James E.; Lentz, Kimberley A.; Li, Jianqing; Lodge, Nicholas J.; Zaczek, Robert; Combs, Andrew P.; Olson, Richard E.; Mattson, Ronald J.; Bronson, Joanne J.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4161-4172</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists.  Selected compds., e.g. I, proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal.  In this article, an in vitro intrinsic clearance-based approach is described to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metab. were identified by incubation with human liver microsomes.  It was found that the rate of metab. could be decreased by incorporation of appropriate substituents at the primary sites of metab.  This led to the discovery of I, a highly potent (IC50 = 1.0 nM) and selective CRF1 receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSxtlvZCt7vrVg90H21EOLACvtfcHk0lgSXLVzZb82EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1Ogurk%253D&md5=9ed4f4c2001a832dcb9fdcceb6ce0067</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjm900302q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900302q%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DRafalski%26aufirst%3DM.%26aulast%3DSchmitz%26aufirst%3DW.%2BD.%26aulast%3DBrenner%26aufirst%3DA.%2BB.%26aulast%3DDenhart%26aufirst%3DD.%2BJ.%26aulast%3DDitta%26aufirst%3DJ.%2BL.%26aulast%3DDeskus%26aufirst%3DJ.%2BA.%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DArvanitis%26aufirst%3DA.%2BG.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26aulast%3DOlson%26aufirst%3DR.%2BE.%26aulast%3DMattson%26aufirst%3DR.%2BJ.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DIn%2520vitro%2520intrinsic%2520clearance-based%2520optimization%2520of%2520N3-phenylpyrazinones%2520as%2520corticotropin-releasing%2520factor-1%2520%2528CRF1%2529%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4161%26epage%3D4172%26doi%3D10.1021%2Fjm900302q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deskus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditta, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian-Cutrone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schartman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span> <span> </span><span class="NLM_article-title">A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7653</span>– <span class="NLM_lpage">7668</span>, <span class="refDoi"> DOI: 10.1021/jm900716v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900716v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7653-7668&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=X.+Zhuoauthor=R.+J.+Mattsonauthor=D.+J.+Denhartauthor=J.+A.+Deskusauthor=V.+M.+Vrudhulaauthor=S.+Panauthor=J.+L.+Dittaauthor=Y.+Z.+Shuauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=S.+Lelasauthor=Y.+W.+Liauthor=T.+F.+Molskiauthor=S.+Krishnananthanauthor=H.+Wongauthor=J.+Qian-Cutroneauthor=R.+Schartmanauthor=R.+Dentonauthor=N.+J.+Lodgeauthor=R.+Zaczekauthor=J.+E.+Macorauthor=J.+J.+Bronson&title=A+strategy+to+minimize+reactive+metabolite+formation%3A+discovery+of+%28S%29-4-%281-cyclopropyl-2-methoxyethyl%29-6-%5B6-%28difluoromethoxy%29-2%2C5-dimethylpyridin-3-ylamino%5D-5-oxo-4%2C5-dihydropyrazine-2-carbonitrile+as+a+potent%2C+orally+bioavailable+corticotropin-releasing+factor-1+receptor+antagonist&doi=10.1021%2Fjm900716v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Zhuo, Xiaoliang; Mattson, Ronald J.; Denhart, Derek J.; Deskus, Jeffrey A.; Vrudhula, Vivekananda M.; Pan, Senliang; Ditta, Jonathan L.; Shu, Yue-Zhong; Grace, James E.; Lentz, Kimberley A.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Krishnananthan, Subramaniam; Wong, Henry; Qian-Cutrone, Jingfang; Schartman, Richard; Denton, Rex; Lodge, Nicholas J.; Zaczek, Robert; Macor, John E.; Bronson, Joanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7653-7668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Detailed metabolic characterization of 8 (VIII), an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF1) receptor antagonist, revealed that this compd. formed significant levels of reactive metabolites, as measured by in vivo and in vitro biotransformation studies.  This was of particular concern due to the body of evidence suggesting that reactive metabolites may be involved in idiosyncratic drug reactions.  Further optimization of the structure-activity relationships and in vivo properties of pyrazinone-based CRF1 receptor antagonists and studies to assess the formation of reactive metabolites led to the discovery of 19e (XIX), a high affinity CRF1 receptor antagonist (IC50 = 0.86 nM) wherein GSH adducts were estd. to be only 0.1% of the total amt. of drug-related material excreted through bile and urine, indicating low levels of reactive metabolite formation in vivo.  A novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group in XIX contributed to the potency and improved in vivo properties of this compd. and related analogs.  XIX had excellent pharmacokinetic properties in rats and dogs and showed efficacy in the defensive withdrawal model of anxiety in rats.  The lowest efficacious dose was 1.8 mg/kg.  The results of a two-week rat safety study with XIX indicated that this compd. was well-tolerated.  Safety: authors caution safety in conversion of 2-amino-3-methylpyridine to 3-methyl-5-nitropyridin-2-ol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXgjp_vZ9dU7Vg90H21EOLACvtfcHk0lgSXLVzZb82EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM&md5=b340d132071b98a2b488952c2bcef4e5</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm900716v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900716v%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DMattson%26aufirst%3DR.%2BJ.%26aulast%3DDenhart%26aufirst%3DD.%2BJ.%26aulast%3DDeskus%26aufirst%3DJ.%2BA.%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DDitta%26aufirst%3DJ.%2BL.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DQian-Cutrone%26aufirst%3DJ.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520strategy%2520to%2520minimize%2520reactive%2520metabolite%2520formation%253A%2520discovery%2520of%2520%2528S%2529-4-%25281-cyclopropyl-2-methoxyethyl%2529-6-%255B6-%2528difluoromethoxy%2529-2%252C5-dimethylpyridin-3-ylamino%255D-5-oxo-4%252C5-dihydropyrazine-2-carbonitrile%2520as%2520a%2520potent%252C%2520orally%2520bioavailable%2520corticotropin-releasing%2520factor-1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7653%26epage%3D7668%26doi%3D10.1021%2Fjm900716v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.109.028910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19833844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=5-15&author=X.+Zhuoauthor=R.+A.+Hartzauthor=J.+J.+Bronsonauthor=H.+Wongauthor=V.+T.+Ahujaauthor=V.+M.+Vrudhulaauthor=J.+E.+Leetauthor=S.+Huangauthor=J.+E.+Macorauthor=Y.+Z.+Shu&title=Comparative+biotransformation+of+pyrazinone-containing+corticotropin-releasing+factor+receptor-1+antagonists%3A+minimizing+the+reactive+metabolite+formation&doi=10.1124%2Fdmd.109.028910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation</span></div><div class="casAuthors">Zhuo, Xiaoliang; Hartz, Richard A.; Bronson, Joanne J.; Wong, Harvey; Ahuja, Vijay T.; Vrudhula, Vivekananda M.; Leet, John E.; Huang, Stella; Macor, John E.; Shu, Yue-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(S)-5-Chloro-1-(1-cyclopropylethyl)-3-(2,6-dichloro-4-(trifluoromethyl)-phenylamino)pyrazin-2(1H)-one (BMS-665053), a pyrazinone-contg. compd., is a potent and selective antagonist of corticotropin-releasing factor receptor-1 (CRF-R1) that showed efficacy in the defensive withdrawal model for anxiety in rats, suggesting its use as a potential treatment for anxiety and depression.  In vitro metab. studies of BMS-665053 in rat and human liver microsomes revealed cytochrome P 450-mediated oxidn. of the pyrazinone moiety, followed by ring opening, as the primary metabolic pathway.  Detection of a series of GSH adducts in trapping expts. suggested the formation of a reactive intermediate, probably as a result of epoxidn. of the pyrazinone moiety.  In addn., BMS-665053 (20 mg/kg i.v.) underwent extensive metab. in bile duct-cannulated (BDC) rats.  The major drug-related materials in rat plasma were the pyrazinone oxidn. products.  In rat bile and urine (0-7 h), only a trace amt. of the parent drug was recovered, whereas significant levels of the pyrazinone epoxide-derived metabolites and GSH-related conjugates were detected.  Further evidence suggested that GSH-related conjugates also formed at the dichloroarylamine moiety possibly via an epoxide or a quinone imine intermediate.  Other major metabolites in BDC rat bile and urine included glucuronide conjugates.  To reduce potential liability due to metabolic activation of BMS-665053, a no. of pyrazinone analogs with different substituents were synthesized and investigated for reactive metabolite formation, leading to the discovery of a CRF-R1 antagonist with diminished in vitro metabolic activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKSmCnHe221LVg90H21EOLACvtfcHk0lgSXLVzZb82EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fE&md5=ce4d9c5f99f96cbc018968130b068e81</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028910%26sid%3Dliteratum%253Aachs%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26atitle%3DComparative%2520biotransformation%2520of%2520pyrazinone-containing%2520corticotropin-releasing%2520factor%2520receptor-1%2520antagonists%253A%2520minimizing%2520the%2520reactive%2520metabolite%2520formation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D5%26epage%3D15%26doi%3D10.1124%2Fdmd.109.028910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF-1) receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1890</span>– <span class="NLM_lpage">1894</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.01.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20176478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFGltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1890-1894&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=W.+D.+Schmitzauthor=T.+F.+Molskiauthor=G.+K.+Mattsonauthor=N.+J.+Lodgeauthor=J.+J.+Bronsonauthor=J.+E.+Macor&title=Synthesis+and+structure-activity+relationships+of+N3-pyridylpyrazinones+as+corticotropin-releasing+factor-1+%28CRF-1%29+receptor+antagonists&doi=10.1016%2Fj.bmcl.2010.01.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of N 3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Schmitz, William D.; Molski, Thaddeus F.; Mattson, Gail K.; Lodge, Nicholas J.; Bronson, Joanne J.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1890-1894</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N 3-pyridylpyrazinones was investigated as corticotropin-releasing factor-1 receptor antagonists.  It was obsd. that the binding affinity of analogs contg. a pyridyl group was influenced not only by the substitution pattern on the pyridyl group, but also by the pK a of the pyridyl nitrogen.  Analogs contg. a novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group e. g., I were among the most potent N3-pyridylpyrazinones synthesized.  The synthesis and SAR of N 3-pyridylpyrazinones is described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAinLk7idiU7Vg90H21EOLACvtfcHk0lj1f1JOQkcNXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFGltbw%253D&md5=62d428f7fa2ac484864efb1107afafa4</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.129%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DSchmitz%26aufirst%3DW.%2BD.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DMattson%26aufirst%3DG.%2BK.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520N3-pyridylpyrazinones%2520as%2520corticotropin-releasing%2520factor-1%2520%2528CRF-1%2529%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1890%26epage%3D1894%26doi%3D10.1016%2Fj.bmcl.2010.01.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagmann, W. K.</span></span> <span> </span><span class="NLM_article-title">The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity</span>. <i>Arch. Pharm. (Weinheim, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1002/ardp.200700255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fardp.200700255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18574849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFaksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=405-411&author=W.+K.+Hagmann&title=The+discovery+of+taranabant%2C+a+selective+cannabinoid-1+receptor+inverse+agonist+for+the+treatment+of+obesity&doi=10.1002%2Fardp.200700255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The cannabinoid-1 receptor (CB1R) has emerged as one of the most important targets for the treatment of obesity.  Pioneering studies with rimonabant helped to validate animal models of food intake redn. and wt. loss and made the connection to wt. loss in the clinic.  A novel, acyclic amide was identified from a high throughput screen (HTS) of the Merck sample collection and found to be a potent and selective CB1R inhibitor.  Further optimization led to more potent compds. that were orally active in reducing food intake and wt. loss in diet-induced obese (DIO) rats.  However, many of these analogs exhibited a high potential for bioactivation and the formation of reactive intermediates and covalent protein binding.  Identification of the products of oxidative metab. guided medicinal chem. efforts to minimize the formation of these unwanted products.  These efforts resulted in the identification of the CB1R inverse agonist, taranabant, which is currently in Phase-III clin. studies for the treatment of obesity.  This mini-review will describe some of the medicinal chem. strategies that were followed from the original high throughput screen hit to the discovery of taranabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzzztvovfew7Vg90H21EOLACvtfcHk0lj1f1JOQkcNXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFaksbs%253D&md5=2f0d6c933877c7a7502eb6677312074f</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fardp.200700255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200700255%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520discovery%2520of%2520taranabant%252C%2520a%2520selective%2520cannabinoid-1%2520receptor%2520inverse%2520agonist%2520for%2520the%2520treatment%2520of%2520obesity%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2008%26volume%3D341%26spage%3D405%26epage%3D411%26doi%3D10.1002%2Fardp.200700255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atherton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Li.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevena, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span> <span> </span><span class="NLM_article-title">A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1954</span>– <span class="NLM_lpage">1965</span>, <span class="refDoi"> DOI: 10.1021/tx700270r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx700270r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1954-1965&author=A.+S.+Kalgutkarauthor=J.+Driscollauthor=S.+X.+Zhaoauthor=G.+S.+Walkerauthor=R.+M.+Shepardauthor=J.+R.+Sogliaauthor=J.+Athertonauthor=Li.+Yuauthor=A.+E.+Mutlibauthor=M.+J.+Munchhofauthor=L.+A.+Reiterauthor=C.+S.+Jonesauthor=J.+L.+Dotyauthor=K.+A.+Trevenaauthor=C.+L.+Shafferauthor=S.+L.+Ripp&title=A+rational+chemical+intervention+strategy+to+circumvent+bioactivation+liabilities+associated+with+a+nonpeptidyl+thrombopoietin+receptor+agonist+containing+a+2-amino-4-arylthiazole+motif&doi=10.1021%2Ftx700270r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif</span></div><div class="casAuthors">Kalgutkar, Amit S.; Driscoll, James; Zhao, Sabrina X.; Walker, Gregory S.; Shepard, Richard M.; Soglia, John R.; Atherton, James; Yu, Linning; Mutlib, Abdul E.; Munchhof, Michael J.; Reiter, Lawrence A.; Jones, Christopher S.; Doty, Johnathan L.; Trevena, Kristen A.; Shaffer, Christopher L.; Ripp, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1954-1965</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The current study examd. the bioactivation potential of a nonpeptidyl thrombopoietin receptor agonist, 1-(3-chloro-5-((4-(4-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)carbamoyl)pyridine-2-yl)piperidine-4-carboxylic acid (1), contg. a 2-carboxamido-4-arylthiazole moiety in the core structure.  Toxicol. risks arising from P 450-catalyzed C4-C5 thiazole ring opening in 1 via the epoxidn. diol sequence were alleviated, since mass spectrometric anal. of human liver microsome and/or hepatocyte incubations of 1 did not reveal the formation of reactive acylthiourea and/or glyoxal metabolites, which are prototypic products derived from thiazole ring scission.  However, 4-(4-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-amine (2), the product of hydrolysis of 1 in human liver microsomes, hepatocytes, and plasma, underwent oxidative bioactivation in human liver microsomes, since trapping studies with glutathione led to the formation of two conjugates derived from the addn. of the thiol nucleophile to 2 and a thiazole-S-oxide metabolite of 2.  Mass spectral fragmentation and NMR anal. indicated that the site of attachment of the glutathionyl moiety in both conjugates was the C5 position in the thiazole ring.  Based on the structures of the glutathione conjugates, two bioactivation pathways are proposed, one involving β-elimination of an initially formed hydroxylamine metabolite and the other involving direct two-electron oxidn. of the electron-rich 2-aminothiazole system to electrophilic intermediates.  This mechanistic insight into the bioactivation process allowed the development of a rational chem. intervention strategy that involved blocking the C5 position with a fluorine atom or replacing the thiazole ring with a 1,2,4-thiadiazole group.  These structural changes not only abrogated the bioactivation liability assocd. with 1 but also resulted in compds. that retained the attractive pharmacol. and pharmacokinetic attributes of the prototype agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxi1Bp9ve-TLVg90H21EOLACvtfcHk0lgGYANK998L3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhtbfM&md5=97c144c6d3c621dcef18a76b63f1806e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Ftx700270r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700270r%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DShepard%26aufirst%3DR.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DLi.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DTrevena%26aufirst%3DK.%2BA.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26atitle%3DA%2520rational%2520chemical%2520intervention%2520strategy%2520to%2520circumvent%2520bioactivation%2520liabilities%2520associated%2520with%2520a%2520nonpeptidyl%2520thrombopoietin%2520receptor%2520agonist%2520containing%2520a%25202-amino-4-arylthiazole%2520motif%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1954%26epage%3D1965%26doi%3D10.1021%2Ftx700270r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antipas, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reim, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shavnya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeets, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevena, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4069</span>– <span class="NLM_lpage">4072</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.05.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20558059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVKntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4069-4072&author=A.+S.+Antipasauthor=L.+C.+Blumbergauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=J.+L.+Dotyauthor=J.+Driscollauthor=T.+M.+Harrisauthor=C.+S.+Jonesauthor=S.+P.+McCurdyauthor=E.+McElroyauthor=M.+Mitton-Fryauthor=M.+J.+Munchhofauthor=D.+A.+Reimauthor=L.+A.+Reiterauthor=S.+L.+Rippauthor=A.+Shavnyaauthor=M.+I.+Smeetsauthor=K.+A.+Trevena&title=Structure-activity+relationships+and+hepatic+safety+risks+of+thiazole+agonists+of+the+thrombopoietin+receptor&doi=10.1016%2Fj.bmcl.2010.05.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor</span></div><div class="casAuthors">Antipas, Amy S.; Blumberg, Laura C.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Doty, Jonathan L.; Driscoll, James; Harris, Thomas M.; Jones, Christopher S.; McCurdy, Sandra P.; McElroy, Eric; Mitton-Fry, Mark; Munchhof, Michael J.; Reim, David A.; Reiter, Lawrence A.; Ripp, Sharon L.; Shavnya, Andrei; Smeets, Marc I.; Trevena, Kristen A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4069-4072</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">5-F substitution of an aminothiazole moiety within a series of thrombopoietin receptor agonists leads to potent agents with an improved hepatic safety profile in rodent toxicol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqkpY1JAPPtbVg90H21EOLACvtfcHk0lgGYANK998L3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVKntb8%253D&md5=81a4421b9190173a80c5475acf99f49d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.087%26sid%3Dliteratum%253Aachs%26aulast%3DAntipas%26aufirst%3DA.%2BS.%26aulast%3DBlumberg%26aufirst%3DL.%2BC.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMcElroy%26aufirst%3DE.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DReim%26aufirst%3DD.%2BA.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DShavnya%26aufirst%3DA.%26aulast%3DSmeets%26aufirst%3DM.%2BI.%26aulast%3DTrevena%26aufirst%3DK.%2BA.%26atitle%3DStructure-activity%2520relationships%2520and%2520hepatic%2520safety%2520risks%2520of%2520thiazole%2520agonists%2520of%2520the%2520thrombopoietin%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4069%26epage%3D4072%26doi%3D10.1016%2Fj.bmcl.2010.05.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surapaneni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiles, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlhieter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: Identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1021/tx900414g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx900414g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=653-663&author=R.+Subramanianauthor=M.+R.+Leeauthor=J.+G.+Allenauthor=M.+P.+Bourbeauauthor=C.+Fotschauthor=F.+T.+Hongauthor=S.+Tadesseauthor=G.+Yaoauthor=C.+C.+Yuanauthor=S.+Surapaneniauthor=G.+L.+Skilesauthor=X.+Wangauthor=G.+E.+Wohlhieterauthor=Q.+Zengauthor=Y.+Zhouauthor=X.+Zhuauthor=C.+Li&title=Cytochrome+P450-mediated+epoxidation+of+2-aminothiazole-based+AKT+inhibitors%3A+Identification+of+novel+GSH+adducts+and+reduction+of+metabolic+activation+through+structural+changes+guided+by+in+silico+and+in+vitro+screening&doi=10.1021%2Ftx900414g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-Mediated Epoxidation of 2-Aminothiazole-Based AKT Inhibitors: Identification of Novel GSH Adducts and Reduction of Metabolic Activation through Structural Changes Guided by in Silico and in Vitro Screening</span></div><div class="casAuthors">Subramanian, Raju; Lee, Matthew R.; Allen, John G.; Bourbeau, Matthew P.; Fotsch, Christopher; Hong, Fang-Tsao; Tadesse, Seifu; Yao, Guomin; Yuan, Chester C.; Surapaneni, Sekhar; Skiles, Gary L.; Wang, Xianghong; Wohlhieter, G. Erich; Zeng, Qingping; Zhou, Yihong; Zhu, Xiaochun; Li, Chun</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-663</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A 2-aminothiazole deriv. 1 was developed as a potential inhibitor of the oncol. target AKT, a serine/threonine kinase.  When incubated in rat and human liver microsomes in the presence of NADPH, 1 underwent significant metabolic activation on its 2-aminothiazole ring, leading to substantial covalent protein binding.  Upon addn. of glutathione, covalent binding was reduced significantly, and multiple glutathione adducts were detected.  Novel metabolites from the in vitro incubates were characterized by LC-MS and NMR to discern the mechanism of bioactivation.  An in silico model was developed based on the proposed mechanism and was employed to predict bioactivation in 23 structural analogs.  The predictions were confirmed empirically for the bioactivation liability, in vitro, by LC-MS methods screening for glutathione incorporation.  New compds. were identified with a low propensity for bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4rBMHrMBdXLVg90H21EOLACvtfcHk0lgGYANK998L3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlKhsg%253D%253D&md5=0d995b86dff19e5f19408fffd42d0cfb</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Ftx900414g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900414g%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DSurapaneni%26aufirst%3DS.%26aulast%3DSkiles%26aufirst%3DG.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWohlhieter%26aufirst%3DG.%2BE.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DCytochrome%2520P450-mediated%2520epoxidation%2520of%25202-aminothiazole-based%2520AKT%2520inhibitors%253A%2520Identification%2520of%2520novel%2520GSH%2520adducts%2520and%2520reduction%2520of%2520metabolic%2520activation%2520through%2520structural%2520changes%2520guided%2520by%2520in%2520silico%2520and%2520in%2520vitro%2520screening%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D653%26epage%3D663%26doi%3D10.1021%2Ftx900414g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlhieter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1652</span>– <span class="NLM_lpage">1666</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.01.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20137932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1652-1666&author=Q.+Zengauthor=M.+P.+Bourbeauauthor=G.+E.+Wohlhieterauthor=G.+Yaoauthor=H.+Monenscheinauthor=J.+T.+Riderauthor=M.+R.+Leeauthor=S.+Zhangauthor=J.+Lofgrenauthor=D.+Freemanauthor=C.+Liauthor=E.+Tomineyauthor=X.+Huangauthor=D.+Hoffmanauthor=H.+Yamaneauthor=A.+S.+Taskerauthor=C.+Dominguezauthor=V.+N.+Viswanadhanauthor=R.+Hungateauthor=X.+Zhang&title=2-Aminothiadiazole+inhibitors+of+AKT1+as+potential+cancer+therapeutics&doi=10.1016%2Fj.bmcl.2010.01.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics</span></div><div class="casAuthors">Zeng, Qingping; Bourbeau, Matthew P.; Wohlhieter, G. Erich; Yao, Guomin; Monenschein, Holger; Rider, James T.; Lee, Matthew R.; Zhang, Shiwen; Lofgren, Julie; Freeman, Daniel; Li, Chun; Tominey, Elizabeth; Huang, Xin; Hoffman, Douglas; Yamane, Harvey; Tasker, Andrew S.; Dominguez, Celia; Viswanadhan, Vellarkad N.; Hungate, Randall; Zhang, Xiaoling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1652-1656</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-aminothiadiazole of inhibitors of AKT1 is described.  SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2).  Moderate selectivity obsd. in several compds. for AKT1 vs. PKA is rationalized by X-ray crystallog. anal.  Key compds. showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1.  Compd. 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodjGAUJDiAZ7Vg90H21EOLACvtfcHk0lh46GC_gUcBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlehsbo%253D&md5=99eddcdaddda9bc7915cb1453349a2bf</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.046%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DWohlhieter%26aufirst%3DG.%2BE.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DRider%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTominey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3D2-Aminothiadiazole%2520inhibitors%2520of%2520AKT1%2520as%2520potential%2520cancer%2520therapeutics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1652%26epage%3D1666%26doi%3D10.1016%2Fj.bmcl.2010.01.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofgren, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Azole-based inhibitors of AKT/PKB for the treatment of cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1559</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.01.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20137943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlehs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1559-1564&author=Q.+Zengauthor=J.+G.+Allenauthor=M.+P.+Bourbeauauthor=X.+Wangauthor=G.+Yaoauthor=S.+Tadesseauthor=J.+T.+Riderauthor=C.+C.+Yuanauthor=F.+T.+Hongauthor=M.+R.+Leeauthor=S.+Zhangauthor=J.+A.+Lofgrenauthor=D.+J.+Freemanauthor=S.+Yangauthor=C.+Liauthor=E.+Tomineyauthor=X.+Huangauthor=D.+Hoffmanauthor=H.+K.+Yamaneauthor=C.+Fotschauthor=C.+Dominguezauthor=R.+Hungateauthor=X.+Zhang&title=Azole-based+inhibitors+of+AKT%2FPKB+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmcl.2010.01.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Azole-based inhibitors of AKT/PKB for the treatment of cancer</span></div><div class="casAuthors">Zeng, Qingping; Allen, John G.; Bourbeau, Matthew P.; Wang, Xianghong; Yao, Guomin; Tadesse, Seifu; Rider, James T.; Yuan, Chester C.; Hong, Fang-Tsao; Lee, Matthew R.; Zhang, Shiwen; Lofgren, Julie A.; Freeman, Daniel J.; Yang, Suijin; Li, Chun; Tominey, Elizabeth; Huang, Xin; Hoffman, Douglas; Yamane, Harvey K.; Fotsch, Christopher; Dominguez, Celia; Hungate, Randall; Zhang, Xiaoling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1559-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Through a combination of screening and structure-based rational design, a series of N1-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines, e.g., I were discovered and developed into potent ATP competitive inhibitors of AKT.  Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions obsd. in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA.  One compd. was shown to have acceptable pharmacokinetic properties and to be a potent inhibitor of AKT signaling and of in vivo xenograft tumor growth in a preclin. model of glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFp-8a3DxypLVg90H21EOLACvtfcHk0lh46GC_gUcBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlehs7w%253D&md5=1e17024d22710486ae8cedb1a4427731</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.067%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DRider%26aufirst%3DJ.%2BT.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%2BA.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTominey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DYamane%26aufirst%3DH.%2BK.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DAzole-based%2520inhibitors%2520of%2520AKT%252FPKB%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1559%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2010.01.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarabu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzarro, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorozniak, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchings, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kester, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahaney, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pignatello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimsby, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of piragliatin – first glucokinase activator studied in type 2 diabetic patients</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7021</span>– <span class="NLM_lpage">7036</span>, <span class="refDoi"> DOI: 10.1021/jm3008689</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008689" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7021-7036&author=R.+Sarabuauthor=F.+T.+Bizzarroauthor=W.+L.+Corbettauthor=M.+T.+Dvorozniakauthor=W.+Gengauthor=J.+F.+Grippoauthor=N.+E.+Haynesauthor=S.+Hutchingsauthor=L.+Garofaloauthor=K.+R.+Guertinauthor=D.+W.+Hilliardauthor=M.+Kabatauthor=R.+F.+Kesterauthor=W.+Kaauthor=Z.+Liangauthor=P.+E.+Mahaneyauthor=L.+Marcusauthor=F.+M.+Matschinskyauthor=D.+Mooreauthor=J.+Rachaauthor=R.+Radinovauthor=Y.+Renauthor=L.+Qiauthor=M.+Pignatelloauthor=C.+L.+Spenceauthor=T.+Steeleauthor=J.+Tengiauthor=J.+Grimsby&title=Discovery+of+piragliatin+%E2%80%93+first+glucokinase+activator+studied+in+type+2+diabetic+patients&doi=10.1021%2Fjm3008689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Piragliatin-First Glucokinase Activator Studied in Type 2 Diabetic Patients</span></div><div class="casAuthors">Sarabu, Ramakanth; Bizzarro, Fred T.; Corbett, Wendy L.; Dvorozniak, Mark T.; Geng, Wanping; Grippo, Joseph F.; Haynes, Nancy-Ellen; Hutchings, Stanley; Garofalo, Lisa; Guertin, Kevin R.; Hilliard, Darryl W.; Kabat, Marek; Kester, Robert F.; Ka, Wang; Liang, Zhenmin; Mahaney, Paige E.; Marcus, Linda; Matschinsky, Franz M.; Moore, David; Racha, Jagdish; Radinov, Roumen; Ren, Yi; Qi, Lida; Pignatello, Michael; Spence, Cheryl L.; Steele, Thomas; Tengi, John; Grimsby, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7021-7036</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized.  Compd. 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicol. studies.  We hypothesized that the hepatic lipidosis was due to the structure-based toxicity and later established that it was due to the formation of a thiourea metabolite, 2.  Subsequent SAR studies of 1 led to the identification of a pyrazine-based lead analog 3, lacking the thiazole moiety.  In vivo metabolite identification studies, followed by the independent synthesis and profiling of the cyclopentyl keto- and hydroxyl- metabolites of 3, led to the selection of piragliatin, 4, as the clin. lead.  Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFOz_zcuFq8rVg90H21EOLACvtfcHk0lgNAPS5_wt9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7rM&md5=318ec25d2fd83b5e331622fd81219564</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm3008689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008689%26sid%3Dliteratum%253Aachs%26aulast%3DSarabu%26aufirst%3DR.%26aulast%3DBizzarro%26aufirst%3DF.%2BT.%26aulast%3DCorbett%26aufirst%3DW.%2BL.%26aulast%3DDvorozniak%26aufirst%3DM.%2BT.%26aulast%3DGeng%26aufirst%3DW.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DHaynes%26aufirst%3DN.%2BE.%26aulast%3DHutchings%26aufirst%3DS.%26aulast%3DGarofalo%26aufirst%3DL.%26aulast%3DGuertin%26aufirst%3DK.%2BR.%26aulast%3DHilliard%26aufirst%3DD.%2BW.%26aulast%3DKabat%26aufirst%3DM.%26aulast%3DKester%26aufirst%3DR.%2BF.%26aulast%3DKa%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DMahaney%26aufirst%3DP.%2BE.%26aulast%3DMarcus%26aufirst%3DL.%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DRacha%26aufirst%3DJ.%26aulast%3DRadinov%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DL.%26aulast%3DPignatello%26aufirst%3DM.%26aulast%3DSpence%26aufirst%3DC.%2BL.%26aulast%3DSteele%26aufirst%3DT.%26aulast%3DTengi%26aufirst%3DJ.%26aulast%3DGrimsby%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520piragliatin%2520%25E2%2580%2593%2520first%2520glucokinase%2520activator%2520studied%2520in%2520type%25202%2520diabetic%2520patients%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7021%26epage%3D7036%26doi%3D10.1021%2Fjm3008689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuklish, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czeskis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luffer-Atlas, D.</span></span> <span> </span><span class="NLM_article-title">Identification and mitigation of reactive metabolites of 2-aminoimidazole-containing microsomal prostaglandin E synthase-1 inhibitors terminated due to clinical drug-induced liver injury</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2041</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2041-2051&author=B.+H.+Normanauthor=M.+J.+Fisherauthor=M.+A.+Schifflerauthor=S.+L.+Kuklishauthor=N.+E.+Hughesauthor=B.+A.+Czeskisauthor=K.+C.+Cassidyauthor=T.+L.+Abrahamauthor=J.+J.+Albertsauthor=D.+Luffer-Atlas&title=Identification+and+mitigation+of+reactive+metabolites+of+2-aminoimidazole-containing+microsomal+prostaglandin+E+synthase-1+inhibitors+terminated+due+to+clinical+drug-induced+liver+injury&doi=10.1021%2Facs.jmedchem.7b01806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury</span></div><div class="casAuthors">Norman, Bryan H.; Fisher, Matthew J.; Schiffler, Matthew A.; Kuklish, Steven L.; Hughes, Norman E.; Czeskis, Boris A.; Cassidy, Kenneth C.; Abraham, Trent L.; Alberts, Jeffrey J.; Luffer-Atlas, Debra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2041-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans.  We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation.  These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYz_L4vs5v2LVg90H21EOLACvtfcHk0lgNAPS5_wt9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D&md5=e4e9f4fac1cae1af730b997dcf663d21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01806%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26aulast%3DSchiffler%26aufirst%3DM.%2BA.%26aulast%3DKuklish%26aufirst%3DS.%2BL.%26aulast%3DHughes%26aufirst%3DN.%2BE.%26aulast%3DCzeskis%26aufirst%3DB.%2BA.%26aulast%3DCassidy%26aufirst%3DK.%2BC.%26aulast%3DAbraham%26aufirst%3DT.%2BL.%26aulast%3DAlberts%26aufirst%3DJ.%2BJ.%26aulast%3DLuffer-Atlas%26aufirst%3DD.%26atitle%3DIdentification%2520and%2520mitigation%2520of%2520reactive%2520metabolites%2520of%25202-aminoimidazole-containing%2520microsomal%2520prostaglandin%2520E%2520synthase-1%2520inhibitors%2520terminated%2520due%2520to%2520clinical%2520drug-induced%2520liver%2520injury%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2041%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.7b01806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNearney, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landschulz, W.</span></span> <span> </span><span class="NLM_article-title">Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1111/bcp.13423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fbcp.13423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Shug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=179-188&author=Y.+Jinauthor=A.+Regevauthor=J.+Kamauthor=K.+Phippsauthor=C.+Smithauthor=J.+Henckauthor=K.+Campanaleauthor=L.+Huauthor=D.+G.+Hallauthor=X.+Y.+Yangauthor=M.+Nakanoauthor=T.+A.+McNearneyauthor=J.+Uetrechtauthor=W.+Landschulz&title=Dose-dependent+acute+liver+injury+with+hypersensitivity+features+in+humans+due+to+a+novel+microsomal+prostaglandin+E+synthase+1+inhibitor&doi=10.1111%2Fbcp.13423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor</span></div><div class="casAuthors">Jin, Yan; Regev, Arie; Kam, Jeanelle; Phipps, Krista; Smith, Claire; Henck, Judith; Campanale, Kristina; Hu, Leijun; Hall, D. Greg; Yang, Xiao Yan; Nakano, Masako; McNearney, Terry Ann; Uetrecht, Jack; Landschulz, William</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : LY3031207, a novel microsomal prostaglandin E synthase 1 inhibitor, was evaluated in a multiple ascending dose study after nonclin. toxicol. studies and a single ascending dose study demonstrated an acceptable toxicity, safety and tolerability profile.  Methods : Healthy subjects were randomized to receive LY3031207 (25, 75 and 275 mg), placebo or celecoxib (400 mg) once daily for 28 days.  The safety, tolerability and pharmacokinetic and pharmacodynamic profiles of LY3031207 were evaluated.  Results : The study was terminated when two subjects experienced drug-induced liver injury (DILI) after they had received 225 mg LY3031207 for 19 days.  Liver biopsy from these subjects revealed acute liver injury with eosinophilic infiltration.  Four addnl. DILI cases were identified after LY3031207 dosing had been stopped.  All six DILI cases shared unique presentations of hepatocellular injury with hypersensitivity features and demonstrated a steep dose-dependent trend.  Prompt discontinuation of the study drug and supportive medical care resulted in full recovery.  Metabolites from metabolic activation of the imidazole ring were obsd. in plasma and urine samples from all subjects randomized to LY3031207 dosing.  Conclusions : This study emphasized the importance of careful safety monitoring and serious adverse events management in phase I trials.  Metabolic activation of the imidazole ring may be involved in the development of hepatotoxicity of LY3031207.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg0xW88KU4LVg90H21EOLACvtfcHk0lgNAPS5_wt9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Shug%253D%253D&md5=d57e0853ca828b7f02b613aea72497f1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13423%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DY.%26aulast%3DRegev%26aufirst%3DA.%26aulast%3DKam%26aufirst%3DJ.%26aulast%3DPhipps%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DHenck%26aufirst%3DJ.%26aulast%3DCampanale%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHall%26aufirst%3DD.%2BG.%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DMcNearney%26aufirst%3DT.%2BA.%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DLandschulz%26aufirst%3DW.%26atitle%3DDose-dependent%2520acute%2520liver%2520injury%2520with%2520hypersensitivity%2520features%2520in%2520humans%2520due%2520to%2520a%2520novel%2520microsomal%2520prostaglandin%2520E%2520synthase%25201%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D179%26epage%3D188%26doi%3D10.1111%2Fbcp.13423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffing, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vage, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lame, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, R. V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildknegt, K.</span></span> <span> </span><span class="NLM_article-title">Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine 2C receptor agonist for the treatment of obesity: role of metabolic activation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">848</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.013649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.106.013649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=17344339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=848-858&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvieauthor=J.+Aubrechtauthor=E.+B.+Smithauthor=S.+L.+Coffingauthor=J.+R.+Cheungauthor=C.+Vageauthor=M.+E.+Lameauthor=P.+Chiangauthor=K.+F.+McClureauthor=T.+S.+Maurerauthor=R.+V.+Coelhoauthor=V.+F.+Solimanauthor=K.+Schildknegt&title=Genotoxicity+of+2-%283-chlorobenzyloxy%29-6-%28piperazinyl%29pyrazine%2C+a+novel+5-hydroxytryptamine+2C+receptor+agonist+for+the+treatment+of+obesity%3A+role+of+metabolic+activation&doi=10.1124%2Fdmd.106.013649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2C receptor agonist for the treatment of obesity: role of metabolic activation</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.; Aubrecht, Jiri; Smith, Evan B.; Coffing, Stephanie L.; Cheung, Jennifer R.; Vage, Chandra; Lame, Mary E.; Chiang, Phoebe; McClure, Kim F.; Maurer, Tristan S.; Coelho, Richard V., Jr.; Soliman, Victor F.; Schildknegt, Klaas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">848-858</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">2-(3-Chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine is a potent and selective 5-HT2C agonist that exhibits dose-dependent inhibition of food intake and redn. in body wt. in rats, making it an attractive candidate for treatment of obesity.  However, examn. of the genotoxicity potential of the compd. in the Salmonella Ames assay using tester strains TA98, TA100, TA1535, and TA1537 revealed a metab. (rat S9/NADPH)- and dose-dependent increase of reverse mutations in strains TA100 and TA1537.  The increase in reverse mutations was attenuated upon coincubation with methoxylamine and glutathione.  The irreversible and concn.-dependent incorporation of radioactivity in calf thymus DNA after incubations with [14C] labeled compd. in the presence of rat S9/NADPH suggested that 3 was bioactivated to a reactive intermediate that covalently bound DNA.  In vitro metab. studies on the compd. with rat S9/NADPH in the presence of methoxylamine and cyanide led to the detection of amine and cyano conjugates of the compd.  The mass spectrum of the amine conjugate was consistent with condensation of amine with an aldehyde metabolite derived from hydroxylation of the secondary piperazine nitrogen-α-carbon bond.  The mass spectrum of the cyano conjugate suggested a bioactivation pathway involving N-hydroxylation of the secondary piperazine nitrogen followed by two-electron oxidn. to generate an electrophilic nitrone, which reacted with cyanide.  The 3-chlorobenzyl motif in the compd. was also bioactivated via initial arom. ring hydroxylation followed by elimination to a quinone-methide species that reacted with glutathione or with the secondary piperazine ring nitrogen in 3 and its monohydroxylated metabolite(s).  The metab. studies described herein provide a mechanistic basis for the mutagenicity of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt51Z2dRy6lbVg90H21EOLACvtfcHk0lhU_FinIZ8MbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7k%253D&md5=1103a9e22f2cee8f133dd769f8506c07</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.013649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.013649%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DCoffing%26aufirst%3DS.%2BL.%26aulast%3DCheung%26aufirst%3DJ.%2BR.%26aulast%3DVage%26aufirst%3DC.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DChiang%26aufirst%3DP.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DCoelho%26aufirst%3DR.%2BV.%26aulast%3DSoliman%26aufirst%3DV.%2BF.%26aulast%3DSchildknegt%26aufirst%3DK.%26atitle%3DGenotoxicity%2520of%25202-%25283-chlorobenzyloxy%2529-6-%2528piperazinyl%2529pyrazine%252C%2520a%2520novel%25205-hydroxytryptamine%25202C%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520obesity%253A%2520role%2520of%2520metabolic%2520activation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D848%26epage%3D858%26doi%3D10.1124%2Fdmd.106.013649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortina, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, J.</span></span> <span> </span><span class="NLM_article-title">Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1559</span>– <span class="NLM_lpage">1563</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2009.02.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19246199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1559-1563&author=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=K.+F.+McClureauthor=J.+Aubrechtauthor=S.+R.+Cortinaauthor=J.+Paralkar&title=Biochemical+basis+for+differences+in+metabolism-dependent+genotoxicity+by+two+diazinylpiperazine-based+5-HT2C+receptor+agonists&doi=10.1016%2Fj.bmcl.2009.02.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists</span></div><div class="casAuthors">Kalgutkar, Amit S.; Bauman, Jonathan N.; McClure, Kim F.; Aubrecht, Jiri; Cortina, Santo R.; Paralkar, Janvi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1559-1563</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The biochem. basis for S9-dependent mutagenic response of the 5-HT2C receptor agonist and diazinylpiperazine deriv. 1 in the Salmonella Ames assay involves P 450-mediated bioactivation to DNA-reactive quinone-methide, aldehyde and nitrone intermediates.  Mechanistic information pertaining to the metab. of 1 was used in the design of diazinylpiperazine 5 to eliminate the safety liability.  While 5 was neg. in the Ames assay, the compd. retained the ability of 1 to form certain electrophilic intermediates.  Plausible hypotheses that can collectively account for the differences in mutagenic response of the two piperazine analogs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmJz1e2Q26ubVg90H21EOLACvtfcHk0lhU_FinIZ8MbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSls7s%253D&md5=f30fd7936610ff123c12fe568328469e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DCortina%26aufirst%3DS.%2BR.%26aulast%3DParalkar%26aufirst%3DJ.%26atitle%3DBiochemical%2520basis%2520for%2520differences%2520in%2520metabolism-dependent%2520genotoxicity%2520by%2520two%2520diazinylpiperazine-based%25205-HT2C%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1559%26epage%3D1563%26doi%3D10.1016%2Fj.bmcl.2009.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensenhauser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopaul, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span> <span> </span><span class="NLM_article-title">Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A)/A(1) antagonist by minimizing bioactivation to an iminium ion reactive intermediate</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1021/tx1004437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx1004437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1012-1030&author=H.+K.+Limauthor=J.+Chenauthor=C.+Sensenhauserauthor=K.+Cookauthor=R.+Prestonauthor=T.+Thomasauthor=B.+Shookauthor=P.+F.+Jacksonauthor=S.+Rassnickauthor=K.+Rhodesauthor=V.+Gopaulauthor=R.+Salterauthor=J.+Silvaauthor=D.+C.+Evans&title=Overcoming+the+genotoxicity+of+a+pyrrolidine+substituted+arylindenopyrimidine+as+a+potent+dual+adenosine+A%282A%29%2FA%281%29+antagonist+by+minimizing+bioactivation+to+an+iminium+ion+reactive+intermediate&doi=10.1021%2Ftx1004437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the Genotoxicity of a Pyrrolidine Substituted Arylindenopyrimidine As a Potent Dual Adenosine A2A/A1 Antagonist by Minimizing Bioactivation to an Iminium Ion Reactive Intermediate</span></div><div class="casAuthors">Lim, Heng-Keang; Chen, Jie; Sensenhauser, Carlo; Cook, Kevin; Preston, Robert; Thomas, Tynisha; Shook, Brian; Jackson, Paul F.; Rassnick, Stefanie; Rhodes, Kenneth; Gopaul, Vedwatee; Salter, Rhys; Silva, Jose; Evans, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1030</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Amino-4-phenyl-8-pyrrolidin-1-ylmethyl-indeno[1,2-d]pyrimidin-5-one (1) is a novel and potent selective dual A2A/A1 adenosine receptor antagonist from the arylindenopyrimidine series that was detd. to be genotoxic in both the Ames and Mouse Lymphoma L5178Y assays only following metabolic activation.  Compd. 1 was identified as a frame-shift mutagen in Salmonella typhimurium tester strain TA1537 as indicated by a significant dose-dependent increase in revertant colonies as compared to the vehicle control.  The metabolic activation-dependent irreversible covalent binding of radioactivity to DNA, recovery of 1 and its enamine metabolite from acid hydrolysis of covalently modified DNA, and protection of covalent binding to DNA by both cyanide ion and methoxylamine suggest that the frame-shift mutation in TA1537 strain involved covalent binding instead of simple intercalation to DNA.  Compd. 1 was bioactivated to endocyclic iminium ion, aldehyde, epoxide, and α,β-unsatd. keto reactive intermediates from the detection of cyano, oxime, and glutathione conjugates by data-dependent high resoln. accurate mass measurements.  Collision-induced dissocn. of these conjugates provided evidence for bioactivation of the pyrrolidine ring of 1.  The epoxide and α,β-unsatd. keto reactive intermediates were unlikely to cause the genotoxicity of 1 because the formation of their glutathione adducts did not ameliorate the binding of compd. related material to DNA.  Instead, the endocyclic iminium ions and amino aldehydes were likely candidates responsible for genotoxicity based on, first, the protection afforded by both cyanide ion and methoxylamine, which reduced the potential to form covalent adducts with DNA, and, second, analogs of 1 designed with low probability to form these reactive intermediates were not genotoxic.  It was concluded that 1 also had the potential to be mutagenic in humans based on observing the endocyclic iminium ion following incubation with a human liver S9 prepn. and the commensurate detection of DNA adducts.  An understanding of this genotoxicity mechanism supported an evidence-based approach to selectively modify the structure of 1 which resulted in analogs being synthesized that were devoid of a genotoxic liability.  In addn., potency and selectivity against both adenosine A2A and A1 receptors were maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9N__9056Cr7Vg90H21EOLACvtfcHk0liZoU7AqiqCSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D&md5=ef0a49a0c0889517eb37018fe808367f</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Ftx1004437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx1004437%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSensenhauser%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DK.%26aulast%3DPreston%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DGopaul%26aufirst%3DV.%26aulast%3DSalter%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26atitle%3DOvercoming%2520the%2520genotoxicity%2520of%2520a%2520pyrrolidine%2520substituted%2520arylindenopyrimidine%2520as%2520a%2520potent%2520dual%2520adenosine%2520A%25282A%2529%252FA%25281%2529%2520antagonist%2520by%2520minimizing%2520bioactivation%2520to%2520an%2520iminium%2520ion%2520reactive%2520intermediate%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1012%26epage%3D1030%26doi%3D10.1021%2Ftx1004437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/tx049711r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx049711r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvVOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=271-276&author=G.+A.+Dossauthor=R.+R.+Millerauthor=Z.+Zhangauthor=Y.+Tefferaauthor=R.+P.+Nargundauthor=B.+Paluckiauthor=M.+K.+Parkauthor=Y.+S.+Tangauthor=D.+C.+Evansauthor=T.+A.+Baillieauthor=R.+A.+Stearns&title=Metabolic+activation+of+1%2C3-disubstituted+piperazine+derivative%3A+evidence+for+a+novel+ring+contraction+to+an+imidazoline&doi=10.1021%2Ftx049711r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Activation of a 1,3-Disubstituted Piperazine Derivative: Evidence for a Novel Ring Contraction to an Imidazoline</span></div><div class="casAuthors">Doss, George A.; Miller, Randall R.; Zhang, Zhoupeng; Teffera, Yohannes; Nargund, Ravi P.; Palucki, Brenda; Park, Min K.; Tang, Yui S.; Evans, David C.; Baillie, Thomas A.; Stearns, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-276</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MB243 (a 1,3-disubstituted piperazine) is a new, potent, and selective melanocortin receptor subtype-4 agonist with potential application in the treatment of obesity and/or erectile dysfunction.  MB243 was obsd. to covalently bind extensively to liver microsomal proteins from rats and humans.  In the presence of glutathione, two thioether adducts were detected in liver microsomal incubations by radiochromatog. and LC/MS/MS anal.  These adducts were also formed when bile duct-cannulated rats were dosed with MB243.  The two adducts were isolated, and their structures were detd. by accurate mass MS/MS and NMR analyses.  The proposed structures resulted from a novel contraction of the piperazine ring to yield a substituted imidazoline.  A mechanism is proposed, which involves an initial six electron oxidn. of the piperazine ring to form a reactive intermediate, which is trapped by glutathione.  Hydrolysis of the glutamic acid residue followed by internal aminolysis by the cysteine amino group resulted in opening of the piperazine ring, which is followed by ring closure to an imidazoline.  The resulting cysteinyl-glycine conjugate underwent subsequent hydrolysis of the glycine residue.  Understanding of the mechanism of bioactivation led to the design of MB243 analogs that exhibited reduced covalent protein binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrABeaKbaNVYrVg90H21EOLACvtfcHk0liZoU7AqiqCSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvVOgsg%253D%253D&md5=4f5773527470679fe6776488b72576e4</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Ftx049711r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx049711r%26sid%3Dliteratum%253Aachs%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DPalucki%26aufirst%3DB.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DTang%26aufirst%3DY.%2BS.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26atitle%3DMetabolic%2520activation%2520of%25201%252C3-disubstituted%2520piperazine%2520derivative%253A%2520evidence%2520for%2520a%2520novel%2520ring%2520contraction%2520to%2520an%2520imidazoline%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D271%26epage%3D276%26doi%3D10.1021%2Ftx049711r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebhat, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyani, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macneil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vongs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Ploeg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2004.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15582434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKrsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=171-175&author=B.+L.+Paluckiauthor=M.+K.+Parkauthor=R.+P.+Nargundauthor=Z.+Yeauthor=I.+K.+Sebhatauthor=P.+G.+Pollardauthor=R.+N.+Kalyaniauthor=R.+Tangauthor=T.+Macneilauthor=D.+H.+Weinbergauthor=A.+Vongsauthor=C.+I.+Rosenblumauthor=G.+A.+Dossauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=Q.+Pengauthor=C.+Tamvakopoulosauthor=E.+McGowanauthor=W.+J.+Martinauthor=J.+M.+Metzgerauthor=C.+A.+Shepherdauthor=A.+M.+Strackauthor=D.+E.+Macintyreauthor=L.+H.+Van+der+Ploegauthor=A.+A.+Patchett&title=Discovery+of+%282S%29-N-%5B%281R%29-2-%5B4-cyclohexyl-4-%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5D-1-piperidinyl%5D-1-%5B%284-fluorophenyl%29methyl%5D-2-oxoethyl%5D-4-methyl-2-piperazinecarboxamide+%28MB243%29%2C+a+potent+and+selective+melanocortin+subtype-4+receptor+agonist&doi=10.1016%2Fj.bmcl.2004.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist</span></div><div class="casAuthors">Palucki, Brenda L.; Park, Min K.; Nargund, Ravi P.; Ye, Zhixiong; Sebhat, Iyassu K.; Pollard, Patrick G.; Kalyani, Rubana N.; Tang, Rui; MacNeil, Tanya; Weinberg, David H.; Vongs, Aurawan; Rosenblum, Charles I.; Doss, George A.; Miller, Randall R.; Stearns, Ralph A.; Peng, Qianping; Tamvakopoulos, Constantin; McGowan, Erin; Martin, William J.; Metzger, Joseph M.; Shepherd, Cherrie A.; Strack, Alison M.; MacIntyre, D. Euan; Van der Ploeg, Lex H. T.; Patchett, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-175</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery and optimization of substituted 2-piperazinecarboxamides as potent and selective agonists of the melanocortin subtype-4 receptor.  Further in vivo development of lead agonist, MB243, is disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNRPbn8mhx6bVg90H21EOLACvtfcHk0liZoU7AqiqCSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKrsLnO&md5=3e9fd4079e3567cade8991f8134c56b2</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DPalucki%26aufirst%3DB.%2BL.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DSebhat%26aufirst%3DI.%2BK.%26aulast%3DPollard%26aufirst%3DP.%2BG.%26aulast%3DKalyani%26aufirst%3DR.%2BN.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DMacneil%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DD.%2BH.%26aulast%3DVongs%26aufirst%3DA.%26aulast%3DRosenblum%26aufirst%3DC.%2BI.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DMcGowan%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DMetzger%26aufirst%3DJ.%2BM.%26aulast%3DShepherd%26aufirst%3DC.%2BA.%26aulast%3DStrack%26aufirst%3DA.%2BM.%26aulast%3DMacintyre%26aufirst%3DD.%2BE.%26aulast%3DVan%2Bder%2BPloeg%26aufirst%3DL.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520%25282S%2529-N-%255B%25281R%2529-2-%255B4-cyclohexyl-4-%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255D-1-piperidinyl%255D-1-%255B%25284-fluorophenyl%2529methyl%255D-2-oxoethyl%255D-4-methyl-2-piperazinecarboxamide%2520%2528MB243%2529%252C%2520a%2520potent%2520and%2520selective%2520melanocortin%2520subtype-4%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D171%26epage%3D175%26doi%3D10.1016%2Fj.bmcl.2004.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacNeil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vongs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Ploeg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span> <span> </span><span class="NLM_article-title">2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">1996</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.02.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2005.02.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15808454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVKgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1993-1996&author=B.+L.+Paluckiauthor=M.+K.+Parkauthor=R.+P.+Nargundauthor=R.+Tangauthor=T.+MacNeilauthor=D.+H.+Weinbergauthor=A.+Vongsauthor=C.+I.+Rosenblumauthor=G.+A.+Dossauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=Q.+Pengauthor=C.+Tamvakopoulosauthor=L.+H.+Van+der+Ploegauthor=A.+A.+Patchett&title=2-Piperazinecarboxamides+as+potent+and+selective+melanocortin+subtype-4+receptor+agonists&doi=10.1016%2Fj.bmcl.2005.02.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists</span></div><div class="casAuthors">Palucki, Brenda L.; Park, Min K.; Nargund, Ravi P.; Tang, Rui; MacNeil, Tanya; Weinberg, David H.; Vongs, Aurawan; Rosenblum, Charles I.; Doss, George A.; Miller, Randall R.; Stearns, Ralph A.; Peng, Qianping; Tamvakopoulos, Constantin; Van der Ploeg, Lex H. T.; Patchett, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1993-1996</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery and optimization of substituted 2-piperazinecarboxamides as potent and selective agonists of the melanocortin subtype-4 receptor.  The 5- and 6-alkylated piperazine compds. exhibit low bioactivation potential as measured by covalent binding in microsome prepns.  The studied compds. were prepd. by multistep synthesis via alkylation of protected diamines and reductive amination/cyclization as key steps, following by coupling with piperidine carboxamide deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDGsr4-SRPobVg90H21EOLACvtfcHk0liTUYOZiSvJKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVKgtrw%253D&md5=95f6d18d31fd8ccab9a9e650dc498bc8</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.02.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.02.068%26sid%3Dliteratum%253Aachs%26aulast%3DPalucki%26aufirst%3DB.%2BL.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DD.%2BH.%26aulast%3DVongs%26aufirst%3DA.%26aulast%3DRosenblum%26aufirst%3DC.%2BI.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DVan%2Bder%2BPloeg%26aufirst%3DL.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26atitle%3D2-Piperazinecarboxamides%2520as%2520potent%2520and%2520selective%2520melanocortin%2520subtype-4%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1993%26epage%3D1996%26doi%3D10.1016%2Fj.bmcl.2005.02.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebhat, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyani, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vongs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacNeil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Ploeg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyvratt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3501</span>– <span class="NLM_lpage">3505</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.05.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2005.05.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15982875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvV2gsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3501-3505&author=Z.+Yeauthor=L.+Guoauthor=K.+J.+Barakatauthor=P.+G.+Pollardauthor=B.+L.+Paluckiauthor=I.+K.+Sebhatauthor=R.+K.+Bakshiauthor=R.+Tangauthor=R.+N.+Kalyaniauthor=A.+Vongsauthor=A.+S.+Chenauthor=H.+Y.+Chenauthor=C.+I.+Rosenblumauthor=T.+MacNeilauthor=D.+H.+Weinbergauthor=Q.+Pengauthor=C.+Tamvakopoulosauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=D.+E.+Cashenauthor=W.+J.+Martinauthor=J.+M.+Metzgerauthor=A.+M.+Strackauthor=D.+E.+MacIntyreauthor=L.+H.+Van+der+Ploegauthor=A.+A.+Patchettauthor=M.+J.+Wyvrattauthor=R.+P.+Nargund&title=Discovery+and+activity+of+%281R%2C4S%2C6R%29-N-%5B%281R%29-2-%5B4-cyclohexyl-4-%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5D-1-piperidinyl%5D-1-%5B%284-fluorophenyl%29methyl%5D-2-oxoethyl%5D-2-methyl-2-azabicyclo%5B2.2.2%5Doctane-6-carboxamide+%283%2C+RY764%29%2C+a+potent+and+selective+melanocortin+subtype-4+receptor+agonist&doi=10.1016%2Fj.bmcl.2005.05.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist</span></div><div class="casAuthors">Ye, Zhixiong; Guo, Liangqin; Barakat, Khaled J.; Pollard, Patrick G.; Palucki, Brenda L.; Sebhat, Iyassu K.; Bakshi, Raman K.; Tang, Rui; Kalyani, Rubana N.; Vongs, Aurawan; Chen, Airu S.; Chen, Howard Y.; Rosenblum, Charles I.; MacNeil, Tanya; Weinberg, David H.; Peng, Qianping; Tamvakopoulos, Constantin; Miller, Randy R.; Stearns, Ralph A.; Cashen, Doreen E.; Martin, William J.; Metzger, Joseph M.; Strack, Alison M.; MacIntyre, D. Euan; Van der Ploeg, Lex H. T.; Patchett, Arthur A.; Wyvratt, Matthew J.; Nargund, Ravi P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3501-3505</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel isoquinuclidine contg. selective melanocortin subtype-4 receptor small mol. agonist (I), (RY764), is reported.  Its in vivo characterization revealed mechanism-based food intake redn. and erectile activity augmentation in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozlndIFJlSh7Vg90H21EOLACvtfcHk0liTUYOZiSvJKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvV2gsb4%253D&md5=f5104be1da706a14bf7bbbf1ea590b01</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.109%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DBarakat%26aufirst%3DK.%2BJ.%26aulast%3DPollard%26aufirst%3DP.%2BG.%26aulast%3DPalucki%26aufirst%3DB.%2BL.%26aulast%3DSebhat%26aufirst%3DI.%2BK.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DKalyani%26aufirst%3DR.%2BN.%26aulast%3DVongs%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DA.%2BS.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DRosenblum%26aufirst%3DC.%2BI.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DD.%2BH.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DCashen%26aufirst%3DD.%2BE.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DMetzger%26aufirst%3DJ.%2BM.%26aulast%3DStrack%26aufirst%3DA.%2BM.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DVan%2Bder%2BPloeg%26aufirst%3DL.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26atitle%3DDiscovery%2520and%2520activity%2520of%2520%25281R%252C4S%252C6R%2529-N-%255B%25281R%2529-2-%255B4-cyclohexyl-4-%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255D-1-piperidinyl%255D-1-%255B%25284-fluorophenyl%2529methyl%255D-2-oxoethyl%255D-2-methyl-2-azabicyclo%255B2.2.2%255Doctane-6-carboxamide%2520%25283%252C%2520RY764%2529%252C%2520a%2520potent%2520and%2520selective%2520melanocortin%2520subtype-4%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3501%26epage%3D3505%26doi%3D10.1016%2Fj.bmcl.2005.05.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baierl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of meloxicam in animals and the relevance to humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">584</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9616195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXjvFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=576-584&author=U.+Buschauthor=J.+Schmidauthor=G.+Heinzelauthor=H.+Schmausauthor=J.+Baierlauthor=C.+Huberauthor=W.+Roth&title=Pharmacokinetics+of+meloxicam+in+animals+and+the+relevance+to+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of meloxicam in animals and the relevance to humans</span></div><div class="casAuthors">Busch, Ulrich; Schmid, Jochen; Heinzel, Gunther; Schmaus, Helmut; Baierl, Jurgen; Huber, Claudia; Roth, Willy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576-584</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The pharmacokinetic profile of the new nonsteroidal anti-inflammatory drug meloxicam was investigated in mice, rats, dogs, minipigs, and baboons after administration of [14C]meloxicam.  The blood plasma concn.-time profiles for meloxicam in rats and dogs were comparable to that in humans, whereas there were marked differences between humans and mice, minipigs, and baboons.  The highest tissue concns. of meloxicam in rats and minipigs were seen in the liver and kidneys.  Low concns. of meloxicam were found in the central nervous system compared with blood plasma.  The excretion balance in minipigs resembled that in humans, with almost equal concns. being eliminated in the urine and feces.  As in humans, meloxicam circulated mainly in the form of the parent compd. in the plasma of mice, rats, dogs, minipigs, and baboons.  The main metabolites in rats, minipigs, and humans were 5'-hydroxymethyl and 5'-carboxy metabolites.  The percentage of meloxicam binding to protein was higher in rats and humans (>99%) than in other species.  The pharmacokinetic profile of meloxicam in rats most closely resembled that in humans.  Thus, reliable clin. predictions can be made from studies in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0_uazW7wy97Vg90H21EOLACvtfcHk0lj98mPIs4DSIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvFejsbs%253D&md5=bfc7fc021e479cb2dfcb4799c3e281ec</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBusch%26aufirst%3DU.%26aulast%3DSchmid%26aufirst%3DJ.%26aulast%3DHeinzel%26aufirst%3DG.%26aulast%3DSchmaus%26aufirst%3DH.%26aulast%3DBaierl%26aufirst%3DJ.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DW.%26atitle%3DPharmacokinetics%2520of%2520meloxicam%2520in%2520animals%2520and%2520the%2520relevance%2520to%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26spage%3D576%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cywin, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorcek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potocki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschantz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutts, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trummlitz, G.</span></span> <span> </span><span class="NLM_article-title">Effect of structural modification of enol-carboxamide-type nonsteroidal anti-inflammatory drugs on COX-2/COX-1 selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1021/jm9607010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9607010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2sXhvVOjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=980-989&author=E.+S.+Lazerauthor=C.+K.+Miaoauthor=C.+L.+Cywinauthor=R.+Sorcekauthor=H.+C.+Wongauthor=Z.+Mengauthor=I.+Potockiauthor=M.+Hoermannauthor=R.+J.+Snowauthor=M.+A.+Tschantzauthor=T.+A.+Kellyauthor=D.+W.+McNeilauthor=S.+J.+Couttsauthor=L.+Churchillauthor=A.+G.+Grahamauthor=E.+Davidauthor=P.+M.+Grobauthor=W.+Engelauthor=H.+Meierauthor=G.+Trummlitz&title=Effect+of+structural+modification+of+enol-carboxamide-type+nonsteroidal+anti-inflammatory+drugs+on+COX-2%2FCOX-1+selectivity&doi=10.1021%2Fjm9607010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Structural Modification of Enol-Carboxamide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity</span></div><div class="casAuthors">Lazer, Edward S.; Miao, Clara K.; Cywin, Charles L.; Sorcek, Ronald; Wong, Hin-Chor; Meng, Zhaoxing; Potocki, Ian; Hoermann, MaryAnn; Snow, Roger J.; Tschantz, Matt A.; Kelly, Terence A.; McNeil, Daniel W.; Coutts, Simon J.; Churchill, Laurie; Graham, Anne G.; David, Eva; Grob, Peter M.; Engel, Wolfhard; Meier, Hans; Trummlitz, Guenter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">980-989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Meloxicam, an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models.  In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs.  We therefore embarked on a study of enol-carboxamide type compds. to det. if COX-2 selectivity and potency could be dramatically improved by structural modification.  Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3-carboxamide, alteration of the N-Me substituent, and amide modification were all examd.  In addn. we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4-dioxoisoquinolines.  While a few examples were found with greater potency in the COX-2 assay, no compd. tested had a better COX-2/COX-1 selectivity profile than that of meloxicam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGKO3Zckl-8LVg90H21EOLACvtfcHk0lj98mPIs4DSIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhvVOjurw%253D&md5=99b952adf74407547babe0337aabcc48</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm9607010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9607010%26sid%3Dliteratum%253Aachs%26aulast%3DLazer%26aufirst%3DE.%2BS.%26aulast%3DMiao%26aufirst%3DC.%2BK.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DSorcek%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DH.%2BC.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DPotocki%26aufirst%3DI.%26aulast%3DHoermann%26aufirst%3DM.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DTschantz%26aufirst%3DM.%2BA.%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DMcNeil%26aufirst%3DD.%2BW.%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DDavid%26aufirst%3DE.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DEngel%26aufirst%3DW.%26aulast%3DMeier%26aufirst%3DH.%26aulast%3DTrummlitz%26aufirst%3DG.%26atitle%3DEffect%2520of%2520structural%2520modification%2520of%2520enol-carboxamide-type%2520nonsteroidal%2520anti-inflammatory%2520drugs%2520on%2520COX-2%252FCOX-1%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D980%26epage%3D989%26doi%3D10.1021%2Fjm9607010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baty, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boissel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, P.</span></span> <span> </span><span class="NLM_article-title">Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal</span>. <i>Gastroenterol. Clin. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7750686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK2M3mvF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1994&pages=1129-1131&author=V.+Batyauthor=B.+Denisauthor=C.+Goudotauthor=V.+Basauthor=P.+Renkesauthor=M.+A.+Bigardauthor=P.+Boisselauthor=P.+Gaucher&title=Hepatitis+induced+by+alpidem+%28Ananxyl%29.+Four+cases%2C+one+of+them+fatal"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal</span></div><div class="casAuthors">Baty V; Denis B; Goudot C; Bas V; Renkes P; Bigard M A; Boissel P; Gaucher P</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterologie clinique et biologique</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1129-31</span>
        ISSN:<span class="NLM_cas:issn">0399-8320</span>.
    </div><div class="casAbstract">Acute hepatitis related to psychotropic drugs has been rarely reported with anxiolytic treatments.  Alpidem (Ananxyl) is a new imidazopyridine derivative with anxiolytic properties which was launched in October 1991.  Several cases of acute hepatitis, some severe, were described with this drug and its liver toxicity was questioned.  Results of a study monitoring drug side-effects caused this drug to be withdrawn from the market for one year.  We report four cases of acute hepatitis and discuss the role of alpidem.  All but one case were presented as severe acute hepatitis with hepatic failure.  One patient ran a fulminant course and died despite liver transplantation.  The mechanism of liver toxicity remains unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqUHGVXEZqWm52AMpI4GK2fW6udTcc2eb60jTFcQ_kTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3mvF2hsQ%253D%253D&md5=27ed8e1c3239d6f6ecae87776fe8c206</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaty%26aufirst%3DV.%26aulast%3DDenis%26aufirst%3DB.%26aulast%3DGoudot%26aufirst%3DC.%26aulast%3DBas%26aufirst%3DV.%26aulast%3DRenkes%26aufirst%3DP.%26aulast%3DBigard%26aufirst%3DM.%2BA.%26aulast%3DBoissel%26aufirst%3DP.%26aulast%3DGaucher%26aufirst%3DP.%26atitle%3DHepatitis%2520induced%2520by%2520alpidem%2520%2528Ananxyl%2529.%2520Four%2520cases%252C%2520one%2520of%2520them%2520fatal%26jtitle%3DGastroenterol.%2520Clin.%2520Biol.%26date%3D1994%26volume%3D18%26spage%3D1129%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2383</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.109.028860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19720731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFajtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2383-2392&author=T.+Usuiauthor=M.+Miseauthor=T.+Hashizumeauthor=M.+Yabukiauthor=S.+Komuro&title=Evaluation+of+the+potential+for+drug-induced+liver+injury+based+on+in+vitro+covalent+binding+to+human+liver+proteins&doi=10.1124%2Fdmd.109.028860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins</span></div><div class="casAuthors">Usui, Toru; Mise, Masashi; Hashizume, Takanori; Yabuki, Masashi; Komuro, Setsuko</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2383-2392</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prediction of idiosyncratic drug-induced liver injury (DILI) is difficult, and the underlying mechanisms are not fully understood.  However, many drugs causing DILI are considered to form reactive metabolites and covalently bind to cellular macromols. in the liver.  The objective of this study was to clarify whether the risk of idiosyncratic DILI can be estd. by comparing in vitro covalent binding (CB) levels among 12 pos. compds. (acetaminophen, alpidem, bromfenac, carbamazepine, diclofenac, flutamide, imipramine, nefazodone, tacrine, ticlopidine, tienilic acid, and troglitazone) for DILI and 12 neg. compds. (acetylsalicylic acid, caffeine, dexamethasone, losartan, ibuprofen, paroxetine, pioglitazone, rosiglitazone, sertraline, theophylline, venlafaxine, and zolpidem).  After incubation with human liver microsomes in the presence of NADPH, there was a large overlap in the distribution of CB amts. between the pos. and neg. groups.  On addn. of UDP-glucuronic acid (UDPGA) as a cofactor for glucuronidation, the CB levels of bromfenac and diclofenac were increased.  With addn. of nucleophilic glutathione (GSH), values for most compds. were decreased.  However, sepn. of the two groups on the basis of CB could not be improved by UDPGA or GSH.  Furthermore, CB with human hepatocytes also failed to discriminate pos. from neg. compds.  Therefore, the CB amt. alone is not sufficient for risk assessment of DILI.  In contrast, when the CB amt. was multiplied by the max. daily dose, which may reflect max. hepatic exposure, the two groups did become discriminated.  Taken together, our findings suggest that the combination of CB amt. and daily dose can est. the risk of idiosyncratic DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvQoojI97OgLVg90H21EOLACvtfcHk0ljR6hXQMYbuuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFajtr7K&md5=19ffc916995d60f9cb0b6b3a2074a082</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028860%26sid%3Dliteratum%253Aachs%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DMise%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DKomuro%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520the%2520potential%2520for%2520drug-induced%2520liver%2520injury%2520based%2520on%2520in%2520vitro%2520covalent%2520binding%2520to%2520human%2520liver%2520proteins%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2383%26epage%3D2392%26doi%3D10.1124%2Fdmd.109.028860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thénot, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morselli, P. L.</span></span> <span> </span><span class="NLM_article-title">Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.3109/03602539208996294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602539208996294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1576937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK38XktF2lu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1992&pages=239-266&author=A.+Durandauthor=J.+P.+Th%C3%A9notauthor=G.+Bianchettiauthor=P.+L.+Morselli&title=Comparative+pharmacokinetic+profile+of+two+imidazopyridine+drugs%3A+zolpidem+and+alpidem&doi=10.3109%2F03602539208996294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacokinetic profile of two imidazopyridine drugs:  zolpidem and alpidem</span></div><div class="casAuthors">Durand, A.; Thenot, J. P.; Bianchetti, G.; Morselli, P. L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-66</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 43 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlHiz2BZluLVg90H21EOLACvtfcHk0ljR6hXQMYbuuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktF2lu70%253D&md5=69026f79912009673c3fa1a0cded3445</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.3109%2F03602539208996294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602539208996294%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DA.%26aulast%3DTh%25C3%25A9not%26aufirst%3DJ.%2BP.%26aulast%3DBianchetti%26aufirst%3DG.%26aulast%3DMorselli%26aufirst%3DP.%2BL.%26atitle%3DComparative%2520pharmacokinetic%2520profile%2520of%2520two%2520imidazopyridine%2520drugs%253A%2520zolpidem%2520and%2520alpidem%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1992%26volume%3D24%26spage%3D239%26epage%3D266%26doi%3D10.3109%2F03602539208996294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descatoire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadrot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tordjmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessayre, D.</span></span> <span> </span><span class="NLM_article-title">Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">800</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=11602696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvV2qtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=793-800&author=A.+Bersonauthor=V.+Descatoireauthor=A.+Suttonauthor=D.+Fauauthor=B.+Maulnyauthor=N.+Vadrotauthor=G.+Feldmannauthor=B.+Berthonauthor=T.+Tordjmannauthor=D.+Pessayre&title=Toxicity+of+alpidem%2C+a+peripheral+benzodiazepine+receptor+ligand%2C+but+not+zolpidem%2C+in+rat+hepatocytes%3A+role+of+mitochondrial+permeability+transition+and+metabolic+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation</span></div><div class="casAuthors">Berson, Alain; Descatoire, Veronique; Sutton, Angela; Fau, Daniel; Maulny, Beatrice; Vadrot, Nathalie; Feldmann, Gerard; Berthon, Brigitte; Tordjmann, Thierry; Pessayre, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">793-800</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Whereas alpidem is hepatotoxic, zolpidem is not.  Despite closely related chem. structures, alpidem, but not zolpidem, is a peripheral benzodiazepine receptor (PBR) ligand, and is also more lipophilic than zolpidem.  We compared their effects in isolated rat liver mitochondria and rat hepatocytes.  Zolpidem did not affect calcium-induced mitochondrial permeability transition (MPT) in mitochondria, caused little glutathione depletion in hepatocytes, and was not toxic, even at 500 μM.  At 250 to 500 μM, alpidem prevented calcium-induced MPT in isolated mitochondria, but caused severe glutathione depletion in hepatocytes that was increased by 3-methylcholanthrene, a cytochrome P 4501A inducer, and decreased by cystine, a glutathione precursor.  Although cell calcium increased, mitochondrial cytochrome c did not translocate to the cytosol and cells died of necrosis.  Cell death was prevented by cystine, but not cyclosporin A, an MPT inhibitor.  At low concns. (25-50 μM), in contrast, alpidem accelerated calcium-induced MPT in mitochondria.  It did not deplete glutathione in hepatocytes, but nevertheless caused some cell death that was prevented by cyclosporin A, but not by cystine.  Alpidem (10 μM) also increased the toxicity of tumor necrosis factor-α (1 ng/mL) in hepatocytes.  In conclusion, low concns. of alpidem increase both calcium-induced MPT in mitochondria, and TNF-α toxicity in cells, like other PBR ligands.  Like other lipophilic protonatable amines, however, alpidem inhibits calcium-induced MPT at high concns.  At these high concns., toxicity involves cytochrome P 4501A-mediated metabolic activation, glutathione depletion, and increased cell calcium, without MPT involvement.  In contrast, zolpidem has no mitochondrial effects, causes little glutathione depletion, and is not toxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV8r95cW7THbVg90H21EOLACvtfcHk0ljR6hXQMYbuuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvV2qtb0%253D&md5=254d3aa9e0b7b09ec5d0402263da7375</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerson%26aufirst%3DA.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DSutton%26aufirst%3DA.%26aulast%3DFau%26aufirst%3DD.%26aulast%3DMaulny%26aufirst%3DB.%26aulast%3DVadrot%26aufirst%3DN.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DBerthon%26aufirst%3DB.%26aulast%3DTordjmann%26aufirst%3DT.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DToxicity%2520of%2520alpidem%252C%2520a%2520peripheral%2520benzodiazepine%2520receptor%2520ligand%252C%2520but%2520not%2520zolpidem%252C%2520in%2520rat%2520hepatocytes%253A%2520role%2520of%2520mitochondrial%2520permeability%2520transition%2520and%2520metabolic%2520activation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D793%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devineni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polidori, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, P. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1002/jcph.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fjcph.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=23670707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=601-610&author=D.+Devineniauthor=C.+R.+Curtinauthor=D.+Polidoriauthor=M.+J.+Gutierrezauthor=J.+Murphyauthor=S.+Ruschauthor=P.+L.+Rothenberg&title=Pharmacokinetics+and+pharmacodynamics+of+canagliflozin%2C+a+sodium+glucose+co-transporter+2+inhibitor%2C+in+subjects+with+type+2+diabetes+mellitus&doi=10.1002%2Fjcph.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus</span></div><div class="casAuthors">Devineni, Damayanthi; Curtin, Christopher R.; Polidori, David; Gutierrez, Maria J.; Murphy, Joseph; Rusch, Sarah; Rothenberg, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-610, 10</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This study characterized single- and multiple-dose pharmacokinetics of canagliflozin and its O-glucuronide metabolites (M5 and M7) and pharmacodynamics (renal threshold for glucose [RTG], urinary glucose excretion [UGE0-24h], and 24-h mean plasma glucose [MPG0-24h]) of canagliflozin in subjects with type 2 diabetes.  Thirty-six randomized subjects received canagliflozin 50, 100, or 300 mg/day or placebo for 7 days.  On Days 1 and 7, area under the plasma concn.-time curve and max. obsd. plasma concn. (Cmax) for canagliflozin and its metabolites increased dose-dependently.  Half-life and time at which Cmax was obsd. were dose-independent.  Systemic molar M5 exposure was half that of canagliflozin; M7 exposure was similar to canagliflozin.  Steady-state plasma canagliflozin concns. were reached by Day 4 in all active treatment groups.  Pharmacodynamic effects were dose- and exposure-dependent.  All canagliflozin doses decreased RTG, increased UGE0-24h, and reduced MPG0-24h vs. placebo on Days 1 and 7.  On Day 7, placebo-subtracted least-squares mean decreases in MPG0-24h ranged from 42-57 mg/dL with canagliflozin treatment.  Adverse events (AEs) were balanced between treatments; no treatment-related serious AEs, AE-related discontinuations, or clin. meaningful adverse changes in routine safety evaluations occurred.  The obsd. pharmacokinetic/pharmacodynamic profile of canagliflozin in subjects with type 2 diabetes supports a once-daily dosing regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSidq1B1s0wLVg90H21EOLACvtfcHk0lh74SgbxlX2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrJ&md5=87e305c019cee8846c2987e9c0de56fb</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1002%2Fjcph.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.88%26sid%3Dliteratum%253Aachs%26aulast%3DDevineni%26aufirst%3DD.%26aulast%3DCurtin%26aufirst%3DC.%2BR.%26aulast%3DPolidori%26aufirst%3DD.%26aulast%3DGutierrez%26aufirst%3DM.%2BJ.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DP.%2BL.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520canagliflozin%252C%2520a%2520sodium%2520glucose%2520co-transporter%25202%2520inhibitor%252C%2520in%2520subjects%2520with%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26spage%3D601%26epage%3D610%26doi%3D10.1002%2Fjcph.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freudenberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinz, C.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1055</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.025551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19196846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1046-1055&author=D.+Langauthor=C.+Freudenbergerauthor=C.+Weinz&title=In+vitro+metabolism+of+rivaroxaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+in+liver+microsomes+and+hepatocytes+of+rats%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.108.025551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans</span></div><div class="casAuthors">Lang, D.; Freudenberger, C.; Weinz, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1046-1055</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The in vitro metab. of rivaroxaban, a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders, was investigated in several species, including humans.  The objective of this study was to elucidate metabolite structures and identify the metabolic pathways to provide support for in vivo safety and clin. studies.  [14C]Rivaroxaban was incubated with liver microsomes and hepatocytes of rats, dogs, and humans.  The samples were analyzed by high-performance liq. chromatog.-14C-tandem mass spectroscopy, to generate metabolite profiles and propose or confirm the structures of the metabolites formed.  In vitro metabolite profiles showed no major differences between species.  The main oxidative metabolic pathways identified for all species were hydroxylation at the morpholinone moiety (M-2, M-3, and M-8) and to a lesser extent at the oxazolidinone moiety (M-9).  M-2 was the main metabolite in all microsomal incubations.  M-1, a morpholinone ring-opened product formed by further oxidn. of M-2, was the main metabolite in all hepatocyte incubations.  Other pathways were amide hydrolysis at the morpholinone ring (M-7) and the chlorothiophene amide moiety (M-13 and M-15).  In hepatocytes, M-13 was readily conjugated with glycine, leading to M-4.  The metabolic fate of unlabeled M-15 was investigated sep.  Incubations with human liver microsomes and hepatocytes showed that M-15 was first oxidized to the aldehyde intermediate M-16 and subsequently reduced to M-17 (alc.) or oxidized to M-18 (carboxylic acid).  No metab. at the chlorothiophene moiety itself was found.  Overall, rivaroxaban showed no species differences in metab., with different independent metabolic pathways and no formation of reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonReqhgur0jrVg90H21EOLACvtfcHk0lh74SgbxlX2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbs%253D&md5=554dd0a5f3447eb140028bd857e44180</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025551%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DD.%26aulast%3DFreudenberger%26aufirst%3DC.%26aulast%3DWeinz%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520rivaroxaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%252C%2520in%2520liver%2520microsomes%2520and%2520hepatocytes%2520of%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1046%26epage%3D1055%26doi%3D10.1124%2Fdmd.108.025551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubitza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span> <span> </span><span class="NLM_article-title">Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1056</span>– <span class="NLM_lpage">1064</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.025569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19196845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1056-1064&author=C.+Weinzauthor=T.+Schwarzauthor=D.+Kubitzaauthor=W.+Mueckauthor=D.+Lang&title=Metabolism+and+excretion+of+rivaroxaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+in+rats%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.108.025569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans</span></div><div class="casAuthors">Weinz, C.; Schwarz, T.; Kubitza, D.; Mueck, W.; Lang, D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1056-1064</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Rivaroxaban is a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders.  The objective of this study was to investigate the in vivo metab. and excretion of rivaroxaban in rats, dogs, and humans.  Single doses of [14C]rivaroxaban (3 and 1 mg/kg) were administered to rats (orally/i.v.) and dogs (orally), resp.  A single oral dose of [14C]rivaroxaban (10 mg) was administered to healthy human males (n = 4).  Plasma and excreta were collected and profiled for radioactivity.  Recovery of total radioactivity was high and ≥92% in all species.  Unchanged rivaroxaban was the major compd. in plasma at all time points investigated, across all species.  No major or pharmacol. active circulating metabolites were detected.  Rivaroxaban and its metabolites were rapidly excreted; urinary excretion of radioactivity was 25 and 52%, and fecal excretion was 67 and 43% of the dose in rats and dogs, resp.  In humans, 66% of the dose was excreted renally (36% unchanged drug) and 28% in the feces.  Radioactivity profiles in excreta were similar across species.  Three metabolic pathways were identified: oxidative degrdn. of the morpholinone moiety (major pathway) and hydrolysis of the central amide bond and of the lactam amide bond in the morpholinone ring (minor pathways).  M-1, the main metabolite in excreta of all species, was eliminated via both renal and fecal/biliary routes.  In total, 82 to 89% of the dose administered was assigned to unchanged rivaroxaban and its metabolites in the excreta of rats, dogs, and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1XRtEaXyDjLVg90H21EOLACvtfcHk0lh74SgbxlX2eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbg%253D&md5=c0a252defe018afa59944549dd4de6d6</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025569%26sid%3Dliteratum%253Aachs%26aulast%3DWeinz%26aufirst%3DC.%26aulast%3DSchwarz%26aufirst%3DT.%26aulast%3DKubitza%26aufirst%3DD.%26aulast%3DMueck%26aufirst%3DW.%26aulast%3DLang%26aufirst%3DD.%26atitle%3DMetabolism%2520and%2520excretion%2520of%2520rivaroxaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%252C%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1056%26epage%3D1064%26doi%3D10.1124%2Fdmd.108.025569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irons, R. D.</span></span> <span> </span><span class="NLM_article-title">Quinones as toxic metabolites of benzene</span>. <i>J. Toxicol. Environ. Health</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1080/15287398509530777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F15287398509530777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4093989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL28XhsVeiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1985&pages=673-678&author=R.+D.+Irons&title=Quinones+as+toxic+metabolites+of+benzene&doi=10.1080%2F15287398509530777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Quinones as toxic metabolites of benzene</span></div><div class="casAuthors">Irons, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicology and Environmental Health</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">673-8</span>CODEN:
                <span class="NLM_cas:coden">JTEHD6</span>;
        ISSN:<span class="NLM_cas:issn">0098-4108</span>.
    </div><div class="casAbstract">A review with 30 refs. on the toxicity of C6H6  [71-43-2] and its dihydroxy metabolites (quinones).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEeYO0-nupULVg90H21EOLACvtfcHk0ljKlHDCtfV5kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhsVeiu7c%253D&md5=80670c1f9f8a7e110d44b2a6fd2f25f3</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1080%2F15287398509530777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15287398509530777%26sid%3Dliteratum%253Aachs%26aulast%3DIrons%26aufirst%3DR.%2BD.%26atitle%3DQuinones%2520as%2520toxic%2520metabolites%2520of%2520benzene%26jtitle%3DJ.%2520Toxicol.%2520Environ.%2520Health%26date%3D1985%26volume%3D16%26spage%3D673%26epage%3D678%26doi%3D10.1080%2F15287398509530777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalf, G. F.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the metabolism and toxicity of benzene</span>. <i>Crit. Rev. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.3109/10408448709089859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F10408448709089859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3311642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL1cXhslehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1987&pages=141-159&author=G.+F.+Kalf&title=Recent+advances+in+the+metabolism+and+toxicity+of+benzene&doi=10.3109%2F10408448709089859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the metabolism and toxicity of benzene</span></div><div class="casAuthors">Kalf, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Toxicology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-59</span>CODEN:
                <span class="NLM_cas:coden">CRTXB2</span>;
        ISSN:<span class="NLM_cas:issn">0045-6446</span>.
    </div><div class="casAbstract">A review with 146 refs. on the metab. of benzene and its genotoxicity, carcinogenicity, and hematotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq9fEWATFb9LVg90H21EOLACvtfcHk0ljKlHDCtfV5kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhslehsQ%253D%253D&md5=450c8d3e62ae25b5f360e731d4d7d63b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.3109%2F10408448709089859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10408448709089859%26sid%3Dliteratum%253Aachs%26aulast%3DKalf%26aufirst%3DG.%2BF.%26atitle%3DRecent%2520advances%2520in%2520the%2520metabolism%2520and%2520toxicity%2520of%2520benzene%26jtitle%3DCrit.%2520Rev.%2520Toxicol.%26date%3D1987%26volume%3D18%26spage%3D141%26epage%3D159%26doi%3D10.3109%2F10408448709089859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claesson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minidis, A.</span></span> <span> </span><span class="NLM_article-title">Systematic approach to organizing structural alerts for reactive metabolite formation from potential drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Wkurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=389-411&author=A.+Claessonauthor=A.+Minidis&title=Systematic+approach+to+organizing+structural+alerts+for+reactive+metabolite+formation+from+potential+drugs&doi=10.1021%2Facs.chemrestox.8b00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Approach to Organizing Structural Alerts for Reactive Metabolite Formation from Potential Drugs</span></div><div class="casAuthors">Claesson, Alf; Minidis, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">389-411</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Reactive metabolites are widely accepted as playing a pivotal role in causing idiosyncratic adverse drug reactions (IDR).  However, much is unknown about the biol. mechanisms of IDR although the initiating event in most cases is an attachment of a reactive intermediate to macromols. leading to immune mediated responses.  Reactive metabolites are also involved in many mutagenesis/ carcinogenesis events by reacting with DNA.  Drug designers thus have all reasons to make large efforts to avoid making test compds. having a liability to generate reactive metabolites.  In this Perspective the authors argue for using structural alerts (SA) as the most straightforward way to link forecasting about chem. hazards of planned test compds. to the accumulated knowledge base.  Although many SAs have been widely recognized and reviewed previously, there are also a lot of observations that have no readily discernable chem. interpretation.  For drug designers to benefit from all published data, the knowledge has to be organized in a way that is readily searchable starting with a query structure.  The authors propose that an increased no. of structural alerts with more details should be applied to obtain improved decision support.  The assocn. of selected SAs with ref. drugs, whose proposed or hypothesized activation mechanisms build the knowledge base, should be readily available in a format comprising of small summaries with included hyperlinks for quick access to the original literature, as outlined in the TOC illustration.  Since some structural alerts are present in drugs that do not cause idiosyncratic adverse reactions or drug-drug interactions, it is important to elaborate on the reasons for this discrepancy as much as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6TRDGoBo8FLVg90H21EOLACvtfcHk0ljKlHDCtfV5kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Wkurw%253D&md5=8822e32efecbf62c90d62ba5dacfda63</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00046%26sid%3Dliteratum%253Aachs%26aulast%3DClaesson%26aufirst%3DA.%26aulast%3DMinidis%26aufirst%3DA.%26atitle%3DSystematic%2520approach%2520to%2520organizing%2520structural%2520alerts%2520for%2520reactive%2520metabolite%2520formation%2520from%2520potential%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26spage%3D389%26epage%3D411%26doi%3D10.1021%2Facs.chemrestox.8b00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, C. A.</span></span> <span> </span><span class="NLM_article-title">Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR</span>. <i>SAR QSAR Environ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1080/10629369908039182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F10629369908039182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10491855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=299-314&author=N.+Greeneauthor=P.+N.+Judsonauthor=J.+J.+Langowskiauthor=C.+A.+Marchant&title=Knowledge-based+expert+systems+for+toxicity+and+metabolism+prediction%3A+DEREK%2C+StAR+and+METEOR&doi=10.1080%2F10629369908039182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR</span></div><div class="casAuthors">Greene, N.; Judson, P. N.; Langowski, J. J.; Marchant, C. A.</div><div class="citationInfo"><span class="NLM_cas:title">SAR and QSAR in Environmental Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">299-314, 2 plates</span>CODEN:
                <span class="NLM_cas:coden">SQERED</span>;
        ISSN:<span class="NLM_cas:issn">1062-936X</span>.
    
            (<span class="NLM_cas:orgname">Gordon & Breach Science Publishers</span>)
        </div><div class="casAbstract">It has long been recognized that the ability to predict the metabolic fate of a chem. substance and the potential toxicity of either the parent compd. or its metabolites are important in novel drug design.  The popularity of using computer models as an aid in this area has grown considerably in recent years.  LHASA Limited has been developing knowledge-based expert systems for toxicity and metab. prediction in collaboration with industry and regulatory authorities.  These systems, DEREK, StAR, and METEOR, use rules to describe the relationship between chem. structure and either toxicity in the case of DEREK and StAR or metabolic fate in the case of METEOR.  The rule refinement process for DEREK often involves assessing the predictions for a novel set of compds. and comparing them to their biol. assay results as a measure of the system's performance.  For example, 266 non-congeneric chems. from the National Toxicol. Program database have been processed through the DEREK mutagenicity knowledge base and the predictions compared to their Salmonella typhimurium mutagenicity data.  Initially, 81 of 114 mutagens (71%) and 117 of 152 non-mutagens (77%) were correctly identified.  Following further knowledge base development, the no. of correctly identified mutagens has increased to 96 (84%).  Further work on improving the predictive capabilities of DEREK, StAR, and METEOR is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp85N5_SGuyybVg90H21EOLACvtfcHk0ljOQ5A9-f1OsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFCgsbc%253D&md5=5988de2a40351b9416bc21a9688a3a6d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1080%2F10629369908039182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10629369908039182%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DJudson%26aufirst%3DP.%2BN.%26aulast%3DLangowski%26aufirst%3DJ.%2BJ.%26aulast%3DMarchant%26aufirst%3DC.%2BA.%26atitle%3DKnowledge-based%2520expert%2520systems%2520for%2520toxicity%2520and%2520metabolism%2520prediction%253A%2520DEREK%252C%2520StAR%2520and%2520METEOR%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D1999%26volume%3D10%26spage%3D299%26epage%3D314%26doi%3D10.1080%2F10629369908039182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Methling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reszka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheuch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terhaag, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span> <span> </span><span class="NLM_article-title">Investigation of the in vitro metabolism of the analgesic flupirtine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.024364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.024364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19074524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislamt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=479-493&author=K.+Methlingauthor=P.+Reszkaauthor=M.+Lalkauthor=O.+Vranaauthor=E.+Scheuchauthor=W.+Siegmundauthor=B.+Terhaagauthor=P.+J.+Bednarski&title=Investigation+of+the+in+vitro+metabolism+of+the+analgesic+flupirtine&doi=10.1124%2Fdmd.108.024364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the in vitro metabolism of the analgesic flupirtine</span></div><div class="casAuthors">Methling, Karen; Reszka, Przyemslaw; Lalk, Michael; Vrana, Oldrich; Scheuch, Eberhard; Siegmund, Werner; Terhaag, Bernd; Bednarski, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-493</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The in vitro metab. of flupirtine, ethyl-N-[2-amino-6-(4-fluoro-phenylmethyl-amino)pyridine-3-yl]carbamate, a centrally acting analgesic with muscle tone-reducing activity, was studied.  Two flupirtine metabolites were already known: the N-acetylated analog D13223 and 4-fluorohippuric acid.  The structure of flupirtine suggested that redox chem. may play a role in metab., and cyclic voltammetry studies showed that the drug undergoes facile and irreversible redox reactions.  Thus, oxidative metab. was investigated first.  With CYP3A1-induced rat liver microsomes an 18% turnover of flupirtine and a 20 to 25% turnover of D13223 took place over 30 min, but less than 5% turnover of flupirtine was obsd. with all human liver microsomal prepns. tested, evidence that cytochrome P 450 does not contribute appreciably to the metab. in humans.  Likewise, no involvement of human monoamine oxidase (isoforms A and B) was found for either flupirtine or D13223.  In contrast, flupirtine was an excellent substrate for both human myeloperoxidase and horse radish peroxidase (HRP).  These enzymes produced detectable amts. of oxidn. products.  Incubations of flupirtine with HRP produced an oxidn. product that could be trapped with glutathione, the resulting glutathione conjugate was characterized by mass spectrometry and NMR.  Metab. of D13223 by both peroxidases was also obsd. but to a much lesser extent.  Porcine liver esterases cleave the carbamate group of flupirtine, and both human N-acetyltransferases 1 and 2 acetylated the hydrolysis product, presumably descarboethoxyflupirtine, with nearly equal efficiencies to yield D13223.  Incubations of human liver microsomes with flupirtine or the metabolite D13223 together with UDP-glucuronic acid gave two isomeric N-glucuronides in both cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJIi-5pzLX4rVg90H21EOLACvtfcHk0ljOQ5A9-f1OsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislamt7g%253D&md5=bc5c607b727a0e617dd76d9c8757f1b3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.024364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.024364%26sid%3Dliteratum%253Aachs%26aulast%3DMethling%26aufirst%3DK.%26aulast%3DReszka%26aufirst%3DP.%26aulast%3DLalk%26aufirst%3DM.%26aulast%3DVrana%26aufirst%3DO.%26aulast%3DScheuch%26aufirst%3DE.%26aulast%3DSiegmund%26aufirst%3DW.%26aulast%3DTerhaag%26aufirst%3DB.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26atitle%3DInvestigation%2520of%2520the%2520in%2520vitro%2520metabolism%2520of%2520the%2520analgesic%2520flupirtine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D479%26epage%3D493%26doi%3D10.1124%2Fdmd.108.024364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheuch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosskopf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terhaag, B.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1111/bcp.12522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fbcp.12522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=25264565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=501-513&author=W.+Siegmundauthor=C.+Modessauthor=E.+Scheuchauthor=K.+Methlingauthor=M.+Keiserauthor=A.+Nassifauthor=D.+Rosskopfauthor=P.+J.+Bednarskiauthor=J.+Borlakauthor=B.+Terhaag&title=Metabolic+activation+and+analgesic+effect+of+flupirtine+in+healthy+subjects%2C+influence+of+the+polymorphic+NAT2%2C+UGT1A1+and+GSTP1&doi=10.1111%2Fbcp.12522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1</span></div><div class="casAuthors">Siegmund, Werner; Modess, Christiane; Scheuch, Eberhard; Methling, Karen; Keiser, Markus; Nassif, Ali; Rosskopf, Dieter; Bednarski, Patrick J.; Borlak, Juergen; Terhaag, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">501-513</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : The rare assocn. of flupirtine with liver injury is most likely caused by reactive quinone diimines and their oxidative formation may be influenced by the activities of N-acetyltransferases (NAT) that conjugate the less toxic metabolite D13223, and by glucuronosyltransferases (UGT) and glutathione S-transferases (GST) that generate stable terminal glucuronides and mercapturic acid derivs., resp.  The influence of genetic polymorphisms of NAT2, UGT1A1 and GSTP1 on generation of the terminal mercapturic acid derivs. and analgesic effects was evaluated to identify potential genetic risk factors for hepatotoxicity of flupirtine.  Methods : Metabolic disposition of flupirtine was measured after i.v. administration (100 mg), after swallowing an immediate-release (IR) tablet (100 mg) and after repeated administration of modified release (MR) tablets (400 mg once daily 8 days) in 36 selected healthy subjects.  Analgesic effects were measured using pain models (delayed onset of muscle soreness, elec. pain).  Results : Flupirtine IR was rapidly but incompletely absorbed (∼72%).  Repeated administration of flupirtine MR showed lower bioavailability (∼60%).  Approx. 12% of bioavailable flupirtine IR and 8% of bioavailable flupiritine MR was eliminated as mercapturic acid derivs. into the urine independent of the UGT1A1, NAT2 and GSTP1 genotype.  Carriers of variant GSTP1 alleles showed lower bioavailability but increased intestinal secretion of flupirtine and increased efficiency in exptl. pain.  Flupirtine was not a substrate for ABCB1 and ABCC2.  Conclusions : Formation of mercapturic acid derivs. is a major elimination route for flupirtine in man.  However, the theor. toxic pathway is not influenced by the frequent polymorphisms of UGT1A1, NAT2 and GSTP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDTzf4blJ7brVg90H21EOLACvtfcHk0ljOQ5A9-f1OsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFaqs7g%253D&md5=12442bde1be4c5c86a928b06f6517b3c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12522%26sid%3Dliteratum%253Aachs%26aulast%3DSiegmund%26aufirst%3DW.%26aulast%3DModess%26aufirst%3DC.%26aulast%3DScheuch%26aufirst%3DE.%26aulast%3DMethling%26aufirst%3DK.%26aulast%3DKeiser%26aufirst%3DM.%26aulast%3DNassif%26aufirst%3DA.%26aulast%3DRosskopf%26aufirst%3DD.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTerhaag%26aufirst%3DB.%26atitle%3DMetabolic%2520activation%2520and%2520analgesic%2520effect%2520of%2520flupirtine%2520in%2520healthy%2520subjects%252C%2520influence%2520of%2520the%2520polymorphic%2520NAT2%252C%2520UGT1A1%2520and%2520GSTP1%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D79%26spage%3D501%26epage%3D513%26doi%3D10.1111%2Fbcp.12522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keisu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span> <span> </span><span class="NLM_article-title">Drug-induced liver injury in humans: the case of ximelagatran</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-00663-0_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2F978-3-642-00663-0_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVymsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2010&pages=407-418&author=M.+Keisuauthor=T.+B.+Andersson&title=Drug-induced+liver+injury+in+humans%3A+the+case+of+ximelagatran&doi=10.1007%2F978-3-642-00663-0_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury in humans: the case of ximelagatran</span></div><div class="casAuthors">Keisu, M.; Andersson, T. B.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">Adverse Drug Reactions</span>),
    <span class="NLM_cas:pages">407-418</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Ximelagatran was the first orally available direct thrombin inhibitor under clin. development that also reached the market.  Ximelagatran was tested in an extensive clin. program.  Short-term use (< 12 days) in humans including the phase III clin. trials did not indicate any hepatotoxic potential.  Increased hepatic enzyme levels were first obsd. at a higher frequency when evaluating the long-term (>35 days) use of ximelagatran (incidence of >3 × upper limit of normal (ULN) plasma ALT was 7.9%).  The frequency of elevated total bilirubin levels was similar in the ximelagatran and the comparator groups.  However, the combination of ALT > 3 × ULN and total bilirubin > 2 × ULN was 0.5% among patients treated with ximelagatran and 0.1% among patients in the comparator group.  Symptoms such as fever and rash potentially indicating hypersensitivity (immunol. type of reaction) were low and did not differ between ximelagatran and the comparators.  The withdrawal of ximelagatran from the market and termination of the ximelagatran development program was triggered by safety data from a 35-day study, indicating that severe hepatic injury in a patient could develop after exposure to the drug has been completed and that regular liver function monitoring may not mitigate the possible risk of severe hepatic injury.  As for many drugs causing liver injury, the std. preclin. toxicol. studies provided no indication that ximelagatran affected hepatic functions.  In addn., extensive investigations using human-based in vitro models have not been able to define mechanisms explaining the pattern of hepatic injury obsd. in long-term clin. trials.  A pharmacogenomic study provided evidence that the ALT increases were assocd. with major histocompatibility complex (MHC) alleles DRB1'07 and DQA1*02 suggesting a possible immunogenic pathogenesis.  This example provides important clues to the mechanism of idiosyncratic drug-induced liver toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8MnjfyasU1bVg90H21EOLACvtfcHk0ljNMY76Nd16sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVymsr8%253D&md5=8713782d6f002abd9d8f8ca6aa41d7e0</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-00663-0_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-00663-0_13%26sid%3Dliteratum%253Aachs%26aulast%3DKeisu%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DDrug-induced%2520liver%2520injury%2520in%2520humans%253A%2520the%2520case%2520of%2520ximelagatran%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2010%26volume%3D196%26spage%3D407%26epage%3D418%26doi%3D10.1007%2F978-3-642-00663-0_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ainscow, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span> <span> </span><span class="NLM_article-title">Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1517/14740338.7.4.351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1517%2F14740338.7.4.351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18613800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1Cgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=351-365&author=E.+K.+Ainscowauthor=J.+E.+Pillingauthor=N.+M.+Brownauthor=A.+T.+Ormeauthor=M.+Sullivanauthor=A.+C.+Hargreavesauthor=E.+L.+Cookeauthor=E.+Sullivanauthor=S.+Carlssonauthor=T.+B.+Andersson&title=Investigations+into+the+liver+effects+of+ximelagatran+using+high+content+screening+of+primary+human+hepatocyte+cultures&doi=10.1517%2F14740338.7.4.351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures</span></div><div class="casAuthors">Ainscow, Edward K.; Pilling, James E.; Brown, Nick M.; Orme, Alexandra T.; Sullivan, Michael; Hargreaves, Andy C.; Cooke, Emma-Louise; Sullivan, Elaine; Carlsson, Stefan; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-365</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Ximelagatran, the first oral agent in the new class of direct thrombin inhibitors, was withdrawn from the market due to increased rates of liver enzyme elevations in long-term treatments.  Despite intensive pre clin. investigations the cellular mechanisms behind the obsd. hepatic effects remain unknown.  The aim of this study was to assess drug-induced cytotoxicity in primary human hepatocyte cultures by ximelagatran and other ref. pharmaceutical agents with known in vivo hepatotoxic profiles.  Drugs cause liver injury by many distinct mechanisms that result in abnormal cellular functioning and different patterns of injury.  To address many potential toxic mechanisms in a human-relevant model, freshly isolated human hepatocytes were used in automated imaging assays.  Ximelagatran was used as a test compd. to study biochem. and morphol. changes in human hepatocytes.  In addn., 11 control, ref. and comparator compds. with known liver-toxic potential in humans were used.  The response to these compds. was assessed across five different hepatocyte donor prepns.  Cytotoxicity induced by a no. of compds. was quant. monitored using an automated imaging technique.  A variety of morphol. changes in hepatocyte cytoskeleton and mitochondrial function could be identified at sublethal doses of test compds.  Doses of ximelagatran up to 500 μM did not cause a cytotoxic response in the majority of prepns. and no subcytotoxic response was obsd. at doses below 125 μM.  The expts. described here demonstrate that primary human hepatocytes may be used in a medium-throughput format for screening using imaging-based assays for the identification of cellular responses.  Overall, it is concluded that ximelagatran did not cause a significant decrease in cell viability when incubated for 24 h at considerably higher concns. than are found in plasma following therapeutic dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBDK7YL3gArVg90H21EOLACvtfcHk0ljNMY76Nd16sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1Cgsrc%253D&md5=3c7f4b85bfd3d063b7fa892fd909459d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1517%2F14740338.7.4.351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.7.4.351%26sid%3Dliteratum%253Aachs%26aulast%3DAinscow%26aufirst%3DE.%2BK.%26aulast%3DPilling%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DN.%2BM.%26aulast%3DOrme%26aufirst%3DA.%2BT.%26aulast%3DSullivan%26aufirst%3DM.%26aulast%3DHargreaves%26aufirst%3DA.%2BC.%26aulast%3DCooke%26aufirst%3DE.%2BL.%26aulast%3DSullivan%26aufirst%3DE.%26aulast%3DCarlsson%26aufirst%3DS.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DInvestigations%2520into%2520the%2520liver%2520effects%2520of%2520ximelagatran%2520using%2520high%2520content%2520screening%2520of%2520primary%2520human%2520hepatocyte%2520cultures%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2008%26volume%3D7%26spage%3D351%26epage%3D365%26doi%3D10.1517%2F14740338.7.4.351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of atorvastatin</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.2165/00003088-200342130-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2165%2F00003088-200342130-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=14531725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BD3svntVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1141-1160&author=H.+Lennernas&title=Clinical+pharmacokinetics+of+atorvastatin&doi=10.2165%2F00003088-200342130-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of atorvastatin</span></div><div class="casAuthors">Lennernas Hans</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1141-60</span>
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.  Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of HMG-CoA reductase.  The mean dose-response relationship has been shown to be log-linear for atorvastatin, but plasma concentrations of atorvastatin acid and its metabolites do not correlate with LDL-cholesterol reduction at a given dose.  The clinical dosage range for atorvastatin is 10-80 mg/day, and it is given in the acid form.  Atorvastatin acid is highly soluble and permeable, and the drug is completely absorbed after oral administration.  However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%.  The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.  Atorvastatin acid is extensively metabolised in both the gut and liver by oxidation, lactonisation and glucuronidation, and the metabolites are eliminated by biliary secretion and direct secretion from blood to the intestine.  In vitro, atorvastatin acid is a substrate for P-glycoprotein, organic anion-transporting polypeptide (OATP) C and H+-monocarboxylic acid cotransporter.  The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.  The renal route is of minor importance (<1%) for the elimination of atorvastatin acid.  In vivo, cytochrome P450 (CYP) 3A4 is responsible for the formation of two active metabolites from the acid and the lactone forms of atorvastatin.  Atorvastatin acid and its metabolites undergo glucuronidation mediated by uridinediphosphoglucuronyltransferases 1A1 and 1A3.  Atorvastatin can be given either in the morning or in the evening.  Food decreases the absorption rate of atorvastatin acid after oral administration, as indicated by decreased peak concentration and increased time to peak concentration.  Women appear to have a slightly lower plasma exposure to atorvastatin for a given dose.  Atorvastatin is subject to metabolism by CYP3A4 and cellular membrane transport by OATP C and P-glycoprotein, and drug-drug interactions with potent inhibitors of these systems, such as itraconazole, nelfinavir, ritonavir, cyclosporin, fibrates, erythromycin and grapefruit juice, have been demonstrated.  An interaction with gemfibrozil seems to be mediated by inhibition of glucuronidation.  A few case studies have reported rhabdomyolysis when the pharmacokinetics of atorvastatin have been affected by interacting drugs.  Atorvastatin increases the bioavailability of digoxin, most probably by inhibition of P-glycoprotein, but does not affect the pharmacokinetics of ritonavir, nelfinavir or terfenadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaNOaBHYDzT90Q2ypr7jHkfW6udTcc2ea2a5qqYxcuXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svntVSrug%253D%253D&md5=21b6bc593a9e04544fe3a1409691448c</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342130-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342130-00005%26sid%3Dliteratum%253Aachs%26aulast%3DLennernas%26aufirst%3DH.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520atorvastatin%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26spage%3D1141%26epage%3D1160%26doi%3D10.2165%2F00003088-200342130-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.027797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding&doi=10.1124%2Fdmd.109.027797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0lhjWTxjYDDt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977%26doi%3D10.1124%2Fdmd.109.027797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashishtha, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1021/tx100141d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx100141d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVChs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1393-1404&author=G.+Wuauthor=S.+C.+Vashishthaauthor=J.+C.+Erve&title=Characterization+of+glutathione+conjugates+of+duloxetine+by+mass+spectrometry+and+evaluation+of+in+silico+approaches+to+rationalize+the+site+of+conjugation+for+thiophene+containing+drugs&doi=10.1021%2Ftx100141d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Glutathione Conjugates of Duloxetine by Mass Spectrometry and Evaluation of in Silico Approaches to Rationalize the Site of Conjugation for Thiophene Containing Drugs</span></div><div class="casAuthors">Wu, Guosheng; Vashishtha, Sarvesh C.; Erve, John C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1393-1404</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vitro bioactivation of the selective serotonin and norepinephrine reuptake inhibitor duloxetine was investigated using liver microsomes and cytosol, expressed glutathione transferase, and recombinant P 450 2D6 and 1A2.  In the presence of glutathione, several conjugates were identified and characterized using a combination of direct infusion nanoelectrospray mass spectrometry on an LTQ/Orbitrap and liq.-chromatog. mass spectrometry on a triple quadrupole.  Structural characterization of these conjugates revealed that glutathione conjugation occurred on naphthalene rather than on thiophene and likely proceeded via a reactive epoxide intermediate.  Expts. with recombinant P450s and the isoform specific inhibitors quinidine and furafylline suggested that both P 450 2D6 and 1A2 were involved in the bioactivation of duloxetine.  To explore the utility of in silico approaches to address bioactivation issues, MetaSite and two docking approaches (rigid and induced-fit docking) utilizing publicly available human P 450 crystal structures or a homol. model for P 450 2C19 were used to predict the sites of bioactivation for duloxetine as well as the thiophene contg. compds. tienilic acid, suprofen, ticlopidine, methapyrilene, and OSI-930 for which glutathione conjugates on the thiophene moiety have been reported.  MetaSite and induced fit docking but not rigid docking correctly predicted that naphthalene rather than thiophene was the preferred site of bioactivation for duloxetine by P 450 2D6.  MetaSite predictions were also consistent with literature reports that thiophene was the site of glutathione conjugation for tienilic acid, suprofen, and OSI-930 but not for ticlopidine or methapyrilene.  Of the two docking approaches investigated, induced fit docking results were consistent with thiophene as the site of bioactivation for all compds. to which it was applied.  In conclusion, our investigation identified the likely bioactivation pathway for duloxetine and demonstrated the utility of in silico approaches MetaSite and induced fit docking to address potential bioactivation liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8qdX22Hx2o7Vg90H21EOLACvtfcHk0lhjWTxjYDDt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVChs7Y%253D&md5=050dddbc03d80c7b79eac7394b0bf0ad</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Ftx100141d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx100141d%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DVashishtha%26aufirst%3DS.%2BC.%26aulast%3DErve%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520glutathione%2520conjugates%2520of%2520duloxetine%2520by%2520mass%2520spectrometry%2520and%2520evaluation%2520of%2520in%2520silico%2520approaches%2520to%2520rationalize%2520the%2520site%2520of%2520conjugation%2520for%2520thiophene%2520containing%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D1393%26epage%3D1404%26doi%3D10.1021%2Ftx100141d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knadler, M. P.</span></span> <span> </span><span class="NLM_article-title">Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1142</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1124/dmd.31.9.1142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.31.9.1142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12920170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmslKlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1142-1150&author=R.+J.+Lantzauthor=T.+A.+Gillespieauthor=T.+J.+Rashauthor=F.+Kuoauthor=M.+Skinnerauthor=H.+Y.+Kuanauthor=M.+P.+Knadler&title=Metabolism%2C+excretion%2C+and+pharmacokinetics+of+duloxetine+in+healthy+human+subjects&doi=10.1124%2Fdmd.31.9.1142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects</span></div><div class="casAuthors">Lantz, R. J.; Gillespie, T. A.; Rash, T. J.; Kuo, F.; Skinner, M.; Kuan, H.-Y.; Knadler, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1142-1150</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Duloxetine is a potent and balanced dual inhibitor of serotonin and norepinephrine reuptake being investigated for the treatment of depression and urinary incontinence.  The disposition of duloxetine was studied in four healthy human subjects after a single 20.2-mg (100.6 μCi) oral dose of [14C]duloxetine in an enteric-coated tablet.  The mean total recovery of radioactivity (± S.E.M.) after 312 h was 90.5% (±0.4%) with 72.0% (±1.1%) excreted in the urine.  Duloxetine was extensively metabolized to numerous metabolites primarily excreted into the urine in the conjugated form.  The major biotransformation pathways for duloxetine involved oxidn. of the naphthyl ring at either the 4-, 5-, or 6- positions followed by further oxidn., methylation, and/or conjugation.  The major metabolites found in plasma were glucuronide conjugates of the following: 4-hydroxy duloxetine (M6), 6-hydroxy-5-methoxy duloxetine (M10), 4, 6-dihydroxy duloxetine (M9), and a sulfate conjugate of 5-hydroxy-6-methoxy duloxetine (M7).  The major metabolites found in plasma were also found in the urine, but the urine contained many addnl. metabolites.  In addn. to duloxetine, 4-hydroxy duloxetine (M14) and an unidentified polar metabolite were obsd. in feces.  Following [14C]duloxetine administration, Cmax was reached at a median of 6 h for both duloxetine and total radioactivity.  Duloxetine accounted for less than 3% of the circulating radioactivity based on mean area under the curve values.  The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH8VCfe6WAh7Vg90H21EOLACvtfcHk0lhjWTxjYDDt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmslKlu7w%253D&md5=f2b2687d099b8e760e5b487f68844c7b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.9.1142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.9.1142%26sid%3Dliteratum%253Aachs%26aulast%3DLantz%26aufirst%3DR.%2BJ.%26aulast%3DGillespie%26aufirst%3DT.%2BA.%26aulast%3DRash%26aufirst%3DT.%2BJ.%26aulast%3DKuo%26aufirst%3DF.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKuan%26aufirst%3DH.%2BY.%26aulast%3DKnadler%26aufirst%3DM.%2BP.%26atitle%3DMetabolism%252C%2520excretion%252C%2520and%2520pharmacokinetics%2520of%2520duloxetine%2520in%2520healthy%2520human%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1142%26epage%3D1150%26doi%3D10.1124%2Fdmd.31.9.1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dansette, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libraire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuy, D.</span></span> <span> </span><span class="NLM_article-title">Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1021/tx8004828</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx8004828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=369-373&author=P.+M.+Dansetteauthor=J.+Libraireauthor=G.+Berthoauthor=D.+Mansuy&title=Metabolic+oxidative+cleavage+of+thioesters%3A+evidence+for+the+formation+of+sulfenic+acid+intermediates+in+the+bioactivation+of+the+antithrombotic+prodrugs+ticlopidine+and+clopidogrel&doi=10.1021%2Ftx8004828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span></div><div class="casAuthors">Dansette, Patrick M.; Libraire, Julie; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabolic cleavage of the CO-S bond of some thioesters RCOSR' with the formation of RCOOH requires a monooxygenase-dependent oxidative activation of this bond.  The nature of the S-contg. product(s) resulting from this cleavage remains unclear in most cases.  This communication provides the first evidence for the formation of sulfenic acid intermediates 4a and 4b during the oxidative cleavage of the CO-S bond of thiolactone metabolites 2a and 2b of antithrombotic prodrugs, ticlopidine and clopidogrel, by rat and human liver microsomes.  These intermediates have been trapped by dimedone, and the corresponding adducts 5a and 5b have been characterized by mass spectrometry (MS) and 1H and 13C NMR spectroscopy.  Their formation is monooxygenase-dependent and almost completely inhibited by microsomal cytochrome P 450 inhibitors.  Moreover, they were also formed upon incubation with microsomes contg. recombinant human P 450 3A4, 3A5, 2C8, 2C9, 2C19, 2D6, or 1A2.  In the presence of thiols such as mercaptoethanol, N-acetylcysteine, or glutathione, microsomal incubations of 2a led to mixed disulfides that have been characterized by MS and should result from reaction of 4a with these thiols.  At high thiol concns., one obsd. in HPLC-MS the formation of a product exhibiting the MS expected for the previously described thiol metabolite 3a, a redn. product of 4a that has been reported as the pharmacol. active metabolite of ticlopidine.  These data provide the first evidence for the formation of sulfenic acid reactive metabolites upon P 450-catalyzed oxidative cleavage of thioesters.  They also provide a first detailed mechanism for the previously described formation of pharmacol. active thiols such as 3a upon oxidative metab. of ticlopidine and clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT08wJDRg6g7Vg90H21EOLACvtfcHk0lhjWTxjYDDt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D&md5=5b7783f3cfabd4dff3de96558bf9a63a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Ftx8004828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004828%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DLibraire%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DMetabolic%2520oxidative%2520cleavage%2520of%2520thioesters%253A%2520evidence%2520for%2520the%2520formation%2520of%2520sulfenic%2520acid%2520intermediates%2520in%2520the%2520bioactivation%2520of%2520the%2520antithrombotic%2520prodrugs%2520ticlopidine%2520and%2520clopidogrel%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D369%26epage%3D373%26doi%3D10.1021%2Ftx8004828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dansette, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuy, D.</span></span> <span> </span><span class="NLM_article-title">Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxanase catalyzes the formation of a minor thiol metabolite isomer</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1021/tx2004085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx2004085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2nurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=348-356&author=P.+M.+Dansetteauthor=J.+Rosiauthor=G.+Berthoauthor=D.+Mansuy&title=Cytochromes+P450+catalyze+both+steps+of+the+major+pathway+of+clopidogrel+bioactivation%2C+whereas+paraoxanase+catalyzes+the+formation+of+a+minor+thiol+metabolite+isomer&doi=10.1021%2Ftx2004085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer</span></div><div class="casAuthors">Dansette, Patrick M.; Rosi, Julien; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">348-356</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mechanism generally admitted for the bioactivation of the antithrombotic prodrug, clopidogrel, is its two-step enzymic conversion into a biol. active thiol metabolite.  The first step is a classical cytochrome P 450-dependent monooxygenation of its thiophene ring leading to 2-oxo-clopidogrel, a thiolactone metabolite.  The second step was described as a P 450-dependent oxidative opening of the thiolactone ring of 2-oxo-clopidogrel, with intermediate formation of a reactive sulfenic acid metabolite that is eventually reduced to the corresponding thiol 4b.  A very recent paper published in Nat. Med. (Bouman et al., (2011) 17, 110) reported that the second step of clopidogrel bioactivation was not catalyzed by P 450 enzymes but by paraoxonase-1(PON-1) and that PON-1 was a major determinant of clopidogrel efficacy.  The results described in the present article show that there are two metabolic pathways for the opening of the thiolactone ring of 2-oxo-clopidogrel.  The major one, that was previously described, results from a P 450-dependent redox bioactivation of 2-oxo-clopidogrel and leads to 4b cis, two previously reported thiol diastereomers bearing an exocyclic double bond.  The second, minor one, results from a hydrolysis of 2-oxo-clopidogrel, which seems to be dependent on PON-1, and leads to an isomer of 4b cis, 4b "endo", in which the double bond has migrated from an exocyclic to an endocyclic position in the piperidine ring.  These results were obtained from a detailed study of the metab. of 2-oxo-clopidogrel by human liver microsomes and human sera and anal. by HPLC-MS under conditions allowing a complete sepn. of the thiol metabolite isomers, either as such or after derivatization with 3'-methoxy phenacyl bromide or N-Et maleimide (NEM).  These results also show that the major bioactive thiol isomer found in the plasma of clopidogrel-treated patients derives from 2-oxo-clopidogrel by the P 450-dependent pathway.  Finally, chem. expts. on 2-oxo-clopidogrel showed that this thiolactone is in equil. with its tautomer having a double bond inside the piperidine ring and that nucleophiles such as CH3O- preferentially react on the thioester function of this tautomer.  This allowed us to understand why 4b cis has to be formed via an oxidative opening of 2-oxo-clopidogrel thiolactone, whereas a hydrolytic opening of this thiolactone ring leads to the "endo" thiol isomer 4b "endo".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyp1u0gkh97Vg90H21EOLACvtfcHk0ljoXNdRfft0hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2nurfK&md5=d9d072a01bf586ed9ccc15e01f5be181</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Ftx2004085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx2004085%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DRosi%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DCytochromes%2520P450%2520catalyze%2520both%2520steps%2520of%2520the%2520major%2520pathway%2520of%2520clopidogrel%2520bioactivation%252C%2520whereas%2520paraoxanase%2520catalyzes%2520the%2520formation%2520of%2520a%2520minor%2520thiol%2520metabolite%2520isomer%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D348%26epage%3D356%26doi%3D10.1021%2Ftx2004085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachayus, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delesque-Touchard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labouret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzabiaga, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereillo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culouscou, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, M.</span></span> <span> </span><span class="NLM_article-title">The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">11069</span>– <span class="NLM_lpage">11074</span>, <span class="refDoi"> DOI: 10.1073/pnas.0510446103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1073%2Fpnas.0510446103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16835302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=11069-11074&author=P.+Saviauthor=J.+L.+Zachayusauthor=N.+Delesque-Touchardauthor=C.+Labouretauthor=C.+Herv%C3%A9author=M.+F.+Uzabiagaauthor=J.+M.+Pereilloauthor=J.+M.+Culouscouauthor=F.+Bonoauthor=P.+Ferraraauthor=M.+Herbert&title=The+active+metabolite+of+Clopidogrel+disrupts+P2Y12+receptor+oligomers+and+partitions+them+out+of+lipid+rafts&doi=10.1073%2Fpnas.0510446103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span></div><div class="casAuthors">Savi, Pierre; Zachayus, Jean-Luc; Delesque-Touchard, Nathalie; Labouret, Catherine; Herve, Caroline; Uzabigaga, Marie-Francoise; Pereillo, Jean-Marie; Culouscou, Jean-Michel; Bono, Francoise; Ferrara, Pascual; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11069-11074</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">P2Y12, a G protein-coupled receptor that plays a central role in platelet activation has been recently identified as the receptor targeted by the antithrombotic drug, clopidogrel.  In this study, we further deciphered the mechanism of action of clopidogrel and of its active metabolite (Act-Met) on P2Y12 receptors.  Using biochem. approaches, we demonstrated the existence of homooligomeric complexes of P2Y12 receptors at the surface of mammalian cells and in freshly isolated platelets.  In vitro treatment with Act-Met or in vivo oral administration to rats with clopidogrel induced the breakdown of these oligomers into dimeric and monomeric entities in P2Y12 expressing HEK293 and platelets resp.  In addn., we showed the predominant assocn. of P2Y12 oligomers to cell membrane lipid rafts and the partitioning of P2Y12 out of rafts in response to clopidogrel and Act-Met.  The raft-assocd. P2Y12 oligomers represented the functional form of the receptor, as demonstrated by binding and signal transduction studies.  Finally, using a series of receptors individually mutated at each cysteine residue and a chimeric P2Y12/P2Y13 receptor, we pointed out the involvement of cysteine 97 within the first extracellular loop of P2Y12 in the mechanism of action of Act-Met.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiqt3k9u_2_7Vg90H21EOLACvtfcHk0liaZ1VFbCCkMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D&md5=607365838851caaf1b5881dd624042bf</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510446103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510446103%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DZachayus%26aufirst%3DJ.%2BL.%26aulast%3DDelesque-Touchard%26aufirst%3DN.%26aulast%3DLabouret%26aufirst%3DC.%26aulast%3DHerv%25C3%25A9%26aufirst%3DC.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DCulouscou%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DM.%26atitle%3DThe%2520active%2520metabolite%2520of%2520Clopidogrel%2520disrupts%2520P2Y12%2520receptor%2520oligomers%2520and%2520partitions%2520them%2520out%2520of%2520lipid%2520rafts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D11069%26epage%3D11074%26doi%3D10.1073%2Fpnas.0510446103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haddock, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, F. R.</span></span> <span> </span><span class="NLM_article-title">Metabolic pathways of paroxetine in animals and man and the comparative pharmacological properties of the metabolites</span>. <i>Acta Psychiatr. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0447.1989.tb07163.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fj.1600-0447.1989.tb07163.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1989&pages=24-26&author=R.+E.+Haddockauthor=A.+M.+Johnsonauthor=P.+F.+Langleyauthor=D.+R.+Nelsonauthor=J.+A.+Popeauthor=D.+R.+Thomasauthor=F.+R.+Woods&title=Metabolic+pathways+of+paroxetine+in+animals+and+man+and+the+comparative+pharmacological+properties+of+the+metabolites&doi=10.1111%2Fj.1600-0447.1989.tb07163.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.1989.tb07163.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.1989.tb07163.x%26sid%3Dliteratum%253Aachs%26aulast%3DHaddock%26aufirst%3DR.%2BE.%26aulast%3DJohnson%26aufirst%3DA.%2BM.%26aulast%3DLangley%26aufirst%3DP.%2BF.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DPope%26aufirst%3DJ.%2BA.%26aulast%3DThomas%26aufirst%3DD.%2BR.%26aulast%3DWoods%26aufirst%3DF.%2BR.%26atitle%3DMetabolic%2520pathways%2520of%2520paroxetine%2520in%2520animals%2520and%2520man%2520and%2520the%2520comparative%2520pharmacological%2520properties%2520of%2520the%2520metabolites%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D1989%26volume%3D80%26spage%3D24%26epage%3D26%26doi%3D10.1111%2Fj.1600-0447.1989.tb07163.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1021/tx700132x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx700132x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1649-1657&author=S.+X.+Zhaoauthor=D.+K.+Dalvieauthor=J.+M.+Kellyauthor=J.+R.+Sogliaauthor=K.+S.+Frederickauthor=E.+B.+Smithauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=NADPH-dependent+covalent+binding+of+%5B3H%5Dparoxetine+to+human+liver+microsomes+and+S-9+fractions%3A+identification+of+an+electrophilic+quinone+metabolite+of+paroxetine&doi=10.1021%2Ftx700132x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH-Dependent Covalent Binding of [3H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine</span></div><div class="casAuthors">Zhao, Sabrina X.; Dalvie, Deepak K.; Kelly, Joan M.; Soglia, John R.; Frederick, Kosea S.; Smith, Evan B.; Obach, R. Scott; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The primary pathway of clearance of the methylenedioxyphenyl-contg. compd. and selective serotonin reuptake inhibitor paroxetine in humans involves P 450 2D6-mediated demethylenation to a catechol intermediate.  The process of demethylenation also results in the mechanism-based inactivation of the P 450 isoenzyme.  While the link between P 450 2D6 inactivation and pharmacokinetic interactions of paroxetine with P 450 2D6 substrates has been firmly established, there is a disconnect in terms of paroxetine's excellent safety record despite the potential for bioactivation.  In the present study, the authors have systematically assessed the NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 prepns. in the absence and presence of cofactors of the various phase II drug-metabolizing enzymes involved in the downstream metab./detoxification of the putative paroxetine-catechol intermediate.  Incubation of [3H]paroxetine with human liver microsomes and S-9 prepns. resulted in irreversible binding of radioactive material to macromols. by a process that was NADPH-dependent.  The addn. of reduced glutathione (GSH) to the microsomal and S-9 incubations resulted in a dramatic redn. of covalent binding.  Following incubations with NADPH- and GSH-supplemented human liver microsomes and S-9, three sulfhydryl conjugates with MH+ ions at 623 Da (GS1), 779 Da (GS2), and 928 Da (GS3), resp., were detected by LC-MS/MS.  The collision-induced dissocn. spectra allowed an insight into the structure of the GSH conjugates, based on which, bioactivation pathways were proposed.  The formation of GS1 was consistent with Michael addn. of GSH to the quinone derived from two-electron oxidn. of paroxetine-catechol.  GS3 was formed by the addn. of a second mol. of GSH to the quinone species obtained via the two-electron oxidn. of GS1.  The mechanism of formation of GS2 can be rationalized via (i) further two-electron oxidn. of the catechol motif in GS3 to the ortho-quinone, (ii) loss of a glutamic acid residue from one of the adducted GSH mols., and (iii) condensation of a cysteine-NH2 with an adjacent carbonyl of the ortho-quinone to yield an ortho-benzoquinoneimine structure.  Inclusion of the catechol-O-methyltransferase cofactor S-adenosylmethionine (SAM) in S-9 incubations also dramatically reduced the covalent binding of [3H]paroxetine, a finding that was consistent with O-methylation of the paroxetine-catechol metabolite to the corresponding guaiacol regioisomers in S-9 incubations.  While the NADPH-dependent covalent binding was attenuated by GSH and SAM, these reagents did not alter paroxetine's ability to inactivate P 450 2D6, suggesting that the reactive intermediate responsible for P 450 inactivation did not leave the active site to react with other proteins.  The results of the studies indicate that in addn. to the low once-a-day dosing regimen (20 mg) of paroxetine, efficient scavenging of the catechol and quinone metabolites by SAM and GSH, resp., serves as an explanation for the excellent safety record of paroxetine despite the fact that it undergoes bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXUHMcbZnN7Vg90H21EOLACvtfcHk0liNp_USe1fdug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK&md5=e7d3aa749a419cc87340271eb9b839a0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Ftx700132x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700132x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DNADPH-dependent%2520covalent%2520binding%2520of%2520%255B3H%255Dparoxetine%2520to%2520human%2520liver%2520microsomes%2520and%2520S-9%2520fractions%253A%2520identification%2520of%2520an%2520electrophilic%2520quinone%2520metabolite%2520of%2520paroxetine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1649%26epage%3D1657%26doi%3D10.1021%2Ftx700132x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngui, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNinno, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.1021/tx0200109</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0200109" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=907-914&author=Q.+Chenauthor=J.+S.+Nguiauthor=G.+A.+Dossauthor=R.+W.+Wangauthor=X.+Caiauthor=F.+P.+DiNinnoauthor=T.+A.+Blizzardauthor=M.+L.+Hammondauthor=R.+A.+Stearnsauthor=D.+C.+Evansauthor=T.+A.+Baillieauthor=W.+Tang&title=Cytochrome+P450+3A4-mediated+bioactivation+of+raloxifene%3A+Irreversible+enzyme+inhibition+and+thiol+adduct+formation&doi=10.1021%2Ftx0200109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation</span></div><div class="casAuthors">Chen, Qing; Ngui, Jason S.; Doss, George A.; Wang, Regina W.; Cai, Xiaoxin; DiNinno, Frank P.; Blizzard, Timothy A.; Hammond, Milton L.; Stearns, Ralph A.; Evans, David C.; Baillie, Thomas A.; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-914</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene is a selective estrogen receptor modulator which is effective in the treatment of osteoporosis in postmenopausal women.  We report herein that cytochrome P 450 3A4 is inhibited by raloxifene in human liver microsomal incubations.  The nature of the inhibition was irreversible and was NADPH- and preincubation time-dependent, with KI and kinact values estd. at 9.9 μM and 0.16 min-1, resp.  The obsd. loss of P 450 3A4 activity was attenuated partially by glutathione (GSH), implying the involvement of a reactive metabolite(s) in the inactivation process.  Subsequently, GSH adducts of raloxifene were identified in incubations with human liver microsomes; substitution with GSH occurred at the 5- or 7-position of the benzothiophene moiety or at the 3'-position of the phenol ring, with the 7-glutathionyl deriv. being most abundant based on LC/MS and NMR analyses.  These adducts are postulated to derive from addn. of GSH to raloxifene arene oxides followed by dehydration and aromatization.  Alternatively, raloxifene may be oxidized to an extended quinone intermediate, which then is trapped by GSH conjugation.  The bioactivation of raloxifene most likely is catalyzed by P 450 3A4, since the formation of GSH adducts was almost abolished when liver microsomes were pretreated with ketoconazole or with an inhibitory anti-P 450 3A4 IgG.  The GSH adducts also were detected in incubations of raloxifene with rat or human hepatocytes, while the corresponding N-acetylcysteine adducts were identified in the bile and urine from rats treated orally with the drug at 5 mg/kg.  Taken together, these data indicate that P 450 3A4-mediated bioactivation of raloxifene in vitro is accompanied by loss of enzyme activity.  The significance of these findings with respect to the clin. use of raloxifene remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvQ7INUtJwIbVg90H21EOLACvtfcHk0lhLSR0WCvb_yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D&md5=cec21bf3d8ce150474291a5e48206744</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Ftx0200109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0200109%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNgui%26aufirst%3DJ.%2BS.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDiNinno%26aufirst%3DF.%2BP.%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26aulast%3DHammond%26aufirst%3DM.%2BL.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DCytochrome%2520P450%25203A4-mediated%2520bioactivation%2520of%2520raloxifene%253A%2520Irreversible%2520enzyme%2520inhibition%2520and%2520thiol%2520adduct%2520formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D907%26epage%3D914%26doi%3D10.1021%2Ftx0200109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2260</span>– <span class="NLM_lpage">2271</span>, <span class="refDoi"> DOI: 10.1021/tx800323w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800323w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=2260-2271&author=D.+Dalvieauthor=P.+Kangauthor=M.+Zientekauthor=C.+Xiangauthor=S.+Zhouauthor=R.+S.+Obach&title=Effect+of+intestinal+glucuronidation+in+limiting+hepatic+exposure+and+bioactivation+of+raloxifene+in+humans+and+rats&doi=10.1021%2Ftx800323w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Intestinal Glucuronidation in Limiting Hepatic Exposure and Bioactivation of Raloxifene in Humans and Rats</span></div><div class="casAuthors">Dalvie, Deepak; Kang, Ping; Zientek, Michael; Xiang, Cathie; Zhou, Sue; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2260-2271</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene (Evista) is a second generation selective estrogen receptor modulator used in the treatment of osteoporosis and for chemoprevention of breast cancer.  It is bioactivated to reactive intermediates, which covalently bind to proteins and form GSH conjugates upon incubation with NADPH and GSH-supplemented human and rat liver microsomes.  Despite these in vitro findings, no major raloxifene-related toxic events have been reported upon its oral administration to humans.  This disconnect between safety of raloxifene and its in vitro bioactivation is attributed to its presystemic metab. via glucuronidation.  Current studies investigated the effect of hepatic and intestinal glucuronidation in modulating hepatic availability of raloxifene and its subsequent bioactivation, in vitro.  The study design involved preincubation of raloxifene with intestinal microsomes followed by a sequential incubation with liver microsomes.  The degree of bioactivation of raloxifene was assessed from the percentage of GSH conjugate formed in liver microsomal incubations or the amt. of covalent binding of raloxifene-related material to liver microsomal proteins.  The results indicated that human intestinal glucuronidation limited the hepatic exposure of raloxifene that underwent bioactivation in the liver.  Similar expts. with rat microsomal prepns. showed very little effect of intestinal glucuronidation.  This effect of intestinal glucuronidation and the obsd. species difference were explained by comparing the efficiency (Clint) of glucuronidation and oxidn. in the two species.  These findings suggested that even though the rate of bioactivation in the two species was similar, the Clint of glucuronidation was 7.5-fold higher in the human intestine as compared to rats.  These results support the hypothesis that intestinal glucuronidation modulates the amt. of raloxifene undergoing bioactivation by liver and corroborate the importance of assessing other competitive metabolic pathways and species differences in metab. prior to extrapolation of bioactivation results from rats to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-CeHG1UEOrVg90H21EOLACvtfcHk0lji_2gnl9S_Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O&md5=69f878c5dd77d57379745df37cf9121b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Ftx800323w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800323w%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DP.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DEffect%2520of%2520intestinal%2520glucuronidation%2520in%2520limiting%2520hepatic%2520exposure%2520and%2520bioactivation%2520of%2520raloxifene%2520in%2520humans%2520and%2520rats%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D2260%26epage%3D2271%26doi%3D10.1021%2Ftx800323w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizuma, T.</span></span> <span> </span><span class="NLM_article-title">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2009.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.ijpharm.2009.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19486934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2009&pages=140-141&author=T.+Mizuma&title=Intestinal+glucuronidation+metabolism+may+have+a+greater+impact+on+oral+bioavailability+than+hepatic+glucuronidation+metabolism+in+humans%3A+a+study+with+raloxifene%2C+substrate+for+UGT1A1%2C+1A8%2C+1A9%2C+and+1A10&doi=10.1016%2Fj.ijpharm.2009.05.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span></div><div class="casAuthors">Mizuma, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">140-141</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kinetic impact of intestinal glucuronidation metab. on oral bioavailability (F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%.  Kinetic anal. showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, resp.  Thus, Fpg was the lowest among factors, which affect oral bioavailability.  In addn., Fpg was much lower than Fh, suggesting that intestinal glucuronidation metab. has a greater impact on oral bioavailability than hepatic glucuronidation metab.  It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine.  Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metab., causing low oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFWR7hNsC17rVg90H21EOLACvtfcHk0lji_2gnl9S_Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D&md5=293c4c269d54a0e92e32c9aa473d50d6</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2009.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2009.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DMizuma%26aufirst%3DT.%26atitle%3DIntestinal%2520glucuronidation%2520metabolism%2520may%2520have%2520a%2520greater%2520impact%2520on%2520oral%2520bioavailability%2520than%2520hepatic%2520glucuronidation%2520metabolism%2520in%2520humans%253A%2520a%2520study%2520with%2520raloxifene%252C%2520substrate%2520for%2520UGT1A1%252C%25201A8%252C%25201A9%252C%2520and%25201A10%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2009%26volume%3D378%26spage%3D140%26epage%3D141%26doi%3D10.1016%2Fj.ijpharm.2009.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandange, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindblom, L.</span></span> <span> </span><span class="NLM_article-title">The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine delta 1’(5′) iminium ion</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(79)91977-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-291X%2879%2991977-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=43154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaL3c7gvFaksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1979&pages=991-996&author=S.+Brandangeauthor=L.+Lindblom&title=The+enzyme+%E2%80%9Caldehyde+oxidase%E2%80%9D+is+an+iminium+oxidase.+Reaction+with+nicotine+delta+1%E2%80%99%285%E2%80%B2%29+iminium+ion&doi=10.1016%2F0006-291X%2879%2991977-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion</span></div><div class="casAuthors">Brandange S; Lindblom L</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and biophysical research communications</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">991-6</span>
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgDHlrG449Po3yKPtYViAGfW6udTcc2ebawVLI052tbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3c7gvFaksQ%253D%253D&md5=88623b9f4b28ae7f18248837cd70e193</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2879%2991977-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252879%252991977-6%26sid%3Dliteratum%253Aachs%26aulast%3DBrandange%26aufirst%3DS.%26aulast%3DLindblom%26aufirst%3DL.%26atitle%3DThe%2520enzyme%2520%25E2%2580%259Caldehyde%2520oxidase%25E2%2580%259D%2520is%2520an%2520iminium%2520oxidase.%2520Reaction%2520with%2520nicotine%2520delta%25201%25E2%2580%2599%25285%25E2%2580%25B2%2529%2520iminium%2520ion%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1979%26volume%3D91%26spage%3D991%26epage%3D996%26doi%3D10.1016%2F0006-291X%2879%2991977-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hukkanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, P.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benowitz, N. L.</span></span> <span> </span><span class="NLM_article-title">Metabolism and disposition kinetics of nicotine</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1124/pr.57.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fpr.57.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15734728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=79-115&author=J.+Hukkanenauthor=P.+Jacobauthor=N.+L.+Benowitz&title=Metabolism+and+disposition+kinetics+of+nicotine&doi=10.1124%2Fpr.57.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and disposition kinetics of nicotine</span></div><div class="casAuthors">Hukkanen, Janne; Jacob, Peyton, III; Benowitz, Neal L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-115</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Nicotine is of importance as the addictive chem. in tobacco, pharmacotherapy for smoking cessation, a potential medication for several diseases, and a useful probe drug for phenotyping cytochrome P 450 2A6 (CYP2A6).  We review current knowledge about the metab. and disposition kinetics of nicotine, some other naturally occurring tobacco alkaloids, and nicotine analogs that are under development as potential therapeutic agents.  The focus is on studies in humans, but animal data are mentioned when relevant to the interpretation of human data.  The pathways of nicotine metab. are described in detail.  Absorption, distribution, metab., and excretion of nicotine and related compds. are reviewed.  Enzymes involved in nicotine metab. including cytochrome P 450 enzymes, aldehyde oxidase, flavin-contg. monooxygenase 3, amine N-methyltransferase, and UDP-glucuronosyltransferases are represented, as well as factors affecting metab., such as genetic variations in metabolic enzymes, effects of diet, age, gender, pregnancy, liver and kidney diseases, and racial and ethnic differences.  Also effects of smoking and various inhibitors and inducers, including oral contraceptives, on nicotine metab. are discussed.  Due to the significance of the CYP2A6 enzyme in nicotine clearance, special emphasis is given to the effects and population distributions of CYP2A6 alleles and the regulation of CYP2A6 enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdiaRmgTT3LrVg90H21EOLACvtfcHk0lji_2gnl9S_Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtro%253D&md5=258913d632a8f4de861b7bbe2650c0e5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DHukkanen%26aufirst%3DJ.%26aulast%3DJacob%26aufirst%3DP.%26aulast%3DBenowitz%26aufirst%3DN.%2BL.%26atitle%3DMetabolism%2520and%2520disposition%2520kinetics%2520of%2520nicotine%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D79%26epage%3D115%26doi%3D10.1124%2Fpr.57.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshihara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP<sup>+</sup>) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1006/abbi.1998.0925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1006%2Fabbi.1998.0925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9826433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=1998&pages=93-98&author=S.+Yoshiharaauthor=S.+Ohta&title=Involvement+of+hepatic+aldehyde+oxidase+in+conversion+of+1-methyl-4-phenyl-2%2C3-dihydropyridinium+%28MPDP%2B%29+to+1-methyl-4-phenyl-5%2C6-dihydro-2-pyridone&doi=10.1006%2Fabbi.1998.0925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone</span></div><div class="casAuthors">Yoshihara, Shin'ichi; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">To obtain direct evidence of the involvement of aldehyde oxidase (AO), a cytosolic molybdoflavoenzyme, in the metab. of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the authors investigated the in vitro metab. of MPTP and the two-electron-oxidized 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+) by using mouse liver enzyme prepns.  Incubation of MPTP with mitochondrial fraction gave exclusively 1-methyl-4-phenylpyridinium (MPP+); this reaction was inhibited by deprenyl, a monoamine oxidase (MAO)-B inhibitor, and KCN.  When the mitochondrial fraction was combined with the cytosolic fraction, MPP+ formation was markedly decreased, while a large amt. of 1-methyl-4-phenyl-5,6-dihydro-2-pyridone (MPTP lactam) was newly formed.  Incubation of MPDP+ with the cytosolic fraction led to rapid formation of MPTP lactam with concomitant disappearance of the substrate.  The cytosol-dependent formation of MPTP lactam was inhibited by known AO inhibitors, such as menadione, norharman, and KCN.  The activity of cytosol in MPTP lactam formation was completely duplicated by purified mouse liver AO.  These results indicate that AO catalyzes the metabolic conversion of MPDP+, produced from MPTP by MAO-B, to MPTP lactam.  This metabolic pathway might be an important detoxification route, averting the formation of toxic MPP+.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yYA8zidMqbVg90H21EOLACvtfcHk0lhBkehEEIHkGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOku7o%253D&md5=6bcbee0b2e811b35b803021accda0f86</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1998.0925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1998.0925%26sid%3Dliteratum%253Aachs%26aulast%3DYoshihara%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DInvolvement%2520of%2520hepatic%2520aldehyde%2520oxidase%2520in%2520conversion%2520of%25201-methyl-4-phenyl-2%252C3-dihydropyridinium%2520%2528MPDP%252B%2529%2520to%25201-methyl-4-phenyl-5%252C6-dihydro-2-pyridone%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1998%26volume%3D360%26spage%3D93%26epage%3D98%26doi%3D10.1006%2Fabbi.1998.0925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldera-Munoz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1021/tx00003a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx00003a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL1cXktFygurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=186-194&author=E.+Wuauthor=T.+Shinkaauthor=P.+Caldera-Munozauthor=H.+Yoshizumiauthor=A.+Trevorauthor=N.+Castagnoli&title=Metabolic+studies+on+the+nigrostriatal+toxin+MPTP+and+its+MAO+B+generated+dihydropyridinium+metabolite+MPDP%2B&doi=10.1021%2Ftx00003a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+</span></div><div class="casAuthors">Wu, Ellen; Shinka, Toshihiro; Caldera-Munoz, Patricia; Yoshizumi, Hideo; Trevor, Anthony; Castagnoli, Neal, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-94</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    </div><div class="casAbstract">Incubations of MPTP (50 μM and 1 mM) with mouse brain prepns. result in the expected MAO B catalyzed formation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+).  The 4-electron oxidn. product, the 1-methyl-4-phenylpyridinium species (MPP+), was the only other metabolite detected.  The oxidn. of 50 μM MPDP+ to MPP+ in the same prepns. appears to be mediated by unidentified components present in membrane contg. structures.  The behavior of MPTP in mouse liver subcellular fractions is considerably more complex.  NADPH-supplemented liver microsomes convert MPTP to the demethyl and N-oxide metabolites.  At high (1 mM) initial concns. of MPTP, there is evidence that NADPH-dependent, pargyline-insensitive liver microsomal enzymes also catalyze the oxidn. of MPTP to MPDP+.  Incubations of MPDP+ with mouse liver prepns. contg. the cytosolic fraction led to the rapid disappearance of the substrate and the quant. formation of a metabolic product with mass spectral and diode array UV characteristics expected for a lactam structure.  Menadione, an inhibitor of the cytosolic enzyme aldehyde oxidase, inhibits the formation of this product.  Unambiguous characterization of this product as 1-methyl-4-phenyl-5,6-dihydro-2-pyridone (I) was achieved by comparison of its high-resoln. 1H NMR and high-resoln. EI mass spectra with the corresponding spectra of a synthetic std.  I is oxidized in a reaction catalyzed by an NADPH-dependent microsomal enzyme system to the corresponding 1-methyl-4-phenyl-2-pyridone.  These tissue-selective metabolic events may regulate the neurotoxicity of MPTP in the mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWIlJRkvlbQLVg90H21EOLACvtfcHk0lhBkehEEIHkGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFygurw%253D&md5=41f65bf0d25cdc7a07041dc4bdb6c863</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Ftx00003a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00003a010%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DE.%26aulast%3DShinka%26aufirst%3DT.%26aulast%3DCaldera-Munoz%26aufirst%3DP.%26aulast%3DYoshizumi%26aufirst%3DH.%26aulast%3DTrevor%26aufirst%3DA.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DMetabolic%2520studies%2520on%2520the%2520nigrostriatal%2520toxin%2520MPTP%2520and%2520its%2520MAO%2520B%2520generated%2520dihydropyridinium%2520metabolite%2520MPDP%252B%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1988%26volume%3D1%26spage%3D186%26epage%3D194%26doi%3D10.1021%2Ftx00003a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosogi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, T.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.dmpk.2017.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.dmpk.2017.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28751116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=255-264&author=J.+Hosogiauthor=R.+Ohashiauthor=H.+Maedaauthor=S.+Tashiroauthor=E.+Fuseauthor=Y.+Yamamotoauthor=T.+Kuwabara&title=Monoamine+oxidase+B+oxidizes+a+novel+multikinase+inhibitor+KW-2449+to+its+iminium+ion+and+aldehyde+oxidase+further+converts+it+to+the+oxo-piperazine+form+in+human&doi=10.1016%2Fj.dmpk.2017.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human</span></div><div class="casAuthors">Hosogi, Jun; Ohashi, Rui; Maeda, Hiroshi; Tashiro, Satoshi; Fuse, Eiichi; Yamamoto, Yorihiro; Kuwabara, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">255-264</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine (KW-2449) is a novel multikinase inhibitor.  During our clin. study, we found that KW-2449 is mainly metabolized to its oxo-piperazine form (M1).  An inhibition study suggested that monoamine oxidase-B (MAO-B) oxidizes KW-2449 to an iminium (intermediate) and aldehyde oxidase (AO) then metabolizes the intermediate to M1.  The conversion of KW-2449 to the iminium (intermediate) by MAO-B was confirmed by the formation of its cyanide adduct.  This cooperative metabolic pathway by MAO-B and AO was newly identified in the metab. of piperazine.  The clearance of KW-2449 by MAO-B and AO in human was estd. based on the kinetic anal. with in vitro-in vivo extrapolation.  The systemic clearance in human was similar to the calcd. value, indicating that the extrapolation approach was applicable to KW-2449 metab.  Finally, we found that (E)-3-amino-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}-pyrrolidine (Compd. A) as a stable compd. against MAO-B and AO.  The total body clearance of Compd. A was reduced to one tenth of KW-2449, demonstrating that preventing the metab. of MAO and AO led to more preferable pharmacokinetic profiles.  As piperazine is often introduced to drug candidates to improve lipophilicity of the compd. to get more hydrophilic nature, the results of this study provide useful information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2fKwc369Ix7Vg90H21EOLACvtfcHk0lhBkehEEIHkGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7nO&md5=1846c419191a12469d1be35860c67cf9</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.dmpk.2017.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dmpk.2017.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DHosogi%26aufirst%3DJ.%26aulast%3DOhashi%26aufirst%3DR.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DTashiro%26aufirst%3DS.%26aulast%3DFuse%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuwabara%26aufirst%3DT.%26atitle%3DMonoamine%2520oxidase%2520B%2520oxidizes%2520a%2520novel%2520multikinase%2520inhibitor%2520KW-2449%2520to%2520its%2520iminium%2520ion%2520and%2520aldehyde%2520oxidase%2520further%2520converts%2520it%2520to%2520the%2520oxo-piperazine%2520form%2520in%2520human%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2017%26volume%3D32%26spage%3D255%26epage%3D264%26doi%3D10.1016%2Fj.dmpk.2017.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warr, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorehead, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemenway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.078899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.117.078899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29311136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsV2ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=237-247&author=J.+Zhengauthor=Y.+Xinauthor=J.+Zhangauthor=R.+Subramanianauthor=B.+P.+Murrayauthor=J.+A.+Whitneyauthor=M.+R.+Warrauthor=J.+Lingauthor=L.+Mooreheadauthor=E.+Kwanauthor=J.+Hemenwayauthor=B.+J.+Smithauthor=J.+A.+Silverman&title=Pharmacokinetics+and+disposition+of+momelotinib+revealed+a+disproportionate+human+metabolite-resolution+for+clinical+development&doi=10.1124%2Fdmd.117.078899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development</span></div><div class="casAuthors">Zheng, Jim; Xin, Yan; Zhang, Jingyu; Subramanian, Raju; Murray, Bernard P.; Whitney, J. Andrew; Warr, Matthew R.; Ling, John; Moorehead, Lisa; Kwan, Ellen; Hemenway, Jeffrey; Smith, Bill J.; Silverman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-247,S1-S28</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Momelotinib (MMB), a small-mol. inhibitor of Janus kinase (JAK)1/2 and of activin A receptor type 1 (ACVR1), is in clin. development for the treatment of myeloproliferative neoplasms.  The pharmacokinetics and disposition of [14C]MMB were characterized in a single-dose, human mass-balance study.  Metab. and the pharmacol. activity of key metabolites were elucidated in multiple in vitro and in vivo expts.  MMB was rapidly absorbed following oral dosing with approx. 97% of the radioactivity recovered, primarily in feces with urine as a secondary route.  Mean blood-to-plasma [14C] area under the plasma concn.-time curve ratio was 0.72, suggesting low assocn. of MMB and metabolites with blood cells. [14C]MMB-derived radioactivity was detectable in blood for ≤48 h, suggesting no irreversible binding of MMB or its metabolites.  The major circulating human metabolite, M21 (a morpholino lactam), is a potent inhibitor of JAK1/2 and ACVR1 in vitro.  Estn. of pharmacol. activity index suggests M21 contributes significantly to the pharmacol. activity of MMB for the inhibition of both JAK1/2 and ACVR1.  M21 was obsd. in disproportionately higher amts. in human plasma than in rat or dog, the rodent and nonrodent species used for the general nonclin. safety assessment of this mol.  This discrepancy was resolved with addnl. nonclin. studies wherein the circulating metabolites and drug-drug interactions were further characterized.  The human metab. of MMB was mediated primarily by multiple cytochrome P 450 enzymes, whereas M21 formation involved initial P 450 oxidn. of the morpholine ring followed by metab. via aldehyde oxidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGdMwZyk81C7Vg90H21EOLACvtfcHk0ljTTgqG5H_skA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsV2ktb8%253D&md5=cf73dce851338a404b11a90fe2287ca4</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.078899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.078899%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BP.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DWarr%26aufirst%3DM.%2BR.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DMoorehead%26aufirst%3DL.%26aulast%3DKwan%26aufirst%3DE.%26aulast%3DHemenway%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DSilverman%26aufirst%3DJ.%2BA.%26atitle%3DPharmacokinetics%2520and%2520disposition%2520of%2520momelotinib%2520revealed%2520a%2520disproportionate%2520human%2520metabolite-resolution%2520for%2520clinical%2520development%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D237%26epage%3D247%26doi%3D10.1124%2Fdmd.117.078899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrard, A. R.</span></span> <span> </span><span class="NLM_article-title">A review of acetaminophen poisoning</span>. <i>Crit. Care Clin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1016/j.ccc.2012.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.ccc.2012.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=22998987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BC38bptVagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=499-516&author=M.+J.+Hodgmanauthor=A.+R.+Garrard&title=A+review+of+acetaminophen+poisoning&doi=10.1016%2Fj.ccc.2012.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">A review of acetaminophen poisoning</span></div><div class="casAuthors">Hodgman Michael J; Garrard Alexander R</div><div class="citationInfo"><span class="NLM_cas:title">Critical care clinics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-516</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acetaminophen poisoning remains one of the more common drugs taken in overdose with potentially fatal consequences.  Early recognition and prompt treatment with N-acetylcysteine can prevent hepatic injury.  With acute overdose, the Rumack-Matthew nomogram is a useful tool to assess risk and guide management.  Equally common to acute overdose is the repeated use of excessive amounts of acetaminophen.  Simultaneous ingestion of several different acetaminophen-containing products may result in excessive dosage.  These patients also benefit from N-acetylcysteine.  Standard courses of N-acetylcysteine may need to be extended in patients with persistently elevated plasma concentrations of acetaminophen or with signs of hepatic injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1gfhcYlWFTcULxIEhxUjPfW6udTcc2eYzx3ZjbcE7RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bptVagtA%253D%253D&md5=1baec0bc1993e99e05adec23e4624668</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ccc.2012.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccc.2012.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DHodgman%26aufirst%3DM.%2BJ.%26aulast%3DGarrard%26aufirst%3DA.%2BR.%26atitle%3DA%2520review%2520of%2520acetaminophen%2520poisoning%26jtitle%3DCrit.%2520Care%2520Clin.%26date%3D2012%26volume%3D28%26spage%3D499%26epage%3D516%26doi%3D10.1016%2Fj.ccc.2012.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, L. E.</span></span> <span> </span><span class="NLM_article-title">The lupus syndrome induced by hydralazine: a common complication with low dose treatment</span>. <i>Br. Med. J. (Clin. Res. Ed.)</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1136/bmj.289.6442.410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1136%2Fbmj.289.6442.410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6432120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaL2c3otFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=1984&pages=410-412&author=H.+A.+Cameronauthor=L.+E.+Ramsay&title=The+lupus+syndrome+induced+by+hydralazine%3A+a+common+complication+with+low+dose+treatment&doi=10.1136%2Fbmj.289.6442.410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The lupus syndrome induced by hydralazine: a common complication with low dose treatment</span></div><div class="casAuthors">Cameron H A; Ramsay L E</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal (Clinical research ed.)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">6442</span>),
    <span class="NLM_cas:pages">410-2</span>
        ISSN:<span class="NLM_cas:issn">0267-0623</span>.
    </div><div class="casAbstract">The true incidence of the lupus syndrome induced by hydralazine was determined in a longitudinal study of 281 patients consecutively starting hydralazine for hypertension over a 51 month period.  Data on the duration of treatment and the maximum dose achieved were examined using life table analysis.  After three years' treatment with hydralazine the incidence of the lupus syndrome was 6.7% (95% confidence limits 3.2-10.2%).  The incidence was dose dependent, with no cases recorded in patients taking 50 mg daily and incidences of 5.4% with 100 mg daily and of 10.4% with 200 mg daily.  The incidence was higher in women (11.6%) than in men (2.8%).  In women taking 200 mg daily the three year incidence was 19.4%.  Hydralazine is an effective antihypertensive drug that has come to be used in restricted dosage (not more than 200 mg daily) because of its risk of inducing the lupus syndrome.  This study shows that the true incidence of the syndrome is still unacceptably high even when the drug is prescribed according to current recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1JKWk4ySoRj0O18WR3iAofW6udTcc2eYzx3ZjbcE7RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c3otFKjsg%253D%253D&md5=5d43bad58f0e2157e2503a7536b011f5</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1136%2Fbmj.289.6442.410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.289.6442.410%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DH.%2BA.%26aulast%3DRamsay%26aufirst%3DL.%2BE.%26atitle%3DThe%2520lupus%2520syndrome%2520induced%2520by%2520hydralazine%253A%2520a%2520common%2520complication%2520with%2520low%2520dose%2520treatment%26jtitle%3DBr.%2520Med.%2520J.%2520%2528Clin.%2520Res.%2520Ed.%2529%26date%3D1984%26volume%3D289%26spage%3D410%26epage%3D412%26doi%3D10.1136%2Fbmj.289.6442.410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letteron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descatoire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amouyal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessayre, D.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of the tricyclic antidepressant amineptine – II Protective role of glutathione against in vitro and in vivo covalent binding</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(87)90290-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-2952%2887%2990290-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3814175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL2sXhvVygu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1987&pages=331-337&author=J.+Gen%C3%A8veauthor=C.+Degottauthor=P.+Letteronauthor=M.+Tinelauthor=V.+Descatoireauthor=D.+Larreyauthor=G.+Amouyalauthor=D.+Pessayre&title=Metabolic+activation+of+the+tricyclic+antidepressant+amineptine+%E2%80%93+II+Protective+role+of+glutathione+against+in+vitro+and+in+vivo+covalent+binding&doi=10.1016%2F0006-2952%2887%2990290-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of the tricyclic antidepressant amineptine.  II.  Protective role of glutathione against in vitro and in vivo covalent binding</span></div><div class="casAuthors">Geneve, Jean; Degott, Claude; Letteron, Philippe; Tinel, Marina; Descatoire, Veronique; Larrey, Dominique; Amouyal, Gilles; Pessayre, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-7</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Incubation of [11-14C]-labeled amineptine  [57574-09-1] (1mM) with an NADPH-generating system and hamster liver microsomes resulted in the in vitro covalent binding of an amineptine metabolite to microsomal proteins; this binding was decreased by 41-71% in the presence of cysteine  [52-90-4], lysine  [56-87-1], glycine  [56-40-6], or glutathione  [70-18-8] (0.5 mM).  An inverse relationship was found between the concn. of glutathione in the incubation mixt. (0.25-4mM) and the extent of covalent binding in vitro, which became undetectable at concns. of glutathione of 2 mM and higher.  Administration of [11-14C]amineptine (300 mg/kg-1 i.p.) to hamsters pretreated with phorone resulted in the in vivo covalent binding of an amineptine metabolite to hepatic proteins.  This binding was increased by phenobarbital-pretreatment and decreased by piperonyl butoxide-pretreatment.  After various doses of phorone (150-500 mg/kg), an inverse relationship was found between hepatic glutathione content and in vivo covalent binding.  Administration of amineptine along (300 mg/kg i.p.) depleted hepatic glutathione by 16% only; in these animals, in vivo covalent binding was undetectable from background.  Amineptine (300 mg/kg i.p.) did not produce hepatic necrosis, even in hamsters pretreated with phorone and/or phenobarbital.  The authors concluded that physiol. concns. of glutathione essentially prevent the in vivo covalent binding of an amineptine metabolite to hepatic proteins, and that this binding does not produce liver cell necrosis in hamsters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroERkwk0ElGLVg90H21EOLACvtfcHk0ljpnMB7_x76WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvVygu7k%253D&md5=2cd2727508018108903f9392f067768d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2887%2990290-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252887%252990290-5%26sid%3Dliteratum%253Aachs%26aulast%3DGen%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DDegott%26aufirst%3DC.%26aulast%3DLetteron%26aufirst%3DP.%26aulast%3DTinel%26aufirst%3DM.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DAmouyal%26aufirst%3DG.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DMetabolic%2520activation%2520of%2520the%2520tricyclic%2520antidepressant%2520amineptine%2520%25E2%2580%2593%2520II%2520Protective%2520role%2520of%2520glutathione%2520against%2520in%2520vitro%2520and%2520in%2520vivo%2520covalent%2520binding%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1987%26volume%3D36%26spage%3D331%26epage%3D337%26doi%3D10.1016%2F0006-2952%2887%2990290-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farid, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrighton, S. A.</span></span> <span> </span><span class="NLM_article-title">Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1177/0091270009343005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1177%2F0091270009343005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19948947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1SksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=126-142&author=N.+A.+Faridauthor=A.+Kuriharaauthor=S.+A.+Wrighton&title=Metabolism+and+disposition+of+the+thienopyridine+antiplatelet+drugs+ticlopidine%2C+clopidogrel%2C+and+prasugrel+in+humans&doi=10.1177%2F0091270009343005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans</span></div><div class="casAuthors">Farid, Nagy A.; Kurihara, Atsushi; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-142</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine-5'-diphosphate (ADP)-mediated platelet aggregation in vivo.  These compds. are converted to thiol-contg. active metabolites through a corresponding thiolactone.  The 3 compds. differ in their metabolic pathways to their active metabolites in humans.  Whereas ticlopidine and clopidogrel are metabolized to their thiolactones in the liver by cytochromes P 450, prasugrel proceeds to its thiolactone following hydrolysis by carboxylesterase 2 during absorption, and a portion of prasugrel's active metabolite is also formed by intestinal CYP3A.  Both ticlopidine and clopidogrel are subject to major competing metabolic pathways to inactive metabolites.  Thus, varying efficiencies in the formation of active metabolites affect obsd. effects on the onset of action and extent of inhibition of platelet aggregation (IPA).  Knowledge of the CYP-dependent formation of ticlopidine and clopidogrel thiolactones helps explain some of the obsd. drug-drug interactions with these mols. and, more important, the role of CYP2C19 genetic polymorphism on the pharmacokinetics of and pharmacodynamic response to clopidogrel.  The lack of drug interaction potential and the absence of CYP2C19 genetic effect result in a predictable response to thienopyridine antiplatelet therapy with prasugrel.  Current literature shows that greater ADP-mediated IPA is assocd. with significantly better clin. outcomes for patients with acute coronary syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6HQhdL8JHLVg90H21EOLACvtfcHk0ljpnMB7_x76WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1SksLo%253D&md5=e9d059885285d3f2bd1fdeb4d2b5a0a0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1177%2F0091270009343005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009343005%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DMetabolism%2520and%2520disposition%2520of%2520the%2520thienopyridine%2520antiplatelet%2520drugs%2520ticlopidine%252C%2520clopidogrel%252C%2520and%2520prasugrel%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D50%26spage%3D126%26epage%3D142%26doi%3D10.1177%2F0091270009343005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-2009&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+between+daily+dose+of+oral+medications+and+idiosyncratic+drug-induced+liver+injury%3A+search+for+signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0ljpnMB7_x76WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520between%2520daily%2520dose%2520of%2520oral%2520medications%2520and%2520idiosyncratic%2520drug-induced%2520liver%2520injury%253A%2520search%2520for%2520signals%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26spage%3D2003%26epage%3D2009%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1002/hep.23317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.23317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19839004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=615-620&author=C.+Lammertauthor=E.+Bjornssonauthor=A.+Niklassonauthor=N.+Chalasani&title=Oral+medications+with+significant+hepatic+metabolism+at+higher+risk+for+hepatic+adverse+events&doi=10.1002%2Fhep.23317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events</span></div><div class="casAuthors">Lammert, Craig; Bjornsson, Einar; Niklasson, Anna; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">615-620</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Reactive metabolites generated by hepatic metab. are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited.  If this is true, then compds. with significant hepatic metab. should cause more DILI than those without it.  We conducted a study to examine the relationship between hepatic metab. and DILI of prescription medications.  We systematically extd. the metab. characteristics of 207 of the most widely prescribed oral medications in the United States.  Compds. with >50% hepatic metab. were characterized as those with significant hepatic metab. (n = 149).  Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI.  Compared with compds. with lesser hepatic metab., compds. belonging to the significant hepatic metab. group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% vs. 11%, P = 0.001), liver failure (28% vs. 9%, P = 0.004), and fatal DILI (23% vs. 4%, P = 0.001), but not jaundice (46% vs. 35%, P = 0.2) or liver transplantation (9% vs. 2%, P = 0.11).  Twelve compds. with no hepatic metab. had no reports of liver failure, liver transplantation, or fatal DILI.  When the relationship between hepatic adverse events and combination of hepatic metab. and daily dose was examd., compds. with both significant hepatic metab. and daily dose >50 mg (n = 50) were significantly more hepatotoxic than compds. belonging to other groups.  Compared with medications without biliary excretion, compds. with biliary excretion (n = 50) had significantly higher frequency of jaundice (74% vs. 40%, P = 0.0001).  Conclusion: Our study finds an important relationship between a compd.'s metab. profile and reports of hepatic adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG7fKH0KK8ObVg90H21EOLACvtfcHk0ljnhprug9kEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D&md5=ba90a857ce677fddb63ac6f3136c6b3b</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fhep.23317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23317%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DOral%2520medications%2520with%2520significant%2520hepatic%2520metabolism%2520at%2520higher%2520risk%2520for%2520hepatic%2520adverse%2520events%26jtitle%3DHepatology%26date%3D2010%26volume%3D51%26spage%3D615%26epage%3D620%26doi%3D10.1002%2Fhep.23317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.056267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.113.056267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24464804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=744-750&author=K.+Yuauthor=X.+Gengauthor=M.+Chenauthor=J.+Zhangauthor=B.+Wangauthor=K.+Ilicauthor=W.+Tong&title=High+daily+dose+and+being+a+substrate+of+cytochrome+P450+enzymes+are+two+important+predictors+of+drug-induced+liver+injury&doi=10.1124%2Fdmd.113.056267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury</span></div><div class="casAuthors">Yu, Ke; Geng, Xingchao; Chen, Minjun; Zhang, Jie; Wang, Bingshun; Ilic, Katarina; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">744-750, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is complicated and difficult to predict.  It has been obsd. that drugs with extensive hepatic metab. have a higher likelihood of causing DILI.  Cytochrome P 450 (P 450) enzymes are primarily involved in hepatic metab.  Identifying the assocns. of DILI with drugs that are P 450 substrates, inhibitors, or inducers will be extremely helpful to clinicians during the decision-making process of caring for a patient suspected of having DILI.  We collected metab. data on P 450 enzymes for 254 orally administered drugs in the Liver Toxicity Knowledge Base Benchmark Dataset with a known daily dose, and applied logistic regression to identify these assocns.  We revealed that drugs that are substrates of P 450 enzymes have a higher likelihood of causing DILI [odds ratio (OR), 3.99; 95% confidence interval (95% CI), 2.07-7.67; P < 0.0001], which is dose-independent, and drugs that are P 450 inhibitors have a higher likelihood of generating DILI only when they are administered at high daily doses (OR, 6.03; 95% CI, 1.32-27.5; P = 0.0098).  However, drugs that are P 450 inducers are not obsd. to be assocd. with DILI (OR, 1.55; 95% CI, 0.65-3.68; P = 0.3246).  Our findings will be useful in identifying the suspected medication as a cause of liver injury in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZV-WvbMYx7Vg90H21EOLACvtfcHk0ljnhprug9kEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D&md5=167814960cb745e13e343242709bb585</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.056267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.056267%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DIlic%26aufirst%3DK.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520daily%2520dose%2520and%2520being%2520a%2520substrate%2520of%2520cytochrome%2520P450%2520enzymes%2520are%2520two%2520important%2520predictors%2520of%2520drug-induced%2520liver%2520injury%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D744%26epage%3D750%26doi%3D10.1124%2Fdmd.113.056267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+lipophilicity+and+high+daily+dose+of+oral+medications+are+associated+with+significant+risk+for+drug-induced+liver+injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0ljnhprug9kEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520lipophilicity%2520and%2520high%2520daily%2520dose%2520of%2520oral%2520medications%2520are%2520associated%2520with%2520significant%2520risk%2520for%2520drug-induced%2520liver%2520injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEuen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1335</span>, <span class="refDoi"> DOI: 10.3390/ijms18071335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3390%2Fijms18071335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1335&author=K.+McEuenauthor=J.+Borlakauthor=W.+Tongauthor=M.+Chen&title=Associations+of+drug+lipophilicity+and+extent+of+metabolism+with+drug-induced+liver+injury&doi=10.3390%2Fijms18071335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury</span></div><div class="casAuthors">McEuen, Kristin; Borlak, Juergen; Tong, Weida; Chen, Minjun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1335/1-1335/11</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI), although rare, is a frequent cause of adverse drug reactions resulting in warnings and withdrawals of numerous medications.  Despite the research community's best efforts, current testing strategies aimed at identifying hepatotoxic drugs prior to human trials are not sufficiently powered to predict the complex mechanisms leading to DILI.  In our previous studies, we demonstrated lipophilicity and dose to be assocd. with increased DILI risk and, and in our latest work, we factored reactive metabolites into the algorithm to predict DILI.  Given the inconsistency in detg. the potential for drugs to cause DILI, the present study comprehensively assesses the relationship between DILI risk and lipophilicity and the extent of metab. using a large published dataset of 1036 Food and Drug Administration (FDA)-approved drugs by considering five independent DILI annotations.  We found that lipophilicity and the extent of metab. alone were assocd. with increased risk for DILI.  Moreover, when analyzed in combination with high daily dose (≥100 mg), lipophilicity was statistically significantly assocd. with the risk of DILI across all datasets (p < 0.05).  Similarly, the combination of extensive hepatic metab. (≥50%) and high daily dose (≥100 mg) was also strongly assocd. with an increased risk of DILI among all datasets analyzed (p < 0.05).  Our results suggest that both lipophilicity and the extent of hepatic metab. can be considered important risk factors for DILI in humans, and that this relationship to DILI risk is much stronger when considered in combination with dose.  The proposed paradigm allows the convergence of different published annotations to a more uniform assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwDM7bNDDUbVg90H21EOLACvtfcHk0ljnhprug9kEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73K&md5=51022ab2f8fd6e5b50769d4aca66e3b5</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.3390%2Fijms18071335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071335%26sid%3Dliteratum%253Aachs%26aulast%3DMcEuen%26aufirst%3DK.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DAssociations%2520of%2520drug%2520lipophilicity%2520and%2520extent%2520of%2520metabolism%2520with%2520drug-induced%2520liver%2520injury%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1335%26doi%3D10.3390%2Fijms18071335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. L.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of targeted therapy for cancer</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1080/17425255.2016.1190831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F17425255.2016.1190831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=27187715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=789-802&author=K.+W.+Leeauthor=S.+L.+Chan&title=Hepatotoxicity+of+targeted+therapy+for+cancer&doi=10.1080%2F17425255.2016.1190831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of targeted therapy for cancer</span></div><div class="casAuthors">Lee, Kirsty Wai-Chung; Chan, Stephen Lam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">789-802</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Understanding the mechanism of DILI with MTA, and how to avoid and manage these toxicities is essential for minimising inferior cancer treatment outcomes.  An organised and comprehensive overview of MTA-assocd. hepatotoxicity is lacking; this review aims to fill the gap.  A literature review was performed based on published case reports and relevant studies or articles pertaining to the topics on PubMed.  Food and Drug Administration drug information documents and search on the US National Library of Medicine LiverTox database was performed for all relevant MTA.  MTA-assocd. hepatotoxicity is common but rarely fatal.  The pattern of hepatotoxicity is predominantly idiosyncratic.  Pharmacogenomics show potential in predicting patients at risk of poorly metabolising or developing immunoallergic responses to MTA, but prospective data is scant.  Preventing reactivation of viral hepatitis using anti-viral drugs, and avoidance of drug combinations at high risk of neg. interactions are the most readily preventable measures for DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFKLyebm6okbVg90H21EOLACvtfcHk0lgtqrxr1Qx2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wlt7s%253D&md5=03b74420f8845aedd5944f8f6b8c7285</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1080%2F17425255.2016.1190831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425255.2016.1190831%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DChan%26aufirst%3DS.%2BL.%26atitle%3DHepatotoxicity%2520of%2520targeted%2520therapy%2520for%2520cancer%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2016%26volume%3D12%26spage%3D789%26epage%3D802%26doi%3D10.1080%2F17425255.2016.1190831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostrubsky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strom, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atherton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mireles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfj095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfj095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16410371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Ons74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2006&pages=451-459&author=S.+E.+Kostrubskyauthor=S.+C.+Stromauthor=A.+S.+Kalgutkarauthor=S.+Kulkarniauthor=J.+Athertonauthor=R.+Mirelesauthor=B.+Fengauthor=R.+Kubikauthor=J.+Hansonauthor=E.+Urdaauthor=A.+E.+Mutlib&title=Inhibition+of+hepatobiliary+transport+as+a+predictive+method+for+clinical+hepatotoxicity+of+nefazodone&doi=10.1093%2Ftoxsci%2Fkfj095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone</span></div><div class="casAuthors">Kostrubsky, Seva E.; Strom, Stephen C.; Kalgutkar, Amit S.; Kulkarni, Shaila; Atherton, James; Mireles, Rouchelle; Feng, Bo; Kubik, Raylene; Hanson, Janean; Urda, Ellen; Mutlib, Abdul E.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">451-459</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Treatment with the antidepressant nefazodone has been assocd. with clin. idiosyncratic hepatotoxicity.  Using membranes expressing human bile salt export pump (BSEP), human sandwich hepatocytes, and intact rats, we compared nefazodone and its marketed analogs, buspirone and trazodone.  We found that nefazodone caused a strong inhibition of BSEP (IC50 = 9 μM), inhibition of taurocholate efflux in human hepatocytes (IC50 = 14 μM), and a transient increase in rat serum bile acids 1 h after oral drug administration.  Buspirone or trazodone had no effect on biliary transport system.  Nefazodone produced time- and concn.-dependent toxicity in human hepatocytes with IC50 = 18 μM and 30 μM measured by inhibition of protein synthesis after 6 h and 24 h incubation, resp.  Toxicity was correlated with the amt. of unmetabolized nefazodone.  Partial recovery in toxicity by 24 h has been assocd. with metab. of nefazodone to sulfate and glucuronide conjugates.  The satn. of nefazodone metab. resulted in sustained decrease in protein synthesis and cell death at 50 μM.  The toxicity was not obsd. with buspirone or trazodone.  Addn. of 1-aminobenzotriazole (ABT), an inhibitor of CYP450, resulted in enhancement of nefazodone toxicity at 10 μM and was assocd. with accumulation of unmetabolized nefazodone.  In human liver microsomes, ABT also prevented metab. of nefazodone and formation of glutathione conjugates.  We suggest that inhibition of bile acid transport by nefazodone is an indicator of potential hepatotoxicity.  Our findings are consistent with the clin. experience and suggest that described methodol. can be applied in the selection of nonhepatotoxic drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQhW2ho1OL0bVg90H21EOLACvtfcHk0lgtqrxr1Qx2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Ons74%253D&md5=b0ff75c0e1b49344f95ea4f6dec1e697</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfj095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfj095%26sid%3Dliteratum%253Aachs%26aulast%3DKostrubsky%26aufirst%3DS.%2BE.%26aulast%3DStrom%26aufirst%3DS.%2BC.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DMireles%26aufirst%3DR.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DKubik%26aufirst%3DR.%26aulast%3DHanson%26aufirst%3DJ.%26aulast%3DUrda%26aufirst%3DE.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26atitle%3DInhibition%2520of%2520hepatobiliary%2520transport%2520as%2520a%2520predictive%2520method%2520for%2520clinical%2520hepatotoxicity%2520of%2520nefazodone%26jtitle%3DToxicol.%2520Sci.%26date%3D2006%26volume%3D90%26spage%3D451%26epage%3D459%26doi%3D10.1093%2Ftoxsci%2Fkfj095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfn056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfn056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18344530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslyhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=335-345&author=J.+A.+Dykensauthor=J.+D.+Jamiesonauthor=L.+D.+Marroquinauthor=S.+Nadanacivaauthor=J.+J.+Xuauthor=M.+C.+Dunnauthor=A.+R.+Smithauthor=Y.+Will&title=In+vitro+assessment+of+mitochondrial+dysfunction+and+cytotoxicity+of+nefazodone%2C+trazodone%2C+and+buspirone&doi=10.1093%2Ftoxsci%2Fkfn056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone</span></div><div class="casAuthors">Dykens, James A.; Jamieson, Joseph D.; Marroquin, Lisa D.; Nadanaciva, Sashi; Xu, Jinghai J.; Dunn, Margaret C.; Smith, Arthur R.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">335-345</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mitochondrial toxicity is increasingly implicated in a host of drug-induced organ toxicities, including hepatotoxicity.  Nefazodone was withdrawn from the U.S. market in 2004 due to hepatotoxicity.  Accordingly, we evaluated nefazodone, another triazolopyridine trazodone, plus the azaspirodecanedione buspirone, for cytotoxicity and effects on mitochondrial function.  In accord with its clin. disposition, nefazodone was the most toxic compd. of the three, trazodone had relatively modest effects, whereas buspirone showed the least toxicity.  Nefazodone profoundly inhibited mitochondrial respiration in isolated rat liver mitochondria and in intact HepG2 cells where this was accompanied by simultaneous acceleration of glycolysis.  Using immunocaptured oxidative phosphorylation (OXPHOS) complexes, we identified Complex 1, and to a lesser amt. Complex IV, as the targets of nefazodone toxicity.  No inhibition was found for trazodone, and buspirone showed 3.4-fold less inhibition of OXPHOS Complex 1 than nefazodone.  In human hepatocytes that express cytochrome P 450, isoform 3A4, after 24 h exposure, nefazodone and trazodone collapsed mitochondrial membrane potential, and imposed oxidative stress, as detected via glutathione depletion, leading to cell death.  Our results suggest that the mitochondrial impairment imposed by nefazodone is profound and likely contributes to its hepatotoxicity, esp. in patients cotreated with other drugs with mitochondrial liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSW4cwpy1jpLVg90H21EOLACvtfcHk0lgtqrxr1Qx2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslyhurs%253D&md5=8bc3f5370a06bb00ea640dc2def3f3b5</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfn056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfn056%26sid%3Dliteratum%253Aachs%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%2BD.%26aulast%3DMarroquin%26aufirst%3DL.%2BD.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DDunn%26aufirst%3DM.%2BC.%26aulast%3DSmith%26aufirst%3DA.%2BR.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520mitochondrial%2520dysfunction%2520and%2520cytotoxicity%2520of%2520nefazodone%252C%2520trazodone%252C%2520and%2520buspirone%26jtitle%3DToxicol.%2520Sci.%26date%3D2008%26volume%3D103%26spage%3D335%26epage%3D345%26doi%3D10.1093%2Ftoxsci%2Fkfn056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span> <span> </span><span class="NLM_article-title">Role of the bile salt export pump, BSEP, in acquired forms of cholestasis</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.3109/03602530903492004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602530903492004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20028269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=437-445&author=B.+Stieger&title=Role+of+the+bile+salt+export+pump%2C+BSEP%2C+in+acquired+forms+of+cholestasis&doi=10.3109%2F03602530903492004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the bile salt export pump, BSEP, in acquired forms of cholestasis</span></div><div class="casAuthors">Stieger, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">437-445</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Generation of bile is a key function of the liver.  Its impairment leads to accumulation of cytotoxic bile salts in hepatocytes and, consequently, to liver disease.  The bile salt export pump, BSEP, is critically involved in the secretion of bile salts into bile.  Its function can be disturbed or abolished by inherited mutations.  This will lead to progressive intrahepatic cholestasis and severe liver disease.  In addn. to mutations, BSEP can be inhibited by acquired factors, such as xenobiotics or drugs, aberrant bile salt metabolites, or pregnancy.  This inhibition will lead to acquired cholestasis.  Some drugs are now known to be competitive inhibitors of Bsep.  In addn., a polymorphism in the gene coding for BSEP has been identified as a potential susceptibility factor for acquired cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYni5fpYpR8bVg90H21EOLACvtfcHk0lgk3b_7bR4CMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7w%253D&md5=4ea89d1fbe6a1da4933b3f72a6c212f9</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.3109%2F03602530903492004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602530903492004%26sid%3Dliteratum%253Aachs%26aulast%3DStieger%26aufirst%3DB.%26atitle%3DRole%2520of%2520the%2520bile%2520salt%2520export%2520pump%252C%2520BSEP%252C%2520in%2520acquired%2520forms%2520of%2520cholestasis%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26spage%3D437%26epage%3D445%26doi%3D10.3109%2F03602530903492004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=156-167&author=P.+Ranaauthor=M.+D.+Aleoauthor=M.+Gosinkauthor=Y.+Will&title=Evaluation+of+in+vitro+mitochondrial+toxicity+assays+and+physicochemical+properties+for+prediction+of+organ+toxicity+using+228+pharmaceutical+drugs&doi=10.1021%2Facs.chemrestox.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span></div><div class="casAuthors">Rana, Payal; Aleo, Michael D.; Gosink, Mark; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-167</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitochondrial toxicity has been shown to contribute to a variety of organ toxicities such as liver, cardiac, and kidney.  In the past decades, two high-throughput applicable screening assays (isolated rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess mitochondrial toxicity have been deployed in many pharmaceutical companies, and numerous publications have demonstrated its usefulness for mechanistic investigations.  However, only two publications have demonstrated the utility of these screens as a predictor of human drug-induced liver injury.  In the present study, the authors screened 73 hepatotoxicants, 46 cardiotoxicants, 49 nephrotoxicants, and 60 compds. not known to cause human organ toxicity for their effects on mitochondrial function(s) in the assays mentioned above.  Predictive performance was evaluated using specificity and sensitivity of the assays for predicting organ toxicity.  The authors' results show that the predictive performance of the mitochondrial assays are superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity (sensitivity 63% vs. 33% and 28% with similar specificity of 93%), when the anal. was done at 100* Cmax (drug concn. in human plasma level).  The authors further explored the assocn. of mitochondrial toxicity with physicochem. properties such as calcd. log partition coeff. (cLogP), topol. polar surface area, ionization status, and mol. wt. of the drugs and found that cLogP was most significantly assocd. mitochondrial toxicity.  Since these assays are amenable to higher throughput, the authors recommend that chemists use these assays to perform structure activity relationship early in the drug discovery process, when chem. matter is abundant.  This assures that compds. that lack the propensity to cause mitochondrial dysfunction (and assocd. organ toxicity) will move forward into animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rad7gm0MrLVg90H21EOLACvtfcHk0lgk3b_7bR4CMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM&md5=82bc95a1604961473a4e5fecb05aab79</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DGosink%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520in%2520vitro%2520mitochondrial%2520toxicity%2520assays%2520and%2520physicochemical%2520properties%2520for%2520prediction%2520of%2520organ%2520toxicity%2520using%2520228%2520pharmaceutical%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26spage%3D156%26epage%3D167%26doi%3D10.1021%2Facs.chemrestox.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Longo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herédi-Szabó, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogyorósi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragan, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span> <span> </span><span class="NLM_article-title">Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfy253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30289550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yrurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=458-467&author=D.+M.+Longoauthor=J.+L.+Woodheadauthor=P.+Walkerauthor=K.+Her%C3%A9di-Szab%C3%B3author=K.+Mogyor%C3%B3siauthor=F.+S.+Wolenskiauthor=Y.+P.+Draganauthor=M.+Mosedaleauthor=Q.+Silerauthor=P.+B.+Watkinsauthor=B.+A.+Howell&title=Quantitative+systems+toxicology+analysis+of+in+vitro+mechanistic+assays+reveals+importance+of+bile+acid+accumulation+and+mitochondrial+dysfunction+in+TAK-875-induced+liver+injury&doi=10.1093%2Ftoxsci%2Fkfy253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury</span></div><div class="casAuthors">Longo, Diane M.; Woodhead, Jeffrey L.; Walker, Paul; Heredi-Szabo, Krisztina; Mogyorosi, Karoly; Wolenski, Francis S.; Dragan, Yvonne P.; Mosedale, Merrie; Siler, Scott Q.; Watkins, Paul B.; Howell, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">458-467</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">TAK-875 (fasiglifam), a GPR40 agonist in development for the treatment of type 2 diabetes (T2D), was voluntarily terminated in Phase III trials due to adverse liver effects.  The potential mechanisms of TAK-875 toxicity were explored by combining in vitro expts. with quant. systems toxicol. (QST) using DILIsym, a math. representation of drug induced liver injury.  In vitro assays revealed that bile acid transporters were inhibited by both TAK-875 and its metabolite, TAK-875-Glu.  Exptl. data indicated that human bile salt export pump (BSEP) inhibition by TAK-875 was mixed whereas sodium taurocholate co-transporting polypeptide (NTCP) inhibition by TAK-875 was competitive.  Furthermore, exptl. data demonstrated that both TAK-875 and TAK-875-Glu inhibit mitochondrial electron transport chain (ETC) enzymes.  These mechanistic data were combined with a physiol. based pharmacokinetic (PBPK) model constructed within DILIsym to est. liver exposure of TAK-875 and TAK-875-Glu.  In a simulated population (SimPops) constructed to reflect T2D patients, 16/245 (6.5%) simulated individuals developed alanine aminotransferase (ALT) elevations, an incidence similar to that obsd. with 200 mg daily dosing in clin. trials.  Detg. the mode of bile acid transporter inhibition (Ki) was crit. to accurate predictions.  In addn., simulations conducted on a sensitive subset of individuals (SimCohorts) revealed that when either BSEP or ETC inhibition was inactive, ALT elevations were not predicted to occur, suggesting that the two mechanisms operate synergistically to produce the obsd. clin. response.  These results demonstrate how utilizing QST methods to interpret in vitro exptl. results can lead to an improved understanding of the clin. relevant mechanisms underlying drug-induced toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPa7jeGLG3LVg90H21EOLACvtfcHk0lgk3b_7bR4CMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yrurzL&md5=cfb9fedecf2df7c3762f4481b648515b</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy253%26sid%3Dliteratum%253Aachs%26aulast%3DLongo%26aufirst%3DD.%2BM.%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DWalker%26aufirst%3DP.%26aulast%3DHer%25C3%25A9di-Szab%25C3%25B3%26aufirst%3DK.%26aulast%3DMogyor%25C3%25B3si%26aufirst%3DK.%26aulast%3DWolenski%26aufirst%3DF.%2BS.%26aulast%3DDragan%26aufirst%3DY.%2BP.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DSiler%26aufirst%3DQ.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26atitle%3DQuantitative%2520systems%2520toxicology%2520analysis%2520of%2520in%2520vitro%2520mechanistic%2520assays%2520reveals%2520importance%2520of%2520bile%2520acid%2520accumulation%2520and%2520mitochondrial%2520dysfunction%2520in%2520TAK-875-induced%2520liver%2520injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2019%26volume%3D167%26spage%3D458%26epage%3D467%26doi%3D10.1093%2Ftoxsci%2Fkfy253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Do in vitro assays predict drug candidate idiosyncratic drug-induced liver injury risk?</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1658</span>– <span class="NLM_lpage">1669</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.118.082719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30021844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1658-1669&author=J.+G.+Kennaauthor=J.+Uetrecht&title=Do+in+vitro+assays+predict+drug+candidate+idiosyncratic+drug-induced+liver+injury+risk%3F&doi=10.1124%2Fdmd.118.082719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?</span></div><div class="casAuthors">Kenna J Gerry; Uetrecht Jack</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1658-1669</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In vitro assays are commonly used during drug discovery to try to decrease the risk of idiosyncratic drug-induced liver injury (iDILI).  But how effective are they at predicting risk? One of the most widely used methods evaluates cell cytotoxicity.  Cytotoxicity assays that used cell lines that are very different from normal hepatocytes, and high concentrations of drug, were not very accurate at predicting idiosyncratic drug reaction risk.  Even cytotoxicity assays that use more biologically normal cells resulted in many false-positive and false-negative results.  Assays that quantify reactive metabolite formation, mitochondrial injury, and bile salt export pump (BSEP) inhibition have also been described.  Although evidence suggests that reactive metabolite formation and BSEP inhibition can play a role in the mechanism of iDILI, these assays are not very accurate at predicting risk.  In contrast, inhibition of the mitochondrial electron transport chain appears not to play an important role in the mechanism of iDILI, although other types of mitochondrial injury may do so.  It is likely that there are many additional mechanisms by which drugs can cause iDILI.  However, simply measuring more parameters is unlikely to provide better predictive assays unless those parameters are actually involved in the mechanism of iDILI.  Hence, a better mechanistic understanding of iDILI is required; however, mechanistic studies of iDILI are very difficult.  There is substantive evidence that most iDILI is immune mediated; therefore, the most accurate assays may involve those that determine immune responses to drugs.  New methods to manipulate immune tolerance may greatly facilitate development of more suitable methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfQDq8PfgS1p6KlWarZTAzfW6udTcc2eYj_TXEE_4iC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D&md5=5300842ef1375b82da597057258f82ce</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082719%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DDo%2520in%2520vitro%2520assays%2520predict%2520drug%2520candidate%2520idiosyncratic%2520drug-induced%2520liver%2520injury%2520risk%253F%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D1658%26epage%3D1669%26doi%3D10.1124%2Fdmd.118.082719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taskar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucha, R. W.</span></span> <span> </span><span class="NLM_article-title">Can bile salt export pump inhibition testing in drug discovery and development reduced liver injury risk? An International Transporter Consortium Perspective</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1002/cpt.1222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fcpt.1222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30137645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2018&pages=916-932&author=J.+G.+Kennaauthor=K.+S.+Taskarauthor=C.+Battistaauthor=D.+L.+Bourdetauthor=K.+L.+R.+Brouwerauthor=K.+R.+Brouwerauthor=D.+Daiauthor=C.+Funkauthor=M.+J.+Hafeyauthor=Y.+Laiauthor=J.+Maherauthor=Y.+A.+Pakauthor=J.+M.+Pedersenauthor=J.+W.+Polliauthor=A.+D.+Rodriguesauthor=P.+B.+Watkinsauthor=K.+Yangauthor=R.+W.+Yucha&title=Can+bile+salt+export+pump+inhibition+testing+in+drug+discovery+and+development+reduced+liver+injury+risk%3F+An+International+Transporter+Consortium+Perspective&doi=10.1002%2Fcpt.1222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective</span></div><div class="casAuthors">Kenna, J. Gerry; Taskar, Kunal S.; Battista, Christina; Bourdet, David L.; Brouwer, Kim L. R.; Brouwer, Kenneth R.; Dai, David; Funk, Christoph; Hafey, Michael J.; Lai, Yurong; Maher, Jonathan; Pak, Y. Anne; Pedersen, Jenny M.; Polli, Joseph W.; Rodrigues, A. David; Watkins, Paul B.; Yang, Kyunghee; Yucha, Robert W.; On behalf of the International Transporter Consortium</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">916-932</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bile salt export pump (BSEP) inhibition has emerged as an important mechanism that may contribute to the initiation of human drug-induced liver injury (DILI).  Proactive evaluation and understanding of BSEP inhibition is recommended in drug discovery and development to aid internal decision making on DILI risk.  BSEP inhibition can be quantified using in vitro assays.  When interpreting assay data, it is important to consider in vivo drug exposure.  Currently, this can be undertaken most effectively by consideration of total plasma steady state drug concns. (Css,plasma).  However, because total drug concns. are not predictive of pharmacol. effect, the relationship between total exposure and BSEP inhibition is not causal.  Various follow-up studies can aid interpretation of in vitroBSEP inhibition data and may be undertaken on a case-by-case basis.  BSEP inhibition is one of several mechanisms by which drugs may cause DILI, therefore, it should be considered alongside other mechanisms when evaluating possible DILI risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAayGrck3BArVg90H21EOLACvtfcHk0ljM39R_WLARLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtb%252FJ&md5=b70c447083b739f21267467888dc8e1e</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1222%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DTaskar%26aufirst%3DK.%2BS.%26aulast%3DBattista%26aufirst%3DC.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26aulast%3DBrouwer%26aufirst%3DK.%2BR.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DFunk%26aufirst%3DC.%26aulast%3DHafey%26aufirst%3DM.%2BJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DPak%26aufirst%3DY.%2BA.%26aulast%3DPedersen%26aufirst%3DJ.%2BM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYucha%26aufirst%3DR.%2BW.%26atitle%3DCan%2520bile%2520salt%2520export%2520pump%2520inhibition%2520testing%2520in%2520drug%2520discovery%2520and%2520development%2520reduced%2520liver%2520injury%2520risk%253F%2520An%2520International%2520Transporter%2520Consortium%2520Perspective%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D104%26spage%3D916%26epage%3D932%26doi%3D10.1002%2Fcpt.1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eakins, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergare, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elebring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span> <span> </span><span class="NLM_article-title">Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fjpet.114.220491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=25467130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=281-290&author=J.+G.+Kennaauthor=S.+H.+Stahlauthor=J.+A.+Eakinsauthor=A.+J.+Fosterauthor=L.+C.+Anderssonauthor=J.+Bergareauthor=M.+Billgerauthor=M.+Elebringauthor=C.+S.+Elmoreauthor=R.+A.+Thompson&title=Multiple+compound-related+adverse+properties+contribute+to+liver+injury+caused+by+endothelin+receptor+antagonists&doi=10.1124%2Fjpet.114.220491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists</span></div><div class="casAuthors">Kenna, J. Gerry; Stahl, Simone H.; Eakins, Julie A.; Foster, Alison J.; Andersson, Linda C.; Bergare, Jonas; Billger, Martin; Elebring, Marie; Elmore, Charles S.; Thompson, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">281-290/1-281-290/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury has been obsd. in patients treated with the endothelin receptor antagonists sitaxentan and bosentan, but not following treatment with ambrisentan.  The aim of our studies was to assess the possible role of multiple contributory mechanisms in this clin. relevant toxicity.  Inhibition of the bile salt export pump (BSEP) and multidrug resistance-assocd. protein 2 was quantified using membrane vesicle assays.  Inhibition of mitochondrial respiration in human liver-derived HuH-7 cells was detd. using a Seahorse XFe96 analyzer.  Cytochrome P 450 (P 450) -independent and P 450-mediated cell toxicity was assessed using transfected SV40-T-antigen-immortalized human liver epithelial (THLE) cell lines.  Exposure-adjusted assay ratios were calcd. by dividing the max. human drug plasma concns. by the IC50 or EC50 values obtained in vitro.  Covalent binding (CVB) of radiolabeled drugs to human hepatocytes was quantified, and CVB body burdens were calcd. by adjusting CVB values for fractional drug turnover in vitro and daily therapeutic dose.  Sitaxentan exhibited pos. exposure-adjusted signals in all five in vitro assays and a high CVB body burden.  Bosentan exhibited a pos. exposure-adjusted signal in one assay (BSEP inhibition) and a moderate CVB body burden.  Ambrisentan exhibited no pos. exposure-adjusted assay signals and a low CVB body burden.  These data indicate that multiple mechanisms contribute to the rare, but potentially severe liver injury caused by sitaxentan in humans; provide a plausible rationale for the markedly lower propensity of bosentan to cause liver injury; and highlight the relative safety of ambrisentan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDXn5oSiJzfbVg90H21EOLACvtfcHk0ljM39R_WLARLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOhu7Y%253D&md5=254850e804c48f295e6ce75e94b95385</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220491%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DStahl%26aufirst%3DS.%2BH.%26aulast%3DEakins%26aufirst%3DJ.%2BA.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DBergare%26aufirst%3DJ.%26aulast%3DBillger%26aufirst%3DM.%26aulast%3DElebring%26aufirst%3DM.%26aulast%3DElmore%26aufirst%3DC.%2BS.%26aulast%3DThompson%26aufirst%3DR.%2BA.%26atitle%3DMultiple%2520compound-related%2520adverse%2520properties%2520contribute%2520to%2520liver%2520injury%2520caused%2520by%2520endothelin%2520receptor%2520antagonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D281%26epage%3D290%26doi%3D10.1124%2Fjpet.114.220491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/tx300091x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300091x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1616-1632&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=L.+Weidolfauthor=K.+Pageauthor=I.+Wilsonauthor=S.+Swallowauthor=B.+Middletonauthor=S.+Stahlauthor=A.+J.+Fosterauthor=H.+Dolgosauthor=R.+Weaverauthor=J.+G.+Kenna&title=In+vitro+approach+to+assess+the+potential+for+risk+of+idiosyncratic+adverse+reactions+caused+by+candidate+drugs&doi=10.1021%2Ftx300091x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weidolf, Lars; Page, Ken; Wilson, Ian; Swallow, Steve; Middleton, Brian; Stahl, Simone; Foster, Alison J.; Dolgos, Hugues; Weaver, Richard; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1616-1632</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling.  IADRs arise from both drug and patient related mechanisms and risk factors.  Drug related risk factors, resulting from parent compd. or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compd. disposition, and/or immune activation.  In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans.  The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance assocd. protein 2, Mrp2.  In addn., the CVB Burden was estd. by detg. the CVB of radiolabeled compd. to human hepatocytes and factoring in both the max. prescribed daily dose and the fraction of metab. leading to CVB.  Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFG8lfWXT4vLVg90H21EOLACvtfcHk0ljB9VWqkFkHKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D&md5=e657aaf23d4efc5466bca68dee95bded</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Ftx300091x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300091x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520vitro%2520approach%2520to%2520assess%2520the%2520potential%2520for%2520risk%2520of%2520idiosyncratic%2520adverse%2520reactions%2520caused%2520by%2520candidate%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D1616%26epage%3D1632%26doi%3D10.1021%2Ftx300091x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Julia Shanu-Wilson, Liam Evans, Stephen Wrigley, Jonathan Steele, James Atherton, <span class="NLM_string-name hlFld-ContribAuthor">Jason Boer</span>. </span><span class="cited-content_cbyCitation_article-title">Biotransformation: Impact and Application of Metabolism in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2087-2107. <a href="https://doi.org/10.1021/acsmedchemlett.0c00202" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00202</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00202%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBiotransformation%25253A%252BImpact%252Band%252BApplication%252Bof%252BMetabolism%252Bin%252BDrug%252BDiscovery%26aulast%3DShanu-Wilson%26aufirst%3DJulia%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21042020%26date%3D13082020%26date%3D28082020%26volume%3D11%26issue%3D11%26spage%3D2087%26epage%3D2107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Bryan H. Norman</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11397-11419. <a href="https://doi.org/10.1021/acs.jmedchem.0c00524" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00524</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00524%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BInduced%252BLiver%252BInjury%252B%252528DILI%252529.%252BMechanisms%252Band%252BMedicinal%252BChemistry%252BAvoidance%25252FMitigation%252BStrategies%26aulast%3DNorman%26aufirst%3DBryan%2BH.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30032020%26date%3D19062020%26date%3D08062020%26volume%3D63%26issue%3D20%26spage%3D11397%26epage%3D11419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">Essential Medicinal Chemistry of Essential Medicines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10170-10187. <a href="https://doi.org/10.1021/acs.jmedchem.0c00415" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00415%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEssential%252BMedicinal%252BChemistry%252Bof%252BEssential%252BMedicines%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11032020%26date%3D12052020%26date%3D30042020%26volume%3D63%26issue%3D18%26spage%3D10170%26epage%3D10187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Falgun Shah, <span class="NLM_string-name hlFld-ContribAuthor">Ian M. Bell</span>. </span><span class="cited-content_cbyCitation_article-title">Cutaneous Adverse Events Caused by Sulfonamide-Containing Drugs: Reality or Perception?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (14)
                                     , 7447-7457. <a href="https://doi.org/10.1021/acs.jmedchem.9b01932" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01932</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01932%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCutaneous%252BAdverse%252BEvents%252BCaused%252Bby%252BSulfonamide-Containing%252BDrugs%25253A%252BReality%252Bor%252BPerception%25253F%26aulast%3DShah%26aufirst%3DFalgun%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22112019%26date%3D24022020%26volume%3D63%26issue%3D14%26spage%3D7447%26epage%3D7457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James P. Driscoll, Corinne M. Sadlowski, Nina R. Shah, <span class="NLM_string-name hlFld-ContribAuthor">Antonio Feula</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism and Bioactivation: It’s Time to Expect the Unexpected. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6303-6314. <a href="https://doi.org/10.1021/acs.jmedchem.0c00026" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMetabolism%252Band%252BBioactivation%25253A%252BIt%2525E2%252580%252599s%252BTime%252Bto%252BExpect%252Bthe%252BUnexpected%26aulast%3DDriscoll%26aufirst%3DJames%2BP.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07012020%26date%3D21042020%26date%3D08042020%26volume%3D63%26issue%3D12%26spage%3D6303%26epage%3D6314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew A. Cerny, Amit S. Kalgutkar, R. Scott Obach, Raman Sharma, Douglas K. Spracklin, <span class="NLM_string-name hlFld-ContribAuthor">Gregory S. Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Effective Application of Metabolite Profiling in Drug Design and Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6387-6406. <a href="https://doi.org/10.1021/acs.jmedchem.9b01840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEffective%252BApplication%252Bof%252BMetabolite%252BProfiling%252Bin%252BDrug%252BDesign%252Band%252BDiscovery%26aulast%3DCerny%26aufirst%3DMatthew%2BA.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D06112019%26date%3D06032020%26date%3D25022020%26volume%3D63%26issue%3D12%26spage%3D6387%26epage%3D6406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ibrahim  Chikowe</span>, <span class="hlFld-ContribAuthor ">Alfred Chipanda  Phiri</span>, <span class="hlFld-ContribAuthor ">Kirios Patrick  Mbewe</span>, <span class="hlFld-ContribAuthor ">Dunstan  Matekenya</span>. </span><span class="cited-content_cbyCitation_article-title">In-silico evaluation of Malawi essential medicines and reactive metabolites for potential drug-induced toxicities. </span><span class="cited-content_cbyCitation_journal-name">BMC Pharmacology and Toxicology</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s40360-021-00499-6" title="DOI URL">https://doi.org/10.1186/s40360-021-00499-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40360-021-00499-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40360-021-00499-6%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Pharmacology%2520and%2520Toxicology%26atitle%3DIn-silico%252Bevaluation%252Bof%252BMalawi%252Bessential%252Bmedicines%252Band%252Breactive%252Bmetabolites%252Bfor%252Bpotential%252Bdrug-induced%252Btoxicities%26aulast%3DChikowe%26aufirst%3DIbrahim%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Somaieh  Soltani</span>, <span class="hlFld-ContribAuthor ">Somayeh  Hallaj-Nezhadi</span>, <span class="hlFld-ContribAuthor ">Mohammad Reza  Rashidi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review of in silico approaches for the prediction and modulation of aldehyde oxidase-mediated drug metabolism: The current features, challenges and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113559. <a href="https://doi.org/10.1016/j.ejmech.2021.113559" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113559</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113559%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Breview%252Bof%252Bin%252Bsilico%252Bapproaches%252Bfor%252Bthe%252Bprediction%252Band%252Bmodulation%252Bof%252Baldehyde%252Boxidase-mediated%252Bdrug%252Bmetabolism%25253A%252BThe%252Bcurrent%252Bfeatures%25252C%252Bchallenges%252Band%252Bfuture%252Bperspectives%26aulast%3DSoltani%26aufirst%3DSomaieh%26date%3D2021%26volume%3D222%26spage%3D113559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Henni‐Karoliina  Ropponen</span>, <span class="hlFld-ContribAuthor ">Chantal D.  Bader</span>, <span class="hlFld-ContribAuthor ">Eleonora  Diamanti</span>, <span class="hlFld-ContribAuthor ">Boris  Illarionov</span>, <span class="hlFld-ContribAuthor ">Matthias  Rottmann</span>, <span class="hlFld-ContribAuthor ">Markus  Fischer</span>, <span class="hlFld-ContribAuthor ">Matthias  Witschel</span>, <span class="hlFld-ContribAuthor ">Rolf  Müller</span>, <span class="hlFld-ContribAuthor ">Anna K. H.  Hirsch</span>. </span><span class="cited-content_cbyCitation_article-title">Search for the Active Ingredients from a 2‐Aminothiazole DMSO Stock Solution with Antimalarial Activity. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (13)
                                     , 2089-2093. <a href="https://doi.org/10.1002/cmdc.202100067" title="DOI URL">https://doi.org/10.1002/cmdc.202100067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100067%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSearch%252Bfor%252Bthe%252BActive%252BIngredients%252Bfrom%252Ba%252B2%2525E2%252580%252590Aminothiazole%252BDMSO%252BStock%252BSolution%252Bwith%252BAntimalarial%252BActivity%26aulast%3DRopponen%26aufirst%3DHenni%25E2%2580%2590Karoliina%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D13%26spage%3D2089%26epage%3D2093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Upendra A.  Argikar</span>, <span class="hlFld-ContribAuthor ">James P.  Driscoll</span>, <span class="hlFld-ContribAuthor ">Carley J. S.  Heck</span>, <span class="hlFld-ContribAuthor ">Lloyd  King</span>, <span class="hlFld-ContribAuthor ">Klarissa D.  Jackson</span>, <span class="hlFld-ContribAuthor ">Wenying  Jian</span>, <span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>, <span class="hlFld-ContribAuthor ">Grover P.  Miller</span>, <span class="hlFld-ContribAuthor ">Valerie  Kramlinger</span>, <span class="hlFld-ContribAuthor ">Ivonne M. C. M.  Rietjens</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Teitelbaum</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Novel advances in biotransformation and bioactivation research – 2020 year in review. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2021,</strong> <em>48 </em>, 1-50. <a href="https://doi.org/10.1080/03602532.2021.1916028" title="DOI URL">https://doi.org/10.1080/03602532.2021.1916028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2021.1916028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2021.1916028%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DNovel%252Badvances%252Bin%252Bbiotransformation%252Band%252Bbioactivation%252Bresearch%252B%2525E2%252580%252593%252B2020%252Byear%252Bin%252Breview%26aulast%3DKhojasteh%26aufirst%3DS.%2BCyrus%26date%3D2021%26date%3D2021%26volume%3D48%26spage%3D1%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Young-Hwan  Jung</span>, <span class="hlFld-ContribAuthor ">Shanu  Jain</span>, <span class="hlFld-ContribAuthor ">Varun  Gopinatth</span>, <span class="hlFld-ContribAuthor ">Ngan B.  Phung</span>, <span class="hlFld-ContribAuthor ">Zhan-Guo  Gao</span>, <span class="hlFld-ContribAuthor ">Kenneth A.  Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y6 receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>41 </em>, 128008. <a href="https://doi.org/10.1016/j.bmcl.2021.128008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%252Bactivity%252Brelationship%252Bof%252B3-nitro-2-%252528trifluoromethyl%252529-2H-chromene%252Bderivatives%252Bas%252BP2Y6%252Breceptor%252Bantagonists%26aulast%3DJung%26aufirst%3DYoung-Hwan%26date%3D2021%26volume%3D41%26spage%3D128008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias R.  Bauer</span>, <span class="hlFld-ContribAuthor ">Paolo  Di Fruscia</span>, <span class="hlFld-ContribAuthor ">Simon C. C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Iacovos N.  Michaelides</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Nelson</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Benjamin C.  Whitehurst</span>. </span><span class="cited-content_cbyCitation_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 448-471. <a href="https://doi.org/10.1039/D0MD00370K" title="DOI URL">https://doi.org/10.1039/D0MD00370K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00370K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPut%252Ba%252Bring%252Bon%252Bit%25253A%252Bapplication%252Bof%252Bsmall%252Baliphatic%252Brings%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DBauer%26aufirst%3DMatthias%2BR.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D448%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angelica  Mazzolari</span>, <span class="hlFld-ContribAuthor ">Luca  Sommaruga</span>, <span class="hlFld-ContribAuthor ">Alessandro  Pedretti</span>, <span class="hlFld-ContribAuthor ">Giulio  Vistoli</span>. </span><span class="cited-content_cbyCitation_article-title">MetaTREE, a Novel Database Focused on Metabolic Trees, Predicts an Important Detoxification Mechanism: The Glutathione Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (7)
                                     , 2098. <a href="https://doi.org/10.3390/molecules26072098" title="DOI URL">https://doi.org/10.3390/molecules26072098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26072098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26072098%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMetaTREE%25252C%252Ba%252BNovel%252BDatabase%252BFocused%252Bon%252BMetabolic%252BTrees%25252C%252BPredicts%252Ban%252BImportant%252BDetoxification%252BMechanism%25253A%252BThe%252BGlutathione%252BConjugation%26aulast%3DMazzolari%26aufirst%3DAngelica%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D7%26spage%3D2098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chikako  Shibazaki</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Ohe</span>, <span class="hlFld-ContribAuthor ">Kyoko  Takahashi</span>, <span class="hlFld-ContribAuthor ">Shigeo  Nakamura</span>, <span class="hlFld-ContribAuthor ">Tadahiko  Mashino</span>. </span><span class="cited-content_cbyCitation_article-title">Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Pharmacokinetics</span><span> <strong>2021,</strong> <em>17 </em>, 100386. <a href="https://doi.org/10.1016/j.dmpk.2021.100386" title="DOI URL">https://doi.org/10.1016/j.dmpk.2021.100386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dmpk.2021.100386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dmpk.2021.100386%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Pharmacokinetics%26atitle%3DDevelopment%252Bof%252Bfluorescent-labeled%252Btrapping%252Breagents%252Bbased%252Bon%252Bcysteine%252Bto%252Bdetect%252Bsoft%252Band%252Bhard%252Belectrophilic%252Breactive%252Bmetabolites%26aulast%3DShibazaki%26aufirst%3DChikako%26date%3D2021%26volume%3D17%26spage%3D100386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches to mitigate the risk of serious adverse reactions in covalent drug design. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 275-287. <a href="https://doi.org/10.1080/17460441.2021.1832079" title="DOI URL">https://doi.org/10.1080/17460441.2021.1832079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1832079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1832079%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApproaches%252Bto%252Bmitigate%252Bthe%252Brisk%252Bof%252Bserious%252Badverse%252Breactions%252Bin%252Bcovalent%252Bdrug%252Bdesign%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D275%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span>, <span class="hlFld-ContribAuthor ">Ingo  Muegge</span>. </span><span class="cited-content_cbyCitation_article-title">Holistic Drug Design for Multiparameter Optimization in Modern Small Molecule Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>10 </em>, 128003. <a href="https://doi.org/10.1016/j.bmcl.2021.128003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHolistic%252BDrug%252BDesign%252Bfor%252BMultiparameter%252BOptimization%252Bin%252BModern%252BSmall%252BMolecule%252BDrug%252BDiscovery%26aulast%3DPennington%26aufirst%3DLewis%2BD.%26date%3D2021%26volume%3D10%26spage%3D128003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoling  Chen</span>, <span class="hlFld-ContribAuthor ">Yanghua  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of the stable and reactive metabolites of tetrahydropiperine using ultrahigh‐performance liquid chromatography combined with diode‐array detection and high‐resolution mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Rapid Communications in Mass Spectrometry</span><span> <strong>2021,</strong> <em>35 </em>
                                    (2)
                                     <a href="https://doi.org/10.1002/rcm.8975" title="DOI URL">https://doi.org/10.1002/rcm.8975</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/rcm.8975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Frcm.8975%26sid%3Dliteratum%253Aachs%26jtitle%3DRapid%2520Communications%2520in%2520Mass%2520Spectrometry%26atitle%3DIdentification%252Bof%252Bthe%252Bstable%252Band%252Breactive%252Bmetabolites%252Bof%252Btetrahydropiperine%252Busing%252Bultrahigh%2525E2%252580%252590performance%252Bliquid%252Bchromatography%252Bcombined%252Bwith%252Bdiode%2525E2%252580%252590array%252Bdetection%252Band%252Bhigh%2525E2%252580%252590resolution%252Bmass%252Bspectrometry%26aulast%3DChen%26aufirst%3DXiaoling%26date%3D2021%26date%3D2020%26volume%3D35%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shazia  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Nabeel  Ahmed</span>, <span class="hlFld-ContribAuthor ">Mausumi  Goswami</span>, <span class="hlFld-ContribAuthor ">Anindita  Chakrabarty</span>, <span class="hlFld-ContribAuthor ">Goutam  Chowdhury</span>. </span><span class="cited-content_cbyCitation_article-title">DNA damage by Withanone as a potential cause of liver toxicity observed for herbal products of Withania somnifera (Ashwagandha). </span><span class="cited-content_cbyCitation_journal-name">Current Research in Toxicology</span><span> <strong>2021,</strong> <em>2 </em>, 72-81. <a href="https://doi.org/10.1016/j.crtox.2021.02.002" title="DOI URL">https://doi.org/10.1016/j.crtox.2021.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.crtox.2021.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.crtox.2021.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Research%2520in%2520Toxicology%26atitle%3DDNA%252Bdamage%252Bby%252BWithanone%252Bas%252Ba%252Bpotential%252Bcause%252Bof%252Bliver%252Btoxicity%252Bobserved%252Bfor%252Bherbal%252Bproducts%252Bof%252BWithania%252Bsomnifera%252B%252528Ashwagandha%252529%26aulast%3DSiddiqui%26aufirst%3DShazia%26date%3D2021%26volume%3D2%26spage%3D72%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">F. Peter  Guengerich</span>, <span class="hlFld-ContribAuthor ">Kevin D.  McCarty</span>, <span class="hlFld-ContribAuthor ">Jesse G.  Chapman</span>. </span><span class="cited-content_cbyCitation_article-title">Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2021,</strong> <em>296 </em>, 100223. <a href="https://doi.org/10.1074/jbc.RA120.016855" title="DOI URL">https://doi.org/10.1074/jbc.RA120.016855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA120.016855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA120.016855%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DKinetics%252Bof%252Bcytochrome%252BP450%252B3A4%252Binhibition%252Bby%252Bheterocyclic%252Bdrugs%252Bdefines%252Ba%252Bgeneral%252Bsequential%252Bmultistep%252Bbinding%252Bprocess%26aulast%3DGuengerich%26aufirst%3DF.%2BPeter%26date%3D2021%26volume%3D296%26spage%3D100223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fotini  Moschona</span>, <span class="hlFld-ContribAuthor ">Ioanna  Savvopoulou</span>, <span class="hlFld-ContribAuthor ">Maria  Tsitopoulou</span>, <span class="hlFld-ContribAuthor ">Despoina  Tataraki</span>, <span class="hlFld-ContribAuthor ">Gerasimos  Rassias</span>. </span><span class="cited-content_cbyCitation_article-title">Epoxide Syntheses and Ring-Opening Reactions in Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2020,</strong> <em>10 </em>
                                    (10)
                                     , 1117. <a href="https://doi.org/10.3390/catal10101117" title="DOI URL">https://doi.org/10.3390/catal10101117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal10101117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal10101117%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DEpoxide%252BSyntheses%252Band%252BRing-Opening%252BReactions%252Bin%252BDrug%252BDevelopment%26aulast%3DMoschona%26aufirst%3DFotini%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D10%26spage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer  Hemmerich</span>, <span class="hlFld-ContribAuthor ">Gerhard F.  Ecker</span>. </span><span class="cited-content_cbyCitation_article-title">In silico toxicology: From structure–activity relationships towards deep learning and adverse outcome pathways. </span><span class="cited-content_cbyCitation_journal-name">WIREs Computational Molecular Science</span><span> <strong>2020,</strong> <em>10 </em>
                                    (4)
                                     <a href="https://doi.org/10.1002/wcms.1475" title="DOI URL">https://doi.org/10.1002/wcms.1475</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/wcms.1475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fwcms.1475%26sid%3Dliteratum%253Aachs%26jtitle%3DWIREs%2520Computational%2520Molecular%2520Science%26atitle%3DIn%252Bsilico%252Btoxicology%25253A%252BFrom%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Btowards%252Bdeep%252Blearning%252Band%252Badverse%252Boutcome%252Bpathways%26aulast%3DHemmerich%26aufirst%3DJennifer%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Drug–protein adducts: past, present, and future. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2020,</strong> <em>29 </em>
                                    (7)
                                     , 1093-1104. <a href="https://doi.org/10.1007/s00044-020-02567-8" title="DOI URL">https://doi.org/10.1007/s00044-020-02567-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02567-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02567-8%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDrug%2525E2%252580%252593protein%252Badducts%25253A%252Bpast%25252C%252Bpresent%25252C%252Band%252Bfuture%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D7%26spage%3D1093%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. CYP-Catalyzed Bioactivation of Acetaminophen (<b>1</b>) to a an Electrophilic Quinone Imine Intermediate <b>2</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Bioactivation Potential of the Hepatotoxin Nefazodone (<b>4</b>) and Non-Hepatotoxin Buspirone (<b>11</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Structure–Metabolism Relationships for Clozapine (<b>14</b>) versus Quetiapine (<b>17</b>) and Loxapine (<b>18</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Mechanisms for Plasma Protein Covalent Binding by Acyl Glucuronide Metabolites of Carboxylic Acid-Containing Drugs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Electrophilicity of Acyl CoA Thioester (<b>26</b>) Metabolites of Carboxylic Acid Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Metabolic Bioactivation of the G-Protein-Coupled Receptor 40 agonist Fasiglifam (<b>28</b>), Which Was Withdrawn from Phase 3 Clinical Trials for iDILI</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Mitigating the Bioactivation Liability of the Antiepileptic Agent Felbamate (<b>32</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0012.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Mitigating the Formation of Electrophilic Quinone-imine with the Antimalarial Drug Amodiaquine (<b>43</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0013.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Mitigating the Formation of Electrophilic Quinone-diimines with 5-Aminooxindole-Containing PYK2 Inhibitor <b>48</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0014.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Structure–Metabolism Studies to Mitigate the Formation of Reactive Metabolites with the Pyrazinone-Based CRF<sub>1</sub> Receptor Antagonist <b>55</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0001.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolism-guided discovery of the cannabinoid-1 receptor inhibitor taranabant (<b>63</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0015.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Mitigating Reactive Metabolite Liability and Preclinical Safety Concerns with Acetamidothiazolyl Nonpeptidyl Thrombopoietin Receptor Agonist <b>64</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0016.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Eliminating the Formation of Reactive Metabolites Obtained by Thiazole Ring Epoxidation with the AKT Inhibitor <b>69</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0017.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Metabolism-Guided Identification of the Glucokinase Activator and Clinical Candidate Piragliatin (<b>87</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0018.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Mitigating Bioactivation on the 2-Aminoimidazole Ring Present in Inhibitors (<b>88</b> and <b>95</b>) of Microsomal Prostaglandin E Synthase-1</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0019.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Bioactivation of the 5-Hydroxytryptamine 2C agonist <b>104</b> to Reactive Metabolites, Which Covalently Modify DNA and Cause a Mutagenic Response in the <i>Salmonella</i> Ames Test</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0020.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Metabolic Activation of a Pyrrolidine Substituted Arylindenopyrimidine Derivative <b>115</b> to Reactive Species, Which Covalently Modify DNA in the Ames Test</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0021.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Mitigating Bioactivation of a 1,3-Disubstitutedpiperazine Ring in the Melanocortin Receptor Agonist <b>122</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0022.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Structure–Metabolism Differences between Hepatotoxic (Sudoxicam (<b>134</b>) and Alpidem (<b>141</b>)) and Nonhepatotoxic (Meloxicam (<b>138</b>) and Zolpidem (<b>145</b>)) in Humans</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0002.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of safe marketed drugs, which contain structural alerts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0023.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. In Vivo Bioactivation of the Analgesic and Idiosyncratic Hepatotoxin Flupirtine (<b>149</b>) in Humans</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0003.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structure of ximelagatran (<b>154</b>), which was withdrawn due to iDILI.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Marketed Drugs That Are Bioactivated to Reactive Metabolites</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Illustrative Examples of the Most Prescribed Drugs from 2009, Which Form Reactive Metabolites</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Detoxication of Iminium Ions by Cytosolic AO</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/medium/jm9b00917_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0004.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Association between total daily dose and IADRs for reactive metabolite-positive drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b00917/20200618/images/large/jm9b00917_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00917&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 178 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shenton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">Animal models of idiosyncratic drug reactions</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2004.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.cbi.2004.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15522261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFOntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=53-70&author=J.+M.+Shentonauthor=J.+Chenauthor=J.+P.+Uetrecht&title=Animal+models+of+idiosyncratic+drug+reactions&doi=10.1016%2Fj.cbi.2004.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of idiosyncratic drug reactions</span></div><div class="casAuthors">Shenton, Jacintha M.; Chen, Jie; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-70</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug reactions represent a major problem.  In most cases the mechanisms of these reactions are unknown, but circumstantial evidence points to the involvement of reactive metabolites and the characteristics of the reactions suggest involvement of the immune system.  If progress is to be made in dealing with these adverse reactions it is essential that the authors have a better understanding of their mechanisms, and it is hard to imagine testing mechanistic hypotheses without good animal models.  Unfortunately, idiosyncratic reactions are also idiosyncratic in animals so few good models exist.  The best models, in which a rodent develops a clin. syndrome similar to that which occurs in humans, appear to be penicillamine-induced autoimmunity in Brown Norway rats and nevirapine-induced skin rash in rats.  Sulfamethoxazole-induced hypersensitivity in dogs and propylthiouracil-induced autoimmunity in cats are also similar to adverse reactions that occur in people, but they have practical limitations.  Halothane-induced liver toxicity in guinea pigs and amodiaquine-induced bone marrow and liver toxicity in rats represent models in which there is an immune response and mild, reversible toxicity.  It is possible that the development of immune tolerance is what limits the toxicity in these models, and if this is true, interventions that prevent tolerance might lead to good models.  Although the history of developing animal models of idiosyncratic drug reactions is mostly one of failure, such models are essential.  A better understanding of immune tolerance may greatly facilitate the development of better models; transgenic technol. may also provide an important tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBKpDqQqY8_bVg90H21EOLACvtfcHk0lijks6UGgouzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFOntb0%253D&md5=001eb894c559412f2b21acb21f2dca71</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2004.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2004.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DShenton%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DAnimal%2520models%2520of%2520idiosyncratic%2520drug%2520reactions%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2004%26volume%3D150%26spage%3D53%26epage%3D70%26doi%3D10.1016%2Fj.cbi.2004.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnhart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwakar, J. A.</span></span>; <span class="NLM_contrib-group">DILIN Network.</span> <span> </span><span class="NLM_article-title">Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2014.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1053%2Fj.gastro.2014.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24681128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2014&pages=96-108&author=R.+J.+Fontanaauthor=P.+H.+Hayashiauthor=J.+Guauthor=K.+R.+Reddyauthor=H.+Barnhartauthor=P.+B.+Watkinsauthor=J.+Serranoauthor=W.+M.+Leeauthor=N.+Chalasaniauthor=A.+Stolzauthor=T.+Davernauthor=J.+A.+Talwakarauthor=DILIN+Network.&title=Idiosyncratic+drug-induced+liver+injury+is+associated+with+substantial+morbidity+and+mortality+within+6+months+from+onset&doi=10.1053%2Fj.gastro.2014.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset</span></div><div class="casAuthors">Fontana, Robert J.; Hayashi, Paul H.; Gu, Jiezhun; Reddy, K. Rajender; Barnhart, Huiman; Watkins, Paul B.; Serrano, Jose; Lee, William M.; Chalasani, Naga; Stolz, Andrew; Davern, Timothy; Talwakar, Jayant A.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-108.e4</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Little is known about the incidence of drug-induced liver injury (DILI) and risk factors for adverse outcomes.  We evaluated short-term outcomes of a large cohort of patients with DILI enrolled in an ongoing multicenter prospective study.  Data were collected from 660 adults with definite, highly likely, or probable DILI.  Regression methods were used to identify risk factors for early liver-related death or liver transplantation and chronic liver injury.Patients' median age was 51.4 years; 59.5% were female and 59.1% required hospitalization.  Within 6 mo of DILI onset, 30 patients received liver transplants (4.5%; 95% confidence interval [CI], 3.0%-6.1%) and 32 died (5%; 95% CI, 3.2%-6.5%); 53% of the deaths were liver related.  Asian race, absence of itching, lung disease, low serum albumin levels, low platelet counts, and high serum levels of alanine aminotransferase and total bilirubin at presentation were independent risk factors for reduced times to liver-related death or liver transplantation (C-statistic = 0.87).  At 6 mo after DILI onset, 18.9% of the 598 evaluable subjects had persistent liver damage.  African-American race, higher serum levels of alk. phosphatase, and prior heart disease or malignancy requiring treatment were independent risk factors for chronic DILI (C-statistic = 0.71).  Nearly 1 in 10 patients die or undergo liver transplantation within 6 mo of DILI onset and nearly 1 in 5 of the remaining patients have evidence of persistent liver injury at 6 mo.  The profile of liver injury at presentation, initial severity, patient's race, and medical comorbidities are important determinants of the likelihood of death/transplantation or persistent liver injury within 6 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoSmPoXLbnOLVg90H21EOLACvtfcHk0lijks6UGgouzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemurzL&md5=f544165ea7a64be953c6e571db8c8e17</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHayashi%26aufirst%3DP.%2BH.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DBarnhart%26aufirst%3DH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DSerrano%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DStolz%26aufirst%3DA.%26aulast%3DDavern%26aufirst%3DT.%26aulast%3DTalwakar%26aufirst%3DJ.%2BA.%26aulast%3D%26atitle%3DIdiosyncratic%2520drug-induced%2520liver%2520injury%2520is%2520associated%2520with%2520substantial%2520morbidity%2520and%2520mortality%2520within%25206%2520months%2520from%2520onset%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D147%26spage%3D96%26epage%3D108%26doi%3D10.1053%2Fj.gastro.2014.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">End, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerbes, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span> <span> </span><span class="NLM_article-title">Drug-induced liver injury: recent advances in diagnosis and risk assessment</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1164</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2016-313369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1136%2Fgutjnl-2016-313369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28341748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGrt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1154-1164&author=G.+A.+Kullak-Ublickauthor=R.+J.+Andradeauthor=M.+Merzauthor=P.+Endauthor=A.+Benesicauthor=A.+L.+Gerbesauthor=G.+P.+Aithal&title=Drug-induced+liver+injury%3A+recent+advances+in+diagnosis+and+risk+assessment&doi=10.1136%2Fgutjnl-2016-313369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury: recent advances in diagnosis and risk assessment</span></div><div class="casAuthors">Kullak-Ublick, Gerd A.; Andrade, Raul J.; Merz, Michael; End, Peter; Benesic, Andreas; Gerbes, Alexander L.; Aithal, Guruprasad P.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1154-1165</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (IDILI) is a rare but potentially severe adverse drug reaction that should be considered in patients who develop lab. criteria for liver injury secondary to the administration of a potentially hepatotoxic drug.  Although currently used liver parameters are sensitive in detecting DILI, they are neither specific nor able to predict the patient's subsequent clin. course.  Genetic risk assessment is useful mainly due to its high neg. predictive value, with several human leukocyte antigen alleles being assocd. with DILI.  New emerging biomarkers which could be useful in assessing DILI include total keratin18 (K18) and caspase-cleaved keratin18 (ccK18), macrophage colony-stimulating factor receptor 1, high mobility group box 1 and microRNA-122.  From the numerous in vitro test systems that are available, monocyte-derived hepatocytes generated from patients with DILI show promise in identifying the DILI-causing agent from among a panel of coprescribed drugs.  Several computer-based algorithms are available that rely on cumulative scores of known risk factors such as the administered dose or potential liabilities such as mitochondrial toxicity, inhibition of the bile salt export pump or the formation of reactive metabolites.  A novel DILI cluster score is being developed which predicts DILI from multiple complimentary cluster and classification models using absorption-distribution-metab.-elimination-related as well as physicochem. properties, diverse substructural descriptors and known structural liabilities.  The provision of more advanced scientific and regulatory guidance for liver safety assessment will depend on validating the new diagnostic markers in the ongoing DILI registries, biobanks and public-private partnerships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg0rCsrcAOVrVg90H21EOLACvtfcHk0lijks6UGgouzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGrt7nE&md5=6b89c8bd16584d2fefe6905a43bb9a5d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-313369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-313369%26sid%3Dliteratum%253Aachs%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DBenesic%26aufirst%3DA.%26aulast%3DGerbes%26aufirst%3DA.%2BL.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26atitle%3DDrug-induced%2520liver%2520injury%253A%2520recent%2520advances%2520in%2520diagnosis%2520and%2520risk%2520assessment%26jtitle%3DGut%26date%3D2017%26volume%3D66%26spage%3D1154%26epage%3D1164%26doi%3D10.1136%2Fgutjnl-2016-313369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wysowski, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, L.</span></span> <span> </span><span class="NLM_article-title">Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1001/archinte.165.12.1363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1001%2Farchinte.165.12.1363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15983284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2005&pages=1363-1369&author=D.+K.+Wysowskiauthor=L.+Swartz&title=Adverse+drug+event+surveillance+and+drug+withdrawals+in+the+United+States%2C+1969%E2%80%932002%3A+the+importance+of+reporting+suspected+reactions&doi=10.1001%2Farchinte.165.12.1363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions</span></div><div class="casAuthors">Wysowski Diane K; Swartz Lynette</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1363-9</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">BACKGROUND:  The Adverse Event Reporting System is the primary surveillance database used by the Food and Drug Administration for identifying postmarketing drug safety problems.  METHODS:  We analyzed all reports of suspected adverse drug reactions submitted to the Food and Drug Administration from the inception of the Adverse Event Reporting System database in 1969 through December 2002.  We documented drug withdrawals and restricted distribution programs based on safety concerns.  RESULTS:  During the 33-year period from 1969 when adverse drug event reporting was initiated through 2002, about 2.3 million case reports of adverse events for the cumulative number of approximately 6000 marketed drugs were entered in the database.  Most reports were for female patients.  During this period, numerous drug reactions have been identified and added to the product labeling as boxed warnings, warnings, precautions, contraindications, and adverse reactions.  More than 75 drugs/drug products have been removed from the market due to safety problems.  In addition, 11 drugs have special requirements for prescriptions or have restricted distribution programs.  Drugs withdrawn or restricted represent a small proportion (about 1%) of marketed drugs.  CONCLUSIONS:  The Food and Drug Administration's Adverse Event Reporting System is the primary surveillance database used for the identification of safety problems of marketed drugs.  Despite the limitations of underreporting, differential reporting, and uneven quality, submitted reports often allow the identification of serious adverse events that are added to the product labeling information.  In rare instances, additional regulations, up to and including market removal, have been required.  We encourage physicians, pharmacists, other health care professionals, and patients to continue to report serious suspected and known adverse drug reactions to manufacturers and the Food and Drug Administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZo2wh-0te33ELvajU9pjPfW6udTcc2ebnW-FVOpeFJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtFCgtg%253D%253D&md5=2bc9a0da05fc6f4cfaee071d354ed04d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1001%2Farchinte.165.12.1363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.165.12.1363%26sid%3Dliteratum%253Aachs%26aulast%3DWysowski%26aufirst%3DD.%2BK.%26aulast%3DSwartz%26aufirst%3DL.%26atitle%3DAdverse%2520drug%2520event%2520surveillance%2520and%2520drug%2520withdrawals%2520in%2520the%2520United%2520States%252C%25201969%25E2%2580%25932002%253A%2520the%2520importance%2520of%2520reporting%2520suspected%2520reactions%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D2005%26volume%3D165%26spage%3D1363%26epage%3D1369%26doi%3D10.1001%2Farchinte.165.12.1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slattery, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonese, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. C.</span></span> <span> </span><span class="NLM_article-title">Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1001/jama.296.1.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1001%2Fjama.296.1.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16820551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1KmsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2006&pages=87-93&author=P.+B.+Watkinsauthor=N.+Kaplowitzauthor=J.+T.+Slatteryauthor=C.+R.+Coloneseauthor=S.+V.+Colucciauthor=P.+W.+Stewartauthor=S.+C.+Harris&title=Aminotransferase+elevations+in+healthy+adults+receiving+4+grams+of+acetaminophen+daily%3A+a+randomized+controlled+trial&doi=10.1001%2Fjama.296.1.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. A randomized controlled trial</span></div><div class="casAuthors">Watkins, Paul B.; Kaplowitz, Neil; Slattery, John T.; Colonese, Connie R.; Colucci, Salvatore V.; Stewart, Paul W.; Harris, Stephen C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: During a clin. trial of a novel hydrocodone/acetaminophen combination, a high incidence of serum alanine aminotransferase (ALT) elevations was obsd.  Objective: To characterize the incidence and magnitude of ALT elevations in healthy participants receiving 4 g of acetaminophen daily, either alone or in combination with selected opioids, as compared with participants treated with placebo.  Design, Setting, and Participants: A randomized, single-blind, placebo-controlled, 5-treatment, parallel-group, inpatient, diet-controlled (meals provided), longitudinal study of 145 healthy adults in 2 US inpatient clin. pharmacol. units.  Intervention: Each participant received either placebo (n = 39), 1 of 3 acetaminophen/opioid combinations (n = 80), or acetaminophen alone (n = 26).  Each active treatment included 4 g of acetaminophen daily, the max. recommended daily dosage.  The intended treatment duration was 14 days.  Main Outcomes: Serum liver chemistries and trough acetaminophen concns. measured daily through 8 days, and at 1- or 2-day intervals thereafter.  Results: None of the 39 participants assigned to placebo had a max. ALT of more than 3 times the upper limit of normal.  In contrast, the incidence of max. ALT of more than 3 times the upper limits of normal was 31% to 44% in the 4 treatment groups receiving acetaminophen, including those participants treated with acetaminophen alone.  Compared with placebo, treatment with acetaminophen was assocd. with a markedly higher median max. ALT (ratio of medians, 2.78; 95% confidence interval, 1.47-4.09; P <.001).  Trough acetaminophen concns. did not exceed therapeutic limits in any participant and, after active treatment was discontinued, often decreased to undetectable levels before ALT elevations resolved.  Conclusions: Initiation of recurrent daily intake of 4 g of acetaminophen in healthy adults is assocd. with ALT elevations and concomitant treatment with opioids does not seem to increase this effect.  History of acetaminophen ingestion should be considered in the differential diagnosis of serum aminotransferase elevations, even in the absence of measurable serum acetaminophen concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrek-7Eqb9QjrVg90H21EOLACvtfcHk0ljckLS0InCstw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1KmsL0%253D&md5=3ced6c5b3b4d44c1072b0f1a6a2935bc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.296.1.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.296.1.87%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DKaplowitz%26aufirst%3DN.%26aulast%3DSlattery%26aufirst%3DJ.%2BT.%26aulast%3DColonese%26aufirst%3DC.%2BR.%26aulast%3DColucci%26aufirst%3DS.%2BV.%26aulast%3DStewart%26aufirst%3DP.%2BW.%26aulast%3DHarris%26aufirst%3DS.%2BC.%26atitle%3DAminotransferase%2520elevations%2520in%2520healthy%2520adults%2520receiving%25204%2520grams%2520of%2520acetaminophen%2520daily%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJAMA%26date%3D2006%26volume%3D296%26spage%3D87%26epage%3D93%26doi%3D10.1001%2Fjama.296.1.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostapowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiødt, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davern, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCashland, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakil, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crippin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blei, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span> <span> </span><span class="NLM_article-title">U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-137-12-200212170-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.7326%2F0003-4819-137-12-200212170-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12484709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BD38jit1Ogsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2002&pages=947-954&author=G.+Ostapowiczauthor=R.+J.+Fontanaauthor=F.+V.+Schi%C3%B8dtauthor=A.+Larsonauthor=T.+J.+Davernauthor=S.+H.+Hanauthor=T.+M.+McCashlandauthor=A.+O.+Shakilauthor=J.+E.+Hayauthor=L.+Hynanauthor=J.+S.+Crippinauthor=A.+T.+Bleiauthor=G.+Samuelauthor=J.+Reischauthor=W.+M.+Lee&title=U.S.+Acute+Liver+Failure+Study+Group.+Results+of+a+prospective+study+of+acute+liver+failure+at+17+tertiary+care+centers+in+the+United+States&doi=10.7326%2F0003-4819-137-12-200212170-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States</span></div><div class="casAuthors">Ostapowicz George; Fontana Robert J; Schiodt Frank V; Larson Anne; Davern Timothy J; Han Steven H B; McCashland Timothy M; Shakil A Obaid; Hay J Eileen; Hynan Linda; Crippin Jeffrey S; Blei Andres T; Samuel Grace; Reisch Joan; Lee William M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">947-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Because acute liver failure is rare, related data have been sparse.  Studies have suggested that viral hepatitis is the most common underlying cause of this condition.  OBJECTIVE:  To describe the clinical features, presumed causes, and short-term outcomes of acute liver failure.  DESIGN:  Prospective cohort study.  SETTING:  17 tertiary care centers participating in the U.S.  Acute Liver Failure Study Group.  PATIENTS:  308 consecutive patients with acute liver failure, admitted over a 41-month period.  MEASUREMENTS:  Detailed clinical and laboratory data collected during hospitalization, including outcome 3 weeks after study admission.  RESULTS:  73% of patients were women; median age was 38 years.  Acetaminophen overdose was the most common apparent cause of acute liver failure, accounting for 39% of cases.  Idiosyncratic drug reactions were the presumptive cause in 13% of cases, viral hepatitis A and B combined were implicated in 12% of cases, and 17% of cases were of indeterminate cause.  Overall patient survival at 3 weeks was 67%.  Twenty-nine percent of patients had liver transplantation, and 43% survived without transplantation.  Short-term transplant-free survival varied greatly, from 68% for patients with acetaminophen-related liver failure to 25% and 17% for those with other drug reactions and liver failure of indeterminate cause, respectively.  Coma grade at admission appeared to be associated with outcome, but age and symptom duration did not.  CONCLUSIONS:  Acetaminophen overdose and idiosyncratic drug reactions have replaced viral hepatitis as the most frequent apparent causes of acute liver failure.  Apparent cause and coma grade at admission were associated with outcome.  Although transplantation may improve patient survival, it was unavailable or unnecessary for most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6T3w9o9NPtZSWdIdmEou5fW6udTcc2ebnW-FVOpeFJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jit1Ogsw%253D%253D&md5=a21fc41e5462193a5d5a520498182585</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-137-12-200212170-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-137-12-200212170-00007%26sid%3Dliteratum%253Aachs%26aulast%3DOstapowicz%26aufirst%3DG.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DSchi%25C3%25B8dt%26aufirst%3DF.%2BV.%26aulast%3DLarson%26aufirst%3DA.%26aulast%3DDavern%26aufirst%3DT.%2BJ.%26aulast%3DHan%26aufirst%3DS.%2BH.%26aulast%3DMcCashland%26aufirst%3DT.%2BM.%26aulast%3DShakil%26aufirst%3DA.%2BO.%26aulast%3DHay%26aufirst%3DJ.%2BE.%26aulast%3DHynan%26aufirst%3DL.%26aulast%3DCrippin%26aufirst%3DJ.%2BS.%26aulast%3DBlei%26aufirst%3DA.%2BT.%26aulast%3DSamuel%26aufirst%3DG.%26aulast%3DReisch%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%2BM.%26atitle%3DU.S.%2520Acute%2520Liver%2520Failure%2520Study%2520Group.%2520Results%2520of%2520a%2520prospective%2520study%2520of%2520acute%2520liver%2520failure%2520at%252017%2520tertiary%2520care%2520centers%2520in%2520the%2520United%2520States%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2002%26volume%3D137%26spage%3D947%26epage%3D954%26doi%3D10.7326%2F0003-4819-137-12-200212170-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. M.</span></span> <span> </span><span class="NLM_article-title">Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a multicenter, prospective study</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2065</span>– <span class="NLM_lpage">2076</span>, <span class="refDoi"> DOI: 10.1002/hep.23937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.23937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20949552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BC3cbosVylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2010&pages=2065-2076&author=A.+Reubenauthor=D.+G.+Kochauthor=W.+M.+Lee&title=Acute+Liver+Failure+Study+Group.+Drug-induced+acute+liver+failure%3A+results+of+a+multicenter%2C+prospective+study&doi=10.1002%2Fhep.23937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced acute liver failure: results of a U.S. multicenter, prospective study</span></div><div class="casAuthors">Reuben Adrian; Koch David G; Lee William M</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2065-76</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Acute liver failure (ALF) due to drug-induced liver injury (DILI), though uncommon, is a concern for both clinicians and patients.  The Acute Liver Failure Study Group has prospectively collected cases of all forms of acute liver failure since 1998.  We describe here cases of idiosyncratic DILI ALF enrolled during a 10.5-year period.  Data were collected prospectively, using detailed case report forms, from 1198 subjects enrolled at 23 sites in the United States, all of which had transplant services.  A total of 133 (11.1%) ALF subjects were deemed by expert opinion to have DILI; 81.1% were considered highly likely, 15.0% probable, and 3.8% possible.  Subjects were mostly women (70.7%) and there was overrepresentation of minorities for unclear reasons.  Over 60 individual agents were implicated, the most common were antimicrobials (46%).  Transplant-free (3-week) survival was poor (27.1%), but with highly successful transplantation in 42.1%, overall survival was 66.2%.  Transplant-free survival in DILI ALF is determined by the degree of liver dysfunction, specifically baseline levels of bilirubin, prothrombin time/international normalized ratio, and Model for End-Stage Liver Disease scores.  CONCLUSION:  DILI is an uncommon cause of ALF that evolves slowly, affects a disproportionate number of women and minorities, and shows infrequent spontaneous recovery, but transplantation affords excellent survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHFYOHUFfJ7-kdrW1FkXG-fW6udTcc2eaFbRRXXJgyLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbosVylsg%253D%253D&md5=56694fae7b7d926de9a472105bfe4a67</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fhep.23937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23937%26sid%3Dliteratum%253Aachs%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DD.%2BG.%26aulast%3DLee%26aufirst%3DW.%2BM.%26atitle%3DAcute%2520Liver%2520Failure%2520Study%2520Group.%2520Drug-induced%2520acute%2520liver%2520failure%253A%2520results%2520of%2520a%2520multicenter%252C%2520prospective%2520study%26jtitle%3DHepatology%26date%3D2010%26volume%3D52%26spage%3D2065%26epage%3D2076%26doi%3D10.1002%2Fhep.23937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span> <span> </span><span class="NLM_article-title">Update on advances in research on idiosyncratic drug-induced liver injury</span>. <i>Allergy, Asthma Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.4168/aair.2016.8.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.4168%2Faair.2016.8.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=26540496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVSlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=3-11&author=S.+H.+Kimauthor=D.+J.+Naisbitt&title=Update+on+advances+in+research+on+idiosyncratic+drug-induced+liver+injury&doi=10.4168%2Faair.2016.8.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Update on advances in research on idiosyncratic drug induced liver injury</span></div><div class="casAuthors">Kim, Seung-Hyun; Naisbitt, Dean J.</div><div class="citationInfo"><span class="NLM_cas:title">Allergy, Asthma & Immunology Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-11</span>CODEN:
                <span class="NLM_cas:coden">AAIRBQ</span>;
        ISSN:<span class="NLM_cas:issn">2092-7355</span>.
    
            (<span class="NLM_cas:orgname">Korean Academy of Asthma, Allergy and Clinical Immunology</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings.  Thus, it is important to identify biomarkers for early prediction to increase our understanding of mechanisms underlying DILI that will ultimately aid in the exploration of novel therapeutic strategies to prevent or manage DILI.  DILI can be subdivided into 'intrinsic' and 'idiosyncratic' categories, although the validity of this classification remains controversial.  Idiosyncratic DILI occurs in a minority of susceptible individuals with a prolonged latency, while intrinsic DILI results from drug- induced direct hepatotoxicity over the course of a few days.  The rare occurrence of idiosyncratic DILI requires multicenter collaborative investigations and phenotype standardization.  Recent progress in research on idiosyncratic DILI is based on key developments in 3 areas: (1) newly developed high-throughput genotyping across the whole genome allowing for the identification of genetic susceptibility markers, (2) new mechanistic concepts on the pathogenesis of DILI revealing a key role of drug-responsive T lymphocytes in the immunol. response, and (3) broad multidisciplinary approaches using different platform "-omics" technologies that have identified novel biomarkers for the prediction of DILI.  An assocn. of a specific human leukocyte antigen (HLA) allele with DILI has been reported for several drugs.  HLA-restricted T-cell immune responses have also been investigated using lymphocytes and T-cell clones isolated from patients.  A microRNA, miR-122, has been discovered as a promising biomarker for the early prediction of DILI.  In this review, we summarize recent advances in research on idiosyncratic DILI with an understanding of the key role of adaptive immune systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosy7gsP5cRU7Vg90H21EOLACvtfcHk0ljzxB0Bx--hJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVSlu7o%253D&md5=28a6aed0fba78a442c96cdd48af244ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4168%2Faair.2016.8.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4168%252Faair.2016.8.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26atitle%3DUpdate%2520on%2520advances%2520in%2520research%2520on%2520idiosyncratic%2520drug-induced%2520liver%2520injury%26jtitle%3DAllergy%252C%2520Asthma%2520Immunol.%2520Res.%26date%3D2016%26volume%3D8%26spage%3D3%26epage%3D11%26doi%3D10.4168%2Faair.2016.8.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic reaction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=295-314&author=T.+Choauthor=J.+P.+Uetrecht&title=How+reactive+metabolites+induce+an+immune+response+that+sometimes+leads+to+an+idiosyncratic+reaction&doi=10.1021%2Facs.chemrestox.6b00357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction</span></div><div class="casAuthors">Cho, Tiffany; Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-314</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Little is known with certainty about the mechanisms of idiosyncratic drug reactions (IDRs); however, there is substantive evidence that reactive metabolites are involved in most, but not all, IDRs.  In addn., evidence also suggests that most IDRs are immune mediated.  That raises the question of how reactive metabolites induce an immune response that can lead to an IDR.  The dominant hypotheses are the hapten and danger hypotheses.  These are complementary hypotheses: a reactive metabolite can act as a hapten to produce neoantigens, and it can also cause cell damage leading to the release of danger-assocd. mol. pattern mols. that activate antigen presenting cells.  Both are required for an immune response.  In addn., drugs may induce an immune response through inflammasome activation.  The authors have found examples in which the ability to activate inflammasomes differentiated drugs that cause IDRs from similar drugs that do not.  There are other hypotheses that do not involve an immune mechanism such as mitochondrial injury and bile salt export pump (BSEP) inhibition.  With some possible exception, these hypotheses are unlikely to be able to completely explain IDRs.  However, some types of mitochondrial injury or BSEP inhibition could produce danger signals.  The major mechanism that protects individuals from IDRs appears to be immune tolerance.  Consistent with this hypothesis, the authors used checkpoint inhibition to develop the first animal model of idiosyncratic drug-induced liver injury that has the same characteristics as the idiosyncratic injury in humans.  This was accomplished by treating Pd-1-/- mice with anti-CTLA-4 antibodies and amodiaquine.  The combination of the Pd-1-/- mouse and anti-CTLA-4 also unmasks the ability of other drugs such as isoniazid to cause delayed type liver injury.  This model should allow rigorous testing of mechanistic hypotheses that was impossible in the past.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHhl49wBgcXLVg90H21EOLACvtfcHk0lgDjPESwm0Wqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslagsb3M&md5=04137ee96f32fea06c39a22eea4e4200</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00357%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DT.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DHow%2520reactive%2520metabolites%2520induce%2520an%2520immune%2520response%2520that%2520sometimes%2520leads%2520to%2520an%2520idiosyncratic%2520reaction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26spage%3D295%26epage%3D314%26doi%3D10.1021%2Facs.chemrestox.6b00357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metushi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, E.</span></span> <span> </span><span class="NLM_article-title">Mechanism of isoniazid-induced hepatotoxicity: then and now</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1030</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1111/bcp.12885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fbcp.12885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=26773235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BC28ngvVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=1030-1036&author=I.+Metushiauthor=J.+Uetrechtauthor=E.+Phillips&title=Mechanism+of+isoniazid-induced+hepatotoxicity%3A+then+and+now&doi=10.1111%2Fbcp.12885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of isoniazid-induced hepatotoxicity: then and now</span></div><div class="casAuthors">Metushi Imir; Uetrecht Jack; Phillips Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1030-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Isoniazid (INH) remains a mainstay for the treatment of tuberculosis despite the fact that it can cause liver failure.  Previous mechanistic hypotheses have classified this type of drug-induced liver injury (DILI) as 'metabolic idiosyncrasy' which was thought not to involve an immune response and was mainly due to the bioactivation of the acetylhydrazine metabolite.  However, more recent studies support an alternative hypothesis, specifically, that INH itself is directly bioactivated to a reactive metabolite, which in some patients leads to an immune response and liver injury.  Furthermore, there appear to be two phenotypes of INH-induced liver injury.  Most cases involve mild liver injury, which resolves with immune tolerance, while other cases appear to have a more severe phenotype that is associated with the production of anti-drug/anti-CYP P450 antibodies and can progress to liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxLs_2BQTg9LesJRIHUP1ofW6udTcc2eZ-ZsAvs-umzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngvVyrtg%253D%253D&md5=a3ac61a3e529fb04b6d365fff5391506</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12885%26sid%3Dliteratum%253Aachs%26aulast%3DMetushi%26aufirst%3DI.%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DE.%26atitle%3DMechanism%2520of%2520isoniazid-induced%2520hepatotoxicity%253A%2520then%2520and%2520now%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D81%26spage%3D1030%26epage%3D1036%26doi%3D10.1111%2Fbcp.12885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hankins, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span> <span> </span><span class="NLM_article-title">Clinical isoflurane metabolism by cytochrome P 450 2E1</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">771</span>, <span class="refDoi"> DOI: 10.1097/00000542-199903000-00019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1097%2F00000542-199903000-00019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10078678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFKhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1999&pages=766-771&author=E.+D.+Kharaschauthor=D.+C.+Hankinsauthor=K.+Cox&title=Clinical+isoflurane+metabolism+by+cytochrome+P+450+2E1&doi=10.1097%2F00000542-199903000-00019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical isoflurane metabolism by cytochrome P450 2E1</span></div><div class="casAuthors">Kharasch, Evan D.; Hankins, Douglas C.; Cox, Kathy</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">766-771</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Some evidence suggests that isoflurane metab. to trifluoroacetic acid and inorg. fluoride by human liver microsomes in vitro is catalyzed by cytochrome P 450 2E1 (CYP2E1).  This investigation tested the hypothesis that P 450 2E1 predominantly catalyzes human isoflurane metab. in vivo.  Disulfiram, which is converted in vivo to a selective inhibitor of P 450 2E1, was used as a metabolic probe for P 450 2E1.  Twenty-two elective surgery patients who provided institutionally-approved written informed consent were randomized to receive disulfiram (500 mg orally, N = 12) or nothing (controls, N = 10) the evening before surgery.  All patients received a std. isoflurane anesthetic (1.5% end-tidal in oxygen) for 8 h.  Urine and plasma trifluoroacetic acid and fluoride concns. were quantitated in samples obtained for 4 days postoperatively.  Patient groups were similar with respect to age, wt., gender, duration of surgery, blood loss, and delivered isoflurane dose, measured by cumulative end-tidal isoflurane concns. (9.7-10.2 MAC-hr).  Postoperative urine excretion of trifluoroacetic acid (days 1-4) and fluoride (days 1-3) was significantly (P < 0.05) diminished in disulfiram-treated patients.  Cumulative 0-96 h excretion of trifluoroacetic acid and fluoride in disulfiram-treated patients was 34 ± 72 and 270 ± 70 μmoles (mean ± SD), resp., compared to 440 ± 360 and 1500 ± 800 μmoles in controls (P < 0.05 for both).  Disulfiram also abolished the rise in plasma metabolite concns.  Disulfiram, a selective inhibitor of human hepatic P 450 2E1, prevented 80-90% of isoflurane metab.  These results suggest that P 450 2E1 is the predominant P 450 isoform responsible for human clin. isoflurane metab. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOiG5F2J-HV7Vg90H21EOLACvtfcHk0lgDjPESwm0Wqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFKhur4%253D&md5=4b4c448ff90ee438102a0aafdf520d67</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2F00000542-199903000-00019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-199903000-00019%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DHankins%26aufirst%3DD.%2BC.%26aulast%3DCox%26aufirst%3DK.%26atitle%3DClinical%2520isoflurane%2520metabolism%2520by%2520cytochrome%2520P%2520450%25202E1%26jtitle%3DAnesthesiology%26date%3D1999%26volume%3D90%26spage%3D766%26epage%3D771%26doi%3D10.1097%2F00000542-199903000-00019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. A.</span></span> <span> </span><span class="NLM_article-title">The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazobenzene</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1947</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaH1cXhsVWrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1947&pages=468-480&author=E.+C.+Millerauthor=J.+A.+Miller&title=The+presence+and+significance+of+bound+aminoazo+dyes+in+the+livers+of+rats+fed+p-dimethylaminoazobenzene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazobenzene</span></div><div class="casAuthors">Miller, Elizabeth C.; Miller, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1947</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">468-80</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">cf. C.A. 41, 198h.  The livers (but not liver tumors) of rats fed p-dimethylaminoazobenzene (I) contained aminoazo dyes bound tightly to a cellular constituent, probably protein.  The bound dye (II), and no free aminoazo dye, appeared in a crude liver powder consisting of at least 97% protein + nucleoprotein.  II liberated by alk. hydrolysis was fractionated into p-methylaminoazobenzene (III), p-aminoazobenzene (IV) and an unidentified polar dye.  No II was found in rat tissues in which I did not produce tumors, i.e., small intestine, kidney, spleen, lung, heart, skeletal muscle.  Small amts. of II were found in blood plasma proteins, none in crythrocytes.  The feeding of III (carcinogenic metabolite of I) led to the same II production as did the feeding of I.  Feeding of IV (noncarcinogenic) led to the production of only bound IV and very low levels of an apparently nonmethylated polar bound dye in the liver.  Mice, which develop liver tumors slowly, showed lower liver II levels than rats.  No II was found in the livers of guinea pigs, rabbits, cotton rats, or chickens, species which resist I carcinogenesis.  When I was fed to rats, the II level in the liver reached a max. in 4-6 weeks, and then slowly decreased.  Throughout a I-feeding period of 5 months, the liver II level was increased by a protective diet high in riboflavin.  The role of II in I carcinogenesis is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrwHW-N3N6BbVg90H21EOLACvtfcHk0lgMgcnNehIAZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaH1cXhsVWrsQ%253D%253D&md5=c81f018b96d098fa2c6a4d877f7e7362</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DE.%2BC.%26aulast%3DMiller%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520presence%2520and%2520significance%2520of%2520bound%2520aminoazo%2520dyes%2520in%2520the%2520livers%2520of%2520rats%2520fed%2520p-dimethylaminoazobenzene%26jtitle%3DCancer%2520Res.%26date%3D1947%26volume%3D7%26spage%3D468%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. A.</span></span> <span> </span><span class="NLM_article-title">The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis. A collaboration with Elizabeth Cavert Miller and our associates</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.3109/03602539808996326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602539808996326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9844805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXotVertrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1998&pages=645-674&author=J.+A.+Miller&title=The+metabolism+of+xenobiotics+to+reactive+electrophiles+in+chemical+carcinogenesis+and+mutagenesis.+A+collaboration+with+Elizabeth+Cavert+Miller+and+our+associates&doi=10.3109%2F03602539808996326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates</span></div><div class="casAuthors">Miller, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">645-674</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review and discussion with 111 refs.  Aminoazo dyes, discovery of the covalent binding of N,N-dimethyl-4-aminoazobenzene to protein and nucleic acids in vivo, discovery of the metab. of aminoazo dyes by hepatic microsomal enzymes, central role of electrophilic xenobiotics in carcinogenesis and mutagenesis, etc., are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8HgUOUGqbS7Vg90H21EOLACvtfcHk0lgMgcnNehIAZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVertrw%253D&md5=f930aaa9697c541a9a17214186f5c12c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3109%2F03602539808996326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602539808996326%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520metabolism%2520of%2520xenobiotics%2520to%2520reactive%2520electrophiles%2520in%2520chemical%2520carcinogenesis%2520and%2520mutagenesis.%2520A%2520collaboration%2520with%2520Elizabeth%2520Cavert%2520Miller%2520and%2520our%2520associates%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1998%26volume%3D30%26spage%3D645%26epage%3D674%26doi%3D10.3109%2F03602539808996326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benigni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossa, C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2536</span>, <span class="refDoi"> DOI: 10.1021/cr100222q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr100222q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=2507-2536&author=R.+Benigniauthor=C.+Bossa&title=Mechanisms+of+chemical+carcinogenicity+and+mutagenicity%3A+a+review+with+implications+for+predictive+toxicology&doi=10.1021%2Fcr100222q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Chemical Carcinogenicity and Mutagenicity: A Review with Implications for Predictive Toxicology</span></div><div class="casAuthors">Benigni, Romualdo; Bossa, Cecilia</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2507-2536</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A review discusses the mechanisms of action of carcinogens and the mutagenicity and carcinogenicity.  It also presents the theor. models on the relationship between chem. structure and the mol. mechanisms of toxic activity; however, this is limited only to those studies that contribute to a better mechanistic understanding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAGOG5oiD49LVg90H21EOLACvtfcHk0lgMgcnNehIAZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKgt7w%253D&md5=a7806197d387db12fd3f875a8511c3cb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fcr100222q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr100222q%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DBossa%26aufirst%3DC.%26atitle%3DMechanisms%2520of%2520chemical%2520carcinogenicity%2520and%2520mutagenicity%253A%2520a%2520review%2520with%2520implications%2520for%2520predictive%2520toxicology%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D2507%26epage%3D2536%26doi%3D10.1021%2Fcr100222q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>International
Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use. Guidance on Genotoxicity Testing
and Data Interpretation for Pharmaceuticals Intended for Human Use;
S2(R1). <a href="https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf" class="extLink">https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf</a> (November, <span class="NLM_year">2011</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=International%0AConference+on+Harmonisation+of+Technical+Requirements+for+Registration%0Aof+Pharmaceuticals+for+Human+Use.+Guidance+on+Genotoxicity+Testing%0Aand+Data+Interpretation+for+Pharmaceuticals+Intended+for+Human+Use%3B%0AS2%28R1%29.+https%3A%2F%2Fwww.ich.org%2Ffileadmin%2FPublic_Web_Site%2FICH_Products%2FGuidelines%2FSafety%2FS2_R1%2FStep4%2FS2R1_Step4.pdf+%28November%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Drug metabolism as a cause of drug toxicity</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4149413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2MXhtV2isw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1973&pages=418-423&author=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Drug+metabolism+as+a+cause+of+drug+toxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Drug metabolism as a cause of drug toxicity</span></div><div class="casAuthors">Mitchell, Jerry R.; Jollow, D. J.; Gillette, James R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">418-23</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">A review with 29 refs. on the metab. of drugs in vivo to produce toxic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBJi3P8Ybo7Vg90H21EOLACvtfcHk0ljkPuPHUM-r0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhtV2isw%253D%253D&md5=5697ed4d6a8a15e2234181846dd15909</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DDrug%2520metabolism%2520as%2520a%2520cause%2520of%2520drug%2520toxicity%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1973%26volume%3D1%26spage%3D418%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4746326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVCmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=185-194&author=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=W.+Z.+Potterauthor=D.+C.+Davisauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+I.+Role+of+drug+metabolism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  I.  Role of drug metabolism</span></div><div class="casAuthors">Mitchell, J. R.; Jollow, D. J.; Potter, W. Z.; Davis, D. C.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-94</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Massive overdoses of acetaminophen (I) [103-90-2] produce an hepatic necrosis in man and such necrosis may be mediated by a toxic metabolite of I.  I concns. in rat and mouse tissues were compared with the severity of liver damage after alteration of the rate of metab. of I.  Phenobarbital [50-06-6] pretreatment stimulated the disappearance of I from tissues but markedly potentiated the hepatic necrosis.  In contrast, piperonyl butoxide [51-03-6] pretreatment inhibited the metab. and disappearance of I from tissues yet dramatically protected against hepatic necrosis.  Cobaltous chloride [7646-79-9], which inhibits synthesis of cytochrome P 450, prevented the hepatic damage.  The data indicate that potent metabolites formed in small quantities are responsible for the I toxicity, and that the toxic metabolite arises from a cytochrome P 450-dependent pathway of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd85kEAGt9arVg90H21EOLACvtfcHk0ljkPuPHUM-r0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVCmsw%253D%253D&md5=45a5734dfc02dfc4b352f09025599d37</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%2520I.%2520Role%2520of%2520drug%2520metabolism%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D185%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4746327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVCmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=195-202&author=D.+J.+Jollowauthor=J.+R.+Mitchellauthor=W.+Z.+Potterauthor=D.+C.+Davisauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+II.+Role+of+covalent+binding+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  II.  Role of covalent binding in vivo</span></div><div class="casAuthors">Jollow, D. J.; Mitchell, J. R.; Potter, W. Z.; Davis, D. C.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-202</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Doses of tritiated acetaminophen (I) [103-90-2] (300-750 mg/kg) that cause necrosis in mice resulted in large amts. of radiolabeled material covalently bound to mouse liver protein in vivo.  Both covalent binding and hepatic necrosis were dose dependent, and the peak level of binding preceded the development of recognizable necrosis by at least 1-2 hr.  Pretreatment of mice with phenobarbital [50-06-6], piperonyl butoxide [51-03-6], or cobaltous chloride [7646-79-9], which changed the rate of metab. of 3H-I and altered the severity of hepatic necrosis, similarly affected the extent of hepatic binding of radiolabeled metabolite.  Furthermore, the degree of binding in individual mice was always directly proportional to the severity of hepatic necrosis regardless of the biol. variation among animals.  Apparently, I-induced hepatic necrosis is caused by the covalent binding of a chem. reactive metabolite to vital hepatic macromols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoSDW2K-BYj7Vg90H21EOLACvtfcHk0ljkPuPHUM-r0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVCmsA%253D%253D&md5=fbf3c4b0e660e7fdd41591e63c72b696</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%2520II.%2520Role%2520of%2520covalent%2520binding%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D195%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">210</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4147720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=203-210&author=W.+Z.+Potterauthor=D.+C.+Davisauthor=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+3.+Cytochrome+P-450-mediated+covalent+binding+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  III.  Cytochrome P 450-mediated covalent binding in vitro</span></div><div class="casAuthors">Potter, W. Z.; Davis, D. C.; Mitchell, J. R.; Jollow, D. J.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">203-10</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The covalent binding of acetaminophen (I) [103-90-2] to rat and mouse hepatic microsomal protein was linear with time and with protein concn.  NADPH and O were necessary for the binding while carbon monoxide or cobaltous chloride pretreatment inhibited it, demonstrating that a cytochrome P 450 [9035-51-2]-dependent, mixed function oxidase [9035-73-8] mediated the binding.  The extent of in vitro binding correlated with treatments that alter hepatic necrosis and in vivo binding, indicating that in vitro binding was a valid index of I-induced hepatotoxicity.  Analogous studies with 2-acetylaminofluorene [53-96-3] showed that its binding to microsomal protein also was dependent on cytochrome P 450.  Since the toxicity of 2-acetylaminofluorene results from its conversion to an N-hydroxy deriv., the hepatotoxic metabolite of I may be an N-hydroxy deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxRuUZA6b7FbVg90H21EOLACvtfcHk0lh2SDBZCs5CzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVehsg%253D%253D&md5=0e7dab9c264d1b753e7afe2caefbedcd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%25203.%2520Cytochrome%2520P-450-mediated%2520covalent%2520binding%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D203%26epage%3D210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, B. B.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">217</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4746329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2cXislQ%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=1973&pages=211-217&author=J.+R.+Mitchellauthor=D.+J.+Jollowauthor=W.+Z.+Potterauthor=J.+R.+Gilletteauthor=B.+B.+Brodie&title=Acetaminophen-induced+hepatic+necrosis.+IV.+Protective+role+of+glutathione"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-induced hepatic necrosis.  IV.  Protective role of glutathione</span></div><div class="casAuthors">Mitchell, J. R.; Jollow, D. J.; Potter, W. Z.; Gillette, J. R.; Brodie, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">211-17</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Pretreatment of mice with diethyl maleate, which depletes hepatic glutathione [70-18-8], potentiated acetaminophen (I) [103-90-2]-induced hepatic necrosis, whereas pretreatment with cysteine, a glutathione precursor, prevented hepatic damage.  Administration of I caused a dose-dependent depletion of hepatic glutathione.  Glutathione depletion by I was enhanced by treatments that potentiate the hepatic necrosis and covalent binding produced by the toxic metabolite of I.  Conversely, glutathione depletion was inhibited by treatments that protect against these toxic effects.  Moreover, covalent binding of this metabolite to hepatic macromols. did not occur until the availability of glutathione was exhausted through conjugation with the metabolite.  Similarly, alteration of glutathione availability by pretreatment with diethyl maleate or cysteine, resp., increased or decreased covalent binding of the toxic metabolite.  Apparently, glutathione protects tissues against electrophilic attack by drug metabolites and other alkylating agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5c4UbpA9FA7Vg90H21EOLACvtfcHk0lh2SDBZCs5CzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXislQ%253D&md5=a73871b7fd81aa793a35337576a2c43a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DGillette%26aufirst%3DJ.%2BR.%26aulast%3DBrodie%26aufirst%3DB.%2BB.%26atitle%3DAcetaminophen-induced%2520hepatic%2520necrosis.%2520IV.%2520Protective%2520role%2520of%2520glutathione%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1973%26volume%3D187%26spage%3D211%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span> <span> </span><span class="NLM_article-title">N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1073/pnas.81.5.1327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1073%2Fpnas.81.5.1327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6424115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL2cXhs1Olurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1984&pages=1327-1331&author=D.+C.+Dahlinauthor=G.+T.+Miwaauthor=A.+Y.+Luauthor=S.+D.+Nelson&title=N-acetyl-p-benzoquinone+imine%3A+a+cytochrome+P-450-mediated+oxidation+product+of+acetaminophen&doi=10.1073%2Fpnas.81.5.1327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">N-Acetyl-p-benzoquinone imine:  a cytochrome P-450-mediated oxidation product of acetaminophen</span></div><div class="casAuthors">Dahlin, David C.; Miwa, Gerald T.; Lu, Anthony Y. H.; Nelson, Sidney D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1327-31</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Direct detection of N-acetyl-p-benzoquinone imine (NAPQI)  [50700-49-7] formed as an oxidn. product of acetaminophen  [103-90-2] by cytochrome P-450  [9035-51-2] and cumene hydroperoxide is presented.  Indirect evidence for NAPQI formation from acetaminophen by cytochrome P-450, NADPH  [53-57-6], and NADPH-cytochrome P-450 reductase  [9039-06-9] is presented.  Evidence is provided for the rapid redn. of NAPQI back to acetaminophen by NADPH and NADPH-cytochrome P-450 reductase such that steady-state levels of NAPQI were below its detection limits of 6.7 × 10-8 M.  In mouse liver microsomal incubations, radiolabeled analogs of both NAPQI and acetaminophen bound covalently to microsomal protein with the loss of ∼20% of the acetyl group as acetamide  [60-35-5].  The binding in each case was decreased by glutathione  [70-18-8] with concomitant formation of 3-S-glutathionylacetaminophen  [64889-81-2].  The binding also was decreased by L-ascorbic acid, NADPH, and NADH  [58-68-4] with redn. of NAPQI to acetaminophen.  Results of partitioning expts. indicate that NAPQI is a major metabolite of acetaminophen, a considerable fraction of which is rapidly reduced back to acetaminophen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX3_U_K2KCf7Vg90H21EOLACvtfcHk0lh2SDBZCs5CzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhs1Olurg%253D&md5=73f702bec27640961cce65b3153b3e4f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.81.5.1327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.81.5.1327%26sid%3Dliteratum%253Aachs%26aulast%3DDahlin%26aufirst%3DD.%2BC.%26aulast%3DMiwa%26aufirst%3DG.%2BT.%26aulast%3DLu%26aufirst%3DA.%2BY.%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DN-acetyl-p-benzoquinone%2520imine%253A%2520a%2520cytochrome%2520P-450-mediated%2520oxidation%2520product%2520of%2520acetaminophen%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1984%26volume%3D81%26spage%3D1327%26epage%3D1331%26doi%3D10.1073%2Fpnas.81.5.1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein-Schwartz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyon, S.</span></span> <span> </span><span class="NLM_article-title">Intravenous acetylcysteine for the treatment of acetaminophen overdose</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1517/14656566.2011.537261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1517%2F14656566.2011.537261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=21126198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFKqurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=119-130&author=W.+Klein-Schwartzauthor=S.+Doyon&title=Intravenous+acetylcysteine+for+the+treatment+of+acetaminophen+overdose&doi=10.1517%2F14656566.2011.537261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Intravenous acetylcysteine for the treatment of acetaminophen overdose</span></div><div class="casAuthors">Klein-Schwartz, Wendy; Doyon, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-130</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Acetaminophen is a leading cause of overdose-related hepatotoxicity.  Although acetylcysteine prevents or minimizes acetaminophen-induced hepatotoxicity and reduces mortality, some patients presenting with complicated overdose scenarios (massive ingestions or combination or modified-release formulations) may develop toxicity despite administration of recommended dosage regimen.  Areas covered in this review: The article evaluates evidence regarding i.v. acetylcysteine's effectiveness in patients with acute overdoses who receive treatment within 10 h or > 10 h, patients with chronic supratherapeutic ingestions, and those with acetaminophen-induced fulminant hepatic failure.  I.v. and oral acetylcysteine are compared.  What the reader will gain: A one-size-fits-all approach towards acetylcysteine therapy provides suboptimal care in some patients.  High-risk patients are identified.  Specific discontinuation criteria are presented.  Take home message: The std. i.v. regimen will effectively treat most early-presenting uncomplicated overdoses.  Acetylcysteine dosing should be individualized in patients with complicated presentations and in particular situations in which plasma acetaminophen concns. may be persistently elevated at the end of the infusion or in late presenters.  More studies are needed to evaluate the optimal i.v. dosage regimen and the role of oral acetylcysteine in these high-risk patients.  Treatment decisions may be aided by consultation with a poison center and/or clin. toxicologist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtbb9lG-qQCLVg90H21EOLACvtfcHk0liENo7eHYWzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFKqurjI&md5=588091f5bdf86d90ee296840c7aeeb2c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14656566.2011.537261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2011.537261%26sid%3Dliteratum%253Aachs%26aulast%3DKlein-Schwartz%26aufirst%3DW.%26aulast%3DDoyon%26aufirst%3DS.%26atitle%3DIntravenous%2520acetylcysteine%2520for%2520the%2520treatment%2520of%2520acetaminophen%2520overdose%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2011%26volume%3D12%26spage%3D119%26epage%3D130%26doi%3D10.1517%2F14656566.2011.537261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jollow, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. R.</span></span> <span> </span><span class="NLM_article-title">Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2099</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(74)90092-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0024-3205%2874%2990092-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4847802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaE2MXhtVKgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1974&pages=2099-2109&author=D.+C.+Davisauthor=W.+Z.+Potterauthor=D.+J.+Jollowauthor=J.+R.+Mitchell&title=Species+differences+in+hepatic+glutathione+depletion%2C+covalent+binding+and+hepatic+necrosis+after+acetaminophen&doi=10.1016%2F0024-3205%2874%2990092-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Species differences in hepatic glutathione depletion, covalent binding, and hepatic necrosis after acetaminophen</span></div><div class="casAuthors">Davis, Donald C.; Potter, William Z.; Jollow, David J.; Mitchell, Jerry R.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2099-109</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">The severity of hepatic injury in 5 mammals after acetaminophen (I) [103-90-2] (150-1500 mg/kg, i.p.) administration correlated with the extent of covalent binding of I by liver microsomes and with the rate of hepatic glutathione [70-18-8] depletion in vivo.  I (300 mg/kg) depleted glutathione ∼80% in hamsters and mice, which were extremely susceptible to I-induced hepatotoxicity, and only 30% in guinea pigs and 10% in rats, which were less susceptible.  Hepatic microsomal enzymes may convert I to a toxic arylating agent which is detoxified by conjugation with glutathione until glutathione availability is exceeded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq41RvgdIp1ZbVg90H21EOLACvtfcHk0liENo7eHYWzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhtVKgsr4%253D&md5=4e650884f843517aab2386997e1d0547</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2874%2990092-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252874%252990092-7%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DD.%2BC.%26aulast%3DPotter%26aufirst%3DW.%2BZ.%26aulast%3DJollow%26aufirst%3DD.%2BJ.%26aulast%3DMitchell%26aufirst%3DJ.%2BR.%26atitle%3DSpecies%2520differences%2520in%2520hepatic%2520glutathione%2520depletion%252C%2520covalent%2520binding%2520and%2520hepatic%2520necrosis%2520after%2520acetaminophen%26jtitle%3DLife%2520Sci.%26date%3D1974%26volume%3D14%26spage%3D2099%26epage%3D2109%26doi%3D10.1016%2F0024-3205%2874%2990092-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of the hepatotoxicity caused by acetaminophen</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1040482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1055%2Fs-2008-1040482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=2281334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK3M7is1Ghuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1990&pages=267-278&author=S.+D.+Nelson&title=Molecular+mechanisms+of+the+hepatotoxicity+caused+by+acetaminophen&doi=10.1055%2Fs-2008-1040482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of the hepatotoxicity caused by acetaminophen</span></div><div class="casAuthors">Nelson S D</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in liver disease</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">267-78</span>
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8S4fz-S7CaIIRAdBLKY41fW6udTcc2eZyYYoLBjBy27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M7is1Ghuw%253D%253D&md5=9e4982d996288af3db4f1894acd7683c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1040482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1040482%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DMolecular%2520mechanisms%2520of%2520the%2520hepatotoxicity%2520caused%2520by%2520acetaminophen%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D1990%26volume%3D10%26spage%3D267%26epage%3D278%26doi%3D10.1055%2Fs-2008-1040482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S. D.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation and drug toxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1021/jm00349a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00349a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL38XktVSjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1982&pages=753-765&author=S.+D.+Nelson&title=Metabolic+activation+and+drug+toxicity&doi=10.1021%2Fjm00349a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation and drug toxicity</span></div><div class="casAuthors">Nelson, Sidney D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">753-65</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A review with 128 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzUsG75cxLYLVg90H21EOLACvtfcHk0ljphMEPTl_EOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktVSjsL8%253D&md5=89c759fff948a83bb8edebef1c8cdbad</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00349a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00349a001%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DS.%2BD.%26atitle%3DMetabolic%2520activation%2520and%2520drug%2520toxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1982%26volume%3D25%26spage%3D753%26epage%3D765%26doi%3D10.1021%2Fjm00349a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, S. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic functional groups</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.2174/1389200054021799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15975040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutkarauthor=I.+Gardnerauthor=R.+S.+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnellauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+functional+groups&doi=10.2174%2F1389200054021799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive listing of bioactivation pathways of organic functional groups</span></div><div class="casAuthors">Kalgutkar, Amit S.; Gardner, Iain; Obach, R. Scott; Shaffer, Christopher L.; Callegari, Ernesto; Henne, Kirk R.; Mutlib, Abdul E.; Dalvie, Deepak K.; Lee, Jae S.; Nakai, Yasuhiro; O'Donnell, John P.; Boer, Jason; Harriman, Shawn P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-225</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of idiosyncratic adverse drug reactions during late clin. trials or after a drug has been released can lead to a severe restriction in its use and even in its withdrawal.  Metabolic activation of relatively inert functional groups to reactive electrophilic intermediates is considered to be an obligatory event in the etiol. of many drug-induced adverse reactions.  Therefore, a thorough examn. of the biochem. reactivity of functional groups/structural motifs in all new drug candidates is essential from a safety standpoint.  A major theme attempted in this review is the comprehensive cataloging of all of the known bioactivation pathways of functional groups or structural motifs commonly utilized in drug design efforts.  Potential strategies in the detection of reactive intermediates in biochem. systems are also discussed.  The intention of this review is not to "black list" functional groups or to immediately discard compds. based on their potential to form reactive metabolites, but rather to serve as a resource describing the structural diversity of these functionalities as well as exptl. approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVj7cmxfwXrVg90H21EOLACvtfcHk0ljphMEPTl_EOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2is7k%253D&md5=b16dfc2de97c40a11218ecc3043bed66</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520functional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225%26doi%3D10.2174%2F1389200054021799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0lgVI-1GrMghCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span>; <span class="NLM_string-name">Dalvie, D.</span>; <span class="NLM_string-name">Obach, R. S.</span>; <span class="NLM_string-name">Smith, D. A.</span></span> <span> </span><span class="NLM_article-title">Pathways of Reactive Metabolite Formation with Toxicophores/Structural Alerts</span>. In  <i>Reactive Drug Metabolites</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannhold, R.</span>, <span class="NLM_string-name">Kubinyi, H.</span>, <span class="NLM_string-name">Folkers, G.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinhheim, Germany</span>, <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">55</span>; pp  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">130</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2F9783527655748.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=93-130&author=A.+S.+Kalgutkar&author=D.+Dalvie&author=R.+S.+Obach&author=D.+A.+Smithauthor=R.+Mannhold&author=H.+Kubinyi&author=G.+Folkers&title=Reactive+Drug+Metabolites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2F9783527655748.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527655748.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DPathways%2520of%2520Reactive%2520Metabolite%2520Formation%2520with%2520Toxicophores%252FStructural%2520Alerts%26btitle%3DReactive%2520Drug%2520Metabolites%26aulast%3DMannhold%26aufirst%3DR.%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2012%26volume%3D55%26spage%3D93%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolleddula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worboys, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span> <span> </span><span class="NLM_article-title">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.3109/03602532.2014.924962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602532.2014.924962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24909234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=379-419&author=J.+Bolleddulaauthor=K.+DeMentauthor=J.+P.+Driscollauthor=P.+Worboysauthor=P.+J.+Brassilauthor=D.+L.+Bourdet&title=Biotransformation+and+bioactivation+reactions+of+alicyclic+amines+in+drug+molecules&doi=10.3109%2F03602532.2014.924962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Biotransformation and bioactivation reactions of alicyclic amines in drug molecules</span></div><div class="casAuthors">Bolleddula, Jayaprakasam; DeMent, Kevin; Driscoll, James P.; Worboys, Philip; Brassil, Patrick J.; Bourdet, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">379-419</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Aliph. nitrogen heterocycles such as piperazine, piperidine, pyrrolidine, morpholine, aziridine, azetidine, and azepane are well known building blocks in drug design and important core structures in approved drug therapies.  These core units have been targets for metabolic attack by P450s and other drug metabolizing enzymes such as aldehyde oxidase and monoamine oxidase (MAOs).  The electron rich nitrogen and/or α-carbons are often major sites of metab. of alicyclic amines.  The most common biotransformations include N-oxidn., N-conjugation, oxidative N-dealkylation, ring oxidn., and ring opening.  In some instances, the metabolic pathways generate electrophilic reactive intermediates and cause bioactivation.  However, potential bioactivation related adverse events can be attenuated by structural modifications.  Hence it is important to understand the biotransformation pathways to design stable drug candidates that are devoid of metabolic liabilities early in the discovery stage.  The current review provides a comprehensive summary of biotransformation and bioactivation pathways of aliph. nitrogen contg. heterocycles and strategies to mitigate metabolic liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgryPqDMy3f7Vg90H21EOLACvtfcHk0lgVI-1GrMghCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlagu7jO&md5=f20339b5306805f531cbd22f0640e8b6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3109%2F03602532.2014.924962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602532.2014.924962%26sid%3Dliteratum%253Aachs%26aulast%3DBolleddula%26aufirst%3DJ.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DDriscoll%26aufirst%3DJ.%2BP.%26aulast%3DWorboys%26aufirst%3DP.%26aulast%3DBrassil%26aufirst%3DP.%2BJ.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26atitle%3DBiotransformation%2520and%2520bioactivation%2520reactions%2520of%2520alicyclic%2520amines%2520in%2520drug%2520molecules%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2014%26volume%3D46%26spage%3D379%26epage%3D419%26doi%3D10.3109%2F03602532.2014.924962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn-Langguth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutschler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E. T.</span></span> <span> </span><span class="NLM_article-title">Predictability of the covalent binding of acidic drugs in man</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(93)90279-C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0024-3205%2893%2990279-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8390596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1993&pages=141-146&author=L.+Z.+Benetauthor=H.+Spahn-Langguthauthor=S.+Iwakawaauthor=C.+Vollandauthor=T.+Mizumaauthor=S.+Mayerauthor=E.+Mutschlerauthor=E.+T.+Lin&title=Predictability+of+the+covalent+binding+of+acidic+drugs+in+man&doi=10.1016%2F0024-3205%2893%2990279-C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of the covalent binding of acidic drugs in man</span></div><div class="casAuthors">Benet, Leslie Z.; Spahn-Langguth, Hildegard; Iwakawa, Seigo; Volland, Christine; Mizuma, Takashi; Mayer, Sascha; Mutschler, Ernst; Lin, Emil T.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">PL141-PL146</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    </div><div class="casAbstract">Although metab. via glucuronide conjugation has generally been considered a detoxification route for carboxylic acids, the newly discovered chem. reactivity of these conjugates, leading to covalent binding with proteins, is consistent with the toxicity obsd. for drugs contg. the carboxylic acid moiety.  Here the authors report that degrdn. rates (intramol. rearrangement and hydrolysis) for 9 drug glucuronide metabolites show an excellent correlation (r2 = 0.995) with the extents of drug covalent binding to albumin in vitro.  Furthermore, this binding capacity is predictable based on chem. structure of the acid and depends on the degree of substitution at the carbon alpha to the carboxylic acid.  The in vivo covalent binding in humans for these drugs is also predictable (r2 = 0.873) when the extent of adduct formation is cor. for the measured plasma glucuronide concns.  These results suggest that the structure of a carboxylic acid drug may predict the degree to which the corresponding acyl glucuronides will form covalent adducts that probably/possibly lead to toxicity.  This information could be a useful adjunct in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroJx0DCGigdrVg90H21EOLACvtfcHk0ljDHSPD45wGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFWltb8%253D&md5=150fa0fdee47150d1a9a280ec40f63b0</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2893%2990279-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252893%252990279-C%26sid%3Dliteratum%253Aachs%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DSpahn-Langguth%26aufirst%3DH.%26aulast%3DIwakawa%26aufirst%3DS.%26aulast%3DVolland%26aufirst%3DC.%26aulast%3DMizuma%26aufirst%3DT.%26aulast%3DMayer%26aufirst%3DS.%26aulast%3DMutschler%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DE.%2BT.%26atitle%3DPredictability%2520of%2520the%2520covalent%2520binding%2520of%2520acidic%2520drugs%2520in%2520man%26jtitle%3DLife%2520Sci.%26date%3D1993%26volume%3D53%26spage%3D141%26epage%3D146%26doi%3D10.1016%2F0024-3205%2893%2990279-C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojingwa, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonagh, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">3797</span>– <span class="NLM_lpage">3801</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.9.3797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1073%2Fpnas.90.9.3797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8483897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3sXktF2ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=3797-3801&author=A.+Dingauthor=J.+C.+Ojingwaauthor=A.+F.+McDonaghauthor=A.+L.+Burlingameauthor=L.+Z.+Benet&title=Evidence+for+covalent+binding+of+acyl+glucuronides+to+serum+albumin+via+an+imine+mechanism+as+revealed+by+tandem+mass+spectrometry&doi=10.1073%2Fpnas.90.9.3797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry</span></div><div class="casAuthors">Ding, Andreas; Ojingwa, Joseph C.; McDonagh, Antony F.; Burlingame, Alma L.; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3797-801</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Acyl glucuronide metabolites of bilirubin and many drugs can react with serum albumin in vivo to form covalent adducts.  Such adducts may be responsible for some toxic effects of carboxylic nonsteroidal antiinflammatory agents.  The mechanism of formation of the adducts and their chem. structures are unknown.  This paper describes the use of tandem mass spectrometry to locate binding sites and elucidate the binding mechanism involved in the formation of covalent adducts from tolmetin glucuronide and albumin in vitro.  Human serum albumin and excess tolmetin glucuronide were coincubated in the presence of sodium cyanoborohydride to trap imine intermediates.  The total protein product was reduced, carboxymethylated, and digested with trypsin.  Six tolmetin-contg. peptides (indicated by absorbance at 313 nm) were isolated by high-pressure liq. chromatog. and analyzed by liq. secondary-ion mass spectrometry and collision-induced dissocn., using a four-sector tandem mass spectrometer.  All six peptides contained tolmetin linked covalently via a glucuronic acid to protein lysine groups.  Major attachment sites on the protein were Lys-195, -199, and -525; minor sites were identified as Lys-137, -351, and -541.  These results show unambiguously that the glucuronic acid moiety of acyl glucuronides can be retained within the structure when these reactive metabolites bind covalently to proteins, and they suggest that acyl migration followed by Schiff base (imine) formation is a credible mechanism for the generation of covalent adducts in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr93nwF0tc3k7Vg90H21EOLACvtfcHk0ljDHSPD45wGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktF2ru7c%253D&md5=00930c76bcd00535b590b8b4e14dfa27</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.9.3797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.9.3797%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DA.%26aulast%3DOjingwa%26aufirst%3DJ.%2BC.%26aulast%3DMcDonagh%26aufirst%3DA.%2BF.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvidence%2520for%2520covalent%2520binding%2520of%2520acyl%2520glucuronides%2520to%2520serum%2520albumin%2520via%2520an%2520imine%2520mechanism%2520as%2520revealed%2520by%2520tandem%2520mass%2520spectrometry%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26spage%3D3797%26epage%3D3801%26doi%3D10.1073%2Fpnas.90.9.3797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Acyl glucuronides: The good, the bad and the ugly</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1002/bdd.720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fbdd.720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20830700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=367-395&author=S.+L.+Reganauthor=J.+L.+Maggsauthor=T.+G.+Hammondauthor=C.+Lambertauthor=D.+P.+Williamsauthor=B.+K.+Park&title=Acyl+glucuronides%3A+The+good%2C+the+bad+and+the+ugly&doi=10.1002%2Fbdd.720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Acyl glucuronides: the good, the bad and the ugly</span></div><div class="casAuthors">Regan, Sophie L.; Maggs, James L.; Hammond, Thomas G.; Lambert, Craig; Williams, Dominic P.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">367-395</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Acyl glucuronidation is the major metabolic conjugation reaction of most carboxylic acid drugs in mammals.  The physiol. consequences of this biotransformation have been investigated incompletely but include effects on drug metab., protein binding, distribution and clearance that impact upon pharmacol. and toxicol. outcomes.  In marked contrast, the exceptional but widely disparate chem. reactivity of acyl glucuronides has attracted far greater attention.  Specifically, the complex transacylation and glycation reactions with proteins have provoked much inconclusive debate over the safety of drugs metabolised to acyl glucuronides.  It has been hypothesised that these covalent modifications could initiate idiosyncratic adverse drug reactions.  However, despite a large body of in vitro data on the reactions of acyl glucuronides with protein, evidence for adduct formation from acyl glucuronides in vivo is limited and potentially ambiguous.  The causal connection of protein adduction to adverse drug reactions remains uncertain.  This review has assessed the intrinsic reactivity, metabolic stability and pharmacokinetic properties of acyl glucuronides in the context of physiol., pharmacol. and toxicol. perspectives.  Although numerous expts. have characterised the reactions of acyl glucuronides with proteins, these might be attenuated substantially in vivo by rapid clearance of the conjugates.  Consequently, to delineate a relationship between acyl glucuronide formation and toxicol. phenomena, detailed pharmacokinetic anal. of systemic exposure to the acyl glucuronide should be undertaken adjacent to detg. protein adduct concns. in vivo.  Further investigation is required to ascertain whether acyl glucuronide clearance is sufficient to prevent covalent modification of endogenous proteins and consequentially a potential immunol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ1hIcbM_oZ7Vg90H21EOLACvtfcHk0ljDHSPD45wGiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2nur3L&md5=8c45d4dbb68c12bd128af1dba7a08c16</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fbdd.720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.720%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DAcyl%2520glucuronides%253A%2520The%2520good%252C%2520the%2520bad%2520and%2520the%2520ugly%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2010%26volume%3D31%26spage%3D367%26epage%3D395%26doi%3D10.1002%2Fbdd.720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidenius, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skonberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. H.</span></span> <span> </span><span class="NLM_article-title">In vitro reactivity of carboxylic acid-CoA thioesters with glutathione</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1021/tx034127o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034127o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFGkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=75-81&author=U.+Sideniusauthor=C.+Skonbergauthor=J.+Olsenauthor=S.+H.+Hansen&title=In+vitro+reactivity+of+carboxylic+acid-CoA+thioesters+with+glutathione&doi=10.1021%2Ftx034127o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Reactivity of Carboxylic Acid-CoA Thioesters with Glutathione</span></div><div class="casAuthors">Sidenius, Ulrik; Skonberg, Christian; Olsen, Jorgen; Hansen, Steen Honore</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The chem. reactivity of acyl-CoA thioesters toward nucleophiles has been demonstrated in several recent studies.  Thus, intracellularly formed acyl-CoAs of xenobiotic carboxylic acids may react covalently with endogenous proteins and potentially lead to adverse effects.  The purpose of this study was to investigate whether a correlation could be found between the structure of acyl-CoA thioesters and their reactivities toward the tripeptide, glutathione (γ-Glu-Cys-Gly).  The acyl-CoA thioesters of eight carboxylic acids (ibuprofen, clofibric acid, indomethacin, fenbufen, tolmetin, salicylic acid, 2-phenoxypropionic acid, and (4-chloro-2-methyl-phenoxy)acetic acid (MCPA)) were synthesized, and each acyl-CoA (0.5 mM) was incubated with glutathione (5.0 mM) in 0.1 M potassium phosphate (pH 7.4, 37°).  All of the acyl-CoAs reacted with glutathione to form the resp. acyl-S-glutathione products, with MCPA-CoA having the highest rate of conjugate formation (120 μM/min) and ibuprofen-CoA having the lowest (1.0 μM/min).  The relative reactivities of the acyl-CoAs were dependent on the substitution at the carbon atom α to the acyl carbon and on the presence of an oxygen atom in a position β to the acyl carbon and were as follows: phenoxyacetic acid > o-hydroxybenzoic acid ∼ phenoxypropionic acid > arylacetic acid derivs. > 2-methyl-2-phenoxypropionic acid ∼ 2-phenylpropionic acid.  For each acyl-CoA thioester, the overall hydrolysis rate was detd. as the time-dependent formation of parent compd.  A linear trend was obsd. when comparing the reactivities of the acyl-CoAs with glutathione with the corresponding overall hydrolysis rates.  Thus, the most reactive compd. (MCPA-CoA) was also the compd. with the highest rate of hydrolysis and the least reactive compds. (ibuprofen-CoA, clofibryl-CoA) were also the compds. least susceptible to hydrolysis.  The possibility of drug toxicity is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob0S3Ko-tAgLVg90H21EOLACvtfcHk0liVyIcIcr5U-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFGkt7c%253D&md5=87cc30ffb83882674fbf75a03850e31e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Ftx034127o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034127o%26sid%3Dliteratum%253Aachs%26aulast%3DSidenius%26aufirst%3DU.%26aulast%3DSkonberg%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vitro%2520reactivity%2520of%2520carboxylic%2520acid-CoA%2520thioesters%2520with%2520glutathione%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D75%26epage%3D81%26doi%3D10.1021%2Ftx034127o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skonberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, M. P.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of carboxylic acids</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1517/17425255.4.4.425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1517%2F17425255.4.4.425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18433345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=425-438&author=C.+Skonbergauthor=J.+Olsenauthor=K.+G.+Madsenauthor=S.+H.+Hansenauthor=M.+P.+Grillo&title=Metabolic+activation+of+carboxylic+acids&doi=10.1517%2F17425255.4.4.425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of carboxylic acids</span></div><div class="casAuthors">Skonberg, Christian; Olsen, Jorgen; Madsen, Kim Grimstrup; Hansen, Steen Honore; Grillo, Mark P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-438</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Carboxylic acids constitute a large and heterogeneous class of both endogenous and xenobiotic compds.  A no. of carboxylic acid drugs have been assocd. with adverse reactions, linked to the metabolic activation of the carboxylic acid moiety of the compds., i.e., formation of acyl-glucuronides and acyl-CoA thioesters.  Objective: The objective is to give an overview of the current knowledge on metabolic activation of carboxylic acids and how such metabolites may play a role in adverse reactions and toxicity.  Methods: Literature concerning the formation and disposition of acyl glucuronides and acyl-CoA thioesters was searched.  Also included were papers on the chem. reactivity of acyl glutathione-thioesters, and literature concerning possible links between metabolic activation of carboxylic acids and reported cellular and clin. effects.  Results/conclusion: This review demonstrates that metabolites of carboxylic acid drugs must be considered chem. reactive, and that the current knowledge about metabolic activation of this compd. class can be a good starting-point for further studies on the consequences of chem. reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdB7y_4L2TirVg90H21EOLACvtfcHk0liVyIcIcr5U-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltVWmt7g%253D&md5=fec1dbee0f4e4bf93c95ba2441b48004</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1517%2F17425255.4.4.425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.4.4.425%26sid%3Dliteratum%253Aachs%26aulast%3DSkonberg%26aufirst%3DC.%26aulast%3DOlsen%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%2BG.%26aulast%3DHansen%26aufirst%3DS.%2BH.%26aulast%3DGrillo%26aufirst%3DM.%2BP.%26atitle%3DMetabolic%2520activation%2520of%2520carboxylic%2520acids%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2008%26volume%3D4%26spage%3D425%26epage%3D438%26doi%3D10.1517%2F17425255.4.4.425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1890</span>– <span class="NLM_lpage">1899</span>, <span class="refDoi"> DOI: 10.1021/tx800185b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800185b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFSls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1890-1899&author=R.+S.+Obachauthor=A.+S.+Kalgutkarauthor=T.+F.+Ryderauthor=G.+S.+Walker&title=In+vitro+metabolism+and+covalent+binding+of+enol-carboxamide+derivatives+and+anti-inflammatory+agents+sudoxicam+and+meloxicam%3A+insights+into+the+hepatotoxicity+of+sudoxicam&doi=10.1021%2Ftx800185b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Metabolism and Covalent Binding of Enol-Carboxamide Derivatives and Anti-Inflammatory Agents Sudoxicam and Meloxicam: Insights into the Hepatotoxicity of Sudoxicam</span></div><div class="casAuthors">Obach, R. Scott; Kalgutkar, Amit S.; Ryder, Tim F.; Walker, Gregory S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1890-1899</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sudoxicam and meloxicam are nonsteroidal anti-inflammatory drugs (NSAIDs) from the enol-carboxamide class.  While the only structural difference between the two NSAIDs is the presence of a Me group on the C5-position of the 2-carboxamidothiazole motif in meloxicam, a marked difference in their toxicol. profile in humans has been discerned.  In clin. trials, sudoxicam was assocd. with several cases of severe hepatotoxicity that led to its discontinuation, while meloxicam has been in the market for over a decade and is devoid of hepatotoxicity.  In an attempt to understand the biochem. basis for the differences in safety profile, an in vitro investigation of the metabolic pathways and covalent binding of the two NSAIDs was conducted in NADPH-supplemented human liver microsomes.  Both compds. demonstrated NADPH-dependent covalent binding to human liver microsomes; however, the extent of binding of [14C]-meloxicam was ∼2-fold greater than that of [14C]-sudoxicam.  While inclusion of glutathione (GSH) in microsomal incubations resulted in a decrease in covalent binding for both NSAIDs, the redn. in binding was more pronounced for meloxicam.  Metabolite identification studies on [14C]-sudoxicam in NADPH-supplemented human liver microsomes indicated that the primary route of metab. involved a P 450-mediated thiazole ring scission to the corresponding acylthiourea metabolite (S3), a well-established pro-toxin.  The mechanism of formation of S3 presumably proceeds via (a) epoxidn. of the C4-C5-thiazole ring double bond, (b) epoxide hydrolysis to the corresponding thiazole-4,5-dihydrodiol deriv., which was obsd. as a stable metabolite (S2), (c) ring opening of the thiazole-4,5-dihydrodiol to an 2-oxoethylidene thiourea intermediate, and (d) hydrolysis of the imine bond within this intermediate to yield S3.  In the case of meloxicam, the corresponding acylthiourea metabolite M3 was also obsd., but to a lesser extent; the main route of meloxicam metab. involved hydroxylation of the 5'-Me group, a finding that is consistent with the known metabolic fate of this NSAID.  Inclusion of GSH led to a decrease in the formation of M3 with the concomitant formation of an unusual two-electron redn. product (metabolite M7).  The formation of M7 is proposed to arise via redn. of the imine bond in 2-oxopropylidene thiourea, an intermediate in the thiazole ring scission pathway in meloxicam.  In conclusion, the results of our anal. suggest that if the covalent binding of the two NSAIDs is important to the overall hepatotoxicity risk, the differences in metab. (differential preponderance of formation of the acylthiourea relative to total metab.), differential effects of GSH on covalent binding, and finally differences in daily doses of the two NSAIDs may serve as a plausible explanation for the marked differences in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr41ErheTuDvLVg90H21EOLACvtfcHk0liVyIcIcr5U-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFSls7o%253D&md5=af142bb2df6107277dcbbb82b0907c21</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Ftx800185b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800185b%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DRyder%26aufirst%3DT.%2BF.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26atitle%3DIn%2520vitro%2520metabolism%2520and%2520covalent%2520binding%2520of%2520enol-carboxamide%2520derivatives%2520and%2520anti-inflammatory%2520agents%2520sudoxicam%2520and%2520meloxicam%253A%2520insights%2520into%2520the%2520hepatotoxicity%2520of%2520sudoxicam%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D1890%26epage%3D1899%26doi%3D10.1021%2Ftx800185b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kassahun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1021/tx000180q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx000180q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosVKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=62-70&author=K.+Kassahunauthor=P.+G.+Pearsonauthor=W.+Tangauthor=I.+McIntoshauthor=K.+Leungauthor=C.+Elmoreauthor=D.+Deanauthor=R.+Wangauthor=G.+Dossauthor=T.+A.+Baillie&title=Studies+on+the+metabolism+of+troglitazone+to+reactive+intermediates+in+vitro+and+in+vivo.+Evidence+for+novel+biotransformation+pathways+involving+quinone+methide+formation+and+thiazolidinedione+ring+scission&doi=10.1021%2Ftx000180q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission</span></div><div class="casAuthors">Kassahun, Kelem; Pearson, Paul G.; Tang, Wei; McIntosh, Ian; Leung, Kwan; Elmore, Charles; Dean, Dennis; Wang, Regina; Doss, George; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-70</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Therapy with the oral antidiabetic agent troglitazone (Rezulin) has been assocd. with cases of severe hepatotoxicity and drug-induced liver failure, which led to the recent withdrawal of the product from the U.S. market.  While the mechanism of this toxicity remains unknown, it is possible that chem. reactive metabolites of the drug play a causative role.  In an effort to address this possibility, this study was undertaken to det. whether troglitazone undergoes metab. in human liver microsomal prepns. to electrophilic intermediates.  Following incubation of troglitazone with human liver microsomes and with cDNA-expressed cytochrome P 450 isoforms in the presence of glutathione (GSH), a total of five GSH conjugates (M1-M5) were detected and identified tentatively by LC-MS/MS anal.  In two cases (M1 and M5), the structures of the adducts were confirmed by NMR spectroscopy and/or by comparison with an authentic std. prepd. by synthesis.  The formation of GSH conjugates M1-M5 revealed the operation of two distinct metabolic activation pathways for troglitazone, one of which involves oxidn. of the substituted chromane ring system to a reactive o-quinone methide deriv., while the second involves a novel oxidative cleavage of the thiazolidinedione (TZD) ring, potentially generating highly electrophilic α-ketoisocyanate and sulfenic acid intermediates.  When troglitazone was administered orally to a rat, samples of bile were found to contain GSH conjugates which reflected the operation of these same metabolic pathways in vivo.  The finding that metab. of the TZD ring of troglitazone was catalyzed selectively by P 450 3A enzymes is significant in light of the recent report that troglitazone is an inducer of this isoform in human hepatocytes.  The implications of these results are discussed in the context of the potential for troglitazone to covalently modify hepatic proteins and to cause oxidative stress through redox cycling processes, either of which may play a role in drug-induced liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob7YBc5ZoVmbVg90H21EOLACvtfcHk0liiYGKWsCKAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosVKjtA%253D%253D&md5=cd7dd61cf7f367a40dc9c5f09757aad7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Ftx000180q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx000180q%26sid%3Dliteratum%253Aachs%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DMcIntosh%26aufirst%3DI.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DElmore%26aufirst%3DC.%26aulast%3DDean%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DDoss%26aufirst%3DG.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DStudies%2520on%2520the%2520metabolism%2520of%2520troglitazone%2520to%2520reactive%2520intermediates%2520in%2520vitro%2520and%2520in%2520vivo.%2520Evidence%2520for%2520novel%2520biotransformation%2520pathways%2520involving%2520quinone%2520methide%2520formation%2520and%2520thiazolidinedione%2520ring%2520scission%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D62%26epage%3D70%26doi%3D10.1021%2Ftx000180q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montavon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahler, A.</span></span> <span> </span><span class="NLM_article-title">Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1106</span>– <span class="NLM_lpage">1116</span>, <span class="refDoi"> DOI: 10.1021/tx050353h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050353h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmsl2ktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=1106-1116&author=R.+Alvarez-Sanchezauthor=F.+Montavonauthor=T.+Hartungauthor=A.+Pahler&title=Thiazolidinedione+bioactivation%3A+a+comparison+of+the+bioactivation+potentials+of+troglitazone%2C+rosiglitazone%2C+and+pioglitazone+using+stable+isotope-labeled+analogues+and+liquid+chromatography+tandem+mass+spectrometry&doi=10.1021%2Ftx050353h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazolidinedione Bioactivation: A Comparison of the Bioactivation Potentials of Troglitazone, Rosiglitazone, and Pioglitazone Using Stable Isotope-Labeled Analogues and Liquid Chromatography Tandem Mass Spectrometry</span></div><div class="casAuthors">Alvarez-Sanchez, Ruben; Montavon, Francois; Hartung, Thomas; Paehler, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1106-1116</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Troglitazone, a thiazolidinedione (TZD) type insulin sensitizer for the treatment of diabetes, was withdrawn from the U.S. Market after several fatal cases of hepatotoxicity.  Although the mechanism(s) of these idiosyncratic adverse reactions are not completely understood, circumstantial evidence suggests at least a partial contribution of reactive metabolite formation.  Despite isolated case reports of hepatotoxicity, the other TZD derivs. pioglitazone and rosiglitazone are comparatively safe.  Herein, the authors report on the bioactivation potential of these drugs and their TZD ring isotope-labeled 2-15N-3,4,5-13C3 analogs in rat and human liver microsomes supplemented with glutathione (GSH).  Screening for GSH adducts as surrogate markers for reactive intermediate formation was performed by liq. chromatog. tandem mass spectrometry.  Chem. characterization of the GSH conjugates was conducted by acquisition of their resp. product ion spectra and the comparison between unlabeled and stable isotope-labeled TZD derivs.  The data suggest that all drugs undergo bioactivation processes via a common metabolic activation on the TZD ring, yielding disulfide type GSH conjugates as evidenced by the loss of labeled positions in the TZD moiety.  Addnl. bioactivation processes leading to GSH adducts not involving TZD ring scission were evident for troglitazone.  In human liver microsomes at low substrate concns., only troglitazone yielded a predominant GSH adduct not involving TZD ring scission.  This property may contribute, together with other factors such as the relatively high dose administered as well as its potential to induce hepatic cholestasis and oxidative stress, to the hepatotoxicity of this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpuWvWcmTx1rVg90H21EOLACvtfcHk0liiYGKWsCKAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmsl2ktrY%253D&md5=f97dbc03b974a05f3c8d2da703ecc274</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Ftx050353h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050353h%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DMontavon%26aufirst%3DF.%26aulast%3DHartung%26aufirst%3DT.%26aulast%3DPahler%26aufirst%3DA.%26atitle%3DThiazolidinedione%2520bioactivation%253A%2520a%2520comparison%2520of%2520the%2520bioactivation%2520potentials%2520of%2520troglitazone%252C%2520rosiglitazone%252C%2520and%2520pioglitazone%2520using%2520stable%2520isotope-labeled%2520analogues%2520and%2520liquid%2520chromatography%2520tandem%2520mass%2520spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D1106%26epage%3D1116%26doi%3D10.1021%2Ftx050353h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayol, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8013286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2cXis1SnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1994&pages=304-311&author=R.+F.+Mayolauthor=C.+A.+Coleauthor=G.+M.+Lukeauthor=K.+L.+Colsonauthor=E.+H.+Kerns&title=Characterization+of+the+metabolites+of+the+antidepressant+drug+nefazodone+in+human+urine+and+plasma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma</span></div><div class="casAuthors">Mayol, R. F.; Cole, C. A.; Luke, G. M.; Colson, K. L.; Kerns, E. H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-11</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">Metab. of the antidepressant drug nefazodone was studied in humans after single and multiple 50 and 200 mg oral doses of [14C] nefazodone as part of a single and multiple dose balance study.  Deuterium was included in the mol. to facilitate structural characterization of the metabolites my mass spectrometry.  Metabolites were isolated from a 0-24 h pooled urine from three subjects and purified to homogeneity by HPLC.  Chem. structures of the metabolites were proposed based on collisionally induced dissocn. (CID) and electron impact ionization MS.  The profile of radioactivity showed three main urinary metabolites, one of which was a conjugate, and several minor metabolites.  The three major metabolites were identified as the phenoxyethyl triazolone propionic acid resulting from N-dealkylation of both nefazodone and hydroxynefazodone (OH-Nef), as well as a corresponding phenoxyethyl triazolone propanol metabolite of N-dealkylated nefazodone, present exclusively as a conjugate.  The more polar minor components were not identified.  The excretion of total radioactivity in the 24-h sample was 49% of the dose, of which the identified metabolites comprised 38% of the dose.  There was no difference in the qual. or quant. urinary profile of the metabolites at 50 or 200 mg dose levels after single or multiple oral dosing.  These N-dealkylated metabolites were also present in pooled human plasma samples along with nefazodone, OH-Nef, and an unknown metabolite that was present in plasma in large amts. relative to nefazodone and OH-Nef.  This metabolite was isolated from plasma and from a human liver S9 incubation and identified by CID tandem MS and NMR as the triazoledione of nefazodone.  A scheme for the metab. of nefazodone is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLYj6lzOLJUrVg90H21EOLACvtfcHk0lgS_KYC3sGghw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1SnurY%253D&md5=6393ad7f1338c3d2d1d2e33df0d47729</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayol%26aufirst%3DR.%2BF.%26aulast%3DCole%26aufirst%3DC.%2BA.%26aulast%3DLuke%26aufirst%3DG.%2BM.%26aulast%3DColson%26aufirst%3DK.%2BL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DCharacterization%2520of%2520the%2520metabolites%2520of%2520the%2520antidepressant%2520drug%2520nefazodone%2520in%2520human%2520urine%2520and%2520plasma%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1994%26volume%3D22%26spage%3D304%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaz, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lame, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramov, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendsch, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">253</span>, <span class="refDoi"> DOI: 10.1124/dmd.104.001735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.104.001735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15523046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Cjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=243-253&author=A.+S.+Kalgutkarauthor=A.+D.+Vazauthor=M.+E.+Lameauthor=K.+R.+Henneauthor=J.+Sogliaauthor=S.+X.+Zhaoauthor=Y.+A.+Abramovauthor=F.+Lombardoauthor=C.+Collinauthor=Z.+S.+Hendschauthor=C.+E.+Hop&title=Bioactivation+of+the+nontricyclic+antidepressant+nefazodone+to+a+reactive+quinone-imine+species+in+human+liver+microsomes+and+recombinant+cytochrome+P450+3A4&doi=10.1124%2Fdmd.104.001735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4</span></div><div class="casAuthors">Kalgutkar, Amit S.; Vaz, Alfin D. N.; Lame, Mary E.; Henne, Kirk R.; Soglia, John; Zhao, Sabrina X.; Abramov, Yuri A.; Lombardo, Franco; Collin, Claire; Hendsch, Zachary S.; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-253</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The therapeutic benefits of the antidepressant nefazodone have been hampered by several cases of acute hepatotoxicity/liver failure.  Although the mechanism of hepatotoxicity remains unknown, it is possible that reactive metabolites of nefazodone play a causative role.  Studies were initiated to det. whether nefazodone undergoes bioactivation in human liver microsomes to electrophilic intermediates.  Following incubation of nefazodone with microsomes or recombinant P 4503A4 in the presence of sulfhydryl nucleophiles, conjugates derived from the addn. of thiol to a monohydroxylated nefazodone metabolite were obsd.  Product ion spectra suggested that hydroxylation and sulfhydryl conjugation occurred on the 3-chlorophenylpiperazine-ring, consistent with a bioactivation pathway involving initial formation of p-hydroxynefazodone, followed by its two-electron oxidn. to the reactive quinone-imine intermediate.  The formation of novel N-dearylated nefazodone metabolites was also discernible in these incubations, and 2-chloro-1,4-benzoquinone, a byproduct of N-dearylation, was trapped with glutathione to afford the corresponding hydroquinone-sulfhydryl adduct.  Nefazodone also displayed NADPH-, time-, and concn.-dependent inactivation of P 450 3A4 activity, suggesting that reactive metabolites derived from nefazodone bioactivation are capable of covalently modifying P 4503A4.  A causative role for 2-chloro-1,4-benzoquinone and/or the quinone-imine intermediate(s) in nefazodone hepatotoxicity is speculated.  Although the antianxiety agent buspirone, which contains a pyrimidine ring in place of the 3-chlorophenyl-ring, also generated p-hydroxybuspirone in liver microsomes, no sulfhydryl conjugates of this metabolite were obsd.  This finding is consistent with the proposal that two-electron oxidn. of p-hydroxybuspirone to the corresponding quinone-imine is less favorable due to differences in the protonation state at physiol. pH and due to weaker resonance stabilization of the oxidn. products as predicted from ab initio measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm8ZzhHTzKarVg90H21EOLACvtfcHk0lgS_KYC3sGghw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Cjsbc%253D&md5=7f6d27921d2236e202256ad0035fedce</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.001735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.001735%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DVaz%26aufirst%3DA.%2BD.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DSoglia%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DAbramov%26aufirst%3DY.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DCollin%26aufirst%3DC.%26aulast%3DHendsch%26aufirst%3DZ.%2BS.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DBioactivation%2520of%2520the%2520nontricyclic%2520antidepressant%2520nefazodone%2520to%2520a%2520reactive%2520quinone-imine%2520species%2520in%2520human%2520liver%2520microsomes%2520and%2520recombinant%2520cytochrome%2520P450%25203A4%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D243%26epage%3D253%26doi%3D10.1124%2Fdmd.104.001735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.020545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18332080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1016-1029&author=J.+S.+Baumanauthor=K.+S.+Frederickauthor=A.+Sawantauthor=R.+L.+Walskyauthor=L.+M.+Coxauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=Comparison+of+the+bioactivation+potential+of+the+antidepressant+and+hepatotoxin+nefazodone+with+aripiprazole%2C+a+structural+analog+and+marketed+drug&doi=10.1124%2Fdmd.108.020545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug</span></div><div class="casAuthors">Bauman, Jonathan N.; Frederick, Kosea S.; Sawant, Aarti; Walsky, Robert L.; Cox, Loretta M.; Obach, Ronald S.; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1016-1029</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In vitro metab./bioactivation of structurally related central nervous system agents nefazodone (hepatotoxin) and aripiprazole (nonhepatotoxin) were undertaken in human liver microsomes in an attempt to understand the differences in toxicol. profile.  NADPH-supplemented microsomal incubations of nefazodone and glutathione generated conjugates derived from addn. of thiol to quinonoid intermediates.  Inclusion of cyanide afforded cyano conjugates to iminium ions derived from α-carbon oxidn. of the piperazine ring in nefazodone and downstream metabolites.  Although the arylpiperazine motif in aripiprazole did not succumb to bioactivation, the dihydroquinolinone group was bioactivated via an intermediate monohydroxy metabolite to a reactive species, which was trapped by glutathione.  Studies with synthetic dehydroaripiprazole metabolite revealed an analogous glutathione conjugate with mol. wt. 2 Da lower.  Based on the proposed structure of the glutathione conjugate(s), a bioactivation sequence involving arom. ortho- or para-hydroxylation on the quinolinone followed by oxidn. to a quinone-imine was proposed.  P 4503A4 inactivation studies in microsomes indicated that, unlike nefazodone, aripiprazole was not a time- and concn.-dependent inactivator of the enzyme.  Overall, these studies reinforce the notion that not all drugs that are bioactivated in vitro elicit a toxicol. response in vivo.  A likely explanation for the markedly improved safety profile of aripiprazole (vs. nefazodone) despite the accompanying bioactivation liability is the vastly improved pharmacokinetics (enhanced oral bioavailability, longer elimination half-life) due to reduced P 4503A4-mediated metab./bioactivation, which result in a lower daily dose (5-20 mg/day) compared with nefazodone (200-400 mg/day).  This attribute probably reduces the total body burden to reactive metabolite exposure and may not exceed a threshold needed for toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpVGcV7pKb7Vg90H21EOLACvtfcHk0lgS_KYC3sGghw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmtbo%253D&md5=fbc3413e2855e61631687d253971a08c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020545%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BS.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSawant%26aufirst%3DA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DCox%26aufirst%3DL.%2BM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DComparison%2520of%2520the%2520bioactivation%2520potential%2520of%2520the%2520antidepressant%2520and%2520hepatotoxin%2520nefazodone%2520with%2520aripiprazole%252C%2520a%2520structural%2520analog%2520and%2520marketed%2520drug%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1016%26epage%3D1029%26doi%3D10.1124%2Fdmd.108.020545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span> <span> </span><span class="NLM_article-title">Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1814</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1021/tx800161s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800161s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=1814-1822&author=R.+S.+Obachauthor=A.+S.+Kalgutkarauthor=J.+R.+Sogliaauthor=S.+X.+Zhao&title=Can+in+vitro+metabolism-dependent+covalent+binding+data+in+liver+microsomes+distinguish+hepatotoxic+from+nonhepatotoxic+drugs%3F+An+analysis+of+18+drugs+with+consideration+of+intrinsic+clearance+and+daily+dose&doi=10.1021%2Ftx800161s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose</span></div><div class="casAuthors">Obach, R. Scott; Kalgutkar, Amit S.; Soglia, John R.; Zhao, Sabrina X.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1814-1822</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vitro covalent binding assessments of drugs have been useful in providing retrospective insights into the assocn. between drug metab. and a resulting toxicol. response.  On the basis of these studies, it has been advocated that in vitro covalent binding to liver microsomal proteins in the presence and the absence of NADPH be used routinely to screen drug candidates.  However, the utility of this approach in predicting toxicities of drug candidates accurately remains an unanswered question.  Importantly, the years of research that have been invested in understanding metabolic bioactivation and covalent binding and its potential role in toxicity have focused only on those compds. that demonstrate toxicity.  Investigations have not frequently queried whether in vitro covalent binding could be obsd. with drugs with good safety records.  Eighteen drugs (nine hepatotoxins and nine nonhepatotoxins in humans) were assessed for in vitro covalent binding in NADPH-supplemented human liver microsomes.  Of the two sets of nine drugs, seven in each set were shown to undergo some degree of covalent binding.  Among hepatotoxic drugs, acetaminophen, carbamazepine, diclofenac, indomethacin, nefazodone, sudoxicam, and tienilic acid demonstrated covalent binding, while benoxaprofen and felbamate did not.  Of the nonhepatotoxic drugs evaluated, buspirone, diphenhydramine, meloxicam, paroxetine, propranolol, raloxifene, and simvastatin demonstrated covalent binding, while ibuprofen and theophylline did not.  A quant. comparison of covalent binding in vitro intrinsic clearance did not sep. the two groups of compds., and in fact, paroxetine, a nonhepatotoxin, showed the greatest amt. of covalent binding in microsomes.  Including factors such as the fraction of total metab. comprised by covalent binding and the total daily dose of each drug improved the discrimination between hepatotoxic and nontoxic drugs based on in vitro covalent binding data; however, the approach still would falsely identify some agents as potentially hepatotoxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9_hVRAC3RD7Vg90H21EOLACvtfcHk0ljW1gHkW8maUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Knurw%253D&md5=67c82883825ef529c84d03f462b1f669</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx800161s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800161s%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26atitle%3DCan%2520in%2520vitro%2520metabolism-dependent%2520covalent%2520binding%2520data%2520in%2520liver%2520microsomes%2520distinguish%2520hepatotoxic%2520from%2520nonhepatotoxic%2520drugs%253F%2520An%2520analysis%2520of%252018%2520drugs%2520with%2520consideration%2520of%2520intrinsic%2520clearance%2520and%2520daily%2520dose%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D1814%26epage%3D1822%26doi%3D10.1021%2Ftx800161s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1021/tx800407w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800407w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlOnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=332-340&author=J.+N.+Baumanauthor=J.+M.+Kellyauthor=S.+Tripathyauthor=S.+X.+Zhaoauthor=W.+W.+Lamauthor=A.+S.+Kalgutkarauthor=R.+S.+Obach&title=Can+in+vitro+metabolism-dependent+covalent+binding+data+distinguish+hepatotoxic+from+nonhepatotoxic+drugs%3F+An+analysis+using+human+hepatocytes+and+liver+S-9+fraction&doi=10.1021%2Ftx800407w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction</span></div><div class="casAuthors">Bauman, Jonathon N.; Kelly, Joan M.; Tripathy, Sakambari; Zhao, Sabrina X.; Lam, Wing W.; Kalgutkar, Amit S.; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-340</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vitro covalent binding studies in which xenobiotics are shown to undergo metab.-dependent covalent binding to macromols. have been commonly used to shed light on the biochem. mechanisms of xenobiotic-induced toxicity.  In this paper hepatotoxins and nonhepatotoxins were tested for their proclivity to demonstrate metab.-dependent covalent binding to macromols. in human liver S-9 fraction (9000 g supernatant) or human hepatocytes, as an extension to previous work that used human liver microsomes published in this journal [Obachet al. (2008) Chem. Res. Toxicol.21, 1814-1822].  In the S-9 fraction, seven out of the nine drugs in each category demonstrated some level of metab.-dependent covalent binding.  Inclusion of reduced glutathione, cofactors needed by conjugating enzymes, and other parameters (total daily dose and fraction of total intrinsic clearance comprised by covalent binding) improved the ability of the system to sep. hepatotoxins from nonhepatotoxins to a limited extent.  Covalent binding in human hepatocytes showed that six out of the nine hepatotoxins and four out of eight nonhepatotoxins demonstrated covalent binding.  Taking into account ests. of total daily body burden of covalent binding from the hepatocyte data showed an improvement over other in vitro systems for distinguishing hepatotoxins from nonhepatotoxins; however, this metab. system still displayed some false positives.  Combined with the previous study using liver microsomes, these findings identify the limitations of in vitro covalent binding data for prospective prediction of hepatotoxicity for new drug candidates and highlight the need for a better understanding of the link between drug bioactivation, covalent adduct formation, and toxicity outcomes.  Directly relating covalent binding to hepatotoxicity is likely an oversimplification of the process whereby adduct formation ultimately leads to toxicity.  Understanding underlying complexities (e.g., which macromols. are important covalent binding targets, interindividual differences in susceptibility, etc.) will be essential to any understanding of the problem of metab.-dependent hepatotoxicity and predicting toxicity from in vitro expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTemi_XkByprVg90H21EOLACvtfcHk0lgfYHcK35Q-bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlOnuw%253D%253D&md5=5904378a0deda8e27d73ab0218b03506</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Ftx800407w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800407w%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DTripathy%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DLam%26aufirst%3DW.%2BW.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DCan%2520in%2520vitro%2520metabolism-dependent%2520covalent%2520binding%2520data%2520distinguish%2520hepatotoxic%2520from%2520nonhepatotoxic%2520drugs%253F%2520An%2520analysis%2520using%2520human%2520hepatocytes%2520and%2520liver%2520S-9%2520fraction%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D332%26epage%3D340%26doi%3D10.1021%2Ftx800407w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jajoo, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayol, R. F.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.3109/00498259009046892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F00498259009046892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=2219961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVCitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1990&pages=779-786&author=H.+K.+Jajooauthor=I.+A.+Blairauthor=L.+J.+Klunkauthor=R.+F.+Mayol&title=In+vitro+metabolism+of+the+antianxiety+drug+buspirone+as+a+predictor+of+its+metabolism+in+vivo&doi=10.3109%2F00498259009046892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo</span></div><div class="casAuthors">Jajoo, H. K.; Blair, I. A.; Klunk, L. J.; Mayol, R. F.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-86</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    </div><div class="casAbstract">Metab. of antianxiety drug buspirone was studied by in vitro incubations with rat liver microsomes and hepatocytes.  Metabolites were isolated and purified by HPLC.  The purified metabolites were identified by co-elution on HPLC with authentic stds. and by GLC-electron impact mass spectrometry of their trimethylsilyl (TMS) derivs.  Five metabolites of buspirone were identified in the microsomal incubate and seven in the hepatocyte incubate.  The major metabolites arose from arom. hydroxylation at C-5, N-dealkylation of the Bu chain, the hydroxylation at C-6' and C-3' on the azaspirodecanedione moiety.  Metab. of buspirone by rat liver microsomes was NADPH-dependent and was completely inhibited by cytochrome P 450 inhibitors SKF-525A and metyrapone.  Metabolites of buspirone formed in vitro were good predictors of the primary metabolites formed in vivo.  Hepatocytes and phenobarbital-induced rat liver microsomes were better predictors of in vivo metab. of buspirone than non-induced rat liver microsomes.  These in vitro systems should provide excellent models for studying the metab. of other azaspirodecanedione-contg. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-cZf5ni68K7Vg90H21EOLACvtfcHk0ljKwbmJKWyw0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVCitLk%253D&md5=f2b54e912a5485f62d19f9e381f54a06</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3109%2F00498259009046892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498259009046892%26sid%3Dliteratum%253Aachs%26aulast%3DJajoo%26aufirst%3DH.%2BK.%26aulast%3DBlair%26aufirst%3DI.%2BA.%26aulast%3DKlunk%26aufirst%3DL.%2BJ.%26aulast%3DMayol%26aufirst%3DR.%2BF.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520the%2520antianxiety%2520drug%2520buspirone%2520as%2520a%2520predictor%2520of%2520its%2520metabolism%2520in%2520vivo%26jtitle%3DXenobiotica%26date%3D1990%26volume%3D20%26spage%3D779%26epage%3D786%26doi%3D10.3109%2F00498259009046892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8531118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK28XhvV2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1995&pages=1476-1483&author=Z.+C.+Liuauthor=J.+P.+Uetrecht&title=Clozapine+is+oxidized+by+activated+human+neutrophils+to+a+reactive+nitrenium+ion+that+irreversibly+binds+to+the+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells</span></div><div class="casAuthors">Liu, Zhao Chao; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1476-83</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Clozapine was oxidized to a reactive intermediate by HOCl, which is the major oxidant produced by activated neutrophils.  A mass spectrum was obtained of this reactive intermediate by using a flow system in which the reactants were fed into a mixing chamber and the products flowed directly into a Sciex API III mass spectrometer.  The intermediate was obsd. at m/z 325, which is 2 mass units less than the protonated mol. ion of the parent drug.  This intermediate reacted with water to form several products with a m/z at 343.  The same products were produced by the oxidn. of clozapine by the combination of myeloperoxidase, hydrogen peroxide and chloride ion.  The reactive intermediate was trapped by glutathione (GSH) and several conjugates were formed.  NMR spectra of the two major conjugates indicated GSH bound to the 6 and 9 positions of the arom. ring.  These data provide further evidence for the formation of a formal nitrenium ion in which the pos. charge is highly delocalized.  Clozapine was also oxidized by activated neutrophils, and in the presence of GSH, the same GSH conjugates were formed.  When therapeutic concns. of radiolabeled clozapine were used, up to 7% of the drug became irreversibly bound to the neutrophils.  Covalent binding was inhibited by about 30% in the presence of 1 mM GSH but was almost abolished at 5 mM GSH.  The putative nitrenium ion formed by activated leukocytes could be responsible for clozapine-induced agranulocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdakyhGXFzVLVg90H21EOLACvtfcHk0ljKwbmJKWyw0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvV2jsw%253D%253D&md5=042000d7c36bd6e330482ab383fc61d8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%2BC.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DClozapine%2520is%2520oxidized%2520by%2520activated%2520human%2520neutrophils%2520to%2520a%2520reactive%2520nitrenium%2520ion%2520that%2520irreversibly%2520binds%2520to%2520the%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D275%26spage%3D1476%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">1463</span>– <span class="NLM_lpage">1475</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8531117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK287gvVKnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1995&pages=1463-1475&author=J.+L.+Maggsauthor=D.+Williamsauthor=M.+Pirmohamedauthor=B.+K.+Park&title=The+metabolic+formation+of+reactive+intermediates+from+clozapine%2C+a+drug+associated+with+agranulocytosis+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man</span></div><div class="casAuthors">Maggs J L; Williams D; Pirmohamed M; Park B K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1463-75</span>
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Clozapine, a dibenzodiazepine antipsychotic, is associated with a 0.8% incidence of agranulocytosis.  This clinically restrictive toxicity has been attributed to its chemically reactive metabolites.  The generation of such metabolites--assessed via covalent binding and formation of thioether adducts--was investigated using human, rat and mouse liver microsomes and human neutrophils and bone marrow cells.  In every instance, one major glutathione adduct of clozapine--C-6 glutathionyl clozapine--was formed in the presence of added glutathione.  Adduct formation by the neutrophils and myeloid cells was dependent on cell activation by phorbol myristate acetate.  Small fractions of drug underwent covalent binding to microsomes (1-6.8%) and to protein coincubated with neutrophils (0.47%) and myeloid cells (0.21%).  Clozapine did not deplete intracellular glutathione in activated neutrophils.  Clozapine was also metabolized in vivo to glutathione conjugates in rats and mice, the conjugates eliminated in bile over a 3-hr period representing 38% and 33% of the dose, respectively.  In addition to the principal clozapine adduct found in vitro, the C-8 glutathionyl derivative of deschloroclozapine was excreted by both species.  It is concluded that clozapine undergoes bioactivation in several tissues and considerable bioactivation in vivo.  The reactive metabolites generated by neutrophils and myeloid cells may play an important role in the metabolic causation of clozapine-induced agranuiocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJ8NBvkV4aL-IHSmpohpd0fW6udTcc2eYM8We1A7z_V7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287gvVKnsQ%253D%253D&md5=16f9d0cd50455f82ea3e9d6ba59d3e6a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520metabolic%2520formation%2520of%2520reactive%2520intermediates%2520from%2520clozapine%252C%2520a%2520drug%2520associated%2520with%2520agranulocytosis%2520in%2520man%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D275%26spage%3D1463%26epage%3D1475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Metabolism and bioactivation of clozapine by human liver in vitro</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">990</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7891353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2MXktl2ksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1995&pages=984-990&author=M.+Pirmohamedauthor=D.+Williamsauthor=S.+Maddenauthor=E.+Templetonauthor=B.+K.+Park&title=Metabolism+and+bioactivation+of+clozapine+by+human+liver+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and bioactivation of clozapine by human liver in vitro</span></div><div class="casAuthors">Pirmohamed, Munir; Williams, Dominic; Madden, Stephen; Templeton, Elizabeth; Park B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">984-90</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The metab. of clozapine by human liver has been investigated in vitro.  Irreversible protein-binding and conjugation with model nucleophiles have been used as markers for bioactivation of clozapine, while stable metabolite formation has been assessed using radiometric HPLC.  In all nine liver microsomal prepns. investigated, clozapine was extensively metabolized to the stable products desmethylclozapine (range 19%-27.2%), N-oxide (1.5-2.0%) and three polar metabolites (0-20.8%), and was bioactivated to a protein-reactive metabolite (0.6-2.1%).  The CYP2D6 genotype did not influence the capacity of the livers to form these metabolites.  All metabolic pathways were inhibited by ketoconazole, indicating the involvement of the cytochrome P 450 enzymes.  Isoenzyme-selective inhibitor studies demonstrated that whereas demethylation was performed by CYP1A2, N-oxidn. and chem. reactive metabolite formation were dependent upon multiple forms of P 450.  The N-oxide was readily reduced back to clozapine in the presence of NADPH, this conversion being inhibited by ascorbic acid.  Glutathione (1 mM) decreased covalent binding by 70%.  The amt. of putative adduct formed in the presence of glutathione (13.4 ± 0.9%) was much greater than the covalent binding (mean 1.1 ± 0.2%).  The bioactivation of clozapine was, like the N-oxidn. of clozapine, a reversible process.  In summary, our results indicate that clozapine undergoes extensive metab. by human liver to both stable and chem. reactive metabolites, the formation of which is catalyzed by the cytochrome P 450 enzymes.  The role of the reactive metabolite, which may be a free radical, in the pathogenesis of clozapine agranulocytosis and hepatotoxicity requires further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorxcmRuhShhbVg90H21EOLACvtfcHk0lgEHl_Jroq71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktl2ksr4%253D&md5=c1293610c13c2196790c180dab37dd7d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DMadden%26aufirst%3DS.%26aulast%3DTempleton%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DMetabolism%2520and%2520bioactivation%2520of%2520clozapine%2520by%2520human%2520liver%2520in%2520vitro%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1995%26volume%3D272%26spage%3D984%26epage%3D990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakhit, S.</span></span> <span> </span><span class="NLM_article-title">Structural features associated with reactive metabolite formation in clozapine analogues</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(97)00017-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2897%2900017-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9212779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2sXkt12ksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1997&pages=117-129&author=J.+P.+Uetrechtauthor=N.+Zahidauthor=A.+Tehimauthor=J.+M.+Fuauthor=S.+Rakhit&title=Structural+features+associated+with+reactive+metabolite+formation+in+clozapine+analogues&doi=10.1016%2FS0009-2797%2897%2900017-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural features associated with reactive metabolite formation in clozapine analogs</span></div><div class="casAuthors">Uetrecht, Jack; Zahid, Nasir; Tehim, Ashik; Fu, J. Mim; Rakhit, Suman</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Clozapine is assocd. with a high incidence of agranulocytosis.  We had previously found that it is oxidized by granulocytes, or simply HOCl, to a reactive metabolite that irreversibly binds to the cells, and we proposed that this reactive metabolite is responsible for clozapine-induced agranulocytosis.  The reactive metabolite appeared to be a nitrenium ion formed by chlorination of the nitrogen bridge between the two arom. rings.  If this is correct, analogs that contain this structural feature should also be oxidized to a reactive intermediate while those not possessing this feature would, at least, not form the same type of reactive intermediate and, therefore, may not induce agranulocytosis.  We tested the first part of this hypothesis, with three clozapine analogs that do contain a nitrogen bridge and three that do not.  Consistent with the hypothesis, the three analogs that do contain the nitrogen bridge formed reactive intermediates that could be trapped with glutathione when oxidized by HOCl, myeloperoxidase or activated neutrophils.  In contrast, we found no evidence of a reactive intermediate on oxidn. of analogs that contained an oxygen or sulfur bridge rather than a nitrogen bridge.  If such reactive metabolites are responsible for drug-induced agranulocytosis, it should be possible to use such a simple screening method to test drugs at an early stage in their development for the potential to induce agranulocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3e71WkafCt7Vg90H21EOLACvtfcHk0lgEHl_Jroq71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt12ksrw%253D&md5=2e2dc1d697c3f9b8cd36a5e7b5965b9f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2897%2900017-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252897%252900017-3%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26aulast%3DZahid%26aufirst%3DN.%26aulast%3DTehim%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DJ.%2BM.%26aulast%3DRakhit%26aufirst%3DS.%26atitle%3DStructural%2520features%2520associated%2520with%2520reactive%2520metabolite%2520formation%2520in%2520clozapine%2520analogues%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1997%26volume%3D104%26spage%3D117%26epage%3D129%26doi%3D10.1016%2FS0009-2797%2897%2900017-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeder, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J. P.</span></span> <span> </span><span class="NLM_article-title">A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1008</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9614201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVOmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=999-1008&author=I.+Gardnerauthor=J.+S.+Leederauthor=T.+Chinauthor=N.+Zahidauthor=J.+P.+Uetrecht&title=A+comparison+of+the+covalent+binding+of+clozapine+and+olanzapine+to+human+neutrophils+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo</span></div><div class="casAuthors">Gardner, Iain; Leeder, J. Steven; Chin, Terrence; Zahid, Nasir; Uetrecht, Jack P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1008</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Covalent binding of a reactive metabolite of clozapine to neutrophils or their precursors is thought to play a role in the development of clozapine-induced agranulocytosis.  Immunoblotting studies with an anti-clozapine antiserum detected covalent binding of clozapine to human neutrophils in vitro when HOCl was used to generate clozapine reactive metabolite (major clozapine adducts of 31, 49, 58, 78, 86, 126, 160, and 204 kDa).  In addn., incubating neutrophils with clozapine and H2O2 (major clozapine adducts of 49 and 58 kDa) or clozapine, H2O2, and human myeloperoxidase (major clozapine adducts of 31, 49, 58, and 126 kDa) also resulted in covalent binding of clozapine to the neutrophils.  The covalent binding of clozapine to neutrophils was inhibited by extracellular glutathione when HOCl, but not H2O2 was used to generate reactive metabolite.  We found that the antiserum against clozapine also recognized olanzapine, an antipsychotic drug that forms a similar reactive metabolite to clozapine but has not been assocd. with induction of agranulocytosis.  Repeating the in vitro expts. with olanzapine revealed that the major olanzapine-modified polypeptides had mol. masses of 96, 130-170, and 218 kDa.  Only relatively low levels of 31, 49, and 58 kDa adducts were obsd.  Clozapine-modified polypeptides also were detected in neutrophils from patients being treated with clozapine.  A major 58-kDa clozapine-modified polypeptide was detected in all patients tested.  In contrast, no drug-modified polypeptides were detected in neutrophils from patients taking olanzapine.  The differences in covalent binding exhibited by the two compds. and, in particular, the lack of olanzapine binding to human neutrophils in vivo may help to explain the difference in toxicity of these two drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsGnBgZHe9dbVg90H21EOLACvtfcHk0lgEHl_Jroq71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVOmtbw%253D&md5=9768c84986d3c1f1a9411e521eadaa24</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DLeeder%26aufirst%3DJ.%2BS.%26aulast%3DChin%26aufirst%3DT.%26aulast%3DZahid%26aufirst%3DN.%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comparison%2520of%2520the%2520covalent%2520binding%2520of%2520clozapine%2520and%2520olanzapine%2520to%2520human%2520neutrophils%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Pharmacol.%26date%3D1998%26volume%3D53%26spage%3D999%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masubuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murayama, N.</span></span> <span> </span><span class="NLM_article-title">Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1021/tx060234h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx060234h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVCjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=455-464&author=N.+Masubuchiauthor=C.+Makinoauthor=N.+Murayama&title=Prediction+of+in+vivo+potential+for+metabolic+activation+of+drugs+into+chemically+reactive+intermediate%3A+correlation+of+in+vitro+and+in+vivo+generation+of+reactive+intermediates+and+in+vitro+glutathione+conjugate+formation+in+rats+and+humans&doi=10.1021%2Ftx060234h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of in Vivo Potential for Metabolic Activation of Drugs into Chemically Reactive Intermediate: Correlation of in Vitro and in Vivo Generation of Reactive Intermediates and in Vitro Glutathione Conjugate Formation in Rats and Humans</span></div><div class="casAuthors">Masubuchi, Noriko; Makino, Chie; Murayama, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The covalent binding of reactive intermediates to macromols. might have potential involvement in severe adverse drug reactions.  Thus, quantification of reactive metabolites is necessary during the early stage of drug discovery to avoid serious toxicity.  In this study, the relation between covalent binding and glutathione (GSH) conjugate formation in rat and human liver microsomes were investigated using 10 representative radioactive compds. that have been reported as hepatotoxic or having other toxicity derived from their reactive intermediates: acetaminophen, amodiaquine, carbamazepine, clozapine, diclofenac, furosemide, imipramine, indomethacin, isoniazid, and tienilic acid, all at a concn. of 10 μM.  The GSH conjugate formation rate correlates well with the covalent binding of radioactivity (both rat and human, r2 = 0.93), which suggests that quantification of the GSH conjugate can be used to est. covalent binding.  To quantify the GSH-conjugation rate with non-radiolabeled compds. in vitro, the validation study for the detn. of GSH conjugate formation using 35S-GSH by radio-HPLC was useful to predict metabolic activation.  Following oral administration of 20 mg/kg of the radiolabeled compds. to rats, radioactivity that covalently bound to plasma and liver proteins was detd.  The in vivo max. covalent binding level in liver based on the free fraction of plasma area under the concn. curve (AUC) and in vitro covalent binding rate was found to correlate well (r2 = 0.79).  Therefore, this model for in vitro covalent binding studies in human and rat and in vivo rat studies might be useful in predicting human metabolic activation of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoslCBzhwS0HrVg90H21EOLACvtfcHk0liH9HJkvMc3bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVCjsb0%253D&md5=110aa3cd8bc1b027d61439cdc933ad80</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Ftx060234h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx060234h%26sid%3Dliteratum%253Aachs%26aulast%3DMasubuchi%26aufirst%3DN.%26aulast%3DMakino%26aufirst%3DC.%26aulast%3DMurayama%26aufirst%3DN.%26atitle%3DPrediction%2520of%2520in%2520vivo%2520potential%2520for%2520metabolic%2520activation%2520of%2520drugs%2520into%2520chemically%2520reactive%2520intermediate%253A%2520correlation%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520generation%2520of%2520reactive%2520intermediates%2520and%2520in%2520vitro%2520glutathione%2520conjugate%2520formation%2520in%2520rats%2520and%2520humans%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D455%26epage%3D464%26doi%3D10.1021%2Ftx060234h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldkind, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, L.</span></span> <span> </span><span class="NLM_article-title">A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1002/pds.1207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fpds.1207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16456879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFGmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=213-220&author=L.+Goldkindauthor=L.+Laine&title=A+systematic+review+of+NSAIDs+withdrawn+from+the+market+due+to+hepatotoxicity%3A+lessons+learned+from+the+bromfenac+experience&doi=10.1002%2Fpds.1207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience</span></div><div class="casAuthors">Goldkind, Lawrence; Laine, Loren</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and Drug Safety</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-220</span>CODEN:
                <span class="NLM_cas:coden">PDSAEA</span>;
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Drug-induced hepatotoxicity is the leading cause of acute liver failure (ALF) in the US and the most common adverse event causing drug non-approval and drug withdrawal by the U.S. Food and Drug Administration (FDA).  Three different nonsteroidal anti-inflammatory drugs (NSAIDs) have been withdrawn in the UK and/or the US due to hepatotoxicity (bromfenac, ibufenac, and benoxaprofen).  A systematic review of clin. trials data for these drugs was performed in an effort to identify possible early signals that could have predicted post-marketing serious hepatotoxicity.  There were very limited published data on benoxaprofen and none on ibufenac or bromfenac.  The publicly accessible archives of the FDA provided information on bromfenac.  Flu-like symptoms assocd. with hepatic enzyme elevation and a case of possible drug-related hepatocellular jaundice may in retrospect have been signals for serious hepatotoxicity in the database of 1195 subjects reviewed by the FDA.  Following approval, rates of acute liver failure for bromfenac were estd. to be in the range of 1:10 000.  In addn., the safety databases of several drugs also accessed through FDA archives have been reviewed (simvastatin, tacrine, troglitazone, and ximelagatran).  These data suggest that while ALT elevations alone do not reliably signal serious hepatotoxicity, elevated transaminases in assocn. with symptomatic hepatitis or jaundice may be predictors of an increased risk of ALF.  At present, however, pre-approval databases are generally not large enough to rule out low rates of serious hepatotoxicity.  Therefore, it remains crit. that clinicians report such cases to the FDA through the MED-WATCH system and that active post-marketing monitoring studies be used to identify potential rare cases of hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFSR7CRsJb7Vg90H21EOLACvtfcHk0liH9HJkvMc3bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFGmsrc%253D&md5=510690d4e5966ac6f0924507e7c27679</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fpds.1207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.1207%26sid%3Dliteratum%253Aachs%26aulast%3DGoldkind%26aufirst%3DL.%26aulast%3DLaine%26aufirst%3DL.%26atitle%3DA%2520systematic%2520review%2520of%2520NSAIDs%2520withdrawn%2520from%2520the%2520market%2520due%2520to%2520hepatotoxicity%253A%2520lessons%2520learned%2520from%2520the%2520bromfenac%2520experience%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2006%26volume%3D15%26spage%3D213%26epage%3D220%26doi%3D10.1002%2Fpds.1207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span> <span> </span><span class="NLM_article-title">Chemistry and reactivity of acyl glucuronides</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.2174/138920011795101822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2174%2F138920011795101822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20946098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVOnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=215-221&author=A.+V.+Stachulski&title=Chemistry+and+reactivity+of+acyl+glucuronides&doi=10.2174%2F138920011795101822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and reactivity of acyl glucuronides</span></div><div class="casAuthors">Stachulski, Andrew V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-221</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review presents a survey of acyl glucuronides (AGs) from the perspective of a synthetic medicinal chemist.  After a brief introduction to the biogenesis of AGs and current attitudes of the pharmaceutical industry towards them, the importance of the availability of pure synthetic AGs as probe mols. is stressed.  Current synthetic methods including the selective acylation method and enzymic procedures are discussed with actual drug examples.  The major reaction pathways of AGs, acyl migration and direct acyl transfer, are then examd. with consideration of both in vitro and in vivo situations.  Both the aglycon and the carbohydrate residue are shown to be important in detg. the reactivity of AGs, esp. the α-substitution in aryl acetates and propionates and aryl substitution in benzoates.  The significance of these effects for important drugs such as the NSAIDs diclofenac and ibuprofen is noted.  Appropriate models of the reactivity of AGs with proteins are presented, from short model peptides to body proteins, and examples where AGs clearly interact with protein in vivo (e. g. mycophenolic acid) are presented.  Recent results with AGs in plasma, where half-lives differ significantly from their values in aq. buffer, show the importance of considering the external medium esp. when other hydrolytic enzymes are present.  Finally, the importance of considering the reactivity of acyl thioesters-which may be formed directly or via AGs as intermediates- is also stressed.  This pathway may lead to different protein reactivity than shown for AGs themselves, including interference with the glutathione pathway as shown for NSAID-like carboxylic acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAwIQ0A8tN7Vg90H21EOLACvtfcHk0liH9HJkvMc3bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVOnu78%253D&md5=f13fcde37949577e4b30ac0681e388e0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F138920011795101822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920011795101822%26sid%3Dliteratum%253Aachs%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26atitle%3DChemistry%2520and%2520reactivity%2520of%2520acyl%2520glucuronides%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2011%26volume%3D12%26spage%3D215%26epage%3D221%26doi%3D10.2174%2F138920011795101822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monrad, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Errey, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iddon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrie, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. G.</span></span> <span> </span><span class="NLM_article-title">Dissecting the reaction of phase II metabolites of ibuprofen and other NSAIDs with human plasma protein</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3789</span>– <span class="NLM_lpage">3794</span>, <span class="refDoi"> DOI: 10.1039/C4SC01329H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1039%2FC4SC01329H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFSltrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3789-3794&author=R.+N.+Monradauthor=J.+C.+Erreyauthor=C.+S.+Barryauthor=M.+Iqbalauthor=X.+Mengauthor=L.+Iddonauthor=J.+A.+Perrieauthor=J.+R.+Hardingauthor=I.+D.+Wilsonauthor=A.+V.+Stachulskiauthor=B.+G.+Davis&title=Dissecting+the+reaction+of+phase+II+metabolites+of+ibuprofen+and+other+NSAIDs+with+human+plasma+protein&doi=10.1039%2FC4SC01329H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting the reaction of Phase II metabolites of ibuprofen and other NSAIDS with human plasma protein</span></div><div class="casAuthors">Monrad, Rune Nygaard; Errey, James C.; Barry, Conor S.; Iqbal, Mazhar; Meng, Xiaoli; Iddon, Lisa; Perrie, Jennifer A.; Harding, John R.; Wilson, Ian D.; Stachulski, Andrew V.; Davis, Benjamin G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3789-3794</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs on the market.  While they are considered safe, several NSAIDs have been withdrawn from the market as a result of adverse drug reactions.  NSAIDs are extensively metabolised to their 1-β-O-acyl glucuronides (AGs), and the risk of NSAID AGs covalently modifying biomacromols. such as proteins or DNA, leading to immune responses and cellular dysfunction constitutes a major concern in drug discovery and development.  The assessment of the degree of protein modification and potential toxicity of individual NSAID AGs is therefore of importance in both drug monitoring and development.  Herein, we report the covalent reaction of 1-β-O-acyl glucuronides of ibuprofen and several NSAID analogs with human serum albumin (HSA) protein in vitro under concns. encountered in therapy.  Stable transacylation and glycosylation adducts are formed; the obsd. protein product ratios can be rationalised by the degree of α-substitution in the acyl group.  Structure-based protein reactivity correlations of AGs, such as these, may prove a useful tool in distinguishing between carboxylic acid-contg. drugs of similar structure that ultimately prove beneficial (e.g., ibuprofen) from those that prove toxic (e.g., ibufenac).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0KHabMaN60LVg90H21EOLACvtfcHk0lhPVt2Qw5VhJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFSltrrL&md5=3106c6381f0bac854d7c628406b3d552</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FC4SC01329H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4SC01329H%26sid%3Dliteratum%253Aachs%26aulast%3DMonrad%26aufirst%3DR.%2BN.%26aulast%3DErrey%26aufirst%3DJ.%2BC.%26aulast%3DBarry%26aufirst%3DC.%2BS.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DIddon%26aufirst%3DL.%26aulast%3DPerrie%26aufirst%3DJ.%2BA.%26aulast%3DHarding%26aufirst%3DJ.%2BR.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DDavis%26aufirst%3DB.%2BG.%26atitle%3DDissecting%2520the%2520reaction%2520of%2520phase%2520II%2520metabolites%2520of%2520ibuprofen%2520and%2520other%2520NSAIDs%2520with%2520human%2520plasma%2520protein%26jtitle%3DChem.%2520Sci.%26date%3D2014%26volume%3D5%26spage%3D3789%26epage%3D3794%26doi%3D10.1039%2FC4SC01329H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcdonagh, A. F.</span></span> <span> </span><span class="NLM_article-title">Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">644</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1981713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3MXhsVE%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1990&pages=639-644&author=P.+C.+Smithauthor=L.+Z.+Benetauthor=A.+F.+Mcdonagh&title=Covalent+binding+of+zomepirac+glucuronide+to+proteins%3A+evidence+for+a+Schiff+base+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent binding of zomepirac glucuronide to proteins:  evidence for a Schiff base mechanism</span></div><div class="casAuthors">Smith, Philip C.; Benet, Leslie Z.; McDonagh, Antony F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-44</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">Carboxylic acids can undergo irreversible binding to proteins via their acyl glucuronide metabolites.  Such binding occurs in humans and in vitro for bilirubin and the anti-inflammatory drugs zomepirac and tolmetin and may have toxicol. significance.  The mechanism of the binding is uncertain, but is thought to involve nucleophilic displacement of glucuronic acid by free cysteine thiols, tyrosine, or lysine residues of the protein.  Evidence is now presented, using zomepirac glucuronide, for an alternative mechanism where irreversible binding occurs by isomerization of the glucuronide and formation of an imine linkage between the glucuronic acid moiety of the conjugate and a lysine or terminal amino group of the protein.  Involvement of a protein thiol in the binding mechanism was ruled out by expts. with the thiol-blocking agent p-hydroxymercuribenzoate.  Moreover, significant irreversible binding occurred when the cysteine-free protein α1-casein was incubated in soln. with zomepirac glucuronide in vitro.  When zomepirac glucuronide was added to solns. with albumin in the presence of the imine-trapping reagent NaCN or the reducing agent NaCNBH3, irreversible binding of zomepirac increased 8.3- and 5.5-fold relative to controls, resp., after 6 h at 37°.  The product formed after treatment of solns. of zomepirac glucuronide and albumin after NaCNBH3 was stable in dil. acid, whereas similar acid treatment of zomepirac-albumin adduct from control incubations, obtained after NaCN exposure, released 30% of the total adduct.  Only isomeric conjugates of zomepirac glucuronide were released from zomepirac-albumin adduct by mild acid; no β1-isomer was detected.  These results support a mechanism of covalent binding of zomepirac glucuronide to proteins in which isomerization of the glucuronide by acyl migration is a prerequisite to imine formation between the 1 position of glucuronic acid and an NH2 group of the protein.  The incomplete hydrolysis of the zomepirac-albumin adduct by dil. acid suggests that further Amadori rearrangement of the imino sugar to a more stable 1-amino-2-ketose product may also be a significant process in the irreversible binding of acyl glucuronides to proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9aI4rDgHKS7Vg90H21EOLACvtfcHk0lhPVt2Qw5VhJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsVE%253D&md5=750bc15e9270db255df0893f6d6fa77d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BC.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DMcdonagh%26aufirst%3DA.%2BF.%26atitle%3DCovalent%2520binding%2520of%2520zomepirac%2520glucuronide%2520to%2520proteins%253A%2520evidence%2520for%2520a%2520Schiff%2520base%2520mechanism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1990%26volume%3D18%26spage%3D639%26epage%3D644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. C.</span></span> <span> </span><span class="NLM_article-title">Disposition and covalent binding of ibuprofen and it acyl glucuronide in the elderly</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/0009-9236(95)90226-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0009-9236%2895%2990226-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7781263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK2MzgtVChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1995&pages=636-644&author=M.+Castilloauthor=Y.+W.+F.+Lamauthor=M.+A.+Dooleyauthor=E.+Stahlauthor=P.+C.+Smith&title=Disposition+and+covalent+binding+of+ibuprofen+and+it+acyl+glucuronide+in+the+elderly&doi=10.1016%2F0009-9236%2895%2990226-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly</span></div><div class="casAuthors">Castillo M; Lam Y W; Dooley M A; Stahl E; Smith P C</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">636-44</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">Ibuprofen is an over-the-counter nonsteroidal anti-inflammatory drug with a low incidence of severe adverse reactions.  It is metabolized by oxidation to carboxyibuprofen and hydroxyibuprofen and by conjugation to an acyl glucuronide.  In vitro studies have indicated that ibuprofen glucuronide is labile and reactive, forming covalent adducts with proteins.  To verify the formation of ibuprofen-protein adducts in vivo, the pharmacokinetics of ibuprofen glucuronide and its covalent binding to plasma proteins were studied in five elderly patients who received long-term administration of oral doses of ibuprofen.  Plasma levels of ibuprofen glucuronide were low relative to those of ibuprofen; the ratio of area under the plasma concentration versus time curve for the glucuronide relative to the parent drug was only 4%.  Covalent binding of ibuprofen to plasma protein was observed in all patients, correlating well with the area under the plasma concentration versus time curve of ibuprofen glucuronide (r = 0.966).  Compared with reports for other nonsteroidal anti-inflammatory drugs that form acyl glucuronides, plasma levels of ibuprofen-protein adduct are low during long-term administration.  The observed lower reactivity in vivo is probably attributable to the greater stability of ibuprofen glucuronide relative to other acyl glucuronides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT421jhw9HMF_6xYuD7tu2XfW6udTcc2ebyV3V09U_9T7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2MzgtVChtg%253D%253D&md5=a017d65c93d744a5526453709995eeeb</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2F0009-9236%2895%2990226-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0009-9236%252895%252990226-0%26sid%3Dliteratum%253Aachs%26aulast%3DCastillo%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DY.%2BW.%2BF.%26aulast%3DDooley%26aufirst%3DM.%2BA.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%2BC.%26atitle%3DDisposition%2520and%2520covalent%2520binding%2520of%2520ibuprofen%2520and%2520it%2520acyl%2520glucuronide%2520in%2520the%2520elderly%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1995%26volume%3D57%26spage%3D636%26epage%3D644%26doi%3D10.1016%2F0009-9236%2895%2990226-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talaat, R.</span></span> <span> </span><span class="NLM_article-title">A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1021/tx049900+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx049900%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt12qurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=1206-1216&author=J.+Wangauthor=M.+Davisauthor=F.+Liauthor=F.+Azamauthor=J.+Scatinaauthor=R.+Talaat&title=A+novel+approach+for+predicting+acyl+glucuronide+reactivity+via+Schiff+base+formation%3A+development+of+rapidly+formed+peptide+adducts+for+LC%2FMS%2FMS+measurements&doi=10.1021%2Ftx049900%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Approach for Predicting Acyl Glucuronide Reactivity via Schiff Base Formation: Development of Rapidly Formed Peptide Adducts for LC/MS/MS Measurements</span></div><div class="casAuthors">Wang, Jianyao; Davis, Margaret; Li, Fangbiao; Azam, Farooq; Scatina, JoAnn; Talaat, Rasmy</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1206-1216</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel technique to study the reactivity of acyl glucuronide metabolites to protein has been developed and is described herein.  Considered here are acyl glucuronide metabolites, which have undergone the rearrangement of the glucuronic acid moiety at physiol. temp. and pH.  The investigation of the reactivity of these electrophilic metabolites was carried out by measuring the rate of reaction of rearranged AG metabolites in forming the corresponding acyl glucuronide-peptide adduct in the presence of Lys-Phe.  This differs from the parallel technique used in forming AG adducts of proteins that have been previously reported.  In the study described here, the Schiff base adduct, diclofenac acyl glucuronide-Lys-Phe product, was generated and structurally elucidated by liq. chromatog. tandem mass spectrometry (LC/MS/MS) anal.  The product structure was proved to be a Schiff base adduct by chem. derivatization by nucleophilic addn. of HCN and chem. redn. with NaCNBH3, followed by LC/MS/MS anal.  It is proposed here that the degree of reactivity of acyl glucuronides as measured by covalent binding to protein is proportional to the amt. of its peptide adduct generated with the peptide technique described.  The application of this technique to the assessment of the degree of reactivity of acyl glucuronide metabolites was validated by developing a reactivity rank of seven carboxylic acid-contg. drugs.  Consistency was achieved between the ranking of reactivity in the peptide technique for these seven compds. and the rankings found in the literature.  In addn., a correlation (R2 = 0.95) was revealed between the formation of a peptide adduct and the rearrangement rate of the primary acyl glucuronide of seven tested compds.  A structure effect on the degree of reactivity has demonstrated the rate order: acetic acid > propionic acid > benzoic acid derivs.  A rational explanation of this order was proposed, based on the inherent electronic and steric properties of each specific aglycon.  In addn., adaptation of this technique to automation in order to more rapidly assess the ranking of reactivity of acyl glucuronide covalent binding to proteins by new chem. entities is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzH7J0RPEhrVg90H21EOLACvtfcHk0liBRFJ0ywE7yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt12qurg%253D&md5=1cee861849c7acb1ae3fe47d7c1b5d87</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Ftx049900%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx049900%252B%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DAzam%26aufirst%3DF.%26aulast%3DScatina%26aufirst%3DJ.%26aulast%3DTalaat%26aufirst%3DR.%26atitle%3DA%2520novel%2520approach%2520for%2520predicting%2520acyl%2520glucuronide%2520reactivity%2520via%2520Schiff%2520base%2520formation%253A%2520development%2520of%2520rapidly%2520formed%2520peptide%2520adducts%2520for%2520LC%252FMS%252FMS%2520measurements%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D1206%26epage%3D1216%26doi%3D10.1021%2Ftx049900%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atherton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reily, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A.</span></span> <span> </span><span class="NLM_article-title">Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1021/tx600297u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx600297u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlvVymtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=876-886&author=G.+S.+Walkerauthor=J.+Athertonauthor=J.+Baumanauthor=C.+Kohlauthor=W.+Lamauthor=M.+Reilyauthor=Z.+Louauthor=A.+Mutlib&title=Determination+of+degradation+pathways+and+kinetics+of+acyl+glucuronides+by+NMR+spectroscopy&doi=10.1021%2Ftx600297u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of Degradation Pathways and Kinetics of Acyl Glucuronides by NMR Spectroscopy</span></div><div class="casAuthors">Walker, Gregory S.; Atherton, James; Bauman, Jonathan; Kohl, Christopher; Lam, Wing; Reily, Michael; Lou, Zhen; Mutlib, Abdul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">876-886</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl glucuronides have been implicated in the toxicity of many xenobiotics and marketed drugs.  These toxicities are hypothesized to be a consequence of covalent binding of the reactive forms of the acyl glucuronide to proteins.  Reactive intermediates of the acyl glucuronide arise from the migration of the aglycon leading to other positional and stereoisomers under physiol. conditions.  In order to screen for the potential liabilities of these metabolites during the early phase of pharmaceutical development, an NMR method based on the disappearance of the anomeric resonance of the O-1-acyl glucuronide was used to monitor the degrdn. kinetics of 11 structurally diverse acyl glucuronides, including those produced from the known nonsteroidal anti-inflammatory drugs (NSAIDs).  The acyl glucuronides were either chem. synthesized or were isolated from biol. matrixes (bile, urine, and liver microsomal exts.).  The half-lives attained utilizing this method were found to be comparable to those reported in the literature.  NMR anal. also enabled the delineation of the two possible pathways of degrdn.: acyl migration and hydrolytic cleavage.  The previously characterized 1H resonances of acyl migrated products are quite distinguishable from those that arise from hydrolysis.  The NMR method described here could be used to rank order acyl glucuronide forming discovery compds. based on the potential reactivity of the conjugates and their routes of decompn. under physiol. conditions.  Furthermore, we have shown that in vitro systems such as liver microsomal prepns. can be used to generate sufficient quantities of acyl glucuronides from early discovery compds. for NMR characterization.  This is particularly important, as we often have limited supply of early discovery compds. to conduct in vivo studies to generate sufficient quantities of acyl glucuronides for further characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aeMkwVvVErVg90H21EOLACvtfcHk0liBRFJ0ywE7yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlvVymtrw%253D&md5=b0ffe295d85c8a7a6816f3e22eac5bec</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Ftx600297u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx600297u%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DLam%26aufirst%3DW.%26aulast%3DReily%26aufirst%3DM.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DMutlib%26aufirst%3DA.%26atitle%3DDetermination%2520of%2520degradation%2520pathways%2520and%2520kinetics%2520of%2520acyl%2520glucuronides%2520by%2520NMR%2520spectroscopy%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D876%26epage%3D886%26doi%3D10.1021%2Ftx600297u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, T.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships for the degradation reaction of 1-beta-O-acyl glucuronides. Part 3: Electronic and steric descriptors predicting the reactivity of aralkyl carboxylic acid 1-beta-O-acyl glucuronides</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.1021/tx9002963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9002963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=1998-2008&author=A.+Babaauthor=T.+Yoshioka&title=Structure-activity+relationships+for+the+degradation+reaction+of+1-beta-O-acyl+glucuronides.+Part+3%3A+Electronic+and+steric+descriptors+predicting+the+reactivity+of+aralkyl+carboxylic+acid+1-beta-O-acyl+glucuronides&doi=10.1021%2Ftx9002963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships for the Degradation Reaction of 1-β-O-Acyl Glucuronides. Part 3: Electronic and Steric Descriptors Predicting the Reactivity of Aralkyl Carboxylic Acid 1-β-O-Acyl Glucuronides</span></div><div class="casAuthors">Baba, Akiko; Yoshioka, Tadao</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1998-2008</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since 1-β-O-acyl glucuronides (βGAs) are thought to be chem. reactive metabolites capable of binding to tissue proteins, possibly leading to adverse drug reactions of the parent carboxylic acid drugs, we have initiated research efforts to derive structure-activity relationships (SARs) of βGAs, with a focus on finding appropriate descriptors that predict their intrinsic electrophilic reactivity or degrdn. rate consts. (k values).  Our previous SAR studies on the k values of βGAs derived from o-, m-, and p-substituted benzoic acids demonstrated that the diversity and complexity of the k values were controlled by the electronic and/or steric effects of the parent carboxylic acids.  In the present study, we performed further SAR studies on the k values of 13 βGAs derived from aralkyl carboxylic acids, focusing on the substituents and stereochem. at the α-position of the parent carboxylic acids.  In single regression analyses, the pKa and 1H NMR chem. shifts (δCOOH) of the parent carboxylic acids correlated well with the log k values of seven βGAs derived from five arylacetic and two (R)-2-arylpropionic acids, whereas the 13C NMR chem. shifts [δC=O and δ(C=O)OH] correlated with the log k values of another seven βGAs derived from the five arylacetic and two (S)-2-arylpropionic acids.  Excellent correlations were also obtained between the log k values of four βGAs with a common 4-phenylbenzyl moiety and the partial at. charges (natural type) of the corresponding carboxylic hydrogen atoms (Hpac), the molar volume (MV), and the molar refractivity (MR).  In multiple regression analyses, appropriate combinations of electronic (δCOOH or pKa) and steric [Taft's steric const. (Es) or δ(C=O)OH] descriptors could predict the log k values of βGAs; electron-withdrawing 1-β-O-acyl groups increased the k values, while increasing steric hindrance around the linkages decreased them.  The std. partial regression coeffs. indicated that the steric effects of the 1-β-O-acyl groups of βGAs affected the k values as strongly as the electronic effects.  External validation of the derived SAR models is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMRVLPvP_JALVg90H21EOLACvtfcHk0liBRFJ0ywE7yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2qu77F&md5=5b25cd783fa5597dff4183ed56474dd3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Ftx9002963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9002963%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DA.%26aulast%3DYoshioka%26aufirst%3DT.%26atitle%3DStructure-activity%2520relationships%2520for%2520the%2520degradation%2520reaction%2520of%25201-beta-O-acyl%2520glucuronides.%2520Part%25203%253A%2520Electronic%2520and%2520steric%2520descriptors%2520predicting%2520the%2520reactivity%2520of%2520aralkyl%2520carboxylic%2520acid%25201-beta-O-acyl%2520glucuronides%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D1998%26epage%3D2008%26doi%3D10.1021%2Ftx9002963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iddon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindon, J. C.</span></span> <span> </span><span class="NLM_article-title">Integrated HPLC-MS and <sup>1</sup>H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.3109/00498250903348720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F00498250903348720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19919325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGrsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=9-23&author=C.+H.+Johnsonauthor=E.+Karlssonauthor=S.+Sardaauthor=L.+Iddonauthor=M.+Iqbalauthor=X.+Mengauthor=J.+R.+Hardingauthor=A.+V.+Stachulskiauthor=J.+K.+Nicholsonauthor=I.+D.+Wilsonauthor=J.+C.+Lindon&title=Integrated+HPLC-MS+and+1H-NMR+spectroscopic+studies+on+acyl+migration+reaction+kinetics+of+model+drug+ester+glucuronides&doi=10.3109%2F00498250903348720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Integrated HPLC-MS and 1H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides</span></div><div class="casAuthors">Johnson, C. H.; Karlsson, E.; Sarda, S.; Iddon, L.; Iqbal, M.; Meng, X.; Harding, J. R.; Stachulski, A. V.; Nicholson, J. K.; Wilson, I. D.; Lindon, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-23</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Acyl glucuronides (AGs) are common, chem. reactive metabolites of acidic xenobiotics.  Concerns about the potential of this class of conjugate to cause toxicity in man require efficient methods for the detn. of reactivity, and this is commonly done by measuring transacylation kinetics.  High-performance liq. chromatog.-mass spectrometry (HPLC-MS) and NMR spectroscopy were applied to the kinetic anal. of AG isomerization and hydrolysis for the 1-β-O-AGs of ibufenac, (R)- and (S)-ibuprofen, and an α,α-dimethylated ibuprofen analog.  Each AG was incubated in either aq. buffer at pH 7.4 or human plasma at 37°C.  Aliquots of these samples, taken throughout the reaction time course, were analyzed by HPLC-MS and 1H-NMR spectroscopy and the results compared.  For identification of the AGs incubated in pH 7.4 buffer and for anal. of kinetic rates, 1H-NMR spectroscopy generally gave the most complete set of data, but for human plasma the use of 1H-NMR spectroscopy was impractical and HPLC-MS was more suitable.  HPLC-MS was more sensitive than 1H-NMR spectroscopy, but the lack of suitable stable-isotope labeled internal stds., together with differences in response between glucuronides and aglycons, made quantification problematic.  Using HPLC-MS a specific 1-β-O-AG-related ion at m/z 193 (the glucuronate fragment) was noted enabling selective detn. of these isomers.  In buffer, transacylation reactions predominated, with relatively little hydrolysis to the free aglycon obsd.  In human plasma incubations the obsd. rates of reaction were much faster than for buffer, and hydrolysis to the free aglycon was the major route.  These results illustrate the strengths and weaknesses of each anal. approach for this class of analyte.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnMhHybe8wv7Vg90H21EOLACvtfcHk0lhDW7wRSz0lZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGrsLfK&md5=299e594ae1826566a644afd9e383f1c0</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.3109%2F00498250903348720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498250903348720%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BH.%26aulast%3DKarlsson%26aufirst%3DE.%26aulast%3DSarda%26aufirst%3DS.%26aulast%3DIddon%26aufirst%3DL.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DHarding%26aufirst%3DJ.%2BR.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DNicholson%26aufirst%3DJ.%2BK.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DLindon%26aufirst%3DJ.%2BC.%26atitle%3DIntegrated%2520HPLC-MS%2520and%25201H-NMR%2520spectroscopic%2520studies%2520on%2520acyl%2520migration%2520reaction%2520kinetics%2520of%2520model%2520drug%2520ester%2520glucuronides%26jtitle%3DXenobiotica%26date%3D2010%26volume%3D40%26spage%3D9%26epage%3D23%26doi%3D10.3109%2F00498250903348720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogiso, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, M.</span></span> <span> </span><span class="NLM_article-title">Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.11.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.ejps.2017.11.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29174986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOiu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2018&pages=132-138&author=H.+Shimadaauthor=Y.+Kobayashiauthor=S.+Tanahashiauthor=A.+Kawaseauthor=T.+Ogisoauthor=M.+Iwaki&title=Correlation+between+glucuronidation+and+covalent+adducts+formation+with+proteins+of+nonsteroidal+anti-inflammatory+drugs&doi=10.1016%2Fj.ejps.2017.11.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs</span></div><div class="casAuthors">Shimada, Hiroaki; Kobayashi, Yuri; Tanahashi, Sakiko; Kawase, Atsushi; Ogiso, Taro; Iwaki, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-138</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause idiosyncratic liver injury.  Mechanisms involved in NSAID-induced liver injury are complex.  Previous studies have suggested that acyl glucuronide of NSAIDs (NSAIDs-Glu) plays an important role in the development of liver injury via covalently binds to proteins and the resultant adduct induces immunol. toxicity.  As only some NSAIDs-Glu are com. available, the evaluation of covalent protein adduct formation using ready-made NSAIDs-Glu is difficult and inconvenient.  Moreover, glucuronidation potency varies with the NSAID, including stereoisomers.  Therefore, in this study, we simultaneously examd. the glucuronidation and covalent adduct formation using enantiomers of parent NSAIDs (ibuprofen, naproxen, pranoprofen, ketoprofen, and flurbiprofen) in rat liver microsomes.  Glucuronides and covalent adducts were quantified by HPLC.  The amt. of covalent adduct increased with NSAIDs-Glu formation in the rat liver microsomes in a time-dependent manner.  A significant pos. correlation was obsd. between the AUC of NSAIDs-Glu and that of covalent adduct, except ketoprofen.  Although ketoprofen exhibited the highest glucuronidation rate among the NSAIDs investigated, the amt. of covalent adduct was similar to that for pranoprofen, which had the lowest glucuronidation rate.  Thus, it may be difficult for ketoprofen glucuronide to covalently bind with proteins in the rat liver microsomes.  Our results suggested that the amt. of glucuronide formed is a key factor in predicting covalent bond formation with protein in NSAIDs, in addn. to degradability and bindability with proteins of NSAIDs-Glu.  Further studies are required to confirm the relationship between the tendency of glucuronidation and the formation of covalent adducts of NSAIDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYDM98-jibbVg90H21EOLACvtfcHk0lhDW7wRSz0lZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOiu73I&md5=2712c60153ccab592202baecf361e266</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.11.018%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTanahashi%26aufirst%3DS.%26aulast%3DKawase%26aufirst%3DA.%26aulast%3DOgiso%26aufirst%3DT.%26aulast%3DIwaki%26aufirst%3DM.%26atitle%3DCorrelation%2520between%2520glucuronidation%2520and%2520covalent%2520adducts%2520formation%2520with%2520proteins%2520of%2520nonsteroidal%2520anti-inflammatory%2520drugs%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D112%26spage%3D132%26epage%3D138%26doi%3D10.1016%2Fj.ejps.2017.11.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sawamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okudaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.034173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.110.034173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20606003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1857-1864&author=R.+Sawamuraauthor=N.+Okudairaauthor=K.+Watanabeauthor=T.+Muraiauthor=Y.+Kobayashiauthor=M.+Tachibanaauthor=T.+Ohnukiauthor=K.+Masudaauthor=H.+Honmaauthor=A.+Kuriharaauthor=O.+Okazaki&title=Predictability+of+idiosyncratic+drug+toxicity+risk+for+carboxylic+acid-containing+drugs+based+on+the+chemical+stability+of+acyl+glucuronide&doi=10.1124%2Fdmd.110.034173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide</span></div><div class="casAuthors">Sawamura, Ryoko; Okudaira, Noriko; Watanabe, Kengo; Murai, Takahiro; Kobayashi, Yoshimasa; Tachibana, Masaya; Ohnuki, Takashi; Masuda, Kayoko; Honma, Hidehito; Kurihara, Atsushi; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Acyl glucuronides (AGs) formed from carboxylic acid-contg. drugs have been considered to be a cause of idiosyncratic drug toxicity (IDT).  Chem. stability of AGs is supposed to relate to their reactivity.  In this study, the half-lives of 21 AGs of carboxylic drugs in potassium phosphate buffer (KPB), human serum albumin (HSA) soln., and human fresh plasma were analyzed in relation to the IDT risk derived from these drugs.  The carboxylic drugs were classified into three safety categories of "safe," "warning," and "withdrawn" in terms of their IDT risk.  As for the results, the half-lives of AGs in KPB correlated with the IDT risk better than those in HSA soln. or in human fresh plasma with regard to the sepn. of the safe drugs from the warning drugs or the withdrawn drugs.  In KPB, whereas the half-lives in the safe category were 7.2 h or longer, those in the withdrawn category were 1.7 h or shorter.  The classification value of the half-life in KPB, which sepd. the safe drugs from the withdrawn drugs was calcd. to be 3.6 h by regression anal.  In conclusion, this is the first report that clearly shows the relationship between the IDT risk and chem. stability of AGs in several in vitro systems.  The KPB system was considered to be the best for evaluating the stability of AGs, and the classification value of the half-life in KPB serves as a useful key predictor for the IDT risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxa_NqrJXKWLVg90H21EOLACvtfcHk0limEEtHqi5mKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1eisLbP&md5=f11cee720da5c3b00314e5a5771d0250</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.034173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.034173%26sid%3Dliteratum%253Aachs%26aulast%3DSawamura%26aufirst%3DR.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTachibana%26aufirst%3DM.%26aulast%3DOhnuki%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DK.%26aulast%3DHonma%26aufirst%3DH.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DPredictability%2520of%2520idiosyncratic%2520drug%2520toxicity%2520risk%2520for%2520carboxylic%2520acid-containing%2520drugs%2520based%2520on%2520the%2520chemical%2520stability%2520of%2520acyl%2520glucuronide%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1857%26epage%3D1864%26doi%3D10.1124%2Fdmd.110.034173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelazo, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, S. N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earnshaw, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span> <span> </span><span class="NLM_article-title">Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.215079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fjpet.114.215079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wqsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=387-402&author=T.+G.+Hammondauthor=X.+Mengauthor=R.+E.+Jenkinsauthor=J.+L.+Maggsauthor=A.+S.+Castelazoauthor=S.+L.+Reganauthor=S.+N.+L.+Bennettauthor=C.+J.+Earnshawauthor=G.+P.+Aithalauthor=I.+Pandeauthor=J.+G.+Kennaauthor=A.+V.+Stachulskiauthor=B.+K.+Parkauthor=D.+P.+Williams&title=Mass+spectrometric+characterization+of+circulating+covalent+protein+adducts+derived+from+a+drug+acyl+glucuronide+metabolite%3A+multiple+albumin+adductions+in+diclofenac+patients&doi=10.1124%2Fjpet.114.215079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients</span></div><div class="casAuthors">Hammond, Thomas G.; Meng, Xiaoli; Jenkins, Rosalind E.; Maggs, James L.; Castelazo, Anahi Santoyo; Regan, Sophie L.; Bennett, Stuart N. L.; Earnshaw, Caroline J.; Aithal, Guruprasad P.; Pande, Ira; Kenna, J. Gerry; Stachulski, Andrew V.; Park, B. Kevin; Williams, Dominic P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-402, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Covalent protein modifications by electrophilic acyl glucuronide (AG) metabolites are hypothetical causes of hypersensitivity reactions assocd. with certain carboxylate drugs.  The complex rearrangements and reactivities of drug AG have been defined in great detail, and protein adducts of carboxylate drugs, such as diclofenac, have been found in liver and plasma of exptl. animals and humans.  However, in the absence of definitive mol. characterization, and specifically, identification of signature glycation conjugates retaining the glucuronyl and carboxyl residues, it cannot be assumed any of these adducts is derived uniquely or even fractionally from AG metabolites.  We have therefore undertaken targeted mass spectrometric analyses of human serum albumin (HSA) isolated from diclofenac patients to characterize drug-derived structures and, thereby, for the first time, have deconstructed conclusively the pathways of adduct formation from a drug AG and its isomeric rearrangement products in vivo.  These analyses were informed by a thorough understanding of the reactions of HSA with diclofenac AG in vitro.  HSA from six patients without drug-related hypersensitivities had either a single drug-derived adduct or one of five combinations of 2-8 adducts from among seven diclofenac N-acylations and three AG glycations on seven of the protein's 59 lysines.  Only acylations were found in every patient.  We present evidence that HSA modifications by diclofenac in vivo are complicated and variable, that at least a fraction of these modifications are derived from the drug's AG metabolite, and that albumin adduction is not inevitably a causation of hypersensitivity to carboxylate drugs or a coincidental assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJaMIu3mSolLVg90H21EOLACvtfcHk0limEEtHqi5mKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wqsb%252FK&md5=4ea9902f538c70aa671bdb1df8149375</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.215079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.215079%26sid%3Dliteratum%253Aachs%26aulast%3DHammond%26aufirst%3DT.%2BG.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DJenkins%26aufirst%3DR.%2BE.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DCastelazo%26aufirst%3DA.%2BS.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DBennett%26aufirst%3DS.%2BN.%2BL.%26aulast%3DEarnshaw%26aufirst%3DC.%2BJ.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DPande%26aufirst%3DI.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26atitle%3DMass%2520spectrometric%2520characterization%2520of%2520circulating%2520covalent%2520protein%2520adducts%2520derived%2520from%2520a%2520drug%2520acyl%2520glucuronide%2520metabolite%253A%2520multiple%2520albumin%2520adductions%2520in%2520diclofenac%2520patients%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D387%26epage%3D402%26doi%3D10.1124%2Fjpet.114.215079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Safety assessment of acyl glucuronides – A simplified paradigm</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">908</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.080515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.118.080515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29559442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=908-912&author=D.+A.+Smithauthor=T.+Hammondauthor=T.+A.+Baillie&title=Safety+assessment+of+acyl+glucuronides+%E2%80%93+A+simplified+paradigm&doi=10.1124%2Fdmd.118.080515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Safety assessment of acyl glucuronides-a simplified paradigm</span></div><div class="casAuthors">Smith, Dennis A.; Hammond, Timothy; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">908-912</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">While simple O-(ether-linked) and N-glucuronide drug conjugates generally are unreactive and considered benign from a safety perspective, the acyl glucuronides that derive from metab. of carboxylic acid-contg. xenobiotics can exhibit a degree of chem. reactivity that is dependent upon their mol. structure.  As a result, concerns have arisen over the safety of acyl glucuronides as a class, several members of which have been implicated in the toxicity of their resp. parent drugs.  However, direct evidence in support of these claims remains sparse, and due to frequently encountered species differences in the systemic exposure to acyl glucuronides (both of the parent drug and oxidized derivs. thereof), coupled with their instability in aq. media and potential to undergo chem. rearrangement (acyl migration), qualification of these conjugates by traditional safety assessment methods can be very challenging.  In this Commentary, we discuss alternative (non-acyl glucuronide)mechanisms by which carboxylic acids may cause serious adverse reactions, and propose a novel, practical approach to compare systemic exposure to acyl glucuronide metabolites in humans to that in animal species used in preclin. safety assessment based on relative ests. of the total body burden of these circulating conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEevJPQ6waKbVg90H21EOLACvtfcHk0limEEtHqi5mKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWltrnK&md5=bb4d99cdc5bf87751b6d796366ed7e46</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.080515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.080515%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DHammond%26aufirst%3DT.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DSafety%2520assessment%2520of%2520acyl%2520glucuronides%2520%25E2%2580%2593%2520A%2520simplified%2520paradigm%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D908%26epage%3D912%26doi%3D10.1124%2Fdmd.118.080515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, T.</span></span> <span> </span><span class="NLM_article-title">Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.tiv.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=26528891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsl2murvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=241-249&author=A.+Iwamuraauthor=M.+Itoauthor=H.+Mitsuiauthor=J.+Hasegawaauthor=K.+Kosakaauthor=I.+Kinoauthor=M.+Tsudaauthor=M.+Nakajimaauthor=T.+Yokoiauthor=T.+Kume&title=Toxicological+evaluation+of+acyl+glucuronides+utilizing+half-lives%2C+peptide+adducts%2C+and+immunostimulation+assays&doi=10.1016%2Fj.tiv.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays</span></div><div class="casAuthors">Iwamura, Atsushi; Ito, Masahito; Mitsui, Hideaki; Hasegawa, Jun; Kosaka, Keigo; Kino, Ichiro; Tsuda, Minoru; Nakajima, Miki; Yokoi, Tsuyoshi; Kume, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1_Part_B</span>),
    <span class="NLM_cas:pages">241-249</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chem. reactivity of acyl glucuronides (AGs) is believed to be involved in the toxicity of carboxylic acid-contg. drugs.  Both direct and immune-mediated toxicity have been suggested as possible mechanisms of toxicity; however, it remains unclear.  In the present study, we performed assays of half-lives, peptide adducts, and immunostimulation to evaluate the potential risk of AGs of 21 drugs and analyzed the relationship to the toxic category.  AGs of all withdrawn drugs tested in this study showed short half-lives and peptide adducts formation, but so did those of several safe drugs.  In contrast, only AGs of withdrawn and warning drugs induced interleukin-8 (IL-8) in human peripheral blood mononuclear cells (hPBMCs).  Using a DNA microarray assay, we found that zomepirac AG induced the mRNAs of 5 genes, including IL-8 in hPBMCs.  In addn., withdrawn and warning drugs were distinguished from safe drugs by an integrated score of relative mRNA expression levels of 5 genes.  The immunostimulation assay showed higher sensitivity, specificity, and accuracy compared with other methods.  In preclin. drug development, the evaluation of the reactivity of AGs using half-lives and peptide adducts assays followed by the evaluation of immunostimulation by highly reactive AGs using hPBMCs can contribute to improved drug safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDeT1JFabzj7Vg90H21EOLACvtfcHk0lg5xuVeVcbUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsl2murvN&md5=7b5a574cc46c21a6d9151999b101c47c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DMitsui%26aufirst%3DH.%26aulast%3DHasegawa%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DK.%26aulast%3DKino%26aufirst%3DI.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DKume%26aufirst%3DT.%26atitle%3DToxicological%2520evaluation%2520of%2520acyl%2520glucuronides%2520utilizing%2520half-lives%252C%2520peptide%2520adducts%252C%2520and%2520immunostimulation%2520assays%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2015%26volume%3D30%26spage%3D241%26epage%3D249%26doi%3D10.1016%2Fj.tiv.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrell, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCaughan, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, R. G.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(00)00981-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0024-3205%2800%2900981-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=11205870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2001&pages=785-797&author=M.+Wangauthor=M.+D.+Gorrellauthor=G.+W.+McCaughanauthor=R.+G.+Dickinson&title=Dipeptidyl+peptidase+IV+is+a+target+for+covalent+adduct+formation+with+the+acyl+glucuronide+metabolite+of+the+anti-inflammatory+drug+zomepirac&doi=10.1016%2FS0024-3205%2800%2900981-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac</span></div><div class="casAuthors">Wang, Min; Gorrell, Mark D.; McCaughan, Geoffrey W.; Dickinson, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">785-797</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The nonsteroidal anti-inflammatory drug zomepirac (ZP) is metabolised to a chem. reactive acyl glucuronide conjugate (ZAG) which can form covalent adducts with proteins.  In vivo, such adducts could initiate immune or toxic responses.  In rats given ZP, the major band detected in liver homogenates by immunoblotting with a polyclonal ZP antiserum was at 110 kDa.  This adduct was identified as ZP-modified dipeptidyl peptidase IV (DPP IV) by immunoblotting using the polyclonal ZP antiserum and monoclonal DPP IV antibodies OX-61 and 236.3.  In vitro, ZAG, but not ZP itself, covalently modified recombinant human and rat DPP IV.  Both monoclonal antibodies recognized DPP IV in livers from ZP- and vehicle-dosed rats.  Confirmation that the 110 kDa bands which were immunoreactive with the ZP and DPP IV antibodies represented the same mol. was obtained from a rat liver ext. reciprocally immunodepleted of antigens reactive with these two antibodies.  Furthermore, immunopptns. with OX-61 antibody followed by immunolotting with ZP antiserum, and the reciprocal expt., showed that both these antibodies recognized the same 110 kDa mol. in exts. of ZP-dosed rat liver.  The results verify that DPP IV is one of the protein targets for covalent modification during hepatic transport and biliary excretion of ZAG in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom8sQEIb9WerVg90H21EOLACvtfcHk0lg5xuVeVcbUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVWhsQ%253D%253D&md5=fcd370f0d6b59f60080fbf2f1844ce51</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2800%2900981-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252800%252900981-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DGorrell%26aufirst%3DM.%2BD.%26aulast%3DMcCaughan%26aufirst%3DG.%2BW.%26aulast%3DDickinson%26aufirst%3DR.%2BG.%26atitle%3DDipeptidyl%2520peptidase%2520IV%2520is%2520a%2520target%2520for%2520covalent%2520adduct%2520formation%2520with%2520the%2520acyl%2520glucuronide%2520metabolite%2520of%2520the%2520anti-inflammatory%2520drug%2520zomepirac%26jtitle%3DLife%2520Sci.%26date%3D2001%26volume%3D68%26spage%3D785%26epage%3D797%26doi%3D10.1016%2FS0024-3205%2800%2900981-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worrall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jersey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, R. G.</span></span> <span> </span><span class="NLM_article-title">Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(98)00071-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2898%2900071-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9826947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXls1Oks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1998&pages=153-166&author=M.+J.+Baileyauthor=S.+Worrallauthor=J.+de+Jerseyauthor=R.+G.+Dickinson&title=Zomepirac+acyl+glucuronide+covalently+modifies+tubulin+in+vitro+and+in+vivo+and+inhibits+its+assembly+in+an+in+vitro+system&doi=10.1016%2FS0009-2797%2898%2900071-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system</span></div><div class="casAuthors">Bailey, Mark J.; Worrall, Simon; de Jersey, John; Dickinson, Ronald G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Drugs possessing a carboxylate functional group usually form acyl glucuronides as major metabolites.  These electrophilic metabolites can undergo several spontaneous reactions, including covalent adduct formation with proteins.  The present study examd. whether covalent adducts were formed with microtubular protein (MTP, 85% α/β-tubulin) and whether this influenced its ability to assemble into microtubules.  Bovine brain microtubular protein (MTP) was purified by assembly-disassembly cycles and incubated with the non-steroidal anti-inflammatory drug (NSAID) zomepirac (ZP), its acyl glucuronide (ZAG) and rearrangement isomers (iso-ZAG) at various concns. for 2 h at room temp. and pH 7.5.  Assembly was monitored by change in turbidity (increase in absorbance at 340 nm).  Both ZAG and iso-ZAG caused dose-dependent inhibition of assembly (50% inhibition at about 1 mM), while ZP caused modest inhibition (<50% inhibition at 4 mM).  In a slightly different system, incubation of performed microtubules with 4 mM ZAG caused about 35% inhibition of reassembly ability, while modification of MTP under similar conditions resulted in about 85% redn. of assembly ability.  Immunoblotting with a ZP antiserum showed that ZAG and iso-ZAG covalently modified MTP in a dose-dependent manner, while ZP itself caused no modification.  Tubulin and many minor proteins comprising MTP were modified.  ZP-modified tubulin was shown to be present in the cytosol of livers from rats dosed twice daily for 3 days with ZP at 50 mg/kg, using a sandwich ELISA with ZP and tubulin antisera.  Whether any perturbation of microtubule assembly occurs in vivo as a result of this in vivo modification is currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVyk4zug18I7Vg90H21EOLACvtfcHk0lg5xuVeVcbUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXls1Oks7Y%253D&md5=ed332b8053c2c29a8d0f32c6a60a0523</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2898%2900071-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252898%252900071-4%26sid%3Dliteratum%253Aachs%26aulast%3DBailey%26aufirst%3DM.%2BJ.%26aulast%3DWorrall%26aufirst%3DS.%26aulast%3Dde%2BJersey%26aufirst%3DJ.%26aulast%3DDickinson%26aufirst%3DR.%2BG.%26atitle%3DZomepirac%2520acyl%2520glucuronide%2520covalently%2520modifies%2520tubulin%2520in%2520vitro%2520and%2520in%2520vivo%2520and%2520inhibits%2520its%2520assembly%2520in%2520an%2520in%2520vitro%2520system%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1998%26volume%3D115%26spage%3D153%26epage%3D166%26doi%3D10.1016%2FS0009-2797%2898%2900071-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishinosono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuneyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span> <span> </span><span class="NLM_article-title">Zomepirac acyl glucuronide is responsible for zomepirac-induced acute kidney injury in mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">888</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.069575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.116.069575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=27112166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWlt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=888-896&author=A.+Iwamuraauthor=K.+Watanabeauthor=S.+Akaiauthor=T.+Nishinosonoauthor=K.+Tsuneyamaauthor=S.+Odaauthor=T.+Kumeauthor=T.+Yokoi&title=Zomepirac+acyl+glucuronide+is+responsible+for+zomepirac-induced+acute+kidney+injury+in+mice&doi=10.1124%2Fdmd.116.069575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Zomepirac acyl glucuronide is responsible for zomepirac-induced acute kidney injury in mice</span></div><div class="casAuthors">Iwamura, Atsushi; Watanabe, Katsuhito; Akai, Sho; Nishinosono, Tsubasa; Tsuneyama, Koichi; Oda, Shingo; Kume, Toshiyuki; Yokoi, Tsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">888-896</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Glucuronidation, an important phase II metabolic route, is generally considered to be a detoxification pathway.  However, acyl glucuronides (AGs) have been implicated in the toxicity of carboxylic acid drugs due to their electrophilic reactivity.  Zomepirac (ZP) was withdrawn from the market because of adverse effects such as renal toxicity.  Although ZP is mainly metabolized to acyl glucuronide (ZP-AG) by UDP-glucuronosyltransferase, the role of ZP-AG in renal toxicity is unknown.  In this study, we established a ZP-induced kidney injury mouse model by pretreatment with tri-o-tolyl phosphate (TOTP), a nonselective esterase inhibitor, and L-buthionine-(S,R)-sulfoximine (BSO), a glutathione synthesis inhibitor.  The role of ZP-AG in renal toxicity was investigated using this model.  The model showed significant increases in blood urea nitrogen (BUN) and creatinine (CRE), but not alanine aminotransferase.  The ZP-AG concns. were elevated by cotreatment with TOTP in the plasma and liver and esp. in the kidney.  The ZP-AG concns. in the kidney correlated with values for BUN and CRE.  Upon histopathol. examn., vacuoles and infiltration of mononuclear cells were obsd. in the model mouse.  In addn. to immune-related responses, oxidative stress markers, such as the glutathione/ disulfide glutathione ratio and malondialdehyde levels, were different in the mouse model.  The suppression of ZP-induced kidney injury by tempol, an antioxidant agent, suggested the involvement of oxidative stress in ZP-induced kidney injury.  This is the first study to demonstrate that AG accumulation in the kidney by TOTP and BSO treatment could explain renal toxicity and to show the in vivo toxicol. potential of AGs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLp4EJB433w7Vg90H21EOLACvtfcHk0lh5AUAE7v_ZMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWlt7rK&md5=dcfdac0221feea276b38d3743ded05d8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.069575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.069575%26sid%3Dliteratum%253Aachs%26aulast%3DIwamura%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DAkai%26aufirst%3DS.%26aulast%3DNishinosono%26aufirst%3DT.%26aulast%3DTsuneyama%26aufirst%3DK.%26aulast%3DOda%26aufirst%3DS.%26aulast%3DKume%26aufirst%3DT.%26aulast%3DYokoi%26aufirst%3DT.%26atitle%3DZomepirac%2520acyl%2520glucuronide%2520is%2520responsible%2520for%2520zomepirac-induced%2520acute%2520kidney%2520injury%2520in%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D888%26epage%3D896%26doi%3D10.1124%2Fdmd.116.069575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flückiger, R.</span></span> <span> </span><span class="NLM_article-title">Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">13542</span>– <span class="NLM_lpage">13545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3759977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL28XlvVKhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1986&pages=13542-13545&author=N.+Ibergauthor=R.+Fl%C3%BCckiger&title=Nonenzymatic+glycosylation+of+albumin+in+vivo.+Identification+of+multiple+glycosylated+sites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Nonenzymic glycosylation of albumin in vivo.  Identification of multiple glycosylated sites</span></div><div class="casAuthors">Iberg, Niggi; Flueckiger, Rudolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13542-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Nonenzymic glycosylation (glycation) of albumin in vivo occurred at multiple sites.  Glucose became attached to lysine-(Lys-) 199, Lys-281, Lys-439, and Lys-525 as well as to some other Lys residues.  The principal glycated site was Lys-525; ∼33% of the overall glycation occurred at this site.  This site specificity was remarkable and was postulated to be a consequence of local catalysis of the glycation reaction.  Apparently, pos. charged amino groups in the protein catalyzed an Amadori rearrangement at specific sites.  The principal glycated site, Lys-525, was in a Lys-Lys sequence; other glycated sites were in Lys-Lys, Lys-His, and Lys-His-Lys sequences or were near disulfide bridges which were likely to place amino groups of more remote parts of the protein closer to these sites.  The occurrence of glycation at most of the identified sites in albumin from diabetic patients was explained by the concept of local acid-base catalysis of the Amadori rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjV56t468B7Vg90H21EOLACvtfcHk0lh5AUAE7v_ZMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XlvVKhsL0%253D&md5=d55f42b2425ec44234bdaed3104f3a48</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIberg%26aufirst%3DN.%26aulast%3DFl%25C3%25BCckiger%26aufirst%3DR.%26atitle%3DNonenzymatic%2520glycosylation%2520of%2520albumin%2520in%2520vivo.%2520Identification%2520of%2520multiple%2520glycosylated%2520sites%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1986%26volume%3D261%26spage%3D13542%26epage%3D13545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garlick, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazer, J. S.</span></span> <span> </span><span class="NLM_article-title">The principal site of nonenzymatic glycosylation of human serum albumin in vivo</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>258</i></span>,  <span class="NLM_fpage">6142</span>– <span class="NLM_lpage">6146</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6853480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL3sXktlCksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1983&pages=6142-6146&author=R.+L.+Garlickauthor=J.+S.+Mazer&title=The+principal+site+of+nonenzymatic+glycosylation+of+human+serum+albumin+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The principal site of nonenzymic glycosylation of human serum albumin in vivo</span></div><div class="casAuthors">Garlick, Robert L.; Mazer, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6142-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The major site of nonenzymic glycosylation of human serum albumin was detd. in vivo.  This was accomplished by reacting freshly purified human serum albumin with Na[3H]BH4 followed by aminoethylation and tryptic digestion.  The tryptic peptides were sepd. into a sol. fraction which contained 88% of the total 3H radioactivity and an insol. fraction.  To isolate the 3H-labeled glycosylated peptides, the sol. tryptic peptide fraction was first subjected to boronic acid affinity chromatog.  Cation-exchange chromatog. then sepd. the sol. glycosylated peptides into a major peak which contained 48% of the total recovered 3H radioactivity and a no. of minor peptide fractions.  The amino acid compn. of the major peptide was: threonine, 2 glutamate, alanine, 2 valine, 2 leucine, lysine, and lysino-1-deoxysorbitol.  In accord with the primary structure of human serum albumin, this amino acid compn. corresponds precisely to residues 525-534.  Glucitol-lysine, the N-terminal residue of this peptide, is totally resistant to cleavage by trypsin.  Thus, lysine-525 is the predominant site of nonenzymic glycosylation of human serum albumin in vivo.  Chromatog. on GlycoGel B boronic acid affinity gel indicates that 10-12% of normal serum albumin is glycosylated.  The rate of nonenzymic glycosylation of this protein in vivo is ∼9-fdd that of human Hb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLDV_9QCWL7Vg90H21EOLACvtfcHk0lh5AUAE7v_ZMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXktlCksrY%253D&md5=2c29884bd986679cbb8bd50293f23b4c</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarlick%26aufirst%3DR.%2BL.%26aulast%3DMazer%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520principal%2520site%2520of%2520nonenzymatic%2520glycosylation%2520of%2520human%2520serum%2520albumin%2520in%2520vivo%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1983%26volume%3D258%26spage%3D6142%26epage%3D6146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baynes, J. W.</span></span> <span> </span><span class="NLM_article-title">Non-enzymatic glycosylation and the chronic complications of diabetes: an overview</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1007/BF00281113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2FBF00281113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6370764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaL2c7otleluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1984&pages=93-98&author=L.+Kennedyauthor=J.+W.+Baynes&title=Non-enzymatic+glycosylation+and+the+chronic+complications+of+diabetes%3A+an+overview&doi=10.1007%2FBF00281113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Non-enzymatic glycosylation and the chronic complications of diabetes: an overview</span></div><div class="casAuthors">Kennedy L; Baynes J W</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-8</span>
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoYEoXH1FwkPtos8R3JUhXfW6udTcc2ebrPmQtTUKkTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7otleluw%253D%253D&md5=32a2347c51ce27998c02b53aadd634ea</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2FBF00281113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00281113%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DL.%26aulast%3DBaynes%26aufirst%3DJ.%2BW.%26atitle%3DNon-enzymatic%2520glycosylation%2520and%2520the%2520chronic%2520complications%2520of%2520diabetes%253A%2520an%2520overview%26jtitle%3DDiabetologia%26date%3D1984%26volume%3D26%26spage%3D93%26epage%3D98%26doi%3D10.1007%2FBF00281113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boelsterli, U. A.</span></span> <span> </span><span class="NLM_article-title">Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/1389200023337315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2174%2F1389200023337315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12093359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlCqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=439-450&author=U.+A.+Boelsterli&title=Xenobiotic+acyl+glucuronides+and+acyl+CoA+thioesters+as+protein-reactive+metabolites+with+the+potential+to+cause+idiosyncratic+drug+reactions&doi=10.2174%2F1389200023337315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions</span></div><div class="casAuthors">Boelsterli, Urs A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-450</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Some carboxylic acid-contg. drugs have been implicated in rare but serious adverse reactions.  These compds. can be bioactivated via two distinct pathways: by UDP-glucuronosyltransferase-catalyzed conjugation with glucuronic acid, resulting in the formation of acyl glucuronides, or by acyl-CoA synthetase-catalyzed formation of acyl-CoA thioesters.  This review compares the two types of potentially reactive metabolites with respect to their stability, protein-reactivity, target selectivity, and disposition in the liver, and summarizes the evidence which links acyl glucuronide and acyl-CoA thioester formation with downstream toxicol. effects.  While with increasing drug concn. the acyl glucuronide pathway may prevail, CoA intermediates may be more reactive.  Both metabolites are electrophilic species which can acylate target proteins if they escape inactivation by S-glutathione-thioester formation.  A crucial factor is the up-concn. of acyl glucuronides in hepatocytes and the biliary tree, due to vectorial transport by conjugate export pumps, where they may selectively acylate canalicular membrane proteins.  Furthermore, positional isomers, which are avidly formed by acyl migration, can glycate proteins in the liver and at more distal sites.  In contrast, acyl-CoA esters may be more rapidly hydrolyzed or further metabolized in hepatocytes, and their hepatobiliary transport has not been well explored.  While there is accumulating evidence that acyl glucuronides can alter cellular function by various mechanisms, including haptenation of peptides, crit. protein acylation or glycation, or direct stimulation of neutrophils and macrophages, the role of acyl-CoA intermediates is less clear.  More work is needed to provide a causal link between protein-reactive acyl glucuronides and acyl-CoA thioesters and the rare and unpredictable idiosyncratic drug reactions in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiV3rWJsqFyLVg90H21EOLACvtfcHk0lgZwi6aYNV2Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlCqtrc%253D&md5=0cf501c56ea4a4ce5ba884ebb14fdba0</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2174%2F1389200023337315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200023337315%26sid%3Dliteratum%253Aachs%26aulast%3DBoelsterli%26aufirst%3DU.%2BA.%26atitle%3DXenobiotic%2520acyl%2520glucuronides%2520and%2520acyl%2520CoA%2520thioesters%2520as%2520protein-reactive%2520metabolites%2520with%2520the%2520potential%2520to%2520cause%2520idiosyncratic%2520drug%2520reactions%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2002%26volume%3D3%26spage%3D439%26epage%3D450%26doi%3D10.2174%2F1389200023337315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Didolkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.004341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.105.004341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16251255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=145-151&author=Q.+Chenauthor=G.+A.+Dossauthor=E.+C.+Tungauthor=W.+Liuauthor=Y.+S.+Tangauthor=M.+P.+Braunauthor=V.+Didolkarauthor=J.+R.+Straussauthor=R.+W.+Wangauthor=R.+A.+Stearnsauthor=D.+C.+Evansauthor=T.+A.+Baillieauthor=W.+Tang&title=Evidence+for+the+bioactivation+of+zomepirac+and+tolmetin+by+an+oxidative+pathway%3A+identification+of+glutathione+adducts+in+vitro+in+human+liver+microsomes+and+in+vivo+in+rats&doi=10.1124%2Fdmd.105.004341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: Identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats</span></div><div class="casAuthors">Chen, Qing; Doss, George A.; Tung, Elaine C.; Liu, Wensheng; Tang, Yui S.; Braun, Matthew P.; Didolkar, Varsha; Strauss, John R.; Wang, Regina W.; Stearns, Ralph A.; Evans, David C.; Baillie, Thomas A.; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although zomepirac (ZP) and tolmetin (TM) induce anaphylactic reactions and form reactive acyl glucuronides, a direct link between the two events remains obscure.  We report herein that, in addn. to acyl glucuronidation, both drugs are subject to oxidative bioactivation.  Following incubations of ZP with human liver microsomes fortified with NADPH and glutathione (GSH), a metabolite with an MH+ ion at m/z 597 was detected by LC/MS/MS.  On the basis of collision-induced dissocn. and NMR evidence, the structure of this metabolite was detd. to be 5-[4'-chlorobenzoyl]-1,4-dimethyl-3-glutathionylpyrrole-2-acetic acid (ZP-SG), suggesting that the pyrrole moiety of ZP had undergone oxidn. to an epoxide intermediate, followed by addn. of GSH and loss of the elements of H2O to yield the obsd. conjugate.  The oxidative bioactivation of ZP most likely is catalyzed by cytochrome P 450 3A4, since the formation of ZP-SG was reduced to ∼10% of control values following pretreatment of human liver microsomes with ketoconazole or with an inhibitory anti-P 450 3A4 IgG.  A similar GSH adduct, namely 5-[4'-methylbenzoyl]-1-methyl-3-glutathionylpyrrole-2-acetic acid (TM-SG), was identified when TM was incubated with human liver microsomal prepns.  The relevance of these in vitro findings to the in vivo situation was established through the detection of the same thiol adducts in rats treated with ZP and TM, resp.  Taken together, these data suggest that, in addn. to the formation of acyl glucuronides, oxidative metab. of ZP and TM affords reactive species that may haptenize proteins and thereby contribute to the drug-mediated anaphylactic reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3QasE3CrJIrVg90H21EOLACvtfcHk0lgZwi6aYNV2Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslyisA%253D%253D&md5=b73ce8c9810c8a60131e488effd82b2c</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004341%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DTung%26aufirst%3DE.%2BC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DY.%2BS.%26aulast%3DBraun%26aufirst%3DM.%2BP.%26aulast%3DDidolkar%26aufirst%3DV.%26aulast%3DStrauss%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DEvidence%2520for%2520the%2520bioactivation%2520of%2520zomepirac%2520and%2520tolmetin%2520by%2520an%2520oxidative%2520pathway%253A%2520identification%2520of%2520glutathione%2520adducts%2520in%2520vitro%2520in%2520human%2520liver%2520microsomes%2520and%2520in%2520vivo%2520in%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D145%26epage%3D151%26doi%3D10.1124%2Fdmd.105.004341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osbild, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bour, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maunit, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaume, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asensio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagrel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapicque, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaglia, E.</span></span> <span> </span><span class="NLM_article-title">Interaction of the electrophilic ketoprofenyl-glucuronide and ketoprofenyl-coenzyme A conjugates with cytosolic glutathione S-transferases</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.016808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.107.016808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=17962374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1yktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=260-267&author=S.+Osbildauthor=J.+Bourauthor=B.+Maunitauthor=C.+Guillaumeauthor=C.+Asensioauthor=J.+F.+Mullerauthor=P.+Netterauthor=G.+Kirschauthor=D.+Bagrelauthor=F.+Lapicqueauthor=E.+Battaglia&title=Interaction+of+the+electrophilic+ketoprofenyl-glucuronide+and+ketoprofenyl-coenzyme+A+conjugates+with+cytosolic+glutathione+S-transferases&doi=10.1124%2Fdmd.107.016808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the electrophilic ketoprofenyl-glucuronide and ketoprofenyl-coenzyme A conjugates with cytosolic glutathione S-transferases</span></div><div class="casAuthors">Osbild, Sandra; Bour, Jerome; Maunit, Benoit; Guillaume, Cecile; Asensio, Carine; Muller, Jean-Francois; Netter, Patrick; Kirsch, Gilbert; Bagrel, Denyse; Lapicque, Francoise; Battaglia, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-267</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Carboxylic acid-contg. drugs are metabolized mainly through the formation of glucuronide and CoA esters.  These conjugates have been suspected to be responsible for the toxicity of several nonsteroidal anti-inflammatory drugs because of the reactivity of the electrophilic ester bond.  In the present study we investigated the reactivity of ketoprofenyl-acylglucuronide (KPF-OG) and ketoprofenyl-acyl-CoA (KPF-SCoA) toward cytosolic rat liver glutathione S-transferases (GST).  We obsd. that KPF-SCoA, but not KPF-OG inhibited the conjugation of 1-chloro-2,4-dinitrobenzene and 4-nitroquinoline N-oxide catalyzed by both purified cytosolic rat liver GST and GST from FAO and H5-6 rat hepatoma cell lines.  Photoaffinity labeling with KPF-SCoA suggested that the binding of this metabolite may overlap the binding site of 4-methylumbelliferone sulfate.  Furthermore, high-performance liq. chromatog. and mass spectrometry anal. showed that both hydrolysis and transacylation reactions were obsd. in the presence of GST and glutathione.  The formation of ketoprofenyl-S-acyl-glutathione could be kinetically characterized (apparent Km = 196.0 ± 70.6 μM).  It is concluded that KPF-SCoA is both a GST inhibitor and a substrate of a GST-dependent transacylation reaction.  The reactivity and inhibitory potency of thioester CoA derivs. toward GST may have potential implications on the reported in vivo toxicity of some carboxylic acid-contg. drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp38LSCw5PvibVg90H21EOLACvtfcHk0lgsfgentNLFZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1yktbY%253D&md5=078ea39bd856f4f95e7d253f8cf56f87</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.016808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.016808%26sid%3Dliteratum%253Aachs%26aulast%3DOsbild%26aufirst%3DS.%26aulast%3DBour%26aufirst%3DJ.%26aulast%3DMaunit%26aufirst%3DB.%26aulast%3DGuillaume%26aufirst%3DC.%26aulast%3DAsensio%26aufirst%3DC.%26aulast%3DMuller%26aufirst%3DJ.%2BF.%26aulast%3DNetter%26aufirst%3DP.%26aulast%3DKirsch%26aufirst%3DG.%26aulast%3DBagrel%26aufirst%3DD.%26aulast%3DLapicque%26aufirst%3DF.%26aulast%3DBattaglia%26aufirst%3DE.%26atitle%3DInteraction%2520of%2520the%2520electrophilic%2520ketoprofenyl-glucuronide%2520and%2520ketoprofenyl-coenzyme%2520A%2520conjugates%2520with%2520cytosolic%2520glutathione%2520S-transferases%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D260%26epage%3D267%26doi%3D10.1124%2Fdmd.107.016808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitholtz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurva, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span> <span> </span><span class="NLM_article-title">Significantly different covalent binding of oxidative metabolites, acyl glucuronides, and S-acyl CoA conjugates formed from xenobiotic carboxylic acids in human liver microsomes</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">886</span>– <span class="NLM_lpage">896</span>, <span class="refDoi"> DOI: 10.1021/tx500514z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500514z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2ht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=886-896&author=M.+Darnellauthor=K.+Breitholtzauthor=E.+M.+Isinauthor=U.+Jurvaauthor=L.+Weidolf&title=Significantly+different+covalent+binding+of+oxidative+metabolites%2C+acyl+glucuronides%2C+and+S-acyl+CoA+conjugates+formed+from+xenobiotic+carboxylic+acids+in+human+liver+microsomes&doi=10.1021%2Ftx500514z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes</span></div><div class="casAuthors">Darnell, Malin; Breitholtz, Katarina; Isin, Emre M.; Jurva, Ulrik; Weidolf, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">886-896</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Xenobiotic carboxylic acids may be metabolized to oxidative metabolites, acyl glucuronides, and/or S-acyl-CoA thioesters (CoA conjugates) in vitro, e.g., in hepatocytes, and in vivo.  These metabolites can potentially be reactive species and bind covalently to tissue proteins and are generally considered to mediate adverse drug reactions in humans.  Acyl glucuronide metabolites have been the focus of reactive metabolite research for decades, whereas drug-CoA conjugates, which have been shown to be up to 40-70 times more reactive, have been given much less attention.  In an attempt to dissect the contribution of different pathways to covalent binding, we utilized human liver microsomes supplemented with NADPH, uridine 5'-diphosphoglucuronic acid (UDPGA), or CoA to evaluate the reactivity of each metabolite sep.  Seven carboxylic acid drugs were included in this study.  While ibuprofen and tolmetin are still on the market, ibufenac, fenclozic acid, tienilic acid, suprofen, and zomepirac were stopped before their launch or withdrawn.  The reactivities of the CoA conjugates of ibuprofen, ibufenac, fenclozic acid, and tolmetin were higher compared to those of their corresponding oxidative metabolites and acyl glucuronides, as measured by the level of covalent binding to human liver microsomal proteins.  The highest covalent binding was obsd. for ibuprofenyl-CoA and ibufenacyl-CoA, to levels of 1000 and 8600 pmol drug eq/mg protein, resp.  In contrast and in agreement with the proposed P 450-mediated toxicity for these drug mols., the reactivities of oxidative metabolites of suprofen and tienilic acid were higher compared to the reactivities of their conjugated metabolites, with NADPH-dependent covalent binding of 250 pmol drug eq/mg protein for both drugs.  The seven drugs all formed UDPGA-dependent acyl glucuronides, but none of these resulted in covalent binding.  This study shows that, unlike studies with hepatocytes or in vivo, human liver microsomes provide an opportunity to investigate the reactivity of individual metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWKWURekmygLVg90H21EOLACvtfcHk0lgsfgentNLFZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2ht7k%253D&md5=770a4825095e7651d8271b66c86568a1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Ftx500514z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500514z%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DM.%26aulast%3DBreitholtz%26aufirst%3DK.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DJurva%26aufirst%3DU.%26aulast%3DWeidolf%26aufirst%3DL.%26atitle%3DSignificantly%2520different%2520covalent%2520binding%2520of%2520oxidative%2520metabolites%252C%2520acyl%2520glucuronides%252C%2520and%2520S-acyl%2520CoA%2520conjugates%2520formed%2520from%2520xenobiotic%2520carboxylic%2520acids%2520in%2520human%2520liver%2520microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26spage%3D886%26epage%3D896%26doi%3D10.1021%2Ftx500514z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brass, E. P.</span></span> <span> </span><span class="NLM_article-title">Overview of coenzyme A metabolism and its role in cellular toxicity</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/0009-2797(94)90010-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0009-2797%2894%2990010-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8168169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFOgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1994&pages=203-214&author=E.+P.+Brass&title=Overview+of+coenzyme+A+metabolism+and+its+role+in+cellular+toxicity&doi=10.1016%2F0009-2797%2894%2990010-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of coenzyme A metabolism and its role in cellular toxicity</span></div><div class="casAuthors">Brass, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-14</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    </div><div class="casAbstract">A review with 72 refs. on the role of CoA as a cofactor for a no. of oxidative and biosynthetic reactions in intermediary metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbhg79FIJiH7Vg90H21EOLACvtfcHk0lhc3n-2yMKUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFOgtbc%253D&md5=01957e5e80b8287f9a210505b9a68059</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0009-2797%2894%2990010-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0009-2797%252894%252990010-8%26sid%3Dliteratum%253Aachs%26aulast%3DBrass%26aufirst%3DE.%2BP.%26atitle%3DOverview%2520of%2520coenzyme%2520A%2520metabolism%2520and%2520its%2520role%2520in%2520cellular%2520toxicity%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1994%26volume%3D90%26spage%3D203%26epage%3D214%26doi%3D10.1016%2F0009-2797%2894%2990010-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A. Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csizmadia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grieves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakilynejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragan, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, P. J.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfx018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28108665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2017&pages=50-61&author=F.+S.+Wolenskiauthor=A.+Z.+X.+Zhuauthor=M.+Johnsonauthor=S.+Yuauthor=Y.+Moriyaauthor=T.+Ebiharaauthor=V.+Csizmadiaauthor=J.+Grievesauthor=M.+Patonauthor=M.+Liaoauthor=C.+Gemskiauthor=L.+Panauthor=M.+Vakilynejadauthor=Y.+P.+Draganauthor=S.+K.+Chowdhuryauthor=P.+J.+Kirby&title=Fasiglifam+%28TAK-875%29+alters+bile+acid+homeostasis+in+rats+and+dogs%3A+a+potential+cause+of+drug+induced+liver+injury&doi=10.1093%2Ftoxsci%2Fkfx018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury</span></div><div class="casAuthors">Wolenski, Francis S.; Zhu, Andy Z. X.; Johnson, Mike; Yu, Shaoxia; Moriya, Yuu; Ebihara, Takuya; Csizmadia, Vilmos; Grieves, Jessica; Paton, Martin; Liao, Mingxiang; Gemski, Christopher; Pan, Liping; Vakilynejad, Majid; Dragan, Yvonne P.; Chowdhury, Swapan K.; Kirby, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-61</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects.  A mechanistic investigation described in this manuscript focused on the inhibition of bile acid (BA) transporters as a driver of the liver findings.  TAK-875 was an in vitro inhibitor of multiple influx (NTCP and OATPs) and efflux (BSEP and MRPs) hepatobiliary BA transporters at micromolar concns.  Repeat dose studies detd. that TAK-875 caused a dose-dependent increase in serum total BA in rats and dogs.  Addnl., there were dose-dependent increases in both unconjugated and conjugated individual BAs in both species.  Rats had an increase in serum markers of liver injury without correlative microscopic signs of tissue damage.  Two of 6 dogs that received the highest dose of TAK-875 developed liver injury with clin. pathol. changes, and by microscopic anal. had portal granulomatous inflammation with neutrophils around a cryst. deposition.  The BA compn. of dog bile also significantly changed in a dose-dependent manner following TAK-875 administration.  At the highest dose, levels of taurocholic acid were 50% greater than in controls with a corresponding 50% decrease in taurochenodeoxycholic acid.  Transporter inhibition by TAK-875 may cause liver injury in dogs through altered bile BA compn. characteristics, as evidenced by cryst. deposition, likely composed of test article, in the bile duct.  In conclusion, a combination of in vitro and in vivo evidence suggests that BA transporter inhibition could contribute to TAK-875-mediated liver injury in dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVd38JAy40nrVg90H21EOLACvtfcHk0lhc3n-2yMKUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsrg%253D&md5=028c43e6fe1d5a2b0f7f75d03926993a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx018%26sid%3Dliteratum%253Aachs%26aulast%3DWolenski%26aufirst%3DF.%2BS.%26aulast%3DZhu%26aufirst%3DA.%2BZ.%2BX.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DMoriya%26aufirst%3DY.%26aulast%3DEbihara%26aufirst%3DT.%26aulast%3DCsizmadia%26aufirst%3DV.%26aulast%3DGrieves%26aufirst%3DJ.%26aulast%3DPaton%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DGemski%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DVakilynejad%26aufirst%3DM.%26aulast%3DDragan%26aufirst%3DY.%2BP.%26aulast%3DChowdhury%26aufirst%3DS.%2BK.%26aulast%3DKirby%26aufirst%3DP.%2BJ.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%2520alters%2520bile%2520acid%2520homeostasis%2520in%2520rats%2520and%2520dogs%253A%2520a%2520potential%2520cause%2520of%2520drug%2520induced%2520liver%2520injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2017%26volume%3D157%26spage%3D50%26epage%3D61%26doi%3D10.1093%2Ftoxsci%2Fkfx018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcinak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munsaka, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span> <span> </span><span class="NLM_article-title">Liver safety of fasiglifam (TAK-875) in patients with type 2 diabetes: review of the global clinical trial experience</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1007/s40264-018-0642-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2Fs40264-018-0642-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29492878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=625-640&author=J.+Marcinakauthor=M.+S.+Munsakaauthor=P.+B.+Watkinsauthor=T.+Ohiraauthor=N.+Smith&title=Liver+safety+of+fasiglifam+%28TAK-875%29+in+patients+with+type+2+diabetes%3A+review+of+the+global+clinical+trial+experience&doi=10.1007%2Fs40264-018-0642-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience</span></div><div class="casAuthors">Marcinak, John F.; Munsaka, Melvin S.; Watkins, Paul B.; Ohira, Takashi; Smith, Neila</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">625-640</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Introduction: Fasiglifam (TAK-875) is a G protein-coupled receptor 40 agonist that was being investigated for treatment of type 2 diabetes mellitus (T2DM).  A development program was terminated late in phase III clin. trials due to liver safety concerns.  Methods: The liver safety of fasiglifam was assessed from data based on six phase II and nine phase III double-blind studies and two open-label studies with emphasis on pooled data from 15 double-blind studies from both global and Japanese development programs.  Taking into consideration different daily doses of fasiglifam administered in clin. studies, the primary comparisons were between all patients exposed to fasiglifam (any dose) vs. placebo, and, where applicable, vs. the two active comparators, sitagliptin or glimepiride.  A Liver Safety Evaluation Committee consisting of hepatologists blinded to treatment assignments evaluated hepatic adverse events (AEs) and serious AEs (SAEs) for causal relationship to study drug.  Results: The anal. included data from 9139 patients with T2DM in 15 double-blind controlled studies who received either fasiglifam (n = 5359, fasiglifam group), fasiglifam and sitagliptin (n = 123), or a comparator agent (n = 3657, non-exposed group consisting of placebo and other antidiabetic agents).  Exposure to treatment for more than 1 yr ranged from 249 patients in the placebo arm, to 370 patients in the glimepiride arm and 617 patients in the fasiglifam 50 mg arm.  The primary focus of the anal. was on the hepatic safety of fasiglifam.  The overall safety profile based on treatment-emergent AEs (TEAEs), SAEs, deaths, and withdrawal due to AEs was similar between fasiglifam and placebo (excluding liver test abnormalities).  However, there was an increased incidence rate of serum alanine aminotransferase (ALT) elevations > 3 × upper limit of normal (ULN), 5 × ULN, and 10 × ULN in fasiglifam-treated patients compared with those treated with placebo or active comparators.  ALT elevations > 3 × ULN for fasiglifam were 2.7% compared with 0.8 and 0.5% for the active comparators and placebo.  There did not appear to be a clear dose response in incidence of ALT elevations between patients receiving 25 or 50 mg daily.  The cumulative incidence of elevations in serum ALT > 3 × ULN was higher in the first 6 mo of treatment with fasiglifam compared with both placebo and the active comparators, but the rate of new ALT elevations appeared to be similar across all treatment groups thereafter.  No demog. or baseline patient characteristics were identified to predict elevations exceeding ALT > 3 × ULN in fasiglifam-treated patients.  The pattern of liver injury with fasiglifam was hepatocellular, and there were no reports of liver-related deaths, liver failure or life-threatening liver injury.  Most fasiglifam-assocd. ALT elevations were asymptomatic and resolved promptly upon discontinuing treatment, but in two patients the recovery was prolonged.  Importantly, three important serious liver injury cases were identified among fasiglifam-treated patients; one case was adjudicated to be a clear Hy's Law case and the two remaining cases were considered to closely approx. Hy's Law cases.  Conclusions: Although the incidence of overall AEs, SAEs, and deaths was similar between fasiglifam and placebo, a liver signal was identified based primarily on the difference in liver chem. values in the fasiglifam group compared with the placebo and active comparator groups.  Three serious liver injuries were attributed to fasiglifam treatment.  Clin. development of fasiglifam was halted due to these liver safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3GJELAHno-rVg90H21EOLACvtfcHk0lhc3n-2yMKUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKnt7s%253D&md5=8b10e5b20ea33dda3dd7871d97569f0f</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs40264-018-0642-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-018-0642-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DMunsaka%26aufirst%3DM.%2BS.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DOhira%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DN.%26atitle%3DLiver%2520safety%2520of%2520fasiglifam%2520%2528TAK-875%2529%2520in%2520patients%2520with%2520type%25202%2520diabetes%253A%2520review%2520of%2520the%2520global%2520clinical%2520trial%2520experience%26jtitle%3DDrug%2520Saf.%26date%3D2018%26volume%3D41%26spage%3D625%26epage%3D640%26doi%3D10.1007%2Fs40264-018-0642-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shavadia, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neaton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLeve, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Home, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckel, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, C. B.</span></span> <span> </span><span class="NLM_article-title">Determination of fasiglifam-induced liver toxicity: insights from the data monitoring committee of the fasiglifam clinical trials program</span>. <i>Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1177/1740774519836766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1177%2F1740774519836766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30880443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BB3cbltVemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=253-262&author=J.+S.+Shavadiaauthor=A.+Sharmaauthor=X.+Guauthor=J.+Neatonauthor=L.+DeLeveauthor=D.+Holmesauthor=P.+Homeauthor=R.+H.+Eckelauthor=P.+B.+Watkinsauthor=C.+B.+Granger&title=Determination+of+fasiglifam-induced+liver+toxicity%3A+insights+from+the+data+monitoring+committee+of+the+fasiglifam+clinical+trials+program&doi=10.1177%2F1740774519836766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program</span></div><div class="casAuthors">Shavadia Jay S; Sharma Abhinav; Gu Xiangqiong; Granger Christopher B; Shavadia Jay S; Neaton James; DeLeve Laurie; Holmes David; Home Phillip; Eckel Robert H; Watkins Paul B</div><div class="citationInfo"><span class="NLM_cas:title">Clinical trials (London, England)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-262</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Different approaches to safety event collection influence the determination of liver toxicity within drug development programs.  Herein, a description of how fasiglifam-induced liver injury was detected is provided.  METHODS:  This eight-trial drug development program was intended to evaluate fasiglifam (25 mg, 50 mg) against placebo or active comparators (glimepiride, sitagliptin) in approximately 11,000 suboptimally controlled patients with type 2 diabetes (terminated Dec 2013 due to liver toxicity).  Liver safety had been pre-identified as a concern, and within the phase 3 trials, was measured through (1) adverse event reporting, (2) central predefined liver monitoring schedule with various thresholds for potential drug-induced liver injury, and (3) blinded adjudication of serious liver toxicity by a panel of experts in drug-induced liver injury.  A single data monitoring committee provided safety oversight across all trials within the program.  FINDINGS:  Prior to program termination, 7595 of 7602 (99.9%) randomized participants across the eight trials received at least one dose of the study drug (fasiglifam, placebo, or active control).  No concerning trends were noted in adverse or serious adverse event frequency, suspected unexpected serious adverse reaction, alanine or aspartate transaminase elevations, or hepatobiliary or gastrointestinal adverse events as reported by local site investigators.  However, the predefined central liver safety measurements revealed a greater frequency of possible Hy's Law cases (5 vs 2) and a 3- to 7-fold greater relative risk in alanine or aspartate transaminase elevation (with respect to upper limit of normal) within fasiglifam recipients compared with placebo/active control: alanine or aspartate transaminase > 3×: relative risk 3.34 (95% confidence interval 2.29-4.90), alanine or aspartate transaminase > 5×: relative risk 6.60 (95% confidence interval 3.03-14.38), alanine or aspartate transaminase > 8×: relative risk 6.14 (95% confidence interval 2.18-17.27), and alanine or aspartate transaminase > 10×: relative risk 6.74 (95% confidence interval 2.05, 22.14).  All elevations resolved on study drug discontinuation.  Drug-induced liver injury was adjudicated as highly likely or probably related in 0.64% of fasiglifam-treated versus 0.06% placebo or active control-treated patients.  CONCLUSION:  In spite of clear liver toxicity detected with a systematic surveillance program, liver safety signals were not identified from investigator adverse event reporting alone.  By integrating key safety monitoring processes within the randomized design of adequately sized clinical trials, the rare but serious liver toxicity signal became clear, leading to timely program termination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLkSQnxSaNr75oR8RchjrrfW6udTcc2eYkXbIDlYOKjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbltVemsA%253D%253D&md5=0a04972e2057f6d04a94f8ace971a312</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1177%2F1740774519836766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1740774519836766%26sid%3Dliteratum%253Aachs%26aulast%3DShavadia%26aufirst%3DJ.%2BS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DNeaton%26aufirst%3DJ.%26aulast%3DDeLeve%26aufirst%3DL.%26aulast%3DHolmes%26aufirst%3DD.%26aulast%3DHome%26aufirst%3DP.%26aulast%3DEckel%26aufirst%3DR.%2BH.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26atitle%3DDetermination%2520of%2520fasiglifam-induced%2520liver%2520toxicity%253A%2520insights%2520from%2520the%2520data%2520monitoring%2520committee%2520of%2520the%2520fasiglifam%2520clinical%2520trials%2520program%26jtitle%3DClin.%2520Trials%26date%3D2019%26volume%3D16%26spage%3D253%26epage%3D262%26doi%3D10.1177%2F1740774519836766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kogame, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagawa, Y.</span></span> <span> </span><span class="NLM_article-title">Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1080/00498254.2018.1453100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F00498254.2018.1453100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29557709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntV2qsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=433-445&author=A.+Kogameauthor=R.+Leeauthor=L.+Panauthor=M.+Sudoauthor=M.+Nonakaauthor=Y.+Moriyaauthor=T.+Higuchiauthor=Y.+Tagawa&title=Disposition+and+metabolism+of+the+G+protein-coupled+receptor+40+agonist+TAK-875+%28fasiglifam%29+in+rats%2C+dogs%2C+and+humans&doi=10.1080%2F00498254.2018.1453100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans</span></div><div class="casAuthors">Kogame, Akifumi; Lee, Ronald; Pan, Liping; Sudo, Miyako; Nonaka, Masami; Moriya, Yuu; Higuchi, Tomoaki; Tagawa, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">433-445</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The absorption, distribution, metab., and excretion of fasiglifam were investigated in rats, dogs, and humans.  The abs. oral bioavailability of fasiglifam was high in all species (>76.0%).  After oral administration of [14C]fasiglifam, the administered radioactivity was quant. recovered and the major route of excretion of radioactivity was via feces in all species.  Fasiglifam was a major component in the plasma and feces in all species.  Its oxidative metabolite (M-I) was obsd. as a minor metabolite in rat and human plasma (<10% of plasma radioactivity).  In human plasma, hydroxylated fasiglifam (T-1676427), the glucuronide of fasiglifam (fasiglifam-G), and the glucuronide of M-I were detected as addnl. minor metabolites (<2% of plasma radioactivity).  None of these metabolites were specific to humans.  Fasiglifam-G was the major component in the rat and dog bile.  In vitro cytochrome P 450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) reaction phenotyping indicated that oxidn. (to form M-I and T-1676427) and glucuronidation of fasiglifam are mainly mediated by CYP3A4/5 and UGT1A3, resp.  Fasiglifam and fasiglifam-G are substrates of BCRP and Mrp2/MRP2, resp.  Glucuronidation of fasiglifam-G was found to be the predominant elimination pathway of fasiglifam in all species tested, including humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEs8-FNDQE47Vg90H21EOLACvtfcHk0ljzYqq8q37DQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntV2qsb8%253D&md5=282fac60fc0726e63958f90a2d7e8fd3</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1080%2F00498254.2018.1453100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498254.2018.1453100%26sid%3Dliteratum%253Aachs%26aulast%3DKogame%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DSudo%26aufirst%3DM.%26aulast%3DNonaka%26aufirst%3DM.%26aulast%3DMoriya%26aufirst%3DY.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DTagawa%26aufirst%3DY.%26atitle%3DDisposition%2520and%2520metabolism%2520of%2520the%2520G%2520protein-coupled%2520receptor%252040%2520agonist%2520TAK-875%2520%2528fasiglifam%2529%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DXenobiotica%26date%3D2019%26volume%3D49%26spage%3D433%26epage%3D445%26doi%3D10.1080%2F00498254.2018.1453100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaggs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span> <span> </span><span class="NLM_article-title">Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">374</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfx040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfx040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28206647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGltbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2018&pages=374-384&author=M.+A.+Otienoauthor=J.+Snoeysauthor=W.+Lamauthor=A.+Ghoshauthor=M.+R.+Playerauthor=A.+Pocaiauthor=R.+Salterauthor=D.+Simicauthor=H.+Skaggsauthor=B.+Singhauthor=H.+K.+Lim&title=Fasiglifam+%28TAK-875%29%3A+mechanistic+investigation+and+retrospective+identification+of+hazards+for+drug+induced+liver+injury&doi=10.1093%2Ftoxsci%2Fkfx040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury</span></div><div class="casAuthors">Otieno, Monicah A.; Snoeys, Jan; Lam, Wing; Ghosh, Avi; Player, Mark R.; Pocai, Alessandro; Salter, Rhys; Simic, Damir; Skaggs, Hollie; Singh, Bhanu; Lim, Heng-Keang</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374-384</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">TAK-875, a GPR40 agonist, was withdrawn from Phase III clin. trials due to drug-induced liver injury (DILI).  Mechanistic studies were conducted to identify potential DILI hazards (covalent binding burden (CVB), hepatic transporter inhibition, mitochondrial toxicity, and liver toxicity in rats) assocd. with TAK-875.  Treatment of hepatocytes with radiolabeled TAK-875 resulted in a CVB of 2.0 mg/day, which is above the threshold of 1 mg/day considered to be a risk for DILI.  Covalent binding to hepatocytes was due to formation of a reactive acyl glucuronide (AG) and, possibly, an acyl-CoA thioester intermediate.  Formation of TAK-875AG in hepatocytes and/or in vivo was in the order of non-rodents > human (in vitro only) > rat.  These data suggest that non-rodents, and presumably humans, form TAK-875AG more efficiently than rats, and that AG-mediated toxicities in rats may only occur at high doses.  TAK-875 (1000 mg/kg/day) formed significant amts. of AG metabolite (≤32.7 μM) in rat liver that was assocd. with increases in ALT (× 4), bilirubin (× 9), and bile acids (× 3.4), and microscopic findings of hepatocellular hypertrophy and single cell necrosis.  TAK-875 and TAK-875AG had similar potencies (within 3-fold) for human multi-drug resistant assocd. protein 2/4 (MRP2/4) and bile salt export pump, but TAK-875AG was exceptionally potent against MRP3 (0.21 μM).  Inhibition of MRPs may contribute to liver accumulation of TAK-875AG.  TAK-875 also inhibited mitochondrial respiration in HepG2 cells, and mitochondrial Complex 1 and 2 activities in isolated rat mitochondria.  In summary, formation of TAK-875AG, and possibly TAK-875CoA in hepatocytes, coupled with inhibition of hepatic transporters and mitochondrial respiration may be key contributors to TAK-875-mediated DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZrkrYD3NSbVg90H21EOLACvtfcHk0liW51_p1FVYUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGltbbO&md5=17b0cf793843a6feb351f3da455fee15</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfx040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfx040%26sid%3Dliteratum%253Aachs%26aulast%3DOtieno%26aufirst%3DM.%2BA.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DLam%26aufirst%3DW.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DSalter%26aufirst%3DR.%26aulast%3DSimic%26aufirst%3DD.%26aulast%3DSkaggs%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DLim%26aufirst%3DH.%2BK.%26atitle%3DFasiglifam%2520%2528TAK-875%2529%253A%2520mechanistic%2520investigation%2520and%2520retrospective%2520identification%2520of%2520hazards%2520for%2520drug%2520induced%2520liver%2520injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2018%26volume%3D163%26spage%3D374%26epage%3D384%26doi%3D10.1093%2Ftoxsci%2Fkfx040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, S. Y.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo metabolic profiles of fasiglifam using ultrahigh-performance liquid chromatography combined with Q-exactive orbitrap tandem mass spectrometry</span>. <i>Rapid Commun. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1387</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1002/rcm.8174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Frcm.8174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29790616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1387-1395&author=J.+Q.+Liauthor=J.+Liauthor=J.+F.+Wangauthor=S.+H.+Zhangauthor=D.+Heauthor=R.+S.+Yongauthor=S.+Y.+She&title=In+vitro+and+in+vivo+metabolic+profiles+of+fasiglifam+using+ultrahigh-performance+liquid+chromatography+combined+with+Q-exactive+orbitrap+tandem+mass+spectrometry&doi=10.1002%2Frcm.8174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo metabolic profiles of fasiglifam using ultrahigh-performance liquid chromatography combined with Q-Exactive Orbitrap tandem mass spectrometry</span></div><div class="casAuthors">Li, Jin-Qi; Li, Jie; Wang, Jia-Feng; Zhang, Shu-han; He, Dan; Yong, Rong-Sheng; She, Shu-Ya</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Rationale : Fasiglifam is an orally available and selective partial agonist of hGPR40 receptor, which was unexpectedly terminated at phase III clin. trials due to its severe hepatotoxicity.  To fully understand the mechanism of action of fasiglifam, it is necessary to investigate its in vitro and in vivo metabolic profiles.  Methods : For in vitro metab., fasiglifam was incubated with rat or human liver microsomes in the presence of β-NADP tetrasodium salt, glutathione (GSH) and uridine diphosphate glucuronic acid trisodium salt for 60 min.  For in vivo metab., fasiglifam was orally administered to rats at a single dose of 20 mg/kg and the bile was collected.  In vitro and in vivo samples were analyzed by the developed ultrahigh-performance liq. chromatog. combined with Q-Exactive Orbitrap tandem mass spectrometry.  The structures of metabolites were proposed according to their accurate masses and fragment ions.  Results : A total of eight metabolites, including an acyl-GSH adduct, were detected and identified.  M1 (acylglucuronide) and M5 (carboxylic acid deriv.) were the major metabolites of fasiglifam.  Metabolic pathways of fasiglifam involved oxygenation, oxidative dealkylation, dehydrogenation, glucuronidation and GSH conjugation.  Fasiglifam may undergo metabolic bioactivation via acylglucuronide.  Conclusions : Oxidative dealkylation and glucuronidation were the predominant metabolic pathways of fasiglifam in vitro and in vivo.  Metabolic bioactivation via acylglucuronide may be the perpetrator of its hepatotoxicity.  The authors findings would be helpful in understanding the disposition of fasiglifam as well as its hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFUjb_33ym1LVg90H21EOLACvtfcHk0liW51_p1FVYUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjtLnF&md5=c705bf3d1d28d6f97737a25ec3c87adc</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Frcm.8174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.8174%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BF.%26aulast%3DZhang%26aufirst%3DS.%2BH.%26aulast%3DHe%26aufirst%3DD.%26aulast%3DYong%26aufirst%3DR.%2BS.%26aulast%3DShe%26aufirst%3DS.%2BY.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520metabolic%2520profiles%2520of%2520fasiglifam%2520using%2520ultrahigh-performance%2520liquid%2520chromatography%2520combined%2520with%2520Q-exactive%2520orbitrap%2520tandem%2520mass%2520spectrometry%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2018%26volume%3D32%26spage%3D1387%26epage%3D1395%26doi%3D10.1002%2Frcm.8174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorrod, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aislaitner, G.</span></span> <span> </span><span class="NLM_article-title">The metabolism of alicyclic amines to reactive iminium ion intermediates</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1007/BF03188923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2FBF03188923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7867663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2MXitlSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1994&pages=209-217&author=J.+W.+Gorrodauthor=G.+Aislaitner&title=The+metabolism+of+alicyclic+amines+to+reactive+iminium+ion+intermediates&doi=10.1007%2FBF03188923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of alicyclic amines to reactive iminium ion intermediates</span></div><div class="casAuthors">Gorrod, J. W.; Aislaitner, G.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-17</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Medecine et Hygiene</span>)
        </div><div class="casAbstract">The evidence implicating the formation of iminium ions as reactive intermediates in the metab. of alicyclic amines has been reviewed with 44 refs.  The mechanism of formation of iminium ions and their conversion to α-carbonyl compds. or demethylated amines is discussed.  The use of a simple cyanide trapping technique for iminium ions has been demonstrated to monitor a large no. of alicyclic drugs for iminium ion formation.  The possible role of iminium ions in the pharmacol. and toxicol. of alicyclic amines is considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeB4VEvyLM2rVg90H21EOLACvtfcHk0liW51_p1FVYUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitlSjtrc%253D&md5=d633c5ff744b9c66373cc8ec85546e90</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2FBF03188923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03188923%26sid%3Dliteratum%253Aachs%26aulast%3DGorrod%26aufirst%3DJ.%2BW.%26aulast%3DAislaitner%26aufirst%3DG.%26atitle%3DThe%2520metabolism%2520of%2520alicyclic%2520amines%2520to%2520reactive%2520iminium%2520ion%2520intermediates%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D1994%26volume%3D19%26spage%3D209%26epage%3D217%26doi%3D10.1007%2FBF03188923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barberia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contillo, L. G.</span></span> <span> </span><span class="NLM_article-title">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2004.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.jpba.2004.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15351054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=105-116&author=J.+R.+Sogliaauthor=S.+P.+Harrimanauthor=S.+Zhaoauthor=J.+Barberiaauthor=M.+J.+Coleauthor=J.+G.+Boydauthor=L.+G.+Contillo&title=The+development+of+a+higher+throughput+reactive+intermediate+screening+assay+incorporating+micro-bore+liquid+chromatography-micro-electrospray+ionization-tandem+mass+spectrometry+and+glutathione+ethyl+ester+as+an+in+vitro+conjugating+agent&doi=10.1016%2Fj.jpba.2004.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent</span></div><div class="casAuthors">Soglia, John R.; Harriman, Shawn P.; Zhao, Sabrina; Barberia, John; Cole, Mark J.; Boyd, James G.; Contillo, Leonard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-116</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An in vitro reactive intermediate screening assay, incorporating the use of the close analog of glutathione, glutathione Et ester (GSH-EE) as a conjugating agent, was developed to identify compds. that form reactive intermediates in an in vitro metabolite generating system.  The biol. assay consisted of substrate [s] = 10 μM, human liver microsomes, an NADPH generating system, and glutathione Et ester.  Conjugates were extd. from the biol. matrix using a combination of protein pptn. and a semi-automated 96-well plate solid phase extn. (SPE) procedure.  A micro-bore liq. chromatog.-micro-electrospray ionization-tandem mass spectrometry (μLC-μESI-MS/MS) method detected glutathione Et ester conjugates using selected reaction monitoring (SRM) to simultaneously monitor for multiple MH+ to [MH - 129]+ transitions, where the 129 mass unit (Da) represents the neutral loss of the pyroglutamate moiety from GSH-EE.  The multiple MH+ to [MH - 129]+ transitions (SRM mass table) were generated for potential reactive intermediates of each compd.  Glutathione (GSH) and GSH-EE conjugate stds. were used to evaluate MS detection sensitivity.  Based on direct comparison of std. curve data, an approx. 10-fold increase in sensitivity was obsd. for conjugates contg. GSH-EE moiety vs. GSH.  In vitro expts. were conducted using literature substrates acetaminophen, rosiglitazone, clozapine, diclofenac and either GSH-EE or GSH as a reactive intermediate conjugating agent.  An increase in detection sensitivity was obsd. for each GSH-EE conjugate and in the case of acetaminophen-GSH-EE the peak area increase was approx. 80-fold.  Twelve drug compds., each having known biotransformation mechanisms, were used to further test the detection capabilities of the assay and establish a concordance to literature data.  When GSH was used in the assay, conjugates were detected for 4 out of the 12 test compds. (33%).  When GSH-EE was used in the assay, conjugates were detected for 10 out of the 12 test compds. (83%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NwMX6-E_3LVg90H21EOLACvtfcHk0lgdUW3v56fdqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlems7w%253D&md5=23e4c3df8558019ad3770d748a1f9815</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2004.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2004.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBarberia%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DM.%2BJ.%26aulast%3DBoyd%26aufirst%3DJ.%2BG.%26aulast%3DContillo%26aufirst%3DL.%2BG.%26atitle%3DThe%2520development%2520of%2520a%2520higher%2520throughput%2520reactive%2520intermediate%2520screening%2520assay%2520incorporating%2520micro-bore%2520liquid%2520chromatography-micro-electrospray%2520ionization-tandem%2520mass%2520spectrometry%2520and%2520glutathione%2520ethyl%2520ester%2520as%2520an%2520in%2520vitro%2520conjugating%2520agent%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2004%26volume%3D36%26spage%3D105%26epage%3D116%26doi%3D10.1016%2Fj.jpba.2004.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1021/tx034170b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx034170b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=3-16&author=D.+C.+Evansauthor=A.+P.+Wattauthor=D.+A.+Nicoll-Griffithauthor=T.+A.+Baillie&title=Drug-protein+adducts%3A+an+industry+perspective+on+minimizing+the+potential+for+drug+bioactivation+in+drug+discovery+and+development&doi=10.1021%2Ftx034170b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development</span></div><div class="casAuthors">Evans, David C.; Watt, Alan P.; Nicoll-Griffith, Deborah A.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-16</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity.  Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Labs. has been to minimize reactive metabolite formation to the extent possible by appropriate structural modification during the lead optimization stage.  This requires a flexible approach to defining bioactivation issues in a variety of metab. vectors and typically involves the initial use of small mol. trapping agents to define the potential for bioactivation.  At some point, however, there is a requirement to synthesize a radiolabeled tracer and to undertake covalent binding studies in vitro, usually in liver microsomal (and sometimes hepatocyte) prepns. from preclin. species and human, and also in vivo, typically in the rat.  This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Labs.  The availability of a dedicated Labeled Compd. Synthesis group, coupled to a close working relationship between Drug Metab. and Medicinal Chem., represents a framework within which this perspective becomes viable; the overall aim is to bring safer drugs to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOsPmSgJDD8rVg90H21EOLACvtfcHk0lgdUW3v56fdqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ymtbg%253D&md5=9ab130c5462b2245e2f4c783afb01d1d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Ftx034170b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx034170b%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DDrug-protein%2520adducts%253A%2520an%2520industry%2520perspective%2520on%2520minimizing%2520the%2520potential%2520for%2520drug%2520bioactivation%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2004%26volume%3D17%26spage%3D3%26epage%3D16%26doi%3D10.1021%2Ftx034170b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Argoti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conteh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bershas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vouros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E.</span></span> <span> </span><span class="NLM_article-title">Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1544</span>, <span class="refDoi"> DOI: 10.1021/tx0501637</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0501637" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1537-1544&author=D.+Argotiauthor=L.+Liangauthor=A.+Contehauthor=L.+Chenauthor=D.+Bershasauthor=C.+P.+Yuauthor=P.+Vourosauthor=E.+Yang&title=Cyanide+trapping+of+iminium+ion+reactive+intermediates+followed+by+detection+and+structure+identification+using+liquid+chromatography-tandem+mass+spectrometry&doi=10.1021%2Ftx0501637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Cyanide Trapping of Iminium Ion Reactive Intermediates Followed by Detection and Structure Identification Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)</span></div><div class="casAuthors">Argoti, Dayana; Liang, Li; Conteh, Abdul; Chen, Liangfu; Bershas, Dave; Yu, Chung-Ping; Vouros, Paul; Yang, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1537-1544</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Secondary and tertiary alicyclic amines are widely found in pharmaceuticals and environmental compds.  The formation of iminium ions as reactive intermediates in the metabolic activation of alicyclic amines has previously been investigated in radiometric assays where radiolabeled cyanide is typically employed.  In this paper, the authors report a relatively high throughput LC-MS/MS method for the detection of the nonradiolabeled cyanide adduct formed in rat or human liver microsomal incubations via const. neutral loss scan followed by structural characterization using product ion scan on a triple quadrupole mass spectrometer.  A total of 14 alicyclic amine compds. were investigated with the cyanide trapping LC-MS/MS screen and also with the glutathione (GSH) trapping screen, a well-established and commonly employed technique for reactive metabolite screening.  The authors' results are found to be in general agreement with the previous metab. reports for these compds., demonstrating the effectiveness, speed, and simplicity of the cyanide trapping LC-MS/MS method to study the iminium ion intermediates from alicyclic amines and its complementarities to GSH trapping method for reactive metabolite screenings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWbsW3G51jQbVg90H21EOLACvtfcHk0lgdUW3v56fdqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrt7%252FI&md5=98c9128150ca5fc710e35a7d81555c69</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Ftx0501637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0501637%26sid%3Dliteratum%253Aachs%26aulast%3DArgoti%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DConteh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBershas%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DC.%2BP.%26aulast%3DVouros%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DE.%26atitle%3DCyanide%2520trapping%2520of%2520iminium%2520ion%2520reactive%2520intermediates%2520followed%2520by%2520detection%2520and%2520structure%2520identification%2520using%2520liquid%2520chromatography-tandem%2520mass%2520spectrometry%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1537%26epage%3D1544%26doi%3D10.1021%2Ftx0501637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, K.</span></span> <span> </span><span class="NLM_article-title">Comparison of the reactivity of trapping reagents towards electrophiles: cysteine derivatives can be bifunctional trapping reagents</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1546</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00129</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=1546-1555&author=K.+Inoueauthor=K.+Fukudaauthor=T.+Yoshimuraauthor=K.+Kusano&title=Comparison+of+the+reactivity+of+trapping+reagents+towards+electrophiles%3A+cysteine+derivatives+can+be+bifunctional+trapping+reagents&doi=10.1021%2Facs.chemrestox.5b00129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the Reactivity of Trapping Reagents toward Electrophiles: Cysteine Derivatives Can Be Bifunctional Trapping Reagents</span></div><div class="casAuthors">Inoue, Kazuko; Fukuda, Katsuyuki; Yoshimura, Tsutomu; Kusano, Kazutomi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1546-1555</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trapping reagents are powerful tools to detect unstable reactive metabolites.  There are a variety of trapping reagents based on chem. reactivity to electrophiles, and we investigated the reactivity of thiol and amine trapping reagents to metabolically generated electrophiles and com. available electrophilic compds.  Glutathione (GSH) and N-acetylcysteine (Nac) trapped soft electrophiles, and amine derivs. such as semicarbazide (SC) and methoxyamine (MeA) reacted as hard nucleophiles to trap aldehydes as imine derivs.  Cysteine (Cys) and homocysteine (HCys) captured both soft electrophiles and hard electrophilic aldehydes.  There were no qual. differences in trapping soft electrophiles among Cys, HCys, GSH, and Nac, although quant. reactivity to trap soft electrophiles varied likely depending on the pKa values of their thiol group.  In the reactivity with aldehydes, Cys and HCys showed relatively lower reactivity as compared with SC and MeA.  Nonetheless, they can trap aldehydes, and the resulting conjugates were stable and detected easily because their amino group formed imines after reaction with aldehydes, which are successively attacked by the intramol. thiol group to form stable ring structures.  This report demonstrated that Cys and HCys are advantageous to evaluate the formations of both soft electrophiles and aldehyde-type derivs. from a lot of drug candidates at early drug discovery by their unique structural characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZLv0MyCEUrVg90H21EOLACvtfcHk0liEinsW3jl0zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKkt7vK&md5=3769df41f5878af170f9791113a0ce9c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00129%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DK.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DYoshimura%26aufirst%3DT.%26aulast%3DKusano%26aufirst%3DK.%26atitle%3DComparison%2520of%2520the%2520reactivity%2520of%2520trapping%2520reagents%2520towards%2520electrophiles%253A%2520cysteine%2520derivatives%2520can%2520be%2520bifunctional%2520trapping%2520reagents%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2015%26volume%3D28%26spage%3D1546%26epage%3D1555%26doi%3D10.1021%2Facs.chemrestox.5b00129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of case reports of aplastic anemia among patients treated with felbamate</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1265</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1157.1997.tb00062.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fj.1528-1157.1997.tb00062.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9578520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXltFaj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=1265-1269&author=D.+W.+Kaufmanauthor=J.+P.+Kellyauthor=T.+Andersonauthor=D.+C.+Harmonauthor=S.+Shapiro&title=Evaluation+of+case+reports+of+aplastic+anemia+among+patients+treated+with+felbamate&doi=10.1111%2Fj.1528-1157.1997.tb00062.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of case reports of aplastic anemia among patients treated with felbamate</span></div><div class="casAuthors">Kaufman, D. W.; Kelly, J. P.; Anderson, T.; Harmon, D. C.; Shapiro, S.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1265-1269</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Felbamate (FBM) is a new antiepileptic drug (AED) that is often effective in seizure disorders refractory to other treatments; its use has been greatly restricted after cases of aplastic anemia were reported.  To elucidate the putative assocn. between FBM and aplastic anemia, we made a detailed evaluation of the first 31 reports.  Hematol. review according to the criteria of the International Agranulocytosis and Aplastic Anemia Study (IAAAS) confirmed 23 cases (74%) as aplastic anemia; FBM was judged to be the only plausible cause for three; confounding (mostly by other drugs) was considered possible, but FBM remained the most likely cause for 11; and there was at least one other plausible cause for 9.  Using a denominator from sales data of 110,000 persons exposed and a numerator of the cases for which FBM was considered the only plausible cause, we established a lower limit of incidence of 27 cases of aplastic anemia per million users as compared with the general population rate of 2.0 per million per yr.  With all confirmed cases used as the numerator, the upper limit of incidence was 209 per million.  The "most probable" incidence was estd. to be 127 per million.  Intensive, systematic investigation can maximize the utility of case reports for assessing risks of newly released drugs.  The present evaluation confirmed an assocn. between FBM and aplastic anemia; however, confounding was significant for most cases and there was a tenfold range in the "best case" and "worst case" incidence ests. among users.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXqFKKAYuTC7Vg90H21EOLACvtfcHk0liEinsW3jl0zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFaj&md5=1eae15e6f92d5308897a7fd7716918ce</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1157.1997.tb00062.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1157.1997.tb00062.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaufman%26aufirst%3DD.%2BW.%26aulast%3DKelly%26aufirst%3DJ.%2BP.%26aulast%3DAnderson%26aufirst%3DT.%26aulast%3DHarmon%26aufirst%3DD.%2BC.%26aulast%3DShapiro%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520case%2520reports%2520of%2520aplastic%2520anemia%2520among%2520patients%2520treated%2520with%2520felbamate%26jtitle%3DEpilepsia%26date%3D1997%26volume%3D38%26spage%3D1265%26epage%3D1269%26doi%3D10.1111%2Fj.1528-1157.1997.tb00062.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdun, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGown, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span> <span> </span><span class="NLM_article-title">Felbamate-associated fatal acute hepatic necrosis</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1212/WNL.46.5.1457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1212%2FWNL.46.5.1457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8628501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK283ht1Gqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1996&pages=1457-1459&author=M.+G.+O%E2%80%99Neilauthor=C.+S.+Perdunauthor=M.+B.+Wilsonauthor=S.+T.+McGownauthor=S.+Patel&title=Felbamate-associated+fatal+acute+hepatic+necrosis&doi=10.1212%2FWNL.46.5.1457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Felbamate-associated fatal acute hepatic necrosis</span></div><div class="casAuthors">O'Neil M G; Perdun C S; Wilson M B; McGown S T; Patel S</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1457-9</span>
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    </div><div class="casAbstract">Thirty-six cases of hepatic toxicity associated with felbamate therapy have been collected by the Food and Drug Administration.  Five patients died.  We describe a case of massive acute hepatic necrosis and death within 40 days of initiation of felbamate therapy for a generalized tonic-clonic seizure disorder.  We describe the clinical and histopathologic features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBxb8aur7NHedfST00W0BcfW6udTcc2ea97U4t4l78Ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283ht1Gqtg%253D%253D&md5=3f2ef7c53040df5e31921b060845d0c8</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1212%2FWNL.46.5.1457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.46.5.1457%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DM.%2BG.%26aulast%3DPerdun%26aufirst%3DC.%2BS.%26aulast%3DWilson%26aufirst%3DM.%2BB.%26aulast%3DMcGown%26aufirst%3DS.%2BT.%26aulast%3DPatel%26aufirst%3DS.%26atitle%3DFelbamate-associated%2520fatal%2520acute%2520hepatic%2520necrosis%26jtitle%3DNeurology%26date%3D1996%26volume%3D46%26spage%3D1457%26epage%3D1459%26doi%3D10.1212%2FWNL.46.5.1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nightingale, S. L.</span></span> <span> </span><span class="NLM_article-title">Recommendation to immediately withdraw patients from treatment with felbamate</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">995</span>, <span class="refDoi"> DOI: 10.1001/jama.1994.03520130027011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1001%2Fjama.1994.03520130027012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8089899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK2czns1emsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1994&pages=995&author=S.+L.+Nightingale&title=Recommendation+to+immediately+withdraw+patients+from+treatment+with+felbamate&doi=10.1001%2Fjama.1994.03520130027011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">From the Food and Drug Administration</span></div><div class="casAuthors">Nightingale S L</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">995</span>
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7nqybF38QiYNpW7w2tapOfW6udTcc2eZQwwnZbkXBLLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2czns1emsA%253D%253D&md5=d5ac9d768a4ce1e6c6def1b301a50d1e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1001%2Fjama.1994.03520130027012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1994.03520130027012%26sid%3Dliteratum%253Aachs%26aulast%3DNightingale%26aufirst%3DS.%2BL.%26atitle%3DRecommendation%2520to%2520immediately%2520withdraw%2520patients%2520from%2520treatment%2520with%2520felbamate%26jtitle%3DJAMA%26date%3D1994%26volume%3D272%26spage%3D995%26doi%3D10.1001%2Fjama.1994.03520130027011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapetanovic, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekawa, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieckhaus, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupferberg, H. J.</span></span> <span> </span><span class="NLM_article-title">Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(02)00058-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2802%2900058-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12399159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVKrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2002&pages=119-134&author=I.+M.+Kapetanovicauthor=C.+D.+Torchinauthor=J.+M.+Strongauthor=W.+D.+Yonekawaauthor=C.+Luauthor=A.+P.+Liauthor=C.+M.+Dieckhausauthor=W.+L.+Santosauthor=T.+L.+Macdonaldauthor=R.+D.+Sofiaauthor=H.+J.+Kupferberg&title=Reactivity+of+atropaldehyde%2C+a+felbamate+metabolite+in+human+liver+tissue+in+vitro&doi=10.1016%2FS0009-2797%2802%2900058-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro</span></div><div class="casAuthors">Kapetanovic, Izet M.; Torchin, Cynthia D.; Strong, John M.; Yonekawa, Wayne D.; Lu, Chuang; Li, Albert P.; Dieckhaus, Christine M.; Santos, Webster L.; MacDonald, Timothy L.; Sofia, R. Duane; Kupferberg, Harvey J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">119-134</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Antiepileptic therapy with a broad spectrum drug felbamate (FBM) has been limited due to reports of hepatotoxicity and aplastic anemia assocd. with its use.  It was proposed that a bioactivation of FBM leading to formation of α,β-unsatd. aldehyde, atropaldehyde (ATPAL) could be responsible for toxicities assocd. with the parent drug.  Other members of this class of compds., acrolein and 4-hydroxynonenal (HNE), are known for their reactivity and toxicity.  It has been proposed that the bioactivation of FBM to ATPAL proceeds though a more stable cyclized product, 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one (CCMF) whose formation has been shown recently.  Aldehyde dehydrogenase (ALDH) and glutathione transferase (GST) are detoxifying enzymes and targets for reactive aldehydes.  This study examd. effects of ATPAL and its precursor, CCMF on ALDH, GST and cell viability in liver, the target tissue for its metab. and toxicity.  A known toxin, HNE, which is also a substrate for ALDH and GST, was used for comparison.  Interspecies difference in metab. of FBM is well documented, therefore, human tissue was deemed most relevant and used for these studies.  ATPAL inhibited ALDH and GST activities and led to a loss of hepatocyte viability.  Several fold greater concns. of CCMF were necessary to demonstrate a similar degree of ALDH inhibition or cytotoxicity as obsd. with ATPAL.  This is consistent with CCMF requiring prior conversion to the more proximate toxin, ATPAL.  GSH was shown to protect against ALDH inhibition by ATPAL.  In this context, ALDH and GST are detoxifying pathways and their inhibition would lead to an accumulation of reactive species from FBM metab. and/or metab. of other endogenous or exogenous compds. and predisposing to or causing toxicity.  Therefore, mechanisms of reactive aldehydes toxicity could include direct interaction with crit. cellular macromols. or indirect interference with cellular detoxification mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowv3ix1_vDHrVg90H21EOLACvtfcHk0lj5OLpO5NPe-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVKrt7w%253D&md5=ca2ca0812084df77f02f42807c9a5372</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2802%2900058-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252802%252900058-3%26sid%3Dliteratum%253Aachs%26aulast%3DKapetanovic%26aufirst%3DI.%2BM.%26aulast%3DTorchin%26aufirst%3DC.%2BD.%26aulast%3DStrong%26aufirst%3DJ.%2BM.%26aulast%3DYonekawa%26aufirst%3DW.%2BD.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DA.%2BP.%26aulast%3DDieckhaus%26aufirst%3DC.%2BM.%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26aulast%3DSofia%26aufirst%3DR.%2BD.%26aulast%3DKupferberg%26aufirst%3DH.%2BJ.%26atitle%3DReactivity%2520of%2520atropaldehyde%252C%2520a%2520felbamate%2520metabolite%2520in%2520human%2520liver%2520tissue%2520in%2520vitro%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2002%26volume%3D142%26spage%3D119%26epage%3D134%26doi%3D10.1016%2FS0009-2797%2802%2900058-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dieckhaus, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of idiosyncratic drug reactions: the case of felbamate</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(02)00057-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2FS0009-2797%2802%2900057-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12399158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVKrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2002&pages=99-117&author=C.+M.+Dieckhausauthor=C.+D.+Thompsonauthor=S.+G.+Rollerauthor=T.+L.+MacDonald&title=Mechanisms+of+idiosyncratic+drug+reactions%3A+the+case+of+felbamate&doi=10.1016%2FS0009-2797%2802%2900057-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of idiosyncratic drug reactions: the case of Felbamate</span></div><div class="casAuthors">Dieckhaus, Christine M.; Thompson, Charles D.; Roller, Shane G.; MacDonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">99-117</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug reactions (IDR) are a specific type of drug toxicity characterized by their delayed onset, low incidence, and reactive metabolite formation with little, if any, correlation between pharmacokinetics or pharmacodynamics and the toxicol. outcome.  As the name implies, IDR are unpredictable and often result in the post-marketing failure of otherwise useful therapies.  Examples of drugs, which have failed as a result of IDR in recent years, include Trovafloxacin, Zileuton, Troglitazone, Tolcapone, and Felbamate.  To date there exists no pre-clin. model to predict these adverse drug reactions and a mechanistic understanding of these toxicities remains limited.  In an attempt to better understand this class of drug toxicities and gain mechanistic insight, the authors have studied the IDR assocd. with a model compd., Felbamate.  The studies with Felbamate are consistent with the theory that compds. which cause IDR undergo bioactivation to a highly reactive electrophilic metabolite that is capable of forming covalent protein adducts in vivo.  In addn., the data suggest that under normal physiol. conditions glutathione plays a protective role in preventing IDR during Felbamate therapy, further emphasizing a correlation between reactive metabolite formation and a toxic outcome.  Clin. studies with Felbamate have been able to demonstrate an assocn. between reactive metabolite formation and a clin. relevant toxicity; however, addnl. research is required to more fully understand the link between reactive metabolite formation and the events which elicit toxicity.  Going forward, it seems reasonable that screening for reactive metabolite formation in early drug discovery may be an important tool in eliminating the post-marketing failure of otherwise useful therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL1vhL9PChYLVg90H21EOLACvtfcHk0lj5OLpO5NPe-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVKrt78%253D&md5=ade528b1c851e1bf204984d1ae9cf957</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2802%2900057-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252802%252900057-1%26sid%3Dliteratum%253Aachs%26aulast%3DDieckhaus%26aufirst%3DC.%2BM.%26aulast%3DThompson%26aufirst%3DC.%2BD.%26aulast%3DRoller%26aufirst%3DS.%2BG.%26aulast%3DMacDonald%26aufirst%3DT.%2BL.%26atitle%3DMechanisms%2520of%2520idiosyncratic%2520drug%2520reactions%253A%2520the%2520case%2520of%2520felbamate%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2002%26volume%3D142%26spage%3D99%26epage%3D117%26doi%3D10.1016%2FS0009-2797%2802%2900057-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adusumalli, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanyshyn, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparadoski, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wichmann, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharczyk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R. D.</span></span> <span> </span><span class="NLM_article-title">Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">710</span>– <span class="NLM_lpage">716</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=8104132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK3sXmtFKksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1993&pages=710-716&author=V.+E.+Adusumalliauthor=Y.+M.+Choiauthor=L.+A.+Romanyshynauthor=R.+E.+Sparadoskiauthor=J.+K.+Wichmannauthor=K.+K.+Wongauthor=N.+Kucharczykauthor=R.+D.+Sofia&title=Isolation+and+identification+of+3-carbamoyloxy-2-phenylpropionic+acid+as+a+major+human+urinary+metabolite+of+felbamate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate</span></div><div class="casAuthors">Adusumalli, V. E.; Choi, Y. M.; Romanyshyn, L. A.; Sparadoski, R. E., Jr.; Wichmann, J. K.; Wong, K. K.; Kucharczyk, N.; Sofia, R. D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">710-16</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">A new metabolite of felbamate, isolated from the polar metabolite fraction of a human urine sample, was identified as 3-carbamoyloxy-2-phenylpropionic acid (CPPA) by electron impact and Cl/MS of the Me ester in the isolated fraction.  Its presence in the unconjugated free form in two different human urine samples was confirmed by HPLC comparison of retention times with authentic synthetic CPPA and by online neg. ion HPLC thermospray tandem mass spectrometric techniques.  The amt. of CPPA in 0-4 h postdose human urine was estd. to be ∼12% of the drug-derived substances present in the urine.  Some CPPA was also found to be present in dog urine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpydnoOlfZIBbVg90H21EOLACvtfcHk0lhJ1Ad7v8hfKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmtFKksr4%253D&md5=0864c86c16f8b162a063e598589eb62c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdusumalli%26aufirst%3DV.%2BE.%26aulast%3DChoi%26aufirst%3DY.%2BM.%26aulast%3DRomanyshyn%26aufirst%3DL.%2BA.%26aulast%3DSparadoski%26aufirst%3DR.%2BE.%26aulast%3DWichmann%26aufirst%3DJ.%2BK.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DKucharczyk%26aufirst%3DN.%26aulast%3DSofia%26aufirst%3DR.%2BD.%26atitle%3DIsolation%2520and%2520identification%2520of%25203-carbamoyloxy-2-phenylpropionic%2520acid%2520as%2520a%2520major%2520human%2520urinary%2520metabolite%2520of%2520felbamate%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1993%26volume%3D21%26spage%3D710%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barthen, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudspeth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perhach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Quantitation in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1111/j.1528-1157.1999.tb00777.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fj.1528-1157.1999.tb00777.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10368077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1MXmt1SjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=769-776&author=C.+D.+Thompsonauthor=M.+T.+Barthenauthor=D.+W.+Hopperauthor=T.+A.+Millerauthor=M.+Quiggauthor=C.+Hudspethauthor=G.+Montourisauthor=L.+Marshauthor=J.+L.+Perhachauthor=R.+D.+Sofiaauthor=T.+L.+Macdonald&title=Quantitation+in+patient+urine+samples+of+felbamate+and+three+metabolites%3A+acid+carbamate+and+two+mercapturic+acids&doi=10.1111%2Fj.1528-1157.1999.tb00777.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids</span></div><div class="casAuthors">Thompson, Charles D.; Barthen, Mary T.; Hopper, Darrin W.; Miller, Thomas A.; Quigg, Mark; Hudspeth, Candice; Montouris, Georgia; Marsh, LaDonna; Perhach, James L.; Sofia, R. Duane; Macdonald, Timothy L.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">769-776</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: Previously we proposed and provided evidence for the metabolic pathway of felbamate (FBM), which leads to the reactive metabolite, 3-carbamoyl-2-phenylpropion-aldehyde.  This aldehyde carbamate was suggested to be the reactive intermediate in the oxidn. of 2-phenyl-1,3-propanediol monocarbamate to the major human metabolite 3-carbamoyl-2-phenylpropionic acid.  In addn., the aldehyde carbamate was found to undergo spontaneous elimination to 2-phenylpropenal, commonly known as atropaldehyde.  Moreover, atropaldehyde was proposed to play a role in the development of toxicity during FBM therapy.  Evidence for atropaldehyde formation in vivo was reported with the identification of modified N-acetyl-cysteine conjugates of atropaldehyde in both human and rat urine after FBM administration.  Identification of the atropaldehyde-derived mercapturic acids in urine after FBM administration is consistent with the hypothesis that atropaldehyde is formed in vivo and that it reacts with thiol nucleophiles.  Based on the hypothesis that the potential for toxicity will correlate to the amt. of atropaldehyde formed, we sought to develop an analytic method that would quantify the amt. of relevant metabolites excreted in patient urine.  Methods: We summarize the results of an LC/MS method used to quantify FBM, 3-carbamoyl-2-phenylpropionic acid and two atropaldehyde-derived mercapturic acids in the patient population.  Results: Anal. was performed on 31 patients undergoing FBM therapy.  The abs. quantities of FBM and three metabolites were measured.  Conclusions: This method demonstrated sufficient precision for the identification of patients exhibiting "abnormal" levels of atropaldehyde conjugates and may hold potential for patient monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjMxzH378jjbVg90H21EOLACvtfcHk0lhJ1Ad7v8hfKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt1SjtLc%253D&md5=a5cb91815151ed3a0a3b3ee843ecec25</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1528-1157.1999.tb00777.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1528-1157.1999.tb00777.x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DC.%2BD.%26aulast%3DBarthen%26aufirst%3DM.%2BT.%26aulast%3DHopper%26aufirst%3DD.%2BW.%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DQuigg%26aufirst%3DM.%26aulast%3DHudspeth%26aufirst%3DC.%26aulast%3DMontouris%26aufirst%3DG.%26aulast%3DMarsh%26aufirst%3DL.%26aulast%3DPerhach%26aufirst%3DJ.%2BL.%26aulast%3DSofia%26aufirst%3DR.%2BD.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DQuantitation%2520in%2520patient%2520urine%2520samples%2520of%2520felbamate%2520and%2520three%2520metabolites%253A%2520acid%2520carbamate%2520and%2520two%2520mercapturic%2520acids%26jtitle%3DEpilepsia%26date%3D1999%26volume%3D40%26spage%3D769%26epage%3D776%26doi%3D10.1111%2Fj.1528-1157.1999.tb00777.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roecklein, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupferberg, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, J. M.</span></span> <span> </span><span class="NLM_article-title">Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by postmitochondrial suspensions</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1842</span>– <span class="NLM_lpage">1848</span>, <span class="refDoi"> DOI: 10.1021/tx050130r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050130r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1eitrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=1842-1848&author=R.+J.+Parkerauthor=N.+R.+Hartmanauthor=B.+A.+Roeckleinauthor=H.+Mortkoauthor=H.+J.+Kupferbergauthor=J.+Stablesauthor=J.+M.+Strong&title=Stability+and+comparative+metabolism+of+selected+felbamate+metabolites+and+postulated+fluorofelbamate+metabolites+by+postmitochondrial+suspensions&doi=10.1021%2Ftx050130r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Stability and Comparative Metabolism of Selected Felbamate Metabolites and Postulated Fluorofelbamate Metabolites by Postmitochondrial Suspensions</span></div><div class="casAuthors">Parker, Robert J.; Hartman, Neil R.; Roecklein, Bryan A.; Mortko, Henry; Kupferberg, Harvey J.; Stables, James; Strong, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1842-1848</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Evidence has been presented suggesting that a reactive metabolite, 2-phenylpropenal (ATPAL), may be responsible for the toxicities obsd. during therapy with the antiepileptic drug felbamate (FBM).  Formation of ATPAL from its unstable immediate precursor, 3-carbamoyl-2-phenylpropionaldedhyde (CBMA) requires the loss of the hydrogen atom at position 2 in the propane chain, and it has been postulated that substitution of this atom with fluorine would prevent the formation of ATPAL.  On the basis of this hypothesis, 2-fluoro-2-phenyl-1,3-propanediol dicarbamate (F-FBM) was synthesized and is presently undergoing drug development.  To test this hypothesis, the authors compared the metab. by human liver postmitochondrial suspensions (S9) in vitro of selected FBM and postulated F-FBM metabolites leading to formation of CBMA or 3-carbamoyl-2-fluoro-2-phenyl-propionaldehyde (F-CBMA).  All S9 incubations included GSH as a trapping agent for any reactive metabolites formed.  Our results indicated that, in phosphate buffer, pH 7.4, at 37°, the half-life for 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one (CCMF) was 2.8 and 3.6 h in the presence or absence of GSH, resp.; compared to 4-hydroxy-5-fluoro-5-phenyl-tetrahydro-1,3-oxazin-2-one (F-CCMF) which lost only 2.5% or 4.9% over 24 h under the same conditions.  When incubated with S9 in the presence of the cofactor, NAD+, 2-phenyl-1,3-propanediol monocarbamate (MCF) was oxidized to CCMF which was further oxidized to 3-carbamoyl-2-phenylpropionic acid (CPPA).  2-Fluoro-2-phenyl-1,3-propanediol monocarbamate (F-MCF) under similar conditions was stable, and no metabolites were obsd.  When CCMF was incubated with S9 in the presence of NAD+ cofactor, oxidn. to CPPA and redn. to MCF were obsd.  In addn., a new atropic acid GSH adduct (ATPA-GSH) was identified by mass spectrometry.  When F-CCMF was incubated under the same conditions as CCMF, both reduced and oxidized metabolites, F-MCF and 3-carbamoyl-2-fluoro-2-phenylpropionic acid (F-CPPA), resp., were formed but at significantly lower rates, and no GSH conjugates were identified.  Our results support the hypothesis that F-FBM and F-CCMF are not metabolized by S9 in vitro to the known reactive FBM metabolite, ATPAL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9aisWkyFRkLVg90H21EOLACvtfcHk0lhJ1Ad7v8hfKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1eitrnP&md5=fb13997626f64f4b726caa7894bb9fa2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Ftx050130r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050130r%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DR.%2BJ.%26aulast%3DHartman%26aufirst%3DN.%2BR.%26aulast%3DRoecklein%26aufirst%3DB.%2BA.%26aulast%3DMortko%26aufirst%3DH.%26aulast%3DKupferberg%26aufirst%3DH.%2BJ.%26aulast%3DStables%26aufirst%3DJ.%26aulast%3DStrong%26aufirst%3DJ.%2BM.%26atitle%3DStability%2520and%2520comparative%2520metabolism%2520of%2520selected%2520felbamate%2520metabolites%2520and%2520postulated%2520fluorofelbamate%2520metabolites%2520by%2520postmitochondrial%2520suspensions%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D1842%26epage%3D1848%26doi%3D10.1021%2Ftx050130r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roecklein, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacks, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortko, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stables, J.</span></span> <span> </span><span class="NLM_article-title">Fluorofelbamate</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2006.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.nurt.2006.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=17199021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFaksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=97-101&author=B.+A.+Roeckleinauthor=H.+J.+Sacksauthor=H.+Mortkoauthor=J.+Stables&title=Fluorofelbamate&doi=10.1016%2Fj.nurt.2006.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Fluoro0felbamate</span></div><div class="casAuthors">Roecklein, Bryan A.; Sacks, Harry J.; Mortko, Henry; Stables, James</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-101</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1933-7213</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The incidence of refractory seizures has remained at 30-40%, even with the approval of nine new anticonvulsants over the past 12 years.  In attempts to reduce seizure frequency and severity, physicians routinely resort to combining two or more anticonvulsants, ideally with different mechanisms of action.  These combinatorial therapies are difficult to administer for both patient and caregiver and often result in tolerability issues.  Hence, a broad spectrum anticonvulsant, with multiple mechanisms of action, that is well tolerated, would provide physicians with an important option in their armamentarium to control seizures.  Felbamate initially fit this profile and was demonstrated to effectively control both partial and generalized seizures in clin. studies supporting registration.  Unfortunately, unanticipated idiosyncratic toxicity was obsd. after approval and the drug is now relegated to second or third line therapy, depending on patient history and seizure type.  Epileptologists still prescribe this drug for refractory seizures, and a recent communication indicates that 35,000 to 46,000 new patients have tried Felbatol (MedPointe Pharmaceuticals, Somerset, NJ) since 1995.  The continued utilization of Felbatol, in light of its risk:benefit issues, highlights the need for new efficacious therapeutic options.  Fluorofelbamate (Med-Pointe Pharmaceuticals), a phase I drug candidate, was designed to retain the broad spectrum multimechanistic activity of felbamate, with a modified metab. that has demonstrated, in vitro, to avoid the prodn. of the reactive metabolite believed to cause the idiosyncratic toxicity.  This drug candidate is one of several carbamates either in development or currently on the market for treatment of seizures and other CNS disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLY6kz-AVDFLVg90H21EOLACvtfcHk0lj790QbBJmMqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFaksLk%253D&md5=24365b8c44f2be9837ac64ede8dca327</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2006.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2006.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DRoecklein%26aufirst%3DB.%2BA.%26aulast%3DSacks%26aufirst%3DH.%2BJ.%26aulast%3DMortko%26aufirst%3DH.%26aulast%3DStables%26aufirst%3DJ.%26atitle%3DFluorofelbamate%26jtitle%3DNeurotherapeutics%26date%3D2007%26volume%3D4%26spage%3D97%26epage%3D101%26doi%3D10.1016%2Fj.nurt.2006.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tingle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitteringham, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Drug – protein conjugates. 14. Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(88)90733-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-2952%2888%2990733-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3342086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL1cXitFGrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1988&pages=303-311&author=J.+L.+Maggsauthor=M.+D.+Tingleauthor=N.+R.+Kitteringhamauthor=B.+K.+Park&title=Drug+%E2%80%93+protein+conjugates.+14.+Mechanisms+of+formation+of+protein-arylating+intermediates+from+amodiaquine%2C+a+myelotoxin+and+hepatotoxin+in+man&doi=10.1016%2F0006-2952%2888%2990733-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-protein conjugates.  XIV.  Mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man</span></div><div class="casAuthors">Maggs, J. L.; Tingle, M. D.; Kitteringham, N. R.; Park, B. K.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">303-11</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The enzymic and nonenzymic formation of protein-arylating intermediates from amodiaquine (I) was studied in vitro.  [14C]-I in phosphate buffer, pH 7.4, under air was autoxidized to a reactive deriv.(s) which possessed characteristics indicative of a semiquinone/quinone imine: redn. by NADPH and ascorbic acid, conjugation with thiols and irreversible binding to microsomal and sol. proteins.  Cysteinyl SH groups were major sites of arylation.  Radiolabeled material irreversibly bound to human serum albumin after 24 h and to human liver microsomes after 4 h represented 26.5 % and 31.4% of incubated [14C]-I (10 μM), resp.  The quinone imine (II) of I was synthesized, and displayed the same oxidative and electrophilic reactions as the product(s) of I autoxidn.  A water-sol. product formed in buffered solns. of I and N-acetylcysteine was identified as an I mercapturate by comparison with an adduct prepd. from synthetic II.  Irreversible binding of [14]C-I was inhibited by a radical scavenger; this indicated that the semiquinone imine contributed to the binding.  Although I was extensively deethylated by human liver microsomes, oxidn. by cytochrome P 450 did not appear to be principally responsible fo its activation and irreversible binding in microsomal incubations.  I was oxidized to protein-arylating intermediates by horseradish peroxidase.  It also formed reactive derivs., possibly N-chloro compds., in chlorine solns.  Thus, I can give rise to chem. reactive species by at least 3 distinct mechanisms, viz. autoxidn. in neutral soln. under air, peroxidase-catalyzed oxidn. and N-chlorination.  Formation of such species in liver and myeloid cells might be responsible for the adverse reactions assocd. with I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogGgzRVYPMorVg90H21EOLACvtfcHk0lj790QbBJmMqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXitFGrtrk%253D&md5=c0e11569fd4d2cb20b50795c2955eeee</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2888%2990733-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252888%252990733-2%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DTingle%26aufirst%3DM.%2BD.%26aulast%3DKitteringham%26aufirst%3DN.%2BR.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DDrug%2520%25E2%2580%2593%2520protein%2520conjugates.%252014.%2520Mechanisms%2520of%2520formation%2520of%2520protein-arylating%2520intermediates%2520from%2520amodiaquine%252C%2520a%2520myelotoxin%2520and%2520hepatotoxin%2520in%2520man%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1988%26volume%3D37%26spage%3D303%26epage%3D311%26doi%3D10.1016%2F0006-2952%2888%2990733-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Irreversible binding of amodiaquine to human liver microsomes: chemical and metabolic factors</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">649</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1987&pages=649&author=J.+L.+Maggsauthor=J.+Colbertauthor=P.+A.+Winstanleyauthor=M.+L.+Ormeauthor=B.+K.+Park&title=Irreversible+binding+of+amodiaquine+to+human+liver+microsomes%3A+chemical+and+metabolic+factors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DColbert%26aufirst%3DJ.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DOrme%26aufirst%3DM.%2BL.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DIrreversible%2520binding%2520of%2520amodiaquine%2520to%2520human%2520liver%2520microsomes%253A%2520chemical%2520and%2520metabolic%2520factors%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1987%26volume%3D23%26spage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tingle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The bioactivation of amodiaquine by human polymorphonuclear leucocytes <i>in vitro</i>: Chemical mechanisms and the effects of fluorine substitution</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1113</span>– <span class="NLM_lpage">1119</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(95)00236-S</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-2952%2895%2900236-S" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7575670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2MXovVSnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=1113-1119&author=M.+D.+Tingleauthor=H.+Jewellauthor=J.+L.+Maggsauthor=P.+M.+O%E2%80%99Neillauthor=B.+K.+Park&title=The+bioactivation+of+amodiaquine+by+human+polymorphonuclear+leucocytes+in+vitro%3A+Chemical+mechanisms+and+the+effects+of+fluorine+substitution&doi=10.1016%2F0006-2952%2895%2900236-S"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The bioactivation of amodiaquine by human polymorphonuclear leukocytes in vitro: chemical mechanisms and the effects of fluorine substitution</span></div><div class="casAuthors">Tingle, M. D.; Jewell, H.; Maggs, J. L.; O'Neill, P. M.; Park, B. K.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1113-19</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Amodiaquine, a 4-aminoquinoline antimalarial, has been assocd. with hepatitis and agranulocytosis in humans.  Drugs hypersensitivity reactions, esp. agranulocytosis have been attributed to reactive intermediates generated by the oxidants discharged from stimulated polymorphonuclear leukocytes (PMN).  The metab. of amodiaquine to both stable and chem. reactive metabolites by human PMN has been investigated in vitro.  Incubation of [14C]-amodiaquine with PMN resulted in irreversible binding of radiolabel to protein and depletion of intracellular reduced glutathione, which were enhanced by phorbol myristate acetate (PMA), a PMN activator.  Two metabolites were identified: the C-5' glutathione adduct of amodiaquine, derived from both endogenous and exogenous glutathione, and 4-amino-7-chloroquinoline, which was presumed to be formed by hydrolysis of amodiaquine quinoneimine.  Desethylamodiaquine, the major plasma metabolic of amodiaquine in humans, also underwent bioactivation to a chem. reactive species in the presence of PMA-stimulated PMN.  Substitution of the 4'-hydroxyl group in amodiaquine with fluorine significantly reduced irreversible binding to protein and abolished depletion of intracellular glutathione in the presence of PMA.  These findings indicate that the bioactivation of amodiaquine by PMN is assocd. with the formation of a quinone-imine intermediate.  Such a reactive metabolite, if produced in PMN or bone marrow in vivo, may be responsible for the drug myelotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyzWCNjsmQLVg90H21EOLACvtfcHk0lj790QbBJmMqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVSnuro%253D&md5=33bab1893484b86d195ab9f5e45f183b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2895%2900236-S&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252895%252900236-S%26sid%3Dliteratum%253Aachs%26aulast%3DTingle%26aufirst%3DM.%2BD.%26aulast%3DJewell%26aufirst%3DH.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520bioactivation%2520of%2520amodiaquine%2520by%2520human%2520polymorphonuclear%2520leucocytes%2520in%2520vitro%253A%2520Chemical%2520mechanisms%2520and%2520the%2520effects%2520of%2520fluorine%2520substitution%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1995%26volume%3D50%26spage%3D1113%26epage%3D1119%26doi%3D10.1016%2F0006-2952%2895%2900236-S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storr, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1362</span>– <span class="NLM_lpage">1370</span>, <span class="refDoi"> DOI: 10.1021/jm00035a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00035a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2cXjt1ehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1362-1370&author=P.+M.+O%E2%80%99Neillauthor=A.+C.+Harrisonauthor=R.+C.+Storrauthor=S.+R.+Hawleyauthor=S.+A.+Wardauthor=B.+K.+Park&title=The+effect+of+fluorine+substitution+on+the+metabolism+and+antimalarial+activity+of+amodiaquine&doi=10.1021%2Fjm00035a017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">The Effect of Fluorine Substitution on the Metabolism and Antimalarial Activity of Amodiaquine</span></div><div class="casAuthors">O'Neill, Paul M.; Harrison, Anthony C.; Storr, Richard C.; Hawley, Shaun R.; Ward, Stephen A.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1362-70</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Amodiaquine (I, R = OH, R1-R3 = H) is a 4-aminoquinoline antimalarial which causes adverse side effects such as agranulocytosis and liver damage.  The obsd. drug toxicity is believed to be related to the formation of an electrophilic metabolite, amodiaquinequinonimine, which can bind to cellular macromols. and initiate hypersensitivity reactions.  Fluoroamodiaquines I (R = OH; R1 = F, R2, R3 = H; R1 = R2 = F, R3 = H; R1 = H, R2 = R3 = F; R1-R3 = F) and I (R = F, R1-R3 = H) have been synthesized to assess the effect of fluorine substitution on the oxidn. potential, metab., and in vitro antimalarial activity of amodiaquine.  The oxidn. potentials were measured by cyclic voltammetry, and it was obsd. that I (R = OH, R1 = H, R2 = R3 = F; R = F, R1-R3 = H) had significantly higher oxidn. potentials than the parent drug.  These analogs were also more resistant to bioactivation.  Thus, I (R = OH, R1 = H, R2 = R3 = F; R = F, R1-R3 = H) produced thioether conjugates corresponding to 2.17% (SD: ±0.27%) and 0% of the dose compared with 11.87% (SD: ±1.31%) of the dose for amodiaquine.  In general the fluorinated analogs had similar in vitro antimalarial activity to amodiaquine against the chloroquine-resistant K1 strain and the chloroquine-sensitive T9-96 strain of Plasmodium falciparum with the notable exception of I (R = OH, R1-R3 = F).  The data presented indicate that I (R = OH, R1 = H, R2 = R3 F; R = F, R1-R3 = H) maintain antimalarial efficacy in vitro and are more resistant to oxidn. and hence less likely to form toxic quinonimine metabolites in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBGBtIXfHxTbVg90H21EOLACvtfcHk0lhUame9paQ_xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjt1ehsbY%253D&md5=9a79eac45b716fc242c4c57d8f73585b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm00035a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00035a017%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DHarrison%26aufirst%3DA.%2BC.%26aulast%3DStorr%26aufirst%3DR.%2BC.%26aulast%3DHawley%26aufirst%3DS.%2BR.%26aulast%3DWard%26aufirst%3DS.%2BA.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DThe%2520effect%2520of%2520fluorine%2520substitution%2520on%2520the%2520metabolism%2520and%2520antimalarial%2520activity%2520of%2520amodiaquine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1362%26epage%3D1370%26doi%3D10.1021%2Fjm00035a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randle, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storr, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4933</span>– <span class="NLM_lpage">4945</span>, <span class="refDoi"> DOI: 10.1021/jm030796n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030796n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Wmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4933-4945&author=P.+M.+O%E2%80%99Neillauthor=A.+Mukhtarauthor=P.+A.+Stocksauthor=L.+E.+Randleauthor=S.+Hindleyauthor=S.+A.+Wardauthor=R.+C.+Storrauthor=J.+F.+Bickleyauthor=I.+A.+O%E2%80%99Neilauthor=J.+L.+Maggsauthor=R.+H.+Hughesauthor=P.+A.+Winstanleyauthor=P.+G.+Brayauthor=B.+K.+Park&title=Isoquine+and+related+amodiaquine+analogues%3A+a+new+generation+of+improved+4-aminoquinoline+antimalarials&doi=10.1021%2Fjm030796n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Isoquine and Related Amodiaquine Analogues: A New Generation of Improved 4-Aminoquinoline Antimalarials</span></div><div class="casAuthors">O'Neill, Paul M.; Mukhtar, Amira; Stocks, Paul A.; Randle, Laura E.; Hindley, Stephen; Ward, Stephen A.; Storr, Richard C.; Bickley, Jamie F.; O'Neil, Ian A.; Maggs, James L.; Hughes, Ruth H.; Winstanley, Peter A.; Bray, Patrick G.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4933-4945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Amodiaquine (AQ) is a 4-aminoquinoline antimalarial that can cause adverse side effects including agranulocytosis and liver damage.  The obsd. drug toxicity is believed to involve the formation of an electrophilic metabolite, amodiaquine quinoneimine (AQQI), which can bind to cellular macromols. and initiate hypersensitivity reactions.  We proposed that interchange of the 3'-hydroxyl and the 4'-Mannich side-chain function of amodiaquine would provide a new series of analogs that cannot form toxic quinoneimine metabolites via cytochrome P 450-mediated metab.  By a simple two-step procedure, 10 isomeric amodiaquine analogs were prepd. and subsequently examd. against the chloroquine resistant K1 and sensitive HB3 strains of Plasmodium falciparum in vitro.  Several analogs displayed potent antimalarial activity against both strains.  On the basis of the results of in vitro testing, isoquine (ISQ1) (IC50 = 6.01 nM ± 8.0 vs. K1 strain), the direct isomer of amodiaquine, was selected for in vivo antimalarial assessment.  The potent in vitro antimalarial activity of isoquine was translated into excellent oral in vivo ED50 activity of 1.6 and 3.7 mg/kg against the P. yoelii NS strain compared to 7.9 and 7.4 mg/kg for amodiaquine.  Subsequent metab. studies in the rat model demonstrated that isoquine does not undergo in vivo bioactivation, as evidenced by the complete lack of glutathione metabolites in bile.  In sharp contrast to amodiaquine, isoquine (and Phase I metabolites) undergoes clearance by Phase II glucuronidation.  On the basis of these promising initial studies, isoquine (ISQ1) represents a new second generation lead worthy of further investigation as a cost-effective and potentially safer alternative to amodiaquine.  Crystal structures of two products were also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWnYDr5dXE7Vg90H21EOLACvtfcHk0lhUame9paQ_xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Wmurk%253D&md5=46f85a3035ce34c0bbe7dd3efb43df67</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm030796n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030796n%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DMukhtar%26aufirst%3DA.%26aulast%3DStocks%26aufirst%3DP.%2BA.%26aulast%3DRandle%26aufirst%3DL.%2BE.%26aulast%3DHindley%26aufirst%3DS.%26aulast%3DWard%26aufirst%3DS.%2BA.%26aulast%3DStorr%26aufirst%3DR.%2BC.%26aulast%3DBickley%26aufirst%3DJ.%2BF.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DI.%2BA.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DHughes%26aufirst%3DR.%2BH.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DIsoquine%2520and%2520related%2520amodiaquine%2520analogues%253A%2520a%2520new%2520generation%2520of%2520improved%25204-aminoquinoline%2520antimalarials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4933%26epage%3D4945%26doi%3D10.1021%2Fjm030796n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shone, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asadollahy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigandi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-de-Las-Heras, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parapini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taramelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4′-fluoro and 4′-chloro analogues of amodiaquine. Identification of a suitable “back-up” compound for N-tert-butyl isoquine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1828</span>– <span class="NLM_lpage">1844</span>, <span class="refDoi"> DOI: 10.1021/jm8012757</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8012757" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1828-1844&author=P.+M.+O%E2%80%99Neillauthor=A.+E.+Shoneauthor=D.+Stanfordauthor=G.+Nixonauthor=E.+Asadollahyauthor=B.+K.+Parkauthor=J.+L.+Maggsauthor=P.+Robertsauthor=P.+A.+Stocksauthor=G.+Biaginiauthor=P.+G.+Brayauthor=J.+Daviesauthor=N.+Berryauthor=C.+Hallauthor=K.+Rimmerauthor=P.+A.+Winstanleyauthor=S.+Hindleyauthor=R.+B.+Bambalauthor=C.+B.+Davisauthor=M.+Batesauthor=S.+L.+Greshamauthor=R.+A.+Brigandiauthor=F.+M.+Gomez-de-Las-Herasauthor=D.+V.+Gargalloauthor=S.+Parapiniauthor=L.+Vivasauthor=H.+Landerauthor=D.+Taramelliauthor=S.+A.+Ward&title=Synthesis%2C+antimalarial+activity%2C+and+preclinical+pharmacology+of+a+novel+series+of+4%E2%80%B2-fluoro+and+4%E2%80%B2-chloro+analogues+of+amodiaquine.+Identification+of+a+suitable+%E2%80%9Cback-up%E2%80%9D+compound+for+N-tert-butyl+isoquine&doi=10.1021%2Fjm8012757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4'-Fluoro and 4'-Chloro Analogues of Amodiaquine. Identification of a Suitable "Back-Up" Compound for N-tert-Butyl Isoquine</span></div><div class="casAuthors">O'Neill, Paul M.; Shone, Alison E.; Stanford, Deborah; Nixon, Gemma; Asadollahy, Eghbaleh; Park, B. Kevin; Maggs, James L.; Roberts, Phil; Stocks, Paul A.; Biagini, Giancarlo; Bray, Patrick G.; Davies, Jill; Berry, Neil; Hall, Charlotte; Rimmer, Karen; Winstanley, Peter A.; Hindley, Stephen; Bambal, Ramesh B.; Davis, Charles B.; Bates, Martin; Gresham, Stephanie L.; Brigandi, Richard A.; Gomez-de-las-Heras, Federico M.; Gargallo, Domingo V.; Parapini, Silvia; Vivas, Livia; Lander, Hollie; Taramelli, Donatella; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1828-1844</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of a mechanistic understanding of the toxicity of the 4-aminoquinoline amodiaquine, three series of amodiaquine analogs have been prepd. where the 4-aminophenol "metabolic alert" has been modified by replacement of the 4'-hydroxy group with a hydrogen, fluorine, or chlorine atom.  Following antimalarial assessment and studies on mechanism of action, two candidates were selected for detailed ADME studies and in vitro and in vivo toxicol. assessment.  4'-Fluoro-N-tert-butylamodiaquine was subsequently identified as a candidate for further development studies based on potent activity vs. chloroquine-sensitive and resistant parasites, moderate to excellent oral bioavailability, low toxicity in in vitro studies, and an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomw8jiAgxkRbVg90H21EOLACvtfcHk0lhUame9paQ_xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKitLo%253D&md5=02183e75ef6d150e2c0d37569cb8c756</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm8012757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012757%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DShone%26aufirst%3DA.%2BE.%26aulast%3DStanford%26aufirst%3DD.%26aulast%3DNixon%26aufirst%3DG.%26aulast%3DAsadollahy%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DStocks%26aufirst%3DP.%2BA.%26aulast%3DBiagini%26aufirst%3DG.%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DDavies%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DRimmer%26aufirst%3DK.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DHindley%26aufirst%3DS.%26aulast%3DBambal%26aufirst%3DR.%2BB.%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DBates%26aufirst%3DM.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DBrigandi%26aufirst%3DR.%2BA.%26aulast%3DGomez-de-Las-Heras%26aufirst%3DF.%2BM.%26aulast%3DGargallo%26aufirst%3DD.%2BV.%26aulast%3DParapini%26aufirst%3DS.%26aulast%3DVivas%26aufirst%3DL.%26aulast%3DLander%26aufirst%3DH.%26aulast%3DTaramelli%26aufirst%3DD.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%252C%2520antimalarial%2520activity%252C%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520novel%2520series%2520of%25204%25E2%2580%25B2-fluoro%2520and%25204%25E2%2580%25B2-chloro%2520analogues%2520of%2520amodiaquine.%2520Identification%2520of%2520a%2520suitable%2520%25E2%2580%259Cback-up%25E2%2580%259D%2520compound%2520for%2520N-tert-butyl%2520isoquine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1828%26epage%3D1844%26doi%3D10.1021%2Fjm8012757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span> <span> </span><span class="NLM_article-title">Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1021/tx0002583</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0002583" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=611-650&author=F.+P.+Guengerich&title=Common+and+uncommon+cytochrome+P450+reactions+related+to+metabolism+and+chemical+toxicity&doi=10.1021%2Ftx0002583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">611-650</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 417 refs.  Cytochrome P 450 enzymes catalyze a variety of reactions and convert chems. to potentially reactive products as well as make compds. less toxic.  Most of the P 450 reactions are oxidns.  The majority of these can be rationalized in the context of an FeO3+ intermediate and odd electron abstraction/rebound mechanisms; however, other iron-oxygen complexes are possible and alternate chemistries can be considered.  Another issue regarding P 450-catalyzed reactions is the delineation of rate-limiting steps in the catalytic cycle and the contribution to reaction selectivity.  In addn. to the rather classical oxidns., P 450s also catalyze less generally discussed reactions including redn., desatn., ester cleavage, ring expansion, ring formation, aldehyde scission, dehydration, ipso attack, one-electron oxidn., coupling reactions, rearrangement of fatty acid and prostaglandin hydroperoxides, and phospholipase activity.  Most of these reactions are rationalized in the context of high-valent iron-oxygen intermediates and Fe2+ redns., but others are not and may involve acid-base catalysis.  Some of these transformations are involved in the bioactivation and detoxication of xenobiotic chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoznx-XkuM1OrVg90H21EOLACvtfcHk0ljAmdHjwS3NHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1Wnsbs%253D&md5=9398501ce17beed3fc0bad4840187eea</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Ftx0002583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0002583%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DCommon%2520and%2520uncommon%2520cytochrome%2520P450%2520reactions%2520related%2520to%2520metabolism%2520and%2520chemical%2520toxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2001%26volume%3D14%26spage%3D611%26epage%3D650%26doi%3D10.1021%2Ftx0002583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shone, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">362</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1002/jps.21469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fjps.21469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18563832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1WitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2009&pages=362-377&author=C.+B.+Davisauthor=R.+Bambalauthor=G.+S.+Moorthyauthor=E.+Huggerauthor=H.+Xiangauthor=B.+K.+Parkauthor=A.+E.+Shoneauthor=P.+M.+O%E2%80%99Neillauthor=S.+A.+Ward&title=Comparative+preclinical+drug+metabolism+and+pharmacokinetic+evaluation+of+novel+4-aminoquinoline+anti-malarials&doi=10.1002%2Fjps.21469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials</span></div><div class="casAuthors">Davis, Charles B.; Bambal, Ramesh; Moorthy, Ganesh S.; Hugger, Erin; Xiang, Hong; Park, Brian Kevin; Shone, Allison E.; O'Neill, Paul M.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">362-377</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The disposition of three 4-aminoquinoline leads, namely isoquine (ISO), des-Et isoquine (DEI) and N-tert-Bu isoquine (NTBI), were studied in a range of in vivo and in vitro assays to assist in selecting an appropriate candidate for further development.  Analogous to amodiaquine (ADQ), ISO undergoes oxidative N-dealkylation to form DEI in vivo.  Blood clearance of DEI was as much as 10-fold lower than that of ISO in animals and after oral administration, metabolite exposure exceeded that of parent by as much as 14-fold.  Replacement of the N-Et with an N-tert-Bu substituent substantially reduced N-dealkylation as blood clearance of NTBI was ∼2 to 3-fold lower than DEI in mouse, rat, dog and monkey.  Mean NTBI oral bioavailability was generally higher than the other leads (≥68%).  Blood cell assocn. was substantial for NTBI, particularly in dog and monkey, where blood to plasma concn. ratios >4 were obsd.  Human plasma protein binding was similar for NTBI, DEI, and des-Et amodiaquine (DEA).  Allometric scaling predicted human blood clearance (CL) for NTBI to be low (∼12% liver blood flow).  All the 4-aminoquinolines inhibited recombinant human cytochrome P 450 2D6 with similar potency; DEI also inhibited 1A2.  On balance, NTBI appeared the most promising lead to progress towards full development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRauKF2IFKXrVg90H21EOLACvtfcHk0ljAmdHjwS3NHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1WitA%253D%253D&md5=2aa5b721095b74bae200438025393144</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1002%2Fjps.21469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21469%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DBambal%26aufirst%3DR.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DXiang%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DShone%26aufirst%3DA.%2BE.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DComparative%2520preclinical%2520drug%2520metabolism%2520and%2520pharmacokinetic%2520evaluation%2520of%2520novel%25204-aminoquinoline%2520anti-malarials%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D98%26spage%3D362%26epage%3D377%26doi%3D10.1002%2Fjps.21469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shone, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winstanley, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhtar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonar-Law, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambal, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigandi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-delas-Heras, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargallo, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1021/jm8012618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8012618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvFShsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1408-1415&author=P.+M.+O%E2%80%99Neillauthor=B.+K.+Parkauthor=A.+E.+Shoneauthor=J.+L.+Maggsauthor=P.+Robertsauthor=P.+A.+Stocksauthor=G.+A.+Biaginiauthor=P.+G.+Brayauthor=P.+Gibbonsauthor=N.+Berryauthor=P.+A.+Winstanleyauthor=A.+Mukhtarauthor=R.+Bonar-Lawauthor=S.+Hindleyauthor=R.+B.+Bambalauthor=C.+B.+Davisauthor=M.+Batesauthor=T.+K.+Hartauthor=S.+L.+Greshamauthor=R.+M.+Lawrenceauthor=R.+A.+Brigandiauthor=F.+M.+Gomez-delas-Herasauthor=D.+V.+Gargalloauthor=S.+A.+Ward&title=Candidate+selection+and+preclinical+evaluation+of+N-tert-butyl+isoquine+%28GSK369796%29%2C+an+affordable+and+effective+4-aminoquinoline+antimalarial+for+the+21st+century&doi=10.1021%2Fjm8012618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Candidate Selection and Preclinical Evaluation of N-tert-Butyl Isoquine (GSK369796), An Affordable and Effective 4-Aminoquinoline Antimalarial for the 21st Century</span></div><div class="casAuthors">O'Neill, Paul M.; Park, B. Kevin; Shone, Alison E.; Maggs, James L.; Roberts, Phillip; Stocks, Paul A.; Biagini, Giancarlo A.; Bray, Patrick G.; Gibbons, Peter; Berry, Neil; Winstanley, Peter A.; Mukhtar, Amira; Bonar-Law, Richard; Hindley, Stephen; Bambal, Ramesh B.; Davis, Charles B.; Bates, Martin; Hart, Timothy K.; Gresham, Stephanie L.; Lawrence, Ron M.; Brigandi, Richard A.; Gomez-delas-Heras, Federico M.; Gargallo, Domingo V.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1408-1415</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-tert-Bu isoquine (4) (GSK369796) is a 4-aminoquinoline drug candidate selected and developed as part of a public-private partnership between academics at Liverpool, MMV, and GSK pharmaceuticals.  This mol. was rationally designed based on chem., toxicol., pharmacokinetic, and pharmacodynamic considerations and was selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo.  The optimized chem. delivered this novel synthetic quinoline in a two-step procedure from cheap and readily available starting materials.  The mol. has a full industry std. preclin. development program allowing first into humans to proceed.  Employing chloroquine (1) and amodiaquine (2) as comparator mols. in the preclin. plan, the first preclin. dossier of pharmacokinetic, toxicity, and safety pharmacol. has also been established for the 4-aminoquinoline antimalarial class.  These studies have revealed preclin. liabilities that have never translated into the human experience.  This has resulted in the availability of crit. information to other drug development teams interested in developing antimalarials within this class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD8p09GaCH5bVg90H21EOLACvtfcHk0ljAmdHjwS3NHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvFShsbo%253D&md5=d08b37c74a7393eaefb5b86fd5a265dc</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm8012618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012618%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DShone%26aufirst%3DA.%2BE.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DStocks%26aufirst%3DP.%2BA.%26aulast%3DBiagini%26aufirst%3DG.%2BA.%26aulast%3DBray%26aufirst%3DP.%2BG.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DBerry%26aufirst%3DN.%26aulast%3DWinstanley%26aufirst%3DP.%2BA.%26aulast%3DMukhtar%26aufirst%3DA.%26aulast%3DBonar-Law%26aufirst%3DR.%26aulast%3DHindley%26aufirst%3DS.%26aulast%3DBambal%26aufirst%3DR.%2BB.%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DBates%26aufirst%3DM.%26aulast%3DHart%26aufirst%3DT.%2BK.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DBrigandi%26aufirst%3DR.%2BA.%26aulast%3DGomez-delas-Heras%26aufirst%3DF.%2BM.%26aulast%3DGargallo%26aufirst%3DD.%2BV.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DCandidate%2520selection%2520and%2520preclinical%2520evaluation%2520of%2520N-tert-butyl%2520isoquine%2520%2528GSK369796%2529%252C%2520an%2520affordable%2520and%2520effective%25204-aminoquinoline%2520antimalarial%2520for%2520the%252021st%2520century%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1408%26epage%3D1415%26doi%3D10.1021%2Fjm8012618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspnes, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-McLeod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlynn, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autry, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnette, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span> <span> </span><span class="NLM_article-title">Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">6071</span>– <span class="NLM_lpage">6077</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2008.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18951788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6071-6077&author=D.+P.+Walkerauthor=F.+C.+Biauthor=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=S.+X.+Zhaoauthor=J.+R.+Sogliaauthor=G.+E.+Aspnesauthor=D.+W.+Kungauthor=J.+Klug-McLeodauthor=M.+P.+Zawistoskiauthor=M.+A.+McGlynnauthor=R.+Oliverauthor=M.+Dunnauthor=J.+C.+Liauthor=D.+T.+Richterauthor=B.+A.+Cooperauthor=J.+C.+Kathauthor=C.+A.+Hulfordauthor=C.+L.+Autryauthor=M.+J.+Luzzioauthor=E.+J.+Ungauthor=W.+G.+Robertsauthor=P.+C.+Bonnetteauthor=L.+Buckbinderauthor=A.+Mistryauthor=M.+C.+Grifforauthor=S.+Hanauthor=A.+Guzman-Perez&title=Trifluoromethylpyrimidine-based+inhibitors+of+proline-rich+tyrosine+kinase+2+%28PYK2%29%3A+structure-activity+relationships+and+strategies+for+the+elimination+of+reactive+metabolite+formation&doi=10.1016%2Fj.bmcl.2008.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure-activity relationships and strategies for the elimination of reactive metabolite formation</span></div><div class="casAuthors">Walker, Daniel P.; Bi, F. Christopher; Kalgutkar, Amit S.; Bauman, Jonathan N.; Zhao, Sabrina X.; Soglia, John R.; Aspnes, Gary E.; Kung, Daniel W.; Klug-McLeod, Jacquelyn; Zawistoski, Michael P.; McGlynn, Molly A.; Oliver, Robert; Dunn, Matthew; Li, Jian-Cheng; Richter, Daniel T.; Cooper, Beth A.; Kath, John C.; Hulford, Catherine A.; Autry, Christopher L.; Luzzio, Michael J.; Ung, Ethan J.; Roberts, W. Gregory; Bonnette, Peter C.; Buckbinder, Leonard; Mistry, Anil; Griffor, Matthew C.; Han, Seungil; Guzman-Perez, Angel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6071-6077</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis and SAR for a series of diaminopyrimidines as PYK2 inhibitors are described.  Using a combination of library and traditional medicinal chem. techniques, a FAK-selective chem. series was transformed into compds. possessing good PYK2 potency and 10- to 20-fold selectivity against FAK.  Subsequent studies found that the majority of the compds. were pos. in a reactive metabolite assay, an indicator for potential toxicol. liabilities.  Based on the proposed mechanism for bioactivation, as well as a combination of structure-based drug design and traditional medicinal chem. techniques, a follow-up series of PYK2 inhibitors was identified that maintained PYK2 potency, FAK selectivity and HLM stability, yet were neg. in the RM assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobVdPk7MYsA7Vg90H21EOLACvtfcHk0lgz17zeNLRaqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhsbbN&md5=614dba2d30b2f139562b7d3c6575d55e</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DAspnes%26aufirst%3DG.%2BE.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DKlug-McLeod%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DMcGlynn%26aufirst%3DM.%2BA.%26aulast%3DOliver%26aufirst%3DR.%26aulast%3DDunn%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BC.%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DB.%2BA.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DHulford%26aufirst%3DC.%2BA.%26aulast%3DAutry%26aufirst%3DC.%2BL.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DUng%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DBonnette%26aufirst%3DP.%2BC.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DMistry%26aufirst%3DA.%26aulast%3DGriffor%26aufirst%3DM.%2BC.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26atitle%3DTrifluoromethylpyrimidine-based%2520inhibitors%2520of%2520proline-rich%2520tyrosine%2520kinase%25202%2520%2528PYK2%2529%253A%2520structure-activity%2520relationships%2520and%2520strategies%2520for%2520the%2520elimination%2520of%2520reactive%2520metabolite%2520formation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6071%26epage%3D6077%26doi%3D10.1016%2Fj.bmcl.2008.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafalski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditta, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deskus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanitis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4161</span>– <span class="NLM_lpage">4172</span>, <span class="refDoi"> DOI: 10.1021/jm900302q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900302q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXns1Ogurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4161-4172&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=M.+Rafalskiauthor=W.+D.+Schmitzauthor=A.+B.+Brennerauthor=D.+J.+Denhartauthor=J.+L.+Dittaauthor=J.+A.+Deskusauthor=E.+W.+Yueauthor=A.+G.+Arvanitisauthor=S.+Lelasauthor=Y.+W.+Liauthor=T.+F.+Molskiauthor=H.+Wongauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=J.+Liauthor=N.+J.+Lodgeauthor=R.+Zaczekauthor=A.+P.+Combsauthor=R.+E.+Olsonauthor=R.+J.+Mattsonauthor=J.+J.+Bronsonauthor=J.+E.+Macor&title=In+vitro+intrinsic+clearance-based+optimization+of+N3-phenylpyrazinones+as+corticotropin-releasing+factor-1+%28CRF1%29+receptor+antagonists&doi=10.1021%2Fjm900302q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Intrinsic Clearance-Based Optimization of N3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF1) Receptor Antagonists</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Rafalski, Maria; Schmitz, William D.; Brenner, Allison B.; Denhart, Derek J.; Ditta, Jonathan L.; Deskus, Jeffrey A.; Yue, Eddy W.; Arvanitis, Argyrios G.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Wong, Harvey; Grace, James E.; Lentz, Kimberley A.; Li, Jianqing; Lodge, Nicholas J.; Zaczek, Robert; Combs, Andrew P.; Olson, Richard E.; Mattson, Ronald J.; Bronson, Joanne J.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4161-4172</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of pyrazinone-based heterocycles was identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists.  Selected compds., e.g. I, proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal.  In this article, an in vitro intrinsic clearance-based approach is described to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metab. were identified by incubation with human liver microsomes.  It was found that the rate of metab. could be decreased by incorporation of appropriate substituents at the primary sites of metab.  This led to the discovery of I, a highly potent (IC50 = 1.0 nM) and selective CRF1 receptor antagonist with good oral bioavailability (F = 52%) in rats and efficacy in the defensive withdrawal anxiety test in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSxtlvZCt7vrVg90H21EOLACvtfcHk0lgz17zeNLRaqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXns1Ogurk%253D&md5=9ed4f4c2001a832dcb9fdcceb6ce0067</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjm900302q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900302q%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DRafalski%26aufirst%3DM.%26aulast%3DSchmitz%26aufirst%3DW.%2BD.%26aulast%3DBrenner%26aufirst%3DA.%2BB.%26aulast%3DDenhart%26aufirst%3DD.%2BJ.%26aulast%3DDitta%26aufirst%3DJ.%2BL.%26aulast%3DDeskus%26aufirst%3DJ.%2BA.%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DArvanitis%26aufirst%3DA.%2BG.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26aulast%3DOlson%26aufirst%3DR.%2BE.%26aulast%3DMattson%26aufirst%3DR.%2BJ.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DIn%2520vitro%2520intrinsic%2520clearance-based%2520optimization%2520of%2520N3-phenylpyrazinones%2520as%2520corticotropin-releasing%2520factor-1%2520%2528CRF1%2529%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4161%26epage%3D4172%26doi%3D10.1021%2Fjm900302q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deskus, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ditta, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnananthan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian-Cutrone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schartman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span> <span> </span><span class="NLM_article-title">A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7653</span>– <span class="NLM_lpage">7668</span>, <span class="refDoi"> DOI: 10.1021/jm900716v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900716v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7653-7668&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=X.+Zhuoauthor=R.+J.+Mattsonauthor=D.+J.+Denhartauthor=J.+A.+Deskusauthor=V.+M.+Vrudhulaauthor=S.+Panauthor=J.+L.+Dittaauthor=Y.+Z.+Shuauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=S.+Lelasauthor=Y.+W.+Liauthor=T.+F.+Molskiauthor=S.+Krishnananthanauthor=H.+Wongauthor=J.+Qian-Cutroneauthor=R.+Schartmanauthor=R.+Dentonauthor=N.+J.+Lodgeauthor=R.+Zaczekauthor=J.+E.+Macorauthor=J.+J.+Bronson&title=A+strategy+to+minimize+reactive+metabolite+formation%3A+discovery+of+%28S%29-4-%281-cyclopropyl-2-methoxyethyl%29-6-%5B6-%28difluoromethoxy%29-2%2C5-dimethylpyridin-3-ylamino%5D-5-oxo-4%2C5-dihydropyrazine-2-carbonitrile+as+a+potent%2C+orally+bioavailable+corticotropin-releasing+factor-1+receptor+antagonist&doi=10.1021%2Fjm900716v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Zhuo, Xiaoliang; Mattson, Ronald J.; Denhart, Derek J.; Deskus, Jeffrey A.; Vrudhula, Vivekananda M.; Pan, Senliang; Ditta, Jonathan L.; Shu, Yue-Zhong; Grace, James E.; Lentz, Kimberley A.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Krishnananthan, Subramaniam; Wong, Henry; Qian-Cutrone, Jingfang; Schartman, Richard; Denton, Rex; Lodge, Nicholas J.; Zaczek, Robert; Macor, John E.; Bronson, Joanne J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7653-7668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Detailed metabolic characterization of 8 (VIII), an earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF1) receptor antagonist, revealed that this compd. formed significant levels of reactive metabolites, as measured by in vivo and in vitro biotransformation studies.  This was of particular concern due to the body of evidence suggesting that reactive metabolites may be involved in idiosyncratic drug reactions.  Further optimization of the structure-activity relationships and in vivo properties of pyrazinone-based CRF1 receptor antagonists and studies to assess the formation of reactive metabolites led to the discovery of 19e (XIX), a high affinity CRF1 receptor antagonist (IC50 = 0.86 nM) wherein GSH adducts were estd. to be only 0.1% of the total amt. of drug-related material excreted through bile and urine, indicating low levels of reactive metabolite formation in vivo.  A novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group in XIX contributed to the potency and improved in vivo properties of this compd. and related analogs.  XIX had excellent pharmacokinetic properties in rats and dogs and showed efficacy in the defensive withdrawal model of anxiety in rats.  The lowest efficacious dose was 1.8 mg/kg.  The results of a two-week rat safety study with XIX indicated that this compd. was well-tolerated.  Safety: authors caution safety in conversion of 2-amino-3-methylpyridine to 3-methyl-5-nitropyridin-2-ol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXgjp_vZ9dU7Vg90H21EOLACvtfcHk0lghG-fYz6bIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOnsrzM&md5=b340d132071b98a2b488952c2bcef4e5</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm900716v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900716v%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DMattson%26aufirst%3DR.%2BJ.%26aulast%3DDenhart%26aufirst%3DD.%2BJ.%26aulast%3DDeskus%26aufirst%3DJ.%2BA.%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DDitta%26aufirst%3DJ.%2BL.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DLelas%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DQian-Cutrone%26aufirst%3DJ.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520strategy%2520to%2520minimize%2520reactive%2520metabolite%2520formation%253A%2520discovery%2520of%2520%2528S%2529-4-%25281-cyclopropyl-2-methoxyethyl%2529-6-%255B6-%2528difluoromethoxy%2529-2%252C5-dimethylpyridin-3-ylamino%255D-5-oxo-4%252C5-dihydropyrazine-2-carbonitrile%2520as%2520a%2520potent%252C%2520orally%2520bioavailable%2520corticotropin-releasing%2520factor-1%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7653%26epage%3D7668%26doi%3D10.1021%2Fjm900716v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.109.028910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19833844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=5-15&author=X.+Zhuoauthor=R.+A.+Hartzauthor=J.+J.+Bronsonauthor=H.+Wongauthor=V.+T.+Ahujaauthor=V.+M.+Vrudhulaauthor=J.+E.+Leetauthor=S.+Huangauthor=J.+E.+Macorauthor=Y.+Z.+Shu&title=Comparative+biotransformation+of+pyrazinone-containing+corticotropin-releasing+factor+receptor-1+antagonists%3A+minimizing+the+reactive+metabolite+formation&doi=10.1124%2Fdmd.109.028910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation</span></div><div class="casAuthors">Zhuo, Xiaoliang; Hartz, Richard A.; Bronson, Joanne J.; Wong, Harvey; Ahuja, Vijay T.; Vrudhula, Vivekananda M.; Leet, John E.; Huang, Stella; Macor, John E.; Shu, Yue-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(S)-5-Chloro-1-(1-cyclopropylethyl)-3-(2,6-dichloro-4-(trifluoromethyl)-phenylamino)pyrazin-2(1H)-one (BMS-665053), a pyrazinone-contg. compd., is a potent and selective antagonist of corticotropin-releasing factor receptor-1 (CRF-R1) that showed efficacy in the defensive withdrawal model for anxiety in rats, suggesting its use as a potential treatment for anxiety and depression.  In vitro metab. studies of BMS-665053 in rat and human liver microsomes revealed cytochrome P 450-mediated oxidn. of the pyrazinone moiety, followed by ring opening, as the primary metabolic pathway.  Detection of a series of GSH adducts in trapping expts. suggested the formation of a reactive intermediate, probably as a result of epoxidn. of the pyrazinone moiety.  In addn., BMS-665053 (20 mg/kg i.v.) underwent extensive metab. in bile duct-cannulated (BDC) rats.  The major drug-related materials in rat plasma were the pyrazinone oxidn. products.  In rat bile and urine (0-7 h), only a trace amt. of the parent drug was recovered, whereas significant levels of the pyrazinone epoxide-derived metabolites and GSH-related conjugates were detected.  Further evidence suggested that GSH-related conjugates also formed at the dichloroarylamine moiety possibly via an epoxide or a quinone imine intermediate.  Other major metabolites in BDC rat bile and urine included glucuronide conjugates.  To reduce potential liability due to metabolic activation of BMS-665053, a no. of pyrazinone analogs with different substituents were synthesized and investigated for reactive metabolite formation, leading to the discovery of a CRF-R1 antagonist with diminished in vitro metabolic activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKSmCnHe221LVg90H21EOLACvtfcHk0lghG-fYz6bIvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1aru7fE&md5=ce4d9c5f99f96cbc018968130b068e81</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028910%26sid%3Dliteratum%253Aachs%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26atitle%3DComparative%2520biotransformation%2520of%2520pyrazinone-containing%2520corticotropin-releasing%2520factor%2520receptor-1%2520antagonists%253A%2520minimizing%2520the%2520reactive%2520metabolite%2520formation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D5%26epage%3D15%26doi%3D10.1124%2Fdmd.109.028910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF-1) receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1890</span>– <span class="NLM_lpage">1894</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.01.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20176478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFGltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1890-1894&author=R.+A.+Hartzauthor=V.+T.+Ahujaauthor=W.+D.+Schmitzauthor=T.+F.+Molskiauthor=G.+K.+Mattsonauthor=N.+J.+Lodgeauthor=J.+J.+Bronsonauthor=J.+E.+Macor&title=Synthesis+and+structure-activity+relationships+of+N3-pyridylpyrazinones+as+corticotropin-releasing+factor-1+%28CRF-1%29+receptor+antagonists&doi=10.1016%2Fj.bmcl.2010.01.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of N 3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists</span></div><div class="casAuthors">Hartz, Richard A.; Ahuja, Vijay T.; Schmitz, William D.; Molski, Thaddeus F.; Mattson, Gail K.; Lodge, Nicholas J.; Bronson, Joanne J.; Macor, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1890-1894</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N 3-pyridylpyrazinones was investigated as corticotropin-releasing factor-1 receptor antagonists.  It was obsd. that the binding affinity of analogs contg. a pyridyl group was influenced not only by the substitution pattern on the pyridyl group, but also by the pK a of the pyridyl nitrogen.  Analogs contg. a novel 6-(difluoromethoxy)-2,5-dimethylpyridin-3-amine group e. g., I were among the most potent N3-pyridylpyrazinones synthesized.  The synthesis and SAR of N 3-pyridylpyrazinones is described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAinLk7idiU7Vg90H21EOLACvtfcHk0lgfrpHjXJ6rfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFGltbw%253D&md5=62d428f7fa2ac484864efb1107afafa4</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.129%26sid%3Dliteratum%253Aachs%26aulast%3DHartz%26aufirst%3DR.%2BA.%26aulast%3DAhuja%26aufirst%3DV.%2BT.%26aulast%3DSchmitz%26aufirst%3DW.%2BD.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DMattson%26aufirst%3DG.%2BK.%26aulast%3DLodge%26aufirst%3DN.%2BJ.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520N3-pyridylpyrazinones%2520as%2520corticotropin-releasing%2520factor-1%2520%2528CRF-1%2529%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1890%26epage%3D1894%26doi%3D10.1016%2Fj.bmcl.2010.01.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagmann, W. K.</span></span> <span> </span><span class="NLM_article-title">The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity</span>. <i>Arch. Pharm. (Weinheim, Ger.)</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1002/ardp.200700255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fardp.200700255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18574849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFaksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=405-411&author=W.+K.+Hagmann&title=The+discovery+of+taranabant%2C+a+selective+cannabinoid-1+receptor+inverse+agonist+for+the+treatment+of+obesity&doi=10.1002%2Fardp.200700255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">405-411</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The cannabinoid-1 receptor (CB1R) has emerged as one of the most important targets for the treatment of obesity.  Pioneering studies with rimonabant helped to validate animal models of food intake redn. and wt. loss and made the connection to wt. loss in the clinic.  A novel, acyclic amide was identified from a high throughput screen (HTS) of the Merck sample collection and found to be a potent and selective CB1R inhibitor.  Further optimization led to more potent compds. that were orally active in reducing food intake and wt. loss in diet-induced obese (DIO) rats.  However, many of these analogs exhibited a high potential for bioactivation and the formation of reactive intermediates and covalent protein binding.  Identification of the products of oxidative metab. guided medicinal chem. efforts to minimize the formation of these unwanted products.  These efforts resulted in the identification of the CB1R inverse agonist, taranabant, which is currently in Phase-III clin. studies for the treatment of obesity.  This mini-review will describe some of the medicinal chem. strategies that were followed from the original high throughput screen hit to the discovery of taranabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzzztvovfew7Vg90H21EOLACvtfcHk0lgfrpHjXJ6rfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFaksbs%253D&md5=2f0d6c933877c7a7502eb6677312074f</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fardp.200700255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200700255%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520discovery%2520of%2520taranabant%252C%2520a%2520selective%2520cannabinoid-1%2520receptor%2520inverse%2520agonist%2520for%2520the%2520treatment%2520of%2520obesity%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D2008%26volume%3D341%26spage%3D405%26epage%3D411%26doi%3D10.1002%2Fardp.200700255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atherton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Li.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevena, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span> <span> </span><span class="NLM_article-title">A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1954</span>– <span class="NLM_lpage">1965</span>, <span class="refDoi"> DOI: 10.1021/tx700270r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx700270r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1954-1965&author=A.+S.+Kalgutkarauthor=J.+Driscollauthor=S.+X.+Zhaoauthor=G.+S.+Walkerauthor=R.+M.+Shepardauthor=J.+R.+Sogliaauthor=J.+Athertonauthor=Li.+Yuauthor=A.+E.+Mutlibauthor=M.+J.+Munchhofauthor=L.+A.+Reiterauthor=C.+S.+Jonesauthor=J.+L.+Dotyauthor=K.+A.+Trevenaauthor=C.+L.+Shafferauthor=S.+L.+Ripp&title=A+rational+chemical+intervention+strategy+to+circumvent+bioactivation+liabilities+associated+with+a+nonpeptidyl+thrombopoietin+receptor+agonist+containing+a+2-amino-4-arylthiazole+motif&doi=10.1021%2Ftx700270r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif</span></div><div class="casAuthors">Kalgutkar, Amit S.; Driscoll, James; Zhao, Sabrina X.; Walker, Gregory S.; Shepard, Richard M.; Soglia, John R.; Atherton, James; Yu, Linning; Mutlib, Abdul E.; Munchhof, Michael J.; Reiter, Lawrence A.; Jones, Christopher S.; Doty, Johnathan L.; Trevena, Kristen A.; Shaffer, Christopher L.; Ripp, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1954-1965</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The current study examd. the bioactivation potential of a nonpeptidyl thrombopoietin receptor agonist, 1-(3-chloro-5-((4-(4-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-yl)carbamoyl)pyridine-2-yl)piperidine-4-carboxylic acid (1), contg. a 2-carboxamido-4-arylthiazole moiety in the core structure.  Toxicol. risks arising from P 450-catalyzed C4-C5 thiazole ring opening in 1 via the epoxidn. diol sequence were alleviated, since mass spectrometric anal. of human liver microsome and/or hepatocyte incubations of 1 did not reveal the formation of reactive acylthiourea and/or glyoxal metabolites, which are prototypic products derived from thiazole ring scission.  However, 4-(4-fluoro-3-(trifluoromethyl)phenyl)thiazol-2-amine (2), the product of hydrolysis of 1 in human liver microsomes, hepatocytes, and plasma, underwent oxidative bioactivation in human liver microsomes, since trapping studies with glutathione led to the formation of two conjugates derived from the addn. of the thiol nucleophile to 2 and a thiazole-S-oxide metabolite of 2.  Mass spectral fragmentation and NMR anal. indicated that the site of attachment of the glutathionyl moiety in both conjugates was the C5 position in the thiazole ring.  Based on the structures of the glutathione conjugates, two bioactivation pathways are proposed, one involving β-elimination of an initially formed hydroxylamine metabolite and the other involving direct two-electron oxidn. of the electron-rich 2-aminothiazole system to electrophilic intermediates.  This mechanistic insight into the bioactivation process allowed the development of a rational chem. intervention strategy that involved blocking the C5 position with a fluorine atom or replacing the thiazole ring with a 1,2,4-thiadiazole group.  These structural changes not only abrogated the bioactivation liability assocd. with 1 but also resulted in compds. that retained the attractive pharmacol. and pharmacokinetic attributes of the prototype agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxi1Bp9ve-TLVg90H21EOLACvtfcHk0lgfrpHjXJ6rfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhtbfM&md5=97c144c6d3c621dcef18a76b63f1806e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Ftx700270r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700270r%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DShepard%26aufirst%3DR.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DLi.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DTrevena%26aufirst%3DK.%2BA.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26atitle%3DA%2520rational%2520chemical%2520intervention%2520strategy%2520to%2520circumvent%2520bioactivation%2520liabilities%2520associated%2520with%2520a%2520nonpeptidyl%2520thrombopoietin%2520receptor%2520agonist%2520containing%2520a%25202-amino-4-arylthiazole%2520motif%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1954%26epage%3D1965%26doi%3D10.1021%2Ftx700270r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antipas, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumberg, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reim, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripp, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shavnya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeets, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevena, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4069</span>– <span class="NLM_lpage">4072</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.05.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.05.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20558059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVKntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=4069-4072&author=A.+S.+Antipasauthor=L.+C.+Blumbergauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=J.+L.+Dotyauthor=J.+Driscollauthor=T.+M.+Harrisauthor=C.+S.+Jonesauthor=S.+P.+McCurdyauthor=E.+McElroyauthor=M.+Mitton-Fryauthor=M.+J.+Munchhofauthor=D.+A.+Reimauthor=L.+A.+Reiterauthor=S.+L.+Rippauthor=A.+Shavnyaauthor=M.+I.+Smeetsauthor=K.+A.+Trevena&title=Structure-activity+relationships+and+hepatic+safety+risks+of+thiazole+agonists+of+the+thrombopoietin+receptor&doi=10.1016%2Fj.bmcl.2010.05.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor</span></div><div class="casAuthors">Antipas, Amy S.; Blumberg, Laura C.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Doty, Jonathan L.; Driscoll, James; Harris, Thomas M.; Jones, Christopher S.; McCurdy, Sandra P.; McElroy, Eric; Mitton-Fry, Mark; Munchhof, Michael J.; Reim, David A.; Reiter, Lawrence A.; Ripp, Sharon L.; Shavnya, Andrei; Smeets, Marc I.; Trevena, Kristen A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4069-4072</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">5-F substitution of an aminothiazole moiety within a series of thrombopoietin receptor agonists leads to potent agents with an improved hepatic safety profile in rodent toxicol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqkpY1JAPPtbVg90H21EOLACvtfcHk0ljytxw4OFmcUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVKntb8%253D&md5=81a4421b9190173a80c5475acf99f49d</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.05.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.05.087%26sid%3Dliteratum%253Aachs%26aulast%3DAntipas%26aufirst%3DA.%2BS.%26aulast%3DBlumberg%26aufirst%3DL.%2BC.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DDriscoll%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMcElroy%26aufirst%3DE.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DReim%26aufirst%3DD.%2BA.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DRipp%26aufirst%3DS.%2BL.%26aulast%3DShavnya%26aufirst%3DA.%26aulast%3DSmeets%26aufirst%3DM.%2BI.%26aulast%3DTrevena%26aufirst%3DK.%2BA.%26atitle%3DStructure-activity%2520relationships%2520and%2520hepatic%2520safety%2520risks%2520of%2520thiazole%2520agonists%2520of%2520the%2520thrombopoietin%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D4069%26epage%3D4072%26doi%3D10.1016%2Fj.bmcl.2010.05.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surapaneni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiles, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlhieter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: Identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screening</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1021/tx900414g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx900414g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=653-663&author=R.+Subramanianauthor=M.+R.+Leeauthor=J.+G.+Allenauthor=M.+P.+Bourbeauauthor=C.+Fotschauthor=F.+T.+Hongauthor=S.+Tadesseauthor=G.+Yaoauthor=C.+C.+Yuanauthor=S.+Surapaneniauthor=G.+L.+Skilesauthor=X.+Wangauthor=G.+E.+Wohlhieterauthor=Q.+Zengauthor=Y.+Zhouauthor=X.+Zhuauthor=C.+Li&title=Cytochrome+P450-mediated+epoxidation+of+2-aminothiazole-based+AKT+inhibitors%3A+Identification+of+novel+GSH+adducts+and+reduction+of+metabolic+activation+through+structural+changes+guided+by+in+silico+and+in+vitro+screening&doi=10.1021%2Ftx900414g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-Mediated Epoxidation of 2-Aminothiazole-Based AKT Inhibitors: Identification of Novel GSH Adducts and Reduction of Metabolic Activation through Structural Changes Guided by in Silico and in Vitro Screening</span></div><div class="casAuthors">Subramanian, Raju; Lee, Matthew R.; Allen, John G.; Bourbeau, Matthew P.; Fotsch, Christopher; Hong, Fang-Tsao; Tadesse, Seifu; Yao, Guomin; Yuan, Chester C.; Surapaneni, Sekhar; Skiles, Gary L.; Wang, Xianghong; Wohlhieter, G. Erich; Zeng, Qingping; Zhou, Yihong; Zhu, Xiaochun; Li, Chun</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-663</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A 2-aminothiazole deriv. 1 was developed as a potential inhibitor of the oncol. target AKT, a serine/threonine kinase.  When incubated in rat and human liver microsomes in the presence of NADPH, 1 underwent significant metabolic activation on its 2-aminothiazole ring, leading to substantial covalent protein binding.  Upon addn. of glutathione, covalent binding was reduced significantly, and multiple glutathione adducts were detected.  Novel metabolites from the in vitro incubates were characterized by LC-MS and NMR to discern the mechanism of bioactivation.  An in silico model was developed based on the proposed mechanism and was employed to predict bioactivation in 23 structural analogs.  The predictions were confirmed empirically for the bioactivation liability, in vitro, by LC-MS methods screening for glutathione incorporation.  New compds. were identified with a low propensity for bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4rBMHrMBdXLVg90H21EOLACvtfcHk0ljytxw4OFmcUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlKhsg%253D%253D&md5=0d995b86dff19e5f19408fffd42d0cfb</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Ftx900414g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx900414g%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DSurapaneni%26aufirst%3DS.%26aulast%3DSkiles%26aufirst%3DG.%2BL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWohlhieter%26aufirst%3DG.%2BE.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DCytochrome%2520P450-mediated%2520epoxidation%2520of%25202-aminothiazole-based%2520AKT%2520inhibitors%253A%2520Identification%2520of%2520novel%2520GSH%2520adducts%2520and%2520reduction%2520of%2520metabolic%2520activation%2520through%2520structural%2520changes%2520guided%2520by%2520in%2520silico%2520and%2520in%2520vitro%2520screening%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D653%26epage%3D663%26doi%3D10.1021%2Ftx900414g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlhieter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1652</span>– <span class="NLM_lpage">1666</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.01.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20137932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlehsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1652-1666&author=Q.+Zengauthor=M.+P.+Bourbeauauthor=G.+E.+Wohlhieterauthor=G.+Yaoauthor=H.+Monenscheinauthor=J.+T.+Riderauthor=M.+R.+Leeauthor=S.+Zhangauthor=J.+Lofgrenauthor=D.+Freemanauthor=C.+Liauthor=E.+Tomineyauthor=X.+Huangauthor=D.+Hoffmanauthor=H.+Yamaneauthor=A.+S.+Taskerauthor=C.+Dominguezauthor=V.+N.+Viswanadhanauthor=R.+Hungateauthor=X.+Zhang&title=2-Aminothiadiazole+inhibitors+of+AKT1+as+potential+cancer+therapeutics&doi=10.1016%2Fj.bmcl.2010.01.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics</span></div><div class="casAuthors">Zeng, Qingping; Bourbeau, Matthew P.; Wohlhieter, G. Erich; Yao, Guomin; Monenschein, Holger; Rider, James T.; Lee, Matthew R.; Zhang, Shiwen; Lofgren, Julie; Freeman, Daniel; Li, Chun; Tominey, Elizabeth; Huang, Xin; Hoffman, Douglas; Yamane, Harvey; Tasker, Andrew S.; Dominguez, Celia; Viswanadhan, Vellarkad N.; Hungate, Randall; Zhang, Xiaoling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1652-1656</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-aminothiadiazole of inhibitors of AKT1 is described.  SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2).  Moderate selectivity obsd. in several compds. for AKT1 vs. PKA is rationalized by X-ray crystallog. anal.  Key compds. showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1.  Compd. 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodjGAUJDiAZ7Vg90H21EOLACvtfcHk0ljytxw4OFmcUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlehsbo%253D&md5=99eddcdaddda9bc7915cb1453349a2bf</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.046%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DWohlhieter%26aufirst%3DG.%2BE.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DRider%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTominey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3D2-Aminothiadiazole%2520inhibitors%2520of%2520AKT1%2520as%2520potential%2520cancer%2520therapeutics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1652%26epage%3D1666%26doi%3D10.1016%2Fj.bmcl.2010.01.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rider, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofgren, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tominey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Azole-based inhibitors of AKT/PKB for the treatment of cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1559</span>– <span class="NLM_lpage">1564</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2010.01.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20137943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlehs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1559-1564&author=Q.+Zengauthor=J.+G.+Allenauthor=M.+P.+Bourbeauauthor=X.+Wangauthor=G.+Yaoauthor=S.+Tadesseauthor=J.+T.+Riderauthor=C.+C.+Yuanauthor=F.+T.+Hongauthor=M.+R.+Leeauthor=S.+Zhangauthor=J.+A.+Lofgrenauthor=D.+J.+Freemanauthor=S.+Yangauthor=C.+Liauthor=E.+Tomineyauthor=X.+Huangauthor=D.+Hoffmanauthor=H.+K.+Yamaneauthor=C.+Fotschauthor=C.+Dominguezauthor=R.+Hungateauthor=X.+Zhang&title=Azole-based+inhibitors+of+AKT%2FPKB+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmcl.2010.01.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Azole-based inhibitors of AKT/PKB for the treatment of cancer</span></div><div class="casAuthors">Zeng, Qingping; Allen, John G.; Bourbeau, Matthew P.; Wang, Xianghong; Yao, Guomin; Tadesse, Seifu; Rider, James T.; Yuan, Chester C.; Hong, Fang-Tsao; Lee, Matthew R.; Zhang, Shiwen; Lofgren, Julie A.; Freeman, Daniel J.; Yang, Suijin; Li, Chun; Tominey, Elizabeth; Huang, Xin; Hoffman, Douglas; Yamane, Harvey K.; Fotsch, Christopher; Dominguez, Celia; Hungate, Randall; Zhang, Xiaoling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1559-1564</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Through a combination of screening and structure-based rational design, a series of N1-(5-(heterocyclyl)-thiazol-2-yl)-3-(4-trifluoromethylphenyl)-1,2-propanediamines, e.g., I were discovered and developed into potent ATP competitive inhibitors of AKT.  Studies of linker strand-binding adenine isosteres identified SAR trends in potency and selectivity that were consistent with binding interactions obsd. in structures of the inhibitors bound to AKT1 and to the counter-screening target PKA.  One compd. was shown to have acceptable pharmacokinetic properties and to be a potent inhibitor of AKT signaling and of in vivo xenograft tumor growth in a preclin. model of glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFp-8a3DxypLVg90H21EOLACvtfcHk0lgfUYs8rSZqIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlehs7w%253D&md5=1e17024d22710486ae8cedb1a4427731</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.067%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DAllen%26aufirst%3DJ.%2BG.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DRider%26aufirst%3DJ.%2BT.%26aulast%3DYuan%26aufirst%3DC.%2BC.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%2BA.%26aulast%3DFreeman%26aufirst%3DD.%2BJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTominey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DYamane%26aufirst%3DH.%2BK.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DAzole-based%2520inhibitors%2520of%2520AKT%252FPKB%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1559%26epage%3D1564%26doi%3D10.1016%2Fj.bmcl.2010.01.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarabu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzarro, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorozniak, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haynes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchings, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kester, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahaney, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pignatello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tengi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimsby, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of piragliatin – first glucokinase activator studied in type 2 diabetic patients</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7021</span>– <span class="NLM_lpage">7036</span>, <span class="refDoi"> DOI: 10.1021/jm3008689</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3008689" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7021-7036&author=R.+Sarabuauthor=F.+T.+Bizzarroauthor=W.+L.+Corbettauthor=M.+T.+Dvorozniakauthor=W.+Gengauthor=J.+F.+Grippoauthor=N.+E.+Haynesauthor=S.+Hutchingsauthor=L.+Garofaloauthor=K.+R.+Guertinauthor=D.+W.+Hilliardauthor=M.+Kabatauthor=R.+F.+Kesterauthor=W.+Kaauthor=Z.+Liangauthor=P.+E.+Mahaneyauthor=L.+Marcusauthor=F.+M.+Matschinskyauthor=D.+Mooreauthor=J.+Rachaauthor=R.+Radinovauthor=Y.+Renauthor=L.+Qiauthor=M.+Pignatelloauthor=C.+L.+Spenceauthor=T.+Steeleauthor=J.+Tengiauthor=J.+Grimsby&title=Discovery+of+piragliatin+%E2%80%93+first+glucokinase+activator+studied+in+type+2+diabetic+patients&doi=10.1021%2Fjm3008689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Piragliatin-First Glucokinase Activator Studied in Type 2 Diabetic Patients</span></div><div class="casAuthors">Sarabu, Ramakanth; Bizzarro, Fred T.; Corbett, Wendy L.; Dvorozniak, Mark T.; Geng, Wanping; Grippo, Joseph F.; Haynes, Nancy-Ellen; Hutchings, Stanley; Garofalo, Lisa; Guertin, Kevin R.; Hilliard, Darryl W.; Kabat, Marek; Kester, Robert F.; Ka, Wang; Liang, Zhenmin; Mahaney, Paige E.; Marcus, Linda; Matschinsky, Franz M.; Moore, David; Racha, Jagdish; Radinov, Roumen; Ren, Yi; Qi, Lida; Pignatello, Michael; Spence, Cheryl L.; Steele, Thomas; Tengi, John; Grimsby, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7021-7036</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized.  Compd. 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicol. studies.  We hypothesized that the hepatic lipidosis was due to the structure-based toxicity and later established that it was due to the formation of a thiourea metabolite, 2.  Subsequent SAR studies of 1 led to the identification of a pyrazine-based lead analog 3, lacking the thiazole moiety.  In vivo metabolite identification studies, followed by the independent synthesis and profiling of the cyclopentyl keto- and hydroxyl- metabolites of 3, led to the selection of piragliatin, 4, as the clin. lead.  Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFOz_zcuFq8rVg90H21EOLACvtfcHk0lgfUYs8rSZqIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7rM&md5=318ec25d2fd83b5e331622fd81219564</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm3008689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008689%26sid%3Dliteratum%253Aachs%26aulast%3DSarabu%26aufirst%3DR.%26aulast%3DBizzarro%26aufirst%3DF.%2BT.%26aulast%3DCorbett%26aufirst%3DW.%2BL.%26aulast%3DDvorozniak%26aufirst%3DM.%2BT.%26aulast%3DGeng%26aufirst%3DW.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DHaynes%26aufirst%3DN.%2BE.%26aulast%3DHutchings%26aufirst%3DS.%26aulast%3DGarofalo%26aufirst%3DL.%26aulast%3DGuertin%26aufirst%3DK.%2BR.%26aulast%3DHilliard%26aufirst%3DD.%2BW.%26aulast%3DKabat%26aufirst%3DM.%26aulast%3DKester%26aufirst%3DR.%2BF.%26aulast%3DKa%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DZ.%26aulast%3DMahaney%26aufirst%3DP.%2BE.%26aulast%3DMarcus%26aufirst%3DL.%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26aulast%3DMoore%26aufirst%3DD.%26aulast%3DRacha%26aufirst%3DJ.%26aulast%3DRadinov%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DL.%26aulast%3DPignatello%26aufirst%3DM.%26aulast%3DSpence%26aufirst%3DC.%2BL.%26aulast%3DSteele%26aufirst%3DT.%26aulast%3DTengi%26aufirst%3DJ.%26aulast%3DGrimsby%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520piragliatin%2520%25E2%2580%2593%2520first%2520glucokinase%2520activator%2520studied%2520in%2520type%25202%2520diabetic%2520patients%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7021%26epage%3D7036%26doi%3D10.1021%2Fjm3008689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuklish, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czeskis, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luffer-Atlas, D.</span></span> <span> </span><span class="NLM_article-title">Identification and mitigation of reactive metabolites of 2-aminoimidazole-containing microsomal prostaglandin E synthase-1 inhibitors terminated due to clinical drug-induced liver injury</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2041</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2041-2051&author=B.+H.+Normanauthor=M.+J.+Fisherauthor=M.+A.+Schifflerauthor=S.+L.+Kuklishauthor=N.+E.+Hughesauthor=B.+A.+Czeskisauthor=K.+C.+Cassidyauthor=T.+L.+Abrahamauthor=J.+J.+Albertsauthor=D.+Luffer-Atlas&title=Identification+and+mitigation+of+reactive+metabolites+of+2-aminoimidazole-containing+microsomal+prostaglandin+E+synthase-1+inhibitors+terminated+due+to+clinical+drug-induced+liver+injury&doi=10.1021%2Facs.jmedchem.7b01806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury</span></div><div class="casAuthors">Norman, Bryan H.; Fisher, Matthew J.; Schiffler, Matthew A.; Kuklish, Steven L.; Hughes, Norman E.; Czeskis, Boris A.; Cassidy, Kenneth C.; Abraham, Trent L.; Alberts, Jeffrey J.; Luffer-Atlas, Debra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2041-2051</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans.  We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation.  These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYz_L4vs5v2LVg90H21EOLACvtfcHk0lgtHMxXm-2uvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2gtbY%253D&md5=e4e9f4fac1cae1af730b997dcf663d21</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01806%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DM.%2BJ.%26aulast%3DSchiffler%26aufirst%3DM.%2BA.%26aulast%3DKuklish%26aufirst%3DS.%2BL.%26aulast%3DHughes%26aufirst%3DN.%2BE.%26aulast%3DCzeskis%26aufirst%3DB.%2BA.%26aulast%3DCassidy%26aufirst%3DK.%2BC.%26aulast%3DAbraham%26aufirst%3DT.%2BL.%26aulast%3DAlberts%26aufirst%3DJ.%2BJ.%26aulast%3DLuffer-Atlas%26aufirst%3DD.%26atitle%3DIdentification%2520and%2520mitigation%2520of%2520reactive%2520metabolites%2520of%25202-aminoimidazole-containing%2520microsomal%2520prostaglandin%2520E%2520synthase-1%2520inhibitors%2520terminated%2520due%2520to%2520clinical%2520drug-induced%2520liver%2520injury%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2041%26epage%3D2051%26doi%3D10.1021%2Facs.jmedchem.7b01806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phipps, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNearney, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landschulz, W.</span></span> <span> </span><span class="NLM_article-title">Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1111/bcp.13423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fbcp.13423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Shug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=179-188&author=Y.+Jinauthor=A.+Regevauthor=J.+Kamauthor=K.+Phippsauthor=C.+Smithauthor=J.+Henckauthor=K.+Campanaleauthor=L.+Huauthor=D.+G.+Hallauthor=X.+Y.+Yangauthor=M.+Nakanoauthor=T.+A.+McNearneyauthor=J.+Uetrechtauthor=W.+Landschulz&title=Dose-dependent+acute+liver+injury+with+hypersensitivity+features+in+humans+due+to+a+novel+microsomal+prostaglandin+E+synthase+1+inhibitor&doi=10.1111%2Fbcp.13423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor</span></div><div class="casAuthors">Jin, Yan; Regev, Arie; Kam, Jeanelle; Phipps, Krista; Smith, Claire; Henck, Judith; Campanale, Kristina; Hu, Leijun; Hall, D. Greg; Yang, Xiao Yan; Nakano, Masako; McNearney, Terry Ann; Uetrecht, Jack; Landschulz, William</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : LY3031207, a novel microsomal prostaglandin E synthase 1 inhibitor, was evaluated in a multiple ascending dose study after nonclin. toxicol. studies and a single ascending dose study demonstrated an acceptable toxicity, safety and tolerability profile.  Methods : Healthy subjects were randomized to receive LY3031207 (25, 75 and 275 mg), placebo or celecoxib (400 mg) once daily for 28 days.  The safety, tolerability and pharmacokinetic and pharmacodynamic profiles of LY3031207 were evaluated.  Results : The study was terminated when two subjects experienced drug-induced liver injury (DILI) after they had received 225 mg LY3031207 for 19 days.  Liver biopsy from these subjects revealed acute liver injury with eosinophilic infiltration.  Four addnl. DILI cases were identified after LY3031207 dosing had been stopped.  All six DILI cases shared unique presentations of hepatocellular injury with hypersensitivity features and demonstrated a steep dose-dependent trend.  Prompt discontinuation of the study drug and supportive medical care resulted in full recovery.  Metabolites from metabolic activation of the imidazole ring were obsd. in plasma and urine samples from all subjects randomized to LY3031207 dosing.  Conclusions : This study emphasized the importance of careful safety monitoring and serious adverse events management in phase I trials.  Metabolic activation of the imidazole ring may be involved in the development of hepatotoxicity of LY3031207.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg0xW88KU4LVg90H21EOLACvtfcHk0lgtHMxXm-2uvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Shug%253D%253D&md5=d57e0853ca828b7f02b613aea72497f1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13423%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DY.%26aulast%3DRegev%26aufirst%3DA.%26aulast%3DKam%26aufirst%3DJ.%26aulast%3DPhipps%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DHenck%26aufirst%3DJ.%26aulast%3DCampanale%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHall%26aufirst%3DD.%2BG.%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DMcNearney%26aufirst%3DT.%2BA.%26aulast%3DUetrecht%26aufirst%3DJ.%26aulast%3DLandschulz%26aufirst%3DW.%26atitle%3DDose-dependent%2520acute%2520liver%2520injury%2520with%2520hypersensitivity%2520features%2520in%2520humans%2520due%2520to%2520a%2520novel%2520microsomal%2520prostaglandin%2520E%2520synthase%25201%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D179%26epage%3D188%26doi%3D10.1111%2Fbcp.13423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffing, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vage, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lame, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coelho, R. V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildknegt, K.</span></span> <span> </span><span class="NLM_article-title">Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine 2C receptor agonist for the treatment of obesity: role of metabolic activation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">848</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.013649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.106.013649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=17344339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=848-858&author=A.+S.+Kalgutkarauthor=D.+K.+Dalvieauthor=J.+Aubrechtauthor=E.+B.+Smithauthor=S.+L.+Coffingauthor=J.+R.+Cheungauthor=C.+Vageauthor=M.+E.+Lameauthor=P.+Chiangauthor=K.+F.+McClureauthor=T.+S.+Maurerauthor=R.+V.+Coelhoauthor=V.+F.+Solimanauthor=K.+Schildknegt&title=Genotoxicity+of+2-%283-chlorobenzyloxy%29-6-%28piperazinyl%29pyrazine%2C+a+novel+5-hydroxytryptamine+2C+receptor+agonist+for+the+treatment+of+obesity%3A+role+of+metabolic+activation&doi=10.1124%2Fdmd.106.013649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2C receptor agonist for the treatment of obesity: role of metabolic activation</span></div><div class="casAuthors">Kalgutkar, Amit S.; Dalvie, Deepak K.; Aubrecht, Jiri; Smith, Evan B.; Coffing, Stephanie L.; Cheung, Jennifer R.; Vage, Chandra; Lame, Mary E.; Chiang, Phoebe; McClure, Kim F.; Maurer, Tristan S.; Coelho, Richard V., Jr.; Soliman, Victor F.; Schildknegt, Klaas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">848-858</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">2-(3-Chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine is a potent and selective 5-HT2C agonist that exhibits dose-dependent inhibition of food intake and redn. in body wt. in rats, making it an attractive candidate for treatment of obesity.  However, examn. of the genotoxicity potential of the compd. in the Salmonella Ames assay using tester strains TA98, TA100, TA1535, and TA1537 revealed a metab. (rat S9/NADPH)- and dose-dependent increase of reverse mutations in strains TA100 and TA1537.  The increase in reverse mutations was attenuated upon coincubation with methoxylamine and glutathione.  The irreversible and concn.-dependent incorporation of radioactivity in calf thymus DNA after incubations with [14C] labeled compd. in the presence of rat S9/NADPH suggested that 3 was bioactivated to a reactive intermediate that covalently bound DNA.  In vitro metab. studies on the compd. with rat S9/NADPH in the presence of methoxylamine and cyanide led to the detection of amine and cyano conjugates of the compd.  The mass spectrum of the amine conjugate was consistent with condensation of amine with an aldehyde metabolite derived from hydroxylation of the secondary piperazine nitrogen-α-carbon bond.  The mass spectrum of the cyano conjugate suggested a bioactivation pathway involving N-hydroxylation of the secondary piperazine nitrogen followed by two-electron oxidn. to generate an electrophilic nitrone, which reacted with cyanide.  The 3-chlorobenzyl motif in the compd. was also bioactivated via initial arom. ring hydroxylation followed by elimination to a quinone-methide species that reacted with glutathione or with the secondary piperazine ring nitrogen in 3 and its monohydroxylated metabolite(s).  The metab. studies described herein provide a mechanistic basis for the mutagenicity of the compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt51Z2dRy6lbVg90H21EOLACvtfcHk0lgtHMxXm-2uvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1ait7k%253D&md5=1103a9e22f2cee8f133dd769f8506c07</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.013649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.013649%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DCoffing%26aufirst%3DS.%2BL.%26aulast%3DCheung%26aufirst%3DJ.%2BR.%26aulast%3DVage%26aufirst%3DC.%26aulast%3DLame%26aufirst%3DM.%2BE.%26aulast%3DChiang%26aufirst%3DP.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DCoelho%26aufirst%3DR.%2BV.%26aulast%3DSoliman%26aufirst%3DV.%2BF.%26aulast%3DSchildknegt%26aufirst%3DK.%26atitle%3DGenotoxicity%2520of%25202-%25283-chlorobenzyloxy%2529-6-%2528piperazinyl%2529pyrazine%252C%2520a%2520novel%25205-hydroxytryptamine%25202C%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520obesity%253A%2520role%2520of%2520metabolic%2520activation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D848%26epage%3D858%26doi%3D10.1124%2Fdmd.106.013649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubrecht, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortina, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, J.</span></span> <span> </span><span class="NLM_article-title">Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1559</span>– <span class="NLM_lpage">1563</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2009.02.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19246199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1559-1563&author=A.+S.+Kalgutkarauthor=J.+N.+Baumanauthor=K.+F.+McClureauthor=J.+Aubrechtauthor=S.+R.+Cortinaauthor=J.+Paralkar&title=Biochemical+basis+for+differences+in+metabolism-dependent+genotoxicity+by+two+diazinylpiperazine-based+5-HT2C+receptor+agonists&doi=10.1016%2Fj.bmcl.2009.02.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists</span></div><div class="casAuthors">Kalgutkar, Amit S.; Bauman, Jonathan N.; McClure, Kim F.; Aubrecht, Jiri; Cortina, Santo R.; Paralkar, Janvi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1559-1563</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The biochem. basis for S9-dependent mutagenic response of the 5-HT2C receptor agonist and diazinylpiperazine deriv. 1 in the Salmonella Ames assay involves P 450-mediated bioactivation to DNA-reactive quinone-methide, aldehyde and nitrone intermediates.  Mechanistic information pertaining to the metab. of 1 was used in the design of diazinylpiperazine 5 to eliminate the safety liability.  While 5 was neg. in the Ames assay, the compd. retained the ability of 1 to form certain electrophilic intermediates.  Plausible hypotheses that can collectively account for the differences in mutagenic response of the two piperazine analogs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmJz1e2Q26ubVg90H21EOLACvtfcHk0li1jBpLhSR6aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSls7s%253D&md5=f30fd7936610ff123c12fe568328469e</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DBauman%26aufirst%3DJ.%2BN.%26aulast%3DMcClure%26aufirst%3DK.%2BF.%26aulast%3DAubrecht%26aufirst%3DJ.%26aulast%3DCortina%26aufirst%3DS.%2BR.%26aulast%3DParalkar%26aufirst%3DJ.%26atitle%3DBiochemical%2520basis%2520for%2520differences%2520in%2520metabolism-dependent%2520genotoxicity%2520by%2520two%2520diazinylpiperazine-based%25205-HT2C%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1559%26epage%3D1563%26doi%3D10.1016%2Fj.bmcl.2009.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensenhauser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassnick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopaul, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span> <span> </span><span class="NLM_article-title">Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A)/A(1) antagonist by minimizing bioactivation to an iminium ion reactive intermediate</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1021/tx1004437</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx1004437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1012-1030&author=H.+K.+Limauthor=J.+Chenauthor=C.+Sensenhauserauthor=K.+Cookauthor=R.+Prestonauthor=T.+Thomasauthor=B.+Shookauthor=P.+F.+Jacksonauthor=S.+Rassnickauthor=K.+Rhodesauthor=V.+Gopaulauthor=R.+Salterauthor=J.+Silvaauthor=D.+C.+Evans&title=Overcoming+the+genotoxicity+of+a+pyrrolidine+substituted+arylindenopyrimidine+as+a+potent+dual+adenosine+A%282A%29%2FA%281%29+antagonist+by+minimizing+bioactivation+to+an+iminium+ion+reactive+intermediate&doi=10.1021%2Ftx1004437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming the Genotoxicity of a Pyrrolidine Substituted Arylindenopyrimidine As a Potent Dual Adenosine A2A/A1 Antagonist by Minimizing Bioactivation to an Iminium Ion Reactive Intermediate</span></div><div class="casAuthors">Lim, Heng-Keang; Chen, Jie; Sensenhauser, Carlo; Cook, Kevin; Preston, Robert; Thomas, Tynisha; Shook, Brian; Jackson, Paul F.; Rassnick, Stefanie; Rhodes, Kenneth; Gopaul, Vedwatee; Salter, Rhys; Silva, Jose; Evans, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1012-1030</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Amino-4-phenyl-8-pyrrolidin-1-ylmethyl-indeno[1,2-d]pyrimidin-5-one (1) is a novel and potent selective dual A2A/A1 adenosine receptor antagonist from the arylindenopyrimidine series that was detd. to be genotoxic in both the Ames and Mouse Lymphoma L5178Y assays only following metabolic activation.  Compd. 1 was identified as a frame-shift mutagen in Salmonella typhimurium tester strain TA1537 as indicated by a significant dose-dependent increase in revertant colonies as compared to the vehicle control.  The metabolic activation-dependent irreversible covalent binding of radioactivity to DNA, recovery of 1 and its enamine metabolite from acid hydrolysis of covalently modified DNA, and protection of covalent binding to DNA by both cyanide ion and methoxylamine suggest that the frame-shift mutation in TA1537 strain involved covalent binding instead of simple intercalation to DNA.  Compd. 1 was bioactivated to endocyclic iminium ion, aldehyde, epoxide, and α,β-unsatd. keto reactive intermediates from the detection of cyano, oxime, and glutathione conjugates by data-dependent high resoln. accurate mass measurements.  Collision-induced dissocn. of these conjugates provided evidence for bioactivation of the pyrrolidine ring of 1.  The epoxide and α,β-unsatd. keto reactive intermediates were unlikely to cause the genotoxicity of 1 because the formation of their glutathione adducts did not ameliorate the binding of compd. related material to DNA.  Instead, the endocyclic iminium ions and amino aldehydes were likely candidates responsible for genotoxicity based on, first, the protection afforded by both cyanide ion and methoxylamine, which reduced the potential to form covalent adducts with DNA, and, second, analogs of 1 designed with low probability to form these reactive intermediates were not genotoxic.  It was concluded that 1 also had the potential to be mutagenic in humans based on observing the endocyclic iminium ion following incubation with a human liver S9 prepn. and the commensurate detection of DNA adducts.  An understanding of this genotoxicity mechanism supported an evidence-based approach to selectively modify the structure of 1 which resulted in analogs being synthesized that were devoid of a genotoxic liability.  In addn., potency and selectivity against both adenosine A2A and A1 receptors were maintained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9N__9056Cr7Vg90H21EOLACvtfcHk0li79oaRL9F60A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVGjsLc%253D&md5=ef0a49a0c0889517eb37018fe808367f</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Ftx1004437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx1004437%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSensenhauser%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DK.%26aulast%3DPreston%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DGopaul%26aufirst%3DV.%26aulast%3DSalter%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26atitle%3DOvercoming%2520the%2520genotoxicity%2520of%2520a%2520pyrrolidine%2520substituted%2520arylindenopyrimidine%2520as%2520a%2520potent%2520dual%2520adenosine%2520A%25282A%2529%252FA%25281%2529%2520antagonist%2520by%2520minimizing%2520bioactivation%2520to%2520an%2520iminium%2520ion%2520reactive%2520intermediate%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1012%26epage%3D1030%26doi%3D10.1021%2Ftx1004437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teffera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/tx049711r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx049711r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvVOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=271-276&author=G.+A.+Dossauthor=R.+R.+Millerauthor=Z.+Zhangauthor=Y.+Tefferaauthor=R.+P.+Nargundauthor=B.+Paluckiauthor=M.+K.+Parkauthor=Y.+S.+Tangauthor=D.+C.+Evansauthor=T.+A.+Baillieauthor=R.+A.+Stearns&title=Metabolic+activation+of+1%2C3-disubstituted+piperazine+derivative%3A+evidence+for+a+novel+ring+contraction+to+an+imidazoline&doi=10.1021%2Ftx049711r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Activation of a 1,3-Disubstituted Piperazine Derivative: Evidence for a Novel Ring Contraction to an Imidazoline</span></div><div class="casAuthors">Doss, George A.; Miller, Randall R.; Zhang, Zhoupeng; Teffera, Yohannes; Nargund, Ravi P.; Palucki, Brenda; Park, Min K.; Tang, Yui S.; Evans, David C.; Baillie, Thomas A.; Stearns, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-276</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MB243 (a 1,3-disubstituted piperazine) is a new, potent, and selective melanocortin receptor subtype-4 agonist with potential application in the treatment of obesity and/or erectile dysfunction.  MB243 was obsd. to covalently bind extensively to liver microsomal proteins from rats and humans.  In the presence of glutathione, two thioether adducts were detected in liver microsomal incubations by radiochromatog. and LC/MS/MS anal.  These adducts were also formed when bile duct-cannulated rats were dosed with MB243.  The two adducts were isolated, and their structures were detd. by accurate mass MS/MS and NMR analyses.  The proposed structures resulted from a novel contraction of the piperazine ring to yield a substituted imidazoline.  A mechanism is proposed, which involves an initial six electron oxidn. of the piperazine ring to form a reactive intermediate, which is trapped by glutathione.  Hydrolysis of the glutamic acid residue followed by internal aminolysis by the cysteine amino group resulted in opening of the piperazine ring, which is followed by ring closure to an imidazoline.  The resulting cysteinyl-glycine conjugate underwent subsequent hydrolysis of the glycine residue.  Understanding of the mechanism of bioactivation led to the design of MB243 analogs that exhibited reduced covalent protein binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrABeaKbaNVYrVg90H21EOLACvtfcHk0li79oaRL9F60A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvVOgsg%253D%253D&md5=4f5773527470679fe6776488b72576e4</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Ftx049711r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx049711r%26sid%3Dliteratum%253Aachs%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DPalucki%26aufirst%3DB.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DTang%26aufirst%3DY.%2BS.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26atitle%3DMetabolic%2520activation%2520of%25201%252C3-disubstituted%2520piperazine%2520derivative%253A%2520evidence%2520for%2520a%2520novel%2520ring%2520contraction%2520to%2520an%2520imidazoline%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D271%26epage%3D276%26doi%3D10.1021%2Ftx049711r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebhat, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyani, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macneil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vongs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macintyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Ploeg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2004.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15582434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKrsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=171-175&author=B.+L.+Paluckiauthor=M.+K.+Parkauthor=R.+P.+Nargundauthor=Z.+Yeauthor=I.+K.+Sebhatauthor=P.+G.+Pollardauthor=R.+N.+Kalyaniauthor=R.+Tangauthor=T.+Macneilauthor=D.+H.+Weinbergauthor=A.+Vongsauthor=C.+I.+Rosenblumauthor=G.+A.+Dossauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=Q.+Pengauthor=C.+Tamvakopoulosauthor=E.+McGowanauthor=W.+J.+Martinauthor=J.+M.+Metzgerauthor=C.+A.+Shepherdauthor=A.+M.+Strackauthor=D.+E.+Macintyreauthor=L.+H.+Van+der+Ploegauthor=A.+A.+Patchett&title=Discovery+of+%282S%29-N-%5B%281R%29-2-%5B4-cyclohexyl-4-%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5D-1-piperidinyl%5D-1-%5B%284-fluorophenyl%29methyl%5D-2-oxoethyl%5D-4-methyl-2-piperazinecarboxamide+%28MB243%29%2C+a+potent+and+selective+melanocortin+subtype-4+receptor+agonist&doi=10.1016%2Fj.bmcl.2004.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist</span></div><div class="casAuthors">Palucki, Brenda L.; Park, Min K.; Nargund, Ravi P.; Ye, Zhixiong; Sebhat, Iyassu K.; Pollard, Patrick G.; Kalyani, Rubana N.; Tang, Rui; MacNeil, Tanya; Weinberg, David H.; Vongs, Aurawan; Rosenblum, Charles I.; Doss, George A.; Miller, Randall R.; Stearns, Ralph A.; Peng, Qianping; Tamvakopoulos, Constantin; McGowan, Erin; Martin, William J.; Metzger, Joseph M.; Shepherd, Cherrie A.; Strack, Alison M.; MacIntyre, D. Euan; Van der Ploeg, Lex H. T.; Patchett, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-175</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery and optimization of substituted 2-piperazinecarboxamides as potent and selective agonists of the melanocortin subtype-4 receptor.  Further in vivo development of lead agonist, MB243, is disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNRPbn8mhx6bVg90H21EOLACvtfcHk0li79oaRL9F60A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKrsLnO&md5=3e9fd4079e3567cade8991f8134c56b2</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DPalucki%26aufirst%3DB.%2BL.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DSebhat%26aufirst%3DI.%2BK.%26aulast%3DPollard%26aufirst%3DP.%2BG.%26aulast%3DKalyani%26aufirst%3DR.%2BN.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DMacneil%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DD.%2BH.%26aulast%3DVongs%26aufirst%3DA.%26aulast%3DRosenblum%26aufirst%3DC.%2BI.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DMcGowan%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DMetzger%26aufirst%3DJ.%2BM.%26aulast%3DShepherd%26aufirst%3DC.%2BA.%26aulast%3DStrack%26aufirst%3DA.%2BM.%26aulast%3DMacintyre%26aufirst%3DD.%2BE.%26aulast%3DVan%2Bder%2BPloeg%26aufirst%3DL.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520%25282S%2529-N-%255B%25281R%2529-2-%255B4-cyclohexyl-4-%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255D-1-piperidinyl%255D-1-%255B%25284-fluorophenyl%2529methyl%255D-2-oxoethyl%255D-4-methyl-2-piperazinecarboxamide%2520%2528MB243%2529%252C%2520a%2520potent%2520and%2520selective%2520melanocortin%2520subtype-4%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D171%26epage%3D175%26doi%3D10.1016%2Fj.bmcl.2004.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacNeil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vongs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Ploeg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span> <span> </span><span class="NLM_article-title">2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1993</span>– <span class="NLM_lpage">1996</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.02.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2005.02.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15808454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVKgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1993-1996&author=B.+L.+Paluckiauthor=M.+K.+Parkauthor=R.+P.+Nargundauthor=R.+Tangauthor=T.+MacNeilauthor=D.+H.+Weinbergauthor=A.+Vongsauthor=C.+I.+Rosenblumauthor=G.+A.+Dossauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=Q.+Pengauthor=C.+Tamvakopoulosauthor=L.+H.+Van+der+Ploegauthor=A.+A.+Patchett&title=2-Piperazinecarboxamides+as+potent+and+selective+melanocortin+subtype-4+receptor+agonists&doi=10.1016%2Fj.bmcl.2005.02.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists</span></div><div class="casAuthors">Palucki, Brenda L.; Park, Min K.; Nargund, Ravi P.; Tang, Rui; MacNeil, Tanya; Weinberg, David H.; Vongs, Aurawan; Rosenblum, Charles I.; Doss, George A.; Miller, Randall R.; Stearns, Ralph A.; Peng, Qianping; Tamvakopoulos, Constantin; Van der Ploeg, Lex H. T.; Patchett, Arthur A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1993-1996</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery and optimization of substituted 2-piperazinecarboxamides as potent and selective agonists of the melanocortin subtype-4 receptor.  The 5- and 6-alkylated piperazine compds. exhibit low bioactivation potential as measured by covalent binding in microsome prepns.  The studied compds. were prepd. by multistep synthesis via alkylation of protected diamines and reductive amination/cyclization as key steps, following by coupling with piperidine carboxamide deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDGsr4-SRPobVg90H21EOLACvtfcHk0lg3Og9lqvcg_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVKgtrw%253D&md5=95f6d18d31fd8ccab9a9e650dc498bc8</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.02.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.02.068%26sid%3Dliteratum%253Aachs%26aulast%3DPalucki%26aufirst%3DB.%2BL.%26aulast%3DPark%26aufirst%3DM.%2BK.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DD.%2BH.%26aulast%3DVongs%26aufirst%3DA.%26aulast%3DRosenblum%26aufirst%3DC.%2BI.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DVan%2Bder%2BPloeg%26aufirst%3DL.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26atitle%3D2-Piperazinecarboxamides%2520as%2520potent%2520and%2520selective%2520melanocortin%2520subtype-4%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1993%26epage%3D1996%26doi%3D10.1016%2Fj.bmcl.2005.02.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palucki, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebhat, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyani, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vongs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacNeil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamvakopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strack, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Ploeg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyvratt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3501</span>– <span class="NLM_lpage">3505</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.05.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.bmcl.2005.05.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15982875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvV2gsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3501-3505&author=Z.+Yeauthor=L.+Guoauthor=K.+J.+Barakatauthor=P.+G.+Pollardauthor=B.+L.+Paluckiauthor=I.+K.+Sebhatauthor=R.+K.+Bakshiauthor=R.+Tangauthor=R.+N.+Kalyaniauthor=A.+Vongsauthor=A.+S.+Chenauthor=H.+Y.+Chenauthor=C.+I.+Rosenblumauthor=T.+MacNeilauthor=D.+H.+Weinbergauthor=Q.+Pengauthor=C.+Tamvakopoulosauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=D.+E.+Cashenauthor=W.+J.+Martinauthor=J.+M.+Metzgerauthor=A.+M.+Strackauthor=D.+E.+MacIntyreauthor=L.+H.+Van+der+Ploegauthor=A.+A.+Patchettauthor=M.+J.+Wyvrattauthor=R.+P.+Nargund&title=Discovery+and+activity+of+%281R%2C4S%2C6R%29-N-%5B%281R%29-2-%5B4-cyclohexyl-4-%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5D-1-piperidinyl%5D-1-%5B%284-fluorophenyl%29methyl%5D-2-oxoethyl%5D-2-methyl-2-azabicyclo%5B2.2.2%5Doctane-6-carboxamide+%283%2C+RY764%29%2C+a+potent+and+selective+melanocortin+subtype-4+receptor+agonist&doi=10.1016%2Fj.bmcl.2005.05.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist</span></div><div class="casAuthors">Ye, Zhixiong; Guo, Liangqin; Barakat, Khaled J.; Pollard, Patrick G.; Palucki, Brenda L.; Sebhat, Iyassu K.; Bakshi, Raman K.; Tang, Rui; Kalyani, Rubana N.; Vongs, Aurawan; Chen, Airu S.; Chen, Howard Y.; Rosenblum, Charles I.; MacNeil, Tanya; Weinberg, David H.; Peng, Qianping; Tamvakopoulos, Constantin; Miller, Randy R.; Stearns, Ralph A.; Cashen, Doreen E.; Martin, William J.; Metzger, Joseph M.; Strack, Alison M.; MacIntyre, D. Euan; Van der Ploeg, Lex H. T.; Patchett, Arthur A.; Wyvratt, Matthew J.; Nargund, Ravi P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3501-3505</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel isoquinuclidine contg. selective melanocortin subtype-4 receptor small mol. agonist (I), (RY764), is reported.  Its in vivo characterization revealed mechanism-based food intake redn. and erectile activity augmentation in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozlndIFJlSh7Vg90H21EOLACvtfcHk0lg3Og9lqvcg_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvV2gsb4%253D&md5=f5104be1da706a14bf7bbbf1ea590b01</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.109%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DBarakat%26aufirst%3DK.%2BJ.%26aulast%3DPollard%26aufirst%3DP.%2BG.%26aulast%3DPalucki%26aufirst%3DB.%2BL.%26aulast%3DSebhat%26aufirst%3DI.%2BK.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DTang%26aufirst%3DR.%26aulast%3DKalyani%26aufirst%3DR.%2BN.%26aulast%3DVongs%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DA.%2BS.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DRosenblum%26aufirst%3DC.%2BI.%26aulast%3DMacNeil%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DD.%2BH.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DTamvakopoulos%26aufirst%3DC.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DCashen%26aufirst%3DD.%2BE.%26aulast%3DMartin%26aufirst%3DW.%2BJ.%26aulast%3DMetzger%26aufirst%3DJ.%2BM.%26aulast%3DStrack%26aufirst%3DA.%2BM.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DVan%2Bder%2BPloeg%26aufirst%3DL.%2BH.%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26atitle%3DDiscovery%2520and%2520activity%2520of%2520%25281R%252C4S%252C6R%2529-N-%255B%25281R%2529-2-%255B4-cyclohexyl-4-%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255D-1-piperidinyl%255D-1-%255B%25284-fluorophenyl%2529methyl%255D-2-oxoethyl%255D-2-methyl-2-azabicyclo%255B2.2.2%255Doctane-6-carboxamide%2520%25283%252C%2520RY764%2529%252C%2520a%2520potent%2520and%2520selective%2520melanocortin%2520subtype-4%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3501%26epage%3D3505%26doi%3D10.1016%2Fj.bmcl.2005.05.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmaus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baierl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of meloxicam in animals and the relevance to humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">584</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9616195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXjvFejsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=576-584&author=U.+Buschauthor=J.+Schmidauthor=G.+Heinzelauthor=H.+Schmausauthor=J.+Baierlauthor=C.+Huberauthor=W.+Roth&title=Pharmacokinetics+of+meloxicam+in+animals+and+the+relevance+to+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of meloxicam in animals and the relevance to humans</span></div><div class="casAuthors">Busch, Ulrich; Schmid, Jochen; Heinzel, Gunther; Schmaus, Helmut; Baierl, Jurgen; Huber, Claudia; Roth, Willy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">576-584</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The pharmacokinetic profile of the new nonsteroidal anti-inflammatory drug meloxicam was investigated in mice, rats, dogs, minipigs, and baboons after administration of [14C]meloxicam.  The blood plasma concn.-time profiles for meloxicam in rats and dogs were comparable to that in humans, whereas there were marked differences between humans and mice, minipigs, and baboons.  The highest tissue concns. of meloxicam in rats and minipigs were seen in the liver and kidneys.  Low concns. of meloxicam were found in the central nervous system compared with blood plasma.  The excretion balance in minipigs resembled that in humans, with almost equal concns. being eliminated in the urine and feces.  As in humans, meloxicam circulated mainly in the form of the parent compd. in the plasma of mice, rats, dogs, minipigs, and baboons.  The main metabolites in rats, minipigs, and humans were 5'-hydroxymethyl and 5'-carboxy metabolites.  The percentage of meloxicam binding to protein was higher in rats and humans (>99%) than in other species.  The pharmacokinetic profile of meloxicam in rats most closely resembled that in humans.  Thus, reliable clin. predictions can be made from studies in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0_uazW7wy97Vg90H21EOLACvtfcHk0lgEdN9oXYk7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvFejsbs%253D&md5=bfc7fc021e479cb2dfcb4799c3e281ec</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBusch%26aufirst%3DU.%26aulast%3DSchmid%26aufirst%3DJ.%26aulast%3DHeinzel%26aufirst%3DG.%26aulast%3DSchmaus%26aufirst%3DH.%26aulast%3DBaierl%26aufirst%3DJ.%26aulast%3DHuber%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DW.%26atitle%3DPharmacokinetics%2520of%2520meloxicam%2520in%2520animals%2520and%2520the%2520relevance%2520to%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26spage%3D576%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cywin, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorcek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potocki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschantz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutts, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trummlitz, G.</span></span> <span> </span><span class="NLM_article-title">Effect of structural modification of enol-carboxamide-type nonsteroidal anti-inflammatory drugs on COX-2/COX-1 selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1021/jm9607010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9607010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK2sXhvVOjurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=980-989&author=E.+S.+Lazerauthor=C.+K.+Miaoauthor=C.+L.+Cywinauthor=R.+Sorcekauthor=H.+C.+Wongauthor=Z.+Mengauthor=I.+Potockiauthor=M.+Hoermannauthor=R.+J.+Snowauthor=M.+A.+Tschantzauthor=T.+A.+Kellyauthor=D.+W.+McNeilauthor=S.+J.+Couttsauthor=L.+Churchillauthor=A.+G.+Grahamauthor=E.+Davidauthor=P.+M.+Grobauthor=W.+Engelauthor=H.+Meierauthor=G.+Trummlitz&title=Effect+of+structural+modification+of+enol-carboxamide-type+nonsteroidal+anti-inflammatory+drugs+on+COX-2%2FCOX-1+selectivity&doi=10.1021%2Fjm9607010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Structural Modification of Enol-Carboxamide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity</span></div><div class="casAuthors">Lazer, Edward S.; Miao, Clara K.; Cywin, Charles L.; Sorcek, Ronald; Wong, Hin-Chor; Meng, Zhaoxing; Potocki, Ian; Hoermann, MaryAnn; Snow, Roger J.; Tschantz, Matt A.; Kelly, Terence A.; McNeil, Daniel W.; Coutts, Simon J.; Churchill, Laurie; Graham, Anne G.; David, Eva; Grob, Peter M.; Engel, Wolfhard; Meier, Hans; Trummlitz, Guenter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">980-989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Meloxicam, an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models.  In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs.  We therefore embarked on a study of enol-carboxamide type compds. to det. if COX-2 selectivity and potency could be dramatically improved by structural modification.  Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3-carboxamide, alteration of the N-Me substituent, and amide modification were all examd.  In addn. we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4-dioxoisoquinolines.  While a few examples were found with greater potency in the COX-2 assay, no compd. tested had a better COX-2/COX-1 selectivity profile than that of meloxicam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGKO3Zckl-8LVg90H21EOLACvtfcHk0lgEdN9oXYk7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhvVOjurw%253D&md5=99b952adf74407547babe0337aabcc48</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm9607010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9607010%26sid%3Dliteratum%253Aachs%26aulast%3DLazer%26aufirst%3DE.%2BS.%26aulast%3DMiao%26aufirst%3DC.%2BK.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26aulast%3DSorcek%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DH.%2BC.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DPotocki%26aufirst%3DI.%26aulast%3DHoermann%26aufirst%3DM.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DTschantz%26aufirst%3DM.%2BA.%26aulast%3DKelly%26aufirst%3DT.%2BA.%26aulast%3DMcNeil%26aufirst%3DD.%2BW.%26aulast%3DCoutts%26aufirst%3DS.%2BJ.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DDavid%26aufirst%3DE.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DEngel%26aufirst%3DW.%26aulast%3DMeier%26aufirst%3DH.%26aulast%3DTrummlitz%26aufirst%3DG.%26atitle%3DEffect%2520of%2520structural%2520modification%2520of%2520enol-carboxamide-type%2520nonsteroidal%2520anti-inflammatory%2520drugs%2520on%2520COX-2%252FCOX-1%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D980%26epage%3D989%26doi%3D10.1021%2Fjm9607010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baty, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renkes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boissel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, P.</span></span> <span> </span><span class="NLM_article-title">Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal</span>. <i>Gastroenterol. Clin. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=7750686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaK2M3mvF2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1994&pages=1129-1131&author=V.+Batyauthor=B.+Denisauthor=C.+Goudotauthor=V.+Basauthor=P.+Renkesauthor=M.+A.+Bigardauthor=P.+Boisselauthor=P.+Gaucher&title=Hepatitis+induced+by+alpidem+%28Ananxyl%29.+Four+cases%2C+one+of+them+fatal"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal</span></div><div class="casAuthors">Baty V; Denis B; Goudot C; Bas V; Renkes P; Bigard M A; Boissel P; Gaucher P</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterologie clinique et biologique</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1129-31</span>
        ISSN:<span class="NLM_cas:issn">0399-8320</span>.
    </div><div class="casAbstract">Acute hepatitis related to psychotropic drugs has been rarely reported with anxiolytic treatments.  Alpidem (Ananxyl) is a new imidazopyridine derivative with anxiolytic properties which was launched in October 1991.  Several cases of acute hepatitis, some severe, were described with this drug and its liver toxicity was questioned.  Results of a study monitoring drug side-effects caused this drug to be withdrawn from the market for one year.  We report four cases of acute hepatitis and discuss the role of alpidem.  All but one case were presented as severe acute hepatitis with hepatic failure.  One patient ran a fulminant course and died despite liver transplantation.  The mechanism of liver toxicity remains unclear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqUHGVXEZqWm52AMpI4GK2fW6udTcc2eby9Kl622xXe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3mvF2hsQ%253D%253D&md5=27ed8e1c3239d6f6ecae87776fe8c206</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaty%26aufirst%3DV.%26aulast%3DDenis%26aufirst%3DB.%26aulast%3DGoudot%26aufirst%3DC.%26aulast%3DBas%26aufirst%3DV.%26aulast%3DRenkes%26aufirst%3DP.%26aulast%3DBigard%26aufirst%3DM.%2BA.%26aulast%3DBoissel%26aufirst%3DP.%26aulast%3DGaucher%26aufirst%3DP.%26atitle%3DHepatitis%2520induced%2520by%2520alpidem%2520%2528Ananxyl%2529.%2520Four%2520cases%252C%2520one%2520of%2520them%2520fatal%26jtitle%3DGastroenterol.%2520Clin.%2520Biol.%26date%3D1994%26volume%3D18%26spage%3D1129%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2383</span>– <span class="NLM_lpage">2392</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.028860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.109.028860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19720731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFajtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=2383-2392&author=T.+Usuiauthor=M.+Miseauthor=T.+Hashizumeauthor=M.+Yabukiauthor=S.+Komuro&title=Evaluation+of+the+potential+for+drug-induced+liver+injury+based+on+in+vitro+covalent+binding+to+human+liver+proteins&doi=10.1124%2Fdmd.109.028860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins</span></div><div class="casAuthors">Usui, Toru; Mise, Masashi; Hashizume, Takanori; Yabuki, Masashi; Komuro, Setsuko</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2383-2392</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prediction of idiosyncratic drug-induced liver injury (DILI) is difficult, and the underlying mechanisms are not fully understood.  However, many drugs causing DILI are considered to form reactive metabolites and covalently bind to cellular macromols. in the liver.  The objective of this study was to clarify whether the risk of idiosyncratic DILI can be estd. by comparing in vitro covalent binding (CB) levels among 12 pos. compds. (acetaminophen, alpidem, bromfenac, carbamazepine, diclofenac, flutamide, imipramine, nefazodone, tacrine, ticlopidine, tienilic acid, and troglitazone) for DILI and 12 neg. compds. (acetylsalicylic acid, caffeine, dexamethasone, losartan, ibuprofen, paroxetine, pioglitazone, rosiglitazone, sertraline, theophylline, venlafaxine, and zolpidem).  After incubation with human liver microsomes in the presence of NADPH, there was a large overlap in the distribution of CB amts. between the pos. and neg. groups.  On addn. of UDP-glucuronic acid (UDPGA) as a cofactor for glucuronidation, the CB levels of bromfenac and diclofenac were increased.  With addn. of nucleophilic glutathione (GSH), values for most compds. were decreased.  However, sepn. of the two groups on the basis of CB could not be improved by UDPGA or GSH.  Furthermore, CB with human hepatocytes also failed to discriminate pos. from neg. compds.  Therefore, the CB amt. alone is not sufficient for risk assessment of DILI.  In contrast, when the CB amt. was multiplied by the max. daily dose, which may reflect max. hepatic exposure, the two groups did become discriminated.  Taken together, our findings suggest that the combination of CB amt. and daily dose can est. the risk of idiosyncratic DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvQoojI97OgLVg90H21EOLACvtfcHk0ljbe_T36P3biQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFajtr7K&md5=19ffc916995d60f9cb0b6b3a2074a082</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.028860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.028860%26sid%3Dliteratum%253Aachs%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DMise%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DKomuro%26aufirst%3DS.%26atitle%3DEvaluation%2520of%2520the%2520potential%2520for%2520drug-induced%2520liver%2520injury%2520based%2520on%2520in%2520vitro%2520covalent%2520binding%2520to%2520human%2520liver%2520proteins%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D2383%26epage%3D2392%26doi%3D10.1124%2Fdmd.109.028860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thénot, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morselli, P. L.</span></span> <span> </span><span class="NLM_article-title">Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.3109/03602539208996294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602539208996294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1576937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK38XktF2lu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1992&pages=239-266&author=A.+Durandauthor=J.+P.+Th%C3%A9notauthor=G.+Bianchettiauthor=P.+L.+Morselli&title=Comparative+pharmacokinetic+profile+of+two+imidazopyridine+drugs%3A+zolpidem+and+alpidem&doi=10.3109%2F03602539208996294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacokinetic profile of two imidazopyridine drugs:  zolpidem and alpidem</span></div><div class="casAuthors">Durand, A.; Thenot, J. P.; Bianchetti, G.; Morselli, P. L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-66</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 43 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorlHiz2BZluLVg90H21EOLACvtfcHk0ljbe_T36P3biQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktF2lu70%253D&md5=69026f79912009673c3fa1a0cded3445</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.3109%2F03602539208996294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602539208996294%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DA.%26aulast%3DTh%25C3%25A9not%26aufirst%3DJ.%2BP.%26aulast%3DBianchetti%26aufirst%3DG.%26aulast%3DMorselli%26aufirst%3DP.%2BL.%26atitle%3DComparative%2520pharmacokinetic%2520profile%2520of%2520two%2520imidazopyridine%2520drugs%253A%2520zolpidem%2520and%2520alpidem%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1992%26volume%3D24%26spage%3D239%26epage%3D266%26doi%3D10.3109%2F03602539208996294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descatoire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadrot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tordjmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessayre, D.</span></span> <span> </span><span class="NLM_article-title">Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">800</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=11602696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvV2qtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=793-800&author=A.+Bersonauthor=V.+Descatoireauthor=A.+Suttonauthor=D.+Fauauthor=B.+Maulnyauthor=N.+Vadrotauthor=G.+Feldmannauthor=B.+Berthonauthor=T.+Tordjmannauthor=D.+Pessayre&title=Toxicity+of+alpidem%2C+a+peripheral+benzodiazepine+receptor+ligand%2C+but+not+zolpidem%2C+in+rat+hepatocytes%3A+role+of+mitochondrial+permeability+transition+and+metabolic+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation</span></div><div class="casAuthors">Berson, Alain; Descatoire, Veronique; Sutton, Angela; Fau, Daniel; Maulny, Beatrice; Vadrot, Nathalie; Feldmann, Gerard; Berthon, Brigitte; Tordjmann, Thierry; Pessayre, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">793-800</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Whereas alpidem is hepatotoxic, zolpidem is not.  Despite closely related chem. structures, alpidem, but not zolpidem, is a peripheral benzodiazepine receptor (PBR) ligand, and is also more lipophilic than zolpidem.  We compared their effects in isolated rat liver mitochondria and rat hepatocytes.  Zolpidem did not affect calcium-induced mitochondrial permeability transition (MPT) in mitochondria, caused little glutathione depletion in hepatocytes, and was not toxic, even at 500 μM.  At 250 to 500 μM, alpidem prevented calcium-induced MPT in isolated mitochondria, but caused severe glutathione depletion in hepatocytes that was increased by 3-methylcholanthrene, a cytochrome P 4501A inducer, and decreased by cystine, a glutathione precursor.  Although cell calcium increased, mitochondrial cytochrome c did not translocate to the cytosol and cells died of necrosis.  Cell death was prevented by cystine, but not cyclosporin A, an MPT inhibitor.  At low concns. (25-50 μM), in contrast, alpidem accelerated calcium-induced MPT in mitochondria.  It did not deplete glutathione in hepatocytes, but nevertheless caused some cell death that was prevented by cyclosporin A, but not by cystine.  Alpidem (10 μM) also increased the toxicity of tumor necrosis factor-α (1 ng/mL) in hepatocytes.  In conclusion, low concns. of alpidem increase both calcium-induced MPT in mitochondria, and TNF-α toxicity in cells, like other PBR ligands.  Like other lipophilic protonatable amines, however, alpidem inhibits calcium-induced MPT at high concns.  At these high concns., toxicity involves cytochrome P 4501A-mediated metabolic activation, glutathione depletion, and increased cell calcium, without MPT involvement.  In contrast, zolpidem has no mitochondrial effects, causes little glutathione depletion, and is not toxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV8r95cW7THbVg90H21EOLACvtfcHk0ljbe_T36P3biQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvV2qtb0%253D&md5=254d3aa9e0b7b09ec5d0402263da7375</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBerson%26aufirst%3DA.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DSutton%26aufirst%3DA.%26aulast%3DFau%26aufirst%3DD.%26aulast%3DMaulny%26aufirst%3DB.%26aulast%3DVadrot%26aufirst%3DN.%26aulast%3DFeldmann%26aufirst%3DG.%26aulast%3DBerthon%26aufirst%3DB.%26aulast%3DTordjmann%26aufirst%3DT.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DToxicity%2520of%2520alpidem%252C%2520a%2520peripheral%2520benzodiazepine%2520receptor%2520ligand%252C%2520but%2520not%2520zolpidem%252C%2520in%2520rat%2520hepatocytes%253A%2520role%2520of%2520mitochondrial%2520permeability%2520transition%2520and%2520metabolic%2520activation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D793%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devineni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtin, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polidori, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, P. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1002/jcph.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fjcph.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=23670707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=601-610&author=D.+Devineniauthor=C.+R.+Curtinauthor=D.+Polidoriauthor=M.+J.+Gutierrezauthor=J.+Murphyauthor=S.+Ruschauthor=P.+L.+Rothenberg&title=Pharmacokinetics+and+pharmacodynamics+of+canagliflozin%2C+a+sodium+glucose+co-transporter+2+inhibitor%2C+in+subjects+with+type+2+diabetes+mellitus&doi=10.1002%2Fjcph.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus</span></div><div class="casAuthors">Devineni, Damayanthi; Curtin, Christopher R.; Polidori, David; Gutierrez, Maria J.; Murphy, Joseph; Rusch, Sarah; Rothenberg, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-610, 10</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">This study characterized single- and multiple-dose pharmacokinetics of canagliflozin and its O-glucuronide metabolites (M5 and M7) and pharmacodynamics (renal threshold for glucose [RTG], urinary glucose excretion [UGE0-24h], and 24-h mean plasma glucose [MPG0-24h]) of canagliflozin in subjects with type 2 diabetes.  Thirty-six randomized subjects received canagliflozin 50, 100, or 300 mg/day or placebo for 7 days.  On Days 1 and 7, area under the plasma concn.-time curve and max. obsd. plasma concn. (Cmax) for canagliflozin and its metabolites increased dose-dependently.  Half-life and time at which Cmax was obsd. were dose-independent.  Systemic molar M5 exposure was half that of canagliflozin; M7 exposure was similar to canagliflozin.  Steady-state plasma canagliflozin concns. were reached by Day 4 in all active treatment groups.  Pharmacodynamic effects were dose- and exposure-dependent.  All canagliflozin doses decreased RTG, increased UGE0-24h, and reduced MPG0-24h vs. placebo on Days 1 and 7.  On Day 7, placebo-subtracted least-squares mean decreases in MPG0-24h ranged from 42-57 mg/dL with canagliflozin treatment.  Adverse events (AEs) were balanced between treatments; no treatment-related serious AEs, AE-related discontinuations, or clin. meaningful adverse changes in routine safety evaluations occurred.  The obsd. pharmacokinetic/pharmacodynamic profile of canagliflozin in subjects with type 2 diabetes supports a once-daily dosing regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSidq1B1s0wLVg90H21EOLACvtfcHk0liZSxZ_XnWozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsLrJ&md5=87e305c019cee8846c2987e9c0de56fb</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1002%2Fjcph.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.88%26sid%3Dliteratum%253Aachs%26aulast%3DDevineni%26aufirst%3DD.%26aulast%3DCurtin%26aufirst%3DC.%2BR.%26aulast%3DPolidori%26aufirst%3DD.%26aulast%3DGutierrez%26aufirst%3DM.%2BJ.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DRusch%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DP.%2BL.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520canagliflozin%252C%2520a%2520sodium%2520glucose%2520co-transporter%25202%2520inhibitor%252C%2520in%2520subjects%2520with%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D53%26spage%3D601%26epage%3D610%26doi%3D10.1002%2Fjcph.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freudenberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinz, C.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1055</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.025551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19196846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1046-1055&author=D.+Langauthor=C.+Freudenbergerauthor=C.+Weinz&title=In+vitro+metabolism+of+rivaroxaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+in+liver+microsomes+and+hepatocytes+of+rats%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.108.025551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans</span></div><div class="casAuthors">Lang, D.; Freudenberger, C.; Weinz, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1046-1055</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The in vitro metab. of rivaroxaban, a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders, was investigated in several species, including humans.  The objective of this study was to elucidate metabolite structures and identify the metabolic pathways to provide support for in vivo safety and clin. studies.  [14C]Rivaroxaban was incubated with liver microsomes and hepatocytes of rats, dogs, and humans.  The samples were analyzed by high-performance liq. chromatog.-14C-tandem mass spectroscopy, to generate metabolite profiles and propose or confirm the structures of the metabolites formed.  In vitro metabolite profiles showed no major differences between species.  The main oxidative metabolic pathways identified for all species were hydroxylation at the morpholinone moiety (M-2, M-3, and M-8) and to a lesser extent at the oxazolidinone moiety (M-9).  M-2 was the main metabolite in all microsomal incubations.  M-1, a morpholinone ring-opened product formed by further oxidn. of M-2, was the main metabolite in all hepatocyte incubations.  Other pathways were amide hydrolysis at the morpholinone ring (M-7) and the chlorothiophene amide moiety (M-13 and M-15).  In hepatocytes, M-13 was readily conjugated with glycine, leading to M-4.  The metabolic fate of unlabeled M-15 was investigated sep.  Incubations with human liver microsomes and hepatocytes showed that M-15 was first oxidized to the aldehyde intermediate M-16 and subsequently reduced to M-17 (alc.) or oxidized to M-18 (carboxylic acid).  No metab. at the chlorothiophene moiety itself was found.  Overall, rivaroxaban showed no species differences in metab., with different independent metabolic pathways and no formation of reactive metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonReqhgur0jrVg90H21EOLACvtfcHk0liZSxZ_XnWozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbs%253D&md5=554dd0a5f3447eb140028bd857e44180</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025551%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DD.%26aulast%3DFreudenberger%26aufirst%3DC.%26aulast%3DWeinz%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520rivaroxaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%252C%2520in%2520liver%2520microsomes%2520and%2520hepatocytes%2520of%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1046%26epage%3D1055%26doi%3D10.1124%2Fdmd.108.025551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubitza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span> <span> </span><span class="NLM_article-title">Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1056</span>– <span class="NLM_lpage">1064</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.025569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19196845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1056-1064&author=C.+Weinzauthor=T.+Schwarzauthor=D.+Kubitzaauthor=W.+Mueckauthor=D.+Lang&title=Metabolism+and+excretion+of+rivaroxaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+in+rats%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.108.025569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans</span></div><div class="casAuthors">Weinz, C.; Schwarz, T.; Kubitza, D.; Mueck, W.; Lang, D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1056-1064</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Rivaroxaban is a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders.  The objective of this study was to investigate the in vivo metab. and excretion of rivaroxaban in rats, dogs, and humans.  Single doses of [14C]rivaroxaban (3 and 1 mg/kg) were administered to rats (orally/i.v.) and dogs (orally), resp.  A single oral dose of [14C]rivaroxaban (10 mg) was administered to healthy human males (n = 4).  Plasma and excreta were collected and profiled for radioactivity.  Recovery of total radioactivity was high and ≥92% in all species.  Unchanged rivaroxaban was the major compd. in plasma at all time points investigated, across all species.  No major or pharmacol. active circulating metabolites were detected.  Rivaroxaban and its metabolites were rapidly excreted; urinary excretion of radioactivity was 25 and 52%, and fecal excretion was 67 and 43% of the dose in rats and dogs, resp.  In humans, 66% of the dose was excreted renally (36% unchanged drug) and 28% in the feces.  Radioactivity profiles in excreta were similar across species.  Three metabolic pathways were identified: oxidative degrdn. of the morpholinone moiety (major pathway) and hydrolysis of the central amide bond and of the lactam amide bond in the morpholinone ring (minor pathways).  M-1, the main metabolite in excreta of all species, was eliminated via both renal and fecal/biliary routes.  In total, 82 to 89% of the dose administered was assigned to unchanged rivaroxaban and its metabolites in the excreta of rats, dogs, and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1XRtEaXyDjLVg90H21EOLACvtfcHk0liZSxZ_XnWozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitbg%253D&md5=c0a252defe018afa59944549dd4de6d6</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025569%26sid%3Dliteratum%253Aachs%26aulast%3DWeinz%26aufirst%3DC.%26aulast%3DSchwarz%26aufirst%3DT.%26aulast%3DKubitza%26aufirst%3DD.%26aulast%3DMueck%26aufirst%3DW.%26aulast%3DLang%26aufirst%3DD.%26atitle%3DMetabolism%2520and%2520excretion%2520of%2520rivaroxaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%252C%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1056%26epage%3D1064%26doi%3D10.1124%2Fdmd.108.025569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Irons, R. D.</span></span> <span> </span><span class="NLM_article-title">Quinones as toxic metabolites of benzene</span>. <i>J. Toxicol. Environ. Health</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">678</span>, <span class="refDoi"> DOI: 10.1080/15287398509530777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F15287398509530777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=4093989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL28XhsVeiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1985&pages=673-678&author=R.+D.+Irons&title=Quinones+as+toxic+metabolites+of+benzene&doi=10.1080%2F15287398509530777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Quinones as toxic metabolites of benzene</span></div><div class="casAuthors">Irons, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicology and Environmental Health</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">673-8</span>CODEN:
                <span class="NLM_cas:coden">JTEHD6</span>;
        ISSN:<span class="NLM_cas:issn">0098-4108</span>.
    </div><div class="casAbstract">A review with 30 refs. on the toxicity of C6H6  [71-43-2] and its dihydroxy metabolites (quinones).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEeYO0-nupULVg90H21EOLACvtfcHk0ljOg3ePHuzwug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhsVeiu7c%253D&md5=80670c1f9f8a7e110d44b2a6fd2f25f3</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1080%2F15287398509530777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15287398509530777%26sid%3Dliteratum%253Aachs%26aulast%3DIrons%26aufirst%3DR.%2BD.%26atitle%3DQuinones%2520as%2520toxic%2520metabolites%2520of%2520benzene%26jtitle%3DJ.%2520Toxicol.%2520Environ.%2520Health%26date%3D1985%26volume%3D16%26spage%3D673%26epage%3D678%26doi%3D10.1080%2F15287398509530777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalf, G. F.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the metabolism and toxicity of benzene</span>. <i>Crit. Rev. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.3109/10408448709089859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F10408448709089859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3311642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL1cXhslehsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1987&pages=141-159&author=G.+F.+Kalf&title=Recent+advances+in+the+metabolism+and+toxicity+of+benzene&doi=10.3109%2F10408448709089859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the metabolism and toxicity of benzene</span></div><div class="casAuthors">Kalf, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Toxicology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-59</span>CODEN:
                <span class="NLM_cas:coden">CRTXB2</span>;
        ISSN:<span class="NLM_cas:issn">0045-6446</span>.
    </div><div class="casAbstract">A review with 146 refs. on the metab. of benzene and its genotoxicity, carcinogenicity, and hematotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq9fEWATFb9LVg90H21EOLACvtfcHk0ljOg3ePHuzwug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhslehsQ%253D%253D&md5=450c8d3e62ae25b5f360e731d4d7d63b</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.3109%2F10408448709089859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10408448709089859%26sid%3Dliteratum%253Aachs%26aulast%3DKalf%26aufirst%3DG.%2BF.%26atitle%3DRecent%2520advances%2520in%2520the%2520metabolism%2520and%2520toxicity%2520of%2520benzene%26jtitle%3DCrit.%2520Rev.%2520Toxicol.%26date%3D1987%26volume%3D18%26spage%3D141%26epage%3D159%26doi%3D10.3109%2F10408448709089859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claesson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minidis, A.</span></span> <span> </span><span class="NLM_article-title">Systematic approach to organizing structural alerts for reactive metabolite formation from potential drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Wkurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2018&pages=389-411&author=A.+Claessonauthor=A.+Minidis&title=Systematic+approach+to+organizing+structural+alerts+for+reactive+metabolite+formation+from+potential+drugs&doi=10.1021%2Facs.chemrestox.8b00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Approach to Organizing Structural Alerts for Reactive Metabolite Formation from Potential Drugs</span></div><div class="casAuthors">Claesson, Alf; Minidis, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">389-411</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Reactive metabolites are widely accepted as playing a pivotal role in causing idiosyncratic adverse drug reactions (IDR).  However, much is unknown about the biol. mechanisms of IDR although the initiating event in most cases is an attachment of a reactive intermediate to macromols. leading to immune mediated responses.  Reactive metabolites are also involved in many mutagenesis/ carcinogenesis events by reacting with DNA.  Drug designers thus have all reasons to make large efforts to avoid making test compds. having a liability to generate reactive metabolites.  In this Perspective the authors argue for using structural alerts (SA) as the most straightforward way to link forecasting about chem. hazards of planned test compds. to the accumulated knowledge base.  Although many SAs have been widely recognized and reviewed previously, there are also a lot of observations that have no readily discernable chem. interpretation.  For drug designers to benefit from all published data, the knowledge has to be organized in a way that is readily searchable starting with a query structure.  The authors propose that an increased no. of structural alerts with more details should be applied to obtain improved decision support.  The assocn. of selected SAs with ref. drugs, whose proposed or hypothesized activation mechanisms build the knowledge base, should be readily available in a format comprising of small summaries with included hyperlinks for quick access to the original literature, as outlined in the TOC illustration.  Since some structural alerts are present in drugs that do not cause idiosyncratic adverse reactions or drug-drug interactions, it is important to elaborate on the reasons for this discrepancy as much as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6TRDGoBo8FLVg90H21EOLACvtfcHk0ljOg3ePHuzwug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Wkurw%253D&md5=8822e32efecbf62c90d62ba5dacfda63</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00046%26sid%3Dliteratum%253Aachs%26aulast%3DClaesson%26aufirst%3DA.%26aulast%3DMinidis%26aufirst%3DA.%26atitle%3DSystematic%2520approach%2520to%2520organizing%2520structural%2520alerts%2520for%2520reactive%2520metabolite%2520formation%2520from%2520potential%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2018%26volume%3D31%26spage%3D389%26epage%3D411%26doi%3D10.1021%2Facs.chemrestox.8b00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langowski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, C. A.</span></span> <span> </span><span class="NLM_article-title">Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR</span>. <i>SAR QSAR Environ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1080/10629369908039182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F10629369908039182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10491855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1999&pages=299-314&author=N.+Greeneauthor=P.+N.+Judsonauthor=J.+J.+Langowskiauthor=C.+A.+Marchant&title=Knowledge-based+expert+systems+for+toxicity+and+metabolism+prediction%3A+DEREK%2C+StAR+and+METEOR&doi=10.1080%2F10629369908039182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR</span></div><div class="casAuthors">Greene, N.; Judson, P. N.; Langowski, J. J.; Marchant, C. A.</div><div class="citationInfo"><span class="NLM_cas:title">SAR and QSAR in Environmental Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">299-314, 2 plates</span>CODEN:
                <span class="NLM_cas:coden">SQERED</span>;
        ISSN:<span class="NLM_cas:issn">1062-936X</span>.
    
            (<span class="NLM_cas:orgname">Gordon & Breach Science Publishers</span>)
        </div><div class="casAbstract">It has long been recognized that the ability to predict the metabolic fate of a chem. substance and the potential toxicity of either the parent compd. or its metabolites are important in novel drug design.  The popularity of using computer models as an aid in this area has grown considerably in recent years.  LHASA Limited has been developing knowledge-based expert systems for toxicity and metab. prediction in collaboration with industry and regulatory authorities.  These systems, DEREK, StAR, and METEOR, use rules to describe the relationship between chem. structure and either toxicity in the case of DEREK and StAR or metabolic fate in the case of METEOR.  The rule refinement process for DEREK often involves assessing the predictions for a novel set of compds. and comparing them to their biol. assay results as a measure of the system's performance.  For example, 266 non-congeneric chems. from the National Toxicol. Program database have been processed through the DEREK mutagenicity knowledge base and the predictions compared to their Salmonella typhimurium mutagenicity data.  Initially, 81 of 114 mutagens (71%) and 117 of 152 non-mutagens (77%) were correctly identified.  Following further knowledge base development, the no. of correctly identified mutagens has increased to 96 (84%).  Further work on improving the predictive capabilities of DEREK, StAR, and METEOR is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp85N5_SGuyybVg90H21EOLACvtfcHk0ljOg3ePHuzwug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFCgsbc%253D&md5=5988de2a40351b9416bc21a9688a3a6d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1080%2F10629369908039182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10629369908039182%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DJudson%26aufirst%3DP.%2BN.%26aulast%3DLangowski%26aufirst%3DJ.%2BJ.%26aulast%3DMarchant%26aufirst%3DC.%2BA.%26atitle%3DKnowledge-based%2520expert%2520systems%2520for%2520toxicity%2520and%2520metabolism%2520prediction%253A%2520DEREK%252C%2520StAR%2520and%2520METEOR%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D1999%26volume%3D10%26spage%3D299%26epage%3D314%26doi%3D10.1080%2F10629369908039182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Methling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reszka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrana, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheuch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terhaag, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span> <span> </span><span class="NLM_article-title">Investigation of the in vitro metabolism of the analgesic flupirtine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.024364</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.108.024364" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19074524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislamt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=479-493&author=K.+Methlingauthor=P.+Reszkaauthor=M.+Lalkauthor=O.+Vranaauthor=E.+Scheuchauthor=W.+Siegmundauthor=B.+Terhaagauthor=P.+J.+Bednarski&title=Investigation+of+the+in+vitro+metabolism+of+the+analgesic+flupirtine&doi=10.1124%2Fdmd.108.024364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the in vitro metabolism of the analgesic flupirtine</span></div><div class="casAuthors">Methling, Karen; Reszka, Przyemslaw; Lalk, Michael; Vrana, Oldrich; Scheuch, Eberhard; Siegmund, Werner; Terhaag, Bernd; Bednarski, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-493</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The in vitro metab. of flupirtine, ethyl-N-[2-amino-6-(4-fluoro-phenylmethyl-amino)pyridine-3-yl]carbamate, a centrally acting analgesic with muscle tone-reducing activity, was studied.  Two flupirtine metabolites were already known: the N-acetylated analog D13223 and 4-fluorohippuric acid.  The structure of flupirtine suggested that redox chem. may play a role in metab., and cyclic voltammetry studies showed that the drug undergoes facile and irreversible redox reactions.  Thus, oxidative metab. was investigated first.  With CYP3A1-induced rat liver microsomes an 18% turnover of flupirtine and a 20 to 25% turnover of D13223 took place over 30 min, but less than 5% turnover of flupirtine was obsd. with all human liver microsomal prepns. tested, evidence that cytochrome P 450 does not contribute appreciably to the metab. in humans.  Likewise, no involvement of human monoamine oxidase (isoforms A and B) was found for either flupirtine or D13223.  In contrast, flupirtine was an excellent substrate for both human myeloperoxidase and horse radish peroxidase (HRP).  These enzymes produced detectable amts. of oxidn. products.  Incubations of flupirtine with HRP produced an oxidn. product that could be trapped with glutathione, the resulting glutathione conjugate was characterized by mass spectrometry and NMR.  Metab. of D13223 by both peroxidases was also obsd. but to a much lesser extent.  Porcine liver esterases cleave the carbamate group of flupirtine, and both human N-acetyltransferases 1 and 2 acetylated the hydrolysis product, presumably descarboethoxyflupirtine, with nearly equal efficiencies to yield D13223.  Incubations of human liver microsomes with flupirtine or the metabolite D13223 together with UDP-glucuronic acid gave two isomeric N-glucuronides in both cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJIi-5pzLX4rVg90H21EOLACvtfcHk0ljEUSkq0_MSag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislamt7g%253D&md5=bc5c607b727a0e617dd76d9c8757f1b3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.024364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.024364%26sid%3Dliteratum%253Aachs%26aulast%3DMethling%26aufirst%3DK.%26aulast%3DReszka%26aufirst%3DP.%26aulast%3DLalk%26aufirst%3DM.%26aulast%3DVrana%26aufirst%3DO.%26aulast%3DScheuch%26aufirst%3DE.%26aulast%3DSiegmund%26aufirst%3DW.%26aulast%3DTerhaag%26aufirst%3DB.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26atitle%3DInvestigation%2520of%2520the%2520in%2520vitro%2520metabolism%2520of%2520the%2520analgesic%2520flupirtine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D479%26epage%3D493%26doi%3D10.1124%2Fdmd.108.024364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheuch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methling, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosskopf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terhaag, B.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1111/bcp.12522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fbcp.12522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=25264565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2015&pages=501-513&author=W.+Siegmundauthor=C.+Modessauthor=E.+Scheuchauthor=K.+Methlingauthor=M.+Keiserauthor=A.+Nassifauthor=D.+Rosskopfauthor=P.+J.+Bednarskiauthor=J.+Borlakauthor=B.+Terhaag&title=Metabolic+activation+and+analgesic+effect+of+flupirtine+in+healthy+subjects%2C+influence+of+the+polymorphic+NAT2%2C+UGT1A1+and+GSTP1&doi=10.1111%2Fbcp.12522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1</span></div><div class="casAuthors">Siegmund, Werner; Modess, Christiane; Scheuch, Eberhard; Methling, Karen; Keiser, Markus; Nassif, Ali; Rosskopf, Dieter; Bednarski, Patrick J.; Borlak, Juergen; Terhaag, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">501-513</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : The rare assocn. of flupirtine with liver injury is most likely caused by reactive quinone diimines and their oxidative formation may be influenced by the activities of N-acetyltransferases (NAT) that conjugate the less toxic metabolite D13223, and by glucuronosyltransferases (UGT) and glutathione S-transferases (GST) that generate stable terminal glucuronides and mercapturic acid derivs., resp.  The influence of genetic polymorphisms of NAT2, UGT1A1 and GSTP1 on generation of the terminal mercapturic acid derivs. and analgesic effects was evaluated to identify potential genetic risk factors for hepatotoxicity of flupirtine.  Methods : Metabolic disposition of flupirtine was measured after i.v. administration (100 mg), after swallowing an immediate-release (IR) tablet (100 mg) and after repeated administration of modified release (MR) tablets (400 mg once daily 8 days) in 36 selected healthy subjects.  Analgesic effects were measured using pain models (delayed onset of muscle soreness, elec. pain).  Results : Flupirtine IR was rapidly but incompletely absorbed (∼72%).  Repeated administration of flupirtine MR showed lower bioavailability (∼60%).  Approx. 12% of bioavailable flupirtine IR and 8% of bioavailable flupiritine MR was eliminated as mercapturic acid derivs. into the urine independent of the UGT1A1, NAT2 and GSTP1 genotype.  Carriers of variant GSTP1 alleles showed lower bioavailability but increased intestinal secretion of flupirtine and increased efficiency in exptl. pain.  Flupirtine was not a substrate for ABCB1 and ABCC2.  Conclusions : Formation of mercapturic acid derivs. is a major elimination route for flupirtine in man.  However, the theor. toxic pathway is not influenced by the frequent polymorphisms of UGT1A1, NAT2 and GSTP1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDTzf4blJ7brVg90H21EOLACvtfcHk0ljEUSkq0_MSag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFaqs7g%253D&md5=12442bde1be4c5c86a928b06f6517b3c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12522%26sid%3Dliteratum%253Aachs%26aulast%3DSiegmund%26aufirst%3DW.%26aulast%3DModess%26aufirst%3DC.%26aulast%3DScheuch%26aufirst%3DE.%26aulast%3DMethling%26aufirst%3DK.%26aulast%3DKeiser%26aufirst%3DM.%26aulast%3DNassif%26aufirst%3DA.%26aulast%3DRosskopf%26aufirst%3DD.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTerhaag%26aufirst%3DB.%26atitle%3DMetabolic%2520activation%2520and%2520analgesic%2520effect%2520of%2520flupirtine%2520in%2520healthy%2520subjects%252C%2520influence%2520of%2520the%2520polymorphic%2520NAT2%252C%2520UGT1A1%2520and%2520GSTP1%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D79%26spage%3D501%26epage%3D513%26doi%3D10.1111%2Fbcp.12522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keisu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span> <span> </span><span class="NLM_article-title">Drug-induced liver injury in humans: the case of ximelagatran</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>196</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-00663-0_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1007%2F978-3-642-00663-0_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVymsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=196&publication_year=2010&pages=407-418&author=M.+Keisuauthor=T.+B.+Andersson&title=Drug-induced+liver+injury+in+humans%3A+the+case+of+ximelagatran&doi=10.1007%2F978-3-642-00663-0_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced liver injury in humans: the case of ximelagatran</span></div><div class="casAuthors">Keisu, M.; Andersson, T. B.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">196</span>
        (<span class="NLM_cas:issue">Adverse Drug Reactions</span>),
    <span class="NLM_cas:pages">407-418</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Ximelagatran was the first orally available direct thrombin inhibitor under clin. development that also reached the market.  Ximelagatran was tested in an extensive clin. program.  Short-term use (< 12 days) in humans including the phase III clin. trials did not indicate any hepatotoxic potential.  Increased hepatic enzyme levels were first obsd. at a higher frequency when evaluating the long-term (>35 days) use of ximelagatran (incidence of >3 × upper limit of normal (ULN) plasma ALT was 7.9%).  The frequency of elevated total bilirubin levels was similar in the ximelagatran and the comparator groups.  However, the combination of ALT > 3 × ULN and total bilirubin > 2 × ULN was 0.5% among patients treated with ximelagatran and 0.1% among patients in the comparator group.  Symptoms such as fever and rash potentially indicating hypersensitivity (immunol. type of reaction) were low and did not differ between ximelagatran and the comparators.  The withdrawal of ximelagatran from the market and termination of the ximelagatran development program was triggered by safety data from a 35-day study, indicating that severe hepatic injury in a patient could develop after exposure to the drug has been completed and that regular liver function monitoring may not mitigate the possible risk of severe hepatic injury.  As for many drugs causing liver injury, the std. preclin. toxicol. studies provided no indication that ximelagatran affected hepatic functions.  In addn., extensive investigations using human-based in vitro models have not been able to define mechanisms explaining the pattern of hepatic injury obsd. in long-term clin. trials.  A pharmacogenomic study provided evidence that the ALT increases were assocd. with major histocompatibility complex (MHC) alleles DRB1'07 and DQA1*02 suggesting a possible immunogenic pathogenesis.  This example provides important clues to the mechanism of idiosyncratic drug-induced liver toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8MnjfyasU1bVg90H21EOLACvtfcHk0ljEUSkq0_MSag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVymsr8%253D&md5=8713782d6f002abd9d8f8ca6aa41d7e0</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-00663-0_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-00663-0_13%26sid%3Dliteratum%253Aachs%26aulast%3DKeisu%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DDrug-induced%2520liver%2520injury%2520in%2520humans%253A%2520the%2520case%2520of%2520ximelagatran%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2010%26volume%3D196%26spage%3D407%26epage%3D418%26doi%3D10.1007%2F978-3-642-00663-0_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ainscow, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilling, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, T. B.</span></span> <span> </span><span class="NLM_article-title">Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1517/14740338.7.4.351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1517%2F14740338.7.4.351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18613800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1Cgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=351-365&author=E.+K.+Ainscowauthor=J.+E.+Pillingauthor=N.+M.+Brownauthor=A.+T.+Ormeauthor=M.+Sullivanauthor=A.+C.+Hargreavesauthor=E.+L.+Cookeauthor=E.+Sullivanauthor=S.+Carlssonauthor=T.+B.+Andersson&title=Investigations+into+the+liver+effects+of+ximelagatran+using+high+content+screening+of+primary+human+hepatocyte+cultures&doi=10.1517%2F14740338.7.4.351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures</span></div><div class="casAuthors">Ainscow, Edward K.; Pilling, James E.; Brown, Nick M.; Orme, Alexandra T.; Sullivan, Michael; Hargreaves, Andy C.; Cooke, Emma-Louise; Sullivan, Elaine; Carlsson, Stefan; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-365</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Ximelagatran, the first oral agent in the new class of direct thrombin inhibitors, was withdrawn from the market due to increased rates of liver enzyme elevations in long-term treatments.  Despite intensive pre clin. investigations the cellular mechanisms behind the obsd. hepatic effects remain unknown.  The aim of this study was to assess drug-induced cytotoxicity in primary human hepatocyte cultures by ximelagatran and other ref. pharmaceutical agents with known in vivo hepatotoxic profiles.  Drugs cause liver injury by many distinct mechanisms that result in abnormal cellular functioning and different patterns of injury.  To address many potential toxic mechanisms in a human-relevant model, freshly isolated human hepatocytes were used in automated imaging assays.  Ximelagatran was used as a test compd. to study biochem. and morphol. changes in human hepatocytes.  In addn., 11 control, ref. and comparator compds. with known liver-toxic potential in humans were used.  The response to these compds. was assessed across five different hepatocyte donor prepns.  Cytotoxicity induced by a no. of compds. was quant. monitored using an automated imaging technique.  A variety of morphol. changes in hepatocyte cytoskeleton and mitochondrial function could be identified at sublethal doses of test compds.  Doses of ximelagatran up to 500 μM did not cause a cytotoxic response in the majority of prepns. and no subcytotoxic response was obsd. at doses below 125 μM.  The expts. described here demonstrate that primary human hepatocytes may be used in a medium-throughput format for screening using imaging-based assays for the identification of cellular responses.  Overall, it is concluded that ximelagatran did not cause a significant decrease in cell viability when incubated for 24 h at considerably higher concns. than are found in plasma following therapeutic dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBDK7YL3gArVg90H21EOLACvtfcHk0lg_FBFETCqKPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1Cgsrc%253D&md5=3c7f4b85bfd3d063b7fa892fd909459d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1517%2F14740338.7.4.351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.7.4.351%26sid%3Dliteratum%253Aachs%26aulast%3DAinscow%26aufirst%3DE.%2BK.%26aulast%3DPilling%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DN.%2BM.%26aulast%3DOrme%26aufirst%3DA.%2BT.%26aulast%3DSullivan%26aufirst%3DM.%26aulast%3DHargreaves%26aufirst%3DA.%2BC.%26aulast%3DCooke%26aufirst%3DE.%2BL.%26aulast%3DSullivan%26aufirst%3DE.%26aulast%3DCarlsson%26aufirst%3DS.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DInvestigations%2520into%2520the%2520liver%2520effects%2520of%2520ximelagatran%2520using%2520high%2520content%2520screening%2520of%2520primary%2520human%2520hepatocyte%2520cultures%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2008%26volume%3D7%26spage%3D351%26epage%3D365%26doi%3D10.1517%2F14740338.7.4.351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of atorvastatin</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1141</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.2165/00003088-200342130-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.2165%2F00003088-200342130-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=14531725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BD3svntVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1141-1160&author=H.+Lennernas&title=Clinical+pharmacokinetics+of+atorvastatin&doi=10.2165%2F00003088-200342130-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of atorvastatin</span></div><div class="casAuthors">Lennernas Hans</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1141-60</span>
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.  Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of HMG-CoA reductase.  The mean dose-response relationship has been shown to be log-linear for atorvastatin, but plasma concentrations of atorvastatin acid and its metabolites do not correlate with LDL-cholesterol reduction at a given dose.  The clinical dosage range for atorvastatin is 10-80 mg/day, and it is given in the acid form.  Atorvastatin acid is highly soluble and permeable, and the drug is completely absorbed after oral administration.  However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%.  The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.  Atorvastatin acid is extensively metabolised in both the gut and liver by oxidation, lactonisation and glucuronidation, and the metabolites are eliminated by biliary secretion and direct secretion from blood to the intestine.  In vitro, atorvastatin acid is a substrate for P-glycoprotein, organic anion-transporting polypeptide (OATP) C and H+-monocarboxylic acid cotransporter.  The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.  The renal route is of minor importance (<1%) for the elimination of atorvastatin acid.  In vivo, cytochrome P450 (CYP) 3A4 is responsible for the formation of two active metabolites from the acid and the lactone forms of atorvastatin.  Atorvastatin acid and its metabolites undergo glucuronidation mediated by uridinediphosphoglucuronyltransferases 1A1 and 1A3.  Atorvastatin can be given either in the morning or in the evening.  Food decreases the absorption rate of atorvastatin acid after oral administration, as indicated by decreased peak concentration and increased time to peak concentration.  Women appear to have a slightly lower plasma exposure to atorvastatin for a given dose.  Atorvastatin is subject to metabolism by CYP3A4 and cellular membrane transport by OATP C and P-glycoprotein, and drug-drug interactions with potent inhibitors of these systems, such as itraconazole, nelfinavir, ritonavir, cyclosporin, fibrates, erythromycin and grapefruit juice, have been demonstrated.  An interaction with gemfibrozil seems to be mediated by inhibition of glucuronidation.  A few case studies have reported rhabdomyolysis when the pharmacokinetics of atorvastatin have been affected by interacting drugs.  Atorvastatin increases the bioavailability of digoxin, most probably by inhibition of P-glycoprotein, but does not affect the pharmacokinetics of ritonavir, nelfinavir or terfenadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaNOaBHYDzT90Q2ypr7jHkfW6udTcc2eaUYFIV-ZcGJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svntVSrug%253D%253D&md5=21b6bc593a9e04544fe3a1409691448c</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342130-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342130-00005%26sid%3Dliteratum%253Aachs%26aulast%3DLennernas%26aufirst%3DH.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520atorvastatin%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26spage%3D1141%26epage%3D1160%26doi%3D10.2165%2F00003088-200342130-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.027797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessment+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding&doi=10.1124%2Fdmd.109.027797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0lir7ZlPSRtNOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessment%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977%26doi%3D10.1124%2Fdmd.109.027797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashishtha, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1021/tx100141d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx100141d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVChs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=1393-1404&author=G.+Wuauthor=S.+C.+Vashishthaauthor=J.+C.+Erve&title=Characterization+of+glutathione+conjugates+of+duloxetine+by+mass+spectrometry+and+evaluation+of+in+silico+approaches+to+rationalize+the+site+of+conjugation+for+thiophene+containing+drugs&doi=10.1021%2Ftx100141d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Glutathione Conjugates of Duloxetine by Mass Spectrometry and Evaluation of in Silico Approaches to Rationalize the Site of Conjugation for Thiophene Containing Drugs</span></div><div class="casAuthors">Wu, Guosheng; Vashishtha, Sarvesh C.; Erve, John C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1393-1404</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The in vitro bioactivation of the selective serotonin and norepinephrine reuptake inhibitor duloxetine was investigated using liver microsomes and cytosol, expressed glutathione transferase, and recombinant P 450 2D6 and 1A2.  In the presence of glutathione, several conjugates were identified and characterized using a combination of direct infusion nanoelectrospray mass spectrometry on an LTQ/Orbitrap and liq.-chromatog. mass spectrometry on a triple quadrupole.  Structural characterization of these conjugates revealed that glutathione conjugation occurred on naphthalene rather than on thiophene and likely proceeded via a reactive epoxide intermediate.  Expts. with recombinant P450s and the isoform specific inhibitors quinidine and furafylline suggested that both P 450 2D6 and 1A2 were involved in the bioactivation of duloxetine.  To explore the utility of in silico approaches to address bioactivation issues, MetaSite and two docking approaches (rigid and induced-fit docking) utilizing publicly available human P 450 crystal structures or a homol. model for P 450 2C19 were used to predict the sites of bioactivation for duloxetine as well as the thiophene contg. compds. tienilic acid, suprofen, ticlopidine, methapyrilene, and OSI-930 for which glutathione conjugates on the thiophene moiety have been reported.  MetaSite and induced fit docking but not rigid docking correctly predicted that naphthalene rather than thiophene was the preferred site of bioactivation for duloxetine by P 450 2D6.  MetaSite predictions were also consistent with literature reports that thiophene was the site of glutathione conjugation for tienilic acid, suprofen, and OSI-930 but not for ticlopidine or methapyrilene.  Of the two docking approaches investigated, induced fit docking results were consistent with thiophene as the site of bioactivation for all compds. to which it was applied.  In conclusion, our investigation identified the likely bioactivation pathway for duloxetine and demonstrated the utility of in silico approaches MetaSite and induced fit docking to address potential bioactivation liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8qdX22Hx2o7Vg90H21EOLACvtfcHk0lir7ZlPSRtNOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVChs7Y%253D&md5=050dddbc03d80c7b79eac7394b0bf0ad</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Ftx100141d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx100141d%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DVashishtha%26aufirst%3DS.%2BC.%26aulast%3DErve%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520glutathione%2520conjugates%2520of%2520duloxetine%2520by%2520mass%2520spectrometry%2520and%2520evaluation%2520of%2520in%2520silico%2520approaches%2520to%2520rationalize%2520the%2520site%2520of%2520conjugation%2520for%2520thiophene%2520containing%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2010%26volume%3D23%26spage%3D1393%26epage%3D1404%26doi%3D10.1021%2Ftx100141d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knadler, M. P.</span></span> <span> </span><span class="NLM_article-title">Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1142</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1124/dmd.31.9.1142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.31.9.1142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=12920170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmslKlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1142-1150&author=R.+J.+Lantzauthor=T.+A.+Gillespieauthor=T.+J.+Rashauthor=F.+Kuoauthor=M.+Skinnerauthor=H.+Y.+Kuanauthor=M.+P.+Knadler&title=Metabolism%2C+excretion%2C+and+pharmacokinetics+of+duloxetine+in+healthy+human+subjects&doi=10.1124%2Fdmd.31.9.1142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects</span></div><div class="casAuthors">Lantz, R. J.; Gillespie, T. A.; Rash, T. J.; Kuo, F.; Skinner, M.; Kuan, H.-Y.; Knadler, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1142-1150</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Duloxetine is a potent and balanced dual inhibitor of serotonin and norepinephrine reuptake being investigated for the treatment of depression and urinary incontinence.  The disposition of duloxetine was studied in four healthy human subjects after a single 20.2-mg (100.6 μCi) oral dose of [14C]duloxetine in an enteric-coated tablet.  The mean total recovery of radioactivity (± S.E.M.) after 312 h was 90.5% (±0.4%) with 72.0% (±1.1%) excreted in the urine.  Duloxetine was extensively metabolized to numerous metabolites primarily excreted into the urine in the conjugated form.  The major biotransformation pathways for duloxetine involved oxidn. of the naphthyl ring at either the 4-, 5-, or 6- positions followed by further oxidn., methylation, and/or conjugation.  The major metabolites found in plasma were glucuronide conjugates of the following: 4-hydroxy duloxetine (M6), 6-hydroxy-5-methoxy duloxetine (M10), 4, 6-dihydroxy duloxetine (M9), and a sulfate conjugate of 5-hydroxy-6-methoxy duloxetine (M7).  The major metabolites found in plasma were also found in the urine, but the urine contained many addnl. metabolites.  In addn. to duloxetine, 4-hydroxy duloxetine (M14) and an unidentified polar metabolite were obsd. in feces.  Following [14C]duloxetine administration, Cmax was reached at a median of 6 h for both duloxetine and total radioactivity.  Duloxetine accounted for less than 3% of the circulating radioactivity based on mean area under the curve values.  The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH8VCfe6WAh7Vg90H21EOLACvtfcHk0lj-OMh9Suc2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmslKlu7w%253D&md5=f2b2687d099b8e760e5b487f68844c7b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.9.1142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.9.1142%26sid%3Dliteratum%253Aachs%26aulast%3DLantz%26aufirst%3DR.%2BJ.%26aulast%3DGillespie%26aufirst%3DT.%2BA.%26aulast%3DRash%26aufirst%3DT.%2BJ.%26aulast%3DKuo%26aufirst%3DF.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKuan%26aufirst%3DH.%2BY.%26aulast%3DKnadler%26aufirst%3DM.%2BP.%26atitle%3DMetabolism%252C%2520excretion%252C%2520and%2520pharmacokinetics%2520of%2520duloxetine%2520in%2520healthy%2520human%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1142%26epage%3D1150%26doi%3D10.1124%2Fdmd.31.9.1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dansette, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libraire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuy, D.</span></span> <span> </span><span class="NLM_article-title">Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1021/tx8004828</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx8004828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=369-373&author=P.+M.+Dansetteauthor=J.+Libraireauthor=G.+Berthoauthor=D.+Mansuy&title=Metabolic+oxidative+cleavage+of+thioesters%3A+evidence+for+the+formation+of+sulfenic+acid+intermediates+in+the+bioactivation+of+the+antithrombotic+prodrugs+ticlopidine+and+clopidogrel&doi=10.1021%2Ftx8004828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel</span></div><div class="casAuthors">Dansette, Patrick M.; Libraire, Julie; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">369-373</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metabolic cleavage of the CO-S bond of some thioesters RCOSR' with the formation of RCOOH requires a monooxygenase-dependent oxidative activation of this bond.  The nature of the S-contg. product(s) resulting from this cleavage remains unclear in most cases.  This communication provides the first evidence for the formation of sulfenic acid intermediates 4a and 4b during the oxidative cleavage of the CO-S bond of thiolactone metabolites 2a and 2b of antithrombotic prodrugs, ticlopidine and clopidogrel, by rat and human liver microsomes.  These intermediates have been trapped by dimedone, and the corresponding adducts 5a and 5b have been characterized by mass spectrometry (MS) and 1H and 13C NMR spectroscopy.  Their formation is monooxygenase-dependent and almost completely inhibited by microsomal cytochrome P 450 inhibitors.  Moreover, they were also formed upon incubation with microsomes contg. recombinant human P 450 3A4, 3A5, 2C8, 2C9, 2C19, 2D6, or 1A2.  In the presence of thiols such as mercaptoethanol, N-acetylcysteine, or glutathione, microsomal incubations of 2a led to mixed disulfides that have been characterized by MS and should result from reaction of 4a with these thiols.  At high thiol concns., one obsd. in HPLC-MS the formation of a product exhibiting the MS expected for the previously described thiol metabolite 3a, a redn. product of 4a that has been reported as the pharmacol. active metabolite of ticlopidine.  These data provide the first evidence for the formation of sulfenic acid reactive metabolites upon P 450-catalyzed oxidative cleavage of thioesters.  They also provide a first detailed mechanism for the previously described formation of pharmacol. active thiols such as 3a upon oxidative metab. of ticlopidine and clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT08wJDRg6g7Vg90H21EOLACvtfcHk0lj-OMh9Suc2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2ksrc%253D&md5=5b7783f3cfabd4dff3de96558bf9a63a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Ftx8004828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx8004828%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DLibraire%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DMetabolic%2520oxidative%2520cleavage%2520of%2520thioesters%253A%2520evidence%2520for%2520the%2520formation%2520of%2520sulfenic%2520acid%2520intermediates%2520in%2520the%2520bioactivation%2520of%2520the%2520antithrombotic%2520prodrugs%2520ticlopidine%2520and%2520clopidogrel%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D369%26epage%3D373%26doi%3D10.1021%2Ftx8004828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dansette, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuy, D.</span></span> <span> </span><span class="NLM_article-title">Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxanase catalyzes the formation of a minor thiol metabolite isomer</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1021/tx2004085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx2004085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2nurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=348-356&author=P.+M.+Dansetteauthor=J.+Rosiauthor=G.+Berthoauthor=D.+Mansuy&title=Cytochromes+P450+catalyze+both+steps+of+the+major+pathway+of+clopidogrel+bioactivation%2C+whereas+paraoxanase+catalyzes+the+formation+of+a+minor+thiol+metabolite+isomer&doi=10.1021%2Ftx2004085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer</span></div><div class="casAuthors">Dansette, Patrick M.; Rosi, Julien; Bertho, Gildas; Mansuy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">348-356</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mechanism generally admitted for the bioactivation of the antithrombotic prodrug, clopidogrel, is its two-step enzymic conversion into a biol. active thiol metabolite.  The first step is a classical cytochrome P 450-dependent monooxygenation of its thiophene ring leading to 2-oxo-clopidogrel, a thiolactone metabolite.  The second step was described as a P 450-dependent oxidative opening of the thiolactone ring of 2-oxo-clopidogrel, with intermediate formation of a reactive sulfenic acid metabolite that is eventually reduced to the corresponding thiol 4b.  A very recent paper published in Nat. Med. (Bouman et al., (2011) 17, 110) reported that the second step of clopidogrel bioactivation was not catalyzed by P 450 enzymes but by paraoxonase-1(PON-1) and that PON-1 was a major determinant of clopidogrel efficacy.  The results described in the present article show that there are two metabolic pathways for the opening of the thiolactone ring of 2-oxo-clopidogrel.  The major one, that was previously described, results from a P 450-dependent redox bioactivation of 2-oxo-clopidogrel and leads to 4b cis, two previously reported thiol diastereomers bearing an exocyclic double bond.  The second, minor one, results from a hydrolysis of 2-oxo-clopidogrel, which seems to be dependent on PON-1, and leads to an isomer of 4b cis, 4b "endo", in which the double bond has migrated from an exocyclic to an endocyclic position in the piperidine ring.  These results were obtained from a detailed study of the metab. of 2-oxo-clopidogrel by human liver microsomes and human sera and anal. by HPLC-MS under conditions allowing a complete sepn. of the thiol metabolite isomers, either as such or after derivatization with 3'-methoxy phenacyl bromide or N-Et maleimide (NEM).  These results also show that the major bioactive thiol isomer found in the plasma of clopidogrel-treated patients derives from 2-oxo-clopidogrel by the P 450-dependent pathway.  Finally, chem. expts. on 2-oxo-clopidogrel showed that this thiolactone is in equil. with its tautomer having a double bond inside the piperidine ring and that nucleophiles such as CH3O- preferentially react on the thioester function of this tautomer.  This allowed us to understand why 4b cis has to be formed via an oxidative opening of 2-oxo-clopidogrel thiolactone, whereas a hydrolytic opening of this thiolactone ring leads to the "endo" thiol isomer 4b "endo".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyp1u0gkh97Vg90H21EOLACvtfcHk0lj-OMh9Suc2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2nurfK&md5=d9d072a01bf586ed9ccc15e01f5be181</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Ftx2004085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx2004085%26sid%3Dliteratum%253Aachs%26aulast%3DDansette%26aufirst%3DP.%2BM.%26aulast%3DRosi%26aufirst%3DJ.%26aulast%3DBertho%26aufirst%3DG.%26aulast%3DMansuy%26aufirst%3DD.%26atitle%3DCytochromes%2520P450%2520catalyze%2520both%2520steps%2520of%2520the%2520major%2520pathway%2520of%2520clopidogrel%2520bioactivation%252C%2520whereas%2520paraoxanase%2520catalyzes%2520the%2520formation%2520of%2520a%2520minor%2520thiol%2520metabolite%2520isomer%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D348%26epage%3D356%26doi%3D10.1021%2Ftx2004085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachayus, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delesque-Touchard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labouret, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hervé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzabiaga, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereillo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culouscou, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, M.</span></span> <span> </span><span class="NLM_article-title">The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">11069</span>– <span class="NLM_lpage">11074</span>, <span class="refDoi"> DOI: 10.1073/pnas.0510446103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1073%2Fpnas.0510446103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16835302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=11069-11074&author=P.+Saviauthor=J.+L.+Zachayusauthor=N.+Delesque-Touchardauthor=C.+Labouretauthor=C.+Herv%C3%A9author=M.+F.+Uzabiagaauthor=J.+M.+Pereilloauthor=J.+M.+Culouscouauthor=F.+Bonoauthor=P.+Ferraraauthor=M.+Herbert&title=The+active+metabolite+of+Clopidogrel+disrupts+P2Y12+receptor+oligomers+and+partitions+them+out+of+lipid+rafts&doi=10.1073%2Fpnas.0510446103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts</span></div><div class="casAuthors">Savi, Pierre; Zachayus, Jean-Luc; Delesque-Touchard, Nathalie; Labouret, Catherine; Herve, Caroline; Uzabigaga, Marie-Francoise; Pereillo, Jean-Marie; Culouscou, Jean-Michel; Bono, Francoise; Ferrara, Pascual; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11069-11074</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">P2Y12, a G protein-coupled receptor that plays a central role in platelet activation has been recently identified as the receptor targeted by the antithrombotic drug, clopidogrel.  In this study, we further deciphered the mechanism of action of clopidogrel and of its active metabolite (Act-Met) on P2Y12 receptors.  Using biochem. approaches, we demonstrated the existence of homooligomeric complexes of P2Y12 receptors at the surface of mammalian cells and in freshly isolated platelets.  In vitro treatment with Act-Met or in vivo oral administration to rats with clopidogrel induced the breakdown of these oligomers into dimeric and monomeric entities in P2Y12 expressing HEK293 and platelets resp.  In addn., we showed the predominant assocn. of P2Y12 oligomers to cell membrane lipid rafts and the partitioning of P2Y12 out of rafts in response to clopidogrel and Act-Met.  The raft-assocd. P2Y12 oligomers represented the functional form of the receptor, as demonstrated by binding and signal transduction studies.  Finally, using a series of receptors individually mutated at each cysteine residue and a chimeric P2Y12/P2Y13 receptor, we pointed out the involvement of cysteine 97 within the first extracellular loop of P2Y12 in the mechanism of action of Act-Met.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiqt3k9u_2_7Vg90H21EOLACvtfcHk0lhJm3JpKnstSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFeltr4%253D&md5=607365838851caaf1b5881dd624042bf</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510446103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510446103%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DZachayus%26aufirst%3DJ.%2BL.%26aulast%3DDelesque-Touchard%26aufirst%3DN.%26aulast%3DLabouret%26aufirst%3DC.%26aulast%3DHerv%25C3%25A9%26aufirst%3DC.%26aulast%3DUzabiaga%26aufirst%3DM.%2BF.%26aulast%3DPereillo%26aufirst%3DJ.%2BM.%26aulast%3DCulouscou%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DF.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DM.%26atitle%3DThe%2520active%2520metabolite%2520of%2520Clopidogrel%2520disrupts%2520P2Y12%2520receptor%2520oligomers%2520and%2520partitions%2520them%2520out%2520of%2520lipid%2520rafts%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D11069%26epage%3D11074%26doi%3D10.1073%2Fpnas.0510446103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haddock, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, F. R.</span></span> <span> </span><span class="NLM_article-title">Metabolic pathways of paroxetine in animals and man and the comparative pharmacological properties of the metabolites</span>. <i>Acta Psychiatr. Scand.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0447.1989.tb07163.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1111%2Fj.1600-0447.1989.tb07163.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1989&pages=24-26&author=R.+E.+Haddockauthor=A.+M.+Johnsonauthor=P.+F.+Langleyauthor=D.+R.+Nelsonauthor=J.+A.+Popeauthor=D.+R.+Thomasauthor=F.+R.+Woods&title=Metabolic+pathways+of+paroxetine+in+animals+and+man+and+the+comparative+pharmacological+properties+of+the+metabolites&doi=10.1111%2Fj.1600-0447.1989.tb07163.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.1989.tb07163.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.1989.tb07163.x%26sid%3Dliteratum%253Aachs%26aulast%3DHaddock%26aufirst%3DR.%2BE.%26aulast%3DJohnson%26aufirst%3DA.%2BM.%26aulast%3DLangley%26aufirst%3DP.%2BF.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DPope%26aufirst%3DJ.%2BA.%26aulast%3DThomas%26aufirst%3DD.%2BR.%26aulast%3DWoods%26aufirst%3DF.%2BR.%26atitle%3DMetabolic%2520pathways%2520of%2520paroxetine%2520in%2520animals%2520and%2520man%2520and%2520the%2520comparative%2520pharmacological%2520properties%2520of%2520the%2520metabolites%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D1989%26volume%3D80%26spage%3D24%26epage%3D26%26doi%3D10.1111%2Fj.1600-0447.1989.tb07163.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1021/tx700132x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx700132x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1649-1657&author=S.+X.+Zhaoauthor=D.+K.+Dalvieauthor=J.+M.+Kellyauthor=J.+R.+Sogliaauthor=K.+S.+Frederickauthor=E.+B.+Smithauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=NADPH-dependent+covalent+binding+of+%5B3H%5Dparoxetine+to+human+liver+microsomes+and+S-9+fractions%3A+identification+of+an+electrophilic+quinone+metabolite+of+paroxetine&doi=10.1021%2Ftx700132x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH-Dependent Covalent Binding of [3H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine</span></div><div class="casAuthors">Zhao, Sabrina X.; Dalvie, Deepak K.; Kelly, Joan M.; Soglia, John R.; Frederick, Kosea S.; Smith, Evan B.; Obach, R. Scott; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The primary pathway of clearance of the methylenedioxyphenyl-contg. compd. and selective serotonin reuptake inhibitor paroxetine in humans involves P 450 2D6-mediated demethylenation to a catechol intermediate.  The process of demethylenation also results in the mechanism-based inactivation of the P 450 isoenzyme.  While the link between P 450 2D6 inactivation and pharmacokinetic interactions of paroxetine with P 450 2D6 substrates has been firmly established, there is a disconnect in terms of paroxetine's excellent safety record despite the potential for bioactivation.  In the present study, the authors have systematically assessed the NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 prepns. in the absence and presence of cofactors of the various phase II drug-metabolizing enzymes involved in the downstream metab./detoxification of the putative paroxetine-catechol intermediate.  Incubation of [3H]paroxetine with human liver microsomes and S-9 prepns. resulted in irreversible binding of radioactive material to macromols. by a process that was NADPH-dependent.  The addn. of reduced glutathione (GSH) to the microsomal and S-9 incubations resulted in a dramatic redn. of covalent binding.  Following incubations with NADPH- and GSH-supplemented human liver microsomes and S-9, three sulfhydryl conjugates with MH+ ions at 623 Da (GS1), 779 Da (GS2), and 928 Da (GS3), resp., were detected by LC-MS/MS.  The collision-induced dissocn. spectra allowed an insight into the structure of the GSH conjugates, based on which, bioactivation pathways were proposed.  The formation of GS1 was consistent with Michael addn. of GSH to the quinone derived from two-electron oxidn. of paroxetine-catechol.  GS3 was formed by the addn. of a second mol. of GSH to the quinone species obtained via the two-electron oxidn. of GS1.  The mechanism of formation of GS2 can be rationalized via (i) further two-electron oxidn. of the catechol motif in GS3 to the ortho-quinone, (ii) loss of a glutamic acid residue from one of the adducted GSH mols., and (iii) condensation of a cysteine-NH2 with an adjacent carbonyl of the ortho-quinone to yield an ortho-benzoquinoneimine structure.  Inclusion of the catechol-O-methyltransferase cofactor S-adenosylmethionine (SAM) in S-9 incubations also dramatically reduced the covalent binding of [3H]paroxetine, a finding that was consistent with O-methylation of the paroxetine-catechol metabolite to the corresponding guaiacol regioisomers in S-9 incubations.  While the NADPH-dependent covalent binding was attenuated by GSH and SAM, these reagents did not alter paroxetine's ability to inactivate P 450 2D6, suggesting that the reactive intermediate responsible for P 450 inactivation did not leave the active site to react with other proteins.  The results of the studies indicate that in addn. to the low once-a-day dosing regimen (20 mg) of paroxetine, efficient scavenging of the catechol and quinone metabolites by SAM and GSH, resp., serves as an explanation for the excellent safety record of paroxetine despite the fact that it undergoes bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXUHMcbZnN7Vg90H21EOLACvtfcHk0lhJm3JpKnstSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK&md5=e7d3aa749a419cc87340271eb9b839a0</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Ftx700132x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700132x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DNADPH-dependent%2520covalent%2520binding%2520of%2520%255B3H%255Dparoxetine%2520to%2520human%2520liver%2520microsomes%2520and%2520S-9%2520fractions%253A%2520identification%2520of%2520an%2520electrophilic%2520quinone%2520metabolite%2520of%2520paroxetine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1649%26epage%3D1657%26doi%3D10.1021%2Ftx700132x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngui, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doss, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNinno, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.1021/tx0200109</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx0200109" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2002&pages=907-914&author=Q.+Chenauthor=J.+S.+Nguiauthor=G.+A.+Dossauthor=R.+W.+Wangauthor=X.+Caiauthor=F.+P.+DiNinnoauthor=T.+A.+Blizzardauthor=M.+L.+Hammondauthor=R.+A.+Stearnsauthor=D.+C.+Evansauthor=T.+A.+Baillieauthor=W.+Tang&title=Cytochrome+P450+3A4-mediated+bioactivation+of+raloxifene%3A+Irreversible+enzyme+inhibition+and+thiol+adduct+formation&doi=10.1021%2Ftx0200109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation</span></div><div class="casAuthors">Chen, Qing; Ngui, Jason S.; Doss, George A.; Wang, Regina W.; Cai, Xiaoxin; DiNinno, Frank P.; Blizzard, Timothy A.; Hammond, Milton L.; Stearns, Ralph A.; Evans, David C.; Baillie, Thomas A.; Tang, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-914</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene is a selective estrogen receptor modulator which is effective in the treatment of osteoporosis in postmenopausal women.  We report herein that cytochrome P 450 3A4 is inhibited by raloxifene in human liver microsomal incubations.  The nature of the inhibition was irreversible and was NADPH- and preincubation time-dependent, with KI and kinact values estd. at 9.9 μM and 0.16 min-1, resp.  The obsd. loss of P 450 3A4 activity was attenuated partially by glutathione (GSH), implying the involvement of a reactive metabolite(s) in the inactivation process.  Subsequently, GSH adducts of raloxifene were identified in incubations with human liver microsomes; substitution with GSH occurred at the 5- or 7-position of the benzothiophene moiety or at the 3'-position of the phenol ring, with the 7-glutathionyl deriv. being most abundant based on LC/MS and NMR analyses.  These adducts are postulated to derive from addn. of GSH to raloxifene arene oxides followed by dehydration and aromatization.  Alternatively, raloxifene may be oxidized to an extended quinone intermediate, which then is trapped by GSH conjugation.  The bioactivation of raloxifene most likely is catalyzed by P 450 3A4, since the formation of GSH adducts was almost abolished when liver microsomes were pretreated with ketoconazole or with an inhibitory anti-P 450 3A4 IgG.  The GSH adducts also were detected in incubations of raloxifene with rat or human hepatocytes, while the corresponding N-acetylcysteine adducts were identified in the bile and urine from rats treated orally with the drug at 5 mg/kg.  Taken together, these data indicate that P 450 3A4-mediated bioactivation of raloxifene in vitro is accompanied by loss of enzyme activity.  The significance of these findings with respect to the clin. use of raloxifene remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvQ7INUtJwIbVg90H21EOLACvtfcHk0liKGdvLkBznhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkt1KrurY%253D&md5=cec21bf3d8ce150474291a5e48206744</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Ftx0200109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0200109%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DNgui%26aufirst%3DJ.%2BS.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDiNinno%26aufirst%3DF.%2BP.%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26aulast%3DHammond%26aufirst%3DM.%2BL.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DCytochrome%2520P450%25203A4-mediated%2520bioactivation%2520of%2520raloxifene%253A%2520Irreversible%2520enzyme%2520inhibition%2520and%2520thiol%2520adduct%2520formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2002%26volume%3D15%26spage%3D907%26epage%3D914%26doi%3D10.1021%2Ftx0200109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2260</span>– <span class="NLM_lpage">2271</span>, <span class="refDoi"> DOI: 10.1021/tx800323w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx800323w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=2260-2271&author=D.+Dalvieauthor=P.+Kangauthor=M.+Zientekauthor=C.+Xiangauthor=S.+Zhouauthor=R.+S.+Obach&title=Effect+of+intestinal+glucuronidation+in+limiting+hepatic+exposure+and+bioactivation+of+raloxifene+in+humans+and+rats&doi=10.1021%2Ftx800323w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Intestinal Glucuronidation in Limiting Hepatic Exposure and Bioactivation of Raloxifene in Humans and Rats</span></div><div class="casAuthors">Dalvie, Deepak; Kang, Ping; Zientek, Michael; Xiang, Cathie; Zhou, Sue; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2260-2271</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Raloxifene (Evista) is a second generation selective estrogen receptor modulator used in the treatment of osteoporosis and for chemoprevention of breast cancer.  It is bioactivated to reactive intermediates, which covalently bind to proteins and form GSH conjugates upon incubation with NADPH and GSH-supplemented human and rat liver microsomes.  Despite these in vitro findings, no major raloxifene-related toxic events have been reported upon its oral administration to humans.  This disconnect between safety of raloxifene and its in vitro bioactivation is attributed to its presystemic metab. via glucuronidation.  Current studies investigated the effect of hepatic and intestinal glucuronidation in modulating hepatic availability of raloxifene and its subsequent bioactivation, in vitro.  The study design involved preincubation of raloxifene with intestinal microsomes followed by a sequential incubation with liver microsomes.  The degree of bioactivation of raloxifene was assessed from the percentage of GSH conjugate formed in liver microsomal incubations or the amt. of covalent binding of raloxifene-related material to liver microsomal proteins.  The results indicated that human intestinal glucuronidation limited the hepatic exposure of raloxifene that underwent bioactivation in the liver.  Similar expts. with rat microsomal prepns. showed very little effect of intestinal glucuronidation.  This effect of intestinal glucuronidation and the obsd. species difference were explained by comparing the efficiency (Clint) of glucuronidation and oxidn. in the two species.  These findings suggested that even though the rate of bioactivation in the two species was similar, the Clint of glucuronidation was 7.5-fold higher in the human intestine as compared to rats.  These results support the hypothesis that intestinal glucuronidation modulates the amt. of raloxifene undergoing bioactivation by liver and corroborate the importance of assessing other competitive metabolic pathways and species differences in metab. prior to extrapolation of bioactivation results from rats to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-CeHG1UEOrVg90H21EOLACvtfcHk0liKGdvLkBznhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSqtb7O&md5=69f878c5dd77d57379745df37cf9121b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Ftx800323w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800323w%26sid%3Dliteratum%253Aachs%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DP.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DXiang%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DEffect%2520of%2520intestinal%2520glucuronidation%2520in%2520limiting%2520hepatic%2520exposure%2520and%2520bioactivation%2520of%2520raloxifene%2520in%2520humans%2520and%2520rats%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D2260%26epage%3D2271%26doi%3D10.1021%2Ftx800323w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mizuma, T.</span></span> <span> </span><span class="NLM_article-title">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2009.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.ijpharm.2009.05.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19486934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2009&pages=140-141&author=T.+Mizuma&title=Intestinal+glucuronidation+metabolism+may+have+a+greater+impact+on+oral+bioavailability+than+hepatic+glucuronidation+metabolism+in+humans%3A+a+study+with+raloxifene%2C+substrate+for+UGT1A1%2C+1A8%2C+1A9%2C+and+1A10&doi=10.1016%2Fj.ijpharm.2009.05.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</span></div><div class="casAuthors">Mizuma, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">140-141</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kinetic impact of intestinal glucuronidation metab. on oral bioavailability (F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%.  Kinetic anal. showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, resp.  Thus, Fpg was the lowest among factors, which affect oral bioavailability.  In addn., Fpg was much lower than Fh, suggesting that intestinal glucuronidation metab. has a greater impact on oral bioavailability than hepatic glucuronidation metab.  It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine.  Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metab., causing low oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFWR7hNsC17rVg90H21EOLACvtfcHk0liKGdvLkBznhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFKqtbs%253D&md5=293c4c269d54a0e92e32c9aa473d50d6</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2009.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2009.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DMizuma%26aufirst%3DT.%26atitle%3DIntestinal%2520glucuronidation%2520metabolism%2520may%2520have%2520a%2520greater%2520impact%2520on%2520oral%2520bioavailability%2520than%2520hepatic%2520glucuronidation%2520metabolism%2520in%2520humans%253A%2520a%2520study%2520with%2520raloxifene%252C%2520substrate%2520for%2520UGT1A1%252C%25201A8%252C%25201A9%252C%2520and%25201A10%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2009%26volume%3D378%26spage%3D140%26epage%3D141%26doi%3D10.1016%2Fj.ijpharm.2009.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandange, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindblom, L.</span></span> <span> </span><span class="NLM_article-title">The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine delta 1’(5′) iminium ion</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(79)91977-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-291X%2879%2991977-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=43154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaL3c7gvFaksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1979&pages=991-996&author=S.+Brandangeauthor=L.+Lindblom&title=The+enzyme+%E2%80%9Caldehyde+oxidase%E2%80%9D+is+an+iminium+oxidase.+Reaction+with+nicotine+delta+1%E2%80%99%285%E2%80%B2%29+iminium+ion&doi=10.1016%2F0006-291X%2879%2991977-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion</span></div><div class="casAuthors">Brandange S; Lindblom L</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and biophysical research communications</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">991-6</span>
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgDHlrG449Po3yKPtYViAGfW6udTcc2ebOBLslmk7b6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3c7gvFaksQ%253D%253D&md5=88623b9f4b28ae7f18248837cd70e193</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2879%2991977-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252879%252991977-6%26sid%3Dliteratum%253Aachs%26aulast%3DBrandange%26aufirst%3DS.%26aulast%3DLindblom%26aufirst%3DL.%26atitle%3DThe%2520enzyme%2520%25E2%2580%259Caldehyde%2520oxidase%25E2%2580%259D%2520is%2520an%2520iminium%2520oxidase.%2520Reaction%2520with%2520nicotine%2520delta%25201%25E2%2580%2599%25285%25E2%2580%25B2%2529%2520iminium%2520ion%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1979%26volume%3D91%26spage%3D991%26epage%3D996%26doi%3D10.1016%2F0006-291X%2879%2991977-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hukkanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, P.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benowitz, N. L.</span></span> <span> </span><span class="NLM_article-title">Metabolism and disposition kinetics of nicotine</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1124/pr.57.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fpr.57.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=15734728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=79-115&author=J.+Hukkanenauthor=P.+Jacobauthor=N.+L.+Benowitz&title=Metabolism+and+disposition+kinetics+of+nicotine&doi=10.1124%2Fpr.57.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and disposition kinetics of nicotine</span></div><div class="casAuthors">Hukkanen, Janne; Jacob, Peyton, III; Benowitz, Neal L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-115</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Nicotine is of importance as the addictive chem. in tobacco, pharmacotherapy for smoking cessation, a potential medication for several diseases, and a useful probe drug for phenotyping cytochrome P 450 2A6 (CYP2A6).  We review current knowledge about the metab. and disposition kinetics of nicotine, some other naturally occurring tobacco alkaloids, and nicotine analogs that are under development as potential therapeutic agents.  The focus is on studies in humans, but animal data are mentioned when relevant to the interpretation of human data.  The pathways of nicotine metab. are described in detail.  Absorption, distribution, metab., and excretion of nicotine and related compds. are reviewed.  Enzymes involved in nicotine metab. including cytochrome P 450 enzymes, aldehyde oxidase, flavin-contg. monooxygenase 3, amine N-methyltransferase, and UDP-glucuronosyltransferases are represented, as well as factors affecting metab., such as genetic variations in metabolic enzymes, effects of diet, age, gender, pregnancy, liver and kidney diseases, and racial and ethnic differences.  Also effects of smoking and various inhibitors and inducers, including oral contraceptives, on nicotine metab. are discussed.  Due to the significance of the CYP2A6 enzyme in nicotine clearance, special emphasis is given to the effects and population distributions of CYP2A6 alleles and the regulation of CYP2A6 enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdiaRmgTT3LrVg90H21EOLACvtfcHk0lj8uDb-oYNg3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1Gmtro%253D&md5=258913d632a8f4de861b7bbe2650c0e5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DHukkanen%26aufirst%3DJ.%26aulast%3DJacob%26aufirst%3DP.%26aulast%3DBenowitz%26aufirst%3DN.%2BL.%26atitle%3DMetabolism%2520and%2520disposition%2520kinetics%2520of%2520nicotine%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D79%26epage%3D115%26doi%3D10.1124%2Fpr.57.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshihara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, S.</span></span> <span> </span><span class="NLM_article-title">Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP<sup>+</sup>) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1006/abbi.1998.0925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1006%2Fabbi.1998.0925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=9826433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFOku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=1998&pages=93-98&author=S.+Yoshiharaauthor=S.+Ohta&title=Involvement+of+hepatic+aldehyde+oxidase+in+conversion+of+1-methyl-4-phenyl-2%2C3-dihydropyridinium+%28MPDP%2B%29+to+1-methyl-4-phenyl-5%2C6-dihydro-2-pyridone&doi=10.1006%2Fabbi.1998.0925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone</span></div><div class="casAuthors">Yoshihara, Shin'ichi; Ohta, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-98</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">To obtain direct evidence of the involvement of aldehyde oxidase (AO), a cytosolic molybdoflavoenzyme, in the metab. of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the authors investigated the in vitro metab. of MPTP and the two-electron-oxidized 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+) by using mouse liver enzyme prepns.  Incubation of MPTP with mitochondrial fraction gave exclusively 1-methyl-4-phenylpyridinium (MPP+); this reaction was inhibited by deprenyl, a monoamine oxidase (MAO)-B inhibitor, and KCN.  When the mitochondrial fraction was combined with the cytosolic fraction, MPP+ formation was markedly decreased, while a large amt. of 1-methyl-4-phenyl-5,6-dihydro-2-pyridone (MPTP lactam) was newly formed.  Incubation of MPDP+ with the cytosolic fraction led to rapid formation of MPTP lactam with concomitant disappearance of the substrate.  The cytosol-dependent formation of MPTP lactam was inhibited by known AO inhibitors, such as menadione, norharman, and KCN.  The activity of cytosol in MPTP lactam formation was completely duplicated by purified mouse liver AO.  These results indicate that AO catalyzes the metabolic conversion of MPDP+, produced from MPTP by MAO-B, to MPTP lactam.  This metabolic pathway might be an important detoxification route, averting the formation of toxic MPP+.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yYA8zidMqbVg90H21EOLACvtfcHk0lj8uDb-oYNg3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFOku7o%253D&md5=6bcbee0b2e811b35b803021accda0f86</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1998.0925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1998.0925%26sid%3Dliteratum%253Aachs%26aulast%3DYoshihara%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DS.%26atitle%3DInvolvement%2520of%2520hepatic%2520aldehyde%2520oxidase%2520in%2520conversion%2520of%25201-methyl-4-phenyl-2%252C3-dihydropyridinium%2520%2528MPDP%252B%2529%2520to%25201-methyl-4-phenyl-5%252C6-dihydro-2-pyridone%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1998%26volume%3D360%26spage%3D93%26epage%3D98%26doi%3D10.1006%2Fabbi.1998.0925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldera-Munoz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1021/tx00003a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx00003a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL1cXktFygurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=186-194&author=E.+Wuauthor=T.+Shinkaauthor=P.+Caldera-Munozauthor=H.+Yoshizumiauthor=A.+Trevorauthor=N.+Castagnoli&title=Metabolic+studies+on+the+nigrostriatal+toxin+MPTP+and+its+MAO+B+generated+dihydropyridinium+metabolite+MPDP%2B&doi=10.1021%2Ftx00003a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+</span></div><div class="casAuthors">Wu, Ellen; Shinka, Toshihiro; Caldera-Munoz, Patricia; Yoshizumi, Hideo; Trevor, Anthony; Castagnoli, Neal, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-94</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    </div><div class="casAbstract">Incubations of MPTP (50 μM and 1 mM) with mouse brain prepns. result in the expected MAO B catalyzed formation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+).  The 4-electron oxidn. product, the 1-methyl-4-phenylpyridinium species (MPP+), was the only other metabolite detected.  The oxidn. of 50 μM MPDP+ to MPP+ in the same prepns. appears to be mediated by unidentified components present in membrane contg. structures.  The behavior of MPTP in mouse liver subcellular fractions is considerably more complex.  NADPH-supplemented liver microsomes convert MPTP to the demethyl and N-oxide metabolites.  At high (1 mM) initial concns. of MPTP, there is evidence that NADPH-dependent, pargyline-insensitive liver microsomal enzymes also catalyze the oxidn. of MPTP to MPDP+.  Incubations of MPDP+ with mouse liver prepns. contg. the cytosolic fraction led to the rapid disappearance of the substrate and the quant. formation of a metabolic product with mass spectral and diode array UV characteristics expected for a lactam structure.  Menadione, an inhibitor of the cytosolic enzyme aldehyde oxidase, inhibits the formation of this product.  Unambiguous characterization of this product as 1-methyl-4-phenyl-5,6-dihydro-2-pyridone (I) was achieved by comparison of its high-resoln. 1H NMR and high-resoln. EI mass spectra with the corresponding spectra of a synthetic std.  I is oxidized in a reaction catalyzed by an NADPH-dependent microsomal enzyme system to the corresponding 1-methyl-4-phenyl-2-pyridone.  These tissue-selective metabolic events may regulate the neurotoxicity of MPTP in the mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWIlJRkvlbQLVg90H21EOLACvtfcHk0lhAv8gCD3CWiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFygurw%253D&md5=41f65bf0d25cdc7a07041dc4bdb6c863</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Ftx00003a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00003a010%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DE.%26aulast%3DShinka%26aufirst%3DT.%26aulast%3DCaldera-Munoz%26aufirst%3DP.%26aulast%3DYoshizumi%26aufirst%3DH.%26aulast%3DTrevor%26aufirst%3DA.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DMetabolic%2520studies%2520on%2520the%2520nigrostriatal%2520toxin%2520MPTP%2520and%2520its%2520MAO%2520B%2520generated%2520dihydropyridinium%2520metabolite%2520MPDP%252B%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1988%26volume%3D1%26spage%3D186%26epage%3D194%26doi%3D10.1021%2Ftx00003a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosogi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, T.</span></span> <span> </span><span class="NLM_article-title">Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1016/j.dmpk.2017.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.dmpk.2017.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=28751116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2017&pages=255-264&author=J.+Hosogiauthor=R.+Ohashiauthor=H.+Maedaauthor=S.+Tashiroauthor=E.+Fuseauthor=Y.+Yamamotoauthor=T.+Kuwabara&title=Monoamine+oxidase+B+oxidizes+a+novel+multikinase+inhibitor+KW-2449+to+its+iminium+ion+and+aldehyde+oxidase+further+converts+it+to+the+oxo-piperazine+form+in+human&doi=10.1016%2Fj.dmpk.2017.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human</span></div><div class="casAuthors">Hosogi, Jun; Ohashi, Rui; Maeda, Hiroshi; Tashiro, Satoshi; Fuse, Eiichi; Yamamoto, Yorihiro; Kuwabara, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">255-264</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine (KW-2449) is a novel multikinase inhibitor.  During our clin. study, we found that KW-2449 is mainly metabolized to its oxo-piperazine form (M1).  An inhibition study suggested that monoamine oxidase-B (MAO-B) oxidizes KW-2449 to an iminium (intermediate) and aldehyde oxidase (AO) then metabolizes the intermediate to M1.  The conversion of KW-2449 to the iminium (intermediate) by MAO-B was confirmed by the formation of its cyanide adduct.  This cooperative metabolic pathway by MAO-B and AO was newly identified in the metab. of piperazine.  The clearance of KW-2449 by MAO-B and AO in human was estd. based on the kinetic anal. with in vitro-in vivo extrapolation.  The systemic clearance in human was similar to the calcd. value, indicating that the extrapolation approach was applicable to KW-2449 metab.  Finally, we found that (E)-3-amino-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}-pyrrolidine (Compd. A) as a stable compd. against MAO-B and AO.  The total body clearance of Compd. A was reduced to one tenth of KW-2449, demonstrating that preventing the metab. of MAO and AO led to more preferable pharmacokinetic profiles.  As piperazine is often introduced to drug candidates to improve lipophilicity of the compd. to get more hydrophilic nature, the results of this study provide useful information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2fKwc369Ix7Vg90H21EOLACvtfcHk0lgXXVfzGaAbqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt7nO&md5=1846c419191a12469d1be35860c67cf9</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.dmpk.2017.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dmpk.2017.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DHosogi%26aufirst%3DJ.%26aulast%3DOhashi%26aufirst%3DR.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DTashiro%26aufirst%3DS.%26aulast%3DFuse%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuwabara%26aufirst%3DT.%26atitle%3DMonoamine%2520oxidase%2520B%2520oxidizes%2520a%2520novel%2520multikinase%2520inhibitor%2520KW-2449%2520to%2520its%2520iminium%2520ion%2520and%2520aldehyde%2520oxidase%2520further%2520converts%2520it%2520to%2520the%2520oxo-piperazine%2520form%2520in%2520human%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2017%26volume%3D32%26spage%3D255%26epage%3D264%26doi%3D10.1016%2Fj.dmpk.2017.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warr, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorehead, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemenway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, J. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.078899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.117.078899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=29311136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsV2ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=237-247&author=J.+Zhengauthor=Y.+Xinauthor=J.+Zhangauthor=R.+Subramanianauthor=B.+P.+Murrayauthor=J.+A.+Whitneyauthor=M.+R.+Warrauthor=J.+Lingauthor=L.+Mooreheadauthor=E.+Kwanauthor=J.+Hemenwayauthor=B.+J.+Smithauthor=J.+A.+Silverman&title=Pharmacokinetics+and+disposition+of+momelotinib+revealed+a+disproportionate+human+metabolite-resolution+for+clinical+development&doi=10.1124%2Fdmd.117.078899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development</span></div><div class="casAuthors">Zheng, Jim; Xin, Yan; Zhang, Jingyu; Subramanian, Raju; Murray, Bernard P.; Whitney, J. Andrew; Warr, Matthew R.; Ling, John; Moorehead, Lisa; Kwan, Ellen; Hemenway, Jeffrey; Smith, Bill J.; Silverman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-247,S1-S28</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Momelotinib (MMB), a small-mol. inhibitor of Janus kinase (JAK)1/2 and of activin A receptor type 1 (ACVR1), is in clin. development for the treatment of myeloproliferative neoplasms.  The pharmacokinetics and disposition of [14C]MMB were characterized in a single-dose, human mass-balance study.  Metab. and the pharmacol. activity of key metabolites were elucidated in multiple in vitro and in vivo expts.  MMB was rapidly absorbed following oral dosing with approx. 97% of the radioactivity recovered, primarily in feces with urine as a secondary route.  Mean blood-to-plasma [14C] area under the plasma concn.-time curve ratio was 0.72, suggesting low assocn. of MMB and metabolites with blood cells. [14C]MMB-derived radioactivity was detectable in blood for ≤48 h, suggesting no irreversible binding of MMB or its metabolites.  The major circulating human metabolite, M21 (a morpholino lactam), is a potent inhibitor of JAK1/2 and ACVR1 in vitro.  Estn. of pharmacol. activity index suggests M21 contributes significantly to the pharmacol. activity of MMB for the inhibition of both JAK1/2 and ACVR1.  M21 was obsd. in disproportionately higher amts. in human plasma than in rat or dog, the rodent and nonrodent species used for the general nonclin. safety assessment of this mol.  This discrepancy was resolved with addnl. nonclin. studies wherein the circulating metabolites and drug-drug interactions were further characterized.  The human metab. of MMB was mediated primarily by multiple cytochrome P 450 enzymes, whereas M21 formation involved initial P 450 oxidn. of the morpholine ring followed by metab. via aldehyde oxidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGdMwZyk81C7Vg90H21EOLACvtfcHk0lgXXVfzGaAbqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsV2ktb8%253D&md5=cf73dce851338a404b11a90fe2287ca4</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.078899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.078899%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DXin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BP.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DWarr%26aufirst%3DM.%2BR.%26aulast%3DLing%26aufirst%3DJ.%26aulast%3DMoorehead%26aufirst%3DL.%26aulast%3DKwan%26aufirst%3DE.%26aulast%3DHemenway%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DSilverman%26aufirst%3DJ.%2BA.%26atitle%3DPharmacokinetics%2520and%2520disposition%2520of%2520momelotinib%2520revealed%2520a%2520disproportionate%2520human%2520metabolite-resolution%2520for%2520clinical%2520development%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D237%26epage%3D247%26doi%3D10.1124%2Fdmd.117.078899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrard, A. R.</span></span> <span> </span><span class="NLM_article-title">A review of acetaminophen poisoning</span>. <i>Crit. Care Clin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1016/j.ccc.2012.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2Fj.ccc.2012.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=22998987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BC38bptVagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=499-516&author=M.+J.+Hodgmanauthor=A.+R.+Garrard&title=A+review+of+acetaminophen+poisoning&doi=10.1016%2Fj.ccc.2012.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">A review of acetaminophen poisoning</span></div><div class="casAuthors">Hodgman Michael J; Garrard Alexander R</div><div class="citationInfo"><span class="NLM_cas:title">Critical care clinics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-516</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acetaminophen poisoning remains one of the more common drugs taken in overdose with potentially fatal consequences.  Early recognition and prompt treatment with N-acetylcysteine can prevent hepatic injury.  With acute overdose, the Rumack-Matthew nomogram is a useful tool to assess risk and guide management.  Equally common to acute overdose is the repeated use of excessive amounts of acetaminophen.  Simultaneous ingestion of several different acetaminophen-containing products may result in excessive dosage.  These patients also benefit from N-acetylcysteine.  Standard courses of N-acetylcysteine may need to be extended in patients with persistently elevated plasma concentrations of acetaminophen or with signs of hepatic injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1gfhcYlWFTcULxIEhxUjPfW6udTcc2easUzDf1WDpBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bptVagtA%253D%253D&md5=1baec0bc1993e99e05adec23e4624668</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.ccc.2012.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccc.2012.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DHodgman%26aufirst%3DM.%2BJ.%26aulast%3DGarrard%26aufirst%3DA.%2BR.%26atitle%3DA%2520review%2520of%2520acetaminophen%2520poisoning%26jtitle%3DCrit.%2520Care%2520Clin.%26date%3D2012%26volume%3D28%26spage%3D499%26epage%3D516%26doi%3D10.1016%2Fj.ccc.2012.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, L. E.</span></span> <span> </span><span class="NLM_article-title">The lupus syndrome induced by hydralazine: a common complication with low dose treatment</span>. <i>Br. Med. J. (Clin. Res. Ed.)</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">410</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1136/bmj.289.6442.410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1136%2Fbmj.289.6442.410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=6432120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADyaL2c3otFKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=1984&pages=410-412&author=H.+A.+Cameronauthor=L.+E.+Ramsay&title=The+lupus+syndrome+induced+by+hydralazine%3A+a+common+complication+with+low+dose+treatment&doi=10.1136%2Fbmj.289.6442.410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">The lupus syndrome induced by hydralazine: a common complication with low dose treatment</span></div><div class="casAuthors">Cameron H A; Ramsay L E</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal (Clinical research ed.)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">6442</span>),
    <span class="NLM_cas:pages">410-2</span>
        ISSN:<span class="NLM_cas:issn">0267-0623</span>.
    </div><div class="casAbstract">The true incidence of the lupus syndrome induced by hydralazine was determined in a longitudinal study of 281 patients consecutively starting hydralazine for hypertension over a 51 month period.  Data on the duration of treatment and the maximum dose achieved were examined using life table analysis.  After three years' treatment with hydralazine the incidence of the lupus syndrome was 6.7% (95% confidence limits 3.2-10.2%).  The incidence was dose dependent, with no cases recorded in patients taking 50 mg daily and incidences of 5.4% with 100 mg daily and of 10.4% with 200 mg daily.  The incidence was higher in women (11.6%) than in men (2.8%).  In women taking 200 mg daily the three year incidence was 19.4%.  Hydralazine is an effective antihypertensive drug that has come to be used in restricted dosage (not more than 200 mg daily) because of its risk of inducing the lupus syndrome.  This study shows that the true incidence of the syndrome is still unacceptably high even when the drug is prescribed according to current recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1JKWk4ySoRj0O18WR3iAofW6udTcc2easUzDf1WDpBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c3otFKjsg%253D%253D&md5=5d43bad58f0e2157e2503a7536b011f5</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1136%2Fbmj.289.6442.410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.289.6442.410%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DH.%2BA.%26aulast%3DRamsay%26aufirst%3DL.%2BE.%26atitle%3DThe%2520lupus%2520syndrome%2520induced%2520by%2520hydralazine%253A%2520a%2520common%2520complication%2520with%2520low%2520dose%2520treatment%26jtitle%3DBr.%2520Med.%2520J.%2520%2528Clin.%2520Res.%2520Ed.%2529%26date%3D1984%26volume%3D289%26spage%3D410%26epage%3D412%26doi%3D10.1136%2Fbmj.289.6442.410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degott, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letteron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descatoire, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amouyal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessayre, D.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of the tricyclic antidepressant amineptine – II Protective role of glutathione against in vitro and in vivo covalent binding</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(87)90290-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1016%2F0006-2952%2887%2990290-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=3814175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADyaL2sXhvVygu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1987&pages=331-337&author=J.+Gen%C3%A8veauthor=C.+Degottauthor=P.+Letteronauthor=M.+Tinelauthor=V.+Descatoireauthor=D.+Larreyauthor=G.+Amouyalauthor=D.+Pessayre&title=Metabolic+activation+of+the+tricyclic+antidepressant+amineptine+%E2%80%93+II+Protective+role+of+glutathione+against+in+vitro+and+in+vivo+covalent+binding&doi=10.1016%2F0006-2952%2887%2990290-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of the tricyclic antidepressant amineptine.  II.  Protective role of glutathione against in vitro and in vivo covalent binding</span></div><div class="casAuthors">Geneve, Jean; Degott, Claude; Letteron, Philippe; Tinel, Marina; Descatoire, Veronique; Larrey, Dominique; Amouyal, Gilles; Pessayre, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-7</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Incubation of [11-14C]-labeled amineptine  [57574-09-1] (1mM) with an NADPH-generating system and hamster liver microsomes resulted in the in vitro covalent binding of an amineptine metabolite to microsomal proteins; this binding was decreased by 41-71% in the presence of cysteine  [52-90-4], lysine  [56-87-1], glycine  [56-40-6], or glutathione  [70-18-8] (0.5 mM).  An inverse relationship was found between the concn. of glutathione in the incubation mixt. (0.25-4mM) and the extent of covalent binding in vitro, which became undetectable at concns. of glutathione of 2 mM and higher.  Administration of [11-14C]amineptine (300 mg/kg-1 i.p.) to hamsters pretreated with phorone resulted in the in vivo covalent binding of an amineptine metabolite to hepatic proteins.  This binding was increased by phenobarbital-pretreatment and decreased by piperonyl butoxide-pretreatment.  After various doses of phorone (150-500 mg/kg), an inverse relationship was found between hepatic glutathione content and in vivo covalent binding.  Administration of amineptine along (300 mg/kg i.p.) depleted hepatic glutathione by 16% only; in these animals, in vivo covalent binding was undetectable from background.  Amineptine (300 mg/kg i.p.) did not produce hepatic necrosis, even in hamsters pretreated with phorone and/or phenobarbital.  The authors concluded that physiol. concns. of glutathione essentially prevent the in vivo covalent binding of an amineptine metabolite to hepatic proteins, and that this binding does not produce liver cell necrosis in hamsters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroERkwk0ElGLVg90H21EOLACvtfcHk0lgEgsx7XbL6yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhvVygu7k%253D&md5=2cd2727508018108903f9392f067768d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2887%2990290-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252887%252990290-5%26sid%3Dliteratum%253Aachs%26aulast%3DGen%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DDegott%26aufirst%3DC.%26aulast%3DLetteron%26aufirst%3DP.%26aulast%3DTinel%26aufirst%3DM.%26aulast%3DDescatoire%26aufirst%3DV.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DAmouyal%26aufirst%3DG.%26aulast%3DPessayre%26aufirst%3DD.%26atitle%3DMetabolic%2520activation%2520of%2520the%2520tricyclic%2520antidepressant%2520amineptine%2520%25E2%2580%2593%2520II%2520Protective%2520role%2520of%2520glutathione%2520against%2520in%2520vitro%2520and%2520in%2520vivo%2520covalent%2520binding%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1987%26volume%3D36%26spage%3D331%26epage%3D337%26doi%3D10.1016%2F0006-2952%2887%2990290-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farid, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrighton, S. A.</span></span> <span> </span><span class="NLM_article-title">Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1177/0091270009343005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1177%2F0091270009343005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19948947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1SksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=126-142&author=N.+A.+Faridauthor=A.+Kuriharaauthor=S.+A.+Wrighton&title=Metabolism+and+disposition+of+the+thienopyridine+antiplatelet+drugs+ticlopidine%2C+clopidogrel%2C+and+prasugrel+in+humans&doi=10.1177%2F0091270009343005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans</span></div><div class="casAuthors">Farid, Nagy A.; Kurihara, Atsushi; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-142</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ticlopidine, clopidogrel, and prasugrel are thienopyridine prodrugs that inhibit adenosine-5'-diphosphate (ADP)-mediated platelet aggregation in vivo.  These compds. are converted to thiol-contg. active metabolites through a corresponding thiolactone.  The 3 compds. differ in their metabolic pathways to their active metabolites in humans.  Whereas ticlopidine and clopidogrel are metabolized to their thiolactones in the liver by cytochromes P 450, prasugrel proceeds to its thiolactone following hydrolysis by carboxylesterase 2 during absorption, and a portion of prasugrel's active metabolite is also formed by intestinal CYP3A.  Both ticlopidine and clopidogrel are subject to major competing metabolic pathways to inactive metabolites.  Thus, varying efficiencies in the formation of active metabolites affect obsd. effects on the onset of action and extent of inhibition of platelet aggregation (IPA).  Knowledge of the CYP-dependent formation of ticlopidine and clopidogrel thiolactones helps explain some of the obsd. drug-drug interactions with these mols. and, more important, the role of CYP2C19 genetic polymorphism on the pharmacokinetics of and pharmacodynamic response to clopidogrel.  The lack of drug interaction potential and the absence of CYP2C19 genetic effect result in a predictable response to thienopyridine antiplatelet therapy with prasugrel.  Current literature shows that greater ADP-mediated IPA is assocd. with significantly better clin. outcomes for patients with acute coronary syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6HQhdL8JHLVg90H21EOLACvtfcHk0liZi0zuWk-Txw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1SksLo%253D&md5=e9d059885285d3f2bd1fdeb4d2b5a0a0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1177%2F0091270009343005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009343005%26sid%3Dliteratum%253Aachs%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DMetabolism%2520and%2520disposition%2520of%2520the%2520thienopyridine%2520antiplatelet%2520drugs%2520ticlopidine%252C%2520clopidogrel%252C%2520and%2520prasugrel%2520in%2520humans%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2010%26volume%3D50%26spage%3D126%26epage%3D142%26doi%3D10.1177%2F0091270009343005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-2009&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+between+daily+dose+of+oral+medications+and+idiosyncratic+drug-induced+liver+injury%3A+search+for+signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0lgn-2pVBaSrcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520between%2520daily%2520dose%2520of%2520oral%2520medications%2520and%2520idiosyncratic%2520drug-induced%2520liver%2520injury%253A%2520search%2520for%2520signals%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26spage%3D2003%26epage%3D2009%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">615</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1002/hep.23317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.23317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=19839004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=615-620&author=C.+Lammertauthor=E.+Bjornssonauthor=A.+Niklassonauthor=N.+Chalasani&title=Oral+medications+with+significant+hepatic+metabolism+at+higher+risk+for+hepatic+adverse+events&doi=10.1002%2Fhep.23317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events</span></div><div class="casAuthors">Lammert, Craig; Bjornsson, Einar; Niklasson, Anna; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">615-620</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Reactive metabolites generated by hepatic metab. are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited.  If this is true, then compds. with significant hepatic metab. should cause more DILI than those without it.  We conducted a study to examine the relationship between hepatic metab. and DILI of prescription medications.  We systematically extd. the metab. characteristics of 207 of the most widely prescribed oral medications in the United States.  Compds. with >50% hepatic metab. were characterized as those with significant hepatic metab. (n = 149).  Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI.  Compared with compds. with lesser hepatic metab., compds. belonging to the significant hepatic metab. group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% vs. 11%, P = 0.001), liver failure (28% vs. 9%, P = 0.004), and fatal DILI (23% vs. 4%, P = 0.001), but not jaundice (46% vs. 35%, P = 0.2) or liver transplantation (9% vs. 2%, P = 0.11).  Twelve compds. with no hepatic metab. had no reports of liver failure, liver transplantation, or fatal DILI.  When the relationship between hepatic adverse events and combination of hepatic metab. and daily dose was examd., compds. with both significant hepatic metab. and daily dose >50 mg (n = 50) were significantly more hepatotoxic than compds. belonging to other groups.  Compared with medications without biliary excretion, compds. with biliary excretion (n = 50) had significantly higher frequency of jaundice (74% vs. 40%, P = 0.0001).  Conclusion: Our study finds an important relationship between a compd.'s metab. profile and reports of hepatic adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG7fKH0KK8ObVg90H21EOLACvtfcHk0ljzQBkWewy6SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVGnsr8%253D&md5=ba90a857ce677fddb63ac6f3136c6b3b</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1002%2Fhep.23317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23317%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DOral%2520medications%2520with%2520significant%2520hepatic%2520metabolism%2520at%2520higher%2520risk%2520for%2520hepatic%2520adverse%2520events%26jtitle%3DHepatology%26date%3D2010%26volume%3D51%26spage%3D615%26epage%3D620%26doi%3D10.1002%2Fhep.23317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.056267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.113.056267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=24464804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=744-750&author=K.+Yuauthor=X.+Gengauthor=M.+Chenauthor=J.+Zhangauthor=B.+Wangauthor=K.+Ilicauthor=W.+Tong&title=High+daily+dose+and+being+a+substrate+of+cytochrome+P450+enzymes+are+two+important+predictors+of+drug-induced+liver+injury&doi=10.1124%2Fdmd.113.056267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury</span></div><div class="casAuthors">Yu, Ke; Geng, Xingchao; Chen, Minjun; Zhang, Jie; Wang, Bingshun; Ilic, Katarina; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">744-750, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is complicated and difficult to predict.  It has been obsd. that drugs with extensive hepatic metab. have a higher likelihood of causing DILI.  Cytochrome P 450 (P 450) enzymes are primarily involved in hepatic metab.  Identifying the assocns. of DILI with drugs that are P 450 substrates, inhibitors, or inducers will be extremely helpful to clinicians during the decision-making process of caring for a patient suspected of having DILI.  We collected metab. data on P 450 enzymes for 254 orally administered drugs in the Liver Toxicity Knowledge Base Benchmark Dataset with a known daily dose, and applied logistic regression to identify these assocns.  We revealed that drugs that are substrates of P 450 enzymes have a higher likelihood of causing DILI [odds ratio (OR), 3.99; 95% confidence interval (95% CI), 2.07-7.67; P < 0.0001], which is dose-independent, and drugs that are P 450 inhibitors have a higher likelihood of generating DILI only when they are administered at high daily doses (OR, 6.03; 95% CI, 1.32-27.5; P = 0.0098).  However, drugs that are P 450 inducers are not obsd. to be assocd. with DILI (OR, 1.55; 95% CI, 0.65-3.68; P = 0.3246).  Our findings will be useful in identifying the suspected medication as a cause of liver injury in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZV-WvbMYx7Vg90H21EOLACvtfcHk0ljzQBkWewy6SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosFGktbc%253D&md5=167814960cb745e13e343242709bb585</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.056267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.056267%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DK.%26aulast%3DGeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DIlic%26aufirst%3DK.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520daily%2520dose%2520and%2520being%2520a%2520substrate%2520of%2520cytochrome%2520P450%2520enzymes%2520are%2520two%2520important%2520predictors%2520of%2520drug-induced%2520liver%2520injury%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D744%26epage%3D750%26doi%3D10.1124%2Fdmd.113.056267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+lipophilicity+and+high+daily+dose+of+oral+medications+are+associated+with+significant+risk+for+drug-induced+liver+injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0ljzQBkWewy6SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520lipophilicity%2520and%2520high%2520daily%2520dose%2520of%2520oral%2520medications%2520are%2520associated%2520with%2520significant%2520risk%2520for%2520drug-induced%2520liver%2520injury%26jtitle%3DHepatology%26date%3D2013%26volume%3D58%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEuen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1335</span>, <span class="refDoi"> DOI: 10.3390/ijms18071335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3390%2Fijms18071335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1335&author=K.+McEuenauthor=J.+Borlakauthor=W.+Tongauthor=M.+Chen&title=Associations+of+drug+lipophilicity+and+extent+of+metabolism+with+drug-induced+liver+injury&doi=10.3390%2Fijms18071335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury</span></div><div class="casAuthors">McEuen, Kristin; Borlak, Juergen; Tong, Weida; Chen, Minjun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1335/1-1335/11</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI), although rare, is a frequent cause of adverse drug reactions resulting in warnings and withdrawals of numerous medications.  Despite the research community's best efforts, current testing strategies aimed at identifying hepatotoxic drugs prior to human trials are not sufficiently powered to predict the complex mechanisms leading to DILI.  In our previous studies, we demonstrated lipophilicity and dose to be assocd. with increased DILI risk and, and in our latest work, we factored reactive metabolites into the algorithm to predict DILI.  Given the inconsistency in detg. the potential for drugs to cause DILI, the present study comprehensively assesses the relationship between DILI risk and lipophilicity and the extent of metab. using a large published dataset of 1036 Food and Drug Administration (FDA)-approved drugs by considering five independent DILI annotations.  We found that lipophilicity and the extent of metab. alone were assocd. with increased risk for DILI.  Moreover, when analyzed in combination with high daily dose (≥100 mg), lipophilicity was statistically significantly assocd. with the risk of DILI across all datasets (p < 0.05).  Similarly, the combination of extensive hepatic metab. (≥50%) and high daily dose (≥100 mg) was also strongly assocd. with an increased risk of DILI among all datasets analyzed (p < 0.05).  Our results suggest that both lipophilicity and the extent of hepatic metab. can be considered important risk factors for DILI in humans, and that this relationship to DILI risk is much stronger when considered in combination with dose.  The proposed paradigm allows the convergence of different published annotations to a more uniform assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwDM7bNDDUbVg90H21EOLACvtfcHk0lhyW4JxowuFbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73K&md5=51022ab2f8fd6e5b50769d4aca66e3b5</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.3390%2Fijms18071335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071335%26sid%3Dliteratum%253Aachs%26aulast%3DMcEuen%26aufirst%3DK.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DAssociations%2520of%2520drug%2520lipophilicity%2520and%2520extent%2520of%2520metabolism%2520with%2520drug-induced%2520liver%2520injury%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1335%26doi%3D10.3390%2Fijms18071335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. L.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of targeted therapy for cancer</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1080/17425255.2016.1190831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1080%2F17425255.2016.1190831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=27187715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Wlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=789-802&author=K.+W.+Leeauthor=S.+L.+Chan&title=Hepatotoxicity+of+targeted+therapy+for+cancer&doi=10.1080%2F17425255.2016.1190831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of targeted therapy for cancer</span></div><div class="casAuthors">Lee, Kirsty Wai-Chung; Chan, Stephen Lam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">789-802</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Understanding the mechanism of DILI with MTA, and how to avoid and manage these toxicities is essential for minimising inferior cancer treatment outcomes.  An organised and comprehensive overview of MTA-assocd. hepatotoxicity is lacking; this review aims to fill the gap.  A literature review was performed based on published case reports and relevant studies or articles pertaining to the topics on PubMed.  Food and Drug Administration drug information documents and search on the US National Library of Medicine LiverTox database was performed for all relevant MTA.  MTA-assocd. hepatotoxicity is common but rarely fatal.  The pattern of hepatotoxicity is predominantly idiosyncratic.  Pharmacogenomics show potential in predicting patients at risk of poorly metabolising or developing immunoallergic responses to MTA, but prospective data is scant.  Preventing reactivation of viral hepatitis using anti-viral drugs, and avoidance of drug combinations at high risk of neg. interactions are the most readily preventable measures for DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFKLyebm6okbVg90H21EOLACvtfcHk0lhyW4JxowuFbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Wlt7s%253D&md5=03b74420f8845aedd5944f8f6b8c7285</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1080%2F17425255.2016.1190831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17425255.2016.1190831%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DChan%26aufirst%3DS.%2BL.%26atitle%3DHepatotoxicity%2520of%2520targeted%2520therapy%2520for%2520cancer%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2016%26volume%3D12%26spage%3D789%26epage%3D802%26doi%3D10.1080%2F17425255.2016.1190831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostrubsky, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strom, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atherton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mireles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfj095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfj095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=16410371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Ons74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2006&pages=451-459&author=S.+E.+Kostrubskyauthor=S.+C.+Stromauthor=A.+S.+Kalgutkarauthor=S.+Kulkarniauthor=J.+Athertonauthor=R.+Mirelesauthor=B.+Fengauthor=R.+Kubikauthor=J.+Hansonauthor=E.+Urdaauthor=A.+E.+Mutlib&title=Inhibition+of+hepatobiliary+transport+as+a+predictive+method+for+clinical+hepatotoxicity+of+nefazodone&doi=10.1093%2Ftoxsci%2Fkfj095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone</span></div><div class="casAuthors">Kostrubsky, Seva E.; Strom, Stephen C.; Kalgutkar, Amit S.; Kulkarni, Shaila; Atherton, James; Mireles, Rouchelle; Feng, Bo; Kubik, Raylene; Hanson, Janean; Urda, Ellen; Mutlib, Abdul E.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">451-459</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Treatment with the antidepressant nefazodone has been assocd. with clin. idiosyncratic hepatotoxicity.  Using membranes expressing human bile salt export pump (BSEP), human sandwich hepatocytes, and intact rats, we compared nefazodone and its marketed analogs, buspirone and trazodone.  We found that nefazodone caused a strong inhibition of BSEP (IC50 = 9 μM), inhibition of taurocholate efflux in human hepatocytes (IC50 = 14 μM), and a transient increase in rat serum bile acids 1 h after oral drug administration.  Buspirone or trazodone had no effect on biliary transport system.  Nefazodone produced time- and concn.-dependent toxicity in human hepatocytes with IC50 = 18 μM and 30 μM measured by inhibition of protein synthesis after 6 h and 24 h incubation, resp.  Toxicity was correlated with the amt. of unmetabolized nefazodone.  Partial recovery in toxicity by 24 h has been assocd. with metab. of nefazodone to sulfate and glucuronide conjugates.  The satn. of nefazodone metab. resulted in sustained decrease in protein synthesis and cell death at 50 μM.  The toxicity was not obsd. with buspirone or trazodone.  Addn. of 1-aminobenzotriazole (ABT), an inhibitor of CYP450, resulted in enhancement of nefazodone toxicity at 10 μM and was assocd. with accumulation of unmetabolized nefazodone.  In human liver microsomes, ABT also prevented metab. of nefazodone and formation of glutathione conjugates.  We suggest that inhibition of bile acid transport by nefazodone is an indicator of potential hepatotoxicity.  Our findings are consistent with the clin. experience and suggest that described methodol. can be applied in the selection of nonhepatotoxic drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQhW2ho1OL0bVg90H21EOLACvtfcHk0lhyW4JxowuFbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Ons74%253D&md5=b0ff75c0e1b49344f95ea4f6dec1e697</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfj095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfj095%26sid%3Dliteratum%253Aachs%26aulast%3DKostrubsky%26aufirst%3DS.%2BE.%26aulast%3DStrom%26aufirst%3DS.%2BC.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKulkarni%26aufirst%3DS.%26aulast%3DAtherton%26aufirst%3DJ.%26aulast%3DMireles%26aufirst%3DR.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DKubik%26aufirst%3DR.%26aulast%3DHanson%26aufirst%3DJ.%26aulast%3DUrda%26aufirst%3DE.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26atitle%3DInhibition%2520of%2520hepatobiliary%2520transport%2520as%2520a%2520predictive%2520method%2520for%2520clinical%2520hepatotoxicity%2520of%2520nefazodone%26jtitle%3DToxicol.%2520Sci.%26date%3D2006%26volume%3D90%26spage%3D451%26epage%3D459%26doi%3D10.1093%2Ftoxsci%2Fkfj095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dykens, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marroquin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfn056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfn056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=18344530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslyhurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=335-345&author=J.+A.+Dykensauthor=J.+D.+Jamiesonauthor=L.+D.+Marroquinauthor=S.+Nadanacivaauthor=J.+J.+Xuauthor=M.+C.+Dunnauthor=A.+R.+Smithauthor=Y.+Will&title=In+vitro+assessment+of+mitochondrial+dysfunction+and+cytotoxicity+of+nefazodone%2C+trazodone%2C+and+buspirone&doi=10.1093%2Ftoxsci%2Fkfn056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone</span></div><div class="casAuthors">Dykens, James A.; Jamieson, Joseph D.; Marroquin, Lisa D.; Nadanaciva, Sashi; Xu, Jinghai J.; Dunn, Margaret C.; Smith, Arthur R.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">335-345</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mitochondrial toxicity is increasingly implicated in a host of drug-induced organ toxicities, including hepatotoxicity.  Nefazodone was withdrawn from the U.S. market in 2004 due to hepatotoxicity.  Accordingly, we evaluated nefazodone, another triazolopyridine trazodone, plus the azaspirodecanedione buspirone, for cytotoxicity and effects on mitochondrial function.  In accord with its clin. disposition, nefazodone was the most toxic compd. of the three, trazodone had relatively modest effects, whereas buspirone showed the least toxicity.  Nefazodone profoundly inhibited mitochondrial respiration in isolated rat liver mitochondria and in intact HepG2 cells where this was accompanied by simultaneous acceleration of glycolysis.  Using immunocaptured oxidative phosphorylation (OXPHOS) complexes, we identified Complex 1, and to a lesser amt. Complex IV, as the targets of nefazodone toxicity.  No inhibition was found for trazodone, and buspirone showed 3.4-fold less inhibition of OXPHOS Complex 1 than nefazodone.  In human hepatocytes that express cytochrome P 450, isoform 3A4, after 24 h exposure, nefazodone and trazodone collapsed mitochondrial membrane potential, and imposed oxidative stress, as detected via glutathione depletion, leading to cell death.  Our results suggest that the mitochondrial impairment imposed by nefazodone is profound and likely contributes to its hepatotoxicity, esp. in patients cotreated with other drugs with mitochondrial liabilities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSW4cwpy1jpLVg90H21EOLACvtfcHk0lgapzheaotODg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslyhurs%253D&md5=8bc3f5370a06bb00ea640dc2def3f3b5</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfn056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfn056%26sid%3Dliteratum%253Aachs%26aulast%3DDykens%26aufirst%3DJ.%2BA.%26aulast%3DJamieson%26aufirst%3DJ.%2BD.%26aulast%3DMarroquin%26aufirst%3DL.%2BD.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DDunn%26aufirst%3DM.%2BC.%26aulast%3DSmith%26aufirst%3DA.%2BR.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520mitochondrial%2520dysfunction%2520and%2520cytotoxicity%2520of%2520nefazodone%252C%2520trazodone%252C%2520and%2520buspirone%26jtitle%3DToxicol.%2520Sci.%26date%3D2008%26volume%3D103%26spage%3D335%26epage%3D345%26doi%3D10.1093%2Ftoxsci%2Fkfn056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span> <span> </span><span class="NLM_article-title">Role of the bile salt export pump, BSEP, in acquired forms of cholestasis</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.3109/03602530903492004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.3109%2F03602530903492004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=20028269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=437-445&author=B.+Stieger&title=Role+of+the+bile+salt+export+pump%2C+BSEP%2C+in+acquired+forms+of+cholestasis&doi=10.3109%2F03602530903492004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the bile salt export pump, BSEP, in acquired forms of cholestasis</span></div><div class="casAuthors">Stieger, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">437-445</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Generation of bile is a key function of the liver.  Its impairment leads to accumulation of cytotoxic bile salts in hepatocytes and, consequently, to liver disease.  The bile salt export pump, BSEP, is critically involved in the secretion of bile salts into bile.  Its function can be disturbed or abolished by inherited mutations.  This will lead to progressive intrahepatic cholestasis and severe liver disease.  In addn. to mutations, BSEP can be inhibited by acquired factors, such as xenobiotics or drugs, aberrant bile salt metabolites, or pregnancy.  This inhibition will lead to acquired cholestasis.  Some drugs are now known to be competitive inhibitors of Bsep.  In addn., a polymorphism in the gene coding for BSEP has been identified as a potential susceptibility factor for acquired cholestasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYni5fpYpR8bVg90H21EOLACvtfcHk0lgapzheaotODg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7w%253D&md5=4ea89d1fbe6a1da4933b3f72a6c212f9</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.3109%2F03602530903492004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602530903492004%26sid%3Dliteratum%253Aachs%26aulast%3DStieger%26aufirst%3DB.%26atitle%3DRole%2520of%2520the%2520bile%2520salt%2520export%2520pump%252C%2520BSEP%252C%2520in%2520acquired%2520forms%2520of%2520cholestasis%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26spage%3D437%26epage%3D445%26doi%3D10.3109%2F03602530903492004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2019&pages=156-167&author=P.+Ranaauthor=M.+D.+Aleoauthor=M.+Gosinkauthor=Y.+Will&title=Evaluation+of+in+vitro+mitochondrial+toxicity+assays+and+physicochemical+properties+for+prediction+of+organ+toxicity+using+228+pharmaceutical+drugs&doi=10.1021%2Facs.chemrestox.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in Vitro Mitochondrial Toxicity Assays and Physicochemical Properties for Prediction of Organ Toxicity Using 228 Pharmaceutical Drugs</span></div><div class="casAuthors">Rana, Payal; Aleo, Michael D.; Gosink, Mark; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-167</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mitochondrial toxicity has been shown to contribute to a variety of organ toxicities such as liver, cardiac, and kidney.  In the past decades, two high-throughput applicable screening assays (isolated rat liver mitochondria; glucose-galactose grown HepG2 cells) to assess mitochondrial toxicity have been deployed in many pharmaceutical companies, and numerous publications have demonstrated its usefulness for mechanistic investigations.  However, only two publications have demonstrated the utility of these screens as a predictor of human drug-induced liver injury.  In the present study, the authors screened 73 hepatotoxicants, 46 cardiotoxicants, 49 nephrotoxicants, and 60 compds. not known to cause human organ toxicity for their effects on mitochondrial function(s) in the assays mentioned above.  Predictive performance was evaluated using specificity and sensitivity of the assays for predicting organ toxicity.  The authors' results show that the predictive performance of the mitochondrial assays are superior for hepatotoxicity as compared to cardiotoxicity and nephrotoxicity (sensitivity 63% vs. 33% and 28% with similar specificity of 93%), when the anal. was done at 100* Cmax (drug concn. in human plasma level).  The authors further explored the assocn. of mitochondrial toxicity with physicochem. properties such as calcd. log partition coeff. (cLogP), topol. polar surface area, ionization status, and mol. wt. of the drugs and found that cLogP was most significantly assocd. mitochondrial toxicity.  Since these assays are amenable to higher throughput, the authors recommend that chemists use these assays to perform structure activity relationship early in the drug discovery process, when chem. matter is abundant.  This assures that compds. that lack the propensity to cause mitochondrial dysfunction (and assocd. organ toxicity) will move forward into animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Rad7gm0MrLVg90H21EOLACvtfcHk0lgapzheaotODg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVens7bM&md5=82bc95a1604961473a4e5fecb05aab79</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DP.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26aulast%3DGosink%26aufirst%3DM.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520in%2520vitro%2520mitochondrial%2520toxicity%2520assays%2520and%2520physicochemical%2520properties%2520for%2520prediction%2520of%2520organ%2520toxicity%2520using%2520228%2520pharmaceutical%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26volume%3D32%26spage%3D156%26epage%3D167%26doi%3D10.1021%2Facs.chemrestox.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Longo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herédi-Szabó, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogyorósi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolenski, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragan, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosedale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siler, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. A.</span></span> <span> </span><span class="NLM_article-title">Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfy253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1093%2Ftoxsci%2Fkfy253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30289550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yrurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=458-467&author=D.+M.+Longoauthor=J.+L.+Woodheadauthor=P.+Walkerauthor=K.+Her%C3%A9di-Szab%C3%B3author=K.+Mogyor%C3%B3siauthor=F.+S.+Wolenskiauthor=Y.+P.+Draganauthor=M.+Mosedaleauthor=Q.+Silerauthor=P.+B.+Watkinsauthor=B.+A.+Howell&title=Quantitative+systems+toxicology+analysis+of+in+vitro+mechanistic+assays+reveals+importance+of+bile+acid+accumulation+and+mitochondrial+dysfunction+in+TAK-875-induced+liver+injury&doi=10.1093%2Ftoxsci%2Fkfy253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury</span></div><div class="casAuthors">Longo, Diane M.; Woodhead, Jeffrey L.; Walker, Paul; Heredi-Szabo, Krisztina; Mogyorosi, Karoly; Wolenski, Francis S.; Dragan, Yvonne P.; Mosedale, Merrie; Siler, Scott Q.; Watkins, Paul B.; Howell, Brett A.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">458-467</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">TAK-875 (fasiglifam), a GPR40 agonist in development for the treatment of type 2 diabetes (T2D), was voluntarily terminated in Phase III trials due to adverse liver effects.  The potential mechanisms of TAK-875 toxicity were explored by combining in vitro expts. with quant. systems toxicol. (QST) using DILIsym, a math. representation of drug induced liver injury.  In vitro assays revealed that bile acid transporters were inhibited by both TAK-875 and its metabolite, TAK-875-Glu.  Exptl. data indicated that human bile salt export pump (BSEP) inhibition by TAK-875 was mixed whereas sodium taurocholate co-transporting polypeptide (NTCP) inhibition by TAK-875 was competitive.  Furthermore, exptl. data demonstrated that both TAK-875 and TAK-875-Glu inhibit mitochondrial electron transport chain (ETC) enzymes.  These mechanistic data were combined with a physiol. based pharmacokinetic (PBPK) model constructed within DILIsym to est. liver exposure of TAK-875 and TAK-875-Glu.  In a simulated population (SimPops) constructed to reflect T2D patients, 16/245 (6.5%) simulated individuals developed alanine aminotransferase (ALT) elevations, an incidence similar to that obsd. with 200 mg daily dosing in clin. trials.  Detg. the mode of bile acid transporter inhibition (Ki) was crit. to accurate predictions.  In addn., simulations conducted on a sensitive subset of individuals (SimCohorts) revealed that when either BSEP or ETC inhibition was inactive, ALT elevations were not predicted to occur, suggesting that the two mechanisms operate synergistically to produce the obsd. clin. response.  These results demonstrate how utilizing QST methods to interpret in vitro exptl. results can lead to an improved understanding of the clin. relevant mechanisms underlying drug-induced toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPa7jeGLG3LVg90H21EOLACvtfcHk0ljSX5v1XLjj-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yrurzL&md5=cfb9fedecf2df7c3762f4481b648515b</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfy253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfy253%26sid%3Dliteratum%253Aachs%26aulast%3DLongo%26aufirst%3DD.%2BM.%26aulast%3DWoodhead%26aufirst%3DJ.%2BL.%26aulast%3DWalker%26aufirst%3DP.%26aulast%3DHer%25C3%25A9di-Szab%25C3%25B3%26aufirst%3DK.%26aulast%3DMogyor%25C3%25B3si%26aufirst%3DK.%26aulast%3DWolenski%26aufirst%3DF.%2BS.%26aulast%3DDragan%26aufirst%3DY.%2BP.%26aulast%3DMosedale%26aufirst%3DM.%26aulast%3DSiler%26aufirst%3DQ.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DHowell%26aufirst%3DB.%2BA.%26atitle%3DQuantitative%2520systems%2520toxicology%2520analysis%2520of%2520in%2520vitro%2520mechanistic%2520assays%2520reveals%2520importance%2520of%2520bile%2520acid%2520accumulation%2520and%2520mitochondrial%2520dysfunction%2520in%2520TAK-875-induced%2520liver%2520injury%26jtitle%3DToxicol.%2520Sci.%26date%3D2019%26volume%3D167%26spage%3D458%26epage%3D467%26doi%3D10.1093%2Ftoxsci%2Fkfy253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.</span></span> <span> </span><span class="NLM_article-title">Do in vitro assays predict drug candidate idiosyncratic drug-induced liver injury risk?</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1658</span>– <span class="NLM_lpage">1669</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fdmd.118.082719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30021844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1658-1669&author=J.+G.+Kennaauthor=J.+Uetrecht&title=Do+in+vitro+assays+predict+drug+candidate+idiosyncratic+drug-induced+liver+injury+risk%3F&doi=10.1124%2Fdmd.118.082719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?</span></div><div class="casAuthors">Kenna J Gerry; Uetrecht Jack</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1658-1669</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In vitro assays are commonly used during drug discovery to try to decrease the risk of idiosyncratic drug-induced liver injury (iDILI).  But how effective are they at predicting risk? One of the most widely used methods evaluates cell cytotoxicity.  Cytotoxicity assays that used cell lines that are very different from normal hepatocytes, and high concentrations of drug, were not very accurate at predicting idiosyncratic drug reaction risk.  Even cytotoxicity assays that use more biologically normal cells resulted in many false-positive and false-negative results.  Assays that quantify reactive metabolite formation, mitochondrial injury, and bile salt export pump (BSEP) inhibition have also been described.  Although evidence suggests that reactive metabolite formation and BSEP inhibition can play a role in the mechanism of iDILI, these assays are not very accurate at predicting risk.  In contrast, inhibition of the mitochondrial electron transport chain appears not to play an important role in the mechanism of iDILI, although other types of mitochondrial injury may do so.  It is likely that there are many additional mechanisms by which drugs can cause iDILI.  However, simply measuring more parameters is unlikely to provide better predictive assays unless those parameters are actually involved in the mechanism of iDILI.  Hence, a better mechanistic understanding of iDILI is required; however, mechanistic studies of iDILI are very difficult.  There is substantive evidence that most iDILI is immune mediated; therefore, the most accurate assays may involve those that determine immune responses to drugs.  New methods to manipulate immune tolerance may greatly facilitate development of more suitable methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfQDq8PfgS1p6KlWarZTAzfW6udTcc2eZeytU8BhQGYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FpsFGjtw%253D%253D&md5=5300842ef1375b82da597057258f82ce</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082719%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DDo%2520in%2520vitro%2520assays%2520predict%2520drug%2520candidate%2520idiosyncratic%2520drug-induced%2520liver%2520injury%2520risk%253F%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D1658%26epage%3D1669%26doi%3D10.1124%2Fdmd.118.082719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taskar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yucha, R. W.</span></span> <span> </span><span class="NLM_article-title">Can bile salt export pump inhibition testing in drug discovery and development reduced liver injury risk? An International Transporter Consortium Perspective</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1002/cpt.1222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1002%2Fcpt.1222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=30137645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2018&pages=916-932&author=J.+G.+Kennaauthor=K.+S.+Taskarauthor=C.+Battistaauthor=D.+L.+Bourdetauthor=K.+L.+R.+Brouwerauthor=K.+R.+Brouwerauthor=D.+Daiauthor=C.+Funkauthor=M.+J.+Hafeyauthor=Y.+Laiauthor=J.+Maherauthor=Y.+A.+Pakauthor=J.+M.+Pedersenauthor=J.+W.+Polliauthor=A.+D.+Rodriguesauthor=P.+B.+Watkinsauthor=K.+Yangauthor=R.+W.+Yucha&title=Can+bile+salt+export+pump+inhibition+testing+in+drug+discovery+and+development+reduced+liver+injury+risk%3F+An+International+Transporter+Consortium+Perspective&doi=10.1002%2Fcpt.1222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective</span></div><div class="casAuthors">Kenna, J. Gerry; Taskar, Kunal S.; Battista, Christina; Bourdet, David L.; Brouwer, Kim L. R.; Brouwer, Kenneth R.; Dai, David; Funk, Christoph; Hafey, Michael J.; Lai, Yurong; Maher, Jonathan; Pak, Y. Anne; Pedersen, Jenny M.; Polli, Joseph W.; Rodrigues, A. David; Watkins, Paul B.; Yang, Kyunghee; Yucha, Robert W.; On behalf of the International Transporter Consortium</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">916-932</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bile salt export pump (BSEP) inhibition has emerged as an important mechanism that may contribute to the initiation of human drug-induced liver injury (DILI).  Proactive evaluation and understanding of BSEP inhibition is recommended in drug discovery and development to aid internal decision making on DILI risk.  BSEP inhibition can be quantified using in vitro assays.  When interpreting assay data, it is important to consider in vivo drug exposure.  Currently, this can be undertaken most effectively by consideration of total plasma steady state drug concns. (Css,plasma).  However, because total drug concns. are not predictive of pharmacol. effect, the relationship between total exposure and BSEP inhibition is not causal.  Various follow-up studies can aid interpretation of in vitroBSEP inhibition data and may be undertaken on a case-by-case basis.  BSEP inhibition is one of several mechanisms by which drugs may cause DILI, therefore, it should be considered alongside other mechanisms when evaluating possible DILI risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAayGrck3BArVg90H21EOLACvtfcHk0ljSX5v1XLjj-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtb%252FJ&md5=b70c447083b739f21267467888dc8e1e</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1222%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DTaskar%26aufirst%3DK.%2BS.%26aulast%3DBattista%26aufirst%3DC.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26aulast%3DBrouwer%26aufirst%3DK.%2BR.%26aulast%3DDai%26aufirst%3DD.%26aulast%3DFunk%26aufirst%3DC.%26aulast%3DHafey%26aufirst%3DM.%2BJ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DPak%26aufirst%3DY.%2BA.%26aulast%3DPedersen%26aufirst%3DJ.%2BM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYucha%26aufirst%3DR.%2BW.%26atitle%3DCan%2520bile%2520salt%2520export%2520pump%2520inhibition%2520testing%2520in%2520drug%2520discovery%2520and%2520development%2520reduced%2520liver%2520injury%2520risk%253F%2520An%2520International%2520Transporter%2520Consortium%2520Perspective%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D104%26spage%3D916%26epage%3D932%26doi%3D10.1002%2Fcpt.1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eakins, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergare, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elebring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span> <span> </span><span class="NLM_article-title">Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=10.1124%2Fjpet.114.220491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=25467130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=281-290&author=J.+G.+Kennaauthor=S.+H.+Stahlauthor=J.+A.+Eakinsauthor=A.+J.+Fosterauthor=L.+C.+Anderssonauthor=J.+Bergareauthor=M.+Billgerauthor=M.+Elebringauthor=C.+S.+Elmoreauthor=R.+A.+Thompson&title=Multiple+compound-related+adverse+properties+contribute+to+liver+injury+caused+by+endothelin+receptor+antagonists&doi=10.1124%2Fjpet.114.220491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists</span></div><div class="casAuthors">Kenna, J. Gerry; Stahl, Simone H.; Eakins, Julie A.; Foster, Alison J.; Andersson, Linda C.; Bergare, Jonas; Billger, Martin; Elebring, Marie; Elmore, Charles S.; Thompson, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">281-290/1-281-290/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Drug-induced liver injury has been obsd. in patients treated with the endothelin receptor antagonists sitaxentan and bosentan, but not following treatment with ambrisentan.  The aim of our studies was to assess the possible role of multiple contributory mechanisms in this clin. relevant toxicity.  Inhibition of the bile salt export pump (BSEP) and multidrug resistance-assocd. protein 2 was quantified using membrane vesicle assays.  Inhibition of mitochondrial respiration in human liver-derived HuH-7 cells was detd. using a Seahorse XFe96 analyzer.  Cytochrome P 450 (P 450) -independent and P 450-mediated cell toxicity was assessed using transfected SV40-T-antigen-immortalized human liver epithelial (THLE) cell lines.  Exposure-adjusted assay ratios were calcd. by dividing the max. human drug plasma concns. by the IC50 or EC50 values obtained in vitro.  Covalent binding (CVB) of radiolabeled drugs to human hepatocytes was quantified, and CVB body burdens were calcd. by adjusting CVB values for fractional drug turnover in vitro and daily therapeutic dose.  Sitaxentan exhibited pos. exposure-adjusted signals in all five in vitro assays and a high CVB body burden.  Bosentan exhibited a pos. exposure-adjusted signal in one assay (BSEP inhibition) and a moderate CVB body burden.  Ambrisentan exhibited no pos. exposure-adjusted assay signals and a low CVB body burden.  These data indicate that multiple mechanisms contribute to the rare, but potentially severe liver injury caused by sitaxentan in humans; provide a plausible rationale for the markedly lower propensity of bosentan to cause liver injury; and highlight the relative safety of ambrisentan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDXn5oSiJzfbVg90H21EOLACvtfcHk0ljwh8IvF8HD8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOhu7Y%253D&md5=254850e804c48f295e6ce75e94b95385</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220491%26sid%3Dliteratum%253Aachs%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DStahl%26aufirst%3DS.%2BH.%26aulast%3DEakins%26aufirst%3DJ.%2BA.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DBergare%26aufirst%3DJ.%26aulast%3DBillger%26aufirst%3DM.%26aulast%3DElebring%26aufirst%3DM.%26aulast%3DElmore%26aufirst%3DC.%2BS.%26aulast%3DThompson%26aufirst%3DR.%2BA.%26atitle%3DMultiple%2520compound-related%2520adverse%2520properties%2520contribute%2520to%2520liver%2520injury%2520caused%2520by%2520endothelin%2520receptor%2520antagonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D281%26epage%3D290%26doi%3D10.1124%2Fjpet.114.220491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidolf, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span> <span> </span><span class="NLM_article-title">In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1021/tx300091x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx300091x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=1616-1632&author=R.+A.+Thompsonauthor=E.+M.+Isinauthor=Y.+Liauthor=L.+Weidolfauthor=K.+Pageauthor=I.+Wilsonauthor=S.+Swallowauthor=B.+Middletonauthor=S.+Stahlauthor=A.+J.+Fosterauthor=H.+Dolgosauthor=R.+Weaverauthor=J.+G.+Kenna&title=In+vitro+approach+to+assess+the+potential+for+risk+of+idiosyncratic+adverse+reactions+caused+by+candidate+drugs&doi=10.1021%2Ftx300091x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs</span></div><div class="casAuthors">Thompson, Richard A.; Isin, Emre M.; Li, Yan; Weidolf, Lars; Page, Ken; Wilson, Ian; Swallow, Steve; Middleton, Brian; Stahl, Simone; Foster, Alison J.; Dolgos, Hugues; Weaver, Richard; Kenna, J. Gerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1616-1632</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Idiosyncratic adverse drug reactions (IADRs) in humans can result in a broad range of clin. significant toxicities leading to attrition during drug development as well as postlicensing withdrawal or labeling.  IADRs arise from both drug and patient related mechanisms and risk factors.  Drug related risk factors, resulting from parent compd. or metabolites, may involve multiple contributory mechanisms including organelle toxicity, effects related to compd. disposition, and/or immune activation.  In the current study, we evaluate an in vitro approach, which explored both cellular effects and covalent binding (CVB) to assess IADR risks for drug candidates using 36 drugs which caused different patterns and severities of IADRs in humans.  The cellular effects were tested in an in vitro Panel of five assays which quantified (1) toxicity to THLE cells (SV40 T-antigen-immortalized human liver epithelial cells), which do not express P450s, (2) toxicity to a THLE cell line which selectively expresses P 450 3A4, (3) cytotoxicity in HepG2 cells in glucose and galactose media, which is indicative of mitochondrial injury, (4) inhibition of the human bile salt export pump, BSEP, and (5) inhibition of the rat multidrug resistance assocd. protein 2, Mrp2.  In addn., the CVB Burden was estd. by detg. the CVB of radiolabeled compd. to human hepatocytes and factoring in both the max. prescribed daily dose and the fraction of metab. leading to CVB.  Combining the aggregated results from the in vitro Panel assays with the CVB Burden data discriminated, with high specificity (78%) and sensitivity (100%), between 27 drugs, which had severe or marked IADR concern, and 9 drugs, which had low IADR concern, we propose that this integrated approach has the potential to enable selection of drug candidates with reduced propensity to cause IADRs in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFG8lfWXT4vLVg90H21EOLACvtfcHk0ljwh8IvF8HD8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqs70%253D&md5=e657aaf23d4efc5466bca68dee95bded</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1021%2Ftx300091x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx300091x%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DR.%2BA.%26aulast%3DIsin%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWeidolf%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DI.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DMiddleton%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DS.%26aulast%3DFoster%26aufirst%3DA.%2BJ.%26aulast%3DDolgos%26aufirst%3DH.%26aulast%3DWeaver%26aufirst%3DR.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26atitle%3DIn%2520vitro%2520approach%2520to%2520assess%2520the%2520potential%2520for%2520risk%2520of%2520idiosyncratic%2520adverse%2520reactions%2520caused%2520by%2520candidate%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D1616%26epage%3D1632%26doi%3D10.1021%2Ftx300091x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00917&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00917%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00917" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c746b0b89c3bf2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
